assay_description,canonical_smiles,document_chembl_id,relation,standard_relation,standard_type,standard_units,standard_value,type,units,value,SMILES,year
Residual activity at human PI3Kgamma at 10 uM in presence of 10 uM ATP relative to control,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1,CHEMBL1138050,=,=,Activity,%,5.0,Activity,%,5.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1,CHEMBL1138050,=,=,IC50,nM,30.0,IC50,nM,30.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1,2006
Inhibition of human PI3Kgamma,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,CHEMBL1138050,=,=,IC50,nM,5.0,IC50,nM,5.0,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,2006
Inhibition of human PI3Kgamma,O=C1NC(=S)S/C1=C\c1ccc(-c2ccc([N+](=O)[O-])cc2Br)o1,CHEMBL1138050,=,=,IC50,nM,3600.0,IC50,uM,3.6,O=C1NC(=S)S/C1=C\c1ccc(-c2ccc([N+](=O)[O-])cc2Br)o1,2006
Inhibition of human PI3Kgamma,O=C1NC(=S)S/C1=C\c1ccc(-c2cccc(C(=O)O)c2)o1,CHEMBL1138050,=,=,IC50,nM,920.0,IC50,uM,0.92,O=C1NC(=S)S/C1=C\c1ccc(-c2cccc(C(=O)O)c2)o1,2006
Inhibition of human PI3Kgamma,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL1138050,=,=,IC50,nM,7260.0,IC50,nM,7260.0,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2006
Inhibition of human PI3Kgamma,O=C1NC(=S)S/C1=C\c1ccc(-c2cc([N+](=O)[O-])ccc2O)o1,CHEMBL1138050,=,=,IC50,nM,200.0,IC50,uM,0.2,O=C1NC(=S)S/C1=C\c1ccc(-c2cc([N+](=O)[O-])ccc2O)o1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3cc(F)cc(F)c3O)s2)S1,CHEMBL1138050,=,=,IC50,nM,29.0,IC50,nM,29.0,O=C1NC(=O)/C(=C/c2ccc(-c3cc(F)cc(F)c3O)s2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3F)o2)S1,CHEMBL1138050,=,=,IC50,nM,3800.0,IC50,nM,3800.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3F)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(O)cc3F)o2)S1,CHEMBL1138050,=,=,IC50,nM,260.0,IC50,nM,260.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(O)cc3F)o2)S1,2006
Inhibition of human PI3Kgamma at 1 uM,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)s2)S1,CHEMBL1138050,=,=,Inhibition,%,4.0,Inhibition,%,4.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)s2)S1,2006
Inhibition of human PI3Kgamma at 1 uM,COc1cc(F)ccc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,CHEMBL1138050,=,=,Inhibition,%,11.0,Inhibition,%,11.0,COc1cc(F)ccc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3cc(C(=O)O)ccc3O)o2)S1,CHEMBL1138050,=,=,IC50,nM,530.0,IC50,nM,530.0,O=C1NC(=O)/C(=C/c2ccc(-c3cc(C(=O)O)ccc3O)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3cccc([N+](=O)[O-])c3O)o2)S1,CHEMBL1138050,=,=,IC50,nM,80.0,IC50,nM,80.0,O=C1NC(=O)/C(=C/c2ccc(-c3cccc([N+](=O)[O-])c3O)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3cc(O)ccc3O)o2)S1,CHEMBL1138050,=,=,IC50,nM,20.0,IC50,nM,20.0,O=C1NC(=O)/C(=C/c2ccc(-c3cc(O)ccc3O)o2)S1,2006
Inhibition of human PI3Kgamma,Cc1ccc(O)c(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,CHEMBL1138050,=,=,IC50,nM,39.0,IC50,nM,39.0,Cc1ccc(O)c(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3cc(OC(F)(F)F)ccc3O)o2)S1,CHEMBL1138050,=,=,IC50,nM,56.0,IC50,nM,56.0,O=C1NC(=O)/C(=C/c2ccc(-c3cc(OC(F)(F)F)ccc3O)o2)S1,2006
Inhibition of human PI3Kgamma,N#Cc1ccc(O)c(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,CHEMBL1138050,=,=,IC50,nM,40.0,IC50,nM,40.0,N#Cc1ccc(O)c(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3cc(Cl)ccc3O)o2)S1,CHEMBL1138050,=,=,IC50,nM,43.0,IC50,nM,43.0,O=C1NC(=O)/C(=C/c2ccc(-c3cc(Cl)ccc3O)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3cc(F)ccc3O)o2)S1,CHEMBL1138050,=,=,IC50,nM,37.0,IC50,nM,37.0,O=C1NC(=O)/C(=C/c2ccc(-c3cc(F)ccc3O)o2)S1,2006
Inhibition of human PI3Kgamma,COC(=O)c1ccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c(O)c1,CHEMBL1138050,=,=,IC50,nM,29.0,IC50,nM,29.0,COC(=O)c1ccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c(O)c1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(O)cc3O)o2)S1,CHEMBL1138050,=,=,IC50,nM,20.0,IC50,nM,20.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(O)cc3O)o2)S1,2006
Inhibition of human PI3Kgamma at 1 uM,O=C1NC(=O)/C(=C/c2ccc(-c3cccc4cccnc34)o2)S1,CHEMBL1138050,=,=,Inhibition,%,17.0,Inhibition,%,17.0,O=C1NC(=O)/C(=C/c2ccc(-c3cccc4cccnc34)o2)S1,2006
Inhibition of human PI3Kgamma at 1 uM,O=C1NC(=O)/C(=C/c2ccc(-c3nccc4ccccc34)o2)S1,CHEMBL1138050,=,=,Inhibition,%,13.0,Inhibition,%,13.0,O=C1NC(=O)/C(=C/c2ccc(-c3nccc4ccccc34)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3cccnc3)o2)S1,CHEMBL1138050,=,=,IC50,nM,950.0,IC50,nM,950.0,O=C1NC(=O)/C(=C/c2ccc(-c3cccnc3)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3ccccn3)o2)S1,CHEMBL1138050,=,=,IC50,nM,110.0,IC50,nM,110.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccccn3)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3ccc([N+](=O)[O-])o3)o2)S1,CHEMBL1138050,=,=,IC50,nM,20000.0,IC50,nM,20000.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccc([N+](=O)[O-])o3)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3ccoc3)o2)S1,CHEMBL1138050,=,=,IC50,nM,840.0,IC50,nM,840.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccoc3)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3ccc4c(c3)OCO4)o2)S1,CHEMBL1138050,=,=,IC50,nM,20000.0,IC50,nM,20000.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccc4c(c3)OCO4)o2)S1,2006
Inhibition of human PI3Kgamma at 1 uM,O=C1NC(=O)/C(=C/c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1,CHEMBL1138050,=,=,Inhibition,%,24.0,Inhibition,%,24.0,O=C1NC(=O)/C(=C/c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1,2006
Inhibition of human PI3Kgamma,COc1cccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,CHEMBL1138050,=,=,IC50,nM,2600.0,IC50,nM,2600.0,COc1cccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,2006
Inhibition of human PI3Kgamma at 1 uM,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3O)s2)S1,CHEMBL1138050,=,=,Inhibition,%,27.0,Inhibition,%,27.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3O)s2)S1,2006
Inhibition of human PI3Kgamma at 1 uM,Nc1ccc([N+](=O)[O-])cc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,CHEMBL1138050,=,=,Inhibition,%,18.0,Inhibition,%,18.0,Nc1ccc([N+](=O)[O-])cc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,2006
Inhibition of human PI3Kgamma at 1 uM,CC(=O)Nc1ccccc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,CHEMBL1138050,=,=,Inhibition,%,24.0,Inhibition,%,24.0,CC(=O)Nc1ccccc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,2006
Inhibition of human PI3Kgamma at 1 uM,O=C(O)Cc1cccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,CHEMBL1138050,=,=,Inhibition,%,15.0,Inhibition,%,15.0,O=C(O)Cc1cccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,2006
Inhibition of human PI3Kgamma,COC(=O)c1cccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,CHEMBL1138050,=,=,IC50,nM,13500.0,IC50,nM,13500.0,COC(=O)c1cccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3cccc(C(=O)O)c3)o2)S1,CHEMBL1138050,=,=,IC50,nM,4300.0,IC50,nM,4300.0,O=C1NC(=O)/C(=C/c2ccc(-c3cccc(C(=O)O)c3)o2)S1,2006
Inhibition of human PI3Kgamma at 1 uM,O=C(O)Cc1ccccc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,CHEMBL1138050,=,=,Inhibition,%,12.0,Inhibition,%,12.0,O=C(O)Cc1ccccc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,2006
Inhibition of human PI3Kgamma at 1 uM,COC(=O)c1ccccc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,CHEMBL1138050,=,=,Inhibition,%,2.0,Inhibition,%,2.0,COC(=O)c1ccccc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,2006
Inhibition of human PI3Kgamma at 1 uM,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3C(=O)O)o2)S1,CHEMBL1138050,=,=,Inhibition,%,4.0,Inhibition,%,4.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3C(=O)O)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3F)o2)S1,CHEMBL1138050,=,=,IC50,nM,1200.0,IC50,nM,1200.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3F)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3Cl)o2)S1,CHEMBL1138050,=,=,IC50,nM,20000.0,IC50,nM,20000.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3Cl)o2)S1,2006
Inhibition of human PI3Kgamma at 1 uM,COc1ccccc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,CHEMBL1138050,=,=,Inhibition,%,44.0,Inhibition,%,44.0,COc1ccccc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(O)cc3)o2)S1,CHEMBL1138050,=,=,IC50,nM,380.0,IC50,nM,380.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(O)cc3)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3cccc(O)c3)o2)S1,CHEMBL1138050,=,=,IC50,nM,290.0,IC50,nM,290.0,O=C1NC(=O)/C(=C/c2ccc(-c3cccc(O)c3)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3O)o2)S1,CHEMBL1138050,=,=,IC50,nM,30.0,IC50,nM,30.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3O)o2)S1,2006
Inhibition of human PI3Kgamma,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3)o2)S1,CHEMBL1138050,=,=,IC50,nM,20000.0,IC50,nM,20000.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3)o2)S1,2006
Inhibition of His-tagged PI3K p110gamma by SPA,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL1144502,=,=,IC50,nM,1600.0,IC50,uM,1.6,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2007
Inhibition of His-tagged PI3K p110gamma by SPA,Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)c1nc(-c2cnc3ccc(Cl)cn23)cs1.Cl,CHEMBL1144502,=,=,IC50,nM,230.0,IC50,uM,0.23,Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)c1nc(-c2cnc3ccc(Cl)cn23)cs1.Cl,2007
Inhibition of PI3Kgamma,C/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br,CHEMBL1144565,>,>,IC50,nM,500000.0,IC50,uM,500.0,C/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br,2007
Inhibition of His-tagged human p110gamma expressed in SF9/Baculovirus system by SPA,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL1143746,=,=,IC50,nM,1600.0,IC50,uM,1.6,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2007
Inhibition of His-tagged human p110gamma expressed in SF9/Baculovirus system by SPA,Cl.Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL1143746,=,=,IC50,nM,250.0,IC50,uM,0.25,Cl.Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2007
Inhibition of His-tagged human p110gamma expressed in SF9/Baculovirus system by SPA,Cl.Oc1cccc(-c2nc(N3CCOCC3)c3sccc3n2)c1,CHEMBL1143746,=,=,IC50,nM,660.0,IC50,uM,0.66,Cl.Oc1cccc(-c2nc(N3CCOCC3)c3sccc3n2)c1,2007
Inhibition of His-tagged human p110gamma expressed in SF9/Baculovirus system by SPA,Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)/N=C/c1cnc2ccc(Br)cn12.Cl,CHEMBL1143746,=,=,IC50,nM,40.0,IC50,uM,0.04,Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)/N=C/c1cnc2ccc(Br)cn12.Cl,2007
Inhibition of p110gamma,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL1144634,=,=,IC50,nM,1600.0,IC50,uM,1.6,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2007
Inhibition of p110gamma,Cl.Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL1144634,=,=,IC50,nM,250.0,IC50,uM,0.25,Cl.Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2007
Inhibition of p110gamma,Cl.Oc1cccc(-c2nc(N3CCOCC3)c3sccc3n2)c1,CHEMBL1144634,=,=,IC50,nM,660.0,IC50,uM,0.66,Cl.Oc1cccc(-c2nc(N3CCOCC3)c3sccc3n2)c1,2007
Inhibition of recombinant PI3Kgamma,Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,CHEMBL1148756,=,=,IC50,nM,83.0,IC50,nM,83.0,Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,2007
Inhibition of recombinant PI3Kgamma,Nc1ncnc2ncc(-c3ccc(O)c(O)c3)nc12,CHEMBL1148756,=,=,IC50,nM,1300.0,IC50,uM,1.3,Nc1ncnc2ncc(-c3ccc(O)c(O)c3)nc12,2007
Inhibition of recombinant PI3Kgamma,Nc1ncnc2nc(-c3ccc(O)c(O)c3)cnc12,CHEMBL1148756,=,=,IC50,nM,5100.0,IC50,uM,5.1,Nc1ncnc2nc(-c3ccc(O)c(O)c3)cnc12,2007
Inhibition of recombinant PI3Kgamma,Nc1ncnc2nc(-c3ccc(O)c(O)c3)c(-c3ccc(O)c(O)c3)nc12,CHEMBL1148756,=,=,IC50,nM,968.0,IC50,uM,0.968,Nc1ncnc2nc(-c3ccc(O)c(O)c3)c(-c3ccc(O)c(O)c3)nc12,2007
Inhibition of recombinant PI3Kgamma,Nc1nc(N)c2nc(-c3cccc(OCC(O)CO)c3)c(-c3cccc(OCC(O)CO)c3)nc2n1,CHEMBL1148756,=,=,IC50,nM,32700.0,IC50,uM,32.7,Nc1nc(N)c2nc(-c3cccc(OCC(O)CO)c3)c(-c3cccc(OCC(O)CO)c3)nc2n1,2007
Inhibition of recombinant PI3Kgamma,COc1cccc(-c2nc3nc(N)nc(N)c3nc2-c2cccc(OC)c2)c1,CHEMBL1148756,=,=,IC50,nM,12.6,IC50,nM,12.6,COc1cccc(-c2nc3nc(N)nc(N)c3nc2-c2cccc(OC)c2)c1,2007
Inhibition of recombinant PI3Kgamma,Nc1nc(N)c2nc(-c3ccccc3)c(-c3ccccc3)nc2n1,CHEMBL1148756,=,=,IC50,nM,8500.0,IC50,uM,8.5,Nc1nc(N)c2nc(-c3ccccc3)c(-c3ccccc3)nc2n1,2007
Inhibition of recombinant PI3Kgamma,Nc1nc(N)c2ncc(-c3ccc(O)c(O)c3)nc2n1,CHEMBL1148756,=,=,IC50,nM,5900.0,IC50,uM,5.9,Nc1nc(N)c2ncc(-c3ccc(O)c(O)c3)nc2n1,2007
Inhibition of recombinant PI3Kgamma,Nc1nc(N)c2ncc(-c3ccc(O)cc3)nc2n1,CHEMBL1148756,=,=,IC50,nM,4700.0,IC50,uM,4.7,Nc1nc(N)c2ncc(-c3ccc(O)cc3)nc2n1,2007
Inhibition of recombinant PI3Kgamma,Nc1nc(N)c2ncc(-c3cccc(O)c3)nc2n1,CHEMBL1148756,=,=,IC50,nM,3000.0,IC50,uM,3.0,Nc1nc(N)c2ncc(-c3cccc(O)c3)nc2n1,2007
Inhibition of recombinant PI3Kgamma,Nc1nc(N)c2nc(-c3ccc(O)cc3)c(-c3ccc(O)cc3)nc2n1,CHEMBL1148756,=,=,IC50,nM,2700.0,IC50,uM,2.7,Nc1nc(N)c2nc(-c3ccc(O)cc3)c(-c3ccc(O)cc3)nc2n1,2007
Inhibition of recombinant PI3Kgamma,Nc1nc(N)c2nc(-c3ccc(O)cc3)cnc2n1,CHEMBL1148756,=,=,IC50,nM,1200.0,IC50,uM,1.2,Nc1nc(N)c2nc(-c3ccc(O)cc3)cnc2n1,2007
Inhibition of recombinant PI3Kgamma,Nc1nc(N)c2nc(-c3ccc(O)c(O)c3)cnc2n1,CHEMBL1148756,=,=,IC50,nM,195.0,IC50,uM,0.195,Nc1nc(N)c2nc(-c3ccc(O)c(O)c3)cnc2n1,2007
Inhibition of recombinant PI3Kgamma,Nc1nc(N)c2nc(-c3cccc(O)c3)cnc2n1,CHEMBL1148756,=,=,IC50,nM,39.9,IC50,uM,0.0399,Nc1nc(N)c2nc(-c3cccc(O)c3)cnc2n1,2007
Inhibition of recombinant PI3Kgamma,Nc1nc(NCCCN2CCOCC2)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,CHEMBL1148756,=,=,IC50,nM,51000.0,IC50,uM,51.0,Nc1nc(NCCCN2CCOCC2)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,2007
Inhibition of recombinant PI3Kgamma,Nc1ncnc2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc12,CHEMBL1148756,=,=,IC50,nM,4000.0,IC50,uM,4.0,Nc1ncnc2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc12,2007
Inhibition of recombinant PI3Kgamma,Nc1nc(O)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,CHEMBL1148756,=,=,IC50,nM,48000.0,IC50,uM,48.0,Nc1nc(O)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,2007
Inhibition of recombinant PI3Kgamma,Oc1cccc(-c2nc3nc(O)nc(O)c3nc2-c2cccc(O)c2)c1,CHEMBL1148756,=,=,IC50,nM,46000.0,IC50,uM,46.0,Oc1cccc(-c2nc3nc(O)nc(O)c3nc2-c2cccc(O)c2)c1,2007
Inhibition of recombinant PI3Kgamma,Nc1ccc2nc(-c3ccc(O)cc3)c(-c3ccc(O)cc3)nc2n1,CHEMBL1148756,,,Activity,,,Activity,,,Nc1ccc2nc(-c3ccc(O)cc3)c(-c3ccc(O)cc3)nc2n1,2007
Inhibition of recombinant PI3Kgamma,Oc1cccc(-c2nc3cncnc3nc2-c2cccc(O)c2)c1,CHEMBL1148756,=,=,IC50,nM,9000.0,IC50,uM,9.0,Oc1cccc(-c2nc3cncnc3nc2-c2cccc(O)c2)c1,2007
Inhibition of recombinant PI3Kgamma,Nc1ccc2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2c1,CHEMBL1148756,=,=,IC50,nM,17000.0,IC50,uM,17.0,Nc1ccc2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2c1,2007
Inhibition of recombinant PI3Kgamma,Nc1nc(N)c2nc(-c3ccc(O)c(O)c3)c(-c3ccc(O)c(O)c3)nc2n1,CHEMBL1148756,=,=,IC50,nM,273.0,IC50,uM,0.273,Nc1nc(N)c2nc(-c3ccc(O)c(O)c3)c(-c3ccc(O)c(O)c3)nc2n1,2007
Inhibition of recombinant PI3Kgamma,Nc1ncnc2nc(-c3ccc(O)cc3)c(-c3ccc(O)cc3)nc12,CHEMBL1148756,=,=,IC50,nM,4000.0,IC50,uM,4.0,Nc1ncnc2nc(-c3ccc(O)cc3)c(-c3ccc(O)cc3)nc12,2007
Inhibition of recombinant PI3Kgamma,Nc1cncc2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc12,CHEMBL1148756,,,Activity,,,Activity,,,Nc1cncc2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc12,2007
Inhibition of recombinant PI3Kgamma,Nc1cncc2nc(-c3ccc(O)cc3)c(-c3ccc(O)cc3)nc12,CHEMBL1148756,,,Activity,,,Activity,,,Nc1cncc2nc(-c3ccc(O)cc3)c(-c3ccc(O)cc3)nc12,2007
Inhibition of recombinant PI3Kgamma,Nc1ccc2nc(-c3ccc(O)c(O)c3)c(-c3ccc(O)c(O)c3)nc2n1,CHEMBL1148756,,,Activity,,,Activity,,,Nc1ccc2nc(-c3ccc(O)c(O)c3)c(-c3ccc(O)c(O)c3)nc2n1,2007
Inhibition of recombinant PI3Kgamma,CCOP(=O)(OCC)Oc1cccc(-c2nc3nc(N)nc(N)c3nc2-c2cccc(OP(=O)(OCC)OCC)c2)c1,CHEMBL1148756,,,Activity,,,Activity,,,CCOP(=O)(OCC)Oc1cccc(-c2nc3nc(N)nc(N)c3nc2-c2cccc(OP(=O)(OCC)OCC)c2)c1,2007
Inhibition of recombinant PI3Kgamma,CCN(CC)CCOc1cccc(-c2nc3nc(N)nc(N)c3nc2-c2cccc(OCCN(CC)CC)c2)c1,CHEMBL1148756,,,Activity,,,Activity,,,CCN(CC)CCOc1cccc(-c2nc3nc(N)nc(N)c3nc2-c2cccc(OCCN(CC)CC)c2)c1,2007
Inhibition of recombinant PI3Kgamma,Oc1cccc(-c2nc3nc(NCCCN4CCOCC4)nc(NCCCN4CCOCC4)c3nc2-c2cccc(O)c2)c1,CHEMBL1148756,,,Activity,,,Activity,,,Oc1cccc(-c2nc3nc(NCCCN4CCOCC4)nc(NCCCN4CCOCC4)c3nc2-c2cccc(O)c2)c1,2007
Inhibition of recombinant PI3Kgamma,Nc1ccc2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,CHEMBL1148756,,,Activity,,,Activity,,,Nc1ccc2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,CHEMBL1138417,=,=,IC50,nM,19.0,IC50,nM,19.0,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(F)c(F)c1)C(=O)CO2,CHEMBL1138417,=,=,IC50,nM,4.84,IC50,nM,4.84,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(F)c(F)c1)C(=O)CO2,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,COc1cccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,CHEMBL1138417,=,=,IC50,nM,2.66,IC50,nM,2.66,COc1cccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,Cc1cccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,CHEMBL1138417,=,=,IC50,nM,4.96,IC50,nM,4.96,Cc1cccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Cl)cc1Cl)C(=O)CO2,CHEMBL1138417,=,=,IC50,nM,4.28,IC50,nM,4.28,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Cl)cc1Cl)C(=O)CO2,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(C(F)(F)F)cc1)C(=O)CO2,CHEMBL1138417,=,=,IC50,nM,1.92,IC50,nM,1.92,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(C(F)(F)F)cc1)C(=O)CO2,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,CC(C)(C)c1ccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,CHEMBL1138417,=,=,IC50,nM,33.2,IC50,nM,33.2,CC(C)(C)c1ccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Cl)c(Cl)c1)C(=O)CO2,CHEMBL1138417,=,=,IC50,nM,4.36,IC50,nM,4.36,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Cl)c(Cl)c1)C(=O)CO2,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1cccc(Cl)c1)C(=O)CO2,CHEMBL1138417,=,=,IC50,nM,4.27,IC50,nM,4.27,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1cccc(Cl)c1)C(=O)CO2,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Br)cc1)C(=O)CO2,CHEMBL1138417,=,=,IC50,nM,2.34,IC50,nM,2.34,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Br)cc1)C(=O)CO2,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,Cc1ccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,CHEMBL1138417,=,=,IC50,nM,8.83,IC50,nM,8.83,Cc1ccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,COc1ccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,CHEMBL1138417,=,=,IC50,nM,6.57,IC50,nM,6.57,COc1ccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Cl)cc1)C(=O)CO2,CHEMBL1138417,=,=,IC50,nM,4.76,IC50,nM,4.76,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Cl)cc1)C(=O)CO2,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,COc1cc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc(OC)c1,CHEMBL1138417,=,=,IC50,nM,2.79,IC50,nM,2.79,COc1cc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc(OC)c1,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,Cc1cc(C)cc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,CHEMBL1138417,=,=,IC50,nM,2.65,IC50,nM,2.65,Cc1cc(C)cc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccccc1)C(=O)CO2,CHEMBL1138417,=,=,IC50,nM,24.5,IC50,nM,24.5,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccccc1)C(=O)CO2,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,Cc1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1C,CHEMBL1138417,=,=,IC50,nM,2.59,IC50,nM,2.59,Cc1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1C,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,Cc1cccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,CHEMBL1138417,=,=,IC50,nM,43.7,IC50,nM,43.7,Cc1cccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(Cc1ccc(C(F)(F)F)cc1)C(=O)CO2,CHEMBL1138417,=,=,IC50,nM,27.5,IC50,nM,27.5,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(Cc1ccc(C(F)(F)F)cc1)C(=O)CO2,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,N#Cc1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,CHEMBL1138417,=,=,IC50,nM,36.1,IC50,nM,36.1,N#Cc1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(Cc1ccc(Cl)cc1)C(=O)CO2,CHEMBL1138417,=,=,IC50,nM,7.16,IC50,nM,7.16,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(Cc1ccc(Cl)cc1)C(=O)CO2,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,CC(C)(C)c1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,CHEMBL1138417,=,=,IC50,nM,2.42,IC50,nM,2.42,CC(C)(C)c1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,Cc1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,CHEMBL1138417,=,=,IC50,nM,29.5,IC50,nM,29.5,Cc1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(Cc1ccccc1)C(=O)CO2,CHEMBL1138417,=,=,IC50,nM,23.0,IC50,nM,23.0,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(Cc1ccccc1)C(=O)CO2,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,COc1cc(O)cc(/C=C2\SC(=S)NC2=O)c1,CHEMBL1138417,=,=,IC50,nM,77.7,IC50,nM,77.7,COc1cc(O)cc(/C=C2\SC(=S)NC2=O)c1,2007
Inhibition of PI3Kgamma assessed as inhibition of 32P-PIP3 formation,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL1138417,=,=,IC50,nM,1720.0,IC50,nM,1720.0,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2007
Inhibition of PI3K p110gamma,N#CCc1ccc(-n2cnc3cnc4ccc(C#Cc5cccnc5)cc4c32)cc1,CHEMBL1142269,=,=,IC50,nM,67.0,IC50,nM,67.0,N#CCc1ccc(-n2cnc3cnc4ccc(C#Cc5cccnc5)cc4c32)cc1,2008
Inhibition of PI3K p110gamma,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(C#Cc4cccnc4)ccc3ncc21,CHEMBL1142269,=,=,IC50,nM,382.0,IC50,nM,382.0,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(C#Cc4cccnc4)ccc3ncc21,2008
Inhibition of PI3K p110gamma,Cc1nc2cnc3ccc(C#Cc4cccnc4)cc3c2n1-c1ccc(C(C)C#N)cc1,CHEMBL1142269,=,=,IC50,nM,117.0,IC50,nM,117.0,Cc1nc2cnc3ccc(C#Cc4cccnc4)cc3c2n1-c1ccc(C(C)C#N)cc1,2008
Inhibition of PI3Kgamma,COC[C@H]1OC(=O)/C(=C/N(C)CCCN(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C,CHEMBL1143164,=,=,IC50,nM,8000.0,IC50,uM,8.0,COC[C@H]1OC(=O)/C(=C/N(C)CCCN(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C,2008
Inhibition of p110gamma PI kinase,Cl.Oc1cccc(-c2nc(N3CCOCC3)c3sccc3n2)c1,CHEMBL1145498,=,=,IC50,nM,660.0,IC50,nM,660.0,Cl.Oc1cccc(-c2nc(N3CCOCC3)c3sccc3n2)c1,2007
Activity of human PI 3-kinase gamma at 1 uM,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,CHEMBL1147076,=,=,Activity,%,106.0,Activity,%,106.0,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,2007
Inhibition of human PI3-Kgamma at 1 uM,CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1,CHEMBL1156453,=,=,Inhibition,%,0.0,INH,%,0.0,CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1,2007
Inhibition of PI3Kgamma,Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,CHEMBL1141705,=,=,IC50,nM,78.0,IC50,nM,78.0,Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,2008
Inhibition of PI3Kgamma,Cc1ccc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,CHEMBL1141705,=,=,IC50,nM,107.0,IC50,nM,107.0,Cc1ccc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,2008
Inhibition of PI3Kgamma,CC1(C)Cc2nc(N3CCOc4ccc(-c5cn[nH]c5)cc43)sc2C(=O)N1,CHEMBL1141705,=,=,IC50,nM,22.0,IC50,nM,22.0,CC1(C)Cc2nc(N3CCOc4ccc(-c5cn[nH]c5)cc43)sc2C(=O)N1,2008
Inhibition of PI3Kgamma,Cc1n[nH]c(C)c1-c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,CHEMBL1141705,=,=,IC50,nM,201.0,IC50,nM,201.0,Cc1n[nH]c(C)c1-c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,2008
Inhibition of PI3Kgamma,CC(C)(O)Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,CHEMBL1141705,=,=,IC50,nM,50.0,IC50,nM,50.0,CC(C)(O)Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,2008
Inhibition of PI3Kgamma,Cc1nn(CC(C)(C)O)c(C)c1-c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,CHEMBL1141705,=,=,IC50,nM,257.0,IC50,nM,257.0,Cc1nn(CC(C)(C)O)c(C)c1-c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,2008
Inhibition of PI3Kgamma,CCn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,CHEMBL1141705,=,=,IC50,nM,70.0,IC50,nM,70.0,CCn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,2008
Inhibition of PI3Kgamma,CCn1nc(C)c(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)c1C,CHEMBL1141705,=,=,IC50,nM,180.0,IC50,nM,180.0,CCn1nc(C)c(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)c1C,2008
Inhibition of PI3Kgamma,COCC(O)Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,CHEMBL1141705,=,=,IC50,nM,52.0,IC50,nM,52.0,COCC(O)Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,2008
Inhibition of PI3Kgamma,CN(C)CCCn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,CHEMBL1141705,=,=,IC50,nM,767.0,IC50,nM,767.0,CN(C)CCCn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,2008
Inhibition of PI3Kgamma,Cc1nn(C)c(C)c1-c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,CHEMBL1141705,=,=,IC50,nM,327.0,IC50,nM,327.0,Cc1nn(C)c(C)c1-c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,2008
Inhibition of PI3Kgamma,CC1(C)Cc2nc(N3CCOc4ccc(-c5cnn(Cc6ccccc6)c5)cc43)sc2C(=O)N1,CHEMBL1141705,=,=,IC50,nM,48.0,IC50,nM,48.0,CC1(C)Cc2nc(N3CCOc4ccc(-c5cnn(Cc6ccccc6)c5)cc43)sc2C(=O)N1,2008
Inhibition of PI3Kgamma,CC1(C)Cc2nc(N3CCOc4ccc(-c5cnn(Cc6cccnc6)c5)cc43)sc2C(=O)N1,CHEMBL1141705,=,=,IC50,nM,35.0,IC50,nM,35.0,CC1(C)Cc2nc(N3CCOc4ccc(-c5cnn(Cc6cccnc6)c5)cc43)sc2C(=O)N1,2008
Inhibition of PI3Kgamma,Cc1nn(C)cc1-c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,CHEMBL1141705,=,=,IC50,nM,18.0,IC50,nM,18.0,Cc1nn(C)cc1-c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,2008
Inhibition of PI3Kgamma,CC1(C)Cc2nc(N3CCOc4ccc(-c5cnn(CCN)c5)cc43)sc2C(=O)N1,CHEMBL1141705,=,=,IC50,nM,131.0,IC50,nM,131.0,CC1(C)Cc2nc(N3CCOc4ccc(-c5cnn(CCN)c5)cc43)sc2C(=O)N1,2008
Inhibition of PI3Kgamma,Cc1nn(CCCN)cc1-c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,CHEMBL1141705,=,=,IC50,nM,51.0,IC50,nM,51.0,Cc1nn(CCCN)cc1-c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,2008
Inhibition of PI3Kgamma,Cn1ncc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)c1N,CHEMBL1141705,=,=,IC50,nM,70.0,IC50,nM,70.0,Cn1ncc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)c1N,2008
Inhibition of PI3Kgamma,COC[C@@H](O)Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,CHEMBL1141705,=,=,IC50,nM,46.0,IC50,nM,46.0,COC[C@@H](O)Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,2008
Inhibition of PI3Kgamma,COC[C@H](O)Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,CHEMBL1141705,=,=,IC50,nM,51.0,IC50,nM,51.0,COC[C@H](O)Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,2008
Inhibition of PI3Kgamma,CC1(C)Cc2nc(N3CCOc4ccc(Nc5ccc(N6CCNCC6)nn5)cc43)sc2C(=O)N1,CHEMBL1141705,=,=,IC50,nM,34.0,IC50,nM,34.0,CC1(C)Cc2nc(N3CCOc4ccc(Nc5ccc(N6CCNCC6)nn5)cc43)sc2C(=O)N1,2008
Inhibition of PI3Kgamma,CN1CCN(c2ccc(Nc3ccc4c(c3)N(c3nc5c(s3)C(=O)NC(C)(C)C5)CCO4)nn2)CC1,CHEMBL1141705,=,=,IC50,nM,35.0,IC50,nM,35.0,CN1CCN(c2ccc(Nc3ccc4c(c3)N(c3nc5c(s3)C(=O)NC(C)(C)C5)CCO4)nn2)CC1,2008
Inhibition of PI3Kgamma,Cc1cc(C)c(Nc2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,CHEMBL1141705,=,=,IC50,nM,203.0,IC50,nM,203.0,Cc1cc(C)c(Nc2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,2008
Inhibition of PI3Kgamma,Cc1ccc(Nc2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,CHEMBL1141705,=,=,IC50,nM,20.0,IC50,nM,20.0,Cc1ccc(Nc2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,2008
Inhibition of PI3Kgamma,CN(C)c1ccc(Nc2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,CHEMBL1141705,=,=,IC50,nM,24.0,IC50,nM,24.0,CN(C)c1ccc(Nc2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,2008
Inhibition of PI3Kgamma,COc1ccc(Nc2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,CHEMBL1141705,=,=,IC50,nM,20.0,IC50,nM,20.0,COc1ccc(Nc2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,2008
Inhibition of PI3Kgamma,CC1(C)Cc2nc(N3CCOc4ccc(Nc5ccc(-c6ccccc6)nn5)cc43)sc2C(=O)N1,CHEMBL1141705,=,=,IC50,nM,34.0,IC50,nM,34.0,CC1(C)Cc2nc(N3CCOc4ccc(Nc5ccc(-c6ccccc6)nn5)cc43)sc2C(=O)N1,2008
Inhibition of PI3Kgamma,CC1(C)Cc2nc(N3CCOc4ccc(-c5ccc(N6CCNCC6)nn5)cc43)sc2C(=O)N1,CHEMBL1141705,=,=,IC50,nM,767.0,IC50,nM,767.0,CC1(C)Cc2nc(N3CCOc4ccc(-c5ccc(N6CCNCC6)nn5)cc43)sc2C(=O)N1,2008
Inhibition of PI3Kgamma,CN1CCN(c2ccc(-c3ccc4c(c3)N(c3nc5c(s3)C(=O)NC(C)(C)C5)CCO4)nn2)CC1,CHEMBL1141705,=,=,IC50,nM,1288.0,IC50,nM,1288.0,CN1CCN(c2ccc(-c3ccc4c(c3)N(c3nc5c(s3)C(=O)NC(C)(C)C5)CCO4)nn2)CC1,2008
Inhibition of PI3Kgamma,CN(C)c1ccc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,CHEMBL1141705,=,=,IC50,nM,138.0,IC50,nM,138.0,CN(C)c1ccc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,2008
Inhibition of PI3Kgamma,COc1ccc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,CHEMBL1141705,=,=,IC50,nM,222.0,IC50,nM,222.0,COc1ccc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,2008
Inhibition of PI3Kgamma,CC1(C)Cc2nc(N3CCOc4ccc(-c5ccc(N)nn5)cc43)sc2C(=O)N1,CHEMBL1141705,=,=,IC50,nM,174.0,IC50,nM,174.0,CC1(C)Cc2nc(N3CCOc4ccc(-c5ccc(N)nn5)cc43)sc2C(=O)N1,2008
Inhibition of human PI3Kgamma,C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F,CHEMBL1153318,=,=,IC50,nM,390.0,IC50,nM,390.0,C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F,2009
Inhibition of GST tagged human recombinant PI3K p110gamma/p85-alpha by radiometric scintillation proximity assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL1140078,=,=,IC50,nM,75.0,IC50,uM,0.075,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2008
Inhibition of human recombinant PI3Kgamma catalytic domain,Cn1c(=O)n(Cc2ccccc2)c(=O)c2c1nc(SCCO)n2Cc1ccccc1,CHEMBL1140099,=,=,IC50,nM,25000.0,IC50,uM,25.0,Cn1c(=O)n(Cc2ccccc2)c(=O)c2c1nc(SCCO)n2Cc1ccccc1,2008
Inhibition of PIK3CG at 1 uM relative to control,COc1ccc(/C=N/Nc2[nH]nc(C)c2C(=O)Nc2cccc(NC(C)=O)c2)cc1,CHEMBL1140919,=,=,Inhibition,%,-3.0,INH,%,-3.0,COc1ccc(/C=N/Nc2[nH]nc(C)c2C(=O)Nc2cccc(NC(C)=O)c2)cc1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1OCc1cc(C(=O)NCCO)cc(N2CCOCC2)n1,CHEMBL1153990,>=,>=,IC50,nM,50000.0,IC50,uM,50.0,Cc1cc(F)ccc1OCc1cc(C(=O)NCCO)cc(N2CCOCC2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1OCc1cc(C(=O)NO)cc(N2CCOCC2)n1,CHEMBL1153990,=,=,IC50,nM,10000.0,IC50,uM,10.0,Cc1cc(F)ccc1OCc1cc(C(=O)NO)cc(N2CCOCC2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1OCc1cc(C(N)=O)cc(N2CCOCC2)n1,CHEMBL1153990,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cc(F)ccc1OCc1cc(C(N)=O)cc(N2CCOCC2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,CCOC(=O)c1cc(COc2ccc(F)cc2C)nc(N2CCOCC2)c1,CHEMBL1153990,<,<,IC50,nM,10000.0,IC50,uM,10.0,CCOC(=O)c1cc(COc2ccc(F)cc2C)nc(N2CCOCC2)c1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1OCc1cc(C(=O)O)cc(N2CCOCC2)n1,CHEMBL1153990,=,=,IC50,nM,23000.0,IC50,uM,23.0,Cc1cc(F)ccc1OCc1cc(C(=O)O)cc(N2CCOCC2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,CCOC(=O)c1cc(CNc2ccc(F)cc2C)nc(N2CCOCC2)c1,CHEMBL1153990,<,<,IC50,nM,10000.0,IC50,uM,10.0,CCOC(=O)c1cc(CNc2ccc(F)cc2C)nc(N2CCOCC2)c1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(CO)cc(N2CCOCC2)n1,CHEMBL1153990,>=,>=,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(CO)cc(N2CCOCC2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C=O)cc(N2CCOCC2)n1,CHEMBL1153990,=,=,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C=O)cc(N2CCOCC2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N2CCOCC2)n1,CHEMBL1153990,=,=,IC50,nM,34000.0,IC50,uM,34.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N2CCOCC2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N2CCNCC2)n1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N2CCNCC2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N2CCCCC2)n1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N2CCCCC2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N2CCCC2)n1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N2CCCC2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N2CCC(O)C2)n1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N2CCC(O)C2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N(C)CCO)n1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N(C)CCO)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(NCCO)n1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(NCCO)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N(CCO)CCO)n1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(N(CCO)CCO)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(-c2ccncc2)n1,CHEMBL1153990,=,=,IC50,nM,42000.0,IC50,uM,42.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(-c2ccncc2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(-c2cccnc2)n1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(-c2cccnc2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(-c2ccc(O)cc2)n1,CHEMBL1153990,=,=,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(-c2ccc(O)cc2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(-c2cccc(O)c2)n1,CHEMBL1153990,=,=,IC50,nM,42000.0,IC50,uM,42.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(-c2cccc(O)c2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(-c2ccccc2O)n1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(-c2ccccc2O)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(Cl)n1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C(=O)O)cc(Cl)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)NCCO)cc(NCCO)n1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C(=O)NCCO)cc(NCCO)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,Cc1cc(F)ccc1NCc1cc(C(=O)N2CCC(O)C2)cc(N2CCC(O)C2)n1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(F)ccc1NCc1cc(C(=O)N2CCC(O)C2)cc(N2CCC(O)C2)n1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,O=C(O)c1ccnc(N2CCOCC2)c1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,O=C(O)c1ccnc(N2CCOCC2)c1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,CCOC(=O)c1ccnc(N2CCOCC2)c1,CHEMBL1153990,>,>,IC50,nM,100000.0,IC50,uM,100.0,CCOC(=O)c1ccnc(N2CCOCC2)c1,2009
Inhibition of PI3Kgamma by luminescent kinase glo assay,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL1153990,=,=,IC50,nM,1200.0,IC50,uM,1.2,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2009
Inhibition of PIK3CG at 3 uM,CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1,CHEMBL1142492,<,<,Inhibition,%,10.0,INH,%,10.0,CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1,2008
Inhibition of PI3Kgamma,CC1(C)CC(=O)c2sc(N3CCOCC3)nc2C1,CHEMBL1155863,=,=,IC50,nM,3453.0,IC50,nM,3453.0,CC1(C)CC(=O)c2sc(N3CCOCC3)nc2C1,2008
Inhibition of PI3Kgamma,CC1(C)CC(=O)c2sc(N3CCOC[C@@H]3Cc3csc4ccccc34)nc2C1,CHEMBL1155863,=,=,IC50,nM,223.0,IC50,nM,223.0,CC1(C)CC(=O)c2sc(N3CCOC[C@@H]3Cc3csc4ccccc34)nc2C1,2008
Inhibition of PI3Kgamma,CC1(C)CC(=O)c2sc(N3CCOCC3Cc3c[nH]c4ncccc34)nc2C1,CHEMBL1155863,=,=,IC50,nM,63.0,IC50,nM,63.0,CC1(C)CC(=O)c2sc(N3CCOCC3Cc3c[nH]c4ncccc34)nc2C1,2008
Inhibition of PI3Kgamma,CC1(C)CC(=O)c2sc(N3CCOC[C@@H]3Cc3c[nH]c4ccccc34)nc2C1,CHEMBL1155863,=,=,IC50,nM,49.0,IC50,nM,49.0,CC1(C)CC(=O)c2sc(N3CCOC[C@@H]3Cc3c[nH]c4ccccc34)nc2C1,2008
Inhibition of PI3Kgamma,CC1(C)CC(=O)c2sc(N3CCOC[C@H]3Cc3c[nH]c4ccccc34)nc2C1,CHEMBL1155863,=,=,IC50,nM,3506.0,IC50,nM,3506.0,CC1(C)CC(=O)c2sc(N3CCOC[C@H]3Cc3c[nH]c4ccccc34)nc2C1,2008
Inhibition of PI3Kgamma,CC1(C)CC(=O)c2sc(N3CCOCC3Cc3ccc4ccccc4c3)nc2C1,CHEMBL1155863,=,=,IC50,nM,1674.0,IC50,nM,1674.0,CC1(C)CC(=O)c2sc(N3CCOCC3Cc3ccc4ccccc4c3)nc2C1,2008
Inhibition of PI3Kgamma,CC1(C)CC(=O)c2sc(N3CCOCC3Cc3cccc4ccccc34)nc2C1,CHEMBL1155863,=,=,IC50,nM,386.0,IC50,nM,386.0,CC1(C)CC(=O)c2sc(N3CCOCC3Cc3cccc4ccccc34)nc2C1,2008
Inhibition of PI3Kgamma,CC1(C)CC(=O)c2sc(N3CCOC[C@@H]3Cc3ccccc3)nc2C1,CHEMBL1155863,=,=,IC50,nM,2076.0,IC50,nM,2076.0,CC1(C)CC(=O)c2sc(N3CCOC[C@@H]3Cc3ccccc3)nc2C1,2008
Inhibition of PI3Kgamma,CC1(C)CC(=O)c2sc(N3CCOC[C@H]3Cc3ccccc3)nc2C1,CHEMBL1155863,>,>,IC50,nM,50000.0,IC50,nM,50000.0,CC1(C)CC(=O)c2sc(N3CCOC[C@H]3Cc3ccccc3)nc2C1,2008
Inhibition of PI3Kgamma,CC1(C)CC(=O)c2sc(N3CCOC[C@@H]3c3ccccc3)nc2C1,CHEMBL1155863,>,>,IC50,nM,50000.0,IC50,nM,50000.0,CC1(C)CC(=O)c2sc(N3CCOC[C@@H]3c3ccccc3)nc2C1,2008
Inhibition of PI3Kgamma,CC1(C)CC(=O)c2sc(N3CCOC[C@H]3c3ccccc3)nc2C1,CHEMBL1155863,>,>,IC50,nM,50000.0,IC50,nM,50000.0,CC1(C)CC(=O)c2sc(N3CCOC[C@H]3c3ccccc3)nc2C1,2008
Inhibition of PI3Kgamma,CC1(C)CC(=O)c2sc(-c3ccncc3)nc2C1,CHEMBL1155863,=,=,IC50,nM,35730.0,IC50,nM,35730.0,CC1(C)CC(=O)c2sc(-c3ccncc3)nc2C1,2008
Inhibition of PI3Kgamma,COCCNc1nc2c(s1)C(=O)CC(C)(C)C2,CHEMBL1155863,>,>,IC50,nM,40000.0,IC50,nM,40000.0,COCCNc1nc2c(s1)C(=O)CC(C)(C)C2,2008
Inhibition of PI3Kgamma,CC1(C)CC(=O)c2sc(N3CCCCC3)nc2C1,CHEMBL1155863,>,>,IC50,nM,40000.0,IC50,nM,40000.0,CC1(C)CC(=O)c2sc(N3CCCCC3)nc2C1,2008
Inhibition of PI3Kgamma,O=C1CC2(CCCCC2)Cc2nc(N3CCOCC3)sc21,CHEMBL1155863,=,=,IC50,nM,6259.0,IC50,nM,6259.0,O=C1CC2(CCCCC2)Cc2nc(N3CCOCC3)sc21,2008
Inhibition of PI3Kgamma,O=C1CC2(CCCC2)Cc2nc(N3CCOCC3)sc21,CHEMBL1155863,=,=,IC50,nM,16060.0,IC50,nM,16060.0,O=C1CC2(CCCC2)Cc2nc(N3CCOCC3)sc21,2008
Inhibition of PI3Kgamma,O=C1CCCc2nc(N3CCOCC3)sc21,CHEMBL1155863,=,=,IC50,nM,16670.0,IC50,nM,16670.0,O=C1CCCc2nc(N3CCOCC3)sc21,2008
Inhibition of PI3Kgamma,O=C1CC(c2ccccc2)Cc2nc(N3CCOCC3)sc21,CHEMBL1155863,>,>,IC50,nM,40000.0,IC50,nM,40000.0,O=C1CC(c2ccccc2)Cc2nc(N3CCOCC3)sc21,2008
Inhibition of PI3Kgamma,CCCC1CC(=O)c2sc(N3CCOCC3)nc2C1,CHEMBL1155863,=,=,IC50,nM,19790.0,IC50,nM,19790.0,CCCC1CC(=O)c2sc(N3CCOCC3)nc2C1,2008
Inhibition of PI3Kgamma,CC1CC(=O)c2sc(N3CCOCC3)nc2C1,CHEMBL1155863,=,=,IC50,nM,16700.0,IC50,nM,16700.0,CC1CC(=O)c2sc(N3CCOCC3)nc2C1,2008
Inhibition of PI3Kgamma,CC1(C)CNC(=O)c2sc(N3CCOC[C@@H]3Cc3c[nH]c4ccccc34)nc2C1,CHEMBL1155863,=,=,IC50,nM,31.0,IC50,nM,31.0,CC1(C)CNC(=O)c2sc(N3CCOC[C@@H]3Cc3c[nH]c4ccccc34)nc2C1,2008
Inhibition of PI3K gamma,CC1(C)CC(=O)c2sc(N3CCOCC3)nc2C1,CHEMBL1155924,=,=,IC50,nM,1660.0,IC50,nM,1660.0,CC1(C)CC(=O)c2sc(N3CCOCC3)nc2C1,2008
Inhibition of PI3K gamma,CC1(C)CC(=O)c2sc(N3CCOc4ccc(-c5ccccc5)cc43)nc2C1,CHEMBL1155924,=,=,IC50,nM,854.0,IC50,nM,854.0,CC1(C)CC(=O)c2sc(N3CCOc4ccc(-c5ccccc5)cc43)nc2C1,2008
Inhibition of PI3K gamma,CC1(C)CC(=O)c2sc(N3CCOc4ccc(Br)cc43)nc2C1,CHEMBL1155924,=,=,IC50,nM,829.0,IC50,nM,829.0,CC1(C)CC(=O)c2sc(N3CCOc4ccc(Br)cc43)nc2C1,2008
Inhibition of PI3K gamma,CC1(C)Cc2nc(N3CCOc4ccc(Br)cc43)sc2C(=O)N1,CHEMBL1155924,=,=,IC50,nM,321.0,IC50,nM,321.0,CC1(C)Cc2nc(N3CCOc4ccc(Br)cc43)sc2C(=O)N1,2008
Inhibition of PI3K gamma,Cc1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,CHEMBL1155924,=,=,IC50,nM,617.0,IC50,nM,617.0,Cc1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,2008
Inhibition of PI3K gamma,COc1ccc2c(c1)OCCN2c1nc2c(s1)C(=O)NC(C)(C)C2,CHEMBL1155924,=,=,IC50,nM,440.0,IC50,nM,440.0,COc1ccc2c(c1)OCCN2c1nc2c(s1)C(=O)NC(C)(C)C2,2008
Inhibition of PI3K gamma,Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)CC(C)(C)C4)CCO3)cn1,CHEMBL1155924,=,=,IC50,nM,52.0,IC50,nM,52.0,Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)CC(C)(C)C4)CCO3)cn1,2008
Inhibition of PI3K gamma,Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,CHEMBL1155924,=,=,IC50,nM,78.0,IC50,nM,78.0,Cn1cc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,2008
Inhibition of PI3K gamma,Cn1ccnc1-c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,CHEMBL1155924,=,=,IC50,nM,819.0,IC50,nM,819.0,Cn1ccnc1-c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,2008
Inhibition of PI3K gamma,Cc1nc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)c[nH]1,CHEMBL1155924,=,=,IC50,nM,107.0,IC50,nM,107.0,Cc1nc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)c[nH]1,2008
Inhibition of PI3K gamma,CC1(C)Cc2nc(N3CCOc4ccc(-c5ccn[nH]5)cc43)sc2C(=O)N1,CHEMBL1155924,=,=,IC50,nM,145.0,IC50,nM,145.0,CC1(C)Cc2nc(N3CCOc4ccc(-c5ccn[nH]5)cc43)sc2C(=O)N1,2008
Inhibition of PI3K gamma,CC1(C)CC(=O)c2sc(N3CCOc4ccc(-c5cn[nH]c5)cc43)nc2C1,CHEMBL1155924,=,=,IC50,nM,77.0,IC50,nM,77.0,CC1(C)CC(=O)c2sc(N3CCOc4ccc(-c5cn[nH]c5)cc43)nc2C1,2008
Inhibition of PI3K gamma,CC1(C)Cc2nc(N3CCOc4ccc(-c5cn[nH]c5)cc43)sc2C(=O)N1,CHEMBL1155924,=,=,IC50,nM,22.0,IC50,nM,22.0,CC1(C)Cc2nc(N3CCOc4ccc(-c5cn[nH]c5)cc43)sc2C(=O)N1,2008
Inhibition of PI3K gamma,CC1(C)Cc2nc(N3CCOc4ccc(-c5cnc[nH]5)cc43)sc2C(=O)N1,CHEMBL1155924,=,=,IC50,nM,163.0,IC50,nM,163.0,CC1(C)Cc2nc(N3CCOc4ccc(-c5cnc[nH]5)cc43)sc2C(=O)N1,2008
Inhibition of PI3K gamma,Cc1ccc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,CHEMBL1155924,=,=,IC50,nM,107.0,IC50,nM,107.0,Cc1ccc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)nn1,2008
Inhibition of PI3K gamma,CC1(C)Cc2nc(N3CCOc4ccc(-c5ncccn5)cc43)sc2C(=O)N1,CHEMBL1155924,=,=,IC50,nM,189.0,IC50,nM,189.0,CC1(C)Cc2nc(N3CCOc4ccc(-c5ncccn5)cc43)sc2C(=O)N1,2008
Inhibition of PI3K gamma,Cc1ccc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)CC(C)(C)C4)CCO3)cn1,CHEMBL1155924,=,=,IC50,nM,73.0,IC50,nM,73.0,Cc1ccc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)CC(C)(C)C4)CCO3)cn1,2008
Inhibition of PI3K gamma,Cc1ccc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,CHEMBL1155924,=,=,IC50,nM,28.0,IC50,nM,28.0,Cc1ccc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1,2008
Inhibition of PI3K gamma,CC1(C)CC(=O)c2sc(N3CCOc4ccc(-c5ccncc5)cc43)nc2C1,CHEMBL1155924,=,=,IC50,nM,159.0,IC50,nM,159.0,CC1(C)CC(=O)c2sc(N3CCOc4ccc(-c5ccncc5)cc43)nc2C1,2008
Inhibition of PI3K gamma,CC1(C)CC(=O)c2sc(N3CCOc4ccc(-c5cccnc5)cc43)nc2C1,CHEMBL1155924,=,=,IC50,nM,113.0,IC50,nM,113.0,CC1(C)CC(=O)c2sc(N3CCOc4ccc(-c5cccnc5)cc43)nc2C1,2008
Inhibition of PI3K gamma,CC1(C)CC(=O)c2sc(N3CCOc4ccc(-c5ccccn5)cc43)nc2C1,CHEMBL1155924,=,=,IC50,nM,258.0,IC50,nM,258.0,CC1(C)CC(=O)c2sc(N3CCOc4ccc(-c5ccccn5)cc43)nc2C1,2008
Inhibition of PI3K gamma,CC1(C)CC(=O)c2sc(N3CCOc4ncccc43)nc2C1,CHEMBL1155924,=,=,IC50,nM,6654.0,IC50,nM,6654.0,CC1(C)CC(=O)c2sc(N3CCOc4ncccc43)nc2C1,2008
Inhibition of PI3K gamma,CC1(C)Cc2nc(N3CCOc4ncccc43)sc2C(=O)N1,CHEMBL1155924,,,IC50,,,IC50,,,CC1(C)Cc2nc(N3CCOc4ncccc43)sc2C(=O)N1,2008
Inhibition of PI3K gamma,CN(C)Cc1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,CHEMBL1155924,>,>,IC50,nM,20000.0,IC50,nM,20000.0,CN(C)Cc1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,2008
Inhibition of PI3K gamma,CC1(C)Cc2nc(N3CCOc4ccc(C5CC5)cc43)sc2C(=O)N1,CHEMBL1155924,=,=,IC50,nM,210.0,IC50,nM,210.0,CC1(C)Cc2nc(N3CCOc4ccc(C5CC5)cc43)sc2C(=O)N1,2008
Inhibition of PI3K gamma,CC1(C)Cc2nc(N3CCOc4ccc(-c5ccccc5)cc43)sc2C(=O)N1,CHEMBL1155924,=,=,IC50,nM,80.0,IC50,nM,80.0,CC1(C)Cc2nc(N3CCOc4ccc(-c5ccccc5)cc43)sc2C(=O)N1,2008
Inhibition of PI3K gamma,CC1(C)CC(=O)c2sc(N3CCOc4cc(-c5ccccc5)ccc43)nc2C1,CHEMBL1155924,>,>,IC50,nM,20000.0,IC50,nM,20000.0,CC1(C)CC(=O)c2sc(N3CCOc4cc(-c5ccccc5)ccc43)nc2C1,2008
Inhibition of PI3K gamma,CC(=O)c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,CHEMBL1155924,=,=,IC50,nM,318.0,IC50,nM,318.0,CC(=O)c1ccc2c(c1)N(c1nc3c(s1)C(=O)NC(C)(C)C3)CCO2,2008
Inhibition of PI3K gamma,CC1(C)CC(=O)c2sc(N3CCOc4cc(Br)ccc43)nc2C1,CHEMBL1155924,=,=,IC50,nM,3130.0,IC50,nM,3130.0,CC1(C)CC(=O)c2sc(N3CCOc4cc(Br)ccc43)nc2C1,2008
Inhibition of PI3K gamma,Cc1ccc2c(c1)OCCN2c1nc2c(s1)C(=O)NC(C)(C)C2,CHEMBL1155924,=,=,IC50,nM,531.0,IC50,nM,531.0,Cc1ccc2c(c1)OCCN2c1nc2c(s1)C(=O)NC(C)(C)C2,2008
Inhibition of PI3K gamma,CC1(C)Cc2nc(N3CCOc4cc(F)ccc43)sc2C(=O)N1,CHEMBL1155924,=,=,IC50,nM,357.0,IC50,nM,357.0,CC1(C)Cc2nc(N3CCOc4cc(F)ccc43)sc2C(=O)N1,2008
Inhibition of PI3K gamma,Cc1cccc2c1OCCN2c1nc2c(s1)C(=O)NC(C)(C)C2,CHEMBL1155924,,,IC50,,,IC50,,,Cc1cccc2c1OCCN2c1nc2c(s1)C(=O)NC(C)(C)C2,2008
Inhibition of PI3K gamma,CC1(C)Cc2nc(N3CCOc4c(F)cccc43)sc2C(=O)N1,CHEMBL1155924,=,=,IC50,nM,16840.0,IC50,nM,16840.0,CC1(C)Cc2nc(N3CCOc4c(F)cccc43)sc2C(=O)N1,2008
Inhibition of PI3K gamma,CC1(C)Cc2nc(N3CCOc4ccccc43)sc2C(=O)N1,CHEMBL1155924,=,=,IC50,nM,959.0,IC50,nM,959.0,CC1(C)Cc2nc(N3CCOc4ccccc43)sc2C(=O)N1,2008
Inhibition of PI3K gamma,CC1(C)CC(=O)c2sc(N3CCOc4ccccc43)nc2C1,CHEMBL1155924,=,=,IC50,nM,829.0,IC50,nM,829.0,CC1(C)CC(=O)c2sc(N3CCOc4ccccc43)nc2C1,2008
Inhibition of PI3K gamma,CC1(C)Cc2nc(N3CCOCC3)sc2C(=O)N1,CHEMBL1155924,=,=,IC50,nM,5285.0,IC50,nM,5285.0,CC1(C)Cc2nc(N3CCOCC3)sc2C(=O)N1,2008
Inhibition of PI3Kgamma,COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1,CHEMBL1151963,=,=,IC50,nM,6315.0,IC50,nM,6315.0,COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1,2009
Inhibition of PI3K-gamma at 1 uM,C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F,CHEMBL1154027,<,<,Inhibition,%,50.0,INH,%,50.0,C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F,2009
Inhibition of PI3K gamma,O=C(O)Cc1c2ccccc2n2c1[nH]c(=O)c1ccccc12,CHEMBL1150975,>,>,IC50,nM,200000.0,IC50,uM,200.0,O=C(O)Cc1c2ccccc2n2c1[nH]c(=O)c1ccccc12,2003
Inhibition of PIK3CG assessed as enzyme activity at 1 uM relative to untreated control,Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl,CHEMBL1155237,=,=,Activity,%,100.0,Activity,%,100.0,Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl,2009
Inhibition of PI3Kgamma,CN1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(N5CC6CCC(C5)O6)c5cnn(CC(F)(F)F)c5n4)cc3)cc2)CC1,CHEMBL1156748,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CN1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(N5CC6CCC(C5)O6)c5cnn(CC(F)(F)F)c5n4)cc3)cc2)CC1,2009
Inhibition of human recombinant PI3Kgamma,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,CHEMBL1156112,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,2009
Binding affinity to human PIK3Cgamma at 200 nM by cell-based competition binding assay relative to control in presence of DTT,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CSSC[C@@H](C(=O)NCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1152541,=,=,Activity,%,100.0,Activity,%,100.0,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CSSC[C@@H](C(=O)NCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2009
Binding affinity to human PIK3Cgamma at 500 nM by cell-based competition binding assay relative to control in presence of DTT,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1152541,=,=,Activity,%,15.0,Activity,%,15.0,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2009
Binding affinity to human PIK3Cgamma at 50 nM by cell-based competition binding assay relative to control in presence of DTT,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CNC(=O)C[C@@H](C(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1152541,=,=,Activity,%,91.0,Activity,%,91.0,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CNC(=O)C[C@@H](C(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2009
Ratio of staurosporine to compound binding affinity to PI3Kgamma in presence of DTT,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1152541,=,=,Selectivity ratio,,6.0,Selectivity ratio,,6.0,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2009
Inhibition of PIK3CG at 10 uM,CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21,CHEMBL1152632,=,=,Inhibition,%,0.0,INH,%,0.0,CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21,2009
Inhibition of PIK3CG at 10 uM,O=C1Nc2ccccc2/C1=C1\C(=O)N(CCCc2ccccc2)c2ccccc21,CHEMBL1152632,=,=,Inhibition,%,19.0,INH,%,19.0,O=C1Nc2ccccc2/C1=C1\C(=O)N(CCCc2ccccc2)c2ccccc21,2009
Inhibition of PI3Kgamma,Oc1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,CHEMBL1153170,=,=,IC50,nM,2343.0,IC50,nM,2343.0,Oc1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,2010
Inhibition of PI3Kgamma,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,133.0,IC50,nM,133.0,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1,2010
Inhibition of PI3Kgamma,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,10000.0,IC50,nM,10000.0,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,2010
Inhibition of PI3Kgamma,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5cccnc5)CC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,583.0,IC50,nM,583.0,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5cccnc5)CC4)c3n2)c1,2010
Inhibition of PI3Kgamma,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(N6CCOCC6)nc5)CC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,368.0,IC50,nM,368.0,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(N6CCOCC6)nc5)CC4)c3n2)c1,2010
Inhibition of PI3Kgamma,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5cncc(Cl)c5)CC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,341.0,IC50,nM,341.0,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5cncc(Cl)c5)CC4)c3n2)c1,2010
Inhibition of PI3Kgamma,COc1ccc(CN2CCC(n3cnc4c(N5CCOCC5)nc(-c5cccc(O)c5)nc43)CC2)cn1,CHEMBL1153170,=,=,IC50,nM,306.0,IC50,nM,306.0,COc1ccc(CN2CCC(n3cnc4c(N5CCOCC5)nc(-c5cccc(O)c5)nc43)CC2)cn1,2010
Inhibition of PI3Kgamma,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,1134.0,IC50,nM,1134.0,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,2010
Inhibition of PI3Kgamma,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,683.0,IC50,nM,683.0,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1,2010
Inhibition of PI3Kgamma,CC(=O)N1CCC(n2cnc3c(N4CCOCC4)nc(-c4cccc(CO)c4)nc32)CC1,CHEMBL1153170,=,=,IC50,nM,1378.0,IC50,nM,1378.0,CC(=O)N1CCC(n2cnc3c(N4CCOCC4)nc(-c4cccc(CO)c4)nc32)CC1,2010
Inhibition of PI3Kgamma,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccn5)CC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,776.0,IC50,nM,776.0,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccn5)CC4)c3n2)c1,2010
Inhibition of PI3Kgamma,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5F)CC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,1102.0,IC50,nM,1102.0,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5F)CC4)c3n2)c1,2010
Inhibition of PI3Kgamma,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(F)cc5)CC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,594.0,IC50,nM,594.0,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(F)cc5)CC4)c3n2)c1,2010
Inhibition of PI3Kgamma,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(-c6ccncc6)cc5)CC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,223.0,IC50,nM,223.0,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(-c6ccncc6)cc5)CC4)c3n2)c1,2010
Inhibition of PI3Kgamma,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(c5ccc(F)cc5F)CC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,640.0,IC50,nM,640.0,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(c5ccc(F)cc5F)CC4)c3n2)c1,2010
Inhibition of PI3Kgamma,CN(C)CCCOc1ccc(CN2CCC(n3cnc4c(N5CCOCC5)nc(-c5cccc(CO)c5)nc43)CC2)cc1,CHEMBL1153170,=,=,IC50,nM,265.0,IC50,nM,265.0,CN(C)CCCOc1ccc(CN2CCC(n3cnc4c(N5CCOCC5)nc(-c5cccc(CO)c5)nc43)CC2)cc1,2010
Inhibition of PI3Kgamma,Oc1cncc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,CHEMBL1153170,=,=,IC50,nM,47.0,IC50,nM,47.0,Oc1cncc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,2010
Inhibition of PI3Kgamma,Oc1cncc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,44.0,IC50,nM,44.0,Oc1cncc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1,2010
Inhibition of PI3Kgamma,Oc1cncc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(Cl)cc5)CC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,119.0,IC50,nM,119.0,Oc1cncc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(Cl)cc5)CC4)c3n2)c1,2010
Inhibition of PI3Kgamma,Cc1ccc(CN2CCC(n3cnc4c(N5CCOCC5)nc(-c5cncc(O)c5)nc43)CC2)cc1,CHEMBL1153170,=,=,IC50,nM,204.0,IC50,nM,204.0,Cc1ccc(CN2CCC(n3cnc4c(N5CCOCC5)nc(-c5cncc(O)c5)nc43)CC2)cc1,2010
Inhibition of PI3Kgamma,Oc1cncc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(F)nc5)CC4)c3n2)c1,CHEMBL1153170,=,=,IC50,nM,61.0,IC50,nM,61.0,Oc1cncc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(F)nc5)CC4)c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,Oc1ccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)cc1,CHEMBL1153204,=,=,IC50,nM,8558.0,IC50,nM,8558.0,Oc1ccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)cc1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,OCc1ccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)cc1,CHEMBL1153204,=,=,IC50,nM,7972.0,IC50,nM,7972.0,OCc1ccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)cc1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,NC(=O)c1ccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)cc1,CHEMBL1153204,=,=,IC50,nM,10000.0,IC50,nM,10000.0,NC(=O)c1ccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)cc1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,CS(=O)(=O)c1ccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)cc1,CHEMBL1153204,=,=,IC50,nM,5830.0,IC50,nM,5830.0,CS(=O)(=O)c1ccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)cc1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,c1cc2ccc(-c3nc(N4CCOCC4)c4nc[nH]c4n3)cc2[nH]1,CHEMBL1153204,=,=,IC50,nM,7371.0,IC50,nM,7371.0,c1cc2ccc(-c3nc(N4CCOCC4)c4nc[nH]c4n3)cc2[nH]1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,c1nc2c(N3CCOCC3)nc(-c3ccc4c(c3)OCCO4)nc2[nH]1,CHEMBL1153204,=,=,IC50,nM,7582.0,IC50,nM,7582.0,c1nc2c(N3CCOCC3)nc(-c3ccc4c(c3)OCCO4)nc2[nH]1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,c1nc2c(N3CCOCC3)nc(-c3ccc4c(c3)OCO4)nc2[nH]1,CHEMBL1153204,=,=,IC50,nM,6907.0,IC50,nM,6907.0,c1nc2c(N3CCOCC3)nc(-c3ccc4c(c3)OCO4)nc2[nH]1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,c1nc2c(N3CCOCC3)nc(-c3ccsc3)nc2[nH]1,CHEMBL1153204,=,=,IC50,nM,8000.0,IC50,nM,8000.0,c1nc2c(N3CCOCC3)nc(-c3ccsc3)nc2[nH]1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,c1nc2c(N3CCOCC3)nc(-c3ccoc3)nc2[nH]1,CHEMBL1153204,=,=,IC50,nM,11000.0,IC50,nM,11000.0,c1nc2c(N3CCOCC3)nc(-c3ccoc3)nc2[nH]1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,Oc1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,CHEMBL1153204,=,=,IC50,nM,2343.0,IC50,nM,2343.0,Oc1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,Oc1cccc(-c2nc(N3CCCCC3)c3nc[nH]c3n2)c1,CHEMBL1153204,=,=,IC50,nM,10322.0,IC50,nM,10322.0,Oc1cccc(-c2nc(N3CCCCC3)c3nc[nH]c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,N#Cc1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,CHEMBL1153204,=,=,IC50,nM,8297.0,IC50,nM,8297.0,N#Cc1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,CS(=O)(=O)c1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,CHEMBL1153204,=,=,IC50,nM,7907.0,IC50,nM,7907.0,CS(=O)(=O)c1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,CS(=O)(=O)Nc1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,CHEMBL1153204,=,=,IC50,nM,7909.0,IC50,nM,7909.0,CS(=O)(=O)Nc1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,Oc1ccccc1-c1nc(N2CCOCC2)c2nc[nH]c2n1,CHEMBL1153204,=,=,IC50,nM,5135.0,IC50,nM,5135.0,Oc1ccccc1-c1nc(N2CCOCC2)c2nc[nH]c2n1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,c1csc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,CHEMBL1153204,=,=,IC50,nM,6742.0,IC50,nM,6742.0,c1csc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(CC4CCN(Cc5ccccc5)CC4)c3n2)c1,CHEMBL1153204,=,=,IC50,nM,1650.0,IC50,nM,1650.0,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(CC4CCN(Cc5ccccc5)CC4)c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(CC4CCN(Cc5ccccc5)CC4)c3n2)c1,CHEMBL1153204,=,=,IC50,nM,2378.0,IC50,nM,2378.0,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(CC4CCN(Cc5ccccc5)CC4)c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,CHEMBL1153204,=,=,IC50,nM,1134.0,IC50,nM,1134.0,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,CHEMBL1153204,=,=,IC50,nM,10815.0,IC50,nM,10815.0,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1,CHEMBL1153204,=,=,IC50,nM,683.0,IC50,nM,683.0,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1,CHEMBL1153204,=,=,IC50,nM,131.0,IC50,nM,131.0,Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,OCc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,CHEMBL1153204,=,=,IC50,nM,975.0,IC50,nM,975.0,OCc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,Oc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,CHEMBL1153204,=,=,IC50,nM,2367.0,IC50,nM,2367.0,Oc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,OCc1cccc(-c2nc(N3CCOCC3)c3ccn(C4CCNCC4)c3n2)c1,CHEMBL1153204,=,=,IC50,nM,510.0,IC50,nM,510.0,OCc1cccc(-c2nc(N3CCOCC3)c3ccn(C4CCNCC4)c3n2)c1,2010
Inhibition of GST-GRP1-fused PI3Kgamma by microtiter plate based fluorescence polarization assay,Oc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCNCC4)c3n2)c1,CHEMBL1153204,=,=,IC50,nM,993.0,IC50,nM,993.0,Oc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCNCC4)c3n2)c1,2010
Inhibition of PI3Kgamma,O=C(Nc1ccccc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,CHEMBL1157610,=,=,IC50,nM,27.0,IC50,nM,27.0,O=C(Nc1ccccc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,2010
Inhibition of PI3Kgamma,CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,CHEMBL1157610,=,=,IC50,nM,814.5,IC50,nM,814.5,CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,2010
Inhibition of PI3Kgamma,CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,CHEMBL1157610,=,=,IC50,nM,789.0,IC50,nM,789.0,CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,2010
Inhibition of PI3Kgamma,O=C(Nc1ccc(F)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,CHEMBL1157610,=,=,IC50,nM,52.5,IC50,nM,52.5,O=C(Nc1ccc(F)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,2010
Inhibition of PI3Kgamma,Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1,CHEMBL1157610,=,=,IC50,nM,438.0,IC50,nM,438.0,Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1,2010
Inhibition of PI3Kgamma,O=C(Nc1ccc(Cl)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,CHEMBL1157610,=,=,IC50,nM,219.5,IC50,nM,219.5,O=C(Nc1ccc(Cl)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,2010
Inhibition of PI3Kgamma,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1ccc(F)cc1F,CHEMBL1157610,=,=,IC50,nM,528.0,IC50,nM,528.0,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1ccc(F)cc1F,2010
Inhibition of PI3Kgamma,O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,CHEMBL1157610,=,=,IC50,nM,14.5,IC50,nM,14.5,O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,2010
Inhibition of PI3Kgamma,O=C(Nc1ccc(CCO)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,CHEMBL1157610,=,=,IC50,nM,21.5,IC50,nM,21.5,O=C(Nc1ccc(CCO)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,2010
Inhibition of PI3Kgamma,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1cccs1,CHEMBL1157610,=,=,IC50,nM,23.0,IC50,nM,23.0,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1cccs1,2010
Inhibition of PI3Kgamma,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1cccnc1,CHEMBL1157610,=,=,IC50,nM,34.0,IC50,nM,34.0,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1cccnc1,2010
Inhibition of PI3Kgamma,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,CHEMBL1157610,=,=,IC50,nM,28.5,IC50,nM,28.5,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,2010
Inhibition of PI3Kgamma,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1ccnnc1,CHEMBL1157610,=,=,IC50,nM,65.0,IC50,nM,65.0,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1ccnnc1,2010
Inhibition of PI3Kgamma,COC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1,CHEMBL1157610,=,=,IC50,nM,85.0,IC50,nM,85.0,COC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1,2010
Inhibition of PI3Kgamma,O=C(Nc1ccc(C(=O)O)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,CHEMBL1157610,=,=,IC50,nM,48.5,IC50,nM,48.5,O=C(Nc1ccc(C(=O)O)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,2010
Inhibition of PI3Kgamma,CNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1,CHEMBL1157610,=,=,IC50,nM,20.0,IC50,nM,20.0,CNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1,2010
Inhibition of PI3Kgamma,CN(C)CCNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1,CHEMBL1157610,=,=,IC50,nM,8.0,IC50,nM,8.0,CN(C)CCNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1,2010
Inhibition of PI3Kgamma,CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1.Cl,CHEMBL1157610,=,=,IC50,nM,9.0,IC50,nM,9.0,CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1.Cl,2010
Inhibition of PI3Kgamma,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,CHEMBL1157610,=,=,IC50,nM,5.4,IC50,nM,5.4,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,2010
Inhibition of PI3Kgamma,O=C(Nc1ccc(C(=O)N2CCC(N3CCCC3)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,CHEMBL1157610,=,=,IC50,nM,10.0,IC50,nM,10.0,O=C(Nc1ccc(C(=O)N2CCC(N3CCCC3)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,2010
Inhibition of PI3Kgamma,O=C(Nc1ccc(C(=O)N2CCC(N3CCCCC3)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,CHEMBL1157610,=,=,IC50,nM,10.0,IC50,nM,10.0,O=C(Nc1ccc(C(=O)N2CCC(N3CCCCC3)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1,2010
Inhibition of PI3Kgamma,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)NN1CCCCC1,CHEMBL1157610,=,=,IC50,nM,7470.0,IC50,nM,7470.0,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)NN1CCCCC1,2010
Inhibition of PI3Kgamma,CN(C)CCN(C)C(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1.Cl,CHEMBL1157610,=,=,IC50,nM,9.0,IC50,nM,9.0,CN(C)CCN(C)C(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1.Cl,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N5CCN(C)CC5)cc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,9.2,IC50,nM,9.2,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N5CCN(C)CC5)cc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,18.5,IC50,nM,18.5,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,21.5,IC50,nM,21.5,CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)c3nnn(C4CC4)c3n2)cc1,CHEMBL1157707,=,=,IC50,nM,13.5,IC50,nM,13.5,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)c3nnn(C4CC4)c3n2)cc1,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccnc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,25.0,IC50,nM,25.0,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccnc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccnc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,48.5,IC50,nM,48.5,CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccnc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,Cn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccnc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,49.0,IC50,nM,49.0,Cn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccnc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,O=C(Nc1ccc(-c2nc(N3CCOCC3)c3nnn(C4CC4)c3n2)cc1)Nc1cccnc1,CHEMBL1157707,=,=,IC50,nM,48.5,IC50,nM,48.5,O=C(Nc1ccc(-c2nc(N3CCOCC3)c3nnn(C4CC4)c3n2)cc1)Nc1cccnc1,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,Cn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccs4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,22.0,IC50,nM,22.0,Cn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccs4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccs4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,11.5,IC50,nM,11.5,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccs4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,O=C(Nc1ccc(-c2nc(N3CCOCC3)c3nnn(C4CC4)c3n2)cc1)Nc1cccs1,CHEMBL1157707,=,=,IC50,nM,19.5,IC50,nM,19.5,O=C(Nc1ccc(-c2nc(N3CCOCC3)c3nnn(C4CC4)c3n2)cc1)Nc1cccs1,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccnc(C)c4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,37.0,IC50,nM,37.0,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccnc(C)c4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(N(C)C)cc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,69.0,IC50,nM,69.0,CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(N(C)C)cc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(CO)cc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,24.8,IC50,nM,24.8,CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(CO)cc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(N)=O)cc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,12.2,IC50,nM,12.2,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(N)=O)cc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(N)=O)cc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,17.5,IC50,nM,17.5,CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(N)=O)cc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)OC)cc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,84.5,IC50,nM,84.5,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)OC)cc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(N5CCOCC5)cc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,78.0,IC50,nM,78.0,CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(N5CCOCC5)cc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4nnn(CC)c4n3)cc2)cc1,CHEMBL1157707,=,=,IC50,nM,17.2,IC50,nM,17.2,CCNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4nnn(CC)c4n3)cc2)cc1,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N(C)C)cc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,12.3,IC50,nM,12.3,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N(C)C)cc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCCCNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4nnn(CC)c4n3)cc2)cc1,CHEMBL1157707,=,=,IC50,nM,33.0,IC50,nM,33.0,CCCCNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4nnn(CC)c4n3)cc2)cc1,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCCN(C)C)cc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,12.0,IC50,nM,12.0,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCCN(C)C)cc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCCc5ccccn5)cc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,22.0,IC50,nM,22.0,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCCc5ccccn5)cc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCCN5CCN(C)CC5)cc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,25.0,IC50,nM,25.0,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCCN5CCN(C)CC5)cc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCCCN(C)C)cc4)cc3)nc21,CHEMBL1157707,=,=,IC50,nM,9.0,IC50,nM,9.0,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCCCN(C)C)cc4)cc3)nc21,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,CHEMBL1157707,=,=,IC50,nM,1134.0,IC50,nM,1134.0,OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,2010
Inhibition of human PI3Kgamma by fluorescence polarization format assay,OCc1cccc(-c2nc(N3CCOCC3)c3nnn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,CHEMBL1157707,=,=,IC50,nM,435.0,IC50,nM,435.0,OCc1cccc(-c2nc(N3CCOCC3)c3nnn(C4CCN(Cc5ccccc5)CC4)c3n2)c1,2010
Inhibition of recombinant PI3Kgamma assessed as PIP3 product formation by fluorescence polarization assay,Cc1nc(N)ncc1-c1nc(N2CCOCC2)c2sc(C(C)(C)O)cc2n1,CHEMBL1154879,=,=,IC50,nM,15.0,IC50,nM,15.0,Cc1nc(N)ncc1-c1nc(N2CCOCC2)c2sc(C(C)(C)O)cc2n1,2010
Inhibition of recombinant PI3Kgamma assessed as PIP3 product formation by fluorescence polarization assay,Cc1nc(N)ncc1-c1nc(N2CCOCC2)c2sc(CN3CCN(S(C)(=O)=O)CC3)cc2n1,CHEMBL1154879,=,=,IC50,nM,5.2,IC50,nM,5.2,Cc1nc(N)ncc1-c1nc(N2CCOCC2)c2sc(CN3CCN(S(C)(=O)=O)CC3)cc2n1,2010
Inhibition of recombinant PI3Kgamma assessed as PIP3 product formation by fluorescence polarization assay,CC(C)(O)c1cc2nc(-c3cnc(N)nc3)nc(N3CCOCC3)c2s1,CHEMBL1154879,=,=,IC50,nM,16.0,IC50,nM,16.0,CC(C)(O)c1cc2nc(-c3cnc(N)nc3)nc(N3CCOCC3)c2s1,2010
Inhibition of recombinant PI3Kgamma assessed as PIP3 product formation by fluorescence polarization assay,CC(C)(O)c1cc2nc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2s1,CHEMBL1154879,,,IC50,,,IC50,,,CC(C)(O)c1cc2nc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2s1,2010
Inhibition of recombinant PI3Kgamma assessed as PIP3 product formation by fluorescence polarization assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,CHEMBL1154879,=,=,IC50,nM,8.4,IC50,nM,8.4,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,2010
Inhibition of recombinant PI3Kgamma assessed as PIP3 product formation by fluorescence polarization assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4ccc(N)nc4)nc(N4CCOCC4)c3s2)CC1,CHEMBL1154879,=,=,IC50,nM,33.0,IC50,nM,33.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4ccc(N)nc4)nc(N4CCOCC4)c3s2)CC1,2010
Inhibition of recombinant PI3Kgamma assessed as PIP3 product formation by fluorescence polarization assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4ccc(N)cc4)nc(N4CCOCC4)c3s2)CC1,CHEMBL1154879,=,=,IC50,nM,1300.0,IC50,nM,1300.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4ccc(N)cc4)nc(N4CCOCC4)c3s2)CC1,2010
Inhibition of recombinant PI3Kgamma assessed as PIP3 product formation by fluorescence polarization assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc(CO)c4)nc(N4CCOCC4)c3s2)CC1,CHEMBL1154879,=,=,IC50,nM,15.0,IC50,nM,15.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc(CO)c4)nc(N4CCOCC4)c3s2)CC1,2010
Inhibition of recombinant PI3Kgamma assessed as PIP3 product formation by fluorescence polarization assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4ccccc4)nc(N4CCOCC4)c3s2)CC1,CHEMBL1154879,,,IC50,,,IC50,,,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4ccccc4)nc(N4CCOCC4)c3s2)CC1,2010
Inhibition of recombinant PI3Kgamma assessed as PIP3 product formation by fluorescence polarization assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4ccncc4)nc(N4CCOCC4)c3s2)CC1,CHEMBL1154879,=,=,IC50,nM,5100.0,IC50,nM,5100.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4ccncc4)nc(N4CCOCC4)c3s2)CC1,2010
Inhibition of recombinant PI3Kgamma assessed as PIP3 product formation by fluorescence polarization assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccnc4)nc(N4CCOCC4)c3s2)CC1,CHEMBL1154879,=,=,IC50,nM,19.0,IC50,nM,19.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccnc4)nc(N4CCOCC4)c3s2)CC1,2010
Inhibition of recombinant PI3Kgamma assessed as PIP3 product formation by fluorescence polarization assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc(O)c4)nc(N4CCOCC4)c3s2)CC1,CHEMBL1154879,=,=,IC50,nM,20.0,IC50,nM,20.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc(O)c4)nc(N4CCOCC4)c3s2)CC1,2010
Inhibition of recombinant PI3Kgamma assessed as PIP3 product formation by fluorescence polarization assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL1154879,=,=,IC50,nM,66.0,IC50,nM,66.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2010
Inhibition of PI3Kgamma,COc1ccc(C2=NNC(=O)/C2=N\Nc2cccc(OC)c2)cc1,CHEMBL1154953,=,=,Ki,nM,1300.0,Ki,nM,1300.0,COc1ccc(C2=NNC(=O)/C2=N\Nc2cccc(OC)c2)cc1,2010
Inhibition of PI3Kgamma,COc1ccc(C2=NNC(=O)/C2=N\Nc2cccnc2)cc1,CHEMBL1154953,=,=,Ki,nM,1000.0,Ki,nM,1000.0,COc1ccc(C2=NNC(=O)/C2=N\Nc2cccnc2)cc1,2010
Inhibition of PI3Kgamma,COc1ccncc1C1=NNC(=O)/C1=N\Nc1ccccc1,CHEMBL1154953,=,=,Ki,nM,540.0,Ki,nM,540.0,COc1ccncc1C1=NNC(=O)/C1=N\Nc1ccccc1,2010
Inhibition PI3K-gamma-mediated PIP2 phosphorylation after 20 mins by alphascreen competition assay,COc1ccc(-c2ccc3c(N4CCOCC4)nc(N4C[C@@H](C)O[C@@H](C)C4)nc3n2)cc1CO,CHEMBL1154286,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(-c2ccc3c(N4CCOCC4)nc(N4C[C@@H](C)O[C@@H](C)C4)nc3n2)cc1CO,2009
Inhibition of PI3Kgamma,Cc1c(CN2CCN(S(C)(=O)=O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL1156214,=,=,IC50,nM,15.0,IC50,nM,15.0,Cc1c(CN2CCN(S(C)(=O)=O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2010
Inhibition of PI3Kgamma,CC(C)N1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1,CHEMBL1156955,=,=,IC50,nM,1256.0,IC50,nM,1256.0,CC(C)N1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCCN1CCN(CCO)CC1,CHEMBL1156153,=,=,IC50,nM,109.0,IC50,nM,109.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCCN1CCN(CCO)CC1,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCCN1CCN(C)CC1,CHEMBL1156153,=,=,IC50,nM,402.0,IC50,nM,402.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCCN1CCN(C)CC1,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCCN1CCOCC1,CHEMBL1156153,=,=,IC50,nM,76.0,IC50,nM,76.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCCN1CCOCC1,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCCN(C)C,CHEMBL1156153,=,=,IC50,nM,404.0,IC50,nM,404.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCCN(C)C,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2CCCN1CCN(CCO)CC1,CHEMBL1156153,=,=,IC50,nM,1358.0,IC50,nM,1358.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2CCCN1CCN(CCO)CC1,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2CCCN1CCOCC1,CHEMBL1156153,=,=,IC50,nM,646.0,IC50,nM,646.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2CCCN1CCOCC1,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2CCCN(C)C,CHEMBL1156153,=,=,IC50,nM,2419.0,IC50,nM,2419.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2CCCN(C)C,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCN1CCN(CCCO)CC1,CHEMBL1156153,=,=,IC50,nM,322.0,IC50,nM,322.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCN1CCN(CCCO)CC1,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCN1CCN(C)CC1,CHEMBL1156153,=,=,IC50,nM,473.0,IC50,nM,473.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCN1CCN(C)CC1,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCN1CCOCC1,CHEMBL1156153,=,=,IC50,nM,155.0,IC50,nM,155.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCN1CCOCC1,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCN(C)C,CHEMBL1156153,=,=,IC50,nM,283.0,IC50,nM,283.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCN(C)C,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2CCN1CCN(CCCO)CC1,CHEMBL1156153,=,=,IC50,nM,976.0,IC50,nM,976.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2CCN1CCN(CCCO)CC1,2010
Inhibition of PI3Kgamma,Cn1c(-c2ccccc2)c(/C=C2\Oc3cc(O)cc(O)c3C2=O)c2ccccc21,CHEMBL1156153,,,IC50,,,IC50,,,Cn1c(-c2ccccc2)c(/C=C2\Oc3cc(O)cc(O)c3C2=O)c2ccccc21,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2C,CHEMBL1156153,=,=,IC50,nM,54.0,IC50,nM,54.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2C,2010
Inhibition of PI3Kgamma,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2C,CHEMBL1156153,=,=,IC50,nM,587.0,IC50,nM,587.0,COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2C,2010
Inhibition of PI3Kgamma,Cn1cc(/C=C2\Oc3cc(O)cc(O)c3C2=O)c2ccccc21,CHEMBL1156153,=,=,IC50,nM,6949.0,IC50,nM,6949.0,Cn1cc(/C=C2\Oc3cc(O)cc(O)c3C2=O)c2ccccc21,2010
Inhibition of PI3Kgamma,COc1ccc2[nH]c(-c3cccnc3)c(/C=C3\Oc4cc(O)cc(O)c4C3=O)c2c1,CHEMBL1156153,=,=,IC50,nM,10.0,IC50,nM,10.0,COc1ccc2[nH]c(-c3cccnc3)c(/C=C3\Oc4cc(O)cc(O)c4C3=O)c2c1,2010
Inhibition of PI3Kgamma,COc1ccc2[nH]c(-c3ccccc3)c(/C=C3\Oc4cc(O)cc(O)c4C3=O)c2c1,CHEMBL1156153,=,=,IC50,nM,11.0,IC50,nM,11.0,COc1ccc2[nH]c(-c3ccccc3)c(/C=C3\Oc4cc(O)cc(O)c4C3=O)c2c1,2010
Inhibition of PI3Kgamma,O=C1/C(=C/c2c(-c3ccc4ccccc4c3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21,CHEMBL1156153,=,=,IC50,nM,1820.0,IC50,nM,1820.0,O=C1/C(=C/c2c(-c3ccc4ccccc4c3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21,2010
Inhibition of PI3Kgamma,O=C1/C(=C/c2c(-c3ccc(Cl)cc3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21,CHEMBL1156153,=,=,IC50,nM,1458.0,IC50,nM,1458.0,O=C1/C(=C/c2c(-c3ccc(Cl)cc3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21,2010
Inhibition of PI3Kgamma,O=C1/C(=C/c2c(-c3ccc(F)cc3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21,CHEMBL1156153,,,IC50,,,IC50,,,O=C1/C(=C/c2c(-c3ccc(F)cc3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21,2010
Inhibition of PI3Kgamma,O=C1/C(=C/c2c(-c3ccccn3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21,CHEMBL1156153,,,IC50,,,IC50,,,O=C1/C(=C/c2c(-c3ccccn3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21,2010
Inhibition of PI3Kgamma,O=C1/C(=C/c2c(-c3ccccc3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21,CHEMBL1156153,=,=,IC50,nM,2781.0,IC50,nM,2781.0,O=C1/C(=C/c2c(-c3ccccc3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21,2010
Inhibition of PI3Kgamma,COc1ccc2[nH]c(C)c(/C=C3\Oc4cc(O)cc(O)c4C3=O)c2c1,CHEMBL1156153,=,=,IC50,nM,25.0,IC50,nM,25.0,COc1ccc2[nH]c(C)c(/C=C3\Oc4cc(O)cc(O)c4C3=O)c2c1,2010
Inhibition of PI3Kgamma,Cc1[nH]c2ccc(Br)cc2c1/C=C1\Oc2cc(O)cc(O)c2C1=O,CHEMBL1156153,=,=,IC50,nM,2220.0,IC50,nM,2220.0,Cc1[nH]c2ccc(Br)cc2c1/C=C1\Oc2cc(O)cc(O)c2C1=O,2010
Inhibition of PI3Kgamma,Cc1[nH]c2ccccc2c1/C=C1\Oc2cc(O)cc(O)c2C1=O,CHEMBL1156153,,,IC50,,,IC50,,,Cc1[nH]c2ccccc2c1/C=C1\Oc2cc(O)cc(O)c2C1=O,2010
Inhibition of PI3Kgamma,O=C1/C(=C/c2c[nH]c3ccc(Oc4ccccc4)cc23)Oc2cc(O)cc(O)c21,CHEMBL1156153,,,IC50,,,IC50,,,O=C1/C(=C/c2c[nH]c3ccc(Oc4ccccc4)cc23)Oc2cc(O)cc(O)c21,2010
Inhibition of PI3Kgamma,COc1ccc2[nH]cc(/C=C3\Oc4cc(O)cc(O)c4C3=O)c2c1,CHEMBL1156153,=,=,IC50,nM,269.0,IC50,nM,269.0,COc1ccc2[nH]cc(/C=C3\Oc4cc(O)cc(O)c4C3=O)c2c1,2010
Inhibition of PI3Kgamma,O=C1/C(=C/c2c[nH]c3ccc(Br)cc23)Oc2cc(O)cc(O)c21,CHEMBL1156153,=,=,IC50,nM,1625.0,IC50,nM,1625.0,O=C1/C(=C/c2c[nH]c3ccc(Br)cc23)Oc2cc(O)cc(O)c21,2010
Inhibition of PI3Kgamma,O=C1/C(=C/c2c[nH]c3ccc(Cl)cc23)Oc2cc(O)cc(O)c21,CHEMBL1156153,=,=,IC50,nM,3628.0,IC50,nM,3628.0,O=C1/C(=C/c2c[nH]c3ccc(Cl)cc23)Oc2cc(O)cc(O)c21,2010
Inhibition of PI3Kgamma,O=C1/C(=C/c2c[nH]c3ccccc23)Oc2cc(O)cc(O)c21,CHEMBL1156153,,,IC50,,,IC50,,,O=C1/C(=C/c2c[nH]c3ccccc23)Oc2cc(O)cc(O)c21,2010
Inhibition of PI3Kgamma by DELFIA assay,CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1,CHEMBL1157009,=,=,IC50,nM,495.0,IC50,uM,0.495,CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1,2009
Inhibition of PI3Kgamma by DELFIA assay,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1,CHEMBL1157009,=,=,IC50,nM,6224.0,IC50,uM,6.224,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1,2009
Inhibition of PI3Kgamma by DELFIA assay,CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1,CHEMBL1157009,=,=,IC50,nM,148.0,IC50,nM,148.0,CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1,2009
Inhibition of PI3Kgamma by DELFIA assay,CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC(C)(C)C)CC4)c3n2)cc1,CHEMBL1157009,=,=,IC50,nM,409.0,IC50,nM,409.0,CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC(C)(C)C)CC4)c3n2)cc1,2009
Inhibition of PI3Kgamma by DELFIA assay,CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1,CHEMBL1157009,=,=,IC50,nM,1290.0,IC50,nM,1290.0,CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1,2009
Inhibition of PI3Kgamma by DELFIA assay,CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC(C)C)CC4)c3n2)cc1,CHEMBL1157009,=,=,IC50,nM,1431.0,IC50,nM,1431.0,CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC(C)C)CC4)c3n2)cc1,2009
Inhibition of PI3Kgamma by DELFIA assay,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1,CHEMBL1157009,=,=,IC50,nM,1697.0,IC50,nM,1697.0,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1,2009
Inhibition of PI3Kgamma by DELFIA assay,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1,CHEMBL1157009,=,=,IC50,nM,1772.0,IC50,nM,1772.0,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1,2009
Inhibition of PI3Kgamma by DELFIA assay,CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1,CHEMBL1157009,=,=,IC50,nM,2526.0,IC50,nM,2526.0,CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1,2009
Inhibition of PI3Kgamma by DELFIA assay,CC(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1,CHEMBL1157009,=,=,IC50,nM,3554.0,IC50,nM,3554.0,CC(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1,2009
Inhibition of PI3Kgamma by DELFIA assay,CC(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1,CHEMBL1157009,=,=,IC50,nM,3765.0,IC50,nM,3765.0,CC(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1,2009
Inhibition of human PI3Kgamma at 10 uM preincubated for 15 mins by HTRF assay,O=C1Nc2ccc([N+](=O)[O-])cc2/C1=C1/Nc2ccc(Cl)cc2/C1=N/O,CHEMBL1157914,,,Inhibition,%,,INH,,,O=C1Nc2ccc([N+](=O)[O-])cc2/C1=C1/Nc2ccc(Cl)cc2/C1=N/O,2010
Inhibition of PI3gamma,COc1cc(F)c2[nH]c(-c3c(C)nn(C)c3C)c(/C=C3/Oc4ccc(NC(=O)Nc5ccc(C(=O)N(C)CCN(C)C)cc5)cc4C3=O)c2c1,CHEMBL1158598,=,=,IC50,nM,2.4,IC50,nM,2.4,COc1cc(F)c2[nH]c(-c3c(C)nn(C)c3C)c(/C=C3/Oc4ccc(NC(=O)Nc5ccc(C(=O)N(C)CCN(C)C)cc5)cc4C3=O)c2c1,2010
Inhibition of PIK3CG at 1 uM,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1,2010
Inhibition of PIK3CG at 1 uM,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1,2010
Inhibition of PIK3CG at 1 uM,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1,2010
Inhibition of PIK3CG at 1 uM,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1,2010
Inhibition of PIK3CG at 1 uM,FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21,2010
Inhibition of PIK3CG at 1 uM,CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1,2010
Inhibition of PIK3CG at 10 uM,CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1,CHEMBL1177794,=,=,Inhibition,%,100.0,INH,%,100.0,CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1,2010
Inhibition of PIK3CG at 10 uM,CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1,CHEMBL1177794,=,=,Inhibition,%,100.0,INH,%,100.0,CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1,2010
Inhibition of p110gamma,Cc1ccccc1-n1c(Cn2cnc3c(N)ncnc32)nc2cccc(C)c2c1=O,CHEMBL1212808,=,=,IC50,nM,61000.0,IC50,nM,61000.0,Cc1ccccc1-n1c(Cn2cnc3c(N)ncnc32)nc2cccc(C)c2c1=O,2010
Inhibition of p110gamma,COc1ccccc1-n1c(CSc2ncnc3[nH]cnc23)nc2cccc(Cl)c2c1=O,CHEMBL1212808,=,=,IC50,nM,17000.0,IC50,nM,17000.0,COc1ccccc1-n1c(CSc2ncnc3[nH]cnc23)nc2cccc(Cl)c2c1=O,2010
Inhibition of p110gamma,Cc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)nc2cccc(C)c2c1=O,CHEMBL1212808,=,=,IC50,nM,33.0,IC50,nM,33.0,Cc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)nc2cccc(C)c2c1=O,2010
Inhibition of p110gamma,Cc1ccccc1-n1c(Cn2nc(-c3ccc(O)c(F)c3)c3c(N)ncnc32)nc2cccc(C)c2c1=O,CHEMBL1212808,=,=,IC50,nM,20.0,IC50,nM,20.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc(O)c(F)c3)c3c(N)ncnc32)nc2cccc(C)c2c1=O,2010
Inhibition of p110gamma,Cc1ccccc1-n1c(Cn2nc(C#CCO)c3c(N)ncnc32)nc2cccc(C)c2c1=O,CHEMBL1212808,=,=,IC50,nM,1300.0,IC50,nM,1300.0,Cc1ccccc1-n1c(Cn2nc(C#CCO)c3c(N)ncnc32)nc2cccc(C)c2c1=O,2010
Inhibition of p110gamma,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5ccccc5nc4N4CCN(C)CC4)c4ncnc(N)c34)cc2s1,CHEMBL1212808,=,=,IC50,nM,185.0,IC50,nM,185.0,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5ccccc5nc4N4CCN(C)CC4)c4ncnc(N)c34)cc2s1,2010
Inhibition of p110gamma,CN1CCN(c2nc3ccccc3cc2Cn2nc(-c3ccc4nc(N)sc4c3)c3c(N)ncnc32)CC1,CHEMBL1212808,=,=,IC50,nM,4.0,IC50,nM,4.0,CN1CCN(c2nc3ccccc3cc2Cn2nc(-c3ccc4nc(N)sc4c3)c3c(N)ncnc32)CC1,2010
Inhibition of p110gamma,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL1212808,=,=,IC50,nM,49.0,IC50,nM,49.0,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2010
Inhibition of p110gamma,CC(C)n1nc(C#Cc2cccnc2)c2c(N)ncnc21,CHEMBL1212808,=,=,IC50,nM,113.0,IC50,nM,113.0,CC(C)n1nc(C#Cc2cccnc2)c2c(N)ncnc21,2010
Inhibition of p110gamma,CC(C)n1nc(C#Cc2cccc(O)c2)c2c(N)ncnc21,CHEMBL1212808,=,=,IC50,nM,69.0,IC50,nM,69.0,CC(C)n1nc(C#Cc2cccc(O)c2)c2c(N)ncnc21,2010
Inhibition of p110gamma,COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(F)cc2)cc(OC)c1,CHEMBL1212808,=,=,IC50,nM,10000.0,IC50,nM,10000.0,COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(F)cc2)cc(OC)c1,2010
Inhibition of p110gamma,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL1212808,=,=,IC50,nM,75.0,IC50,nM,75.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2010
Inhibition of p110gamma,COc1ccccc1-n1c(SCC(=O)Nc2ccc3nccnc3c2)nc2c(c1=O)CCCC2,CHEMBL1212808,=,=,IC50,nM,20000.0,IC50,nM,20000.0,COc1ccccc1-n1c(SCC(=O)Nc2ccc3nccnc3c2)nc2c(c1=O)CCCC2,2010
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc(O)cc(Br)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,270.0,IC50,uM,0.27,CC(C)n1nc(-c2cc(O)cc(Br)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COCOc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1Br,CHEMBL1240340,=,=,IC50,nM,7900.0,IC50,uM,7.9,COCOc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1Br,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,39.0,IC50,uM,0.039,Cn1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Br)c(O)c1)nn2C1CCC1,CHEMBL1240340,=,=,IC50,nM,44.0,IC50,uM,0.044,Nc1ncnc2c1c(-c1ccc(Br)c(O)c1)nn2C1CCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Br)c(O)c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,54.0,IC50,uM,0.054,Nc1ncnc2c1c(-c1ccc(Br)c(O)c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,209.0,IC50,uM,0.209,CC(C)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,C[C@H](CN)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,808.0,IC50,uM,0.808,C[C@H](CN)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,C[C@@H](CN)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,606.0,IC50,uM,0.606,C[C@@H](CN)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,N#CCCCn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,502.0,IC50,uM,0.502,N#CCCCn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,N#CCCCCn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,448.0,IC50,uM,0.448,N#CCCCCn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCC1,CHEMBL1240340,=,=,IC50,nM,1070.0,IC50,uM,1.07,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CNC1,CHEMBL1240340,=,=,IC50,nM,633.0,IC50,uM,0.633,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CNC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,257.0,IC50,uM,0.257,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC1CCC(n2nc(-c3ccc(F)c(O)c3)c3c(N)ncnc32)C1,CHEMBL1240340,=,=,IC50,nM,283.0,IC50,uM,0.283,CC1CCC(n2nc(-c3ccc(F)c(O)c3)c3c(N)ncnc32)C1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@H]1CCNC1,CHEMBL1240340,=,=,IC50,nM,780.0,IC50,uM,0.78,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@H]1CCNC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@@H]1CCNC1,CHEMBL1240340,=,=,IC50,nM,1190.0,IC50,uM,1.19,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@@H]1CCNC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@H]1CCOC1,CHEMBL1240340,=,=,IC50,nM,554.0,IC50,uM,0.554,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@H]1CCOC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@@H]1CCOC1,CHEMBL1240340,=,=,IC50,nM,342.0,IC50,uM,0.342,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@@H]1CCOC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCCCCC1,CHEMBL1240340,=,=,IC50,nM,808.0,IC50,uM,0.808,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCCCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2CC1CCNCC1,CHEMBL1240340,=,=,IC50,nM,16400.0,IC50,uM,16.4,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2CC1CCNCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1nn(-c2ccccc2)nc1Cn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,1070.0,IC50,uM,1.07,Cc1nn(-c2ccccc2)nc1Cn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2Cc1ocnc1-c1ccccc1,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2Cc1ocnc1-c1ccccc1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1F,CHEMBL1240340,=,=,IC50,nM,551.0,IC50,uM,0.551,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1F,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,140.0,IC50,uM,0.14,CC(C)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,C[C@H](CN)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,637.0,IC50,uM,0.637,C[C@H](CN)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,C[C@@H](CN)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,80.0,IC50,uM,0.08,C[C@@H](CN)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2C1CCC1,CHEMBL1240340,=,=,IC50,nM,293.0,IC50,uM,0.293,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2C1CCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1NC(=O)OC(C)(C)C,CHEMBL1240340,=,=,IC50,nM,1800.0,IC50,uM,1.8,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1NC(=O)OC(C)(C)C,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,100.0,IC50,uM,0.1,CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,1100.0,IC50,uM,1.1,Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,43.0,IC50,uM,0.043,CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC,CHEMBL1240340,=,=,IC50,nM,72.0,IC50,uM,0.072,COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,1300.0,IC50,uM,1.3,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccn3ccnc3c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,2400.0,IC50,uM,2.4,Nc1ncnc2c1c(-c1ccn3ccnc3c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)nc2cccc(C)c2c1=O,CHEMBL1240340,=,=,IC50,nM,200.0,IC50,uM,0.2,Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)nc2cccc(C)c2c1=O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,1500.0,IC50,uM,1.5,CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,570.0,IC50,uM,0.57,Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(-c3ccccc3)c12,CHEMBL1240340,=,=,IC50,nM,10900.0,IC50,uM,10.9,Nc1ncnc2[nH]nc(-c3ccccc3)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccc(-c2n[nH]c3ncnc(N)c23)cc1,CHEMBL1240340,=,=,IC50,nM,7700.0,IC50,uM,7.7,Cc1ccc(-c2n[nH]c3ncnc(N)c23)cc1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1cccc(-c2n[nH]c3ncnc(N)c23)c1,CHEMBL1240340,=,=,IC50,nM,2400.0,IC50,uM,2.4,Cc1cccc(-c2n[nH]c3ncnc(N)c23)c1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccccc1-c1n[nH]c2ncnc(N)c12,CHEMBL1240340,=,=,IC50,nM,25000.0,IC50,uM,25.0,Cc1ccccc1-c1n[nH]c2ncnc(N)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1cccc(-c2n[nH]c3ncnc(N)c23)c1C,CHEMBL1240340,=,=,IC50,nM,15000.0,IC50,uM,15.0,Cc1cccc(-c2n[nH]c3ncnc(N)c23)c1C,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)(C)c1ccc(-c2n[nH]c3ncnc(N)c23)cc1,CHEMBL1240340,=,=,IC50,nM,15000.0,IC50,uM,15.0,CC(C)(C)c1ccc(-c2n[nH]c3ncnc(N)c23)cc1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(O)cc2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,680.0,IC50,uM,0.68,CC(C)n1nc(-c2ccc(O)cc2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(-c3cccc(O)c3)c12,CHEMBL1240340,=,=,IC50,nM,1700.0,IC50,uM,1.7,Nc1ncnc2[nH]nc(-c3cccc(O)c3)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1cc(-c2cccc(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,6400.0,IC50,uM,6.4,CC(C)n1cc(-c2cccc(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CNc1ncnc2c1c(-c1cccc(O)c1)nn2C(C)C,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,CNc1ncnc2c1c(-c1cccc(O)c1)nn2C(C)C,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1cc(O)ccc1-c1nn(C(C)C)c2ncnc(N)c12,CHEMBL1240340,=,=,IC50,nM,1500.0,IC50,uM,1.5,Cc1cc(O)ccc1-c1nn(C(C)C)c2ncnc(N)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccc(-c2n[nH]c3ncnc(N)c23)cc1OCc1ccccc1,CHEMBL1240340,=,=,IC50,nM,3340.0,IC50,uM,3.34,Cc1ccc(-c2n[nH]c3ncnc(N)c23)cc1OCc1ccccc1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccc(-c2n[nH]c3ncnc(N)c23)cc1O,CHEMBL1240340,=,=,IC50,nM,852.0,IC50,uM,0.852,Cc1ccc(-c2n[nH]c3ncnc(N)c23)cc1O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccc(-c2nn(C)c3ncnc(N)c23)cc1O,CHEMBL1240340,=,=,IC50,nM,550.0,IC50,uM,0.55,Cc1ccc(-c2nn(C)c3ncnc(N)c23)cc1O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1O,CHEMBL1240340,=,=,IC50,nM,435.0,IC50,uM,0.435,Cc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CCC(C)n1nc(-c2ccc(C)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,772.0,IC50,uM,0.772,CCC(C)n1nc(-c2ccc(C)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(O)c2F)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,1470.0,IC50,uM,1.47,CC(C)n1nc(-c2cccc(O)c2F)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1cccc(O)c1F)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,1210.0,IC50,uM,1.21,Nc1ncnc2c1c(-c1cccc(O)c1F)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc(O)cc(F)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,340.0,IC50,uM,0.34,CC(C)n1nc(-c2cc(O)cc(F)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1cc(O)cc(F)c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,640.0,IC50,uM,0.64,Nc1ncnc2c1c(-c1cc(O)cc(F)c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(Br)cc(-c2nn(C(C)C)c3ncnc(N)c23)c1,CHEMBL1240340,=,=,IC50,nM,4250.0,IC50,uM,4.25,COc1cc(Br)cc(-c2nn(C(C)C)c3ncnc(N)c23)c1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C[C@@H](C)CO)c3ncnc(N)c23)cc1OC,CHEMBL1240340,=,=,IC50,nM,2300.0,IC50,uM,2.3,COc1ccc(-c2nn(C[C@@H](C)CO)c3ncnc(N)c23)cc1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1OC,CHEMBL1240340,=,=,IC50,nM,87.0,IC50,uM,0.087,COc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1ccc(-c2n[nH]c3ncnc(N)c23)cc1OC,CHEMBL1240340,=,=,IC50,nM,909.0,IC50,uM,0.909,CCOc1ccc(-c2n[nH]c3ncnc(N)c23)cc1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1OC,CHEMBL1240340,=,=,IC50,nM,5160.0,IC50,uM,5.16,CCOc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,C=CCn1nc(-c2ccc(OCC)c(OC)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,311.0,IC50,uM,0.311,C=CCn1nc(-c2ccc(OCC)c(OC)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1OC,CHEMBL1240340,=,=,IC50,nM,116.0,IC50,uM,0.116,CCOc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1ccc(-c2nn(C3CCCCC3)c3ncnc(N)c23)cc1OC,CHEMBL1240340,=,=,IC50,nM,353.0,IC50,uM,0.353,CCOc1ccc(-c2nn(C3CCCCC3)c3ncnc(N)c23)cc1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)cc(OC)c1OC,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)cc(OC)c1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1OC,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,COc1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1OC,CHEMBL1240340,=,=,IC50,nM,723.0,IC50,uM,0.723,CCOc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1cc(-c2nn(CCO)c3ncnc(N)c23)ccc1OC,CHEMBL1240340,=,=,IC50,nM,2010.0,IC50,uM,2.01,CCOc1cc(-c2nn(CCO)c3ncnc(N)c23)ccc1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ncc(-c2nn(C(C)C)c3ncnc(N)c23)c(OC)n1,CHEMBL1240340,=,=,IC50,nM,8020.0,IC50,uM,8.02,COc1ncc(-c2nn(C(C)C)c3ncnc(N)c23)c(OC)n1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1,CHEMBL1240340,=,=,IC50,nM,1400.0,IC50,uM,1.4,COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(-c3ccccc3O)c12,CHEMBL1240340,=,=,IC50,nM,50000.0,IC50,uM,50.0,Nc1ncnc2[nH]nc(-c3ccccc3O)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(N)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,1450.0,IC50,uM,1.45,CC(C)n1nc(-c2ccc(N)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1N,CHEMBL1240340,=,=,IC50,nM,700.0,IC50,uM,0.7,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1N,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1NC(C)CO,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1NC(C)CO,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O,CHEMBL1240340,=,=,IC50,nM,735.0,IC50,uM,0.735,Nc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C3CCCC3)c3ncnc(N)c23)ccc1N,CHEMBL1240340,=,=,IC50,nM,271.0,IC50,uM,0.271,COc1cc(-c2nn(C3CCCC3)c3ncnc(N)c23)ccc1N,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ccc(-c2n[nH]c3ncnc(N)c23)cc1,CHEMBL1240340,=,=,IC50,nM,11000.0,IC50,uM,11.0,Nc1ccc(-c2n[nH]c3ncnc(N)c23)cc1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1cccc(-c2n[nH]c3ncnc(N)c23)c1,CHEMBL1240340,=,=,IC50,nM,9600.0,IC50,uM,9.6,Nc1cccc(-c2n[nH]c3ncnc(N)c23)c1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(-c3ccc([N+](=O)[O-])cc3)c12,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,Nc1ncnc2[nH]nc(-c3ccc([N+](=O)[O-])cc3)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(-c3cccc([N+](=O)[O-])c3)c12,CHEMBL1240340,=,=,IC50,nM,3000.0,IC50,uM,3.0,Nc1ncnc2[nH]nc(-c3cccc([N+](=O)[O-])c3)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(CO)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,890.0,IC50,uM,0.89,CC(C)n1nc(-c2cccc(CO)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(CC#N)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,1300.0,IC50,uM,1.3,CC(C)n1nc(-c2cccc(CC#N)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(CC#N)cc2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,10000.0,IC50,uM,10.0,CC(C)n1nc(-c2ccc(CC#N)cc2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(C#N)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,2400.0,IC50,uM,2.4,CC(C)n1nc(-c2cccc(C#N)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(F)c(C#N)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,3500.0,IC50,uM,3.5,CC(C)n1nc(-c2ccc(F)c(C#N)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(C#N)c(F)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,6200.0,IC50,uM,6.2,CC(C)n1nc(-c2ccc(C#N)c(F)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(C#N)nc2)c2c(N)ncnc21,CHEMBL1240340,,,IC50,,,IC50,,,CC(C)n1nc(-c2ccc(C#N)nc2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccnc2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,2300.0,IC50,uM,2.3,CC(C)n1nc(-c2cccnc2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cncnc2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,CC(C)n1nc(-c2cncnc2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(=O)c1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1,CHEMBL1240340,=,=,IC50,nM,860.0,IC50,uM,0.86,CC(=O)c1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(C=O)c(F)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,2400.0,IC50,uM,2.4,CC(C)n1nc(-c2ccc(C=O)c(F)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc(F)c(C=O)c(F)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,4200.0,IC50,uM,4.2,CC(C)n1nc(-c2cc(F)c(C=O)c(F)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(C(N)=O)c(Cl)c2)c2c(N)ncnc21,CHEMBL1240340,,,IC50,,,IC50,,,CC(C)n1nc(-c2ccc(C(N)=O)c(Cl)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(=O)c1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1,CHEMBL1240340,=,=,IC50,nM,1200.0,IC50,uM,1.2,CC(=O)c1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc(C=O)co2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,940.0,IC50,uM,0.94,CC(C)n1nc(-c2cc(C=O)co2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1cc(-c2nn(C(C)C)c3ncnc(N)c23)sc1C=O,CHEMBL1240340,=,=,IC50,nM,1400.0,IC50,uM,1.4,Cc1cc(-c2nn(C(C)C)c3ncnc(N)c23)sc1C=O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(NS(C)(=O)=O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,680.0,IC50,uM,0.68,CC(C)n1nc(-c2cccc(NS(C)(=O)=O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(NS(C)(=O)=O)cc2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,7200.0,IC50,uM,7.2,CC(C)n1nc(-c2ccc(NS(C)(=O)=O)cc2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(S(N)(=O)=O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,900.0,IC50,uM,0.9,CC(C)n1nc(-c2cccc(S(N)(=O)=O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(S(N)(=O)=O)cc2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,4000.0,IC50,uM,4.0,CC(C)n1nc(-c2ccc(S(N)(=O)=O)cc2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(C(=O)NC3=NCCS3)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,990.0,IC50,uM,0.99,CC(C)n1nc(-c2cccc(C(=O)NC3=NCCS3)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(-c3ccc(NC(=O)c4ccc(-c5ccccc5)cc4)cc3)c12,CHEMBL1240340,=,=,IC50,nM,25000.0,IC50,uM,25.0,Nc1ncnc2[nH]nc(-c3ccc(NC(=O)c4ccc(-c5ccccc5)cc4)cc3)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(-c3ccc(Oc4ccccc4)cc3)c12,CHEMBL1240340,=,=,IC50,nM,50000.0,IC50,uM,50.0,Nc1ncnc2[nH]nc(-c3ccc(Oc4ccccc4)cc3)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(-c3cccc(Oc4ccccc4)c3)c12,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,Nc1ncnc2[nH]nc(-c3cccc(Oc4ccccc4)c3)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2ccc(OCc3ccccc3)cc2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,Cn1nc(-c2ccc(OCc3ccccc3)cc2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(-c3cccc(OCc4ccccc4)c3)c12,CHEMBL1240340,=,=,IC50,nM,20000.0,IC50,uM,20.0,Nc1ncnc2[nH]nc(-c3cccc(OCc4ccccc4)c3)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(-c3cccc(OCc4c(Cl)cccc4Cl)c3)c12,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,Nc1ncnc2[nH]nc(-c3cccc(OCc4c(Cl)cccc4Cl)c3)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2CCc1ccccc1,CHEMBL1240340,=,=,IC50,nM,6300.0,IC50,uM,6.3,Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2CCc1ccccc1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,NC(=O)Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,5100.0,IC50,uM,5.1,NC(=O)Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2CC1CC1,CHEMBL1240340,=,=,IC50,nM,4000.0,IC50,uM,4.0,Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2CC1CC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)CCn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,16000.0,IC50,uM,16.0,CC(C)CCn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2C/C=C/c1ccccc1,CHEMBL1240340,,,IC50,,,IC50,,,Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2C/C=C/c1ccccc1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,147.0,IC50,uM,0.147,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@@H]1CCNC1,CHEMBL1240340,=,=,IC50,nM,366.0,IC50,uM,0.366,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@@H]1CCNC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@H]1CCOC1,CHEMBL1240340,=,=,IC50,nM,58.0,IC50,uM,0.058,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@H]1CCOC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@@H]1CCOC1,CHEMBL1240340,=,=,IC50,nM,43.0,IC50,uM,0.043,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@@H]1CCOC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCCN1,CHEMBL1240340,=,=,IC50,nM,1820.0,IC50,uM,1.82,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCCN1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCNC1,CHEMBL1240340,=,=,IC50,nM,1390.0,IC50,uM,1.39,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCNC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCCNC1,CHEMBL1240340,=,=,IC50,nM,12500.0,IC50,uM,12.5,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCCNC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCNCC1,CHEMBL1240340,=,=,IC50,nM,1530.0,IC50,uM,1.53,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCNCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CCC1CCCNC1,CHEMBL1240340,=,=,IC50,nM,2410.0,IC50,uM,2.41,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CCC1CCCNC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(C#N)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,28.0,IC50,uM,0.028,CC(C)n1nc(-c2ccc(C#N)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(O)c(F)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,187.0,IC50,uM,0.187,CC(C)n1nc(-c2ccc(O)c(F)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(F)c(-c2nn(C(C)C)c3ncnc(N)c23)cc1F,CHEMBL1240340,=,=,IC50,nM,821.0,IC50,uM,0.821,COc1cc(F)c(-c2nn(C(C)C)c3ncnc(N)c23)cc1F,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc(F)c(O)cc2F)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,118.0,IC50,uM,0.118,CC(C)n1nc(-c2cc(F)c(O)cc2F)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1,CHEMBL1240340,=,=,IC50,nM,1100.0,IC50,uM,1.1,COc1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1O,CHEMBL1240340,=,=,IC50,nM,190.0,IC50,uM,0.19,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2n[nH]c3ncnc(N)c23)cc1O,CHEMBL1240340,=,=,IC50,nM,523.0,IC50,uM,0.523,COc1ccc(-c2n[nH]c3ncnc(N)c23)cc1O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C)c3ncnc(N)c23)cc1O,CHEMBL1240340,=,=,IC50,nM,200.0,IC50,uM,0.2,COc1ccc(-c2nn(C)c3ncnc(N)c23)cc1O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CCn1nc(-c2ccc(OC)c(O)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,355.0,IC50,uM,0.355,CCn1nc(-c2ccc(OC)c(O)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1O,CHEMBL1240340,=,=,IC50,nM,340.0,IC50,uM,0.34,COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O,CHEMBL1240340,=,=,IC50,nM,120.0,IC50,uM,0.12,COc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C3CCC(C)C3)c3ncnc(N)c23)cc1O,CHEMBL1240340,=,=,IC50,nM,113.0,IC50,uM,0.113,COc1ccc(-c2nn(C3CCC(C)C3)c3ncnc(N)c23)cc1O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C3CNC3)c3ncnc(N)c23)cc1O,CHEMBL1240340,=,=,IC50,nM,460.0,IC50,uM,0.46,COc1ccc(-c2nn(C3CNC3)c3ncnc(N)c23)cc1O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn([C@@H]3CCNC3)c3ncnc(N)c23)cc1O,CHEMBL1240340,=,=,IC50,nM,1270.0,IC50,uM,1.27,COc1ccc(-c2nn([C@@H]3CCNC3)c3ncnc(N)c23)cc1O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O,CHEMBL1240340,=,=,IC50,nM,381.0,IC50,uM,0.381,CCOc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1OC,CHEMBL1240340,=,=,IC50,nM,200.0,IC50,uM,0.2,COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1OC,CHEMBL1240340,=,=,IC50,nM,1080.0,IC50,uM,1.08,COc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C[C@H](C)CO)c3ncnc(N)c23)cc1OC,CHEMBL1240340,=,=,IC50,nM,1900.0,IC50,uM,1.9,COc1ccc(-c2nn(C[C@H](C)CO)c3ncnc(N)c23)cc1OC,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,C#CCn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,CHEMBL1240340,,,IC50,,,IC50,,,C#CCn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1ccc2cc(-c3nn(C)c4ncnc(N)c34)ccc2c1,CHEMBL1240340,=,=,IC50,nM,2700.0,IC50,uM,2.7,CCOc1ccc2cc(-c3nn(C)c4ncnc(N)c34)ccc2c1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3cc(O)ccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,587.0,IC50,uM,0.587,CC(C)n1nc(-c2ccc3cc(O)ccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc3ccccc3nc2Cl)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,CC(C)n1nc(-c2cc3ccccc3nc2Cl)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cnc3ccccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,2700.0,IC50,uM,2.7,CC(C)n1nc(-c2cnc3ccccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1cnc3ccccc3c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,1300.0,IC50,uM,1.3,Nc1ncnc2c1c(-c1cnc3ccccc3c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,220.0,IC50,uM,0.22,Cn1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2cccc(-c3ccccc3)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,Cn1nc(-c2cccc(-c3ccccc3)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(-c3ccc(-c4ccccc4)cc3)c12,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,Nc1ncnc2[nH]nc(-c3ccc(-c4ccccc4)cc3)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(C3CCc4ccccc4C3)c12,CHEMBL1240340,=,=,IC50,nM,50000.0,IC50,uM,50.0,Nc1ncnc2[nH]nc(C3CCc4ccccc4C3)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(-c3ccc4ccccc4c3)c12,CHEMBL1240340,=,=,IC50,nM,970.0,IC50,uM,0.97,Nc1ncnc2[nH]nc(-c3ccc4ccccc4c3)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CCn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,CHEMBL1240340,,,IC50,,,IC50,,,CCn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,C=CCn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,3600.0,IC50,uM,3.6,C=CCn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,4500.0,IC50,uM,4.5,CC(C)n1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)(C)n1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,CC(C)(C)n1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,6800.0,IC50,uM,6.8,Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2Cc1ccccc1,CHEMBL1240340,=,=,IC50,nM,17000.0,IC50,uM,17.0,Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2Cc1ccccc1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3ncccc3c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,590.0,IC50,uM,0.59,Nc1ncnc2c1c(-c1ccc3ncccc3c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2n1,CHEMBL1240340,=,=,IC50,nM,461.0,IC50,uM,0.461,Cc1ccc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2n1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nc(Cl)ccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,184.0,IC50,uM,0.184,CC(C)n1nc(-c2ccc3nc(Cl)ccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nccnc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,95.0,IC50,uM,0.095,CC(C)n1nc(-c2ccc3nccnc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cnc3nccnc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,CC(C)n1nc(-c2cnc3nccnc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nc[nH]c(=O)c3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,89.0,IC50,uM,0.089,CC(C)n1nc(-c2ccc3nc[nH]c(=O)c3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3[nH]c(=O)ccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,CC(C)n1nc(-c2ccc3[nH]c(=O)ccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3[nH]c(=O)ccc3c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,Nc1ncnc2c1c(-c1ccc3[nH]c(=O)ccc3c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nc(N)ccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,242.0,IC50,uM,0.242,CC(C)n1nc(-c2ccc3nc(N)ccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nc(NN)ccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,586.0,IC50,uM,0.586,CC(C)n1nc(-c2ccc3nc(NN)ccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nccc(NC(=O)OC(C)(C)C)c3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,7300.0,IC50,uM,7.3,CC(C)n1nc(-c2ccc3nccc(NC(=O)OC(C)(C)C)c3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nccc(N)c3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,6900.0,IC50,uM,6.9,CC(C)n1nc(-c2ccc3nccc(N)c3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2ccc3occc(=O)c3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,3000.0,IC50,uM,3.0,Cn1nc(-c2ccc3occc(=O)c3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3occc(=O)c3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,3000.0,IC50,uM,3.0,CC(C)n1nc(-c2ccc3occc(=O)c3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3occc(=O)c3c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,60.0,IC50,uM,0.06,Nc1ncnc2c1c(-c1ccc3occc(=O)c3c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3cnccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,CC(C)n1nc(-c2ccc3cnccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3ccncc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,167.0,IC50,uM,0.167,CC(C)n1nc(-c2ccc3ccncc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc2n1,CHEMBL1240340,=,=,IC50,nM,228.0,IC50,uM,0.228,Cc1ccc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc2n1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,640.0,IC50,uM,0.64,Cn1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,1300.0,IC50,uM,1.3,CC(C)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3[nH]ccc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,123.0,IC50,uM,0.123,CC(C)n1nc(-c2ccc3[nH]ccc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3[nH]ccc3c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,435.0,IC50,uM,0.435,Nc1ncnc2c1c(-c1ccc3[nH]ccc3c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3c(ccn3C)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,627.0,IC50,uM,0.627,CC(C)n1nc(-c2ccc3c(ccn3C)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1ccc2cc(-c3nn(C4CCCC4)c4ncnc(N)c34)ccc21,CHEMBL1240340,=,=,IC50,nM,31000.0,IC50,uM,31.0,Cn1ccc2cc(-c3nn(C4CCCC4)c4ncnc(N)c34)ccc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3[nH]ncc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,113.0,IC50,uM,0.113,CC(C)n1nc(-c2ccc3[nH]ncc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3[nH]ncc3c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,90.0,IC50,uM,0.09,Nc1ncnc2c1c(-c1ccc3[nH]ncc3c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3c(N)n[nH]c3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,101.0,IC50,uM,0.101,CC(C)n1nc(-c2ccc3c(N)n[nH]c3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3cn[nH]c3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,330.0,IC50,uM,0.33,CC(C)n1nc(-c2ccc3cn[nH]c3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3cn[nH]c3c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,830.0,IC50,uM,0.83,Nc1ncnc2c1c(-c1ccc3cn[nH]c3c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc(F)c3cn[nH]c3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,625.0,IC50,uM,0.625,CC(C)n1nc(-c2cc(F)c3cn[nH]c3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2ccc3cc[nH]c3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,1800.0,IC50,uM,1.8,Cn1nc(-c2ccc3cc[nH]c3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3cc[nH]c3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,2000.0,IC50,uM,2.0,CC(C)n1nc(-c2ccc3cc[nH]c3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3cc[nH]c3c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,1500.0,IC50,uM,1.5,Nc1ncnc2c1c(-c1ccc3cc[nH]c3c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccn3ccnc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,100000.0,IC50,uM,100.0,CC(C)n1nc(-c2ccn3ccnc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3c(C=O)c[nH]c3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,140.0,IC50,uM,0.14,CC(C)n1nc(-c2ccc3c(C=O)c[nH]c3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc3[nH]ccc23)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,1022.0,IC50,uM,1.022,CC(C)n1nc(-c2cccc3[nH]ccc23)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1cccc3[nH]ccc13)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,1140.0,IC50,uM,1.14,Nc1ncnc2c1c(-c1cccc3[nH]ccc13)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3c(ccn3C(=O)OC(C)(C)C)c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,799.0,IC50,uM,0.799,CC(C)n1nc(-c2ccc3c(ccn3C(=O)OC(C)(C)C)c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)(C)OC(=O)n1ccc2cc(-c3nn(C4CCCC4)c4ncnc(N)c34)ccc21,CHEMBL1240340,=,=,IC50,nM,873.0,IC50,uM,0.873,CC(C)(C)OC(=O)n1ccc2cc(-c3nn(C4CCCC4)c4ncnc(N)c34)ccc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3occc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,347.0,IC50,uM,0.347,CC(C)n1nc(-c2ccc3occc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3occc3c1)nn2C1CCCC1,CHEMBL1240340,=,=,IC50,nM,239.0,IC50,uM,0.239,Nc1ncnc2c1c(-c1ccc3occc3c1)nn2C1CCCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nonc3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,5900.0,IC50,uM,5.9,CC(C)n1nc(-c2ccc3nonc3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3[nH]c(=O)[nH]c3c2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,22000.0,IC50,uM,22.0,CC(C)n1nc(-c2ccc3[nH]c(=O)[nH]c3c2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3c(c2)CCO3)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,430.0,IC50,uM,0.43,CC(C)n1nc(-c2ccc3c(c2)CCO3)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2[nH]nc(-c3ccc4c(c3)OCO4)c12,CHEMBL1240340,=,=,IC50,nM,4000.0,IC50,uM,4.0,Nc1ncnc2[nH]nc(-c3ccc4c(c3)OCO4)c12,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3c(c2)OCCO3)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,1100.0,IC50,uM,1.1,CC(C)n1nc(-c2ccc3c(c2)OCCO3)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2cc3ccccc3s2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,1600.0,IC50,uM,1.6,Cn1nc(-c2cc3ccccc3s2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc3cc(C=O)ccc3s2)c2c(N)ncnc21,CHEMBL1240340,=,=,IC50,nM,2400.0,IC50,uM,2.4,CC(C)n1nc(-c2cc3cc(C=O)ccc3s2)c2c(N)ncnc21,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,CHEMBL1240340,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,CHEMBL1240340,>,>,IC50,nM,50000.0,IC50,uM,50.0,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,2008
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,CHEMBL1240340,=,=,IC50,nM,13000.0,IC50,uM,13.0,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,2008
Binding affinity to PIK3CG,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,CHEMBL1240346,=,=,Kd,nM,350.0,Kd,nM,350.0,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,2009
Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,CHEMBL1240340,>,>,IC50,nM,50000.0,IC50,uM,50.0,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,2008
Binding affinity to PIK3CG,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,CHEMBL1240346,>,>,Kd,nM,10000.0,Kd,uM,10.0,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,2009
Binding affinity to PIK3CG,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,CHEMBL1240346,>,>,Kd,nM,10000.0,Kd,uM,10.0,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,2009
Binding affinity to PIK3CG,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,CHEMBL1240346,>,>,Kd,nM,10000.0,Kd,uM,10.0,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,2009
Binding affinity to PIK3CG,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,CHEMBL1240346,>,>,Kd,nM,10000.0,Kd,uM,10.0,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,2009
Binding affinity to PIK3CG,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1240346,>,>,Kd,nM,10000.0,Kd,uM,10.0,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2009
Binding affinity to PIK3CG,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,CHEMBL1240346,>,>,Kd,nM,10000.0,Kd,uM,10.0,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,2009
Inhibition of PI3K-gamma,O=C(Nc1ccccc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,CHEMBL1255533,=,=,IC50,nM,51.0,IC50,nM,51.0,O=C(Nc1ccccc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,2010
Inhibition of PI3K-gamma,O=C(Nc1ccc(F)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,CHEMBL1255533,=,=,IC50,nM,154.0,IC50,nM,154.0,O=C(Nc1ccc(F)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,2010
Inhibition of PI3K-gamma,Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1,CHEMBL1255533,=,=,IC50,nM,122.0,IC50,nM,122.0,Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1,2010
Inhibition of PI3K-gamma,N#Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1,CHEMBL1255533,=,=,IC50,nM,290.0,IC50,nM,290.0,N#Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1,2010
Inhibition of PI3K-gamma,COc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1OC,CHEMBL1255533,=,=,IC50,nM,358.0,IC50,nM,358.0,COc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1OC,2010
Inhibition of PI3K-gamma,O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,CHEMBL1255533,=,=,IC50,nM,98.0,IC50,nM,98.0,O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,2010
Inhibition of PI3K-gamma,O=C(Nc1ccc(CCO)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,CHEMBL1255533,=,=,IC50,nM,74.0,IC50,nM,74.0,O=C(Nc1ccc(CCO)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,2010
Inhibition of PI3K-gamma,CN(C)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1,CHEMBL1255533,=,=,IC50,nM,717.0,IC50,nM,717.0,CN(C)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1,2010
Inhibition of PI3K-gamma,CN1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1,CHEMBL1255533,=,=,IC50,nM,45.2,IC50,nM,45.2,CN1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1,2010
Inhibition of PI3K-gamma,CN(C)CCOc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1,CHEMBL1255533,=,=,IC50,nM,100.0,IC50,nM,100.0,CN(C)CCOc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1,2010
Inhibition of PI3K-gamma,CN1CCN(Cc2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1,CHEMBL1255533,=,=,IC50,nM,189.5,IC50,nM,189.5,CN1CCN(Cc2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1,2010
Inhibition of PI3K-gamma,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1cccnc1,CHEMBL1255533,=,=,IC50,nM,150.0,IC50,nM,150.0,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1cccnc1,2010
Inhibition of PI3K-gamma,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,CHEMBL1255533,=,=,IC50,nM,74.0,IC50,nM,74.0,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,2010
Inhibition of PI3K-gamma,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1ccnc(Cl)c1,CHEMBL1255533,=,=,IC50,nM,99.0,IC50,nM,99.0,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1ccnc(Cl)c1,2010
Inhibition of PI3K-gamma,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1ccc(-c2cccnc2)nc1,CHEMBL1255533,=,=,IC50,nM,44.0,IC50,nM,44.0,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1ccc(-c2cccnc2)nc1,2010
Inhibition of PI3K-gamma,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1cncnc1,CHEMBL1255533,=,=,IC50,nM,240.0,IC50,nM,240.0,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1cncnc1,2010
Inhibition of PI3K-gamma,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1ccnnc1,CHEMBL1255533,=,=,IC50,nM,149.0,IC50,nM,149.0,O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1ccnnc1,2010
Inhibition of PI3K-gamma,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4COCC3[C@@H](O)C4)n2)cc1,CHEMBL1255533,=,=,IC50,nM,33.0,IC50,nM,33.0,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4COCC3[C@@H](O)C4)n2)cc1,2010
Inhibition of PI3Kgamma,Cn1ncc2c(Oc3ccc(S(C)(=O)=O)cc3)cc(-c3cccc4[nH]ncc34)nc21,CHEMBL1255193,=,=,IC50,nM,8.0,IC50,uM,0.008,Cn1ncc2c(Oc3ccc(S(C)(=O)=O)cc3)cc(-c3cccc4[nH]ncc34)nc21,2010
Inhibition of P110gamma,CCC(=O)N1CCN(c2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1,CHEMBL1255226,=,=,IC50,nM,171.0,IC50,nM,171.0,CCC(=O)N1CCN(c2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1,2010
Inhibition of PI3Kgamma at 10,Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccccn1,CHEMBL1275350,=,=,Inhibition,%,0.0,INH,%,0.0,Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccccn1,2010
Inhibition of PI3Kgamma,Oc1cccc(-c2cc(Nc3ccc4[nH]ncc4c3)nc(N3CCOCC3)n2)c1,CHEMBL1287711,=,=,IC50,nM,570.0,IC50,uM,0.57,Oc1cccc(-c2cc(Nc3ccc4[nH]ncc4c3)nc(N3CCOCC3)n2)c1,2010
Inhibition of PI3Kgamma,COc1ccc(Nc2cc(-c3cccc(O)c3)nc(N3CCOCC3)n2)cn1,CHEMBL1287711,,,IC50,,,IC50,,,COc1ccc(Nc2cc(-c3cccc(O)c3)nc(N3CCOCC3)n2)cn1,2010
Inhibition of PI3Kgamma,Nc1cccc(C#Cc2n[nH]c3ccccc23)c1,CHEMBL1629532,>,>,IC50,nM,100000.0,IC50,uM,100.0,Nc1cccc(C#Cc2n[nH]c3ccccc23)c1,2010
Inhibition of PI3Kgamma,Nc1ccc(C#Cc2n[nH]c3ccccc23)cc1,CHEMBL1629532,>,>,IC50,nM,100000.0,IC50,uM,100.0,Nc1ccc(C#Cc2n[nH]c3ccccc23)cc1,2010
Inhibition of PI3Kgamma,C(#Cc1n[nH]c2ccccc12)c1ccncc1,CHEMBL1629532,=,=,IC50,nM,40000.0,IC50,uM,40.0,C(#Cc1n[nH]c2ccccc12)c1ccncc1,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,C[C@@H]1CC[C@H]2C(C)(C)CCC[C@]2(C)c2c1oc1c(C=O)c(O)c(O)cc21,CHEMBL1629458,=,=,IC50,nM,1000.0,IC50,uM,1.0,C[C@@H]1CC[C@H]2C(C)(C)CCC[C@]2(C)c2c1oc1c(C=O)c(O)c(O)cc21,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,CHEMBL1629458,,,IC50,,,IC50,,,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL1629458,,,IC50,,,IC50,,,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,C[C@@H]1CC[C@H]2C(C)(C)CCC[C@]2(C)C2=C3C=C(O)C(=O)C(Br)=C3OC21O,CHEMBL1629458,>,>,IC50,nM,10000.0,IC50,uM,10.0,C[C@@H]1CC[C@H]2C(C)(C)CCC[C@]2(C)C2=C3C=C(O)C(=O)C(Br)=C3OC21O,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,C[C@@H]1CCCC(C)(C)C12CC[C@H](C)c1oc3c(Br)c(O)c(O)cc3c12,CHEMBL1629458,=,=,IC50,nM,5300.0,IC50,uM,5.3,C[C@@H]1CCCC(C)(C)C12CC[C@H](C)c1oc3c(Br)c(O)c(O)cc3c12,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,COc1ccc2c3c(oc2c1Br)[C@H](C)CC[C@H]1C(C)(C)CCC[C@]31C,CHEMBL1629458,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc2c3c(oc2c1Br)[C@H](C)CC[C@H]1C(C)(C)CCC[C@]31C,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,C[C@@H]1CC[C@H]2C(C)(C)CCC[C@]2(C)c2c1oc1c(Br)c(O)ccc21,CHEMBL1629458,=,=,IC50,nM,5700.0,IC50,uM,5.7,C[C@@H]1CC[C@H]2C(C)(C)CCC[C@]2(C)c2c1oc1c(Br)c(O)ccc21,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,C[C@@H]1CC[C@H]2C(C)(C)CCC[C@]2(C)c2c1oc1ccc(O)cc21,CHEMBL1629458,=,=,IC50,nM,1900.0,IC50,uM,1.9,C[C@@H]1CC[C@H]2C(C)(C)CCC[C@]2(C)c2c1oc1ccc(O)cc21,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,C[C@@H]1CC[C@H]2C(C)(C)CCC[C@]2(C)c2c1oc1cc(O)ccc21,CHEMBL1629458,>,>,IC50,nM,10000.0,IC50,uM,10.0,C[C@@H]1CC[C@H]2C(C)(C)CCC[C@]2(C)c2c1oc1cc(O)ccc21,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,C[C@H]1CC[C@H]2C(C)(C)CCC[C@]2(C)c2c1oc1cc(O)ccc21,CHEMBL1629458,=,=,IC50,nM,2200.0,IC50,uM,2.2,C[C@H]1CC[C@H]2C(C)(C)CCC[C@]2(C)c2c1oc1cc(O)ccc21,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,CC1(C)CCC[C@]2(C)C3=C4C=C(O)C(=O)C=C4OC3(O)CC[C@@H]12,CHEMBL1629458,=,=,IC50,nM,9570.0,IC50,uM,9.57,CC1(C)CCC[C@]2(C)C3=C4C=C(O)C(=O)C=C4OC3(O)CC[C@@H]12,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,COc1cc2c3c(oc2c(C=O)c1OC)CC[C@H]1C(C)(C)CCC[C@]31C,CHEMBL1629458,=,=,IC50,nM,2640.0,IC50,uM,2.64,COc1cc2c3c(oc2c(C=O)c1OC)CC[C@H]1C(C)(C)CCC[C@]31C,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,CC1(C)CCC[C@]2(C)c3c(oc4c(C=O)c(O)c(O)cc34)CC[C@@H]12,CHEMBL1629458,=,=,IC50,nM,1800.0,IC50,uM,1.8,CC1(C)CCC[C@]2(C)c3c(oc4c(C=O)c(O)c(O)cc34)CC[C@@H]12,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,COc1cc2c3c(oc2c(C=O)c1O)CC[C@H]1C(C)(C)CCC[C@]31C,CHEMBL1629458,=,=,IC50,nM,5150.0,IC50,uM,5.15,COc1cc2c3c(oc2c(C=O)c1O)CC[C@H]1C(C)(C)CCC[C@]31C,2010
Inhibition of human PI3Kgamma expressed in Sf9 cells by fluorescent polarization assay,CC1(C)CCC[C@]2(C)c3c(oc4c(C(N)=O)c(O)c(O)cc34)CC[C@@H]12,CHEMBL1629458,=,=,IC50,nM,1400.0,IC50,uM,1.4,CC1(C)CCC[C@]2(C)c3c(oc4c(C(N)=O)c(O)c(O)cc34)CC[C@@H]12,2010
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,CHEMBL1641442,=,=,IC50,nM,89.0,IC50,uM,0.089,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,c1cc(-c2cnc3[nH]ccc3c2)ccn1,CHEMBL1641442,=,=,IC50,nM,70000.0,IC50,uM,70.0,c1cc(-c2cnc3[nH]ccc3c2)ccn1,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,Nc1ncnc2sc(-c3ccncc3)nc12,CHEMBL1641442,=,=,IC50,nM,43500.0,IC50,uM,43.5,Nc1ncnc2sc(-c3ccncc3)nc12,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,N#Cc1cc(-c2ccncc2)cnc1O,CHEMBL1641442,>,>,IC50,nM,83300.0,IC50,uM,83.3,N#Cc1cc(-c2ccncc2)cnc1O,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,Oc1ccc2oc(-c3ccncc3)nc2c1,CHEMBL1641442,>,>,IC50,nM,83300.0,IC50,uM,83.3,Oc1ccc2oc(-c3ccncc3)nc2c1,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,Cc1cc(-c2cnc(N)c(C(N)=O)c2)ccn1,CHEMBL1641442,,,IC50,,,IC50,,,Cc1cc(-c2cnc(N)c(C(N)=O)c2)ccn1,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,Nc1nc2nc(-c3ccncc3)ccn2n1,CHEMBL1641442,=,=,IC50,nM,55400.0,IC50,uM,55.4,Nc1nc2nc(-c3ccncc3)ccn2n1,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,Nc1ccc2oc(-c3ccncc3)nc2c1,CHEMBL1641442,>,>,IC50,nM,83300.0,IC50,uM,83.3,Nc1ccc2oc(-c3ccncc3)nc2c1,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,O=c1[nH]cnc2cc(N3CCOCC3)ccc12,CHEMBL1641442,>,>,IC50,nM,83300.0,IC50,uM,83.3,O=c1[nH]cnc2cc(N3CCOCC3)ccc12,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,c1cc(N2CCOCC2)c2cn[nH]c2n1,CHEMBL1641442,>,>,IC50,nM,83300.0,IC50,uM,83.3,c1cc(N2CCOCC2)c2cn[nH]c2n1,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,Cc1nc(N2CCOCC2)sc1C(=O)O,CHEMBL1641442,>,>,IC50,nM,83300.0,IC50,uM,83.3,Cc1nc(N2CCOCC2)sc1C(=O)O,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,Nc1ncnc2nc(N3CCOCC3)ncc12,CHEMBL1641442,>,>,IC50,nM,83300.0,IC50,uM,83.3,Nc1ncnc2nc(N3CCOCC3)ncc12,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,CN(C)c1nc(N2CCOCC2)cc(=O)[nH]1,CHEMBL1641442,,,IC50,,,IC50,,,CN(C)c1nc(N2CCOCC2)cc(=O)[nH]1,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,COc1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL1641442,,,IC50,,,IC50,,,COc1ccc(-c2ccc3nc(N)sc3c2)cn1,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,Nc1nc2cc(-c3ccncc3)ccc2s1,CHEMBL1641442,=,=,IC50,nM,77000.0,IC50,uM,77.0,Nc1nc2cc(-c3ccncc3)ccc2s1,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,Nc1nc2ccc(-c3ccncc3)cc2s1,CHEMBL1641442,=,=,IC50,nM,9700.0,IC50,uM,9.7,Nc1nc2ccc(-c3ccncc3)cc2s1,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,Nc1nc2ccc(-c3cccc(O)c3)cc2s1,CHEMBL1641442,=,=,IC50,nM,9100.0,IC50,uM,9.1,Nc1nc2ccc(-c3cccc(O)c3)cc2s1,2011
Inhibition of human PI3K p110gamma catalytic subunit by AlphaScreen assay,Cn1ccc2cc(N)ncc21,CHEMBL1641442,,,IC50,,,IC50,,,Cn1ccc2cc(N)ncc21,2011
Inhibition of human PI3K p110gamma catalytic subunit at 83.3 uM by AlphaScreen assay,Nc1nonc1-c1noc(Cc2cccs2)n1,CHEMBL1641442,,,IC50,,,IC50,,,Nc1nonc1-c1noc(Cc2cccs2)n1,2011
Inhibition of human recombinant PI3K p110gamma after 1 hr by radiometric scintillation proximity assay,Oc1cccc(-c2nc(-c3ccccn3)cc(N3CCOCC3)n2)c1,CHEMBL1641516,=,=,IC50,nM,44.0,IC50,uM,0.044,Oc1cccc(-c2nc(-c3ccccn3)cc(N3CCOCC3)n2)c1,2011
Inhibition of human recombinant PI3K p110gamma after 1 hr by radiometric scintillation proximity assay,Oc1cccc(-c2nc(-c3cccnc3)cc(N3CCOCC3)n2)c1,CHEMBL1641516,=,=,IC50,nM,340.0,IC50,uM,0.34,Oc1cccc(-c2nc(-c3cccnc3)cc(N3CCOCC3)n2)c1,2011
Inhibition of human recombinant PI3K p110gamma after 1 hr by radiometric scintillation proximity assay,Oc1cccc(-c2nc(-c3ccncc3)cc(N3CCOCC3)n2)c1,CHEMBL1641516,=,=,IC50,nM,150.0,IC50,uM,0.15,Oc1cccc(-c2nc(-c3ccncc3)cc(N3CCOCC3)n2)c1,2011
Inhibition of human recombinant PI3K p110gamma after 1 hr by radiometric scintillation proximity assay,Oc1cccc(-c2cc(NCc3ccccn3)nc(N3CCOCC3)n2)c1,CHEMBL1641516,=,=,IC50,nM,7600.0,IC50,uM,7.6,Oc1cccc(-c2cc(NCc3ccccn3)nc(N3CCOCC3)n2)c1,2011
Inhibition of human recombinant PI3K p110gamma after 1 hr by radiometric scintillation proximity assay,Oc1cccc(-c2cc(NCCc3ccccn3)nc(N3CCOCC3)n2)c1,CHEMBL1641516,=,=,IC50,nM,830.0,IC50,uM,0.83,Oc1cccc(-c2cc(NCCc3ccccn3)nc(N3CCOCC3)n2)c1,2011
Inhibition of human recombinant PI3K p110gamma after 1 hr by radiometric scintillation proximity assay,Oc1cccc(-c2cc(NCCc3cccnc3)nc(N3CCOCC3)n2)c1,CHEMBL1641516,=,=,IC50,nM,960.0,IC50,uM,0.96,Oc1cccc(-c2cc(NCCc3cccnc3)nc(N3CCOCC3)n2)c1,2011
Inhibition of human recombinant PI3K p110gamma after 1 hr by radiometric scintillation proximity assay,Oc1cccc(-c2cc(NCCc3ccncc3)nc(N3CCOCC3)n2)c1,CHEMBL1641516,=,=,IC50,nM,740.0,IC50,uM,0.74,Oc1cccc(-c2cc(NCCc3ccncc3)nc(N3CCOCC3)n2)c1,2011
Inhibition of human recombinant PI3K p110gamma after 1 hr by radiometric scintillation proximity assay,Oc1cccc(-c2cc(N3CCOCC3)nc(NCCc3ccccn3)n2)c1,CHEMBL1641516,=,=,IC50,nM,380.0,IC50,uM,0.38,Oc1cccc(-c2cc(N3CCOCC3)nc(NCCc3ccccn3)n2)c1,2011
Inhibition of human recombinant PI3K p110gamma after 1 hr by radiometric scintillation proximity assay,Oc1cccc(-c2cc(OCc3ccccn3)nc(N3CCOCC3)n2)c1,CHEMBL1641516,=,=,IC50,nM,730.0,IC50,uM,0.73,Oc1cccc(-c2cc(OCc3ccccn3)nc(N3CCOCC3)n2)c1,2011
Inhibition of PI3Kgamma after 15 mins,COc1ccc(Nc2cc(-c3cnc(N)nc3)nc(N3CCOCC3)n2)cn1,CHEMBL1671825,=,=,IC50,nM,9.0,IC50,uM,0.009,COc1ccc(Nc2cc(-c3cnc(N)nc3)nc(N3CCOCC3)n2)cn1,2011
Inhibition of PI3Kgamma,CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21,CHEMBL1681712,=,=,IC50,nM,36.0,IC50,uM,0.036,CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21,2011
Inhibition of PI3Kgamma,CC(=O)NC[C@H]1CC[C@H](c2nc(-c3cc4ccccc4[nH]3)c3c(N)nccn32)CC1,CHEMBL1759853,>,>,IC50,nM,30000.0,IC50,uM,30.0,CC(=O)NC[C@H]1CC[C@H](c2nc(-c3cc4ccccc4[nH]3)c3c(N)nccn32)CC1,2011
Inhibition of PI3Kgamma,CN(C)C(=O)N1CCC(c2nc(-c3cc4ccccc4[nH]3)c3c(N)nccn23)CC1,CHEMBL1759853,>,>,IC50,nM,30000.0,IC50,uM,30.0,CN(C)C(=O)N1CCC(c2nc(-c3cc4ccccc4[nH]3)c3c(N)nccn23)CC1,2011
Inhibition of PI3Kgamma,N#CCNc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,100.0,IC50,uM,0.1,N#CCNc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,8.0,IC50,uM,0.008,Cc1nc(N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3ccccc3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,470.0,IC50,uM,0.47,Cc1nc(N)nc(-n2c(Nc3ccccc3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3cc(O)cc(O)c3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,5.0,IC50,uM,0.005,Cc1nc(N)nc(-n2c(Nc3cc(O)cc(O)c3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3cccc(C(N)=O)c3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,480.0,IC50,uM,0.48,Cc1nc(N)nc(-n2c(Nc3cccc(C(N)=O)c3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,CNC(=O)Nc1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)cc1,CHEMBL1759974,=,=,IC50,nM,13.0,IC50,uM,0.013,CNC(=O)Nc1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)cc1,2011
Inhibition of PI3Kgamma,CC(=O)Nc1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)cc1,CHEMBL1759974,=,=,IC50,nM,20.0,IC50,uM,0.02,CC(=O)Nc1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)cc1,2011
Inhibition of PI3Kgamma,CC(=O)Nc1cccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)c1,CHEMBL1759974,=,=,IC50,nM,110.0,IC50,uM,0.11,CC(=O)Nc1cccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)c1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3ccc4cc[nH]c4c3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,340.0,IC50,uM,0.34,Cc1nc(N)nc(-n2c(Nc3ccc4cc[nH]c4c3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3ccc4cn[nH]c4c3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,200.0,IC50,uM,0.2,Cc1nc(N)nc(-n2c(Nc3ccc4cn[nH]c4c3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,320.0,IC50,uM,0.32,Cc1nc(N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3ccn(C)n3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,4100.0,IC50,uM,4.1,Cc1nc(N)nc(-n2c(Nc3ccn(C)n3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3ccn(C(F)F)n3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,860.0,IC50,uM,0.86,Cc1nc(N)nc(-n2c(Nc3ccn(C(F)F)n3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3ccon3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,2300.0,IC50,uM,2.3,Cc1nc(N)nc(-n2c(Nc3ccon3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3n[nH]c4ccccc34)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,190.0,IC50,uM,0.19,Cc1nc(N)nc(-n2c(Nc3n[nH]c4ccccc34)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3cn[nH]c3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,610.0,IC50,uM,0.61,Cc1nc(N)nc(-n2c(Nc3cn[nH]c3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3ccnn3C)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,2300.0,IC50,uM,2.3,Cc1nc(N)nc(-n2c(Nc3ccnn3C)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,CNC(=O)c1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)o1,CHEMBL1759974,=,=,IC50,nM,26.0,IC50,uM,0.026,CNC(=O)c1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)o1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3nc[nH]n3)nc3ccccc32)n1,CHEMBL1759974,,,IC50,,,IC50,,,Cc1nc(N)nc(-n2c(Nc3nc[nH]n3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(NC3CCOCC3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,30.0,IC50,uM,0.03,Cc1nc(N)nc(-n2c(NC3CCOCC3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,CNc1nc(C)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,3200.0,IC50,uM,3.2,CNc1nc(C)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(NCC#N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,3600.0,IC50,uM,3.6,Cc1nc(NCC#N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(NCCC#N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,6200.0,IC50,uM,6.2,Cc1nc(NCCC#N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,C#CCNc1nc(C)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1,CHEMBL1759974,=,=,IC50,nM,3700.0,IC50,uM,3.7,C#CCNc1nc(C)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1,2011
Inhibition of PI3Kgamma,Cc1nc(N)nc(-n2c(Nc3cc[nH]n3)nc3cc(F)c(F)cc32)n1,CHEMBL1759974,=,=,IC50,nM,250.0,IC50,uM,0.25,Cc1nc(N)nc(-n2c(Nc3cc[nH]n3)nc3cc(F)c(F)cc32)n1,2011
Binding affinity to PIK3CG at 10 uM by high-throughput binding assay relative to control,Cc1nc(-c2cnc3ccc(-c4cncc(NS(=O)(=O)c5ccccc5)c4)cn23)no1,CHEMBL1765062,=,=,Activity,%,0.0,Activity,%,0.0,Cc1nc(-c2cnc3ccc(-c4cncc(NS(=O)(=O)c5ccccc5)c4)cn23)no1,2011
Binding affinity to PIK3CG at 1 uM relative to control,Nc1ccc(-c2ccc3ncc4ccc(=O)n(-c5cccc(C(F)(F)F)c5)c4c3c2)cn1,CHEMBL1765054,=,=,Activity,%,0.2,Activity,%,0.2,Nc1ccc(-c2ccc3ncc4ccc(=O)n(-c5cccc(C(F)(F)F)c5)c4c3c2)cn1,2011
Inhibition of P110gamma,Nc1ccc(-c2ccc3ncc4ccc(=O)n(-c5cccc(C(F)(F)F)c5)c4c3c2)cn1,CHEMBL1765054,=,=,IC50,nM,5.67,IC50,nM,5.67,Nc1ccc(-c2ccc3ncc4ccc(=O)n(-c5cccc(C(F)(F)F)c5)c4c3c2)cn1,2011
Inhibition of PI3Kgamma,CNc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2C[C@@H](C(=O)NC3CCCCC3)CC[C@H]2C)n1,CHEMBL1765070,=,=,IC50,nM,25118.0,IC50,nM,25118.0,CNc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2C[C@@H](C(=O)NC3CCCCC3)CC[C@H]2C)n1,2011
Binding affinity to human PIK3CG ,Cc1nc(CN(C)c2ncnc3ccc(-c4ccc5c(c4)OCO5)cc23)cs1,CHEMBL1770051,=,=,Kd,nM,370.0,Kd,nM,370.0,Cc1nc(CN(C)c2ncnc3ccc(-c4ccc5c(c4)OCO5)cc23)cs1,2011
Inhibition of human PI3Kgamma expressed in Sf9 cells,CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2s1,CHEMBL1773016,=,=,Ki,nM,4.7,Ki,nM,4.7,CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2s1,2011
Inhibition of P110gamma,CN1CCC(NC(=O)c2ccc(-c3ccc(-n4c(=O)ccc5cnc6ccc(-c7cnc8ccccc8c7)cc6c54)cc3C(F)(F)F)cc2)CC1,CHEMBL1795255,=,=,IC50,nM,1170.0,IC50,nM,1170.0,CN1CCC(NC(=O)c2ccc(-c3ccc(-n4c(=O)ccc5cnc6ccc(-c7cnc8ccccc8c7)cc6c54)cc3C(F)(F)F)cc2)CC1,2011
Inhibition of PI3Kgamma,CNC(=O)c1ccc2c(c1)OCCc1cc(C(=O)N(C)c3ccc(C(=O)N(C)C)cc3Cl)sc1-2,CHEMBL1795251,=,=,IC50,nM,5.0,IC50,nM,5.0,CNC(=O)c1ccc2c(c1)OCCc1cc(C(=O)N(C)c3ccc(C(=O)N(C)C)cc3Cl)sc1-2,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,CHEMBL1806467,=,=,IC50,nM,11.0,IC50,nM,11.0,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N5CCN(C)CC5)cc4)cc3)nc21,CHEMBL1806467,=,=,IC50,nM,9.0,IC50,nM,9.0,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N5CCN(C)CC5)cc4)cc3)nc21,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,CN(C)CCN(C)C(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(O[C@H]4CCOC4)nc(N4CCOCC4)n3)cc2)cc1,CHEMBL1806467,=,=,IC50,nM,4.8,IC50,nM,4.8,CN(C)CCN(C)C(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(O[C@H]4CCOC4)nc(N4CCOCC4)n3)cc2)cc1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)NCCN4CCCCC4)cc3)cc2)nc(N2CCOCC2)n1,CHEMBL1806467,=,=,IC50,nM,20.5,IC50,nM,20.5,COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)NCCN4CCCCC4)cc3)cc2)nc(N2CCOCC2)n1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N(C)CCN(C)C)cc3)cc2)nc(N2CCOCC2)n1,CHEMBL1806467,=,=,IC50,nM,7.0,IC50,nM,7.0,COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N(C)CCN(C)C)cc3)cc2)nc(N2CCOCC2)n1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)NCCN(C)C)cc3)cc2)nc(N2CCOCC2)n1,CHEMBL1806467,=,=,IC50,nM,10.5,IC50,nM,10.5,COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)NCCN(C)C)cc3)cc2)nc(N2CCOCC2)n1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,CNCCN(C)C(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(OC)nc(N4CCOCC4)n3)cc2)cc1,CHEMBL1806467,=,=,IC50,nM,9.5,IC50,nM,9.5,CNCCN(C)C(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(OC)nc(N4CCOCC4)n3)cc2)cc1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)cc2)nc(N2CCOCC2)n1,CHEMBL1806467,=,=,IC50,nM,13.5,IC50,nM,13.5,COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)cc2)nc(N2CCOCC2)n1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCNC(C)(C)C4)cc3)cc2)nc(N2CCOCC2)n1,CHEMBL1806467,=,=,IC50,nM,4.0,IC50,nM,4.0,COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCNC(C)(C)C4)cc3)cc2)nc(N2CCOCC2)n1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(OC5COC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,CHEMBL1806467,=,=,IC50,nM,9.5,IC50,nM,9.5,CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(OC5COC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,CC(C)Oc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)cc2)nc(N2CCOCC2)n1,CHEMBL1806467,=,=,IC50,nM,49.5,IC50,nM,49.5,CC(C)Oc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)cc2)nc(N2CCOCC2)n1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,CC(C)Oc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N(C)CCN(C)C)cc3)cc2)nc(N2CCOCC2)n1,CHEMBL1806467,=,=,IC50,nM,18.0,IC50,nM,18.0,CC(C)Oc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N(C)CCN(C)C)cc3)cc2)nc(N2CCOCC2)n1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,CC(C)Oc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)NCCN(C)C)cc3)cc2)nc(N2CCOCC2)n1,CHEMBL1806467,=,=,IC50,nM,24.5,IC50,nM,24.5,CC(C)Oc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)NCCN(C)C)cc3)cc2)nc(N2CCOCC2)n1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(O[C@H]5CCOC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,CHEMBL1806467,=,=,IC50,nM,6.5,IC50,nM,6.5,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(O[C@H]5CCOC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,O=C(Nc1ccc(C(=O)NCCN2CCCCC2)cc1)Nc1ccc(-c2nc(O[C@H]3CCOC3)nc(N3CCOCC3)n2)cc1,CHEMBL1806467,=,=,IC50,nM,8.0,IC50,nM,8.0,O=C(Nc1ccc(C(=O)NCCN2CCCCC2)cc1)Nc1ccc(-c2nc(O[C@H]3CCOC3)nc(N3CCOCC3)n2)cc1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,O=C(Nc1ccc(C(=O)NCCN2CCCC2)cc1)Nc1ccc(-c2nc(O[C@H]3CCOC3)nc(N3CCOCC3)n2)cc1,CHEMBL1806467,=,=,IC50,nM,6.0,IC50,nM,6.0,O=C(Nc1ccc(C(=O)NCCN2CCCC2)cc1)Nc1ccc(-c2nc(O[C@H]3CCOC3)nc(N3CCOCC3)n2)cc1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(O[C@H]5CCOC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,CHEMBL1806467,=,=,IC50,nM,14.3,IC50,nM,14.3,CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(O[C@H]5CCOC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,CN1C2CCC1CC(Oc1nc(-c3ccc(NC(=O)Nc4ccc(C(N)=O)cc4)cc3)nc(N3CCOCC3)n1)C2,CHEMBL1806467,=,=,IC50,nM,72.5,IC50,nM,72.5,CN1C2CCC1CC(Oc1nc(-c3ccc(NC(=O)Nc4ccc(C(N)=O)cc4)cc3)nc(N3CCOCC3)n1)C2,2011
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay,CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(=O)nc(N5CCOCC5)[nH]4)cc3)cc2)CC1,CHEMBL1806467,=,=,IC50,nM,96.5,IC50,nM,96.5,CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(=O)nc(N5CCOCC5)[nH]4)cc3)cc2)CC1,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,Nc1[nH]cnc2ncnc1-2,CHEMBL1817560,=,=,Inhibition,%,66.0,INH,%,66.0,Nc1[nH]cnc2ncnc1-2,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,c1ccc(Nc2ncccn2)cc1,CHEMBL1817560,=,=,Inhibition,%,16.0,INH,%,16.0,c1ccc(Nc2ncccn2)cc1,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,c1cnc2[nH]ccc2c1,CHEMBL1817560,=,=,Inhibition,%,20.0,INH,%,20.0,c1cnc2[nH]ccc2c1,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,c1ccc2[nH]ncc2c1,CHEMBL1817560,=,=,Inhibition,%,0.0,INH,%,0.0,c1ccc2[nH]ncc2c1,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,Nc1ncccc1OCc1ccccc1,CHEMBL1817560,=,=,Inhibition,%,100.0,INH,%,100.0,Nc1ncccc1OCc1ccccc1,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,Nc1[nH]nc2ccccc12,CHEMBL1817560,=,=,Inhibition,%,10.0,INH,%,10.0,Nc1[nH]nc2ccccc12,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,Nc1n[nH]c2ncccc12,CHEMBL1817560,=,=,Inhibition,%,20.0,INH,%,20.0,Nc1n[nH]c2ncccc12,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,c1n[nH]c2c1CCCC2,CHEMBL1817560,=,=,Inhibition,%,13.0,INH,%,13.0,c1n[nH]c2c1CCCC2,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,Nc1ccc2ncc(-c3ccccc3)n2n1,CHEMBL1817560,=,=,Inhibition,%,70.0,INH,%,70.0,Nc1ccc2ncc(-c3ccccc3)n2n1,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,c1ccc(-c2cnc3nccnn23)cc1,CHEMBL1817560,=,=,Inhibition,%,92.0,INH,%,92.0,c1ccc(-c2cnc3nccnn23)cc1,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,Cc1ccc(NC(=O)Nc2cc(C(C)(C)C)nn2-c2ccccc2)cc1,CHEMBL1817560,=,=,Inhibition,%,2.0,INH,%,2.0,Cc1ccc(NC(=O)Nc2cc(C(C)(C)C)nn2-c2ccccc2)cc1,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,CC(C)(C)c1cc(NC(=O)Nc2ccccc2)no1,CHEMBL1817560,=,=,Inhibition,%,9.0,INH,%,9.0,CC(C)(C)c1cc(NC(=O)Nc2ccccc2)no1,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,Cc1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)cc1,CHEMBL1817560,=,=,Inhibition,%,0.0,INH,%,0.0,Cc1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)cc1,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,O=C(Nc1ccccc1)Nc1cccc(C(F)(F)F)c1,CHEMBL1817560,=,=,Inhibition,%,7.0,INH,%,7.0,O=C(Nc1ccccc1)Nc1cccc(C(F)(F)F)c1,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,O=C(Nc1ccccc1)Nc1ccccc1,CHEMBL1817560,=,=,Inhibition,%,9.0,INH,%,9.0,O=C(Nc1ccccc1)Nc1ccccc1,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,Cc1ccc(C(=O)NC2CC2)cc1F,CHEMBL1817560,=,=,Inhibition,%,13.0,INH,%,13.0,Cc1ccc(C(=O)NC2CC2)cc1F,2011
Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay,c1ccc(Nc2ccccc2)cc1,CHEMBL1817560,=,=,Inhibition,%,2.0,INH,%,2.0,c1ccc(Nc2ccccc2)cc1,2011
"Inhibition of human N-terminal His-tagged PI3Kgamma expressed in insect Sf9 cells using PI(4,5)P2 as substrate after 20 mins by alphascreen assay in presence of 8 uM ATP",CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1,CHEMBL1821651,=,=,Ki,nM,1.9,Ki,nM,1.9,CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1,2011
Activity of PIK3CG kinase at 1 uM,CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1,CHEMBL1821651,=,=,Activity,%,0.0,Activity,%,0.0,CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1,2011
Binding constant for PIK3CG kinase domain,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,2011
Binding constant for PIK3CG kinase domain,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,2011
Binding constant for PIK3CG kinase domain,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,2011
Binding constant for PIK3CG kinase domain,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,2011
Binding constant for PIK3CG kinase domain,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,2011
Binding constant for PIK3CG kinase domain,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,2011
Binding constant for PIK3CG kinase domain,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1,2011
Binding constant for PIK3CG kinase domain,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,2011
Binding constant for PIK3CG kinase domain,CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,2011
Binding constant for PIK3CG kinase domain,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,2011
Binding constant for PIK3CG kinase domain,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,2011
Binding constant for PIK3CG kinase domain,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL1908390,=,=,Kd,nM,16.0,Kd,nM,16.0,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2011
Binding constant for PIK3CG kinase domain,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,2011
Binding constant for PIK3CG kinase domain,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,2011
Binding constant for PIK3CG kinase domain,CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl,2011
Binding constant for PIK3CG kinase domain,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2011
Binding constant for PIK3CG kinase domain,Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,CHEMBL1908390,=,=,Kd,nM,5.3,Kd,nM,5.3,Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,2011
Binding constant for PIK3CG kinase domain,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,2011
Binding constant for PIK3CG kinase domain,COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1,2011
Binding constant for PIK3CG kinase domain,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,2011
Binding constant for PIK3CG kinase domain,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,CHEMBL1908390,=,=,Kd,nM,7500.0,Kd,nM,7500.0,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,2011
Binding constant for PIK3CG kinase domain,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,2011
Binding constant for PIK3CG kinase domain,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,2011
Binding constant for PIK3CG kinase domain,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,2011
Binding constant for PIK3CG kinase domain,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21,CHEMBL1908390,=,=,Kd,nM,42.0,Kd,nM,42.0,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21,2011
Binding constant for PIK3CG kinase domain,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,2011
Binding constant for PIK3CG kinase domain,Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12,2011
Binding constant for PIK3CG kinase domain,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,2011
Binding constant for PIK3CG kinase domain,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2011
Binding constant for PIK3CG kinase domain,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,2011
Binding constant for PIK3CG kinase domain,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,2011
Binding constant for PIK3CG kinase domain,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,2011
Binding constant for PIK3CG kinase domain,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,2011
Binding constant for PIK3CG kinase domain,Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1,2011
Binding constant for PIK3CG kinase domain,OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1,2011
Binding constant for PIK3CG kinase domain,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,2011
Binding constant for PIK3CG kinase domain,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,2011
Binding constant for PIK3CG kinase domain,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,2011
Binding constant for PIK3CG kinase domain,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL1908390,=,=,Kd,nM,48.0,Kd,nM,48.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2011
Binding constant for PIK3CG kinase domain,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,2011
Binding constant for PIK3CG kinase domain,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC,2011
Binding constant for PIK3CG kinase domain,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,2011
Binding constant for PIK3CG kinase domain,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,2011
Binding constant for PIK3CG kinase domain,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,2011
Binding constant for PIK3CG kinase domain,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,2011
Binding constant for PIK3CG kinase domain,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,2011
Binding constant for PIK3CG kinase domain,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,2011
Binding constant for PIK3CG kinase domain,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,CHEMBL1908390,=,=,Kd,nM,350.0,Kd,nM,350.0,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,2011
Binding constant for PIK3CG kinase domain,COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C,2011
Binding constant for PIK3CG kinase domain,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,2011
Binding constant for PIK3CG kinase domain,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,2011
Binding constant for PIK3CG kinase domain,CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12,2011
Binding constant for PIK3CG kinase domain,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,2011
Binding constant for PIK3CG kinase domain,Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1,2011
Binding constant for PIK3CG kinase domain,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,2011
Binding constant for PIK3CG kinase domain,C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F,CHEMBL1908390,=,=,Kd,nM,1900.0,Kd,nM,1900.0,C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F,2011
Binding constant for PIK3CG kinase domain,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,2011
Binding constant for PIK3CG kinase domain,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,2011
Binding constant for PIK3CG kinase domain,CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1,2011
Binding constant for PIK3CG kinase domain,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,2011
Binding constant for PIK3CG kinase domain,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21,2011
Binding constant for PIK3CG kinase domain,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,2011
Binding constant for PIK3CG kinase domain,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,2011
Binding constant for PIK3CG kinase domain,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,2011
Binding constant for PIK3CG kinase domain,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,2011
Binding constant for PIK3CG kinase domain,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,2011
Binding constant for PIK3CG kinase domain,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,2011
Binding constant for PIK3CG kinase domain,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1908390,=,=,Kd,nM,1800.0,Kd,nM,1800.0,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2011
Binding constant for PIK3CG kinase domain,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1,2011
Binding constant for PIK3CG kinase domain,O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl,2011
Binding constant for PIK3CG kinase domain,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,2011
Binding constant for PIK3CG kinase domain,CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1,2011
Inhibition of human His-tagged PI3K p110gamma after 2 hrs by HTRF assay,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL1909493,=,=,IC50,nM,83.0,IC50,nM,83.0,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2011
Inhibition of human His-tagged PI3K p110gamma after 2 hrs by HTRF assay,Oc1cccc2c1nc(C(F)F)n2-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL1909493,=,=,IC50,nM,6.0,IC50,nM,6.0,Oc1cccc2c1nc(C(F)F)n2-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2011
Inhibition of human His-tagged PI3K p110gamma after 2 hrs by HTRF assay,FC(F)Oc1cccc2c1nc(C(F)F)n2-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL1909493,=,=,IC50,nM,56.0,IC50,nM,56.0,FC(F)Oc1cccc2c1nc(C(F)F)n2-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2011
Inhibition of human His-tagged PI3K p110gamma after 2 hrs by HTRF assay,COc1ccc2c(nc(C(F)F)n2-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)c1O,CHEMBL1909493,=,=,IC50,nM,52.0,IC50,nM,52.0,COc1ccc2c(nc(C(F)F)n2-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)c1O,2011
Inhibition of human His-tagged PI3K p110gamma after 2 hrs by HTRF assay,COc1cc(N)cc2c1nc(C(F)F)n2-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL1909493,=,=,IC50,nM,32.0,IC50,nM,32.0,COc1cc(N)cc2c1nc(C(F)F)n2-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2011
"Inhibition of N-terminus polyHis-tagged human recombinant PI3Kgamma expressed in baculovirus infected insect Sf9 cells using phosphoinositol-4,5-bisphosphate as substrate after 1.5 hrs by spectrophotometric analysis",O=S(=O)(Nc1cc(-c2ccc3ncc(N4CCOCC4)nc3c2)cnc1Cl)c1ccc(F)cc1,CHEMBL1914426,=,=,IC50,nM,2.4,IC50,nM,2.4,O=S(=O)(Nc1cc(-c2ccc3ncc(N4CCOCC4)nc3c2)cnc1Cl)c1ccc(F)cc1,2011
"Inhibition of N-terminus polyHis-tagged human recombinant PI3Kgamma expressed in baculovirus infected insect Sf9 cells using phosphoinositol-4,5-bisphosphate as substrate after 1.5 hrs by spectrophotometric analysis",O=S(=O)(Nc1cc(-c2ccc3nccc(N4CCN(Cc5ccncc5)CC4)c3c2)cnc1Cl)c1ccc(F)cc1,CHEMBL1914426,=,=,IC50,nM,6.5,IC50,nM,6.5,O=S(=O)(Nc1cc(-c2ccc3nccc(N4CCN(Cc5ccncc5)CC4)c3c2)cnc1Cl)c1ccc(F)cc1,2011
"Inhibition of N-terminus polyHis-tagged human recombinant PI3Kgamma expressed in baculovirus infected insect Sf9 cells using phosphoinositol-4,5-bisphosphate as substrate after 1.5 hrs by spectrophotometric analysis",O=S(=O)(Nc1cc(-c2ccc3nccc(-c4ccncc4)c3c2)cnc1Cl)c1ccc(F)cc1,CHEMBL1914426,=,=,IC50,nM,13.0,IC50,nM,13.0,O=S(=O)(Nc1cc(-c2ccc3nccc(-c4ccncc4)c3c2)cnc1Cl)c1ccc(F)cc1,2011
"Inhibition of N-terminus polyHis-tagged human recombinant PI3Kgamma expressed in baculovirus infected insect Sf9 cells using phosphoinositol-4,5-bisphosphate as substrate after 1.5 hrs by spectrophotometric analysis",O=S(=O)(Nc1cc(-c2ccc3ncc(NCCN4CCOCC4)nc3c2)cnc1Cl)c1ccc(F)cc1,CHEMBL1914426,=,=,IC50,nM,16.0,IC50,nM,16.0,O=S(=O)(Nc1cc(-c2ccc3ncc(NCCN4CCOCC4)nc3c2)cnc1Cl)c1ccc(F)cc1,2011
"Inhibition of N-terminus polyHis-tagged human recombinant PI3Kgamma expressed in baculovirus infected insect Sf9 cells using phosphoinositol-4,5-bisphosphate as substrate after 1.5 hrs by spectrophotometric analysis",CC(C)N1CCN(c2cnc3ccc(-c4cnc(Cl)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc3n2)CC1,CHEMBL1914426,=,=,IC50,nM,13.0,IC50,nM,13.0,CC(C)N1CCN(c2cnc3ccc(-c4cnc(Cl)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc3n2)CC1,2011
"Inhibition of N-terminus polyHis-tagged human recombinant PI3Kgamma expressed in baculovirus infected insect Sf9 cells using phosphoinositol-4,5-bisphosphate as substrate after 1.5 hrs by spectrophotometric analysis",O=S(=O)(Nc1cc(-c2ccc3nccc(N4CCOCC4)c3c2)cnc1Cl)c1ccc(F)cc1,CHEMBL1914426,=,=,IC50,nM,8.1,IC50,nM,8.1,O=S(=O)(Nc1cc(-c2ccc3nccc(N4CCOCC4)c3c2)cnc1Cl)c1ccc(F)cc1,2011
"Inhibition of N-terminus polyHis-tagged human recombinant PI3Kgamma expressed in baculovirus infected insect Sf9 cells using phosphoinositol-4,5-bisphosphate as substrate after 1.5 hrs by spectrophotometric analysis",O=S(=O)(Nc1cc(-c2ccc3nccc(-c4cccnc4)c3c2)cnc1Cl)c1ccc(F)cc1,CHEMBL1914426,=,=,IC50,nM,7.7,IC50,nM,7.7,O=S(=O)(Nc1cc(-c2ccc3nccc(-c4cccnc4)c3c2)cnc1Cl)c1ccc(F)cc1,2011
Inhibition of recombinant human PI3Kgamma assessed as depletion of ATP by kinase-glo luciferase assay,Nc1cn2cc(Br)ccc2n1,CHEMBL1914382,=,=,IC50,nM,156000.0,IC50,uM,156.0,Nc1cn2cc(Br)ccc2n1,2011
Inhibition of recombinant human PI3Kgamma assessed as depletion of ATP by kinase-glo luciferase assay,Nc1nc2ccc(Cl)cc2o1,CHEMBL1914382,=,=,IC50,nM,380000.0,IC50,uM,380.0,Nc1nc2ccc(Cl)cc2o1,2011
Inhibition of recombinant human PI3Kgamma assessed as depletion of ATP by kinase-glo luciferase assay,Cc1cc(C)n2nc(N)nc2n1,CHEMBL1914382,>,>,IC50,nM,1600000.0,IC50,uM,1600.0,Cc1cc(C)n2nc(N)nc2n1,2011
Inhibition of recombinant human PI3Kgamma assessed as depletion of ATP by kinase-glo luciferase assay,Cc1cc(Cl)n2ncnc2n1,CHEMBL1914382,>,>,IC50,nM,1670000.0,IC50,uM,1670.0,Cc1cc(Cl)n2ncnc2n1,2011
Inhibition of recombinant human PI3Kgamma assessed as depletion of ATP by kinase-glo luciferase assay,CC(C)c1nn2cccnc2c1C#N,CHEMBL1914382,=,=,IC50,nM,395000.0,IC50,uM,395.0,CC(C)c1nn2cccnc2c1C#N,2011
Inhibition of recombinant human PI3Kgamma assessed as depletion of ATP by kinase-glo luciferase assay,Cc1nn2cccnc2c1C#N,CHEMBL1914382,=,=,IC50,nM,773000.0,IC50,uM,773.0,Cc1nn2cccnc2c1C#N,2011
Inhibition of recombinant human PI3Kgamma assessed as depletion of ATP by kinase-glo luciferase assay,Nc1nnc2cc(Cl)ccc2n1,CHEMBL1914382,=,=,IC50,nM,53000.0,IC50,uM,53.0,Nc1nnc2cc(Cl)ccc2n1,2011
Inhibition of recombinant human PI3Kgamma assessed as depletion of ATP by kinase-glo luciferase assay,Cc1cc(C)n2nc(N)cc2n1,CHEMBL1914382,=,=,IC50,nM,915000.0,IC50,uM,915.0,Cc1cc(C)n2nc(N)cc2n1,2011
Inhibition of recombinant human PI3Kgamma by HTRF assay,CC(=O)Nc1cc2nc(C)cc(C)n2n1,CHEMBL1914382,=,=,IC50,nM,19000.0,IC50,uM,19.0,CC(=O)Nc1cc2nc(C)cc(C)n2n1,2011
Inhibition of recombinant human PI3Kgamma by HTRF assay,CC(=O)Nc1cn2cc(/C=C3\SC(=O)NC3=O)ccc2n1,CHEMBL1914382,=,=,IC50,nM,34.0,IC50,nM,34.0,CC(=O)Nc1cn2cc(/C=C3\SC(=O)NC3=O)ccc2n1,2011
Inhibition of recombinant human PI3Kgamma by HTRF assay,O=C1NC(=O)/C(=C/c2ccc3nccn3c2)S1,CHEMBL1914382,=,=,IC50,nM,230.0,IC50,nM,230.0,O=C1NC(=O)/C(=C/c2ccc3nccn3c2)S1,2011
Inhibition of recombinant human PI3Kgamma by HTRF assay,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1,CHEMBL1914382,=,=,IC50,nM,30.0,IC50,nM,30.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1,2011
Inhibition of PI3Kgamma in human neutrophils assessed as inhibition of fMLP-stimulated superoxide production,CC(=O)Nc1cn2cc(/C=C3\SC(=O)NC3=O)ccc2n1,CHEMBL1914382,=,=,IC50,nM,760.0,IC50,uM,0.76,CC(=O)Nc1cn2cc(/C=C3\SC(=O)NC3=O)ccc2n1,2011
Inhibition of PI3K subunit p110gamma assessed as formation of phosphatidylinositide-3-phosphate product formation after 30 mins by fluorescence polarization assay,Cc1c(CN2CCN(C(=O)CN)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL1921798,=,=,IC50,nM,17.0,IC50,nM,17.0,Cc1c(CN2CCN(C(=O)CN)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2011
Inhibition of PI3K subunit p110gamma assessed as formation of phosphatidylinositide-3-phosphate product formation after 30 mins by fluorescence polarization assay,Cc1c(CN2CCN(C(=O)[C@H](C)N)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL1921798,=,=,IC50,nM,37.0,IC50,nM,37.0,Cc1c(CN2CCN(C(=O)[C@H](C)N)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2011
Inhibition of PI3K subunit p110gamma assessed as formation of phosphatidylinositide-3-phosphate product formation after 30 mins by fluorescence polarization assay,Cc1c(CN2CCN(C(=O)C(C)(C)N)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL1921798,=,=,IC50,nM,20.0,IC50,nM,20.0,Cc1c(CN2CCN(C(=O)C(C)(C)N)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2011
Inhibition of PI3K subunit p110gamma assessed as formation of phosphatidylinositide-3-phosphate product formation after 30 mins by fluorescence polarization assay,Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL1921798,=,=,IC50,nM,14.0,IC50,nM,14.0,Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2011
Inhibition of PI3K subunit p110gamma assessed as formation of phosphatidylinositide-3-phosphate product formation after 30 mins by fluorescence polarization assay,Cc1c(CN2CCN(C(=O)[C@@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL1921798,=,=,IC50,nM,33.0,IC50,nM,33.0,Cc1c(CN2CCN(C(=O)[C@@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2011
Inhibition of PI3K subunit p110gamma assessed as formation of phosphatidylinositide-3-phosphate product formation after 30 mins by fluorescence polarization assay,Cc1c(CN2CCN(C(=O)C(C)(C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL1921798,=,=,IC50,nM,25.0,IC50,nM,25.0,Cc1c(CN2CCN(C(=O)C(C)(C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2011
Inhibition of PIK3 gamma-mediated Akt phosphorylation at Ser473 in human PC3 cells by ELISA,Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL1921798,=,=,IC50,nM,36.0,IC50,nM,36.0,Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2011
Inhibition of PI3K subunit p110gamma assessed as formation of phosphatidylinositide-3-phosphate product formation after 30 mins by fluorescence polarization assay,Cc1c(CN2CCN(C(=O)CO)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL1921798,=,=,IC50,nM,10.0,IC50,nM,10.0,Cc1c(CN2CCN(C(=O)CO)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2011
Inhibition of PI3Kgamma assessed as enzyme activity relative to control,Nc1ncc(-c2cncc(NS(=O)(=O)c3ccccc3)c2)cn1,CHEMBL1921668,=,=,Activity,%,24.0,Activity,%,24.0,Nc1ncc(-c2cncc(NS(=O)(=O)c3ccccc3)c2)cn1,2011
Inhibition of PI3Kgamma assessed as enzyme activity relative to control,Nc1cncc(-c2cnc(N)nc2)c1,CHEMBL1921668,=,=,Activity,%,100.0,Activity,%,100.0,Nc1cncc(-c2cnc(N)nc2)c1,2011
Inhibition of PI3Kgamma assessed as enzyme activity relative to control,CC(=O)Nc1cncc(-c2cnc(N)nc2)c1,CHEMBL1921668,=,=,Activity,%,98.0,Activity,%,98.0,CC(=O)Nc1cncc(-c2cnc(N)nc2)c1,2011
Inhibition of PI3Kgamma assessed as enzyme activity relative to control,CS(=O)(=O)Nc1cncc(-c2cnc(N)nc2)c1,CHEMBL1921668,=,=,Activity,%,43.0,Activity,%,43.0,CS(=O)(=O)Nc1cncc(-c2cnc(N)nc2)c1,2011
Inhibition of PI3Kgamma assessed as enzyme activity relative to control,Nc1ncc(-c2cncc(NS(=O)(=O)c3cccc(C(F)(F)F)c3)c2)cn1,CHEMBL1921668,=,=,Activity,%,9.6,Activity,%,9.6,Nc1ncc(-c2cncc(NS(=O)(=O)c3cccc(C(F)(F)F)c3)c2)cn1,2011
Inhibition of PI3Kgamma assessed as enzyme activity relative to control,Nc1ncc(-c2cncc(NS(=O)(=O)c3ccc(F)cc3F)c2)cn1,CHEMBL1921668,=,=,Activity,%,7.2,Activity,%,7.2,Nc1ncc(-c2cncc(NS(=O)(=O)c3ccc(F)cc3F)c2)cn1,2011
Inhibition of PI3Kgamma assessed as enzyme activity relative to control,Cc1ccc(S(=O)(=O)Nc2cncc(-c3cnc(N)nc3)c2)cc1[N+](=O)[O-],CHEMBL1921668,=,=,Activity,%,5.3,Activity,%,5.3,Cc1ccc(S(=O)(=O)Nc2cncc(-c3cnc(N)nc3)c2)cc1[N+](=O)[O-],2011
Inhibition of PI3Kgamma assessed as enzyme activity relative to control,Cc1ccc(S(=O)(=O)Nc2cncc(-c3cnc(N)nc3)c2)cc1,CHEMBL1921668,=,=,Activity,%,8.2,Activity,%,8.2,Cc1ccc(S(=O)(=O)Nc2cncc(-c3cnc(N)nc3)c2)cc1,2011
Inhibition of PI3Kgamma assessed as enzyme activity relative to control,Nc1ncc(-c2cncc(NS(=O)(=O)c3ccc([N+](=O)[O-])cc3)c2)cn1,CHEMBL1921668,=,=,Activity,%,6.7,Activity,%,6.7,Nc1ncc(-c2cncc(NS(=O)(=O)c3ccc([N+](=O)[O-])cc3)c2)cn1,2011
Inhibition of PI3Kgamma assessed as enzyme activity relative to control,COc1ccc(S(=O)(=O)Nc2cncc(-c3cnc(N)nc3)c2)cc1,CHEMBL1921668,=,=,Activity,%,20.0,Activity,%,20.0,COc1ccc(S(=O)(=O)Nc2cncc(-c3cnc(N)nc3)c2)cc1,2011
Inhibition of PI3Kgamma assessed as enzyme activity relative to control,Nc1ncc(-c2cncc(NS(=O)(=O)c3ccc4ccccc4c3)c2)cn1,CHEMBL1921668,=,=,Activity,%,25.0,Activity,%,25.0,Nc1ncc(-c2cncc(NS(=O)(=O)c3ccc4ccccc4c3)c2)cn1,2011
Inhibition of PI3K p110gamma,Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)/N=C/c1cnn2ccc(C#N)cc12,CHEMBL1926509,=,=,IC50,nM,14.0,IC50,nM,14.0,Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)/N=C/c1cnn2ccc(C#N)cc12,2012
Inhibition of PI3K p110gamma,Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(CCO)/N=C/c1cnn2ccc(C#N)cc12,CHEMBL1926530,=,=,IC50,nM,11.0,IC50,nM,11.0,Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(CCO)/N=C/c1cnn2ccc(C#N)cc12,2012
Inhibition of human PIK3CG in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM,C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,CHEMBL1938230,<,<,Inhibition,%,35.0,INH,%,35.0,C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,2012
Inhibition of human PIK3CG in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM,C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23,CHEMBL1938230,<,<,Inhibition,%,35.0,INH,%,35.0,C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23,2012
Inhibition of human PIK3CG in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM,C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,CHEMBL1938230,<,<,Inhibition,%,35.0,INH,%,35.0,C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,2012
Inhibition of human PIK3CG in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM,C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23,CHEMBL1938230,<,<,Inhibition,%,35.0,INH,%,35.0,C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23,2012
Inhibition of PI3Kgamma using ATP as substrate,Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCNCC1)NC2=O,CHEMBL1944596,=,=,IC50,nM,3100.0,IC50,uM,3.1,Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCNCC1)NC2=O,2012
Inhibition of PI3Kgamma after 4 hrs,CC(=O)Oc1ccccc1C1OC(c2ccc3c(c2)OCCO3)=NN1C(C)=O,CHEMBL1944540,=,=,IC50,nM,2060.0,IC50,uM,2.06,CC(=O)Oc1ccccc1C1OC(c2ccc3c(c2)OCCO3)=NN1C(C)=O,2012
Inhibition of PI3Kgamma after 4 hrs,CC(=O)Oc1ccc(Cl)cc1C1OC(c2ccc3c(c2)OCCO3)=NN1C(C)=O,CHEMBL1944540,=,=,IC50,nM,980.0,IC50,uM,0.98,CC(=O)Oc1ccc(Cl)cc1C1OC(c2ccc3c(c2)OCCO3)=NN1C(C)=O,2012
Inhibition of PI3Kgamma after 4 hrs,CC(=O)Oc1ccc(Br)cc1C1OC(c2ccc3c(c2)OCCO3)=NN1C(C)=O,CHEMBL1944540,=,=,IC50,nM,1310.0,IC50,uM,1.31,CC(=O)Oc1ccc(Br)cc1C1OC(c2ccc3c(c2)OCCO3)=NN1C(C)=O,2012
Inhibition of PI3Kgamma after 4 hrs,CC(=O)Oc1c(Cl)cc(Cl)cc1C1OC(c2ccc3c(c2)OCCO3)=NN1C(C)=O,CHEMBL1944540,=,=,IC50,nM,1750.0,IC50,uM,1.75,CC(=O)Oc1c(Cl)cc(Cl)cc1C1OC(c2ccc3c(c2)OCCO3)=NN1C(C)=O,2012
Inhibition of PI3Kgamma after 4 hrs,CC(=O)Oc1c(Br)cc(Br)cc1C1OC(c2ccc3c(c2)OCCO3)=NN1C(C)=O,CHEMBL1944540,=,=,IC50,nM,1980.0,IC50,uM,1.98,CC(=O)Oc1c(Br)cc(Br)cc1C1OC(c2ccc3c(c2)OCCO3)=NN1C(C)=O,2012
Inhibition of PI3Kgamma using PIP3 as substrate after 30 mins by fluorescence polarization assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL1949622,=,=,IC50,nM,66.0,IC50,nM,66.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2011
Inhibition of PI3Kgamma using PIP3 as substrate after 30 mins by fluorescence polarization assay,Cc1c(CN2CCN(S(C)(=O)=O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL1949622,=,=,IC50,nM,15.0,IC50,nM,15.0,Cc1c(CN2CCN(S(C)(=O)=O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2011
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCOCC2)nc2n(Cc3ccccc3F)ccn12,CHEMBL1955857,=,=,IC50,nM,6300.0,IC50,uM,6.3,O=c1cc(N2CCOCC2)nc2n(Cc3ccccc3F)ccn12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCOCC2)nc2n(Cc3cccc(F)c3)ccn12,CHEMBL1955857,>,>,IC50,nM,6300.0,IC50,uM,6.3,O=c1cc(N2CCOCC2)nc2n(Cc3cccc(F)c3)ccn12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCOCC2)nc2n(Cc3ccc(F)cc3)ccn12,CHEMBL1955857,>,>,IC50,nM,4000.0,IC50,uM,4.0,O=c1cc(N2CCOCC2)nc2n(Cc3ccc(F)cc3)ccn12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCOCC2)nc2n(Cc3cccc(Cl)c3)ccn12,CHEMBL1955857,>,>,IC50,nM,6300.0,IC50,uM,6.3,O=c1cc(N2CCOCC2)nc2n(Cc3cccc(Cl)c3)ccn12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCOCC2)nc2n(Cc3ccc(Cl)cc3)ccn12,CHEMBL1955857,>,>,IC50,nM,6300.0,IC50,uM,6.3,O=c1cc(N2CCOCC2)nc2n(Cc3ccc(Cl)cc3)ccn12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1ccccc1Cn1ccn2c(=O)cc(N3CCOCC3)nc12,CHEMBL1955857,=,=,IC50,nM,5000.0,IC50,uM,5.0,Cc1ccccc1Cn1ccn2c(=O)cc(N3CCOCC3)nc12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1cccc(Cn2ccn3c(=O)cc(N4CCOCC4)nc23)c1,CHEMBL1955857,=,=,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc(Cn2ccn3c(=O)cc(N4CCOCC4)nc23)c1,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCOCC2)nc2n(Cc3cccc(C(F)(F)F)c3)ccn12,CHEMBL1955857,>,>,IC50,nM,6300.0,IC50,uM,6.3,O=c1cc(N2CCOCC2)nc2n(Cc3cccc(C(F)(F)F)c3)ccn12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCOCC2)nc2n(Cc3ccc(Cl)c(Cl)c3)ccn12,CHEMBL1955857,>,>,IC50,nM,6300.0,IC50,uM,6.3,O=c1cc(N2CCOCC2)nc2n(Cc3ccc(Cl)c(Cl)c3)ccn12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCOCC2)nc2n(Cc3ccc(F)c(Cl)c3)ccn12,CHEMBL1955857,>,>,IC50,nM,6300.0,IC50,uM,6.3,O=c1cc(N2CCOCC2)nc2n(Cc3ccc(F)c(Cl)c3)ccn12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCOCC2)nc2n(Cc3cccc(Cl)c3Cl)ccn12,CHEMBL1955857,=,=,IC50,nM,1300.0,IC50,uM,1.3,O=c1cc(N2CCOCC2)nc2n(Cc3cccc(Cl)c3Cl)ccn12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCOCC2)nc2n(Cc3cccc4ccccc34)ccn12,CHEMBL1955857,=,=,IC50,nM,3200.0,IC50,uM,3.2,O=c1cc(N2CCOCC2)nc2n(Cc3cccc4ccccc34)ccn12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1c(Cn2ccn3c(=O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,CHEMBL1955857,=,=,IC50,nM,3200.0,IC50,uM,3.2,Cc1c(Cn2ccn3c(=O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1cn2c(=O)cc(N3CCOCC3)nc2n1Cc1cccc(Cl)c1Cl,CHEMBL1955857,=,=,IC50,nM,1600.0,IC50,uM,1.6,Cc1cn2c(=O)cc(N3CCOCC3)nc2n1Cc1cccc(Cl)c1Cl,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1c(Cn2c(C)cn3c(=O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,CHEMBL1955857,=,=,IC50,nM,1000.0,IC50,uM,1.0,Cc1c(Cn2c(C)cn3c(=O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,CCc1cn2c(=O)cc(N3CCOCC3)nc2n1Cc1cccc(C(F)(F)F)c1C,CHEMBL1955857,=,=,IC50,nM,1600.0,IC50,uM,1.6,CCc1cn2c(=O)cc(N3CCOCC3)nc2n1Cc1cccc(C(F)(F)F)c1C,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCOCC2)nc2n(Cc3cccc(Cl)c3Cl)c3ccccc3n12,CHEMBL1955857,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=c1cc(N2CCOCC2)nc2n(Cc3cccc(Cl)c3Cl)c3ccccc3n12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1c(C)n2c(=O)cc(N3CCOCC3)nc2n1Cc1cccc(Cl)c1Cl,CHEMBL1955857,=,=,IC50,nM,2500.0,IC50,uM,2.5,Cc1c(C)n2c(=O)cc(N3CCOCC3)nc2n1Cc1cccc(Cl)c1Cl,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1c(Cn2c(C)c(C)n3c(=O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,CHEMBL1955857,=,=,IC50,nM,4000.0,IC50,uM,4.0,Cc1c(Cn2c(C)c(C)n3c(=O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCOCC2)nc2n(Cc3cccc4ccccc34)c3ccccc3n12,CHEMBL1955857,=,=,IC50,nM,7900.0,IC50,uM,7.9,O=c1cc(N2CCOCC2)nc2n(Cc3cccc4ccccc34)c3ccccc3n12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1c(Cn2c3ccccc3n3c(=O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,CHEMBL1955857,=,=,IC50,nM,1600.0,IC50,uM,1.6,Cc1c(Cn2c3ccccc3n3c(=O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1c(F)c(N2CCOCC2)nc2n(Cc3cccc(Cl)c3Cl)ccn12,CHEMBL1955857,=,=,IC50,nM,1300.0,IC50,uM,1.3,O=c1c(F)c(N2CCOCC2)nc2n(Cc3cccc(Cl)c3Cl)ccn12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1nc(N2CCOCC2)cc2n(Cc3cccc(Cl)c3Cl)ccn12,CHEMBL1955857,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=c1nc(N2CCOCC2)cc2n(Cc3cccc(Cl)c3Cl)ccn12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1c(Cn2ccn3c(=O)nc(N4CCOCC4)cc23)cccc1C(F)(F)F,CHEMBL1955857,>,>,IC50,nM,7900.0,IC50,uM,7.9,Cc1c(Cn2ccn3c(=O)nc(N4CCOCC4)cc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,CC1CN(c2cc(=O)n3ccn(Cc4cccc(Cl)c4Cl)c3n2)CCO1,CHEMBL1955857,=,=,IC50,nM,400.0,IC50,uM,0.4,CC1CN(c2cc(=O)n3ccn(Cc4cccc(Cl)c4Cl)c3n2)CCO1,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,CC1CN(c2cc(=O)n3ccn(Cc4cccc(Cl)c4Cl)c3n2)CCO1,CHEMBL1955857,>,>,IC50,nM,1000.0,IC50,uM,1.0,CC1CN(c2cc(=O)n3ccn(Cc4cccc(Cl)c4Cl)c3n2)CCO1,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,CC1CN(c2cc(=O)n3ccn(Cc4cccc(Cl)c4Cl)c3n2)CCO1,CHEMBL1955857,=,=,IC50,nM,320.0,IC50,uM,0.32,CC1CN(c2cc(=O)n3ccn(Cc4cccc(Cl)c4Cl)c3n2)CCO1,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,CC1(C)CN(c2cc(=O)n3ccn(Cc4cccc(Cl)c4Cl)c3n2)CCO1,CHEMBL1955857,=,=,IC50,nM,1600.0,IC50,uM,1.6,CC1(C)CN(c2cc(=O)n3ccn(Cc4cccc(Cl)c4Cl)c3n2)CCO1,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1c(Cn2ccn3c(=O)cc(N4CCOC(C)C4)nc23)cccc1C(F)(F)F,CHEMBL1955857,=,=,IC50,nM,1300.0,IC50,uM,1.3,Cc1c(Cn2ccn3c(=O)cc(N4CCOC(C)C4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1c(Cn2ccn3c(=O)cc(N4CCO[C@@H](C)C4)nc23)cccc1C(F)(F)F,CHEMBL1955857,=,=,IC50,nM,3200.0,IC50,uM,3.2,Cc1c(Cn2ccn3c(=O)cc(N4CCO[C@@H](C)C4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1c(Cn2ccn3c(=O)cc(N4CCO[C@H](C)C4)nc23)cccc1C(F)(F)F,CHEMBL1955857,=,=,IC50,nM,400.0,IC50,uM,0.4,Cc1c(Cn2ccn3c(=O)cc(N4CCO[C@H](C)C4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCOC(CO)C2)nc2n(Cc3cccc(Cl)c3Cl)ccn12,CHEMBL1955857,=,=,IC50,nM,2500.0,IC50,uM,2.5,O=c1cc(N2CCOC(CO)C2)nc2n(Cc3cccc(Cl)c3Cl)ccn12,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1c(Cn2ccn3c(=O)cc(C4=CCOCC4)nc23)cccc1C(F)(F)F,CHEMBL1955857,>,>,IC50,nM,6300.0,IC50,uM,6.3,Cc1c(Cn2ccn3c(=O)cc(C4=CCOCC4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,Cc1c(Cn2ccn3c(=O)cc(C4CCOCC4)nc23)cccc1C(F)(F)F,CHEMBL1955857,>,>,IC50,nM,6300.0,IC50,uM,6.3,Cc1c(Cn2ccn3c(=O)cc(C4CCOCC4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by time-resolved FRET displacement assay,O=c1cc(N2CCSCC2)nc2n(Cc3cccc(Cl)c3Cl)ccn12,CHEMBL1955857,=,=,IC50,nM,1600.0,IC50,uM,1.6,O=c1cc(N2CCSCC2)nc2n(Cc3cccc(Cl)c3Cl)ccn12,2012
Inhibition of human PI3K p110gamma,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1,CHEMBL1955823,>,>,Ki,nM,500.0,Ki(app),nM,500.0,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1,2012
Inhibition of human PI3K p110gamma,CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cccc5[nH]ncc45)cn3c2Br)CC1,CHEMBL1955823,>,>,Ki,nM,500.0,Ki(app),nM,500.0,CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cccc5[nH]ncc45)cn3c2Br)CC1,2012
Inhibition of human PI3K p110gamma,CS(=O)(=O)N1CCN(Cc2cn3c(C#N)c(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1,CHEMBL1955823,>,>,Ki,nM,500.0,Ki(app),nM,500.0,CS(=O)(=O)N1CCN(Cc2cn3c(C#N)c(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1,2012
Inhibition of human PI3K p110gamma,CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1,CHEMBL1955823,>,>,Ki,nM,500.0,Ki(app),nM,500.0,CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1,2012
Inhibition of human PI3K p110gamma,CNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1,CHEMBL1955823,>,>,Ki,nM,500.0,Ki(app),nM,500.0,CNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1,2012
Inhibition of human PI3K p110gamma,O=C(NCCN1CCOCC1)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1,CHEMBL1955823,>,>,Ki,nM,500.0,Ki(app),nM,500.0,O=C(NCCN1CCOCC1)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1,2012
Inhibition of human PI3K p110gamma,CN(C)CCCNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1,CHEMBL1955823,>,>,Ki,nM,500.0,Ki(app),nM,500.0,CN(C)CCCNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1,2012
Inhibition of human PI3K p110gamma,COCCCNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1,CHEMBL1955823,>,>,Ki,nM,500.0,Ki(app),nM,500.0,COCCCNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1,2012
Inhibition of recombinant PI3Kgamma HTRF assay,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL1955734,=,=,IC50,nM,49.0,IC50,nM,49.0,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,Cc1nn2c(=O)cc(N3CCOCC3)nc2n1Cc1cccc(Cl)c1Cl,CHEMBL2016550,=,=,IC50,nM,500.0,IC50,uM,0.5,Cc1nn2c(=O)cc(N3CCOCC3)nc2n1Cc1cccc(Cl)c1Cl,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,CSc1nn2c(=O)cc(N3CCOCC3)nc2n1Cc1cccc(Cl)c1Cl,CHEMBL2016550,=,=,IC50,nM,500.0,IC50,uM,0.5,CSc1nn2c(=O)cc(N3CCOCC3)nc2n1Cc1cccc(Cl)c1Cl,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,O=c1cc(N2CCOCC2)nc2n(Cc3cccc(Cl)c3Cl)c(C3CC3)nn12,CHEMBL2016550,=,=,IC50,nM,2500.0,IC50,uM,2.5,O=c1cc(N2CCOCC2)nc2n(Cc3cccc(Cl)c3Cl)c(C3CC3)nn12,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,Cc1nn2c(=O)cc(N3CCOC(C)C3)nc2n1Cc1cccc(Cl)c1Cl,CHEMBL2016550,=,=,IC50,nM,250.0,IC50,uM,0.25,Cc1nn2c(=O)cc(N3CCOC(C)C3)nc2n1Cc1cccc(Cl)c1Cl,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,CSc1nn2c(=O)cc(-c3ccncc3)nc2n1Cc1cccc(Cl)c1Cl,CHEMBL2016550,=,=,IC50,nM,2000.0,IC50,uM,2.0,CSc1nn2c(=O)cc(-c3ccncc3)nc2n1Cc1cccc(Cl)c1Cl,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,Cc1c(Cn2c(C)nn3c(=O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,CHEMBL2016550,=,=,IC50,nM,790.0,IC50,uM,0.79,Cc1c(Cn2c(C)nn3c(=O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,CSc1nn2c(=O)cc(N3CCOCC3)nc2n1Cc1cccc(C(F)(F)F)c1C,CHEMBL2016550,=,=,IC50,nM,1300.0,IC50,uM,1.3,CSc1nn2c(=O)cc(N3CCOCC3)nc2n1Cc1cccc(C(F)(F)F)c1C,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,Cc1c(Cn2c(C3CC3)nn3c(=O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,CHEMBL2016550,=,=,IC50,nM,1600.0,IC50,uM,1.6,Cc1c(Cn2c(C3CC3)nn3c(=O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,Cc1c(Cn2c(C)nn3c(=O)cc(N4CCOC(C)C4)nc23)cccc1C(F)(F)F,CHEMBL2016550,=,=,IC50,nM,160.0,IC50,uM,0.16,Cc1c(Cn2c(C)nn3c(=O)cc(N4CCOC(C)C4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,CSc1nn2c(=O)cc(N3CCOC(C)C3)nc2n1Cc1cccc(C(F)(F)F)c1C,CHEMBL2016550,=,=,IC50,nM,200.0,IC50,uM,0.2,CSc1nn2c(=O)cc(N3CCOC(C)C3)nc2n1Cc1cccc(C(F)(F)F)c1C,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,Cc1c(Cn2c(C)nn3c(=O)cc(N4CCOC(C)C4)nc23)cccc1C(F)(F)F,CHEMBL2016550,=,=,IC50,nM,790.0,IC50,uM,0.79,Cc1c(Cn2c(C)nn3c(=O)cc(N4CCOC(C)C4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,Cc1c(Cn2c(C)nn3c(=O)cc(N4CCOC(C)C4)nc23)cccc1C(F)(F)F,CHEMBL2016550,=,=,IC50,nM,60.0,IC50,uM,0.06,Cc1c(Cn2c(C)nn3c(=O)cc(N4CCOC(C)C4)nc23)cccc1C(F)(F)F,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,Cc1nn2c(=O)cc(N3CCOC(C)C3)nc2n1Cc1cccc(Cl)c1Cl,CHEMBL2016550,=,=,IC50,nM,7900.0,IC50,uM,7.9,Cc1nn2c(=O)cc(N3CCOC(C)C3)nc2n1Cc1cccc(Cl)c1Cl,2012
Inhibition of PI3Kgamma by continuous read time resolved fluorescence resonance energy transfer displacement assay,Cc1nn2c(=O)cc(N3CCOC(C)C3)nc2n1Cc1cccc(Cl)c1Cl,CHEMBL2016550,=,=,IC50,nM,500.0,IC50,uM,0.5,Cc1nn2c(=O)cc(N3CCOC(C)C3)nc2n1Cc1cccc(Cl)c1Cl,2012
Inhibition of PI3K p110gamma subunit using [gamma33P]ATP by filter binding assay,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,CHEMBL2016472,=,=,IC50,nM,262.0,IC50,uM,0.262,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,2011
Inhibition of PI3Kgamma,COc1ccc(Nc2cc(-c3cnc(N)nc3)nc(N3CCOCC3)n2)cc1OC,CHEMBL2016472,=,=,IC50,nM,142.0,IC50,uM,0.142,COc1ccc(Nc2cc(-c3cnc(N)nc3)nc(N3CCOCC3)n2)cc1OC,2011
Inhibition of PI3Kgamma at 1 uM,N[C@@H]1CCCN(c2c(Br)cccc2/C=C2\SC(=O)NC2=O)C1,CHEMBL2046384,,,Inhibition,%,,INH,,,N[C@@H]1CCCN(c2c(Br)cccc2/C=C2\SC(=O)NC2=O)C1,2012
Inhibition of PI3Kgamma,CC(C)C[C@H]1CN(c2ccc(C(F)(F)F)c(C(=O)c3cccnc3N)n2)CCN1,CHEMBL2046282,>,>,Ki,nM,4000.0,Ki,uM,4.0,CC(C)C[C@H]1CN(c2ccc(C(F)(F)F)c(C(=O)c3cccnc3N)n2)CCN1,2012
Inhibition of PI3Kgamma after 4 hrs,COc1cc(-c2nnc(SCc3ccc(C)cc3)o2)ccc1O,CHEMBL2057140,=,=,IC50,nM,7410.0,IC50,uM,7.41,COc1cc(-c2nnc(SCc3ccc(C)cc3)o2)ccc1O,2012
Inhibition of PI3Kgamma after 4 hrs,COc1cc(-c2nnc(SCc3ccccc3C)o2)ccc1O,CHEMBL2057140,=,=,IC50,nM,6480.0,IC50,uM,6.48,COc1cc(-c2nnc(SCc3ccccc3C)o2)ccc1O,2012
Inhibition of PI3Kgamma after 4 hrs,COc1cc(-c2nnc(SCc3ccccc3)o2)ccc1O,CHEMBL2057140,=,=,IC50,nM,1340.0,IC50,uM,1.34,COc1cc(-c2nnc(SCc3ccccc3)o2)ccc1O,2012
Inhibition of PI3Kgamma after 4 hrs,COc1cccc(CSc2nnc(-c3ccc(O)c(OC)c3)o2)c1,CHEMBL2057140,=,=,IC50,nM,2870.0,IC50,uM,2.87,COc1cccc(CSc2nnc(-c3ccc(O)c(OC)c3)o2)c1,2012
Inhibition of PI3Kgamma after 4 hrs,COc1cc(-c2nnc(SCc3ccccc3F)o2)ccc1OCc1ccccc1F,CHEMBL2057140,=,=,IC50,nM,5120.0,IC50,uM,5.12,COc1cc(-c2nnc(SCc3ccccc3F)o2)ccc1OCc1ccccc1F,2012
Inhibition of PI3Kgamma after 4 hrs,COc1cc(-c2nnc(SCc3c(F)cccc3F)o2)ccc1OCc1c(F)cccc1F,CHEMBL2057140,=,=,IC50,nM,5740.0,IC50,uM,5.74,COc1cc(-c2nnc(SCc3c(F)cccc3F)o2)ccc1OCc1c(F)cccc1F,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(=O)Nc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,CHEMBL2057090,=,=,IC50,nM,79.43,pIC50,,7.1,CC(=O)Nc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,100.0,pIC50,,7.0,CS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,25.12,pIC50,,7.6,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CNC(=O)Nc1nc2ccc(-c3cncc(S(=O)(=O)NC(C)(C)C)c3)cn2n1,CHEMBL2057090,=,=,IC50,nM,12.59,pIC50,,7.9,CNC(=O)Nc1nc2ccc(-c3cncc(S(=O)(=O)NC(C)(C)C)c3)cn2n1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)N4CCOCC4)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,125.89,pIC50,,6.9,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)N4CCOCC4)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CN(C)CCNC(=O)Nc1nc2ccc(-c3cncc(S(=O)(=O)NC(C)(C)C)c3)cn2n1,CHEMBL2057090,=,=,IC50,nM,125.89,pIC50,,6.9,CN(C)CCNC(=O)Nc1nc2ccc(-c3cncc(S(=O)(=O)NC(C)(C)C)c3)cn2n1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCN4CCOCC4)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,15.85,pIC50,,7.8,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCN4CCOCC4)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)Nc4ccccc4)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,251.19,pIC50,,6.6,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)Nc4ccccc4)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCc4ccccc4)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,63.1,pIC50,,7.2,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCc4ccccc4)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCc4ccccc4)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,31.62,pIC50,,7.5,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCc4ccccc4)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,Cc1noc(C)c1CCNC(=O)Nc1nc2ccc(-c3cncc(S(=O)(=O)NC(C)(C)C)c3)cn2n1,CHEMBL2057090,=,=,IC50,nM,25.12,pIC50,,7.6,Cc1noc(C)c1CCNC(=O)Nc1nc2ccc(-c3cncc(S(=O)(=O)NC(C)(C)C)c3)cn2n1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CN(C)C(=O)CNC(=O)Nc1nc2ccc(-c3cncc(S(=O)(=O)NC(C)(C)C)c3)cn2n1,CHEMBL2057090,=,=,IC50,nM,3.162,pIC50,,8.5,CN(C)C(=O)CNC(=O)Nc1nc2ccc(-c3cncc(S(=O)(=O)NC(C)(C)C)c3)cn2n1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCn4cccn4)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,25.12,pIC50,,7.6,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCn4cccn4)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,Cc1nc(CCNC(=O)Nc2nc3ccc(-c4cncc(S(=O)(=O)NC(C)(C)C)c4)cn3n2)cs1,CHEMBL2057090,=,=,IC50,nM,7.943,pIC50,,8.1,Cc1nc(CCNC(=O)Nc2nc3ccc(-c4cncc(S(=O)(=O)NC(C)(C)C)c4)cn3n2)cs1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCc4cnccn4)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,6.31,pIC50,,8.2,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCc4cnccn4)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCc4nnc(C5CC5)o4)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,10.0,pIC50,,8.0,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCc4nnc(C5CC5)o4)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCn4nnc(C5CC5)n4)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,2.512,pIC50,,8.6,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCn4nnc(C5CC5)n4)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCCn4nnc(C5CC5)n4)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,63.1,pIC50,,7.2,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCCCn4nnc(C5CC5)n4)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CNC(=O)CNC(=O)Nc1nc2ccc(-c3cncc(S(=O)(=O)NC(C)(C)C)c3)cn2n1,CHEMBL2057090,=,=,IC50,nM,15.85,pIC50,,7.8,CNC(=O)CNC(=O)Nc1nc2ccc(-c3cncc(S(=O)(=O)NC(C)(C)C)c3)cn2n1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCC(=O)N4CCCC4)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,6.31,pIC50,,8.2,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCC(=O)N4CCCC4)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCC(=O)N4CCOCC4)nn3c2)c1,CHEMBL2057090,=,=,IC50,nM,3.981,pIC50,,8.4,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCC(=O)N4CCOCC4)nn3c2)c1,2012
Inhibition of PI3Kgamma in human HL60 cell lysate by kinobead assay,CN1CCN(C(=O)CNC(=O)Nc2nc3ccc(-c4cncc(S(=O)(=O)NC(C)(C)C)c4)cn3n2)CC1,CHEMBL2057090,=,=,IC50,nM,2.512,pIC50,,8.6,CN1CCN(C(=O)CNC(=O)Nc2nc3ccc(-c4cncc(S(=O)(=O)NC(C)(C)C)c4)cn3n2)CC1,2012
Inhibition of PI3Kgamma at 1 uM,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCC(=O)N4CCOCC4)nn3c2)c1,CHEMBL2057090,,,Inhibition,%,,INH,,,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(NC(=O)NCC(=O)N4CCOCC4)nn3c2)c1,2012
Inhibition of PI3Kgamma assessed as accumulation of ADP,COCCNC(=O)c1nc2c(N3CCOCC3)nc(-c3cnc(N)nc3)cn2c1C,CHEMBL2057167,=,=,Ki,nM,62.9,Ki(app),nM,62.9,COCCNC(=O)c1nc2c(N3CCOCC3)nc(-c3cnc(N)nc3)cn2c1C,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,COc1ccccc1-c1ccc2nc(NC(C)=O)nn2c1,CHEMBL2062454,=,=,IC50,nM,3981.07,pIC50,,5.4,COc1ccccc1-c1ccc2nc(NC(C)=O)nn2c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3cc(C)c(O)c(C)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,1995.26,pIC50,,5.7,CC(=O)Nc1nc2ccc(-c3cc(C)c(O)c(C)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,COc1cccc(-c2ccc3nc(NC(C)=O)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,158.49,pIC50,,6.8,COc1cccc(-c2ccc3nc(NC(C)=O)nn3c2)c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,COc1ccc(-c2ccc3nc(NC(C)=O)nn3c2)cc1,CHEMBL2062454,=,=,IC50,nM,1000.0,pIC50,,6.0,COc1ccc(-c2ccc3nc(NC(C)=O)nn3c2)cc1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,COc1ccc(-c2ccc3nc(NC(C)=O)nn3c2)cc1OC,CHEMBL2062454,=,=,IC50,nM,39.81,pIC50,,7.4,COc1ccc(-c2ccc3nc(NC(C)=O)nn3c2)cc1OC,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3cccc(S(C)(=O)=O)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,501.19,pIC50,,6.3,CC(=O)Nc1nc2ccc(-c3cccc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3cccc(NS(C)(=O)=O)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,316.23,pIC50,,6.5,CC(=O)Nc1nc2ccc(-c3cccc(NS(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CNS(=O)(=O)c1cccc(-c2ccc3nc(NC(C)=O)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,251.19,pIC50,,6.6,CNS(=O)(=O)c1cccc(-c2ccc3nc(NC(C)=O)nn3c2)c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CNC(=O)c1cccc(-c2ccc3nc(NC(C)=O)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,630.96,pIC50,,6.2,CNC(=O)c1cccc(-c2ccc3nc(NC(C)=O)nn3c2)c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3ccc(S(C)(=O)=O)cc3)cn2n1,CHEMBL2062454,<,>,IC50,nM,100000.0,pIC50,,4.0,CC(=O)Nc1nc2ccc(-c3ccc(S(C)(=O)=O)cc3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CNS(=O)(=O)c1ccc(-c2ccc3nc(NC(C)=O)nn3c2)cc1,CHEMBL2062454,<,>,IC50,nM,50118.72,pIC50,,4.3,CNS(=O)(=O)c1ccc(-c2ccc3nc(NC(C)=O)nn3c2)cc1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CCCCNS(=O)(=O)c1cccc(-c2ccc3nc(NC(C)=O)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,199.53,pIC50,,6.7,CCCCNS(=O)(=O)c1cccc(-c2ccc3nc(NC(C)=O)nn3c2)c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3cccc(S(=O)(=O)NCc4ccccc4)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,501.19,pIC50,,6.3,CC(=O)Nc1nc2ccc(-c3cccc(S(=O)(=O)NCc4ccccc4)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3cccc(-c4ccccc4)c3)cn2n1,CHEMBL2062454,<,>,IC50,nM,3981.07,pIC50,,5.4,CC(=O)Nc1nc2ccc(-c3cccc(-c4ccccc4)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,COc1ccc(-c2ccc3nc(NC(C)=O)nn3c2)cc1S(=O)(=O)NCc1ccccc1,CHEMBL2062454,<,>,IC50,nM,100000.0,pIC50,,4.0,COc1ccc(-c2ccc3nc(NC(C)=O)nn3c2)cc1S(=O)(=O)NCc1ccccc1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3cccnc3)cn2n1,CHEMBL2062454,=,=,IC50,nM,251.19,pIC50,,6.6,CC(=O)Nc1nc2ccc(-c3cccnc3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3cncnc3)cn2n1,CHEMBL2062454,=,=,IC50,nM,3981.07,pIC50,,5.4,CC(=O)Nc1nc2ccc(-c3cncnc3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3cncc4ccccc34)cn2n1,CHEMBL2062454,=,=,IC50,nM,3162.28,pIC50,,5.5,CC(=O)Nc1nc2ccc(-c3cncc4ccccc34)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3ccncc3)cn2n1,CHEMBL2062454,=,=,IC50,nM,1584.89,pIC50,,5.8,CC(=O)Nc1nc2ccc(-c3ccncc3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3sc(C)nc3C)cn2n1,CHEMBL2062454,<,>,IC50,nM,12589.25,pIC50,,4.9,CC(=O)Nc1nc2ccc(-c3sc(C)nc3C)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3cnn(C)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,3981.07,pIC50,,5.4,CC(=O)Nc1nc2ccc(-c3cnn(C)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3ccsc3)cn2n1,CHEMBL2062454,=,=,IC50,nM,398.11,pIC50,,6.4,CC(=O)Nc1nc2ccc(-c3ccsc3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,COc1cncc(-c2ccc3nc(NC(C)=O)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,63.1,pIC50,,7.2,COc1cncc(-c2ccc3nc(NC(C)=O)nn3c2)c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,79.43,pIC50,,7.1,CC(=O)Nc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3cncc(S(=O)(=O)NCc4ccccc4)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,39.81,pIC50,,7.4,CC(=O)Nc1nc2ccc(-c3cncc(S(=O)(=O)NCc4ccccc4)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3cncc(CS(N)(=O)=O)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,7.943,pIC50,,8.1,CC(=O)Nc1nc2ccc(-c3cncc(CS(N)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,100.0,pIC50,,7.0,CS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CS(=O)(=O)Nc1cccc(-c2ccc3nc(NC(=O)C4CCCCC4)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,316.23,pIC50,,6.5,CS(=O)(=O)Nc1cccc(-c2ccc3nc(NC(=O)C4CCCCC4)nn3c2)c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)N(C)c1nc2ccc(-c3cccc(S(C)(=O)=O)c3)cn2n1,CHEMBL2062454,<,>,IC50,nM,31622.78,pIC50,,4.5,CC(=O)N(C)c1nc2ccc(-c3cccc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CNc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,316.23,pIC50,,6.5,CNc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CN(C)c1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,3162.28,pIC50,,5.5,CN(C)c1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CS(=O)(=O)Nc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,CHEMBL2062454,<,>,IC50,nM,39810.72,pIC50,,4.4,CS(=O)(=O)Nc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,Nc1nc2ccc(-c3cncc(S(=O)(=O)Nc4cccc5ccccc45)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,7.943,pIC50,,8.1,Nc1nc2ccc(-c3cncc(S(=O)(=O)Nc4cccc5ccccc45)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,Nc1nc2ccc(-c3cncc(NS(=O)(=O)c4ccc(Cl)cc4)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,6.31,pIC50,,8.2,Nc1nc2ccc(-c3cncc(NS(=O)(=O)c4ccc(Cl)cc4)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,Nc1nc2ccc(-c3cncc(S(=O)(=O)Nc4ccc(Cl)cc4)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,630.96,pIC50,,6.2,Nc1nc2ccc(-c3cncc(S(=O)(=O)Nc4ccc(Cl)cc4)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,Nc1nc2ccc(-c3cncc(S(=O)(=O)NCc4ccccc4)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,251.19,pIC50,,6.6,Nc1nc2ccc(-c3cncc(S(=O)(=O)NCc4ccccc4)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,25.12,pIC50,,7.6,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,31.62,pIC50,,7.5,CC(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,Nc1nc2ccc(-c3cncc(S(=O)(=O)NCC4CC4)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,15.85,pIC50,,7.8,Nc1nc2ccc(-c3cncc(S(=O)(=O)NCC4CC4)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(C)(C)S(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,158.49,pIC50,,6.8,CC(C)(C)S(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2c(C)cc(-c3cncc(S(C)(=O)=O)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,100.0,pIC50,,7.0,CC(=O)Nc1nc2c(C)cc(-c3cncc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2cc(C)c(-c3cncc(S(C)(=O)=O)c3)cn2n1,CHEMBL2062454,<,>,IC50,nM,100000.0,pIC50,,4.0,CC(=O)Nc1nc2cc(C)c(-c3cncc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)c(C)n2n1,CHEMBL2062454,=,=,IC50,nM,1000.0,pIC50,,6.0,CC(=O)Nc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)c(C)n2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CS(=O)(=O)c1cncc(-c2cc(C(F)(F)F)c3nc(N)nn3c2)c1,CHEMBL2062454,<,>,IC50,nM,100000.0,pIC50,,4.0,CS(=O)(=O)c1cncc(-c2cc(C(F)(F)F)c3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CS(=O)(=O)c1cncc(-c2cc(Cl)c3nc(N)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,1995.26,pIC50,,5.7,CS(=O)(=O)c1cncc(-c2cc(Cl)c3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(=O)Nc1nc2c(F)cc(-c3cncc(S(C)(=O)=O)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,125.89,pIC50,,6.9,CC(=O)Nc1nc2c(F)cc(-c3cncc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2cc(F)c3nc(N)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,25.12,pIC50,,7.6,CC(C)(C)NS(=O)(=O)c1cncc(-c2cc(F)c3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma by high throughput chemoproteomics binding assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2cn3nc(N)nc3cc2F)c1,CHEMBL2062454,=,=,IC50,nM,25118.86,pIC50,,4.6,CC(C)(C)NS(=O)(=O)c1cncc(-c2cn3nc(N)nc3cc2F)c1,2012
Inhibition of PI3Kgamma assessed as inhibition of C5a-induced AKT phosphorylation at Ser473 by cell based assay,CC(=O)Nc1nc2ccc(-c3cccc(S(C)(=O)=O)c3)cn2n1,CHEMBL2062454,<,>,IC50,nM,12589.25,pIC50,,4.9,CC(=O)Nc1nc2ccc(-c3cccc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of C5a-induced AKT phosphorylation at Ser473 by cell based assay,CC(=O)Nc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,CHEMBL2062454,<,>,IC50,nM,63095.73,pIC50,,4.2,CC(=O)Nc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of C5a-induced AKT phosphorylation at Ser473 by cell based assay,CS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,1995.26,pIC50,,5.7,CS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma assessed as inhibition of fMLP-induced neutrophil migration assay by cell based assay,CC(=O)Nc1nc2ccc(-c3cccc(S(C)(=O)=O)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,3981.07,pIC50,,5.4,CC(=O)Nc1nc2ccc(-c3cccc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of fMLP-induced neutrophil migration assay by cell based assay,CC(=O)Nc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,1995.26,pIC50,,5.7,CC(=O)Nc1nc2ccc(-c3cncc(S(C)(=O)=O)c3)cn2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of fMLP-induced neutrophil migration assay by cell based assay,CS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,1995.26,pIC50,,5.7,CS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma assessed as inhibition of C5a-induced AKT phosphorylation at Ser473 by cell based assay,Nc1nc2ccc(-c3cncc(S(=O)(=O)Nc4cccc5ccccc45)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,501.19,pIC50,,6.3,Nc1nc2ccc(-c3cncc(S(=O)(=O)Nc4cccc5ccccc45)c3)cn2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of fMLP-induced neutrophil migration assay by cell based assay,Nc1nc2ccc(-c3cncc(S(=O)(=O)Nc4cccc5ccccc45)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,19952.62,pIC50,,4.7,Nc1nc2ccc(-c3cncc(S(=O)(=O)Nc4cccc5ccccc45)c3)cn2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of C5a-induced AKT phosphorylation at Ser473 by cell based assay,Nc1nc2ccc(-c3cncc(NS(=O)(=O)c4ccc(Cl)cc4)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,1995.26,pIC50,,5.7,Nc1nc2ccc(-c3cncc(NS(=O)(=O)c4ccc(Cl)cc4)c3)cn2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of fMLP-induced neutrophil migration assay by cell based assay,Nc1nc2ccc(-c3cncc(NS(=O)(=O)c4ccc(Cl)cc4)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,15848.93,pIC50,,4.8,Nc1nc2ccc(-c3cncc(NS(=O)(=O)c4ccc(Cl)cc4)c3)cn2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of C5a-induced AKT phosphorylation at Ser473 by cell based assay,Nc1nc2ccc(-c3cncc(S(=O)(=O)Nc4ccc(Cl)cc4)c3)cn2n1,CHEMBL2062454,<,>,IC50,nM,12589.25,pIC50,,4.9,Nc1nc2ccc(-c3cncc(S(=O)(=O)Nc4ccc(Cl)cc4)c3)cn2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of C5a-induced AKT phosphorylation at Ser473 by cell based assay,Nc1nc2ccc(-c3cncc(S(=O)(=O)NCc4ccccc4)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,1258.93,pIC50,,5.9,Nc1nc2ccc(-c3cncc(S(=O)(=O)NCc4ccccc4)c3)cn2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of fMLP-induced neutrophil migration assay by cell based assay,Nc1nc2ccc(-c3cncc(S(=O)(=O)NCc4ccccc4)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,7943.28,pIC50,,5.1,Nc1nc2ccc(-c3cncc(S(=O)(=O)NCc4ccccc4)c3)cn2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of C5a-induced AKT phosphorylation at Ser473 by cell based assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,1995.26,pIC50,,5.7,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma assessed as inhibition of fMLP-induced neutrophil migration assay by cell based assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,1000.0,pIC50,,6.0,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma assessed as inhibition of C5a-induced AKT phosphorylation at Ser473 by cell based assay,CC(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,1584.89,pIC50,,5.8,CC(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma assessed as inhibition of fMLP-induced neutrophil migration assay by cell based assay,CC(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,CHEMBL2062454,=,=,IC50,nM,630.96,pIC50,,6.2,CC(C)NS(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma assessed as inhibition of C5a-induced AKT phosphorylation at Ser473 by cell based assay,Nc1nc2ccc(-c3cncc(S(=O)(=O)NCC4CC4)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,1995.26,pIC50,,5.7,Nc1nc2ccc(-c3cncc(S(=O)(=O)NCC4CC4)c3)cn2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of fMLP-induced neutrophil migration assay by cell based assay,Nc1nc2ccc(-c3cncc(S(=O)(=O)NCC4CC4)c3)cn2n1,CHEMBL2062454,=,=,IC50,nM,1584.89,pIC50,,5.8,Nc1nc2ccc(-c3cncc(S(=O)(=O)NCC4CC4)c3)cn2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of C5a-induced AKT phosphorylation at Ser473 by cell based assay,CC(C)(C)S(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,CHEMBL2062454,<,>,IC50,nM,10000.0,pIC50,,5.0,CC(C)(C)S(=O)(=O)c1cncc(-c2ccc3nc(N)nn3c2)c1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cc1cc(C(C)Nc2ccccc2)c2nc(N3CCOCC3)cc(=O)n2c1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cc(C(C)Nc2ccccc2)c2nc(N3CCOCC3)cc(=O)n2c1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cc1cc(F)ccc1Oc1cccc2c(=O)cc(N3CCOCC3)[nH]c12,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cc(F)ccc1Oc1cccc2c(=O)cc(N3CCOCC3)[nH]c12,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cc1cc(C(C)Nc2ccccc2)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cc(C(C)Nc2ccccc2)c2oc(N3CCOCC3)cc(=O)c2c1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)c(F)ccc3o2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)c(F)ccc3o2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccncc4)cccc3o2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccncc4)cccc3o2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4cccnc4)cccc3o2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4cccnc4)cccc3o2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccn4)cccc3o2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccn4)cccc3o2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4cccs4)cccc3o2)[nH]1,CHEMBL2062364,=,=,IC50,nM,5742.0,IC50,nM,5742.0,O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4cccs4)cccc3o2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3cccc(-c4ccccc4)c3o2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3cccc(-c4ccccc4)c3o2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)cccc3o2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)cccc3o2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3c(Br)cccc3o2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3c(Br)cccc3o2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cc1cccc2nc(Cc3nc(N4CCOCC4)cc(=O)[nH]3)oc12,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cccc2nc(Cc3nc(N4CCOCC4)cc(=O)[nH]3)oc12,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cc1ccc2nc(Cc3nc(N4CCOCC4)cc(=O)[nH]3)oc2c1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1ccc2nc(Cc3nc(N4CCOCC4)cc(=O)[nH]3)oc2c1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cc1cccc2oc(Cc3nc(N4CCOCC4)cc(=O)[nH]3)nc12,CHEMBL2062364,=,=,IC50,nM,3333.0,IC50,nM,3333.0,Cc1cccc2oc(Cc3nc(N4CCOCC4)cc(=O)[nH]3)nc12,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3cccc(F)c3o2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3cccc(F)c3o2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3ccc(F)cc3o2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3ccc(F)cc3o2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3o2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3o2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3c(F)cccc3o2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3c(F)cccc3o2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccc(-c3ccccc3)cc21,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccc(-c3ccccc3)cc21,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cc(-c3ccccc3)ccc21,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cc(-c3ccccc3)ccc21,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cccc(-c3ccccc3)c21,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cccc(-c3ccccc3)c21,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2c(-c3ccccc3)cccc21,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2c(-c3ccccc3)cccc21,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)cccc3[nH]2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)cccc3[nH]2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2Cc2ccccc2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2Cc2ccccc2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2-c2ccccc2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2-c2ccccc2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2C2CCCCC2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2C2CCCCC2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",COCCn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cc(F)ccc21,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COCCn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cc(F)ccc21,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3n2C2CC2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3n2C2CC2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",CCn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21,CHEMBL2062364,=,=,IC50,nM,8270.0,IC50,nM,8270.0,CCn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3cc(C(F)(F)F)ccc3[nH]2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3cc(C(F)(F)F)ccc3[nH]2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",COc1ccc2[nH]c(Cc3nc(N4CCOCC4)cc(=O)[nH]3)nc2c1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COc1ccc2[nH]c(Cc3nc(N4CCOCC4)cc(=O)[nH]3)nc2c1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cc1ccc2[nH]c(Cc3nc(N4CCOCC4)cc(=O)[nH]3)nc2c1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1ccc2[nH]c(Cc3nc(N4CCOCC4)cc(=O)[nH]3)nc2c1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3cc(Cl)ccc3[nH]2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3cc(Cl)ccc3[nH]2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3cc(Br)ccc3[nH]2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3cc(Br)ccc3[nH]2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccc(F)cc21,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccc(F)cc21,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cc(F)ccc21,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cc(F)ccc21,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cn1c(Cc2nc3cc(F)ccc3[nH]2)nc(N2CCOCC2)cc1=O,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(Cc2nc3cc(F)ccc3[nH]2)nc(N2CCOCC2)cc1=O,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3[nH]2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3[nH]2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3o2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3o2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3[nH]2)[nH]1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3[nH]2)[nH]1,2012
"Inhibition of N-terminus poly-His tagged human PI3Kgamma expressed in baculovirus infected insect sf9 cells using PI(4,5)P2 as substrate preincubated with compound for 15 mins measured after 10 mins by HTRF assay",O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1,2012
Inhibition of human PI3Kgamma-mediated Akt phosphorylation at Ser473 residue expressed in mouse RAW264.7 cells after 0.5 to 2 hrs by Western blot analysis,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21,CHEMBL2062364,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21,2012
Inhibition of human PI3Kgamma-mediated Akt phosphorylation at Ser473 residue expressed in mouse RAW264.7 cells after 0.5 to 2 hrs by Western blot analysis,Cc1cc(C(C)Nc2ccccc2)c2nc(N3CCOCC3)cc(=O)n2c1,CHEMBL2062364,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1cc(C(C)Nc2ccccc2)c2nc(N3CCOCC3)cc(=O)n2c1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma by KinaseGlo assay,NC(=O)[C@@H]1CCCN1C(=O)Nc1nc2ccc(-c3cnc(N)c(C(F)(F)F)c3)cc2s1,CHEMBL2069199,=,=,IC50,nM,1190.0,IC50,uM,1.19,NC(=O)[C@@H]1CCCN1C(=O)Nc1nc2ccc(-c3cnc(N)c(C(F)(F)F)c3)cc2s1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,CC(=O)Nc1nc(C)c(-c2ccc(S(N)(=O)=O)cc2)s1,CHEMBL2069199,=,=,Ki,nM,110.0,Ki,uM,0.11,CC(=O)Nc1nc(C)c(-c2ccc(S(N)(=O)=O)cc2)s1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)cc2)s1,CHEMBL2069199,=,=,Ki,nM,230.0,Ki,uM,0.23,CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)cc2)s1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)c(Cl)c2)s1,CHEMBL2069199,=,=,Ki,nM,57.0,Ki,uM,0.057,CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)c(Cl)c2)s1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)c(Br)c2)s1,CHEMBL2069199,=,=,Ki,nM,32.0,Ki,uM,0.032,CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)c(Br)c2)s1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)c(F)c2)s1,CHEMBL2069199,=,=,Ki,nM,183.0,Ki,uM,0.183,CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)c(F)c2)s1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)c(C#N)c2)s1,CHEMBL2069199,=,=,Ki,nM,62.0,Ki,uM,0.062,CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)c(C#N)c2)s1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)c(C(F)(F)F)c2)s1,CHEMBL2069199,=,=,Ki,nM,61.0,Ki,uM,0.061,CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)c(C(F)(F)F)c2)s1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,CC(=O)Nc1nc(C)c(-c2ccc(-n3cccn3)cc2)s1,CHEMBL2069199,=,=,Ki,nM,110.0,Ki,uM,0.11,CC(=O)Nc1nc(C)c(-c2ccc(-n3cccn3)cc2)s1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,CC(=O)Nc1nc(C)c(-c2ccc(C(C)=O)cc2)s1,CHEMBL2069199,=,=,Ki,nM,260.0,Ki,uM,0.26,CC(=O)Nc1nc(C)c(-c2ccc(C(C)=O)cc2)s1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccc(S(C)(=O)=O)cc1,CHEMBL2069199,=,=,Ki,nM,5810.0,Ki,uM,5.81,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccc(S(C)(=O)=O)cc1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccc(S(C)(=O)=O)c(F)c1,CHEMBL2069199,=,=,Ki,nM,3060.0,Ki,uM,3.06,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccc(S(C)(=O)=O)c(F)c1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccc(S(C)(=O)=O)c(C(F)(F)F)c1,CHEMBL2069199,=,=,Ki,nM,1140.0,Ki,uM,1.14,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccc(S(C)(=O)=O)c(C(F)(F)F)c1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccc(-n2cccn2)cc1,CHEMBL2069199,=,=,Ki,nM,530.0,Ki,uM,0.53,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccc(-n2cccn2)cc1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(S(C)(=O)=O)c(F)c3)s2)no1,CHEMBL2069199,=,=,Ki,nM,120.0,Ki,uM,0.12,Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(S(C)(=O)=O)c(F)c3)s2)no1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(-n4cccn4)cc3)s2)no1,CHEMBL2069199,=,=,Ki,nM,1020.0,Ki,uM,1.02,Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(-n4cccn4)cc3)s2)no1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,Cc1nc(NC(=O)NCCC(=O)OC(C)(C)C)sc1-c1ccc(S(C)(=O)=O)c(F)c1,CHEMBL2069199,=,=,Ki,nM,20.0,Ki,uM,0.02,Cc1nc(NC(=O)NCCC(=O)OC(C)(C)C)sc1-c1ccc(S(C)(=O)=O)c(F)c1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,CC(=O)c1ccc(-c2sc(NC(=O)NCCC(=O)NC(C)(C)C)nc2C)cc1,CHEMBL2069199,=,=,Ki,nM,88.0,Ki,uM,0.088,CC(=O)c1ccc(-c2sc(NC(=O)NCCC(=O)NC(C)(C)C)nc2C)cc1,2012
Inhibition of recombinant GST-tagged PI3K p110gamma using [32P]ATP after 60 mins by scintillation proximity assay,CCn1nnc(CCNC(=O)Nc2nc(C)c(-c3ccc(S(C)(=O)=O)c(F)c3)s2)n1,CHEMBL2069199,=,=,Ki,nM,36.0,Ki,uM,0.036,CCn1nnc(CCNC(=O)Nc2nc(C)c(-c3ccc(S(C)(=O)=O)c(F)c3)s2)n1,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cl)cccc1Cn1c(N)nc(=O)c2sc(N3CCOCC3)nc21,CHEMBL2086270,=,=,IC50,nM,500.0,IC50,uM,0.5,Cc1c(Cl)cccc1Cn1c(N)nc(=O)c2sc(N3CCOCC3)nc21,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cl)cccc1Cn1c(SCC(=O)O)nc(=O)c2sc(N3CCOCC3)nc21,CHEMBL2086270,=,=,IC50,nM,160.0,IC50,uM,0.16,Cc1c(Cl)cccc1Cn1c(SCC(=O)O)nc(=O)c2sc(N3CCOCC3)nc21,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,CSc1nc(=O)c2sc(N3CCOCC3)nc2n1Cc1cccc(Cl)c1C,CHEMBL2086270,=,=,IC50,nM,2500.0,IC50,uM,2.5,CSc1nc(=O)c2sc(N3CCOCC3)nc2n1Cc1cccc(Cl)c1C,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cl)cccc1Cn1c(S)nc(=O)c2sc(N3CCOCC3)nc21,CHEMBL2086270,>,>,IC50,nM,3200.0,IC50,uM,3.2,Cc1c(Cl)cccc1Cn1c(S)nc(=O)c2sc(N3CCOCC3)nc21,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,COc1nc(=O)c2sc(N3CCOCC3)nc2n1Cc1cccc(Cl)c1C,CHEMBL2086270,=,=,IC50,nM,400.0,IC50,uM,0.4,COc1nc(=O)c2sc(N3CCOCC3)nc2n1Cc1cccc(Cl)c1C,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cl)cccc1Cn1c(=O)[nH]c(=O)c2sc(N3CCOCC3)nc21,CHEMBL2086270,>,>,IC50,nM,6300.0,IC50,uM,6.3,Cc1c(Cl)cccc1Cn1c(=O)[nH]c(=O)c2sc(N3CCOCC3)nc21,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cl)cccc1Cn1c(CO)nc(=O)c2sc(N3CCOCC3)nc21,CHEMBL2086270,=,=,IC50,nM,250.0,IC50,uM,0.25,Cc1c(Cl)cccc1Cn1c(CO)nc(=O)c2sc(N3CCOCC3)nc21,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cn2c(CN)nc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,CHEMBL2086270,>,>,IC50,nM,7900.0,IC50,uM,7.9,Cc1c(Cn2c(CN)nc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cn2c(CO)nc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,CHEMBL2086270,=,=,IC50,nM,250.0,IC50,uM,0.25,Cc1c(Cn2c(CO)nc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cn2c(Cc3ccccc3)nc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,CHEMBL2086270,=,=,IC50,nM,2000.0,IC50,uM,2.0,Cc1c(Cn2c(Cc3ccccc3)nc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cn2c(-c3ccccc3)nc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,CHEMBL2086270,=,=,IC50,nM,4000.0,IC50,uM,4.0,Cc1c(Cn2c(-c3ccccc3)nc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cn2c(C3CC3)nc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,CHEMBL2086270,=,=,IC50,nM,1000.0,IC50,uM,1.0,Cc1c(Cn2c(C3CC3)nc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,CCc1nc(=O)c2sc(N3CCOCC3)nc2n1Cc1cccc(C(F)(F)F)c1C,CHEMBL2086270,=,=,IC50,nM,1300.0,IC50,uM,1.3,CCc1nc(=O)c2sc(N3CCOCC3)nc2n1Cc1cccc(C(F)(F)F)c1C,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cl)cccc1Cn1c(C)nc(=O)c2sc(N3CCOCC3)nc21,CHEMBL2086270,=,=,IC50,nM,1000.0,IC50,uM,1.0,Cc1c(Cl)cccc1Cn1c(C)nc(=O)c2sc(N3CCOCC3)nc21,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cn2c(C)nc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,CHEMBL2086270,=,=,IC50,nM,790.0,IC50,uM,0.79,Cc1c(Cn2c(C)nc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cl)cccc1Cn1cnc(=O)c2sc(N3CCOCC3)nc21,CHEMBL2086270,=,=,IC50,nM,2500.0,IC50,uM,2.5,Cc1c(Cl)cccc1Cn1cnc(=O)c2sc(N3CCOCC3)nc21,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1c(Cn2cnc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,CHEMBL2086270,=,=,IC50,nM,1600.0,IC50,uM,1.6,Cc1c(Cn2cnc(=O)c3sc(N4CCOCC4)nc32)cccc1C(F)(F)F,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,O=c1ncn(Cc2cccc(Cl)c2Cl)c2nc(N3CCOCC3)sc12,CHEMBL2086270,=,=,IC50,nM,1300.0,IC50,uM,1.3,O=c1ncn(Cc2cccc(Cl)c2Cl)c2nc(N3CCOCC3)sc12,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,O=c1ncn(Cc2cccc(Cl)c2)c2nc(N3CCOCC3)sc12,CHEMBL2086270,>,>,IC50,nM,790.0,IC50,uM,0.79,O=c1ncn(Cc2cccc(Cl)c2)c2nc(N3CCOCC3)sc12,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,O=c1ncn(Cc2ccsc2Cl)c2nc(N3CCOCC3)sc12,CHEMBL2086270,=,=,IC50,nM,4000.0,IC50,uM,4.0,O=c1ncn(Cc2ccsc2Cl)c2nc(N3CCOCC3)sc12,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,O=c1ncn(Cc2ccccc2Cl)c2nc(N3CCOCC3)sc12,CHEMBL2086270,=,=,IC50,nM,7900.0,IC50,uM,7.9,O=c1ncn(Cc2ccccc2Cl)c2nc(N3CCOCC3)sc12,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,O=c1ncn(CCc2ccccc2)c2nc(N3CCOCC3)sc12,CHEMBL2086270,=,=,IC50,nM,3200.0,IC50,uM,3.2,O=c1ncn(CCc2ccccc2)c2nc(N3CCOCC3)sc12,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,CC(c1ccccc1)n1cnc(=O)c2sc(N3CCOCC3)nc21,CHEMBL2086270,=,=,IC50,nM,5000.0,IC50,uM,5.0,CC(c1ccccc1)n1cnc(=O)c2sc(N3CCOCC3)nc21,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,Cc1ccccc1Cn1cnc(=O)c2sc(N3CCOCC3)nc21,CHEMBL2086270,=,=,IC50,nM,2500.0,IC50,uM,2.5,Cc1ccccc1Cn1cnc(=O)c2sc(N3CCOCC3)nc21,2012
Inhibition of PI3K gamma by continuous TR-FRET assay,O=c1ncn(Cc2ccccc2)c2nc(N3CCOCC3)sc12,CHEMBL2086270,=,=,IC50,nM,6300.0,IC50,uM,6.3,O=c1ncn(Cc2ccccc2)c2nc(N3CCOCC3)sc12,2012
Inhibition of human PI3Kgamma by ADP accumulation based HTRF assay,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,CHEMBL2086238,=,=,Ki,nM,179.0,Ki(app),nM,179.0,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,2012
Inhibition of human PI3Kgamma by ADP accumulation based HTRF assay,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4C(F)(F)F)nc(N4CCOCC4)c3n2)CC1,CHEMBL2086238,=,=,Ki,nM,26.7,Ki(app),nM,26.7,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4C(F)(F)F)nc(N4CCOCC4)c3n2)CC1,2012
Inhibition of human PI3Kgamma by ADP accumulation based HTRF assay,C[C@H]1CN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CCN1S(C)(=O)=O,CHEMBL2086238,=,=,Ki,nM,124.0,Ki(app),nM,124.0,C[C@H]1CN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CCN1S(C)(=O)=O,2012
Inhibition of human PI3Kgamma by ADP accumulation based HTRF assay,Cc1c(CN2CCN(S(C)(=O)=O)CC2)nc2c(N3CCOCC3)nc(-c3cnc(N)nc3)cn12,CHEMBL2086238,=,=,Ki,nM,59.8,Ki(app),nM,59.8,Cc1c(CN2CCN(S(C)(=O)=O)CC2)nc2c(N3CCOCC3)nc(-c3cnc(N)nc3)cn12,2012
Inhibition of human PI3Kgamma by ADP accumulation based HTRF assay,CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,CHEMBL2086238,=,=,Ki,nM,84.0,Ki(app),nM,84.0,CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,2012
Inhibition of PI3Kgamma assessed as residual activity at 1 uM,O=S(=O)(Nc1cc(Sc2ncn[nH]2)c(O)c2ccccc12)c1ccc(-c2ccccc2)cc1,CHEMBL2086356,=,=,Activity,%,75.0,Activity,%,75.0,O=S(=O)(Nc1cc(Sc2ncn[nH]2)c(O)c2ccccc12)c1ccc(-c2ccccc2)cc1,2012
Inhibition of PI3Kgamma at 1 uM,CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1,CHEMBL2151019,=,=,Inhibition,%,6.1,INH,%,6.1,CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL2150966,=,=,IC50,nM,298.0,IC50,nM,298.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,COc1ccc(-c2cccc(S(=O)(=O)N3CCN(c4nccnc4-c4ccc(OC)cc4)CC3)c2)cc1,CHEMBL2150966,=,=,IC50,nM,441.0,IC50,nM,441.0,COc1ccc(-c2cccc(S(=O)(=O)N3CCN(c4nccnc4-c4ccc(OC)cc4)CC3)c2)cc1,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2cccc(-c3nnn[nH]3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,21.0,IC50,nM,21.0,CNC(=O)c1nc(-c2cccc(-c3nnn[nH]3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,COc1ccc(-c2nccnc2N2CCN(S(=O)(=O)c3cccc(-c4cnc(N)nc4)c3)CC2)cc1,CHEMBL2150966,=,=,IC50,nM,10.0,IC50,nM,10.0,COc1ccc(-c2nccnc2N2CCN(S(=O)(=O)c3cccc(-c4cnc(N)nc4)c3)CC2)cc1,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CC(C)c1ccc(-c2nccnc2N2CCN(S(=O)(=O)c3cccc(-c4cnc(N)nc4)c3)CC2)cc1,CHEMBL2150966,=,=,IC50,nM,18.0,IC50,nM,18.0,CC(C)c1ccc(-c2nccnc2N2CCN(S(=O)(=O)c3cccc(-c4cnc(N)nc4)c3)CC2)cc1,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CC(C)c1ccc(-c2ncccc2N2CCN(S(=O)(=O)c3cccc(-c4cnc(N)nc4)c3)CC2)cc1,CHEMBL2150966,=,=,IC50,nM,18.0,IC50,nM,18.0,CC(C)c1ccc(-c2ncccc2N2CCN(S(=O)(=O)c3cccc(-c4cnc(N)nc4)c3)CC2)cc1,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2cccc(C(F)(F)F)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,777.0,IC50,nM,777.0,CNC(=O)c1nc(-c2cccc(C(F)(F)F)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2cccc(S(=O)(=O)Nc3ccccc3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,60.0,IC50,nM,60.0,CNC(=O)c1nc(-c2cccc(S(=O)(=O)Nc3ccccc3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccccc3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,39.0,IC50,nM,39.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccccc3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)NC)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,17.0,IC50,nM,17.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)NC)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(N)(=O)=O)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,26.0,IC50,nM,26.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(N)(=O)=O)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)NCC(F)(F)F)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,65.0,IC50,nM,65.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)NCC(F)(F)F)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(OC)c(S(=O)(=O)Nc3ccccc3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,507.0,IC50,nM,507.0,CNC(=O)c1nc(-c2ccc(OC)c(S(=O)(=O)Nc3ccccc3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(F)c(S(=O)(=O)Nc3ccccc3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,152.0,IC50,nM,152.0,CNC(=O)c1nc(-c2ccc(F)c(S(=O)(=O)Nc3ccccc3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2cnc(N)c(S(=O)(=O)Nc3ccccc3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,53.0,IC50,nM,53.0,CNC(=O)c1nc(-c2cnc(N)c(S(=O)(=O)Nc3ccccc3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2cccc(NS(=O)(=O)c3ccccc3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,167.0,IC50,nM,167.0,CNC(=O)c1nc(-c2cccc(NS(=O)(=O)c3ccccc3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2cccc(NS(=O)(=O)c3cccc(Cl)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,161.0,IC50,nM,161.0,CNC(=O)c1nc(-c2cccc(NS(=O)(=O)c3cccc(Cl)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(NS(=O)(=O)c3cccc(Cl)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,11.0,IC50,nM,11.0,CNC(=O)c1nc(-c2ccc(Cl)c(NS(=O)(=O)c3cccc(Cl)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(C)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,48.0,IC50,nM,48.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(C)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,43.0,IC50,nM,43.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(OC)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,31.0,IC50,nM,31.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(OC)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(C(F)(F)F)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,49.0,IC50,nM,49.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(C(F)(F)F)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(Cl)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,18.0,IC50,nM,18.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(Cl)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccccc3Cl)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,20.0,IC50,nM,20.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccccc3Cl)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(Cl)cc3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,26.0,IC50,nM,26.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(Cl)cc3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2cccc(S(=O)(=O)Nc3cccc(Cl)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,42.0,IC50,nM,42.0,CNC(=O)c1nc(-c2cccc(S(=O)(=O)Nc3cccc(Cl)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(F)cc3Cl)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,5.0,IC50,nM,5.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(F)cc3Cl)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3Cl)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,21.0,IC50,nM,21.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3Cl)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(Cl)cc3Cl)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,8.0,IC50,nM,8.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(Cl)cc3Cl)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(Cl)c3Cl)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,18.0,IC50,nM,18.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(Cl)c3Cl)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2cccc(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,102.0,IC50,nM,102.0,CNC(=O)c1nc(-c2cccc(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,18.0,IC50,nM,18.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3C)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,34.0,IC50,nM,34.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3C)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,Nc1cnc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cn1,CHEMBL2150966,=,=,IC50,nM,497.0,IC50,nM,497.0,Nc1cnc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cn1,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,Nc1ncc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cn1,CHEMBL2150966,=,=,IC50,nM,60.0,IC50,nM,60.0,Nc1ncc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cn1,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,COc1nc(N)ncc1-c1ccc(Cl)c(S(=O)(=O)Nc2cccc(F)c2F)c1,CHEMBL2150966,=,=,IC50,nM,20.0,IC50,nM,20.0,COc1nc(N)ncc1-c1ccc(Cl)c(S(=O)(=O)Nc2cccc(F)c2F)c1,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,Nc1ncc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)c(OCC(F)(F)F)n1,CHEMBL2150966,=,=,IC50,nM,6.0,IC50,nM,6.0,Nc1ncc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)c(OCC(F)(F)F)n1,2012
Inhibition of human PI3Kgamma expressed in sf9 cells assessed as amount of ATP consumed by luciferase-luciferin chemiluminescence assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL2150966,=,=,IC50,nM,42.0,IC50,nM,42.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,COc1ccc(-c2cccc(S(=O)(=O)N3CCN(c4nccnc4-c4ccc(OC)cc4)CC3)c2)cc1,CHEMBL2150966,=,=,IC50,nM,3608.0,IC50,nM,3608.0,COc1ccc(-c2cccc(S(=O)(=O)N3CCN(c4nccnc4-c4ccc(OC)cc4)CC3)c2)cc1,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2cccc(-c3nnn[nH]3)c2)cnc1N,CHEMBL2150966,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CNC(=O)c1nc(-c2cccc(-c3nnn[nH]3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,COc1ccc(-c2nccnc2N2CCN(S(=O)(=O)c3cccc(-c4cnc(N)nc4)c3)CC2)cc1,CHEMBL2150966,=,=,IC50,nM,264.0,IC50,nM,264.0,COc1ccc(-c2nccnc2N2CCN(S(=O)(=O)c3cccc(-c4cnc(N)nc4)c3)CC2)cc1,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CC(C)c1ccc(-c2nccnc2N2CCN(S(=O)(=O)c3cccc(-c4cnc(N)nc4)c3)CC2)cc1,CHEMBL2150966,=,=,IC50,nM,182.0,IC50,nM,182.0,CC(C)c1ccc(-c2nccnc2N2CCN(S(=O)(=O)c3cccc(-c4cnc(N)nc4)c3)CC2)cc1,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CC(C)c1ccc(-c2ncccc2N2CCN(S(=O)(=O)c3cccc(-c4cnc(N)nc4)c3)CC2)cc1,CHEMBL2150966,=,=,IC50,nM,213.0,IC50,nM,213.0,CC(C)c1ccc(-c2ncccc2N2CCN(S(=O)(=O)c3cccc(-c4cnc(N)nc4)c3)CC2)cc1,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2cccc(C(F)(F)F)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,5430.0,IC50,nM,5430.0,CNC(=O)c1nc(-c2cccc(C(F)(F)F)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2cccc(S(=O)(=O)Nc3ccccc3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,326.0,IC50,nM,326.0,CNC(=O)c1nc(-c2cccc(S(=O)(=O)Nc3ccccc3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccccc3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,69.0,IC50,nM,69.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccccc3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(C)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,572.0,IC50,nM,572.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(C)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,171.0,IC50,nM,171.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(OC)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,431.0,IC50,nM,431.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(OC)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(C(F)(F)F)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,552.0,IC50,nM,552.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(C(F)(F)F)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(Cl)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,184.0,IC50,nM,184.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(Cl)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccccc3Cl)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,507.0,IC50,nM,507.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccccc3Cl)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(Cl)cc3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,394.0,IC50,nM,394.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(Cl)cc3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2cccc(S(=O)(=O)Nc3cccc(Cl)c3)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,409.0,IC50,nM,409.0,CNC(=O)c1nc(-c2cccc(S(=O)(=O)Nc3cccc(Cl)c3)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(F)cc3Cl)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,528.0,IC50,nM,528.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(F)cc3Cl)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3Cl)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,1575.0,IC50,nM,1575.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3Cl)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(Cl)cc3Cl)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,464.0,IC50,nM,464.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(Cl)cc3Cl)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(Cl)c3Cl)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,587.0,IC50,nM,587.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(Cl)c3Cl)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2cccc(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,1877.0,IC50,nM,1877.0,CNC(=O)c1nc(-c2cccc(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,773.0,IC50,nM,773.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N,2012
Inhibition of human PI3Kgamma expressed in C5a-stimulated mouse RAW 264.7 cells assessed as inhibition of AKT phosphorylation by ELISA,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3C)c2)cnc1N,CHEMBL2150966,=,=,IC50,nM,805.0,IC50,nM,805.0,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3C)c2)cnc1N,2012
Inhibition of PI3Kgamma,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1,2012
Inhibition of PI3Kgamma,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1F,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1F,2012
Inhibition of PI3Kgamma,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(F)c1,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(F)c1,2012
Inhibition of PI3Kgamma,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)cc1,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)cc1,2012
Inhibition of PI3Kgamma,Cc1ccccc1NC(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1ccccc1NC(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,2012
Inhibition of PI3Kgamma,Cc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1,CHEMBL2150988,=,=,IC50,nM,7070.0,IC50,nM,7070.0,Cc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1,2012
Inhibition of PI3Kgamma,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(Cl)cc1,CHEMBL2150988,=,=,IC50,nM,5090.0,IC50,nM,5090.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(Cl)cc1,2012
Inhibition of PI3Kgamma,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Cl)c1,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Cl)c1,2012
Inhibition of PI3Kgamma,COc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1,2012
Inhibition of PI3Kgamma,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Br)c1,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Br)c1,2012
Inhibition of PI3Kgamma,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(F)c1,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(F)c1,2012
Inhibition of PI3Kgamma,Cc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F,CHEMBL2150988,=,=,IC50,nM,8010.0,IC50,nM,8010.0,Cc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F,2012
Inhibition of PI3Kgamma,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Cl)c1,CHEMBL2150988,=,=,IC50,nM,6710.0,IC50,nM,6710.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Cl)c1,2012
Inhibition of PI3Kgamma,COc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F,2012
Inhibition of PI3Kgamma,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Br)c1,CHEMBL2150988,=,=,IC50,nM,6610.0,IC50,nM,6610.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Br)c1,2012
Inhibition of PI3Kgamma,COC(=O)c1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COC(=O)c1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F,2012
Inhibition of PI3Kgamma,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c([N+](=O)[O-])c1,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c([N+](=O)[O-])c1,2012
Inhibition of PI3Kgamma,Cn1c(CC(=O)Nc2ccccc2)nc(N2CCOCC2)cc1=O,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(CC(=O)Nc2ccccc2)nc(N2CCOCC2)cc1=O,2012
Inhibition of PI3Kgamma,Cn1c(CC(=O)Nc2ccc(F)cc2)nc(N2CCOCC2)cc1=O,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(CC(=O)Nc2ccc(F)cc2)nc(N2CCOCC2)cc1=O,2012
Inhibition of PI3Kgamma,Cn1c(CC(=O)Nc2ccc(F)c(F)c2)nc(N2CCOCC2)cc1=O,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(CC(=O)Nc2ccc(F)c(F)c2)nc(N2CCOCC2)cc1=O,2012
Inhibition of PI3Kgamma,Cn1c(CC(=O)Nc2ccc(F)c(Br)c2)nc(N2CCOCC2)cc1=O,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(CC(=O)Nc2ccc(F)c(Br)c2)nc(N2CCOCC2)cc1=O,2012
Inhibition of PI3Kgamma,COc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)n2C)ccc1F,CHEMBL2150988,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)n2C)ccc1F,2012
Inhibition of PI3Kgamma,Cn1c(CC(=O)Nc2ccc(F)c(Cl)c2)nc(N2CCOCC2)cc1=O,CHEMBL2150988,=,=,IC50,nM,8280.0,IC50,nM,8280.0,Cn1c(CC(=O)Nc2ccc(F)c(Cl)c2)nc(N2CCOCC2)cc1=O,2012
Inhibition of PI3K p110gamma,O=c1cc(N2CCOCC2)nc(NCc2cccc3ccccc23)[nH]1,CHEMBL2157861,=,=,IC50,nM,18500.0,IC50,uM,18.5,O=c1cc(N2CCOCC2)nc(NCc2cccc3ccccc23)[nH]1,2012
Inhibition of PI3Kgamma using diC8-tagged PIP2 as substrate after 30 to 60 mins by TAMRA-based fluorescence polarization assay,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(Cl)c(S(=O)(=O)NC)c4)n3)ccn2)cc1,CHEMBL2157945,,,IC50,,,IC50,,,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(Cl)c(S(=O)(=O)NC)c4)n3)ccn2)cc1,2012
Inhibition of PI3Kgamma using diC8-tagged PIP2 as substrate after 30 to 60 mins by TAMRA-based fluorescence polarization assay,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(N)(=O)=O)c4)n3)ccn2)cc1,CHEMBL2157945,,,IC50,,,IC50,,,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(N)(=O)=O)c4)n3)ccn2)cc1,2012
Inhibition of PI3Kgamma using diC8-tagged PIP2 as substrate after 30 to 60 mins by TAMRA-based fluorescence polarization assay,CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1C,CHEMBL2157945,=,=,IC50,nM,93.0,IC50,uM,0.093,CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1C,2012
Inhibition of PI3Kgamma using diC8-tagged PIP2 as substrate after 30 to 60 mins by TAMRA-based fluorescence polarization assay,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccn2)cc1,CHEMBL2157945,=,=,IC50,nM,91.0,IC50,uM,0.091,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccn2)cc1,2012
Inhibition of PI3Kgamma using diC8-tagged PIP2 as substrate after 30 to 60 mins by TAMRA-based fluorescence polarization assay,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4cccc(S(=O)(=O)NC)c4)n3)ccn2)cc1,CHEMBL2157945,=,=,IC50,nM,82.0,IC50,uM,0.082,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4cccc(S(=O)(=O)NC)c4)n3)ccn2)cc1,2012
Inhibition of PI3Kgamma using diC8-tagged PIP2 as substrate after 30 to 60 mins by TAMRA-based fluorescence polarization assay,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(=O)(=O)N(C)C)c4)n3)ccn2)cc1,CHEMBL2157945,=,=,IC50,nM,72.0,IC50,uM,0.072,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(=O)(=O)N(C)C)c4)n3)ccn2)cc1,2012
Inhibition of PI3Kgamma using diC8-tagged PIP2 as substrate after 30 to 60 mins by TAMRA-based fluorescence polarization assay,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(=O)(=O)NC)c4)n3)ccn2)cc1,CHEMBL2157945,=,=,IC50,nM,63.0,IC50,uM,0.063,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(=O)(=O)NC)c4)n3)ccn2)cc1,2012
Inhibition of PI3Kgamma using diC8-tagged PIP2 as substrate after 30 to 60 mins by TAMRA-based fluorescence polarization assay,CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1Cl,CHEMBL2157945,=,=,IC50,nM,60.0,IC50,uM,0.06,CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1Cl,2012
Inhibition of PI3Kgamma using diC8-tagged PIP2 as substrate after 30 to 60 mins by TAMRA-based fluorescence polarization assay,CCN(CC)S(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)c1,CHEMBL2157945,=,=,IC50,nM,59.0,IC50,uM,0.059,CCN(CC)S(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)c1,2012
Inhibition of PI3Kgamma using diC8-tagged PIP2 as substrate after 30 to 60 mins by TAMRA-based fluorescence polarization assay,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(Cl)c(S(=O)(=O)N(C)C)c4)n3)ccn2)cc1,CHEMBL2157945,=,=,IC50,nM,54.0,IC50,uM,0.054,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(Cl)c(S(=O)(=O)N(C)C)c4)n3)ccn2)cc1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(Cc3ccc(S(C)(=O)=O)cc3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,7.0,Ki,nM,7.0,COc1ccc(Nc2ncc(Cc3ccc(S(C)(=O)=O)cc3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(Cc3ccccc3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,11.0,Ki,nM,11.0,COc1ccc(Nc2ncc(Cc3ccccc3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCS(=O)(=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,30.0,Ki,nM,30.0,COc1ccc(Nc2ncc(CN3CCS(=O)(=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCC(S(C)(=O)=O)C3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,5.0,Ki,nM,5.0,COc1ccc(Nc2ncc(CN3CCC(S(C)(=O)=O)C3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,46.0,Ki,nM,46.0,COc1ccc(Nc2ncc(CN3CCCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CC3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,8.0,Ki,nM,8.0,COc1ccc(Nc2ncc(CC3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCC(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,9.0,Ki,nM,9.0,COc1ccc(Nc2ncc(CN3CCC(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCN(S(=O)(=O)N(C)C)CC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,9.0,Ki,nM,9.0,COc1ccc(Nc2ncc(CN3CCN(S(=O)(=O)N(C)C)CC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,4.0,Ki,nM,4.0,COc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCN(C(=O)N(C)C)CC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,8.0,Ki,nM,8.0,COc1ccc(Nc2ncc(CN3CCN(C(=O)N(C)C)CC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COC(=O)N1CCN(Cc2cnc(Nc3ccc(OC)nc3)c(-c3nc(C)nc(N)n3)c2)CC1,CHEMBL2163268,=,=,Ki,nM,18.0,Ki,nM,18.0,COC(=O)N1CCN(Cc2cnc(Nc3ccc(OC)nc3)c(-c3nc(C)nc(N)n3)c2)CC1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCN(C)CC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,130.0,Ki,nM,130.0,COc1ccc(Nc2ncc(CN3CCN(C)CC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCNCC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,200.0,Ki,nM,200.0,COc1ccc(Nc2ncc(CN3CCNCC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CC[C@@H](CO)C3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,100.0,Ki,nM,100.0,COc1ccc(Nc2ncc(CN3CC[C@@H](CO)C3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCC(O)CC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,110.0,Ki,nM,110.0,COc1ccc(Nc2ncc(CN3CCC(O)CC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCOCC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,17.0,Ki,nM,17.0,COc1ccc(Nc2ncc(CN3CCOCC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCCCC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,80.0,Ki,nM,80.0,COc1ccc(Nc2ncc(CN3CCCCC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCCC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,210.0,Ki,nM,210.0,COc1ccc(Nc2ncc(CN3CCCC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CN3CCC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,140.0,Ki,nM,140.0,COc1ccc(Nc2ncc(CN3CCC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(-c3cnn(C)c3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,6.0,Ki,nM,6.0,COc1ccc(Nc2ncc(-c3cnn(C)c3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(-c3ccc(C)nc3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,8.0,Ki,nM,8.0,COc1ccc(Nc2ncc(-c3ccc(C)nc3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(N3CCN(C)CC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,21.0,Ki,nM,21.0,COc1ccc(Nc2ncc(N3CCN(C)CC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(C3=CCOCC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,2.0,Ki,nM,2.0,COc1ccc(Nc2ncc(C3=CCOCC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(N3CCOCC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,4.0,Ki,nM,4.0,COc1ccc(Nc2ncc(N3CCOCC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COCCNCc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc(N)n2)c1,CHEMBL2163268,=,=,Ki,nM,99.0,Ki,nM,99.0,COCCNCc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc(N)n2)c1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COCc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc(N)n2)c1,CHEMBL2163268,=,=,Ki,nM,9.0,Ki,nM,9.0,COCc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc(N)n2)c1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(CO)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,24.0,Ki,nM,24.0,COc1ccc(Nc2ncc(CO)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc(N)n2)c1,CHEMBL2163268,=,=,Ki,nM,9.0,Ki,nM,9.0,COc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc(N)n2)c1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(C)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,54.0,Ki,nM,54.0,COc1ccc(Nc2ncc(C)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(Br)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,22.0,Ki,nM,22.0,COc1ccc(Nc2ncc(Br)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncc(Cl)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,40.0,Ki,nM,40.0,COc1ccc(Nc2ncc(Cl)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2nccnc2-c2cc(N)nc(C)n2)cn1,CHEMBL2163268,=,=,Ki,nM,58.0,Ki,nM,58.0,COc1ccc(Nc2nccnc2-c2cc(N)nc(C)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2nccnc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,90.0,Ki,nM,90.0,COc1ccc(Nc2nccnc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncncc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,59.0,Ki,nM,59.0,COc1ccc(Nc2ncncc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2cccnc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,480.0,Ki,nM,480.0,COc1ccc(Nc2cccnc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2cnccc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,690.0,Ki,nM,690.0,COc1ccc(Nc2cnccc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ccccc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,380.0,Ki,nM,380.0,COc1ccc(Nc2ccccc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Cc1cc(-c2cccnc2Nc2cccc(O)c2)nc(N)n1,CHEMBL2163268,=,=,Ki,nM,2600.0,Ki,nM,2600.0,Cc1cc(-c2cccnc2Nc2cccc(O)c2)nc(N)n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(N(C)c2ncccc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,>,>,Ki,nM,10000.0,Ki,nM,10000.0,COc1ccc(N(C)c2ncccc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Cc1cc(-c2cccnc2Oc2cccc3[nH]ccc23)nc(N)n1,CHEMBL2163268,>,>,Ki,nM,10000.0,Ki,nM,10000.0,Cc1cc(-c2cccnc2Oc2cccc3[nH]ccc23)nc(N)n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Cc1nc(-c2cccnc2Nc2cccc3n[nH]cc23)c2c[nH]nc2n1,CHEMBL2163268,=,=,Ki,nM,450.0,Ki,nM,450.0,Cc1nc(-c2cccnc2Nc2cccc3n[nH]cc23)c2c[nH]nc2n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncccc2-c2ncnc3nc[nH]c23)cn1,CHEMBL2163268,=,=,Ki,nM,1100.0,Ki,nM,1100.0,COc1ccc(Nc2ncccc2-c2ncnc3nc[nH]c23)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,c1cnc(Nc2cccc3n[nH]cc23)c(-c2ncnc3nc[nH]c23)c1,CHEMBL2163268,=,=,Ki,nM,750.0,Ki,nM,750.0,c1cnc(Nc2cccc3n[nH]cc23)c(-c2ncnc3nc[nH]c23)c1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncccc2-c2nc(C)nc3nc[nH]c23)cn1,CHEMBL2163268,=,=,Ki,nM,12.0,Ki,nM,12.0,COc1ccc(Nc2ncccc2-c2nc(C)nc3nc[nH]c23)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Cc1nc(-c2cccnc2Nc2cccc3[nH]ccc23)c2[nH]cnc2n1,CHEMBL2163268,=,=,Ki,nM,23.0,Ki,nM,23.0,Cc1nc(-c2cccnc2Nc2cccc3[nH]ccc23)c2[nH]cnc2n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Cc1nc(-c2cccnc2Nc2cccc3n[nH]cc23)c2[nH]cnc2n1,CHEMBL2163268,=,=,Ki,nM,12.0,Ki,nM,12.0,Cc1nc(-c2cccnc2Nc2cccc3n[nH]cc23)c2[nH]cnc2n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Nc1cc(-c2cccnc2Nc2cccc3[nH]ncc23)nc(C(F)(F)F)n1,CHEMBL2163268,=,=,Ki,nM,3600.0,Ki,nM,3600.0,Nc1cc(-c2cccnc2Nc2cccc3[nH]ncc23)nc(C(F)(F)F)n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Cc1nc(N)c(F)c(-c2cccnc2Nc2cccc3[nH]ncc23)n1,CHEMBL2163268,=,=,Ki,nM,330.0,Ki,nM,330.0,Cc1nc(N)c(F)c(-c2cccnc2Nc2cccc3[nH]ncc23)n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Cc1nc(N)cc(-c2cccnc2Nc2cccc3[nH]ncc23)n1,CHEMBL2163268,=,=,Ki,nM,91.0,Ki,nM,91.0,Cc1nc(N)cc(-c2cccnc2Nc2cccc3[nH]ncc23)n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Cc1nc(N)cc(-c2cccnc2Nc2cccc(O)c2)n1,CHEMBL2163268,=,=,Ki,nM,51.0,Ki,nM,51.0,Cc1nc(N)cc(-c2cccnc2Nc2cccc(O)c2)n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,COc1ccc(Nc2ncccc2-c2nc(C)nc(N)n2)cn1,CHEMBL2163268,=,=,Ki,nM,29.0,Ki,nM,29.0,COc1ccc(Nc2ncccc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Cc1nc(N)nc(-c2cccnc2Nc2cccc3[nH]ccc23)n1,CHEMBL2163268,=,=,Ki,nM,45.0,Ki,nM,45.0,Cc1nc(N)nc(-c2cccnc2Nc2cccc3[nH]ccc23)n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Cc1nc(N)nc(-c2cccnc2Nc2cccc3[nH]ncc23)n1,CHEMBL2163268,=,=,Ki,nM,88.0,Ki,nM,88.0,Cc1nc(N)nc(-c2cccnc2Nc2cccc3[nH]ncc23)n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Cc1nc(N)nc(-c2cccnc2Nc2cccc(O)c2)n1,CHEMBL2163268,=,=,Ki,nM,12.0,Ki,nM,12.0,Cc1nc(N)nc(-c2cccnc2Nc2cccc(O)c2)n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Cc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1,CHEMBL2163268,=,=,Ki,nM,4.0,Ki,nM,4.0,Cc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,Cc1nc(NCC#N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1,CHEMBL2163268,=,=,Ki,nM,69.0,Ki,nM,69.0,Cc1nc(NCC#N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1,2012
Inhibition of human N-terminal poly-His tagged-PI3Kgamma expressed in Sf9 baculovirus system co-expressing p85alpha after 20 mins by AlphaScreen assay,N#CCNc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1,CHEMBL2163268,=,=,Ki,nM,120.0,Ki,nM,120.0,N#CCNc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1,2012
"Inhibition of human recombinant His6-tagged PI3K p110bgamma expressed in baculovirus infected cells using DiC8-PI(4,5)P2 as substrate after 20 mins by AlphaScreen assay",C[C@H]1CN(c2cc(N(CCO)Cc3cccc4ccccc34)[nH]c(=O)n2)CCO1,CHEMBL2163325,=,=,IC50,nM,97400.0,IC50,uM,97.4,C[C@H]1CN(c2cc(N(CCO)Cc3cccc4ccccc34)[nH]c(=O)n2)CCO1,2012
Inhibition of PI3Kgamma,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL2169756,<,<,IC50,nM,10.0,IC50,nM,10.0,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2012
Inhibition of PI3Kgamma by ATP bioluminescence assay,Cc1nc2ccccc2c(N2CC(C)(C)c3ccc(N4CCOCC4)cc32)c1C,CHEMBL2169853,=,=,IC50,nM,18000.0,IC50,uM,18.0,Cc1nc2ccccc2c(N2CC(C)(C)c3ccc(N4CCOCC4)cc32)c1C,2012
Inhibition of PI3Kgamma by ATP bioluminescence assay,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC(C)(C)c2ncc(N3CCOCC3)cc21,CHEMBL2169853,=,=,Ki,nM,92.0,Ki,nM,92.0,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC(C)(C)c2ncc(N3CCOCC3)cc21,2012
Inhibition of PI3Kgamma by ATP bioluminescence assay,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC(C)(C)c2ccc(-c3ccnc(N)n3)cc21,CHEMBL2169853,=,=,Ki,nM,90.0,Ki,nM,90.0,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC(C)(C)c2ccc(-c3ccnc(N)n3)cc21,2012
Inhibition of PI3Kgamma by ATP bioluminescence assay,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC2(CS(=O)(=O)C2)c2ccc(N3CCOCC3)cc21,CHEMBL2169853,=,=,Ki,nM,7340.0,Ki,nM,7340.0,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC2(CS(=O)(=O)C2)c2ccc(N3CCOCC3)cc21,2012
Inhibition of PI3Kgamma by ATP bioluminescence assay,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC2(CCOCC2)c2ncc(N3CCOCC3)cc21,CHEMBL2169853,=,=,Ki,nM,509.0,Ki,nM,509.0,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC2(CCOCC2)c2ncc(N3CCOCC3)cc21,2012
Inhibition of PI3Kgamma by ATP bioluminescence assay,Cc1cc(-c2ccc3c(c2)N(c2c(C)c(-c4ccccn4)nc4cc(F)ccc24)CC3(C)C)nc(N)n1,CHEMBL2169853,=,=,Ki,nM,364.0,Ki,nM,364.0,Cc1cc(-c2ccc3c(c2)N(c2c(C)c(-c4ccccn4)nc4cc(F)ccc24)CC3(C)C)nc(N)n1,2012
Inhibition of PI3Kgamma by ATP bioluminescence assay,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC(C)(C)c2ncc(-c3ccnc(N)n3)cc21,CHEMBL2169853,=,=,Ki,nM,28.0,Ki,nM,28.0,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC(C)(C)c2ncc(-c3ccnc(N)n3)cc21,2012
Inhibition of PI3Kgamma by ATP bioluminescence assay,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC(C)(C)c2ccc(N3CCOCC3)cc21,CHEMBL2169853,=,=,IC50,nM,2010.0,IC50,nM,2010.0,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC(C)(C)c2ccc(N3CCOCC3)cc21,2012
Inhibition of PI3Kgamma by ATP bioluminescence assay,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC(CO)(CO)c2ccc(N3CCOCC3)cc21,CHEMBL2169853,=,=,Ki,nM,16000.0,Ki,nM,16000.0,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC(CO)(CO)c2ccc(N3CCOCC3)cc21,2012
Inhibition of PI3Kgamma by ATP bioluminescence assay,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC(C)(C)c2ccc(-c3ccncc3)cc21,CHEMBL2169853,=,=,IC50,nM,1400.0,IC50,nM,1400.0,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC(C)(C)c2ccc(-c3ccncc3)cc21,2012
Inhibition of PI3Kgamma assessed as inhibition of PIP3 production for 30 mins by fluorescence polarization assay,CN(C)c1nc2ccccc2n1-c1nc(N2CCOCC2)c2nc(CN3CCC(C(C)(C)O)CC3)n(C)c2n1,CHEMBL2169748,=,=,IC50,nM,540.0,IC50,nM,540.0,CN(C)c1nc2ccccc2n1-c1nc(N2CCOCC2)c2nc(CN3CCC(C(C)(C)O)CC3)n(C)c2n1,2012
Inhibition of PI3Kgamma assessed as inhibition of PIP3 production for 30 mins by fluorescence polarization assay,CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2nc(CN3CCC(C(C)(C)O)CC3)n(C)c2n1,CHEMBL2169748,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2nc(CN3CCC(C(C)(C)O)CC3)n(C)c2n1,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ncc(Nc2ncc(C(C)(C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F,CHEMBL2169865,=,=,Ki,nM,9.0,Ki,nM,9.0,COc1ncc(Nc2ncc(C(C)(C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ncc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cc1F,CHEMBL2169865,=,=,Ki,nM,9.0,Ki,nM,9.0,COc1ncc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cc1F,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cc1F,CHEMBL2169865,=,=,Ki,nM,8.0,Ki,nM,8.0,COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cc1F,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ncc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)C[C@H]3C)cc2-c2nc(C)nc(N)n2)cc1F,CHEMBL2169865,=,=,Ki,nM,12.0,Ki,nM,12.0,COc1ncc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)C[C@H]3C)cc2-c2nc(C)nc(N)n2)cc1F,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)C[C@H]3C)cc2-c2nc(C)nc(N)n2)cc1F,CHEMBL2169865,=,=,Ki,nM,12.0,Ki,nM,12.0,COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)C[C@H]3C)cc2-c2nc(C)nc(N)n2)cc1F,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ncc(Nc2ncc([C@H](N3CCN(S(C)(=O)=O)CC3)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cc1F,CHEMBL2169865,=,=,Ki,nM,34.0,Ki,nM,34.0,COc1ncc(Nc2ncc([C@H](N3CCN(S(C)(=O)=O)CC3)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cc1F,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ncc(Nc2ncc([C@@H](N3CCN(S(C)(=O)=O)CC3)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cc1F,CHEMBL2169865,=,=,Ki,nM,20.0,Ki,nM,20.0,COc1ncc(Nc2ncc([C@@H](N3CCN(S(C)(=O)=O)CC3)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cc1F,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cc1F,CHEMBL2169865,=,=,Ki,nM,9.0,Ki,nM,9.0,COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cc1F,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)C[C@H]3C)cc2-c2nc(C)nc(N)n2)cc1F,CHEMBL2169865,=,=,Ki,nM,9.0,Ki,nM,9.0,COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)C[C@H]3C)cc2-c2nc(C)nc(N)n2)cc1F,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F,CHEMBL2169865,=,=,Ki,nM,1.0,Ki,nM,1.0,COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ncc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F,CHEMBL2169865,=,=,Ki,nM,7.0,Ki,nM,7.0,COc1ncc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1cncc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)c1,CHEMBL2169865,=,=,Ki,nM,7.0,Ki,nM,7.0,COc1cncc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)c1,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2cncc(F)c2)n1,CHEMBL2169865,=,=,Ki,nM,24.0,Ki,nM,24.0,Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2cncc(F)c2)n1,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F,CHEMBL2169865,=,=,Ki,nM,21.0,Ki,nM,21.0,COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2169865,=,=,Ki,nM,16.0,Ki,nM,16.0,COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc(C(F)(F)F)nc2)n1,CHEMBL2169865,=,=,Ki,nM,136.0,Ki,nM,136.0,Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc(C(F)(F)F)nc2)n1,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,Cc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2169865,=,=,Ki,nM,31.0,Ki,nM,31.0,Cc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc(Cl)nc2)n1,CHEMBL2169865,=,=,Ki,nM,21.0,Ki,nM,21.0,Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc(Cl)nc2)n1,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc(=O)[nH]c2)n1,CHEMBL2169865,=,=,Ki,nM,2350.0,Ki,nM,2350.0,Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc(=O)[nH]c2)n1,2012
Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using ATP as substrate after 20 mins by spectrophotometric analysis,COc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,CHEMBL2169865,=,=,Ki,nM,8.0,Ki,nM,8.0,COc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1,2012
Inhibition of PI3Kgamma at 1 uM,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4)n2)CCN(c2ncccn2)C3)cc1,CHEMBL2176927,=,=,Inhibition,%,50.0,INH,%,50.0,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4)n2)CCN(c2ncccn2)C3)cc1,2012
"Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using Phosphatidylinositol-4,5-bisphosphate as substrate after 20 mins by AlphaScreen assay",COCCOc1cnc(Nc2cnc(Cl)c(NS(C)(=O)=O)c2)c(-c2nc(C)nc(N)n2)c1,CHEMBL2203208,=,=,Ki,nM,14.0,Ki,nM,14.0,COCCOc1cnc(Nc2cnc(Cl)c(NS(C)(=O)=O)c2)c(-c2nc(C)nc(N)n2)c1,2012
"Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using Phosphatidylinositol-4,5-bisphosphate as substrate after 20 mins by AlphaScreen assay",COc1cnc(Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)c(-c2nc(C)nc(N)n2)c1,CHEMBL2203208,=,=,Ki,nM,2.2,Ki,nM,2.2,COc1cnc(Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)c(-c2nc(C)nc(N)n2)c1,2012
"Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using Phosphatidylinositol-4,5-bisphosphate as substrate after 20 mins by AlphaScreen assay",Cc1nc(N)nc(-c2cc(Cl)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1,CHEMBL2203208,=,=,Ki,nM,1.0,Ki,nM,1.0,Cc1nc(N)nc(-c2cc(Cl)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1,2012
"Inhibition of human N-terminal polyHis-tagged PI3K p110gamma expressed in baculovirus infected Hi5 cells using Phosphatidylinositol-4,5-bisphosphate as substrate after 20 mins by AlphaScreen assay",Cc1nc(N)nc(-c2cccnc2Nc2cnc(Cl)c(NS(C)(=O)=O)c2)n1,CHEMBL2203208,=,=,Ki,nM,2.4,Ki,nM,2.4,Cc1nc(N)nc(-c2cccnc2Nc2cnc(Cl)c(NS(C)(=O)=O)c2)n1,2012
Inhibition of PIK3CG assessed as residual activity at 10 uM relative to control,O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1,CHEMBL2203081,=,=,Activity,%,100.0,Activity,%,100.0,O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1,2012
Inhibition of PI3Kgamma by HTRF assay in presence of ATP,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL2203170,=,=,IC50,nM,26.0,IC50,uM,0.026,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2012
Inhibition of PI3Kgamma by HTRF assay in presence of ATP,Nc1ccc(-c2cccc3c(=O)nc(N4CCOCC4)oc23)c(F)c1,CHEMBL2203170,=,=,IC50,nM,17780.0,IC50,uM,17.78,Nc1ccc(-c2cccc3c(=O)nc(N4CCOCC4)oc23)c(F)c1,2012
Inhibition of PI3Kgamma by HTRF assay in presence of ATP,Nc1ccc(-c2cccc3c(=O)nc(N4CCOCC4)oc23)cc1,CHEMBL2203170,=,=,IC50,nM,20500.0,IC50,uM,20.5,Nc1ccc(-c2cccc3c(=O)nc(N4CCOCC4)oc23)cc1,2012
Inhibition of PI3Kgamma by HTRF assay in presence of ATP,Cc1c(OCc2cccnc2)ccc2c(=O)nc(N3CCOCC3)oc12,CHEMBL2203170,=,=,IC50,nM,720.0,IC50,uM,0.72,Cc1c(OCc2cccnc2)ccc2c(=O)nc(N3CCOCC3)oc12,2012
Inhibition of PI3Kgamma by HTRF assay in presence of ATP,Cc1c(OCCN2CCN(C)CC2)ccc2c(=O)nc(N3CCOCC3)oc12,CHEMBL2203170,>=,>=,IC50,nM,100000.0,IC50,uM,100.0,Cc1c(OCCN2CCN(C)CC2)ccc2c(=O)nc(N3CCOCC3)oc12,2012
Inhibition of PI3Kgamma by HTRF assay in presence of ATP,O=c1nc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL2203170,=,=,IC50,nM,1500.0,IC50,uM,1.5,O=c1nc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2012
Inhibition of PI3Kgamma by kinobeads assay,CCN(CC)S(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,CHEMBL2203257,=,=,IC50,nM,7.943,pIC50,,8.1,CCN(CC)S(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,2012
Inhibition of PI3Kgamma by kinobeads assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,CHEMBL2203257,=,=,IC50,nM,12.59,pIC50,,7.9,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,2012
Inhibition of PI3Kgamma by kinobeads assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2cc(F)n3nc(N)nc3c2)c1,CHEMBL2203257,=,=,IC50,nM,15.85,pIC50,,7.8,CC(C)(C)NS(=O)(=O)c1cncc(-c2cc(F)n3nc(N)nc3c2)c1,2012
Inhibition of PI3Kgamma by kinobeads assay,CC(C)(NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1)C(F)(F)F,CHEMBL2203257,=,=,IC50,nM,19.95,pIC50,,7.7,CC(C)(NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1)C(F)(F)F,2012
Inhibition of PI3Kgamma by kinobeads assay,Nc1nc2cc(-c3cncc(S(=O)(=O)NCC(F)(F)F)c3)ccn2n1,CHEMBL2203257,=,=,IC50,nM,19.95,pIC50,,7.7,Nc1nc2cc(-c3cncc(S(=O)(=O)NCC(F)(F)F)c3)ccn2n1,2012
Inhibition of PI3Kgamma by kinobeads assay,Nc1nc2cc(-c3cncc(S(N)(=O)=O)c3)ccn2n1,CHEMBL2203257,=,=,IC50,nM,19.95,pIC50,,7.7,Nc1nc2cc(-c3cncc(S(N)(=O)=O)c3)ccn2n1,2012
Inhibition of PIK3Cg,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,CHEMBL2203257,=,=,IC50,nM,24.55,pIC50,,7.61,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,2012
Inhibition of PI3Kgamma by kinobeads assay,CC(C)(C)NS(=O)(=O)c1cncc(-c2cc(F)c3nc(N)nn3c2)c1,CHEMBL2203257,=,=,IC50,nM,25.12,pIC50,,7.6,CC(C)(C)NS(=O)(=O)c1cncc(-c2cc(F)c3nc(N)nn3c2)c1,2012
Inhibition of PI3Kgamma by kinobeads assay,CC1(C)CCN1S(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,CHEMBL2203257,=,=,IC50,nM,25.12,pIC50,,7.6,CC1(C)CCN1S(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,2012
Inhibition of PI3Kgamma by kinobeads assay,CC(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,CHEMBL2203257,=,=,IC50,nM,25.12,pIC50,,7.6,CC(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,2012
Inhibition of PI3Kgamma by kinobeads assay,CNS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,CHEMBL2203257,=,=,IC50,nM,25.12,pIC50,,7.6,CNS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,2012
Inhibition of PI3Kgamma by kinobeads assay,CCCNS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,CHEMBL2203257,=,=,IC50,nM,31.62,pIC50,,7.5,CCCNS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,2012
Inhibition of PI3Kgamma by kinobeads assay,Nc1nc2cc(-c3cncc(S(=O)(=O)Nc4ccccc4)c3)ccn2n1,CHEMBL2203257,=,=,IC50,nM,39.81,pIC50,,7.4,Nc1nc2cc(-c3cncc(S(=O)(=O)Nc4ccccc4)c3)ccn2n1,2012
Inhibition of PI3Kgamma by kinobeads assay,CS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,CHEMBL2203257,=,=,IC50,nM,79.43,pIC50,,7.1,CS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,2012
Inhibition of PI3Kgamma by kinobeads assay,Nc1nc2cc(-c3cncc(S(=O)(=O)NCc4ccccc4)c3)ccn2n1,CHEMBL2203257,=,=,IC50,nM,100.0,pIC50,,7.0,Nc1nc2cc(-c3cncc(S(=O)(=O)NCc4ccccc4)c3)ccn2n1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(C(C)(C)C)o2)s1,CHEMBL2203244,=,=,IC50,nM,3.0,IC50,nM,3.0,CC(=O)Nc1nc(C)c(-c2cnc(C(C)(C)C)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(C(C)(C)O)o2)s1,CHEMBL2203244,=,=,IC50,nM,25.0,IC50,nM,25.0,CC(=O)Nc1nc(C)c(-c2cnc(C(C)(C)O)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(CO)o2)s1,CHEMBL2203244,=,=,IC50,nM,161.0,IC50,nM,161.0,CC(=O)Nc1nc(C)c(-c2cnc(CO)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(CC(F)(F)F)o2)s1,CHEMBL2203244,=,=,IC50,nM,10.0,IC50,nM,10.0,CC(=O)Nc1nc(C)c(-c2cnc(CC(F)(F)F)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(C)o2)s1,CHEMBL2203244,=,=,IC50,nM,181.0,IC50,nM,181.0,CC(=O)Nc1nc(C)c(-c2cnc(C)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(-c3cccnc3)o2)s1,CHEMBL2203244,=,=,IC50,nM,3.0,IC50,nM,3.0,CC(=O)Nc1nc(C)c(-c2cnc(-c3cccnc3)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(Sc3cccnc3)o2)s1,CHEMBL2203244,=,=,IC50,nM,16.0,IC50,nM,16.0,CC(=O)Nc1nc(C)c(-c2cnc(Sc3cccnc3)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(Oc3cccnc3)o2)s1,CHEMBL2203244,=,=,IC50,nM,117.0,IC50,nM,117.0,CC(=O)Nc1nc(C)c(-c2cnc(Oc3cccnc3)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(Cc3cccnc3)o2)s1,CHEMBL2203244,=,=,IC50,nM,95.0,IC50,nM,95.0,CC(=O)Nc1nc(C)c(-c2cnc(Cc3cccnc3)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(Nc3cccnc3)o2)s1,CHEMBL2203244,=,=,IC50,nM,12.0,IC50,nM,12.0,CC(=O)Nc1nc(C)c(-c2cnc(Nc3cccnc3)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(Nc3ccc(Cl)nc3)o2)s1,CHEMBL2203244,=,=,IC50,nM,24.0,IC50,nM,24.0,CC(=O)Nc1nc(C)c(-c2cnc(Nc3ccc(Cl)nc3)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(Nc3ccc(Cl)cc3)o2)s1,CHEMBL2203244,=,=,IC50,nM,346.0,IC50,nM,346.0,CC(=O)Nc1nc(C)c(-c2cnc(Nc3ccc(Cl)cc3)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(Cc3cccc(C(=O)O)c3)o2)s1,CHEMBL2203244,=,=,IC50,nM,223.0,IC50,nM,223.0,CC(=O)Nc1nc(C)c(-c2cnc(Cc3cccc(C(=O)O)c3)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(Nc3cccc(C(=O)O)c3)o2)s1,CHEMBL2203244,=,=,IC50,nM,12.0,IC50,nM,12.0,CC(=O)Nc1nc(C)c(-c2cnc(Nc3cccc(C(=O)O)c3)o2)s1,2012
Inhibition of PI3Kgamma,CC(=O)Nc1nc(C)c(-c2csc(Nc3cccc(C(=O)O)c3)n2)s1,CHEMBL2203244,=,=,IC50,nM,5.0,IC50,nM,5.0,CC(=O)Nc1nc(C)c(-c2csc(Nc3cccc(C(=O)O)c3)n2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(S(C)(=O)=O)o2)s1,CHEMBL2203244,=,=,IC50,nM,12.0,IC50,nM,12.0,CC(=O)Nc1nc(C)c(-c2cnc(S(C)(=O)=O)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CSc1ncc(-c2sc(NC(C)=O)nc2C)o1,CHEMBL2203244,=,=,IC50,nM,22.0,IC50,nM,22.0,CSc1ncc(-c2sc(NC(C)=O)nc2C)o1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,COc1ncc(-c2sc(NC(C)=O)nc2C)o1,CHEMBL2203244,=,=,IC50,nM,250.0,IC50,nM,250.0,COc1ncc(-c2sc(NC(C)=O)nc2C)o1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(N3CCCC(O)C3)o2)s1,CHEMBL2203244,=,=,IC50,nM,14.0,IC50,nM,14.0,CC(=O)Nc1nc(C)c(-c2cnc(N3CCCC(O)C3)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(N3CCOCC3)o2)s1,CHEMBL2203244,=,=,IC50,nM,24.0,IC50,nM,24.0,CC(=O)Nc1nc(C)c(-c2cnc(N3CCOCC3)o2)s1,2012
Inhibition of human PI3Kgamma using phosphatidylinositol as substrate and [33gammaP]ATP after 2 hrs by scintillation counting,CC(=O)Nc1nc(C)c(-c2cnc(N(C)C)o2)s1,CHEMBL2203244,=,=,IC50,nM,46.0,IC50,nM,46.0,CC(=O)Nc1nc(C)c(-c2cnc(N(C)C)o2)s1,2012
Inhibition of PI3Kgamma at 1 uM,CC(c1oc2ccccc2c(=O)c1-c1cccc(F)c1)n1cnc2c(N)ncnc21,CHEMBL2216751,<,<,Inhibition,%,25.0,INH,%,25.0,CC(c1oc2ccccc2c(=O)c1-c1cccc(F)c1)n1cnc2c(N)ncnc21,2012
Inhibition of PI3Kgamma-mediated Akt phosphorylation in T cells by flow cytometry,Cc1nc(C(=O)Nc2cc(-c3ccnc4[nH]ccc34)cc3[nH]ncc23)cs1,CHEMBL2216751,>=,<=,IC50,nM,1000.0,pIC50,,6.0,Cc1nc(C(=O)Nc2cc(-c3ccnc4[nH]ccc34)cc3[nH]ncc23)cs1,2012
Inhibition of PI3Kgamma-mediated Akt phosphorylation in T cells by flow cytometry,CN1CCOC(C(=O)Nc2cc(-c3cccc4[nH]ccc34)cc3[nH]ncc23)C1,CHEMBL2216751,>=,<=,IC50,nM,1000.0,pIC50,,6.0,CN1CCOC(C(=O)Nc2cc(-c3cccc4[nH]ccc34)cc3[nH]ncc23)C1,2012
Inhibition of PI3Kgamma-mediated Akt phosphorylation in T cells by flow cytometry,O=C(Nc1cc(-c2cnc3[nH]ncc3c2)cc2[nH]ncc12)c1cccc(CN2CCS(=O)(=O)CC2)n1,CHEMBL2216751,>=,<=,IC50,nM,10000.0,pIC50,,5.0,O=C(Nc1cc(-c2cnc3[nH]ncc3c2)cc2[nH]ncc12)c1cccc(CN2CCS(=O)(=O)CC2)n1,2012
Inhibition of PI3Kgamma in presence of 10 uM ATP,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL2216751,=,=,IC50,nM,150.0,IC50,uM,0.15,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2012
Inhibition of PI3Kgamma in presence of 10 uM ATP,COc1ccc2c(c1OC)N=C(NC(=O)c1cccnc1)N1CCN=C21,CHEMBL2216751,=,=,IC50,nM,18.0,IC50,uM,0.018,COc1ccc2c(c1OC)N=C(NC(=O)c1cccnc1)N1CCN=C21,2012
Inhibition of PI3Kgamma in presence of 10 uM ATP,COc1ccccc1-n1c(CSc2ncnc3[nH]cnc23)nc2cccc(Cl)c2c1=O,CHEMBL2216751,=,=,IC50,nM,17000.0,IC50,uM,17.0,COc1ccccc1-n1c(CSc2ncnc3[nH]cnc23)nc2cccc(Cl)c2c1=O,2012
Inhibition of PI3Kgamma in presence of 10 uM ATP,Cc1ccccc1-n1c(Cn2cnc3c(N)ncnc32)nc2cccc(C)c2c1=O,CHEMBL2216751,=,=,IC50,nM,61000.0,IC50,uM,61.0,Cc1ccccc1-n1c(Cn2cnc3c(N)ncnc32)nc2cccc(C)c2c1=O,2012
Inhibition of PI3Kgamma using phosphatidylinositol as substrate by gamma33P[ATP] incorporation assay,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL2216751,=,=,IC50,nM,6600.0,IC50,uM,6.6,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2012
Inhibition of PI3Kgamma,O=C1NC(=O)/C(=C\c2ccc3c(c2)OC(F)(F)O3)S1,CHEMBL2216751,=,=,IC50,nM,250.0,IC50,uM,0.25,O=C1NC(=O)/C(=C\c2ccc3c(c2)OC(F)(F)O3)S1,2012
Inhibition of PI3Kgamma,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,CHEMBL2216751,=,=,IC50,nM,5.0,IC50,uM,0.005,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,2012
Inhibition of PI3Kgamma (unknown origin) using [33gammaP]ATP and phosphotidylinositol as substrate by scintillation proximity assay,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL3044666,=,=,IC50,nM,7260.0,IC50,uM,7.26,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2013
Inhibition of PI3Kgamma (unknown origin) using [33gammaP]ATP and phosphotidylinositol as substrate by scintillation proximity assay,Cc1ccc(C(=O)N/N=C/c2cc(Br)cc(Br)c2O)c(O)c1,CHEMBL3044666,=,=,IC50,nM,7120.0,IC50,uM,7.12,Cc1ccc(C(=O)N/N=C/c2cc(Br)cc(Br)c2O)c(O)c1,2013
Inhibition of PI3Kgamma (unknown origin) using [33gammaP]ATP and phosphotidylinositol as substrate by scintillation proximity assay,Cc1ccc(C(=O)N/N=C/c2cc(Cl)cc(Cl)c2O)c(O)c1,CHEMBL3044666,=,=,IC50,nM,4810.0,IC50,uM,4.81,Cc1ccc(C(=O)N/N=C/c2cc(Cl)cc(Cl)c2O)c(O)c1,2013
Inhibition of PI3Kgamma (unknown origin) using [33gammaP]ATP and phosphotidylinositol as substrate by scintillation proximity assay,Cc1ccc(C(=O)N/N=C/c2cc(Br)ccc2O)c(O)c1,CHEMBL3044666,=,=,IC50,nM,2600.0,IC50,uM,2.6,Cc1ccc(C(=O)N/N=C/c2cc(Br)ccc2O)c(O)c1,2013
Inhibition of PI3Kgamma (unknown origin) using [33gammaP]ATP and phosphotidylinositol as substrate by scintillation proximity assay,Cc1ccc(C(=O)N/N=C/c2cc(Cl)ccc2O)c(O)c1,CHEMBL3044666,=,=,IC50,nM,3690.0,IC50,uM,3.69,Cc1ccc(C(=O)N/N=C/c2cc(Cl)ccc2O)c(O)c1,2013
Inhibition of PI3Kgamma (unknown origin) using [33gammaP]ATP and phosphotidylinositol as substrate by scintillation proximity assay,Cc1ccc(C(=O)N/N=C/c2ccccc2O)c(O)c1,CHEMBL3044666,=,=,IC50,nM,2170.0,IC50,uM,2.17,Cc1ccc(C(=O)N/N=C/c2ccccc2O)c(O)c1,2013
Binding affinity to human PI3Kgamma after 1 hr by MALDI TOF/TOF mass spectrometry,CC(C)=CC(=O)CCC(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL2311296,,,Activity,,,Activity,,,CC(C)=CC(=O)CCC(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2013
Inhibition of PI3Kgamma (unknown origin) by HTRF assay,CC(C)=CC(=O)CCC(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL2311296,=,=,IC50,nM,240.3,IC50(app),nM,240.3,CC(C)=CC(=O)CCC(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2013
Binding affinity to PI3Kgamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccc(N4CCOCC4)cc3)csc12,CHEMBL2321770,,,Activity,,,Activity,,,O=c1cc(N2CCOCC2)oc2c(-c3ccc(N4CCOCC4)cc3)csc12,2013
Binding affinity to PI3Kgamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(N3CCCCC3)csc12,CHEMBL2321770,,,Activity,,,Activity,,,O=c1cc(N2CCOCC2)oc2c(N3CCCCC3)csc12,2013
Ratio of LY294002 IC50 to compound IC50 for PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)csc12,CHEMBL2321770,=,=,Ratio IC50,,1.1,Ratio IC50,,1.1,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL2321770,=,=,IC50,nM,89.0,IC50,nM,89.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2013
Inhibition of PI3K p110gamma (unknown origin),CN1CCN(c2ncc(-c3csc4c(=O)cc(N5CCOCC5)oc34)cn2)CC1,CHEMBL2321770,=,=,IC50,nM,1080.0,IC50,nM,1080.0,CN1CCN(c2ncc(-c3csc4c(=O)cc(N5CCOCC5)oc34)cn2)CC1,2013
Inhibition of PI3K p110gamma (unknown origin),COC(=O)c1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,CHEMBL2321770,=,=,IC50,nM,547.0,IC50,nM,547.0,COC(=O)c1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,2013
Inhibition of PI3K p110gamma (unknown origin),CCOC(=O)c1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,CHEMBL2321770,=,=,IC50,nM,1170.0,IC50,nM,1170.0,CCOC(=O)c1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,2013
Inhibition of PI3K p110gamma (unknown origin),S=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL2321770,=,=,IC50,nM,3945.0,IC50,nM,3945.0,S=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL2321770,=,=,IC50,nM,1775.0,IC50,nM,1775.0,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2013
Inhibition of PI3K p110gamma (unknown origin),CNc1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,CHEMBL2321770,=,=,IC50,nM,410.0,IC50,nM,410.0,CNc1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,2013
Inhibition of PI3K p110gamma (unknown origin),CC(=O)Nc1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,CHEMBL2321770,=,=,IC50,nM,441.0,IC50,nM,441.0,CC(=O)Nc1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,2013
Inhibition of PI3K p110gamma (unknown origin),COc1ccc(C#Cc2csc3c(=O)cc(N4CCOCC4)oc23)cc1,CHEMBL2321770,=,=,IC50,nM,503.0,IC50,nM,503.0,COc1ccc(C#Cc2csc3c(=O)cc(N4CCOCC4)oc23)cc1,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccc(C(F)(F)F)cc3)csc12,CHEMBL2321770,=,=,IC50,nM,808.0,IC50,nM,808.0,O=c1cc(N2CCOCC2)oc2c(-c3ccc(C(F)(F)F)cc3)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccc(Cl)c(Cl)c3)csc12,CHEMBL2321770,=,=,IC50,nM,5560.0,IC50,nM,5560.0,O=c1cc(N2CCOCC2)oc2c(-c3ccc(Cl)c(Cl)c3)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)csc12,CHEMBL2321770,=,=,IC50,nM,586.0,IC50,nM,586.0,O=c1cc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),N#Cc1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,CHEMBL2321770,=,=,IC50,nM,2310.0,IC50,nM,2310.0,N#Cc1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(Cc3ccccc3)csc12,CHEMBL2321770,>,>,IC50,nM,50000.0,IC50,nM,50000.0,O=c1cc(N2CCOCC2)oc2c(Cc3ccccc3)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),COc1cccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)c1,CHEMBL2321770,=,=,IC50,nM,1090.0,IC50,nM,1090.0,COc1cccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)c1,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccc4c(c3)OCCO4)csc12,CHEMBL2321770,=,=,IC50,nM,1310.0,IC50,nM,1310.0,O=c1cc(N2CCOCC2)oc2c(-c3ccc4c(c3)OCCO4)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccoc3)csc12,CHEMBL2321770,=,=,IC50,nM,158.0,IC50,nM,158.0,O=c1cc(N2CCOCC2)oc2c(-c3ccoc3)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccsc3)csc12,CHEMBL2321770,=,=,IC50,nM,9180.0,IC50,nM,9180.0,O=c1cc(N2CCOCC2)oc2c(-c3ccsc3)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccc4[nH]ccc4c3)csc12,CHEMBL2321770,=,=,IC50,nM,4990.0,IC50,nM,4990.0,O=c1cc(N2CCOCC2)oc2c(-c3ccc4[nH]ccc4c3)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),Cc1cccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)c1,CHEMBL2321770,=,=,IC50,nM,667.0,IC50,nM,667.0,Cc1cccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)c1,2013
Inhibition of PI3K p110gamma (unknown origin),Cc1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,CHEMBL2321770,=,=,IC50,nM,1390.0,IC50,nM,1390.0,Cc1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3cccs3)csc12,CHEMBL2321770,=,=,IC50,nM,5200.0,IC50,nM,5200.0,O=c1cc(N2CCOCC2)oc2c(-c3cccs3)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),CS(=O)(=O)c1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,CHEMBL2321770,=,=,IC50,nM,7500.0,IC50,nM,7500.0,CS(=O)(=O)c1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3cc4ccccc4[nH]3)csc12,CHEMBL2321770,=,=,IC50,nM,314.0,IC50,nM,314.0,O=c1cc(N2CCOCC2)oc2c(-c3cc4ccccc4[nH]3)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),Nc1cccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)c1,CHEMBL2321770,=,=,IC50,nM,6300.0,IC50,nM,6300.0,Nc1cccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)c1,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2ccsc12,CHEMBL2321770,>,>,IC50,nM,50000.0,IC50,nM,50000.0,O=c1cc(N2CCOCC2)oc2ccsc12,2013
Inhibition of PI3K p110gamma (unknown origin),CN(C)c1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,CHEMBL2321770,=,=,IC50,nM,211.0,IC50,nM,211.0,CN(C)c1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,2013
Inhibition of PI3K p110gamma (unknown origin),COc1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,CHEMBL2321770,=,=,IC50,nM,553.0,IC50,nM,553.0,COc1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccc4c(c3)OCO4)csc12,CHEMBL2321770,=,=,IC50,nM,385.0,IC50,nM,385.0,O=c1cc(N2CCOCC2)oc2c(-c3ccc4c(c3)OCO4)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccco3)csc12,CHEMBL2321770,=,=,IC50,nM,4220.0,IC50,nM,4220.0,O=c1cc(N2CCOCC2)oc2c(-c3ccco3)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccncc3)csc12,CHEMBL2321770,=,=,IC50,nM,5460.0,IC50,nM,5460.0,O=c1cc(N2CCOCC2)oc2c(-c3ccncc3)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3cccnc3)csc12,CHEMBL2321770,=,=,IC50,nM,8780.0,IC50,nM,8780.0,O=c1cc(N2CCOCC2)oc2c(-c3cccnc3)csc12,2013
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)csc12,CHEMBL2321770,=,=,IC50,nM,1570.0,IC50,nM,1570.0,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)csc12,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nn2c(NC(N)=O)cc(N3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL2321733,<,>,IC50,nM,6309.57,pIC50,,5.2,Cc1nn2c(NC(N)=O)cc(N3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,2013
Inhibition of PI3Kgamma (unknown origin),CC(=O)Nc1cc(N2CCOCC2)nc2c(Cc3cccc(C(F)(F)F)c3C)c(C)nn12,CHEMBL2321733,<,>,IC50,nM,5011.87,pIC50,,5.3,CC(=O)Nc1cc(N2CCOCC2)nc2c(Cc3cccc(C(F)(F)F)c3C)c(C)nn12,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nn2c(NCCO)cc(C3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL2321733,=,=,IC50,nM,5011.87,pIC50,,5.3,Cc1nn2c(NCCO)cc(C3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nn2c(NO)cc(C3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL2321733,<,>,IC50,nM,6309.57,pIC50,,5.2,Cc1nn2c(NO)cc(C3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,2013
Inhibition of PI3Kgamma (unknown origin),CNc1cc(N2CCOCC2)nc2c(Cc3cccc(C(F)(F)F)c3C)c(C)nn12,CHEMBL2321733,<,>,IC50,nM,6309.57,pIC50,,5.2,CNc1cc(N2CCOCC2)nc2c(Cc3cccc(C(F)(F)F)c3C)c(C)nn12,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nn2c(N)cc(N3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL2321733,<,>,IC50,nM,1479.11,pIC50,,5.83,Cc1nn2c(N)cc(N3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nn2c(C#N)cc(N3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL2321733,<,>,IC50,nM,3162.28,pIC50,,5.5,Cc1nn2c(C#N)cc(N3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nn2c(C(N)=O)cc(N3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL2321733,<,>,IC50,nM,6309.57,pIC50,,5.2,Cc1nn2c(C(N)=O)cc(N3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nn2c(C(=O)O)cc(N3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL2321733,<,>,IC50,nM,6309.57,pIC50,,5.2,Cc1nn2c(C(=O)O)cc(N3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nn2ccc(C3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL2321733,=,=,IC50,nM,1995.26,pIC50,,5.7,Cc1nn2ccc(C3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,2013
Inhibition of PI3Kgamma (unknown origin),Cc1c(Cc2cnn3c(Cl)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,CHEMBL2321733,<,>,IC50,nM,5011.87,pIC50,,5.3,Cc1c(Cc2cnn3c(Cl)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,2013
Inhibition of PI3Kgamma (unknown origin),COc1cc(N2CCOCC2)nc2c(Cc3cccc(C(F)(F)F)c3C)cnn12,CHEMBL2321733,<,>,IC50,nM,5011.87,pIC50,,5.3,COc1cc(N2CCOCC2)nc2c(Cc3cccc(C(F)(F)F)c3C)cnn12,2013
Inhibition of PI3Kgamma (unknown origin),Nc1nn2c(O)cc(C3CCOCC3)nc2c1Cc1cccc(Cl)c1Cl,CHEMBL2321733,<,>,IC50,nM,3981.07,pIC50,,5.4,Nc1nn2c(O)cc(C3CCOCC3)nc2c1Cc1cccc(Cl)c1Cl,2013
Inhibition of PI3Kgamma (unknown origin),COc1nn2c(O)cc(-c3ccncc3)nc2c1Cc1cccc(Cl)c1Cl,CHEMBL2321733,=,=,IC50,nM,501.19,pIC50,,6.3,COc1nn2c(O)cc(-c3ccncc3)nc2c1Cc1cccc(Cl)c1Cl,2013
Inhibition of PI3Kgamma (unknown origin),Cc1c(Cc2c(=O)[nH]n3c(=O)cc(C4CCOCC4)[nH]c23)cccc1C(F)(F)F,CHEMBL2321733,<,>,IC50,nM,5011.87,pIC50,,5.3,Cc1c(Cc2c(=O)[nH]n3c(=O)cc(C4CCOCC4)[nH]c23)cccc1C(F)(F)F,2013
Inhibition of PI3Kgamma (unknown origin),Oc1cc(C2CCOCC2)nc2c(Cc3cccc(Cl)c3Cl)c(C(F)(F)F)nn12,CHEMBL2321733,<,>,IC50,nM,6309.57,pIC50,,5.2,Oc1cc(C2CCOCC2)nc2c(Cc3cccc(Cl)c3Cl)c(C(F)(F)F)nn12,2013
Inhibition of PI3Kgamma (unknown origin),Oc1cc(-c2ccncc2)nc2c(Cc3cccc(Cl)c3Cl)c(C(F)(F)F)nn12,CHEMBL2321733,=,=,IC50,nM,398.11,pIC50,,6.4,Oc1cc(-c2ccncc2)nc2c(Cc3cccc(Cl)c3Cl)c(C(F)(F)F)nn12,2013
Inhibition of PI3Kgamma (unknown origin),Oc1cc(N2CCOCC2)nc2c(Cc3cccc(Cl)c3Cl)c(C(F)(F)F)nn12,CHEMBL2321733,=,=,IC50,nM,251.19,pIC50,,6.6,Oc1cc(N2CCOCC2)nc2c(Cc3cccc(Cl)c3Cl)c(C(F)(F)F)nn12,2013
Inhibition of PI3Kgamma (unknown origin),CCc1nn2c(O)cc(C3CCOCC3)nc2c1Cc1cccc(Cl)c1Cl,CHEMBL2321733,<,>,IC50,nM,7943.28,pIC50,,5.1,CCc1nn2c(O)cc(C3CCOCC3)nc2c1Cc1cccc(Cl)c1Cl,2013
Inhibition of PI3Kgamma (unknown origin),CCc1nn2c(O)cc(-c3ccncc3)nc2c1Cc1cccc(Cl)c1Cl,CHEMBL2321733,=,=,IC50,nM,398.11,pIC50,,6.4,CCc1nn2c(O)cc(-c3ccncc3)nc2c1Cc1cccc(Cl)c1Cl,2013
Inhibition of PI3Kgamma (unknown origin),Cc1c(Cc2cnn3c(O)cc(-c4ccncc4)nc23)cccc1C(F)(F)F,CHEMBL2321733,=,=,IC50,nM,316.23,pIC50,,6.5,Cc1c(Cc2cnn3c(O)cc(-c4ccncc4)nc23)cccc1C(F)(F)F,2013
Inhibition of PI3Kgamma (unknown origin),Cc1c(Cc2cnn3c(O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,CHEMBL2321733,=,=,IC50,nM,501.19,pIC50,,6.3,Cc1c(Cc2cnn3c(O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nn2c(O)cc(N3CCOC(C)C3)nc2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL2321733,=,=,IC50,nM,398.11,pIC50,,6.4,Cc1nn2c(O)cc(N3CCOC(C)C3)nc2c1Cc1cccc(C(F)(F)F)c1C,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nn2c(O)cc(N3CCOCC3=O)nc2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL2321733,=,=,IC50,nM,3162.28,pIC50,,5.5,Cc1nn2c(O)cc(N3CCOCC3=O)nc2c1Cc1cccc(C(F)(F)F)c1C,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nn2c(O)cc(C3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL2321733,=,=,IC50,nM,2511.89,pIC50,,5.6,Cc1nn2c(O)cc(C3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nn2c(O)cc(N3CCOCC3)nc2c1Cc1cccc2ccccc12,CHEMBL2321733,=,=,IC50,nM,630.96,pIC50,,6.2,Cc1nn2c(O)cc(N3CCOCC3)nc2c1Cc1cccc2ccccc12,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nn2c(O)cc(N3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL2321733,=,=,IC50,nM,316.23,pIC50,,6.5,Cc1nn2c(O)cc(N3CCOCC3)nc2c1Cc1cccc(C(F)(F)F)c1C,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,CN(C)CC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL2321664,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN(C)CC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,CN[C@@H](C)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL2321664,=,=,IC50,nM,8000.0,IC50,nM,8000.0,CN[C@@H](C)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,NCCC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL2321664,=,=,IC50,nM,3900.0,IC50,nM,3900.0,NCCC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,NCCCC[C@H](N)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL2321664,>,>,IC50,nM,10000.0,IC50,uM,10.0,NCCCC[C@H](N)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,O=C([C@@H]1CCCN1)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL2321664,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C([C@@H]1CCCN1)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL2321664,>,>,IC50,nM,10000.0,IC50,uM,10.0,N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,CC[C@H](C)[C@H](N)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL2321664,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC[C@H](C)[C@H](N)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,N[C@H](Cc1ccccc1)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL2321664,>,>,IC50,nM,10000.0,IC50,uM,10.0,N[C@H](Cc1ccccc1)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,N[C@@H](Cc1ccccc1)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL2321664,=,=,IC50,nM,100000.0,IC50,uM,100.0,N[C@@H](Cc1ccccc1)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,C[C@@H](N)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL2321664,=,=,IC50,nM,2000.0,IC50,nM,2000.0,C[C@@H](N)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,C[C@H](N)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL2321664,=,=,IC50,nM,3600.0,IC50,nM,3600.0,C[C@H](N)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,CC(=O)NCC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL2321664,=,=,IC50,nM,380.0,IC50,nM,380.0,CC(=O)NCC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,NCC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL2321664,=,=,IC50,nM,9900.0,IC50,nM,9900.0,NCC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2013
Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL2321664,=,=,IC50,nM,38.0,IC50,nM,38.0,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2013
Inhibition of PI3Kgamma (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay,COc1ccc2nc(C(C)C)n(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)c2c1,CHEMBL2321769,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc2nc(C(C)C)n(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)c2c1,2013
Inhibition of PI3Kgamma (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay,COc1ccc2c(c1)nc(C(C)C)n2-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL2321769,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc2c(c1)nc(C(C)C)n2-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2013
Inhibition of PI3Kgamma (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay,COc1ccc2nc(C)n(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)c2c1,CHEMBL2321769,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc2nc(C)n(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)c2c1,2013
Inhibition of PI3Kgamma (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay,COc1ccc2c(c1)nc(C)n2-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL2321769,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc2c(c1)nc(C)n2-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2013
Inhibition of PI3Kgamma (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay,COc1ccc2nc(C(F)F)n(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)c2c1,CHEMBL2321769,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc2nc(C(F)F)n(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)c2c1,2013
Inhibition of PI3Kgamma (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay,COc1ccc2c(c1)nc(C(F)F)n2-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL2321769,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc2c(c1)nc(C(F)F)n2-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2013
Inhibition of PI3Kgamma (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay,CC(C)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL2321769,=,=,IC50,nM,2530.0,IC50,uM,2.53,CC(C)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2013
Inhibition of PI3Kgamma (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay,Cc1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL2321769,=,=,IC50,nM,1860.0,IC50,uM,1.86,Cc1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2013
Inhibition of PI3Kgamma (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL2321769,=,=,IC50,nM,38.0,IC50,uM,0.038,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2013
Inhibition of human PI3Kgamma,Cc1ccc(-c2ccc3ncc4c(c3n2)n(C2CCN(C(=O)[C@H](C)O)CC2)c(=O)n4C)cn1,CHEMBL2331555,=,=,Ki,nM,0.111,Ki,nM,0.111,Cc1ccc(-c2ccc3ncc4c(c3n2)n(C2CCN(C(=O)[C@H](C)O)CC2)c(=O)n4C)cn1,2013
Inhibition of PI3Kgamma (unknown origin),Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F,CHEMBL2331117,>,>,IC50,nM,5000.0,IC50,nM,5000.0,Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F,2013
Inhibition of recombinant PIK3CG (unknown origin) at 5 uM after 1 hr by FRET-based adapta assay,O=C1/C(=C/c2ccccn2)CNC/C1=C\c1ccccn1,CHEMBL2331439,=,=,Inhibition,%,34.0,INH,%,34.0,O=C1/C(=C/c2ccccn2)CNC/C1=C\c1ccccn1,2013
Inhibition of PI3Kgamma (unknown origin) using lipid PIP2 as substrate,COc1ccc(-c2ccc3c(N4CCOCC4)nc(N4C[C@@H](C)O[C@@H](C)C4)nc3n2)cc1CO,CHEMBL2331448,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(-c2ccc3c(N4CCOCC4)nc(N4C[C@@H](C)O[C@@H](C)C4)nc3n2)cc1CO,2013
Inhibition of PI3Kgamma (unknown origin) assessed as remaining activity at 1 uM relative to control,CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1,CHEMBL2346597,=,=,Activity,%,116.0,Activity,%,116.0,CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1,2013
Inhibition of PI3Kgamma (unknown origin) assessed as remaining activity at 10 uM relative to control,CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1,CHEMBL2346597,=,=,Activity,%,87.0,Activity,%,87.0,CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(-c3cnn(CCO)c3)ccc1-2,CHEMBL2380305,=,=,Ki,nM,0.55,Ki(app),nM,0.55,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(-c3cnn(CCO)c3)ccc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1cc2c(s1)-c1ccc(C(N)=O)cc1OCC2,CHEMBL2380305,=,=,IC50,nM,2.2,IC50,nM,2.2,CC(C)n1ncnc1-c1cc2c(s1)-c1ccc(C(N)=O)cc1OCC2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL2380305,=,=,Ki,nM,1.4,Ki(app),nM,1.4,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)(O)Cn1cc(-c2ccc3c(c2)OCCc2sc(-c4ncnn4CC(F)(F)F)nc2-3)cn1,CHEMBL2380305,=,=,IC50,nM,1.4,IC50,nM,1.4,CC(C)(O)Cn1cc(-c2ccc3c(c2)OCCc2sc(-c4ncnn4CC(F)(F)F)nc2-3)cn1,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(-c3ccc(N)nc3)ccc1-2,CHEMBL2380305,=,=,IC50,nM,3.7,IC50,nM,3.7,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(-c3ccc(N)nc3)ccc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(-c3ccc[nH]c3=O)ccc1-2,CHEMBL2380305,=,=,IC50,nM,11.0,IC50,nM,11.0,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(-c3ccc[nH]c3=O)ccc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(-c3cn(C)cn3)ccc1-2,CHEMBL2380305,=,=,IC50,nM,0.6,IC50,nM,0.6,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(-c3cn(C)cn3)ccc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(-c3ncc[nH]3)ccc1-2,CHEMBL2380305,=,=,IC50,nM,1.5,IC50,nM,1.5,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(-c3ncc[nH]3)ccc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(-c3cn[nH]c3)ccc1-2,CHEMBL2380305,=,=,IC50,nM,0.7,IC50,nM,0.7,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(-c3cn[nH]c3)ccc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(C3CCNCC3)ccc1-2,CHEMBL2380305,=,=,IC50,nM,8.4,IC50,nM,8.4,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(C3CCNCC3)ccc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(C3CCCN3)ccc1-2,CHEMBL2380305,=,=,IC50,nM,36.0,IC50,nM,36.0,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(C3CCCN3)ccc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(C3CCNC3)ccc1-2,CHEMBL2380305,=,=,IC50,nM,4.3,IC50,nM,4.3,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(C3CCNC3)ccc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(C3CNC3)ccc1-2,CHEMBL2380305,=,=,IC50,nM,3.5,IC50,nM,3.5,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(C3CNC3)ccc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(CNCCO)ccc1-2,CHEMBL2380305,=,=,IC50,nM,80.0,IC50,nM,80.0,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(CNCCO)ccc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(=O)NCc1ccc2c(c1)OCCc1sc(-c3ncnn3C(C)C)nc1-2,CHEMBL2380305,=,=,IC50,nM,55.0,IC50,nM,55.0,CC(=O)NCc1ccc2c(c1)OCCc1sc(-c3ncnn3C(C)C)nc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(C(O)CO)ccc1-2,CHEMBL2380305,=,=,IC50,nM,19.1,IC50,nM,19.1,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(C(O)CO)ccc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(CO)ccc1-2,CHEMBL2380305,=,=,IC50,nM,8.4,IC50,nM,8.4,CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(CO)ccc1-2,2013
Inhibition of GST-fused human recombinant PI3Kgamma expressed in baculovirus infected SF9 cells after 1 hr by scintillation proximity assay in presence of [gamma-33P]-ATP,CC(C)n1ncnc1-c1nc2c(s1)CCOc1ccccc1-2,CHEMBL2380305,=,=,IC50,nM,3.0,IC50,nM,3.0,CC(C)n1ncnc1-c1nc2c(s1)CCOc1ccccc1-2,2013
Inhibition of PI3Kgamma (unknown origin),Cc1nc(-c2cn3c(n2)-c2ccc(-c4cnn(C(C)(C)C(N)=O)c4)cc2OCC3)n(C(C)C)n1,CHEMBL2384988,=,=,Ki,nM,0.97,Ki,nM,0.97,Cc1nc(-c2cn3c(n2)-c2ccc(-c4cnn(C(C)(C)C(N)=O)c4)cc2OCC3)n(C(C)C)n1,2013
Inhibition of PI3Kgamma (unknown origin) at 1 uM,Cc1nc(-c2cn3c(n2)-c2ccc(-c4cnn(C(C)(C)C(N)=O)c4)cc2OCC3)n(C(C)C)n1,CHEMBL2384988,=,=,Inhibition,%,90.6,INH,%,90.6,Cc1nc(-c2cn3c(n2)-c2ccc(-c4cnn(C(C)(C)C(N)=O)c4)cc2OCC3)n(C(C)C)n1,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2(C)CC2)n1,CHEMBL2396607,=,=,IC50,nM,690.0,IC50,uM,0.69,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2(C)CC2)n1,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,CCN(CC)c1nccc(-c2sc(NC(=O)N3CCC[C@H]3C(N)=O)nc2C)n1,CHEMBL2396607,=,=,IC50,nM,410.0,IC50,uM,0.41,CCN(CC)c1nccc(-c2sc(NC(=O)N3CCC[C@H]3C(N)=O)nc2C)n1,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,CC(C)(c1cc(-c2sc(NC(=O)N3CCC[C@H]3C(N)=O)nc2Cl)ccn1)C(F)(F)F,CHEMBL2396607,=,=,IC50,nM,1400.0,IC50,uM,1.4,CC(C)(c1cc(-c2sc(NC(=O)N3CCC[C@H]3C(N)=O)nc2Cl)ccn1)C(F)(F)F,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,CC(C)(c1cc(-c2cnc(NC(=O)N3CCC[C@H]3C(N)=O)s2)ccn1)C(F)(F)F,CHEMBL2396607,=,=,IC50,nM,830.0,IC50,uM,0.83,CC(C)(c1cc(-c2cnc(NC(=O)N3CCC[C@H]3C(N)=O)s2)ccn1)C(F)(F)F,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1cc(C(C)C)ncn1,CHEMBL2396607,,,IC50,,,IC50,,,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1cc(C(C)C)ncn1,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2CCC2)n1,CHEMBL2396607,=,=,IC50,nM,610.0,IC50,uM,0.61,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2CCC2)n1,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)C)n1,CHEMBL2396607,=,=,IC50,nM,1400.0,IC50,uM,1.4,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)C)n1,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2(C#N)CC2)c1,CHEMBL2396607,=,=,IC50,nM,1100.0,IC50,uM,1.1,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2(C#N)CC2)c1,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,CHEMBL2396607,=,=,IC50,nM,250.0,IC50,uM,0.25,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,Cc1nc(NC(=O)N2CC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1,CHEMBL2396607,=,=,IC50,nM,320.0,IC50,uM,0.32,Cc1nc(NC(=O)N2CC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,Cc1nc(NC(=O)N2CCC[C@@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)c1,CHEMBL2396607,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1nc(NC(=O)N2CCC[C@@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)c1,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,Cc1nc(NC(=O)N2CCCC2)sc1-c1ccnc(C(C)(C)C)c1,CHEMBL2396607,=,=,IC50,nM,930.0,IC50,uM,0.93,Cc1nc(NC(=O)N2CCCC2)sc1-c1ccnc(C(C)(C)C)c1,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,CNC(=O)[C@@H]1CCCN1C(=O)Nc1nc(C)c(-c2ccnc(C(C)(C)C)c2)s1,CHEMBL2396607,=,=,IC50,nM,4600.0,IC50,uM,4.6,CNC(=O)[C@@H]1CCCN1C(=O)Nc1nc(C)c(-c2ccnc(C(C)(C)C)c2)s1,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)c1,CHEMBL2396607,=,=,IC50,nM,430.0,IC50,uM,0.43,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)c1,2013
Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1,CHEMBL2396607,=,=,IC50,nM,210.0,IC50,uM,0.21,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1,2013
Inhibition of p110gamma (unknown origin) at 10 uM relative to control,CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1,CHEMBL2401733,=,=,Inhibition,%,10.0,INH,%,10.0,CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1,2013
Inhibition of PI-3K gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL2417539,=,=,IC50,nM,3020.0,IC50,uM,3.02,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2013
Inhibition of PI3Kgamma (unknown origin) using 1alpha-phosphotidylinositol by luminescence assay,CC(=O)Nc1cn2cc(-c3cnc(N)c(C(F)(F)F)c3)ccc2n1,CHEMBL2417393,=,=,IC50,nM,8.2,IC50,uM,0.0082,CC(=O)Nc1cn2cc(-c3cnc(N)c(C(F)(F)F)c3)ccc2n1,2013
Inhibition of PI3Kgamma (unknown origin) using 1alpha-phosphotidylinositol by luminescence assay,COC(=O)c1ccc2nc(NC(C)=O)sc2c1,CHEMBL2417393,=,=,IC50,nM,4200.0,IC50,uM,4.2,COC(=O)c1ccc2nc(NC(C)=O)sc2c1,2013
Inhibition of PI-3K gamma (unknown origin),CCN1CCN(CC(=O)Nc2ccc(-c3cccc4c(=O)cc(N5CCOCC5)oc34)c3sc4ccccc4c23)CC1,CHEMBL2417539,=,=,IC50,nM,590.0,IC50,uM,0.59,CCN1CCN(CC(=O)Nc2ccc(-c3cccc4c(=O)cc(N5CCOCC5)oc34)c3sc4ccccc4c23)CC1,2013
Inhibition of PI-3K gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cccc12,CHEMBL2417539,=,=,IC50,nM,220.0,IC50,uM,0.22,O=c1cc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cccc12,2013
Inhibition of PI3Kgamma (unknown origin) at 30 uM,O=C(Nc1ccc2c(c1)B(O)OC2)c1c(C(F)(F)F)ccc(Cl)c1F,CHEMBL2440005,,,Inhibition,%,,INH,,,O=C(Nc1ccc2c(c1)B(O)OC2)c1c(C(F)(F)F)ccc(Cl)c1F,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,Cc1nc(N)sc1-c1nc(C(C)(C)C)no1,CHEMBL3091363,=,=,IC50,nM,68.0,IC50,nM,68.0,Cc1nc(N)sc1-c1nc(C(C)(C)C)no1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,Cc1nc(N)sc1-c1cnc(C(C)(C)C)o1,CHEMBL3091363,=,=,IC50,nM,81.0,IC50,nM,81.0,Cc1nc(N)sc1-c1cnc(C(C)(C)C)o1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2cnc(C(C)(C)C)o2)s1,CHEMBL3091363,=,=,IC50,nM,3.0,IC50,nM,3.0,CC(=O)Nc1nc(C)c(-c2cnc(C(C)(C)C)o2)s1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2nc(N3CCOCC3)no2)s1,CHEMBL3091363,=,=,IC50,nM,100.0,IC50,nM,100.0,CC(=O)Nc1nc(C)c(-c2nc(N3CCOCC3)no2)s1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2nc(C3CCOC3)no2)s1,CHEMBL3091363,=,=,IC50,nM,57.0,IC50,nM,57.0,CC(=O)Nc1nc(C)c(-c2nc(C3CCOC3)no2)s1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,COCC(C)(C)Cc1noc(-c2sc(NC(C)=O)nc2C)n1,CHEMBL3091363,=,=,IC50,nM,68.0,IC50,nM,68.0,COCC(C)(C)Cc1noc(-c2sc(NC(C)=O)nc2C)n1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2nc(N3CCCC(O)C3)no2)s1,CHEMBL3091363,=,=,IC50,nM,29.0,IC50,nM,29.0,CC(=O)Nc1nc(C)c(-c2nc(N3CCCC(O)C3)no2)s1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2nc(CC(C)(C)C(C)O)no2)s1,CHEMBL3091363,=,=,IC50,nM,17.0,IC50,nM,17.0,CC(=O)Nc1nc(C)c(-c2nc(CC(C)(C)C(C)O)no2)s1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2nc(CCC(C)(C)O)no2)s1,CHEMBL3091363,=,=,IC50,nM,203.0,IC50,nM,203.0,CC(=O)Nc1nc(C)c(-c2nc(CCC(C)(C)O)no2)s1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2nc(CC(C)(C)CO)no2)s1,CHEMBL3091363,=,=,IC50,nM,7.2,IC50,nM,7.2,CC(=O)Nc1nc(C)c(-c2nc(CC(C)(C)CO)no2)s1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2nc(C(C)(C)CCO)no2)s1,CHEMBL3091363,=,=,IC50,nM,62.0,IC50,nM,62.0,CC(=O)Nc1nc(C)c(-c2nc(C(C)(C)CCO)no2)s1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2nc(CCCO)no2)s1,CHEMBL3091363,=,=,IC50,nM,121.0,IC50,nM,121.0,CC(=O)Nc1nc(C)c(-c2nc(CCCO)no2)s1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2nc(CC(C)(C)O)no2)s1,CHEMBL3091363,=,=,IC50,nM,68.0,IC50,nM,68.0,CC(=O)Nc1nc(C)c(-c2nc(CC(C)(C)O)no2)s1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2nc(C(C)(C)CO)no2)s1,CHEMBL3091363,=,=,IC50,nM,52.0,IC50,nM,52.0,CC(=O)Nc1nc(C)c(-c2nc(C(C)(C)CO)no2)s1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2nc(CCO)no2)s1,CHEMBL3091363,=,=,IC50,nM,158.0,IC50,nM,158.0,CC(=O)Nc1nc(C)c(-c2nc(CCO)no2)s1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2nc(CC(F)(F)F)no2)s1,CHEMBL3091363,=,=,IC50,nM,28.0,IC50,nM,28.0,CC(=O)Nc1nc(C)c(-c2nc(CC(F)(F)F)no2)s1,2013
Inhibition of human PI3Kgamma using PtdIns/PtdSer as substrate after 2 hrs by scintillation counting analysis in presence of gamma[33P]ATP,CC(=O)Nc1nc(C)c(-c2nc(C(C)(C)C)no2)s1,CHEMBL3091363,=,=,IC50,nM,14.0,IC50,nM,14.0,CC(=O)Nc1nc(C)c(-c2nc(C(C)(C)C)no2)s1,2013
Inhibition of PIK3CG (unknown origin) assessed as residual activity at 10 uM after 1 hr by qPCR analysis relative to control,O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,CHEMBL3108735,=,=,Activity,%,2.5,Activity,%,2.5,O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,O=C(Nc1ccc(CO)cc1)Nc1cccc(-c2nc(N3CCOCC3)c3ncccc3n2)c1,CHEMBL3108735,=,=,IC50,nM,22000.0,IC50,uM,22.0,O=C(Nc1ccc(CO)cc1)Nc1cccc(-c2nc(N3CCOCC3)c3ncccc3n2)c1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,O=C(Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1)Nc1cccnc1,CHEMBL3108735,=,=,IC50,nM,79.0,IC50,uM,0.079,O=C(Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1)Nc1cccnc1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,CHEMBL3108735,=,=,IC50,nM,153.0,IC50,uM,0.153,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,O=C(Nc1ccc(O)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,CHEMBL3108735,=,=,IC50,nM,264.0,IC50,uM,0.264,O=C(Nc1ccc(O)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,O=C(Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1)Nc1cccc(O)c1,CHEMBL3108735,=,=,IC50,nM,353.0,IC50,uM,0.353,O=C(Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1)Nc1cccc(O)c1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,CHEMBL3108735,=,=,IC50,nM,26.0,IC50,uM,0.026,O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,O=C(Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1)Nc1cccc(CO)c1,CHEMBL3108735,=,=,IC50,nM,62.0,IC50,uM,0.062,O=C(Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1)Nc1cccc(CO)c1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,CHEMBL3108735,=,=,IC50,nM,227.0,IC50,uM,0.227,CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,Nc1ncc(-c2nc(N3CCOCC3)c3cccnc3n2)cn1,CHEMBL3108735,=,=,IC50,nM,4700.0,IC50,uM,4.7,Nc1ncc(-c2nc(N3CCOCC3)c3cccnc3n2)cn1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,OCc1cccc(-c2nc(N3CCOCC3)c3cccnc3n2)c1,CHEMBL3108735,>,>,IC50,nM,50000.0,IC50,uM,50.0,OCc1cccc(-c2nc(N3CCOCC3)c3cccnc3n2)c1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,Oc1cccc(-c2nc(N3CCOCC3)c3cccnc3n2)c1,CHEMBL3108735,=,=,IC50,nM,741.0,IC50,uM,0.741,Oc1cccc(-c2nc(N3CCOCC3)c3cccnc3n2)c1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,CC(=O)N(C(C)=O)c1ncc(-c2nc(N3CCOCC3)c3ncccc3n2)cn1,CHEMBL3108735,>,>,IC50,nM,50000.0,IC50,uM,50.0,CC(=O)N(C(C)=O)c1ncc(-c2nc(N3CCOCC3)c3ncccc3n2)cn1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,CC(=O)Nc1ncc(-c2nc(N3CCOCC3)c3ncccc3n2)cn1,CHEMBL3108735,=,=,IC50,nM,12300.0,IC50,uM,12.3,CC(=O)Nc1ncc(-c2nc(N3CCOCC3)c3ncccc3n2)cn1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,Nc1ncc(-c2nc(N3CCOCC3)c3ncccc3n2)cn1,CHEMBL3108735,=,=,IC50,nM,81.0,IC50,uM,0.081,Nc1ncc(-c2nc(N3CCOCC3)c3ncccc3n2)cn1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cn1,CHEMBL3108735,=,=,IC50,nM,87.0,IC50,uM,0.087,Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cn1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,c1cnc2c(N3CCOCC3)nc(-c3cccc4[nH]ncc34)nc2c1,CHEMBL3108735,=,=,IC50,nM,3400.0,IC50,uM,3.4,c1cnc2c(N3CCOCC3)nc(-c3cccc4[nH]ncc34)nc2c1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,c1cnc2c(N3CCOCC3)nc(-c3ccc4cn[nH]c4c3)nc2c1,CHEMBL3108735,=,=,IC50,nM,7880.0,IC50,uM,7.88,c1cnc2c(N3CCOCC3)nc(-c3ccc4cn[nH]c4c3)nc2c1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,c1cncc(-c2nc(N3CCOCC3)c3ncccc3n2)c1,CHEMBL3108735,>,>,IC50,nM,50000.0,IC50,uM,50.0,c1cncc(-c2nc(N3CCOCC3)c3ncccc3n2)c1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,CHEMBL3108735,>,>,IC50,nM,50000.0,IC50,uM,50.0,Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,Nc1cccc(-c2nc(N3CCOCC3)c3ncccc3n2)c1,CHEMBL3108735,=,=,IC50,nM,6300.0,IC50,uM,6.3,Nc1cccc(-c2nc(N3CCOCC3)c3ncccc3n2)c1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,OCc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,CHEMBL3108735,=,=,IC50,nM,30700.0,IC50,uM,30.7,OCc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,OCc1cccc(-c2nc(N3CCOCC3)c3ncccc3n2)c1,CHEMBL3108735,=,=,IC50,nM,183.0,IC50,uM,0.183,OCc1cccc(-c2nc(N3CCOCC3)c3ncccc3n2)c1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,COc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,CHEMBL3108735,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,COc1cccc(-c2nc(N3CCOCC3)c3ncccc3n2)c1,CHEMBL3108735,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1cccc(-c2nc(N3CCOCC3)c3ncccc3n2)c1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,Oc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,CHEMBL3108735,=,=,IC50,nM,6390.0,IC50,uM,6.39,Oc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,Oc1ccccc1-c1nc(N2CCOCC2)c2ncccc2n1,CHEMBL3108735,=,=,IC50,nM,9360.0,IC50,uM,9.36,Oc1ccccc1-c1nc(N2CCOCC2)c2ncccc2n1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,C[C@@H]1CN(c2nc(-c3cccc(O)c3)nc3cccnc23)C[C@H](C)O1,CHEMBL3108735,=,=,IC50,nM,574.0,IC50,uM,0.574,C[C@@H]1CN(c2nc(-c3cccc(O)c3)nc3cccnc23)C[C@H](C)O1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,Oc1cccc(-c2nc(N3CCC(F)(F)CC3)c3ncccc3n2)c1,CHEMBL3108735,>,>,IC50,nM,50000.0,IC50,uM,50.0,Oc1cccc(-c2nc(N3CCC(F)(F)CC3)c3ncccc3n2)c1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,CN1CCN(c2nc(-c3cccc(O)c3)nc3cccnc23)CC1,CHEMBL3108735,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2nc(-c3cccc(O)c3)nc3cccnc23)CC1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,O=S1(=O)CCN(c2nc(-c3cccc(O)c3)nc3cccnc23)CC1,CHEMBL3108735,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=S1(=O)CCN(c2nc(-c3cccc(O)c3)nc3cccnc23)CC1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,Oc1cccc(-c2nc(N3CCSCC3)c3ncccc3n2)c1,CHEMBL3108735,>,>,IC50,nM,50000.0,IC50,uM,50.0,Oc1cccc(-c2nc(N3CCSCC3)c3ncccc3n2)c1,2014
Inhibition of PI3Kgamma (unknown origin) after 1 hr by TR-FRET assay,Oc1cccc(-c2nc(N3CCOCC3)c3ncccc3n2)c1,CHEMBL3108735,=,=,IC50,nM,31.0,IC50,uM,0.031,Oc1cccc(-c2nc(N3CCOCC3)c3ncccc3n2)c1,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",C[C@@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,CHEMBL3112424,=,=,IC50,nM,3315.0,IC50,nM,3315.0,C[C@@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,CHEMBL3112424,=,=,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",CC1(C)CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21,CHEMBL3112424,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CC1(C)CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",CC1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21,CHEMBL3112424,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CC1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",CC1(C)Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,CHEMBL3112424,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CC1(C)Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",CC1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,CHEMBL3112424,=,=,IC50,nM,9149.0,IC50,nM,9149.0,CC1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",Cn1c(CC(=O)N2CCc3ccccc32)nc(N2CCOCC2)cc1=O,CHEMBL3112424,=,=,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(CC(=O)N2CCc3ccccc32)nc(N2CCOCC2)cc1=O,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",CN1CCN(Cc2cccc3c2CCN3C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)CC1,CHEMBL3112424,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CN1CCN(Cc2cccc3c2CCN3C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)CC1,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",CN1CCN(c2cccc3c2CCN3C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)CC1,CHEMBL3112424,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CN1CCN(c2cccc3c2CCN3C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)CC1,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccncc3)cccc21,CHEMBL3112424,=,=,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccncc3)cccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3cccnc3)cccc21,CHEMBL3112424,=,=,IC50,nM,2461.0,IC50,nM,2461.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3cccnc3)cccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccn3)cccc21,CHEMBL3112424,=,=,IC50,nM,8966.0,IC50,nM,8966.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccn3)cccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccc3)cccc21,CHEMBL3112424,=,=,IC50,nM,1532.0,IC50,nM,1532.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccc3)cccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(OC(F)(F)F)cccc21,CHEMBL3112424,=,=,IC50,nM,7418.0,IC50,nM,7418.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(OC(F)(F)F)cccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c1cccc2C(F)(F)F,CHEMBL3112424,=,=,IC50,nM,8400.0,IC50,nM,8400.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c1cccc2C(F)(F)F,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",COc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,CHEMBL3112424,=,=,IC50,nM,10000.0,IC50,nM,10000.0,COc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",Cc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,CHEMBL3112424,=,=,IC50,nM,1780.0,IC50,nM,1780.0,Cc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Br)cccc21,CHEMBL3112424,=,=,IC50,nM,3975.0,IC50,nM,3975.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Br)cccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Cl)cccc21,CHEMBL3112424,=,=,IC50,nM,1131.0,IC50,nM,1131.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Cl)cccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(F)cccc21,CHEMBL3112424,=,=,IC50,nM,6215.0,IC50,nM,6215.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(F)cccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(Cl)ccc21,CHEMBL3112424,=,=,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(Cl)ccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(F)ccc21,CHEMBL3112424,=,=,IC50,nM,1590.0,IC50,nM,1590.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(F)ccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21,CHEMBL3112424,=,=,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21,CHEMBL3112424,=,=,IC50,nM,10000.0,IC50,nM,10000.0,Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21,2014
"Inhibition of C-terminal ploy-His-tagged human PI3Kgamma expressed in baculovirus-infected sf9 cells using PI(4,5)P2 as substrate after 15 mins by HTRF assay",Cc1cc(C(C)Nc2ccccc2)c2nc(N3CCOCC3)cc(=O)n2c1,CHEMBL3112424,=,=,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cc(C(C)Nc2ccccc2)c2nc(N3CCOCC3)cc(=O)n2c1,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4C(F)(F)F)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,3162.28,pIC50,,5.5,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4C(F)(F)F)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4C(F)(F)F)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,2511.89,pIC50,,5.6,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4C(F)(F)F)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4C(C)C)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,1000.0,pIC50,,6.0,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4C(C)C)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4C)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,316.23,pIC50,,6.5,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4C)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccc(C(F)(F)F)cc4)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,398.11,pIC50,,6.4,COc1ncc(-c2ccc3nc(N)n(-c4ccc(C(F)(F)F)cc4)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4cccc(C(F)(F)F)c4)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,1584.89,pIC50,,5.8,COc1ncc(-c2ccc3nc(N)n(-c4cccc(C(F)(F)F)c4)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4C(F)(F)F)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,3162.28,pIC50,,5.5,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4C(F)(F)F)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(C4CCOCC4)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,501.19,pIC50,,6.3,COc1ncc(-c2ccc3nc(N)n(C4CCOCC4)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,CCn1c(N)nc2ccc(-c3cnc(OC)c(S(=O)(=O)Nc4ccc(F)cc4F)c3)cc2c1=O,CHEMBL3120088,=,=,IC50,nM,158.49,pIC50,,6.8,CCn1c(N)nc2ccc(-c3cnc(OC)c(S(=O)(=O)Nc4ccc(F)cc4F)c3)cc2c1=O,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,1258.93,pIC50,,5.9,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1S(=O)(=O)Nc1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1cccnc1,CHEMBL3120088,=,=,IC50,nM,6.31,pIC50,,8.2,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1cccnc1,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(C#N)cc1,CHEMBL3120088,=,=,IC50,nM,50.12,pIC50,,7.3,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(C#N)cc1,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(C)cc1,CHEMBL3120088,,,pIC50,,,pIC50,,,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(C)cc1,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1cccc(C)c1,CHEMBL3120088,=,=,IC50,nM,50.12,pIC50,,7.3,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1cccc(C)c1,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccccc1C,CHEMBL3120088,=,=,IC50,nM,39.81,pIC50,,7.4,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccccc1C,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccccc1,CHEMBL3120088,,,pIC50,,,pIC50,,,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccccc1,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)C(C)C,CHEMBL3120088,=,=,IC50,nM,501.19,pIC50,,6.3,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)C(C)C,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(C)(=O)=O,CHEMBL3120088,=,=,IC50,nM,794.33,pIC50,,6.1,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(C)(=O)=O,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1N(C)S(=O)(=O)c1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,3981.07,pIC50,,5.4,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1N(C)S(=O)(=O)c1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,Nc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3120088,,,pIC50,,,pIC50,,,Nc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ccc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,316.23,pIC50,,6.5,COc1ccc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,3.981,pIC50,,8.4,COc1ncc(-c2ccc3nc(N)n(-c4ccccc4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)c(-c4ccccc4)nc3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,7.943,pIC50,,8.1,COc1ncc(-c2ccc3nc(N)c(-c4ccccc4)nc3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)c(-c4ccccc4)cc3n2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,25118.86,pIC50,,4.6,COc1ncc(-c2ccc3nc(N)c(-c4ccccc4)cc3n2)cc1NS(=O)(=O)c1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2cc3cc(-c4ccccc4)c(N)nc3cn2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,1258.93,pIC50,,5.9,COc1ncc(-c2cc3cc(-c4ccccc4)c(N)nc3cn2)cc1NS(=O)(=O)c1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2cnc3nc(N)c(-c4ccccc4)cc3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,6309.57,pIC50,,5.2,COc1ncc(-c2cnc3nc(N)c(-c4ccccc4)cc3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)c(-c4ccccc4)cc3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,63.1,pIC50,,7.2,COc1ncc(-c2ccc3nc(N)c(-c4ccccc4)cc3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3nc(N)c(-c4ccc(N5CCOCC5)cc4)cc3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,630.96,pIC50,,6.2,COc1ncc(-c2ccc3nc(N)c(-c4ccc(N5CCOCC5)cc4)cc3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2014
Inhibition of PI3Kgamma (2 to 1102) (unknown origin) using diC8-PIP2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins,COc1ncc(-c2ccc3ncnc(N4CCOCC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3120088,=,=,IC50,nM,2.512,pIC50,,8.6,COc1ncc(-c2ccc3ncnc(N4CCOCC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2014
Inhibition of human PI3Kgamma after 15 mins,CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,2014
Inhibition of human PI3Kgamma after 15 mins,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,2014
Inhibition of human PI3Kgamma after 15 mins,CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,2014
Inhibition of human PI3Kgamma after 15 mins,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(Br)ccc21,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(Br)ccc21,2014
Inhibition of human PI3Kgamma after 15 mins,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(Cl)ccc21,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(Cl)ccc21,2014
Inhibition of human PI3Kgamma after 15 mins,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21,2014
Inhibition of human PI3Kgamma after 15 mins,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21,2014
Inhibition of human PI3Kgamma after 15 mins,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(F)cccc21,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(F)cccc21,2014
Inhibition of human PI3Kgamma after 15 mins,CC1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CC1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,2014
Inhibition of human PI3Kgamma after 15 mins,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2ccccc21,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2ccccc21,2014
Inhibition of human PI3Kgamma after 15 mins,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21,2014
Inhibition of human PI3Kgamma after 15 mins,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(Br)ccc21,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(Br)ccc21,2014
Inhibition of human PI3Kgamma after 15 mins,CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O,2014
Inhibition of human PI3Kgamma after 15 mins,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21,2014
Inhibition of human PI3Kgamma after 15 mins,CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O,2014
Inhibition of human PI3Kgamma after 15 mins,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21,2014
Inhibition of human PI3Kgamma after 15 mins,CC1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CC1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O,2014
Inhibition of human PI3Kgamma after 15 mins,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2ccccc21,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2ccccc21,2014
Inhibition of human PI3Kgamma after 15 mins,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)Nc1ccc(F)c(Cl)c1,CHEMBL3124816,>,>,IC50,nM,10000.0,IC50,nM,10000.0,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)Nc1ccc(F)c(Cl)c1,2014
Inhibition of human PI3Kgamma after 15 mins,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O,CHEMBL3124816,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O,2014
Inhibition of human PI3Kgamma after 15 mins,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21,CHEMBL3124816,=,=,IC50,nM,8135.0,IC50,nM,8135.0,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21,2014
Inhibition of human PI3Kgamma after 15 mins,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O,CHEMBL3124816,=,=,IC50,nM,4350.0,IC50,nM,4350.0,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O,2014
Inhibition of human PI3Kgamma after 15 mins,CC1CN(C(=O)Cc2nc(N3CCOCC3)sc2C(N)=O)c2ccccc21,CHEMBL3124816,=,=,IC50,nM,4203.0,IC50,nM,4203.0,CC1CN(C(=O)Cc2nc(N3CCOCC3)sc2C(N)=O)c2ccccc21,2014
Inhibition of human PI3Kgamma after 15 mins,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,CHEMBL3124816,=,=,IC50,nM,3259.0,IC50,nM,3259.0,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,2014
Inhibition of human PI3K p120gamma assessed as residual activity at 1 uM relative to control,COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1,CHEMBL3124838,=,=,Activity,%,90.0,Activity,%,90.0,COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1,2014
Inhibition of human PI3K p120gamma assessed as residual activity at 1 uM relative to control,COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1,CHEMBL3124838,=,=,Activity,%,86.0,Activity,%,86.0,COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1,2014
Inhibition of human PI3K p120gamma assessed as residual activity at 1 uM relative to control,COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1,CHEMBL3124838,=,=,Activity,%,85.0,Activity,%,85.0,COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1,2014
Inhibition of human PI3Kgamma,Clc1ccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)c(Cl)c1,CHEMBL3132747,=,=,IC50,nM,267.98,pIC50,,6.5719,Clc1ccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)c(Cl)c1,2014
Inhibition of human PI3Kgamma,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)cc1,CHEMBL3132747,=,=,IC50,nM,386.01,pIC50,,6.4134,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)cc1,2014
Inhibition of human PI3Kgamma,COc1cccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)c1,CHEMBL3132747,=,=,IC50,nM,277.97,pIC50,,6.556,COc1cccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)c1,2014
Inhibition of human PI3Kgamma,Cc1cccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)c1,CHEMBL3132747,=,=,IC50,nM,274.03,pIC50,,6.5622,Cc1cccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)c1,2014
Inhibition of human PI3Kgamma,Clc1ccc(Nc2nccc(-c3ccc(Cl)c(Cl)c3)n2)c(Cl)c1,CHEMBL3132747,=,=,IC50,nM,249.98,pIC50,,6.6021,Clc1ccc(Nc2nccc(-c3ccc(Cl)c(Cl)c3)n2)c(Cl)c1,2014
Inhibition of human PI3Kgamma,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(Cl)c(Cl)c3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,153.99,pIC50,,6.8125,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(Cl)c(Cl)c3)n2)cc1,2014
Inhibition of human PI3Kgamma,COc1cccc(Nc2nccc(-c3ccc(Cl)c(Cl)c3)n2)c1,CHEMBL3132747,=,=,IC50,nM,217.02,pIC50,,6.6635,COc1cccc(Nc2nccc(-c3ccc(Cl)c(Cl)c3)n2)c1,2014
Inhibition of human PI3Kgamma,Clc1ccc(Nc2nccc(-c3ccc(Br)cc3)n2)c(Cl)c1,CHEMBL3132747,=,=,IC50,nM,230.99,pIC50,,6.6364,Clc1ccc(Nc2nccc(-c3ccc(Br)cc3)n2)c(Cl)c1,2014
Inhibition of human PI3Kgamma,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(Br)cc3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,264.97,pIC50,,6.5768,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(Br)cc3)n2)cc1,2014
Inhibition of human PI3Kgamma,Clc1ccc(Nc2nccc(-c3ccc(Br)cc3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,302.0,pIC50,,6.52,Clc1ccc(Nc2nccc(-c3ccc(Br)cc3)n2)cc1,2014
Inhibition of human PI3Kgamma,CC(C)c1ccccc1Nc1nccc(-c2ccc(Br)cc2)n1,CHEMBL3132747,=,=,IC50,nM,312.97,pIC50,,6.5045,CC(C)c1ccccc1Nc1nccc(-c2ccc(Br)cc2)n1,2014
Inhibition of human PI3Kgamma,COc1cccc(Nc2nccc(-c3ccc(Br)cc3)n2)c1,CHEMBL3132747,=,=,IC50,nM,357.03,pIC50,,6.4473,COc1cccc(Nc2nccc(-c3ccc(Br)cc3)n2)c1,2014
Inhibition of human PI3Kgamma,Cc1cccc(Nc2nccc(-c3ccc(Br)cc3)n2)c1,CHEMBL3132747,=,=,IC50,nM,341.98,pIC50,,6.466,Cc1cccc(Nc2nccc(-c3ccc(Br)cc3)n2)c1,2014
Inhibition of human PI3Kgamma,COc1cc(Nc2nccc(-c3ccc(Cl)cc3)n2)cc(OC)c1OC,CHEMBL3132747,=,=,IC50,nM,65.0,pIC50,,7.1871,COc1cc(Nc2nccc(-c3ccc(Cl)cc3)n2)cc(OC)c1OC,2014
Inhibition of human PI3Kgamma,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(F)cc3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,247.0,pIC50,,6.6073,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(F)cc3)n2)cc1,2014
Inhibition of human PI3Kgamma,COc1cccc(Nc2nccc(-c3ccc(F)cc3)n2)c1,CHEMBL3132747,=,=,IC50,nM,333.96,pIC50,,6.4763,COc1cccc(Nc2nccc(-c3ccc(F)cc3)n2)c1,2014
Inhibition of human PI3Kgamma,Cc1ccc(-c2ccnc(Nc3ccc(Cl)cc3Cl)n2)cc1,CHEMBL3132747,=,=,IC50,nM,371.02,pIC50,,6.4306,Cc1ccc(-c2ccnc(Nc3ccc(Cl)cc3Cl)n2)cc1,2014
Inhibition of human PI3Kgamma,COc1ccc(-c2ccnc(Nc3ccc(Cl)cc3Cl)n2)cc1,CHEMBL3132747,=,=,IC50,nM,235.02,pIC50,,6.6289,COc1ccc(-c2ccnc(Nc3ccc(Cl)cc3Cl)n2)cc1,2014
Inhibition of human PI3Kgamma,COc1ccc(-c2ccnc(Nc3ccc([N+](=O)[O-])cc3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,142.99,pIC50,,6.8447,COc1ccc(-c2ccnc(Nc3ccc([N+](=O)[O-])cc3)n2)cc1,2014
Inhibition of human PI3Kgamma,COc1ccc(-c2ccnc(Nc3ccc(Cl)cc3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,166.99,pIC50,,6.7773,COc1ccc(-c2ccnc(Nc3ccc(Cl)cc3)n2)cc1,2014
Inhibition of human PI3Kgamma,COc1ccc(-c2ccnc(Nc3cccc(OC)c3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,194.98,pIC50,,6.71,COc1ccc(-c2ccnc(Nc3cccc(OC)c3)n2)cc1,2014
Inhibition of human PI3Kgamma,COc1ccc(-c2ccnc(Nc3ccc([N+](=O)[O-])cc3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,143.0,IC50,nM,143.0,COc1ccc(-c2ccnc(Nc3ccc([N+](=O)[O-])cc3)n2)cc1,2014
Inhibition of human PI3Kgamma,COc1cccc(Nc2nccc(-c3ccc(F)cc3)n2)c1,CHEMBL3132747,=,=,IC50,nM,334.0,IC50,nM,334.0,COc1cccc(Nc2nccc(-c3ccc(F)cc3)n2)c1,2014
Inhibition of human PI3Kgamma,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)cc1,CHEMBL3132747,=,=,IC50,nM,386.0,IC50,nM,386.0,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)cc1,2014
Inhibition of human PI3Kgamma,Cc1cccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)c1,CHEMBL3132747,=,=,IC50,nM,274.0,IC50,nM,274.0,Cc1cccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)c1,2014
Inhibition of human PI3Kgamma,CC(C)c1ccccc1Nc1nccc(-c2ccc(Br)cc2)n1,CHEMBL3132747,=,=,IC50,nM,313.0,IC50,nM,313.0,CC(C)c1ccccc1Nc1nccc(-c2ccc(Br)cc2)n1,2014
Inhibition of human PI3Kgamma,COc1cccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)c1,CHEMBL3132747,=,=,IC50,nM,278.0,IC50,nM,278.0,COc1cccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)c1,2014
Inhibition of human PI3Kgamma,COc1cccc(Nc2nccc(-c3ccc(Br)cc3)n2)c1,CHEMBL3132747,=,=,IC50,nM,357.0,IC50,nM,357.0,COc1cccc(Nc2nccc(-c3ccc(Br)cc3)n2)c1,2014
Inhibition of human PI3Kgamma,Clc1ccc(Nc2nccc(-c3ccc(Br)cc3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,302.0,IC50,nM,302.0,Clc1ccc(Nc2nccc(-c3ccc(Br)cc3)n2)cc1,2014
Inhibition of human PI3Kgamma,Nc1nc(N)c2nc(-c3cccc(O)c3)cnc2n1,CHEMBL3132747,=,=,IC50,nM,127.0,IC50,nM,127.0,Nc1nc(N)c2nc(-c3cccc(O)c3)cnc2n1,2014
Inhibition of human PI3Kgamma,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(Cl)c(Cl)c3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,154.0,IC50,nM,154.0,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(Cl)c(Cl)c3)n2)cc1,2014
Inhibition of human PI3Kgamma,Clc1ccc(Nc2nccc(-c3ccc(Cl)c(Cl)c3)n2)c(Cl)c1,CHEMBL3132747,=,=,IC50,nM,250.0,IC50,nM,250.0,Clc1ccc(Nc2nccc(-c3ccc(Cl)c(Cl)c3)n2)c(Cl)c1,2014
Inhibition of human PI3Kgamma,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(Br)cc3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,265.0,IC50,nM,265.0,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(Br)cc3)n2)cc1,2014
Inhibition of human PI3Kgamma,Clc1ccc(Nc2nccc(-c3ccc(Br)cc3)n2)c(Cl)c1,CHEMBL3132747,=,=,IC50,nM,231.0,IC50,nM,231.0,Clc1ccc(Nc2nccc(-c3ccc(Br)cc3)n2)c(Cl)c1,2014
Inhibition of human PI3Kgamma,Clc1ccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)c(Cl)c1,CHEMBL3132747,=,=,IC50,nM,268.0,IC50,nM,268.0,Clc1ccc(Nc2nccc(-c3ccc(Cl)cc3Cl)n2)c(Cl)c1,2014
Inhibition of human PI3Kgamma,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(F)cc3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,247.0,IC50,nM,247.0,O=[N+]([O-])c1ccc(Nc2nccc(-c3ccc(F)cc3)n2)cc1,2014
Inhibition of human PI3Kgamma,Cc1ccc(-c2ccnc(Nc3ccc(Cl)cc3Cl)n2)cc1,CHEMBL3132747,=,=,IC50,nM,371.0,IC50,nM,371.0,Cc1ccc(-c2ccnc(Nc3ccc(Cl)cc3Cl)n2)cc1,2014
Inhibition of human PI3Kgamma,COc1cc(Nc2nccc(-c3ccc(Cl)cc3)n2)cc(OC)c1OC,CHEMBL3132747,<=,<=,IC50,nM,65.0,IC50,nM,65.0,COc1cc(Nc2nccc(-c3ccc(Cl)cc3)n2)cc(OC)c1OC,2014
Inhibition of human PI3Kgamma,Cc1cccc(Nc2nccc(-c3ccc(Br)cc3)n2)c1,CHEMBL3132747,=,=,IC50,nM,342.0,IC50,nM,342.0,Cc1cccc(Nc2nccc(-c3ccc(Br)cc3)n2)c1,2014
Inhibition of human PI3Kgamma,COc1ccc(-c2ccnc(Nc3cccc(OC)c3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,195.0,IC50,nM,195.0,COc1ccc(-c2ccnc(Nc3cccc(OC)c3)n2)cc1,2014
Inhibition of human PI3Kgamma,COc1cccc(Nc2nccc(-c3ccc(Cl)c(Cl)c3)n2)c1,CHEMBL3132747,=,=,IC50,nM,217.0,IC50,nM,217.0,COc1cccc(Nc2nccc(-c3ccc(Cl)c(Cl)c3)n2)c1,2014
Inhibition of human PI3Kgamma,COc1ccc(-c2ccnc(Nc3ccc(Cl)cc3Cl)n2)cc1,CHEMBL3132747,=,=,IC50,nM,235.0,IC50,nM,235.0,COc1ccc(-c2ccnc(Nc3ccc(Cl)cc3Cl)n2)cc1,2014
Inhibition of human PI3Kgamma,COc1ccc(-c2ccnc(Nc3ccc(Cl)cc3)n2)cc1,CHEMBL3132747,=,=,IC50,nM,167.0,IC50,nM,167.0,COc1ccc(-c2ccnc(Nc3ccc(Cl)cc3)n2)cc1,2014
Inhibition of PI3Kgamma (unknown origin),CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,CHEMBL3217752,=,=,IC50,nM,5.4,IC50,uM,0.0054,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,2012
Inhibition of PI3Kgamma (unknown origin) by lipid kinase assay,O=C1NC(=O)/C(=C/c2ccc3nccnc3c2)S1,CHEMBL3217752,=,=,IC50,nM,8.0,IC50,uM,0.008,O=C1NC(=O)/C(=C/c2ccc3nccnc3c2)S1,2012
Inhibition of PI3Kgamma (unknown origin),Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL3217752,=,=,IC50,nM,14.0,IC50,uM,0.014,Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2012
Inhibition of PI3Kgamma (unknown origin),CC(=O)/N=c1/[nH]c(C)c(-c2ccc(Cl)c(S(=O)(=O)NCCO)c2)s1,CHEMBL3217752,=,=,IC50,nM,16.0,IC50,uM,0.016,CC(=O)/N=c1/[nH]c(C)c(-c2ccc(Cl)c(S(=O)(=O)NCCO)c2)s1,2012
Inhibition of PI3Kgamma (unknown origin) by lipid kinase assay,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1,CHEMBL3217752,=,=,IC50,nM,30.0,IC50,uM,0.03,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1,2012
Inhibition of PI3Kgamma (unknown origin),CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21,CHEMBL3217752,=,=,IC50,nM,43.0,IC50,uM,0.043,CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21,2012
Inhibition of PI3Kgamma (unknown origin),O=C1NC(=S)S/C1=C/c1ccc2c(c1)N(Cc1ccc(F)c(Cl)c1)C(=O)CO2,CHEMBL3217752,=,=,IC50,nM,54.0,IC50,uM,0.054,O=C1NC(=S)S/C1=C/c1ccc2c(c1)N(Cc1ccc(F)c(Cl)c1)C(=O)CO2,2012
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC,CHEMBL3217752,=,=,IC50,nM,72.0,IC50,uM,0.072,COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC,2012
Inhibition of PI3Kgamma (unknown origin),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL3217752,=,=,IC50,nM,89.0,IC50,uM,0.089,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2012
Inhibition of PI3Kgamma (unknown origin),COc1ccc2c(c1OC)N=C(NC(=O)c1cccnc1)N1CCN=C21,CHEMBL3217752,=,=,IC50,nM,180.0,IC50,uM,0.18,COc1ccc2c(c1OC)N=C(NC(=O)c1cccnc1)N1CCN=C21,2012
Inhibition of PI3Kgamma (unknown origin) by lipid kinase assay,O=C1NC(=O)/C(=C\c2ccc3c(c2)OC(F)(F)O3)S1,CHEMBL3217752,=,=,IC50,nM,250.0,IC50,uM,0.25,O=C1NC(=O)/C(=C\c2ccc3c(c2)OC(F)(F)O3)S1,2012
Inhibition of PI3Kgamma (unknown origin),Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,CHEMBL3217752,=,=,IC50,nM,570.0,IC50,uM,0.57,Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,2012
Inhibition of PI3Kgamma (unknown origin),Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1,CHEMBL3217752,=,=,IC50,nM,1100.0,IC50,uM,1.1,Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1,2012
Inhibition of PI3Kgamma (unknown origin),CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21,CHEMBL3217752,=,=,IC50,nM,1500.0,IC50,uM,1.5,CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21,2012
Inhibition of PI3Kgamma (unknown origin),N=C(N)NCCCC(NC(=O)CCC(=O)OC[N+]1(c2cc(=O)c3cccc(-c4ccccc4)c3o2)CCOCC1)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)[O-],CHEMBL3217752,=,=,IC50,nM,1774.0,IC50,uM,1.774,N=C(N)NCCCC(NC(=O)CCC(=O)OC[N+]1(c2cc(=O)c3cccc(-c4ccccc4)c3o2)CCOCC1)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)[O-],2012
Inhibition of PI3Kgamma (unknown origin),Cc1cc(C(C)Nc2ccccc2)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3217752,=,=,IC50,nM,4100.0,IC50,uM,4.1,Cc1cc(C(C)Nc2ccccc2)c2oc(N3CCOCC3)cc(=O)c2c1,2012
Inhibition of PI3Kgamma (unknown origin),Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL3217752,=,=,IC50,nM,5.0,IC50,nM,5.0,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2012
Inhibition of PI3Kgamma (unknown origin),COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1,CHEMBL3217752,=,=,IC50,nM,9.0,IC50,nM,9.0,COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1,2012
Inhibition of PI3Kgamma (unknown origin),Cc1cc(C(C)Nc2ccccc2)c2oc(-c3ccncc3)cc(=O)c2c1,CHEMBL3217752,=,=,IC50,nM,10000.0,IC50,uM,10.0,Cc1cc(C(C)Nc2ccccc2)c2oc(-c3ccncc3)cc(=O)c2c1,2012
Inhibition of PI3Kgamma (unknown origin) by lipid kinase assay,CN1CCOc2cc(/C=C3\SC(=O)NC3=O)ccc21,CHEMBL3217752,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN1CCOc2cc(/C=C3\SC(=O)NC3=O)ccc21,2012
Inhibition of PI3Kgamma (unknown origin),Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1,CHEMBL3217752,=,=,IC50,nM,23.0,IC50,nM,23.0,Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1,2012
Inhibition of PI3Kgamma (unknown origin),Cc1ccccc1-n1c(Cn2cnc3c(N)ncnc32)nc2cccc(C)c2c1=O,CHEMBL3217752,=,=,IC50,nM,29000.0,IC50,uM,29.0,Cc1ccccc1-n1c(Cn2cnc3c(N)ncnc32)nc2cccc(C)c2c1=O,2012
Inhibition of PI3Kgamma (unknown origin),O=Cc1ccc(N2CCOCC2)cc1O,CHEMBL3217752,=,=,IC50,nM,37000.0,IC50,uM,37.0,O=Cc1ccc(N2CCOCC2)cc1O,2012
Inhibition of PI3Kgamma (unknown origin),FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL3217752,=,=,IC50,nM,49.0,IC50,nM,49.0,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2012
Inhibition of PI3Kgamma (unknown origin),O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O,CHEMBL3217752,=,=,IC50,nM,100000.0,IC50,uM,100.0,O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O,2012
Inhibition of PI3Kgamma (unknown origin),Cc1cc(Oc2ccccc2C)c2[nH]c(N3CCOCC3)cc(=O)c2c1,CHEMBL3217752,=,=,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(Oc2ccccc2C)c2[nH]c(N3CCOCC3)cc(=O)c2c1,2012
Inhibition of PI3Kgamma (unknown origin),Cc1cc(NCc2ccccc2C)c2nc(N3CCOCC3)cc(=O)n2c1,CHEMBL3217752,=,=,IC50,nM,100000.0,IC50,uM,100.0,Cc1cc(NCc2ccccc2C)c2nc(N3CCOCC3)cc(=O)n2c1,2012
Inhibition of PI3Kgamma (unknown origin),Cn1c(=O)c2[nH]cnc2n(C)c1=O,CHEMBL3217752,=,=,IC50,nM,800000.0,IC50,uM,800.0,Cn1c(=O)c2[nH]cnc2n(C)c1=O,2012
Inhibition of PI3Kgamma (unknown origin),Cn1c(=O)c2c(ncn2C)n(C)c1=O,CHEMBL3217752,=,=,IC50,nM,1000000.0,IC50,uM,1000.0,Cn1c(=O)c2c(ncn2C)n(C)c1=O,2012
Inhibition of PI3Kgamma (unknown origin),CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL3217752,=,=,IC50,nM,75.0,IC50,uM,0.075,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2012
Inhibition of PI3Kgamma (unknown origin),CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21,CHEMBL3217752,=,=,IC50,nM,36.0,IC50,uM,0.036,CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21,2012
Inhibition of PIK3CG (unknown origin) at 5 uM,Clc1nc(Cl)c2sccc2n1,CHEMBL3232736,<,<,Inhibition,%,40.0,INH,%,40.0,Clc1nc(Cl)c2sccc2n1,2014
"Inhibition of human PI3K-gamma assessed as inhibition of Ptdlns(3,4,5)P3 phosphorylation after 1 hr by TR-FRET analysis",Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL3286093,=,=,IC50,nM,100.0,IC50,uM,0.1,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2014
"Inhibition of human PI3K-gamma assessed as inhibition of Ptdlns(3,4,5)P3 phosphorylation after 1 hr by TR-FRET analysis",Cn1cc(-c2ccc3ncc4c(c3c2)n(-c2ccc(C(C)(C)C#N)cc2)c(=O)n4C)cn1,CHEMBL3286093,=,=,IC50,nM,126.0,IC50,uM,0.126,Cn1cc(-c2ccc3ncc4c(c3c2)n(-c2ccc(C(C)(C)C#N)cc2)c(=O)n4C)cn1,2014
"Inhibition of human PI3K-gamma assessed as inhibition of Ptdlns(3,4,5)P3 phosphorylation after 1 hr by TR-FRET analysis",Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3ccccc3ncc21,CHEMBL3286093,=,=,IC50,nM,1995.0,IC50,uM,1.995,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3ccccc3ncc21,2014
"Inhibition of human PI3K-gamma assessed as inhibition of Ptdlns(3,4,5)P3 phosphorylation after 1 hr by TR-FRET analysis",Cc1ccc(-n2c(=O)n(C)c3cnc4ccc(-c5ccncc5)cc4c32)cc1,CHEMBL3286093,=,=,IC50,nM,251.0,IC50,uM,0.251,Cc1ccc(-n2c(=O)n(C)c3cnc4ccc(-c5ccncc5)cc4c32)cc1,2014
"Inhibition of human PI3K-gamma assessed as inhibition of Ptdlns(3,4,5)P3 phosphorylation after 1 hr by TR-FRET analysis",COc1ccc(-n2c(=O)n(C)c3cnc4ccc(-c5ccncc5)cc4c32)cc1,CHEMBL3286093,=,=,IC50,nM,316.0,IC50,uM,0.316,COc1ccc(-n2c(=O)n(C)c3cnc4ccc(-c5ccncc5)cc4c32)cc1,2014
Inhibition of human PI3KCgamma by non-radiometric ADP-Glo assay,CC(=O)/N=c1/[nH]c(C)c(-c2ccc(Cl)c(S(=O)(=O)NCCO)c2)s1,CHEMBL3352433,=,=,IC50,nM,16.0,IC50,uM,0.016,CC(=O)/N=c1/[nH]c(C)c(-c2ccc(Cl)c(S(=O)(=O)NCCO)c2)s1,2015
Inhibition of PI3Kgamma (unknown origin) assessed as PI3Kalpha-mediated Akt1/2 (S473) phosphorylation rate by cellular assay,N#Cc1c(N)ncnc1N1CSC[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3351852,=,=,IC50,nM,129.0,IC50,uM,0.129,N#Cc1c(N)ncnc1N1CSC[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) by TR-FRET assay,N#Cc1c(N)ncnc1N1CSC[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3351852,=,=,IC50,nM,129.0,IC50,uM,0.129,N#Cc1c(N)ncnc1N1CSC[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) assessed as PI3Kalpha-mediated Akt1/2 (S473) phosphorylation rate by cellular assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1,CHEMBL3351852,=,=,IC50,nM,150.0,IC50,uM,0.15,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1,2015
Inhibition of PI3Kgamma (unknown origin) by TR-FRET assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1N1CCOCC1,CHEMBL3351852,=,=,IC50,nM,200.0,IC50,uM,0.2,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1N1CCOCC1,2015
Inhibition of PI3Kgamma (unknown origin) by TR-FRET assay,N#Cc1cnc(N)nc1N1CCC[C@H]1c1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccccc1,CHEMBL3351852,=,=,IC50,nM,230.0,IC50,uM,0.23,N#Cc1cnc(N)nc1N1CCC[C@H]1c1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) by TR-FRET assay,COc1cccc2nc([C@@H]3CCCN3c3ncnc(N)c3C#N)n(-c3ccccc3)c(=O)c12,CHEMBL3351852,=,=,IC50,nM,5200.0,IC50,uM,5.2,COc1cccc2nc([C@@H]3CCCN3c3ncnc(N)c3C#N)n(-c3ccccc3)c(=O)c12,2015
Inhibition of PI3Kgamma (unknown origin) assessed as PI3Kalpha-mediated Akt1/2 (S473) phosphorylation rate by cellular assay,COc1cccc2nc([C@@H]3CCCN3c3ncnc(N)c3C#N)n(-c3ccccc3)c(=O)c12,CHEMBL3351852,=,=,IC50,nM,5200.0,IC50,uM,5.2,COc1cccc2nc([C@@H]3CCCN3c3ncnc(N)c3C#N)n(-c3ccccc3)c(=O)c12,2015
Inhibition of PI3Kgamma (unknown origin) by TR-FRET assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1,CHEMBL3351852,=,=,IC50,nM,150.0,IC50,uM,0.15,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1,2015
Inhibition of PI3Kgamma (unknown origin) by TR-FRET assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cc(F)cc(F)c2c(=O)n1-c1ccccc1,CHEMBL3351852,>,>,IC50,nM,10000.0,IC50,uM,10.0,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cc(F)cc(F)c2c(=O)n1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) by TR-FRET assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccccc1,CHEMBL3351852,=,=,IC50,nM,140.0,IC50,uM,0.14,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) by TR-FRET assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1C1CCOCC1,CHEMBL3351852,=,=,IC50,nM,280.0,IC50,uM,0.28,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1C1CCOCC1,2015
Inhibition of PI3Kgamma (unknown origin) by TR-FRET assay,Cn1cnc2c(N3CCC[C@H]3c3nc4cccc(Cl)c4c(=O)n3-c3ccccc3)nc(N)nc21,CHEMBL3351852,=,=,IC50,nM,305.0,IC50,uM,0.305,Cn1cnc2c(N3CCC[C@H]3c3nc4cccc(Cl)c4c(=O)n3-c3ccccc3)nc(N)nc21,2015
Inhibition of PI3Kgamma (unknown origin) assessed as PI3Kalpha-mediated Akt1/2 (S473) phosphorylation rate by cellular assay,Cn1cnc2c(N3CCC[C@H]3c3nc4cccc(Cl)c4c(=O)n3-c3ccccc3)nc(N)nc21,CHEMBL3351852,=,=,IC50,nM,305.0,IC50,uM,0.305,Cn1cnc2c(N3CCC[C@H]3c3nc4cccc(Cl)c4c(=O)n3-c3ccccc3)nc(N)nc21,2015
Inhibition of PI3Kgamma (unknown origin) by TR-FRET assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3351852,=,=,IC50,nM,24.0,IC50,uM,0.024,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) assessed as PI3Kalpha-mediated Akt1/2 (S473) phosphorylation rate by cellular assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3351852,=,=,IC50,nM,24.0,IC50,uM,0.024,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) assessed as PI3Kalpha-mediated Akt1/2 (S473) phosphorylation rate by cellular assay,N#Cc1cnc(N)nc1N1CCC[C@H]1c1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccccc1,CHEMBL3351852,=,=,IC50,nM,230.0,IC50,uM,0.23,N#Cc1cnc(N)nc1N1CCC[C@H]1c1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) by TR-FRET assay,Cc1ccccc1-n1c([C@@H]2CCCN2c2ncnc(N)c2C#N)nc2cccc(Cl)c2c1=O,CHEMBL3351852,=,=,IC50,nM,70.0,IC50,uM,0.07,Cc1ccccc1-n1c([C@@H]2CCCN2c2ncnc(N)c2C#N)nc2cccc(Cl)c2c1=O,2015
Inhibition of PI3Kgamma (unknown origin) assessed as PI3Kalpha-mediated Akt1/2 (S473) phosphorylation rate by cellular assay,Cc1ccccc1-n1c([C@@H]2CCCN2c2ncnc(N)c2C#N)nc2cccc(Cl)c2c1=O,CHEMBL3351852,=,=,IC50,nM,70.0,IC50,uM,0.07,Cc1ccccc1-n1c([C@@H]2CCCN2c2ncnc(N)c2C#N)nc2cccc(Cl)c2c1=O,2015
Inhibition of PI3Kgamma (unknown origin) assessed as PI3Kalpha-mediated Akt1/2 (S473) phosphorylation rate by cellular assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cc(F)cc(F)c2c(=O)n1-c1ccccc1,CHEMBL3351852,>,>,IC50,nM,10000.0,IC50,uM,10.0,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cc(F)cc(F)c2c(=O)n1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) assessed as PI3Kalpha-mediated Akt1/2 (S473) phosphorylation rate by cellular assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccccc1,CHEMBL3351852,=,=,IC50,nM,140.0,IC50,uM,0.14,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) assessed as PI3Kalpha-mediated Akt1/2 (S473) phosphorylation rate by cellular assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1C1CCOCC1,CHEMBL3351852,=,=,IC50,nM,280.0,IC50,uM,0.28,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1C1CCOCC1,2015
Inhibition of PI3Kgamma (unknown origin) assessed as PI3Kalpha-mediated Akt1/2 (S473) phosphorylation rate by cellular assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1N1CCOCC1,CHEMBL3351852,=,=,IC50,nM,200.0,IC50,uM,0.2,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(Cl)c2c(=O)n1N1CCOCC1,2015
Inhibition of PI3Kgamma (unknown origin) by TR-FRET assay,CO[C@H]1C[C@@H](c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)N(c2ncnc(N)c2C#N)C1,CHEMBL3351852,=,=,IC50,nM,35.0,IC50,uM,0.035,CO[C@H]1C[C@@H](c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)N(c2ncnc(N)c2C#N)C1,2015
Inhibition of PI3Kgamma (unknown origin) assessed as PI3Kalpha-mediated Akt1/2 (S473) phosphorylation rate by cellular assay,CO[C@H]1C[C@@H](c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)N(c2ncnc(N)c2C#N)C1,CHEMBL3351852,=,=,IC50,nM,35.0,IC50,uM,0.035,CO[C@H]1C[C@@H](c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)N(c2ncnc(N)c2C#N)C1,2015
Inhibition of PI3Kgamma (unknown origin) at <8 uM,C[C@@H]1COCCN1c1nc(-c2cncc3[nH]ccc23)cc2c1ncn2[C@@H](C)S(C)(=O)=O,CHEMBL3352352,,,Inhibition,%,,INH,,,C[C@@H]1COCCN1c1nc(-c2cncc3[nH]ccc23)cc2c1ncn2[C@@H](C)S(C)(=O)=O,2015
Inhibition of human recombinant PI3Kgamma assessed as PIP3 production by AlphaScreen assay,Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1,CHEMBL3352617,=,=,IC50,nM,1090.0,IC50,uM,1.09,Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1,2014
Inhibition of human recombinant PI3Kgamma assessed as PIP3 production by AlphaScreen assay,C[C@@H](Oc1ccccc1)c1cc(C(=O)N(C)CCO)cn2c(=O)cc(N3CCOCC3)nc12,CHEMBL3352617,=,=,IC50,nM,83000.0,IC50,uM,83.0,C[C@@H](Oc1ccccc1)c1cc(C(=O)N(C)CCO)cn2c(=O)cc(N3CCOCC3)nc12,2014
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,COc1cncc(-c2ccc3nc(NC(=O)NCCOc4ccccc4)sc3c2)c1,CHEMBL3351310,=,=,Ki,nM,19.0,Ki,uM,0.019,COc1cncc(-c2ccc3nc(NC(=O)NCCOc4ccccc4)sc3c2)c1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,COc1cncc(-c2ccc3nc(NC(=O)NCCc4cncn4C)sc3c2)c1,CHEMBL3351310,=,=,Ki,nM,22.0,Ki,uM,0.022,COc1cncc(-c2ccc3nc(NC(=O)NCCc4cncn4C)sc3c2)c1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,CCCn1cnc(CCNC(=O)Nc2nc3ccc(-c4cncc(OC)c4)cc3s2)c1,CHEMBL3351310,=,=,Ki,nM,2.0,Ki,uM,0.002,CCCn1cnc(CCNC(=O)Nc2nc3ccc(-c4cncc(OC)c4)cc3s2)c1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,CCn1cnc(CCNC(=O)Nc2nc3ccc(-c4cncc(OC)c4)cc3s2)c1,CHEMBL3351310,=,=,Ki,nM,2.0,Ki,uM,0.002,CCn1cnc(CCNC(=O)Nc2nc3ccc(-c4cncc(OC)c4)cc3s2)c1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,COc1cncc(-c2ccc3nc(NC(=O)NCCc4cn(C)cn4)sc3c2)c1,CHEMBL3351310,=,=,Ki,nM,7.0,Ki,uM,0.007,COc1cncc(-c2ccc3nc(NC(=O)NCCc4cn(C)cn4)sc3c2)c1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,COc1cncc(-c2ccc3nc(NC(=O)NCCc4c[nH]cn4)sc3c2)c1,CHEMBL3351310,=,=,Ki,nM,5.0,Ki,uM,0.005,COc1cncc(-c2ccc3nc(NC(=O)NCCc4c[nH]cn4)sc3c2)c1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,COc1cncc(-c2ccc3nc(NC(=O)NCCC(=O)NCC(F)(F)F)sc3c2)c1,CHEMBL3351310,=,=,Ki,nM,1.0,Ki,uM,0.001,COc1cncc(-c2ccc3nc(NC(=O)NCCC(=O)NCC(F)(F)F)sc3c2)c1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,COc1cncc(-c2ccc3nc(NC(=O)NCC(=O)NCC(F)(F)F)sc3c2)c1,CHEMBL3351310,=,=,Ki,nM,6.0,Ki,uM,0.006,COc1cncc(-c2ccc3nc(NC(=O)NCC(=O)NCC(F)(F)F)sc3c2)c1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,COc1cncc(-c2ccc3nc(NC(=O)NCCCN(C)C)sc3c2)c1,CHEMBL3351310,=,=,Ki,nM,190.0,Ki,uM,0.19,COc1cncc(-c2ccc3nc(NC(=O)NCCCN(C)C)sc3c2)c1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,CCNC(=O)Nc1nc2ccc(-c3cncc(OC)c3)cc2s1,CHEMBL3351310,=,=,Ki,nM,7.0,Ki,uM,0.007,CCNC(=O)Nc1nc2ccc(-c3cncc(OC)c3)cc2s1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,COc1cncc(-c2ccc3nc(NC(=O)N(C)C)sc3c2)c1,CHEMBL3351310,=,=,Ki,nM,9.0,Ki,uM,0.009,COc1cncc(-c2ccc3nc(NC(=O)N(C)C)sc3c2)c1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,CC(=O)Nc1nc2ccc(-c3cnc4nccnc4c3)cc2s1,CHEMBL3351310,=,=,Ki,nM,21.0,Ki,uM,0.021,CC(=O)Nc1nc2ccc(-c3cnc4nccnc4c3)cc2s1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,COc1cc(-c2ccc3nc(NC(C)=O)sc3c2)cnc1N,CHEMBL3351310,=,=,Ki,nM,13.0,Ki,uM,0.013,COc1cc(-c2ccc3nc(NC(C)=O)sc3c2)cnc1N,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,CCc1ncc(-c2ccc3nc(NC(C)=O)sc3c2)cc1OC,CHEMBL3351310,=,=,Ki,nM,19.0,Ki,uM,0.019,CCc1ncc(-c2ccc3nc(NC(C)=O)sc3c2)cc1OC,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,COc1cc(-c2ccc3nc(NC(C)=O)sc3c2)cnc1OC,CHEMBL3351310,=,=,Ki,nM,1.0,Ki,uM,0.001,COc1cc(-c2ccc3nc(NC(C)=O)sc3c2)cnc1OC,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,COc1ccc(-c2ccc3nc(NC(C)=O)sc3c2)cn1,CHEMBL3351310,=,=,Ki,nM,36.0,Ki,uM,0.036,COc1ccc(-c2ccc3nc(NC(C)=O)sc3c2)cn1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,CC(=O)Nc1nc2ccc(-c3cncc(C#N)c3)cc2s1,CHEMBL3351310,=,=,Ki,nM,44.0,Ki,uM,0.044,CC(=O)Nc1nc2ccc(-c3cncc(C#N)c3)cc2s1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,CC(=O)Nc1nc2ccc(-c3cncc(F)c3)cc2s1,CHEMBL3351310,=,=,Ki,nM,36.0,Ki,uM,0.036,CC(=O)Nc1nc2ccc(-c3cncc(F)c3)cc2s1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,CCOc1cncc(-c2ccc3nc(NC(C)=O)sc3c2)c1,CHEMBL3351310,=,=,Ki,nM,6.0,Ki,uM,0.006,CCOc1cncc(-c2ccc3nc(NC(C)=O)sc3c2)c1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,COc1cncc(-c2ccc3nc(NC(C)=O)sc3c2)c1,CHEMBL3351310,=,=,Ki,nM,4.0,Ki,uM,0.004,COc1cncc(-c2ccc3nc(NC(C)=O)sc3c2)c1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,CC(=O)Nc1nc2ccc(-c3cncc(C)c3)cc2s1,CHEMBL3351310,=,=,Ki,nM,13.0,Ki,uM,0.013,CC(=O)Nc1nc2ccc(-c3cncc(C)c3)cc2s1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,CC(=O)Nc1nc2ccc(-c3cccnc3)cc2s1,CHEMBL3351310,=,=,Ki,nM,39.0,Ki,uM,0.039,CC(=O)Nc1nc2ccc(-c3cccnc3)cc2s1,2015
Inhibition of PI3K-gamma (unknown origin) using [33P]ATP as substrate after 15 mins by liquid scintillation counting analysis,CC(=O)Nc1nc2ccc(-c3ccccc3)cc2s1,CHEMBL3351310,=,=,Ki,nM,770.0,Ki,uM,0.77,CC(=O)Nc1nc2ccc(-c3ccccc3)cc2s1,2015
Inhibition of PI3K-gamma (unknown origin),CC(=O)/N=c1/[nH]c(C)c(-c2ccc(Cl)c(S(=O)(=O)NCCO)c2)s1,CHEMBL3351310,=,=,Ki,nM,7.0,Ki,nM,7.0,CC(=O)/N=c1/[nH]c(C)c(-c2ccc(Cl)c(S(=O)(=O)NCCO)c2)s1,2015
Inhibition of PI3K-G (unknown origin) at 100 nM,O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1,CHEMBL3297705,=,=,Inhibition,%,7.0,INH,%,7.0,O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1,2014
Inhibition of human PI3K gamma by TR-FRET/summary (Abse5) assay,COc1ccc(S(=O)(=O)Nc2c(C)cc(C)cc2C)cc1,CHEMBL3351646,<,>,IC50,nM,25118.86,pIC50,,4.6,COc1ccc(S(=O)(=O)Nc2c(C)cc(C)cc2C)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1cc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc(OC)c1,CHEMBL3351785,=,=,IC50,nM,11.8,IC50,uM,0.0118,COc1cc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc(OC)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cc1cc(C)cc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,CHEMBL3351785,=,=,IC50,nM,11.2,IC50,uM,0.0112,Cc1cc(C)cc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccccc1)C(=O)CO2,CHEMBL3351785,=,=,IC50,nM,103.4,IC50,uM,0.1034,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccccc1)C(=O)CO2,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,CC(C)(C)c1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,CHEMBL3351785,=,=,IC50,nM,10.2,IC50,uM,0.0102,CC(C)(C)c1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cc1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1C,CHEMBL3351785,=,=,IC50,nM,11.0,IC50,uM,0.011,Cc1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1C,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cc1cccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,CHEMBL3351785,=,=,IC50,nM,184.5,IC50,uM,0.1845,Cc1cccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(Cc1ccc(C(F)(F)F)cc1)C(=O)CO2,CHEMBL3351785,=,=,IC50,nM,116.0,IC50,uM,0.116,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(Cc1ccc(C(F)(F)F)cc1)C(=O)CO2,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,N#Cc1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,CHEMBL3351785,=,=,IC50,nM,152.4,IC50,uM,0.1524,N#Cc1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(Cc1ccc(Cl)cc1)C(=O)CO2,CHEMBL3351785,=,=,IC50,nM,30.0,IC50,uM,0.03,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(Cc1ccc(Cl)cc1)C(=O)CO2,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cc1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,CHEMBL3351785,=,=,IC50,nM,124.0,IC50,uM,0.124,Cc1ccc(CN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(Cc1ccccc1)C(=O)CO2,CHEMBL3351785,=,=,IC50,nM,97.0,IC50,uM,0.097,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(Cc1ccccc1)C(=O)CO2,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cn1c(=O)c2c(ncn2C)n(C)c1=O,CHEMBL3351785,=,=,IC50,nM,3630000.0,IC50,uM,3630.0,Cn1c(=O)c2c(ncn2C)n(C)c1=O,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cn1c(=O)c2[nH]cnc2n(C)c1=O,CHEMBL3351785,=,=,IC50,nM,2904000.0,IC50,uM,2904.0,Cn1c(=O)c2[nH]cnc2n(C)c1=O,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cc1cc(F)ccc1Oc1cccc2c(=O)cc(N3CCOCC3)[nH]c12,CHEMBL3351785,=,=,IC50,nM,18150.0,IC50,uM,18.15,Cc1cc(F)ccc1Oc1cccc2c(=O)cc(N3CCOCC3)[nH]c12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1cc(N2CCOCC2)[nH]c2c(Oc3ccccc3F)cccc12,CHEMBL3351785,=,=,IC50,nM,7260.0,IC50,uM,7.26,O=c1cc(N2CCOCC2)[nH]c2c(Oc3ccccc3F)cccc12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1ccccc1CNc1cc(C)cc2c(=O)cc(N3CCOCC3)[nH]c12,CHEMBL3351785,=,=,IC50,nM,10710.0,IC50,uM,10.71,COc1ccccc1CNc1cc(C)cc2c(=O)cc(N3CCOCC3)[nH]c12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1cc(N2CCOCC2)[nH]c2c(Oc3ccc(F)cc3)cccc12,CHEMBL3351785,=,=,IC50,nM,18150.0,IC50,uM,18.15,O=c1cc(N2CCOCC2)[nH]c2c(Oc3ccc(F)cc3)cccc12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1cc(N2CCOCC2)[nH]c2c(Cc3ccccc3)cccc12,CHEMBL3351785,=,=,IC50,nM,10890.0,IC50,uM,10.89,O=c1cc(N2CCOCC2)[nH]c2c(Cc3ccccc3)cccc12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1cc(N2CCOCC2)[nH]c2c(OCc3ccccc3)cccc12,CHEMBL3351785,=,=,IC50,nM,10890.0,IC50,uM,10.89,O=c1cc(N2CCOCC2)[nH]c2c(OCc3ccccc3)cccc12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL3351785,=,=,IC50,nM,7260.0,IC50,uM,7.26,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1c(O)c(-c2cc(O)c(O)c(O)c2)oc2cc(O)cc(O)c12,CHEMBL3351785,=,=,IC50,nM,4720.0,IC50,uM,4.72,O=c1c(O)c(-c2cc(O)c(O)c(O)c2)oc2cc(O)cc(O)c12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,CHEMBL3351785,=,=,IC50,nM,13790.0,IC50,uM,13.79,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1c2ccccc2nc(CSc2ncnc3[nH]cnc23)n1N1CCOCC1,CHEMBL3351785,=,=,IC50,nM,137900.0,IC50,uM,137.9,O=c1c2ccccc2nc(CSc2ncnc3[nH]cnc23)n1N1CCOCC1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,CCCCn1c(CSc2ncnc3[nH]cnc23)nc2ccccc2c1=O,CHEMBL3351785,=,=,IC50,nM,217800.0,IC50,uM,217.8,CCCCn1c(CSc2ncnc3[nH]cnc23)nc2ccccc2c1=O,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1ccccc1-n1c(CSc2ncnc3[nH]cnc23)nc2cccc(C)c2c1=O,CHEMBL3351785,=,=,IC50,nM,1820.0,IC50,uM,1.82,COc1ccccc1-n1c(CSc2ncnc3[nH]cnc23)nc2cccc(C)c2c1=O,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cc1cccc2nc(CSc3ncnc4[nH]cnc34)n(-c3ccccc3Cl)c(=O)c12,CHEMBL3351785,=,=,IC50,nM,6170.0,IC50,uM,6.17,Cc1cccc2nc(CSc3ncnc4[nH]cnc34)n(-c3ccccc3Cl)c(=O)c12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1c2c(Cl)cccc2nc(CSc2ncnc3[nH]cnc23)n1-c1ccccc1Cl,CHEMBL3351785,=,=,IC50,nM,5450.0,IC50,uM,5.45,O=c1c2c(Cl)cccc2nc(CSc2ncnc3[nH]cnc23)n1-c1ccccc1Cl,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1c2ccc(F)cc2nc(CSc2ncnc3[nH]cnc23)n1-c1ccccc1Cl,CHEMBL3351785,=,=,IC50,nM,145200.0,IC50,uM,145.2,O=c1c2ccc(F)cc2nc(CSc2ncnc3[nH]cnc23)n1-c1ccccc1Cl,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1c2c(F)cccc2nc(CSc2ncnc3[nH]cnc23)n1-c1ccccc1Cl,CHEMBL3351785,=,=,IC50,nM,13070.0,IC50,uM,13.07,O=c1c2c(F)cccc2nc(CSc2ncnc3[nH]cnc23)n1-c1ccccc1Cl,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1ccccc1-n1c(CSc2ncnc3[nH]cnc23)nc2cccc(Cl)c2c1=O,CHEMBL3351785,=,=,IC50,nM,2030.0,IC50,uM,2.03,COc1ccccc1-n1c(CSc2ncnc3[nH]cnc23)nc2cccc(Cl)c2c1=O,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1c2c(Cl)cccc2nc(CSc2ncnc3[nH]cnc23)n1-c1ccccc1-c1ccccc1,CHEMBL3351785,=,=,IC50,nM,7620.0,IC50,uM,7.62,O=c1c2c(Cl)cccc2nc(CSc2ncnc3[nH]cnc23)n1-c1ccccc1-c1ccccc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1c2c(Cl)cccc2nc(CSc2ncnc3[nH]cnc23)n1-c1ccccc1F,CHEMBL3351785,=,=,IC50,nM,3630.0,IC50,uM,3.63,O=c1c2c(Cl)cccc2nc(CSc2ncnc3[nH]cnc23)n1-c1ccccc1F,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cc1ccccc1-n1c(CSc2ncnc3[nH]cnc23)nc2cccc(Cl)c2c1=O,CHEMBL3351785,=,=,IC50,nM,2540.0,IC50,uM,2.54,Cc1ccccc1-n1c(CSc2ncnc3[nH]cnc23)nc2cccc(Cl)c2c1=O,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=c1c2ccccc2nc(CSc2[nH]cnc3ncnc2-3)n1-c1ccccc1Cl,CHEMBL3351785,=,=,IC50,nM,27950.0,IC50,uM,27.95,O=c1c2ccccc2nc(CSc2[nH]cnc3ncnc2-3)n1-c1ccccc1Cl,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=C(O)Cc1ccc(OCCCCCOc2ccc(CC(=O)O)cc2)cc1,CHEMBL3351785,=,=,Inhibition,%,7.0,INH,%,7.0,O=C(O)Cc1ccc(OCCCCCOc2ccc(CC(=O)O)cc2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,CCCC(NC(=O)OCc1ccccc1)C(=O)NC(Cc1ccc(O)cc1)C(=O)O,CHEMBL3351785,=,=,Inhibition,%,10.0,INH,%,10.0,CCCC(NC(=O)OCc1ccccc1)C(=O)NC(Cc1ccc(O)cc1)C(=O)O,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=S(=O)(O)c1ccc(OCCCCCCCCCCOc2ccc(S(=O)(=O)O)cc2)cc1,CHEMBL3351785,=,=,Inhibition,%,11.0,INH,%,11.0,O=S(=O)(O)c1ccc(OCCCCCCCCCCOc2ccc(S(=O)(=O)O)cc2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,COc1ccccc1/N=N/c1c(O)ccc2cc(S(=O)(=O)O)ccc12,CHEMBL3351785,=,=,Inhibition,%,19.0,INH,%,19.0,COc1ccccc1/N=N/c1c(O)ccc2cc(S(=O)(=O)O)ccc12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,CCCCOc1ccc(CCC(=O)O)cc1OCCCC,CHEMBL3351785,=,=,Inhibition,%,20.0,INH,%,20.0,CCCCOc1ccc(CCC(=O)O)cc1OCCCC,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=C(O)Cc1ccc(OCCCOc2ccc(CC(=O)O)cc2)cc1,CHEMBL3351785,=,=,Inhibition,%,24.0,INH,%,24.0,O=C(O)Cc1ccc(OCCCOc2ccc(CC(=O)O)cc2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,CSCCC(NCc1c(O)ccc2c(-c3ccccc3)cc(=O)oc12)C(=O)O,CHEMBL3351785,=,=,Inhibition,%,27.0,INH,%,27.0,CSCCC(NCc1c(O)ccc2c(-c3ccccc3)cc(=O)oc12)C(=O)O,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=S(=O)(O)c1cc(O)c2ccc(Nc3ccc4c(O)cc(S(=O)(=O)O)cc4c3)cc2c1,CHEMBL3351785,=,=,Inhibition,%,31.0,INH,%,31.0,O=S(=O)(O)c1cc(O)c2ccc(Nc3ccc4c(O)cc(S(=O)(=O)O)cc4c3)cc2c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=C(NC(Cc1ccc(O)cc1)C(=O)O)C(=O)c1c[nH]c2ccc([N+](=O)[O-])cc12,CHEMBL3351785,=,=,Inhibition,%,34.0,INH,%,34.0,O=C(NC(Cc1ccc(O)cc1)C(=O)O)C(=O)c1c[nH]c2ccc([N+](=O)[O-])cc12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=C(NC(Cc1ccccc1)C(=O)NC(Cc1ccc(O)cc1)C(=O)O)OCc1ccccc1,CHEMBL3351785,=,=,Inhibition,%,34.0,INH,%,34.0,O=C(NC(Cc1ccccc1)C(=O)NC(Cc1ccc(O)cc1)C(=O)O)OCc1ccccc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=C(CCCCn1cnc2c(SCc3ccccc3)ncnc21)Nc1ccc(C(=O)O)c(O)c1,CHEMBL3351785,=,=,Inhibition,%,37.0,INH,%,37.0,O=C(CCCCn1cnc2c(SCc3ccccc3)ncnc21)Nc1ccc(C(=O)O)c(O)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=C(NC(CSCc1ccccc1)C(=O)NC(Cc1ccc(O)cc1)C(=O)O)OCc1ccccc1,CHEMBL3351785,=,=,Inhibition,%,40.0,INH,%,40.0,O=C(NC(CSCc1ccccc1)C(=O)NC(Cc1ccc(O)cc1)C(=O)O)OCc1ccccc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,CCOc1nc(OCC)c2[nH]c(C(=O)O)c(Br)c2n1,CHEMBL3351785,=,=,Inhibition,%,50.0,INH,%,50.0,CCOc1nc(OCC)c2[nH]c(C(=O)O)c(Br)c2n1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=C(O)CCC(=O)c1ccc(Oc2ccc(Cl)cc2)cc1,CHEMBL3351785,=,=,Inhibition,%,51.0,INH,%,51.0,O=C(O)CCC(=O)c1ccc(Oc2ccc(Cl)cc2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=C(O)C(Nc1ccc(Oc2ccc(NC(C(=O)O)c3ccccc3)cc2)cc1)c1ccccc1,CHEMBL3351785,=,=,Inhibition,%,57.0,INH,%,57.0,O=C(O)C(Nc1ccc(Oc2ccc(NC(C(=O)O)c3ccccc3)cc2)cc1)c1ccccc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,CC(C)CC(NC(=O)OCc1ccccc1)C(=O)NC(Cc1ccc(O)cc1)C(=O)O,CHEMBL3351785,=,=,Inhibition,%,57.0,INH,%,57.0,CC(C)CC(NC(=O)OCc1ccccc1)C(=O)NC(Cc1ccc(O)cc1)C(=O)O,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,Cc1cc2c(cc1C(=O)CCC(=O)O)CC1(C2)Cc2cc(C)c(C(=O)CCC(=O)O)cc2C1,CHEMBL3351785,=,=,Inhibition,%,67.0,INH,%,67.0,Cc1cc2c(cc1C(=O)CCC(=O)O)CC1(C2)Cc2cc(C)c(C(=O)CCC(=O)O)cc2C1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,COc1ccccc1/N=N/c1c(O)c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)ccc12,CHEMBL3351785,=,=,Inhibition,%,76.0,INH,%,76.0,COc1ccccc1/N=N/c1c(O)c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)ccc12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=S(=O)(O)c1ccc(OCCCCCCCCOc2ccc(S(=O)(=O)O)cc2)cc1,CHEMBL3351785,=,=,Inhibition,%,83.0,INH,%,83.0,O=S(=O)(O)c1ccc(OCCCCCCCCOc2ccc(S(=O)(=O)O)cc2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,CHEMBL3351785,=,=,Inhibition,%,100.0,INH,%,100.0,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=C(COc1ccc(Cl)cc1C(=O)O)Nc1cccc(NC(=O)Nc2cccc(S(=O)(=O)F)c2)c1,CHEMBL3351785,=,=,Inhibition,%,51.0,INH,%,51.0,O=C(COc1ccc(Cl)cc1C(=O)O)Nc1cccc(NC(=O)Nc2cccc(S(=O)(=O)F)c2)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,COc1cc2cc3c4cc(OC)c(OC)cc4cc[n+]3c(CCC(=O)O)c2cc1OC,CHEMBL3351785,=,=,Inhibition,%,57.0,INH,%,57.0,COc1cc2cc3c4cc(OC)c(OC)cc4cc[n+]3c(CCC(=O)O)c2cc1OC,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,COc1ccc(C(CC(=O)O)c2cc(OC)c(OC)c(OC)c2)cc1OC,CHEMBL3351785,=,=,Inhibition,%,58.0,INH,%,58.0,COc1ccc(C(CC(=O)O)c2cc(OC)c(OC)c(OC)c2)cc1OC,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,COc1cc(C(CC(=O)O)CC(=O)O)ccc1OCc1ccccc1,CHEMBL3351785,=,=,Inhibition,%,57.0,INH,%,57.0,COc1cc(C(CC(=O)O)CC(=O)O)ccc1OCc1ccccc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,COc1ccc2cc(C(=O)CCCC(C)C(=O)O)ccc2c1,CHEMBL3351785,=,=,Inhibition,%,58.0,INH,%,58.0,COc1ccc2cc(C(=O)CCCC(C)C(=O)O)ccc2c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,COc1cc(/N=N\c2ccc(S(=O)(=O)O)cc2)ccc1/N=N/c1c(O)ccc2cc(S(=O)(=O)O)ccc12,CHEMBL3351785,=,=,Inhibition,%,62.0,INH,%,62.0,COc1cc(/N=N\c2ccc(S(=O)(=O)O)cc2)ccc1/N=N/c1c(O)ccc2cc(S(=O)(=O)O)ccc12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,Cc1ccccc1/N=N\c1ccc(/N=N/c2c(O)ccc3cc(S(=O)(=O)O)ccc23)c(C)c1,CHEMBL3351785,=,=,Inhibition,%,64.0,INH,%,64.0,Cc1ccccc1/N=N\c1ccc(/N=N/c2c(O)ccc3cc(S(=O)(=O)O)ccc23)c(C)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=C(O)C[S+]([O-])c1ccc2c3c(cccc13)C(=O)c1ccccc1-2,CHEMBL3351785,=,=,Inhibition,%,67.0,INH,%,67.0,O=C(O)C[S+]([O-])c1ccc2c3c(cccc13)C(=O)c1ccccc1-2,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=S(=O)(O)c1ccc2c(/N=N/c3ccccc3Cl)c(O)ccc2c1,CHEMBL3351785,=,=,Inhibition,%,76.0,INH,%,76.0,O=S(=O)(O)c1ccc2c(/N=N/c3ccccc3Cl)c(O)ccc2c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,Cc1cc(C(=O)O)c(C)cc1SSc1cc(C)c(C(=O)O)cc1C,CHEMBL3351785,=,=,Inhibition,%,83.0,INH,%,83.0,Cc1cc(C(=O)O)c(C)cc1SSc1cc(C)c(C(=O)O)cc1C,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,CCOc1ccc(Nc2ccc3c(O)cc(S(=O)(=O)O)cc3c2)cc1,CHEMBL3351785,=,=,Inhibition,%,72.0,INH,%,72.0,CCOc1ccc(Nc2ccc3c(O)cc(S(=O)(=O)O)cc3c2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,CCN1C(=O)/C(=C\c2cc([N+](=O)[O-])ccc2OCC(=O)O)SC1=S,CHEMBL3351785,=,=,Inhibition,%,81.0,INH,%,81.0,CCN1C(=O)/C(=C\c2cc([N+](=O)[O-])ccc2OCC(=O)O)SC1=S,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,COc1cc(C[C@@H](CC(=O)c2ccc3c(c2)OCO3)C(=O)O)cc(OC)c1OC,CHEMBL3351785,=,=,Inhibition,%,83.0,INH,%,83.0,COc1cc(C[C@@H](CC(=O)c2ccc3c(c2)OCO3)C(=O)O)cc(OC)c1OC,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=C(NC(Cc1ccc(OC(=O)OCc2ccccc2)cc1)C(=O)O)OCc1ccccc1,CHEMBL3351785,=,=,Inhibition,%,79.0,INH,%,79.0,O=C(NC(Cc1ccc(OC(=O)OCc2ccccc2)cc1)C(=O)O)OCc1ccccc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,CCCCCCCCCCCCCCCC1=NN(c2ccc(S(=O)(=O)O)cc2)C(=O)C1/N=N/c1ccccc1,CHEMBL3351785,=,=,Inhibition,%,92.0,INH,%,92.0,CCCCCCCCCCCCCCCC1=NN(c2ccc(S(=O)(=O)O)cc2)C(=O)C1/N=N/c1ccccc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,COc1ccc(C(CC(=O)c2ccc3c(c2)OCO3)C(=O)O)cc1OC,CHEMBL3351785,=,=,Inhibition,%,94.0,INH,%,94.0,COc1ccc(C(CC(=O)c2ccc3c(c2)OCO3)C(=O)O)cc1OC,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,O=C(O)c1ccccc1SC(Sc1ccccc1C(=O)O)c1cccc(Cl)c1,CHEMBL3351785,=,=,Inhibition,%,88.0,INH,%,88.0,O=C(O)c1ccccc1SC(Sc1ccccc1C(=O)O)c1cccc(Cl)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,CCCCOc1ccc(C(CC(=O)O)CC(=O)O)cc1OC,CHEMBL3351785,=,=,Inhibition,%,98.0,INH,%,98.0,CCCCOc1ccc(C(CC(=O)O)CC(=O)O)cc1OC,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate at 10 uM,COc1cc2cc(C(=O)O)[nH]c2cc1OCc1ccccc1,CHEMBL3351785,=,=,Inhibition,%,100.0,INH,%,100.0,COc1cc2cc(C(=O)O)[nH]c2cc1OCc1ccccc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Cl)cc1)C(=O)CO2,CHEMBL3351785,=,=,IC50,nM,20.1,IC50,uM,0.0201,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Cl)cc1)C(=O)CO2,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1ccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,CHEMBL3351785,=,=,IC50,nM,27.7,IC50,uM,0.0277,COc1ccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cc1ccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,CHEMBL3351785,=,=,IC50,nM,37.3,IC50,uM,0.0373,Cc1ccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Br)cc1)C(=O)CO2,CHEMBL3351785,=,=,IC50,nM,9.9,IC50,uM,0.0099,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Br)cc1)C(=O)CO2,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1cccc(Cl)c1)C(=O)CO2,CHEMBL3351785,=,=,IC50,nM,18.0,IC50,uM,0.018,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1cccc(Cl)c1)C(=O)CO2,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Cl)c(Cl)c1)C(=O)CO2,CHEMBL3351785,=,=,IC50,nM,18.4,IC50,uM,0.0184,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Cl)c(Cl)c1)C(=O)CO2,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(C(F)(F)F)cc1)C(=O)CO2,CHEMBL3351785,=,=,IC50,nM,8.1,IC50,uM,0.0081,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(C(F)(F)F)cc1)C(=O)CO2,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Cl)cc1Cl)C(=O)CO2,CHEMBL3351785,=,=,IC50,nM,18.1,IC50,uM,0.0181,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(Cl)cc1Cl)C(=O)CO2,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cc1cccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,CHEMBL3351785,=,=,IC50,nM,20.9,IC50,uM,0.0209,Cc1cccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1cccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,CHEMBL3351785,=,=,IC50,nM,11.22,IC50,uM,0.01122,COc1cccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(F)c(F)c1)C(=O)CO2,CHEMBL3351785,=,=,IC50,nM,20.43,IC50,uM,0.02043,O=C1NC(=S)S/C1=C\c1ccc2c(c1)N(CCc1ccc(F)c(F)c1)C(=O)CO2,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,CC(C)(C)c1ccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,CHEMBL3351785,=,=,IC50,nM,140.0,IC50,uM,0.14,CC(C)(C)c1ccc(CCN2C(=O)COc3ccc(/C=C4\SC(=S)NC4=O)cc32)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3)o2)S1,CHEMBL3351785,=,=,IC50,nM,20000.0,IC50,uM,20.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3O)o2)S1,CHEMBL3351785,=,=,IC50,nM,30.0,IC50,uM,0.03,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3O)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3cccc(O)c3)o2)S1,CHEMBL3351785,=,=,IC50,nM,290.0,IC50,uM,0.29,O=C1NC(=O)/C(=C/c2ccc(-c3cccc(O)c3)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(O)cc3)o2)S1,CHEMBL3351785,=,=,IC50,nM,380.0,IC50,uM,0.38,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(O)cc3)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1ccccc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,CHEMBL3351785,=,=,IC50,nM,1000.0,IC50,uM,1.0,COc1ccccc1-c1ccc(/C=C2\SC(=O)NC2=O)o1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3Cl)o2)S1,CHEMBL3351785,=,=,IC50,nM,20000.0,IC50,uM,20.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3Cl)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3F)o2)S1,CHEMBL3351785,=,=,IC50,nM,1200.0,IC50,uM,1.2,O=C1NC(=O)/C(=C/c2ccc(-c3ccccc3F)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc(-c2cccc(C(=O)O)c2)o1,CHEMBL3351785,=,=,IC50,nM,920.0,IC50,uM,0.92,O=C1NC(=S)S/C1=C\c1ccc(-c2cccc(C(=O)O)c2)o1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COC(=O)c1cccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,CHEMBL3351785,=,=,IC50,nM,13500.0,IC50,uM,13.5,COC(=O)c1cccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc(-c2cc([N+](=O)[O-])ccc2O)o1,CHEMBL3351785,=,=,IC50,nM,200.0,IC50,uM,0.2,O=C1NC(=S)S/C1=C\c1ccc(-c2cc([N+](=O)[O-])ccc2O)o1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=S)S/C1=C\c1ccc(-c2cc([N+](=O)[O-])ccc2Br)o1,CHEMBL3351785,=,=,IC50,nM,3600.0,IC50,uM,3.6,O=C1NC(=S)S/C1=C\c1ccc(-c2cc([N+](=O)[O-])ccc2Br)o1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1cccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,CHEMBL3351785,=,=,IC50,nM,2600.0,IC50,uM,2.6,COc1cccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3cccc(C(=O)O)c3)o2)S1,CHEMBL3351785,=,=,IC50,nM,4300.0,IC50,uM,4.3,O=C1NC(=O)/C(=C/c2ccc(-c3cccc(C(=O)O)c3)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1,CHEMBL3351785,=,=,IC50,nM,33.0,IC50,uM,0.033,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(O)cc3O)o2)S1,CHEMBL3351785,=,=,IC50,nM,20.0,IC50,uM,0.02,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(O)cc3O)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3cc(F)ccc3O)o2)S1,CHEMBL3351785,=,=,IC50,nM,37.0,IC50,uM,0.037,O=C1NC(=O)/C(=C/c2ccc(-c3cc(F)ccc3O)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3cc(Cl)ccc3O)o2)S1,CHEMBL3351785,=,=,IC50,nM,43.0,IC50,uM,0.043,O=C1NC(=O)/C(=C/c2ccc(-c3cc(Cl)ccc3O)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,N#Cc1ccc(O)c(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,CHEMBL3351785,=,=,IC50,nM,40.0,IC50,uM,0.04,N#Cc1ccc(O)c(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3cc(OC(F)(F)F)ccc3O)o2)S1,CHEMBL3351785,=,=,IC50,nM,56.0,IC50,uM,0.056,O=C1NC(=O)/C(=C/c2ccc(-c3cc(OC(F)(F)F)ccc3O)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cc1ccc(O)c(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,CHEMBL3351785,=,=,IC50,nM,39.0,IC50,uM,0.039,Cc1ccc(O)c(-c2ccc(/C=C3\SC(=O)NC3=O)o2)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3cc(O)ccc3O)o2)S1,CHEMBL3351785,=,=,IC50,nM,20.0,IC50,uM,0.02,O=C1NC(=O)/C(=C/c2ccc(-c3cc(O)ccc3O)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3cccc([N+](=O)[O-])c3O)o2)S1,CHEMBL3351785,=,=,IC50,nM,80.0,IC50,uM,0.08,O=C1NC(=O)/C(=C/c2ccc(-c3cccc([N+](=O)[O-])c3O)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3cc(C(=O)O)ccc3O)o2)S1,CHEMBL3351785,=,=,IC50,nM,530.0,IC50,uM,0.53,O=C1NC(=O)/C(=C/c2ccc(-c3cc(C(=O)O)ccc3O)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(O)cc3F)o2)S1,CHEMBL3351785,=,=,IC50,nM,260.0,IC50,uM,0.26,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(O)cc3F)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3F)o2)S1,CHEMBL3351785,=,=,IC50,nM,3800.0,IC50,uM,3.8,O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3F)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3cc(F)cc(F)c3O)o2)S1,CHEMBL3351785,=,=,IC50,nM,29.0,IC50,uM,0.029,O=C1NC(=O)/C(=C/c2ccc(-c3cc(F)cc(F)c3O)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3ccc4c(c3)OCO4)o2)S1,CHEMBL3351785,=,=,IC50,nM,20000.0,IC50,uM,20.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccc4c(c3)OCO4)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3ccoc3)o2)S1,CHEMBL3351785,=,=,IC50,nM,840.0,IC50,uM,0.84,O=C1NC(=O)/C(=C/c2ccc(-c3ccoc3)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3ccc([N+](=O)[O-])o3)o2)S1,CHEMBL3351785,=,=,IC50,nM,20000.0,IC50,uM,20.0,O=C1NC(=O)/C(=C/c2ccc(-c3ccc([N+](=O)[O-])o3)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3ccccn3)o2)S1,CHEMBL3351785,=,=,IC50,nM,110.0,IC50,uM,0.11,O=C1NC(=O)/C(=C/c2ccc(-c3ccccn3)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C1NC(=O)/C(=C/c2ccc(-c3cccnc3)o2)S1,CHEMBL3351785,=,=,IC50,nM,950.0,IC50,uM,0.95,O=C1NC(=O)/C(=C/c2ccc(-c3cccnc3)o2)S1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1cc(O)cc(/C=C2\SC(=S)NC2=O)c1,CHEMBL3351785,=,=,IC50,nM,328.0,IC50,uM,0.328,COc1cc(O)cc(/C=C2\SC(=S)NC2=O)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1cc2cc(C(=O)O)[nH]c2cc1OCc1ccccc1,CHEMBL3351785,=,=,IC50,nM,105000.0,IC50,uM,105.0,COc1cc2cc(C(=O)O)[nH]c2cc1OCc1ccccc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,CCCCOc1ccc(C(CC(=O)O)CC(=O)O)cc1OC,CHEMBL3351785,=,=,IC50,nM,134000.0,IC50,uM,134.0,CCCCOc1ccc(C(CC(=O)O)CC(=O)O)cc1OC,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C(O)c1ccccc1SC(Sc1ccccc1C(=O)O)c1cccc(Cl)c1,CHEMBL3351785,=,=,IC50,nM,187000.0,IC50,uM,187.0,O=C(O)c1ccccc1SC(Sc1ccccc1C(=O)O)c1cccc(Cl)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1ccc(C(CC(=O)c2ccc3c(c2)OCO3)C(=O)O)cc1OC,CHEMBL3351785,=,=,IC50,nM,234000.0,IC50,uM,234.0,COc1ccc(C(CC(=O)c2ccc3c(c2)OCO3)C(=O)O)cc1OC,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,CCCCCCCCCCCCCCCC1=NN(c2ccc(S(=O)(=O)O)cc2)C(=O)C1/N=N/c1ccccc1,CHEMBL3351785,=,=,IC50,nM,241000.0,IC50,uM,241.0,CCCCCCCCCCCCCCCC1=NN(c2ccc(S(=O)(=O)O)cc2)C(=O)C1/N=N/c1ccccc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C(NC(Cc1ccc(OC(=O)OCc2ccccc2)cc1)C(=O)O)OCc1ccccc1,CHEMBL3351785,=,=,IC50,nM,324000.0,IC50,uM,324.0,O=C(NC(Cc1ccc(OC(=O)OCc2ccccc2)cc1)C(=O)O)OCc1ccccc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1cc(C[C@@H](CC(=O)c2ccc3c(c2)OCO3)C(=O)O)cc(OC)c1OC,CHEMBL3351785,=,=,IC50,nM,575000.0,IC50,uM,575.0,COc1cc(C[C@@H](CC(=O)c2ccc3c(c2)OCO3)C(=O)O)cc(OC)c1OC,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,CCN1C(=O)/C(=C\c2cc([N+](=O)[O-])ccc2OCC(=O)O)SC1=S,CHEMBL3351785,=,=,IC50,nM,612000.0,IC50,uM,612.0,CCN1C(=O)/C(=C\c2cc([N+](=O)[O-])ccc2OCC(=O)O)SC1=S,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,CCOc1ccc(Nc2ccc3c(O)cc(S(=O)(=O)O)cc3c2)cc1,CHEMBL3351785,=,=,IC50,nM,992000.0,IC50,uM,992.0,CCOc1ccc(Nc2ccc3c(O)cc(S(=O)(=O)O)cc3c2)cc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cc1cc(C(=O)O)c(C)cc1SSc1cc(C)c(C(=O)O)cc1C,CHEMBL3351785,=,=,IC50,nM,1460000.0,IC50,uM,1460.0,Cc1cc(C(=O)O)c(C)cc1SSc1cc(C)c(C(=O)O)cc1C,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=S(=O)(O)c1ccc2c(/N=N/c3ccccc3Cl)c(O)ccc2c1,CHEMBL3351785,=,=,IC50,nM,1498000.0,IC50,uM,1498.0,O=S(=O)(O)c1ccc2c(/N=N/c3ccccc3Cl)c(O)ccc2c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C(O)C[S+]([O-])c1ccc2c3c(cccc13)C(=O)c1ccccc1-2,CHEMBL3351785,=,=,IC50,nM,1570000.0,IC50,uM,1570.0,O=C(O)C[S+]([O-])c1ccc2c3c(cccc13)C(=O)c1ccccc1-2,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,Cc1ccccc1/N=N\c1ccc(/N=N/c2c(O)ccc3cc(S(=O)(=O)O)ccc23)c(C)c1,CHEMBL3351785,=,=,IC50,nM,2415000.0,IC50,uM,2415.0,Cc1ccccc1/N=N\c1ccc(/N=N/c2c(O)ccc3cc(S(=O)(=O)O)ccc23)c(C)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1cc(/N=N\c2ccc(S(=O)(=O)O)cc2)ccc1/N=N/c1c(O)ccc2cc(S(=O)(=O)O)ccc12,CHEMBL3351785,=,=,IC50,nM,2437000.0,IC50,uM,2437.0,COc1cc(/N=N\c2ccc(S(=O)(=O)O)cc2)ccc1/N=N/c1c(O)ccc2cc(S(=O)(=O)O)ccc12,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1ccc2cc(C(=O)CCCC(C)C(=O)O)ccc2c1,CHEMBL3351785,=,=,IC50,nM,5184000.0,IC50,uM,5184.0,COc1ccc2cc(C(=O)CCCC(C)C(=O)O)ccc2c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1cc(C(CC(=O)O)CC(=O)O)ccc1OCc1ccccc1,CHEMBL3351785,=,=,IC50,nM,5876000.0,IC50,uM,5876.0,COc1cc(C(CC(=O)O)CC(=O)O)ccc1OCc1ccccc1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1ccc(C(CC(=O)O)c2cc(OC)c(OC)c(OC)c2)cc1OC,CHEMBL3351785,=,=,IC50,nM,6074000.0,IC50,uM,6074.0,COc1ccc(C(CC(=O)O)c2cc(OC)c(OC)c(OC)c2)cc1OC,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COc1cc2cc3c4cc(OC)c(OC)cc4cc[n+]3c(CCC(=O)O)c2cc1OC,CHEMBL3351785,=,=,IC50,nM,7333000.0,IC50,uM,7333.0,COc1cc2cc3c4cc(OC)c(OC)cc4cc[n+]3c(CCC(=O)O)c2cc1OC,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,O=C(COc1ccc(Cl)cc1C(=O)O)Nc1cccc(NC(=O)Nc2cccc(S(=O)(=O)F)c2)c1,CHEMBL3351785,=,=,IC50,nM,9157000.0,IC50,uM,9157.0,O=C(COc1ccc(Cl)cc1C(=O)O)Nc1cccc(NC(=O)Nc2cccc(S(=O)(=O)F)c2)c1,2014
Inhibition of PI3Kgamma (unknown origin) assessed as decrease in fluorescence intensity using phosphorylated substrate,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,CHEMBL3351785,=,=,IC50,nM,55000.0,IC50,uM,55.0,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,2014
Inhibition of human recombinant PI3Kgamma assessed as depletion of ATP substrate by Ultra Glo luciferase assay,CC(Nc1ccccc1)c1cc(C(=O)N(C)C)cn2c(=O)cc(N3CCOCC3)nc12,CHEMBL3351561,=,=,IC50,nM,6000.0,IC50,uM,6.0,CC(Nc1ccccc1)c1cc(C(=O)N(C)C)cn2c(=O)cc(N3CCOCC3)nc12,2014
Inhibition of human recombinant PI3Kgamma assessed as depletion of ATP substrate by Ultra Glo luciferase assay,CC(Nc1ccccc1)c1cc(C(=O)NCCN(C)C)cn2c(=O)cc(N3CCOCC3)nc12,CHEMBL3351561,=,=,IC50,nM,6900.0,IC50,uM,6.9,CC(Nc1ccccc1)c1cc(C(=O)NCCN(C)C)cn2c(=O)cc(N3CCOCC3)nc12,2014
Inhibition of human recombinant PI3Kgamma assessed as depletion of ATP substrate by Ultra Glo luciferase assay,CC(Nc1cccc(Cl)c1F)c1cc(C(=O)NCCN(C)C)cn2c(=O)cc(N3CCOCC3)nc12,CHEMBL3351561,=,=,IC50,nM,670.0,IC50,uM,0.67,CC(Nc1cccc(Cl)c1F)c1cc(C(=O)NCCN(C)C)cn2c(=O)cc(N3CCOCC3)nc12,2014
Inhibition of human recombinant PI3Kgamma assessed as depletion of ATP substrate by Ultra Glo luciferase assay,CC(Nc1ccc(F)cc1)c1cc(C(=O)N(C)C)cn2c(=O)cc(N3CCOCC3)nc12,CHEMBL3351561,=,=,IC50,nM,13500.0,IC50,uM,13.5,CC(Nc1ccc(F)cc1)c1cc(C(=O)N(C)C)cn2c(=O)cc(N3CCOCC3)nc12,2014
Inhibition of human recombinant PI3Kgamma assessed as depletion of ATP substrate by Ultra Glo luciferase assay,CC(Nc1ccc(F)c(F)c1)c1cc(C(=O)N(C)C)cn2c(=O)cc(N3CCOCC3)nc12,CHEMBL3351561,=,=,IC50,nM,3000.0,IC50,uM,3.0,CC(Nc1ccc(F)c(F)c1)c1cc(C(=O)N(C)C)cn2c(=O)cc(N3CCOCC3)nc12,2014
Inhibition of human recombinant PI3Kgamma assessed as depletion of ATP substrate by Ultra Glo luciferase assay,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cn2c(=O)cc(N3CCOCC3)nc12,CHEMBL3351561,=,=,IC50,nM,510.0,IC50,uM,0.51,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cn2c(=O)cc(N3CCOCC3)nc12,2014
Inhibition of PI3Kgamma (unknown origin) by KINOMEScan assay,O/N=C1/c2ccccc2-c2nc3ccccc3nc21,CHEMBL3393060,=,=,Kd,nM,470.0,Kd,uM,0.47,O/N=C1/c2ccccc2-c2nc3ccccc3nc21,2015
Inhibition of PI3Kgamma (unknown origin) by KINOMEScan assay,O=C(O/N=C1/c2ccccc2-c2nc3ccccc3nc21)c1ccco1,CHEMBL3393060,=,=,Kd,nM,430.0,Kd,uM,0.43,O=C(O/N=C1/c2ccccc2-c2nc3ccccc3nc21)c1ccco1,2015
Inhibition of PI3Kgamma (unknown origin) by KINOMEScan assay,COc1ccc(C(=O)O/N=C2/c3ccccc3-c3nc4ccccc4nc32)cc1OC,CHEMBL3393060,=,=,Kd,nM,12000.0,Kd,uM,12.0,COc1ccc(C(=O)O/N=C2/c3ccccc3-c3nc4ccccc4nc32)cc1OC,2015
Inhibition of PI3K p110gamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL3392967,=,=,IC50,nM,12000.0,IC50,uM,12.0,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2015
Inhibition of PI3K p110gamma (unknown origin),Cc1c(CN2CCN(C(=O)[C@@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL3392967,=,=,IC50,nM,6.7,IC50,nM,6.7,Cc1c(CN2CCN(C(=O)[C@@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2015
Inhibition of PI3K p110gamma (unknown origin),CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N5CCN(C)CC5)cc4)cc3)nc21,CHEMBL3392967,=,=,IC50,nM,16.0,IC50,nM,16.0,CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N5CCN(C)CC5)cc4)cc3)nc21,2015
Inhibition of PI3K p110gamma (unknown origin),FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL3392967,=,=,IC50,nM,5.0,IC50,nM,5.0,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2015
Inhibition of PI3K p110gamma (unknown origin),Cc1nc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc2n1C(C)C,CHEMBL3392967,=,=,IC50,nM,25.0,IC50,nM,25.0,Cc1nc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc2n1C(C)C,2015
"Inhibition of recombinant PI3Kgamma (unknown origin) using PI(3,4)P2 as substrate after 3 hrs incubation by competitive fluorescence polarization kinase activity assay",Cc1ccc2c(c1)-c1nc3cc([N+](=O)[O-])ccc3n1CCO2,CHEMBL3400096,=,=,IC50,nM,9443.0,IC50,uM,9.443,Cc1ccc2c(c1)-c1nc3cc([N+](=O)[O-])ccc3n1CCO2,2015
"Inhibition of recombinant PI3Kgamma (unknown origin) using PI(3,4)P2 as substrate after 3 hrs incubation by competitive fluorescence polarization kinase activity assay",Brc1ccc2c(c1)-c1nc3cc(Br)ccc3n1CCO2,CHEMBL3400096,=,=,IC50,nM,19479.0,IC50,uM,19.479,Brc1ccc2c(c1)-c1nc3cc(Br)ccc3n1CCO2,2015
"Inhibition of recombinant PI3Kgamma (unknown origin) using PI(3,4)P2 as substrate after 3 hrs incubation by competitive fluorescence polarization kinase activity assay",Cc1ccc2c(c1)-c1nc3cc(Br)ccc3n1CCO2,CHEMBL3400096,=,=,IC50,nM,44117.0,IC50,uM,44.117,Cc1ccc2c(c1)-c1nc3cc(Br)ccc3n1CCO2,2015
"Inhibition of recombinant PI3Kgamma (unknown origin) using PI(3,4)P2 as substrate after 3 hrs incubation by competitive fluorescence polarization kinase activity assay",Clc1ccc2c(c1)nc1n2CCOc2ccc(Br)cc2-1,CHEMBL3400096,=,=,IC50,nM,11812.0,IC50,uM,11.812,Clc1ccc2c(c1)nc1n2CCOc2ccc(Br)cc2-1,2015
"Inhibition of recombinant PI3Kgamma (unknown origin) using PI(3,4)P2 as substrate after 3 hrs incubation by competitive fluorescence polarization kinase activity assay",Clc1ccc2c(c1)-c1nc3cc(Cl)ccc3n1CCO2,CHEMBL3400096,=,=,IC50,nM,24342.0,IC50,uM,24.342,Clc1ccc2c(c1)-c1nc3cc(Cl)ccc3n1CCO2,2015
"Inhibition of recombinant PI3Kgamma (unknown origin) using PI(3,4)P2 as substrate after 3 hrs incubation by competitive fluorescence polarization kinase activity assay",Fc1ccc2c(c1)nc1n2CCOc2ccc(Br)cc2-1,CHEMBL3400096,=,=,IC50,nM,27916.0,IC50,uM,27.916,Fc1ccc2c(c1)nc1n2CCOc2ccc(Br)cc2-1,2015
"Inhibition of recombinant PI3Kgamma (unknown origin) using PI(3,4)P2 as substrate after 3 hrs incubation by competitive fluorescence polarization kinase activity assay",Fc1ccc2c(c1)nc1n2CCOc2ccc(Cl)cc2-1,CHEMBL3400096,=,=,IC50,nM,21668.0,IC50,uM,21.668,Fc1ccc2c(c1)nc1n2CCOc2ccc(Cl)cc2-1,2015
"Inhibition of recombinant PI3Kgamma (unknown origin) using PI(3,4)P2 as substrate after 3 hrs incubation by competitive fluorescence polarization kinase activity assay",Cc1ccc2c(c1)-c1nc3cc(F)ccc3n1CCO2,CHEMBL3400096,=,=,IC50,nM,34624.0,IC50,uM,34.624,Cc1ccc2c(c1)-c1nc3cc(F)ccc3n1CCO2,2015
"Inhibition of recombinant PI3Kgamma (unknown origin) using PI(3,4)P2 as substrate after 3 hrs incubation by competitive fluorescence polarization kinase activity assay",Cc1ccc2c(c1)-c1nc3cc(C)ccc3n1CCO2,CHEMBL3400096,=,=,IC50,nM,17087.0,IC50,uM,17.087,Cc1ccc2c(c1)-c1nc3cc(C)ccc3n1CCO2,2015
"Inhibition of recombinant PI3Kgamma (unknown origin) using PI(3,4)P2 as substrate after 3 hrs incubation by competitive fluorescence polarization kinase activity assay",Cc1ccc2c(c1)-c1nc3cc(C(F)(F)F)ccc3n1CCO2,CHEMBL3400096,=,=,IC50,nM,41626.0,IC50,uM,41.626,Cc1ccc2c(c1)-c1nc3cc(C(F)(F)F)ccc3n1CCO2,2015
"Inhibition of recombinant PI3Kgamma (unknown origin) using PI(3,4)P2 as substrate after 3 hrs incubation by competitive fluorescence polarization kinase activity assay",O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL3400096,=,=,IC50,nM,947.0,IC50,uM,0.947,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(S(C)(=O)=O)c1-c1ccccc1,CHEMBL3400094,=,=,IC50,nM,220.0,IC50,uM,0.22,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(S(C)(=O)=O)c1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,COc1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,CHEMBL3400094,=,=,IC50,nM,11.0,IC50,uM,0.011,COc1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(O)c1-c1ccccc1,CHEMBL3400094,=,=,IC50,nM,210.0,IC50,uM,0.21,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(O)c1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c([S+]([O-])CCO)c1-c1ccccc1,CHEMBL3400094,=,=,IC50,nM,380.0,IC50,uM,0.38,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c([S+]([O-])CCO)c1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C#N)c1-c1ccccc1,CHEMBL3400094,=,=,IC50,nM,62.0,IC50,uM,0.062,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C#N)c1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(NCCO)c1-c1ccccc1,CHEMBL3400094,=,=,IC50,nM,120.0,IC50,uM,0.12,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(NCCO)c1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,COCCNc1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,CHEMBL3400094,=,=,IC50,nM,13.0,IC50,uM,0.013,COCCNc1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(NCCN(C)C)c1-c1ccccc1,CHEMBL3400094,=,=,IC50,nM,1600.0,IC50,uM,1.6,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(NCCN(C)C)c1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(NCCS(C)(=O)=O)c1-c1ccccc1,CHEMBL3400094,=,=,IC50,nM,19.0,IC50,uM,0.019,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(NCCS(C)(=O)=O)c1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2cc1-c1ccccn1,CHEMBL3400094,=,=,IC50,nM,1100.0,IC50,uM,1.1,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2cc1-c1ccccn1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(Cl)c1-c1ccccn1,CHEMBL3400094,=,=,IC50,nM,250.0,IC50,uM,0.25,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(Cl)c1-c1ccccn1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(N(C)C)c1-c1ccccn1,CHEMBL3400094,=,=,IC50,nM,290.0,IC50,uM,0.29,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(N(C)C)c1-c1ccccn1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(N2CC(O)C2)c1-c1ccccn1,CHEMBL3400094,=,=,IC50,nM,510.0,IC50,uM,0.51,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(N2CC(O)C2)c1-c1ccccn1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(N2CCOCC2)c1-c1ccccn1,CHEMBL3400094,=,=,IC50,nM,200.0,IC50,uM,0.2,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(N2CCOCC2)c1-c1ccccn1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,COCc1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,CHEMBL3400094,=,=,IC50,nM,4950.0,IC50,uM,4.95,COCc1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C#N)c1-c1ccccn1,CHEMBL3400094,=,=,IC50,nM,1420.0,IC50,uM,1.42,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C#N)c1-c1ccccn1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(-c2ccccn2)c1-c1ccccn1,CHEMBL3400094,=,=,IC50,nM,850.0,IC50,uM,0.85,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(-c2ccccn2)c1-c1ccccn1,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,Cc1cccnc1-c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,CHEMBL3400094,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1cccnc1-c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,2015
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL3400094,=,=,IC50,nM,580.0,IC50,uM,0.58,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2015
Inhibition of PI3Kgamma (unknown origin),Fc1cnc2[nH]cc(-c3ncc(F)c(N[C@H]4C5CCC(CC5)[C@@H]4c4nnn[nH]4)n3)c2c1,CHEMBL3399966,=,=,Ki,nM,2900.0,Ki,uM,2.9,Fc1cnc2[nH]cc(-c3ncc(F)c(N[C@H]4C5CCC(CC5)[C@@H]4c4nnn[nH]4)n3)c2c1,2015
Inhibition of PI3Kgamma (unknown origin),O=P(O)(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,O=P(O)(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015
Inhibition of PI3Kgamma (unknown origin),O=P(O)(O)CC[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,=,=,Ki,nM,400.0,Ki,uM,0.4,O=P(O)(O)CC[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015
Inhibition of PI3Kgamma (unknown origin),O=c1[nH]c(=O)n(C[C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)o1,CHEMBL3399966,=,=,Ki,nM,630.0,Ki,uM,0.63,O=c1[nH]c(=O)n(C[C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)o1,2015
Inhibition of PI3Kgamma (unknown origin),Oc1cc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)no1,CHEMBL3399966,=,=,Ki,nM,750.0,Ki,uM,0.75,Oc1cc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)no1,2015
Inhibition of PI3Kgamma (unknown origin),CC(=O)NS(=O)(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,=,=,Ki,nM,1500.0,Ki,uM,1.5,CC(=O)NS(=O)(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015
Inhibition of PI3Kgamma (unknown origin),Oc1cc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)on1,CHEMBL3399966,=,=,Ki,nM,690.0,Ki,uM,0.69,Oc1cc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)on1,2015
Inhibition of PI3Kgamma (unknown origin),O=c1nc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)[nH]o1,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,O=c1nc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)[nH]o1,2015
Inhibition of PI3Kgamma (unknown origin),NS(=O)(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,=,=,Ki,nM,1100.0,Ki,uM,1.1,NS(=O)(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015
Inhibition of PI3Kgamma (unknown origin),OCC(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,=,=,Ki,nM,710.0,Ki,uM,0.71,OCC(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015
Inhibition of PI3Kgamma (unknown origin),Oc1cc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)[nH]n1,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,Oc1cc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)[nH]n1,2015
Inhibition of PI3Kgamma (unknown origin),CNC(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,CNC(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015
Inhibition of PI3Kgamma (unknown origin),CC(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,=,=,Ki,nM,780.0,Ki,uM,0.78,CC(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015
Inhibition of PI3Kgamma (unknown origin),Cc1noc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)n1,CHEMBL3399966,=,=,Ki,nM,1400.0,Ki,uM,1.4,Cc1noc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nnc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)o1,CHEMBL3399966,=,=,Ki,nM,2800.0,Ki,uM,2.8,Cc1nnc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)o1,2015
Inhibition of PI3Kgamma (unknown origin),CS(=O)(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,=,=,Ki,nM,1200.0,Ki,uM,1.2,CS(=O)(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CC(Nc1ccc(F)cc1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,13000.0,IC50,uM,13.0,CC(Nc1ccc(F)cc1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CC(Nc1cccc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,2600.0,IC50,uM,2.6,CC(Nc1cccc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CC(Nc1cccc(Cl)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,700.0,IC50,uM,0.7,CC(Nc1cccc(Cl)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CC(Nc1cccc(F)c1F)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,4200.0,IC50,uM,4.2,CC(Nc1cccc(F)c1F)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,C[C@@H](Nc1ccc(F)c(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,2500.0,IC50,uM,2.5,C[C@@H](Nc1ccc(F)c(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,675.0,IC50,uM,0.675,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CC(Nc1cc(F)ccc1F)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,6000.0,IC50,uM,6.0,CC(Nc1cc(F)ccc1F)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,C[C@@H](Nc1cccc(Cl)c1F)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,320.0,IC50,uM,0.32,C[C@@H](Nc1cccc(Cl)c1F)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CC(Nc1ccc(F)c(Cl)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,1800.0,IC50,uM,1.8,CC(Nc1ccc(F)c(Cl)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,C[C@@H](Nc1cc(F)cc(Cl)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,210.0,IC50,uM,0.21,C[C@@H](Nc1cc(F)cc(Cl)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,Cc1cc(F)cc(NC(C)c2cc(C(=O)N(C)C)cc3c(=O)cc(N4CCOCC4)oc23)c1,CHEMBL3407416,=,=,IC50,nM,2200.0,IC50,uM,2.2,Cc1cc(F)cc(NC(C)c2cc(C(=O)N(C)C)cc3c(=O)cc(N4CCOCC4)oc23)c1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,COc1cc(F)cc(NC(C)c2cc(C(=O)N(C)C)cc3c(=O)cc(N4CCOCC4)oc23)c1,CHEMBL3407416,=,=,IC50,nM,1600.0,IC50,uM,1.6,COc1cc(F)cc(NC(C)c2cc(C(=O)N(C)C)cc3c(=O)cc(N4CCOCC4)oc23)c1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CC(Nc1cc(Cl)cc(Cl)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,630.0,IC50,uM,0.63,CC(Nc1cc(Cl)cc(Cl)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,C[C@@H](Nc1cc(F)c(F)c(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,1400.0,IC50,uM,1.4,C[C@@H](Nc1cc(F)c(F)c(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,C[C@@H](Nc1cc(F)cc(F)c1F)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,1500.0,IC50,uM,1.5,C[C@@H](Nc1cc(F)cc(F)c1F)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CCN(C)C(=O)c1cc(C(C)Nc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3407416,=,=,IC50,nM,930.0,IC50,uM,0.93,CCN(C)C(=O)c1cc(C(C)Nc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,COCCN(C)C(=O)c1cc(C(C)Nc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3407416,=,=,IC50,nM,2600.0,IC50,uM,2.6,COCCN(C)C(=O)c1cc(C(C)Nc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CC(Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)CCO)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,530.0,IC50,uM,0.53,CC(Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)CCO)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CCN(CC)C(=O)c1cc(C(C)Nc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3407416,=,=,IC50,nM,1200.0,IC50,uM,1.2,CCN(CC)C(=O)c1cc(C(C)Nc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N2CCC2)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,350.0,IC50,uM,0.35,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N2CCC2)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CC(Nc1cc(F)cc(F)c1)c1cc(C(=O)N2CCCC2)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,700.0,IC50,uM,0.7,CC(Nc1cc(F)cc(F)c1)c1cc(C(=O)N2CCCC2)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CC(Nc1cc(F)cc(F)c1)c1cc(C(=O)N2CCCCC2)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,1000.0,IC50,uM,1.0,CC(Nc1cc(F)cc(F)c1)c1cc(C(=O)N2CCCCC2)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CC(Nc1cc(F)cc(F)c1)c1cc(C(=O)N2CCOCC2)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,2400.0,IC50,uM,2.4,CC(Nc1cc(F)cc(F)c1)c1cc(C(=O)N2CCOCC2)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CC(Nc1cc(F)cc(F)c1)c1cc(C(=O)N2CCC(O)CC2)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,830.0,IC50,uM,0.83,CC(Nc1cc(F)cc(F)c1)c1cc(C(=O)N2CCC(O)CC2)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CNC(=O)c1cc([C@@H](C)Nc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3407416,=,=,IC50,nM,250.0,IC50,uM,0.25,CNC(=O)c1cc([C@@H](C)Nc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CCNC(=O)c1cc(C(C)Nc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3407416,=,=,IC50,nM,710.0,IC50,uM,0.71,CCNC(=O)c1cc(C(C)Nc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,COCCNC(=O)c1cc(C(C)Nc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3407416,=,=,IC50,nM,520.0,IC50,uM,0.52,COCCNC(=O)c1cc(C(C)Nc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,C[C@H]1CN(c2cc(=O)c3cc(C(=O)N(C)C)cc([C@@H](C)Nc4cc(F)cc(F)c4)c3o2)CCO1,CHEMBL3407416,=,=,IC50,nM,140.0,IC50,uM,0.14,C[C@H]1CN(c2cc(=O)c3cc(C(=O)N(C)C)cc([C@@H](C)Nc4cc(F)cc(F)c4)c3o2)CCO1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,C[C@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCO[C@@H](C)C3)oc12,CHEMBL3407416,=,=,IC50,nM,2900.0,IC50,uM,2.9,C[C@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCO[C@@H](C)C3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CN(C)C(=O)c1cc(CNc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3407416,=,=,IC50,nM,3200.0,IC50,uM,3.2,CN(C)C(=O)c1cc(CNc2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CN(C)C(=O)c1cc(CN(C)c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3407416,=,=,IC50,nM,1400.0,IC50,uM,1.4,CN(C)C(=O)c1cc(CN(C)c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,C[C@H](c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12)N(C)c1cc(F)cc(F)c1,CHEMBL3407416,=,=,IC50,nM,3500.0,IC50,uM,3.5,C[C@H](c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12)N(C)c1cc(F)cc(F)c1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,C[C@@H](Oc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3407416,=,=,IC50,nM,13000.0,IC50,uM,13.0,C[C@@H](Oc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,CC(c1cc(C(=O)N2CCCC2)cc2c(=O)cc(N3CCOCC3)oc12)N(C)c1cc(F)cc(F)c1,CHEMBL3407416,=,=,IC50,nM,3500.0,IC50,uM,3.5,CC(c1cc(C(=O)N2CCCC2)cc2c(=O)cc(N3CCOCC3)oc12)N(C)c1cc(F)cc(F)c1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,C[C@H](c1cc(C(=O)N(C)CCO)cc2c(=O)cc(N3CCOCC3)oc12)N(C)c1cc(F)cc(F)c1,CHEMBL3407416,=,=,IC50,nM,1200.0,IC50,uM,1.2,C[C@H](c1cc(C(=O)N(C)CCO)cc2c(=O)cc(N3CCOCC3)oc12)N(C)c1cc(F)cc(F)c1,2015
Inhibition of human recombinant PI3Kgamma using PIP2 by Kinase-Glo Plus assay,C[C@H](c1cc(C(=O)N2CCC(O)CC2)cc2c(=O)cc(N3CCOCC3)oc12)N(C)c1cc(F)cc(F)c1,CHEMBL3407416,=,=,IC50,nM,1600.0,IC50,uM,1.6,C[C@H](c1cc(C(=O)N2CCC(O)CC2)cc2c(=O)cc(N3CCOCC3)oc12)N(C)c1cc(F)cc(F)c1,2015
Inhibition of recombinant PI3Kgamma (unknown origin) using biotinylated PIP2 as substrate,C[C@H]1COCCN1c1cc(C2(S(=O)(=O)C3CC3)CC2)nc(-c2ccc(NC(=S)NCCO)cc2)n1,CHEMBL3407414,=,=,IC50,nM,6309.57,pIC50,,5.2,C[C@H]1COCCN1c1cc(C2(S(=O)(=O)C3CC3)CC2)nc(-c2ccc(NC(=S)NCCO)cc2)n1,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2c(C)nn3c(NCCNC(C)=O)cc(C)nc23)cc1OC,CHEMBL3425480,<=,<=,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2c(C)nn3c(NCCNC(C)=O)cc(C)nc23)cc1OC,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2c(C)nn3c(NCCNC(=O)C(C)C)cc(C)nc23)cc1OC,CHEMBL3425480,<=,<=,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2c(C)nn3c(NCCNC(=O)C(C)C)cc(C)nc23)cc1OC,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2c(C)nn3c(NCCNS(C)(=O)=O)cc(C)nc23)cc1OC,CHEMBL3425480,<=,<=,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2c(C)nn3c(NCCNS(C)(=O)=O)cc(C)nc23)cc1OC,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2c(C)nn3c(NCCOC(C)=O)cc(C)nc23)cc1OC,CHEMBL3425480,<=,<=,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2c(C)nn3c(NCCOC(C)=O)cc(C)nc23)cc1OC,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2c(C)nc3c(NCCN4CCOCC4)ccnn23)cc1OC,CHEMBL3425480,<=,<=,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2c(C)nc3c(NCCN4CCOCC4)ccnn23)cc1OC,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2c(C)nc3c(NCCNC(C)=O)cc(Cl)nn23)cc1OC,CHEMBL3425480,<=,<=,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2c(C)nc3c(NCCNC(C)=O)cc(Cl)nn23)cc1OC,2015
Inhibition of PI3Kgamma (unknown origin),CC(=O)NCCNc1cc(Cl)nn2c(-c3ccc(F)c(C=O)c3)c(C)nc12,CHEMBL3425480,<=,<=,IC50,nM,10000.0,IC50,uM,10.0,CC(=O)NCCNc1cc(Cl)nn2c(-c3ccc(F)c(C=O)c3)c(C)nc12,2015
Inhibition of PI3Kgamma (unknown origin),CC(=O)NCCNc1cc(Cl)nn2c(-c3cccc(S(=O)(=O)NC(C)C)c3)c(C)nc12,CHEMBL3425480,<=,<=,IC50,nM,10000.0,IC50,uM,10.0,CC(=O)NCCNc1cc(Cl)nn2c(-c3cccc(S(=O)(=O)NC(C)C)c3)c(C)nc12,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2c(C)nc3c(NCCNC(C)=O)ccnn23)cc1OC,CHEMBL3425480,<=,<=,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2c(C)nc3c(NCCNC(C)=O)ccnn23)cc1OC,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2c(C)nc3c(N)cc(Cl)nn23)cc1OC,CHEMBL3425480,<=,<=,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2c(C)nc3c(N)cc(Cl)nn23)cc1OC,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2c(C)nn3c(NCCN4CCOCC4)cc(C)nc23)cc1OC,CHEMBL3425480,<=,<=,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2c(C)nn3c(NCCN4CCOCC4)cc(C)nc23)cc1OC,2015
Binding affinity to PI3K-gamma (unknown origin) by fluorescence polarization assay,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,CHEMBL3526043,=,=,Activity,nM,51.0,Activity,nM,51.0,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,2011
Binding affinity to PI3K-gamma (unknown origin) by fluorescence polarization assay,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3[C@H]4COC[C@@H]3[C@H](O)C4)n2)cc1,CHEMBL3526043,=,=,Activity,nM,50.0,Activity,nM,50.0,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3[C@H]4COC[C@@H]3[C@H](O)C4)n2)cc1,2011
Binding affinity to PI3K-gamma (unknown origin) by fluorescence polarization assay,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3[C@@H]4COC[C@H]3[C@@H](O)C4)n2)cc1,CHEMBL3526043,=,=,Activity,nM,93.0,Activity,nM,93.0,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3[C@@H]4COC[C@H]3[C@@H](O)C4)n2)cc1,2011
Binding affinity to PI3K-gamma (unknown origin) by fluorescence polarization assay,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4COCC3C(O)C4)n2)cc1,CHEMBL3526043,=,=,Activity,nM,33.0,Activity,nM,33.0,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4COCC3C(O)C4)n2)cc1,2011
Inhibition of PI3Kgamma (unknown origin) using PIP2/PS as substrate after 1 hr by luciferase-based luminescence assay,COc1ncc(-c2cc3c(-c4ccncc4)ncnc3s2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3576869,=,=,IC50,nM,21.1,IC50,nM,21.1,COc1ncc(-c2cc3c(-c4ccncc4)ncnc3s2)cc1NS(=O)(=O)c1ccc(F)cc1F,2015
Inhibition of PI3Kgamma (unknown origin) using PIP2/PS as substrate after 1 hr by luciferase-based luminescence assay,O=S(=O)(Nc1cc(-c2cc3c(-c4ccncc4)ncnc3s2)cnc1Cl)c1ccc(F)cc1F,CHEMBL3576869,=,=,IC50,nM,10.2,IC50,nM,10.2,O=S(=O)(Nc1cc(-c2cc3c(-c4ccncc4)ncnc3s2)cnc1Cl)c1ccc(F)cc1F,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2cc(CNc3ccc(S(=O)(=O)Nc4nnc(C)s4)cc3)cc(C(=O)NCCc3ccccc3F)c2)cn1,CHEMBL3580636,=,=,IC50,nM,4.4,IC50,nM,4.4,COc1ccc(-c2cc(CNc3ccc(S(=O)(=O)Nc4nnc(C)s4)cc3)cc(C(=O)NCCc3ccccc3F)c2)cn1,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2cc(CNc3ccc(S(=O)(=O)Nc4nnc(C)s4)cc3)cc(C(=O)NCCC(C)C)c2)cn1,CHEMBL3580636,=,=,IC50,nM,10.0,IC50,nM,10.0,COc1ccc(-c2cc(CNc3ccc(S(=O)(=O)Nc4nnc(C)s4)cc3)cc(C(=O)NCCC(C)C)c2)cn1,2015
Inhibition of PI3Kgamma (unknown origin),COC(=O)c1cc(I)cc(CNc2ccc(S(=O)(=O)Nc3nnc(C)s3)cc2)c1,CHEMBL3580636,,,IC50,,,IC50,,,COC(=O)c1cc(I)cc(CNc2ccc(S(=O)(=O)Nc3nnc(C)s3)cc2)c1,2015
Inhibition of PI3Kgamma (unknown origin),COC(=O)c1cc(CNc2ccc(S(=O)(=O)Nc3nnc(C)s3)cc2)cc(-c2ccc(OC)nc2)c1,CHEMBL3580636,,,IC50,,,IC50,,,COC(=O)c1cc(CNc2ccc(S(=O)(=O)Nc3nnc(C)s3)cc2)cc(-c2ccc(OC)nc2)c1,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2cc(CNc3ccc(S(=O)(=O)Nc4nnc(C)s4)cc3)cc(C(=O)O)c2)cn1,CHEMBL3580636,=,=,IC50,nM,2.6,IC50,nM,2.6,COc1ccc(-c2cc(CNc3ccc(S(=O)(=O)Nc4nnc(C)s4)cc3)cc(C(=O)O)c2)cn1,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2cccc(CNc3ccc(S(=O)(=O)Nc4nnc(C)s4)cc3)c2)cn1,CHEMBL3580636,=,=,IC50,nM,52.0,IC50,nM,52.0,COc1ccc(-c2cccc(CNc3ccc(S(=O)(=O)Nc4nnc(C)s4)cc3)c2)cn1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nnc(NS(=O)(=O)c2ccc(NCc3cc(C(=O)O)cc(-c4ccc5c(c4)OCCO5)c3)cc2)s1,CHEMBL3580636,=,=,IC50,nM,2.0,IC50,nM,2.0,Cc1nnc(NS(=O)(=O)c2ccc(NCc3cc(C(=O)O)cc(-c4ccc5c(c4)OCCO5)c3)cc2)s1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nnc(NS(=O)(=O)c2ccc(NCc3cc(C(=O)O)cc(-c4ccc5c(c4)OCO5)c3)cc2)s1,CHEMBL3580636,=,=,IC50,nM,4.0,IC50,nM,4.0,Cc1nnc(NS(=O)(=O)c2ccc(NCc3cc(C(=O)O)cc(-c4ccc5c(c4)OCO5)c3)cc2)s1,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2cc(CNc3ccc(S(=O)(=O)N(C)c4nnc(C)s4)cc3)cc(C(=O)NCCc3ccccc3F)c2)cn1,CHEMBL3580636,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COc1ccc(-c2cc(CNc3ccc(S(=O)(=O)N(C)c4nnc(C)s4)cc3)cc(C(=O)NCCc3ccccc3F)c2)cn1,2015
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2cc(CNc3ccc(S(=O)(=O)Nc4nnc(C)s4)cc3)cc(C(=O)NC(CO)CO)c2)cn1,CHEMBL3580636,=,=,IC50,nM,25.0,IC50,nM,25.0,COc1ccc(-c2cc(CNc3ccc(S(=O)(=O)Nc4nnc(C)s4)cc3)cc(C(=O)NC(CO)CO)c2)cn1,2015
Inhibition of PI3Kgamma in human THP1 cells assessed as inhibition of MCP1-stimulated chemotaxis pre-incubated for 1 hr before MCP1 stimulation,COc1cc(N2CCc3nc(NC(=O)NCCc4cn(CC(F)F)cn4)sc3C2)cnc1Cl,CHEMBL3585282,=,=,IC50,nM,185.0,IC50,uM,0.185,COc1cc(N2CCc3nc(NC(=O)NCCc4cn(CC(F)F)cn4)sc3C2)cnc1Cl,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(CCO)cn4)sc3C2)c1,CHEMBL3585282,=,=,Ki,nM,0.025,Ki,nM,0.025,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(CCO)cn4)sc3C2)c1,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(CC(F)(F)F)cn4)sc3C2)c1,CHEMBL3585282,=,=,Ki,nM,0.009,Ki,nM,0.009,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(CC(F)(F)F)cn4)sc3C2)c1,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,COc1cc(N2CCc3nc(NC(=O)NCCc4cn(CC(F)F)cn4)sc3C2)cnc1Cl,CHEMBL3585282,=,=,Ki,nM,0.003,Ki,nM,0.003,COc1cc(N2CCc3nc(NC(=O)NCCc4cn(CC(F)F)cn4)sc3C2)cnc1Cl,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(CC(F)F)cn4)sc3C2)n1,CHEMBL3585282,=,=,Ki,nM,0.002,Ki,nM,0.002,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(CC(F)F)cn4)sc3C2)n1,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(CC(F)F)cn4)sc3C2)c1,CHEMBL3585282,=,=,Ki,nM,0.003,Ki,nM,0.003,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(CC(F)F)cn4)sc3C2)c1,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(CCF)cn4)sc3C2)c1,CHEMBL3585282,=,=,Ki,nM,0.006,Ki,nM,0.006,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(CCF)cn4)sc3C2)c1,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(CC(C)C)cn4)sc3C2)c1,CHEMBL3585282,=,=,Ki,nM,0.034,Ki,nM,0.034,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(CC(C)C)cn4)sc3C2)c1,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,CCCn1cnc(CCNC(=O)Nc2nc3c(s2)CN(c2cncc(OC)c2)CC3)c1,CHEMBL3585282,=,=,Ki,nM,0.01,Ki,nM,0.01,CCCn1cnc(CCNC(=O)Nc2nc3c(s2)CN(c2cncc(OC)c2)CC3)c1,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(C(C)C)cn4)sc3C2)c1,CHEMBL3585282,=,=,Ki,nM,0.016,Ki,nM,0.016,COc1cncc(N2CCc3nc(NC(=O)NCCc4cn(C(C)C)cn4)sc3C2)c1,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,CCCOCCNC(=O)Nc1nc2c(s1)CN(c1cncc(OC)c1)CC2,CHEMBL3585282,=,=,Ki,nM,0.011,Ki,nM,0.011,CCCOCCNC(=O)Nc1nc2c(s1)CN(c1cncc(OC)c1)CC2,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,CCNC(=O)Nc1nc2c(s1)CN(c1cncc(OC)c1)CC2,CHEMBL3585282,=,=,Ki,nM,0.066,Ki,nM,0.066,CCNC(=O)Nc1nc2c(s1)CN(c1cncc(OC)c1)CC2,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,COc1cncc(N2CCc3nc(NC(C)=O)sc3C2)n1,CHEMBL3585282,=,=,Ki,nM,0.017,Ki,nM,0.017,COc1cncc(N2CCc3nc(NC(C)=O)sc3C2)n1,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,COc1cc(N2CCc3nc(NC(C)=O)sc3C2)cnc1Cl,CHEMBL3585282,=,=,Ki,nM,0.024,Ki,nM,0.024,COc1cc(N2CCc3nc(NC(C)=O)sc3C2)cnc1Cl,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,COc1cc(N2CCc3nc(NC(C)=O)sc3C2)cnc1OC,CHEMBL3585282,=,=,Ki,nM,0.013,Ki,nM,0.013,COc1cc(N2CCc3nc(NC(C)=O)sc3C2)cnc1OC,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,COc1ccc(N2CCc3nc(NC(C)=O)sc3C2)cn1,CHEMBL3585282,=,=,Ki,nM,0.33,Ki,nM,0.33,COc1ccc(N2CCc3nc(NC(C)=O)sc3C2)cn1,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,COc1cncc(N2CCc3nc(NC(C)=O)sc3C2)c1,CHEMBL3585282,=,=,Ki,nM,0.048,Ki,nM,0.048,COc1cncc(N2CCc3nc(NC(C)=O)sc3C2)c1,2015
Inhibition of PI3Kgamma (unknown origin) using [33P]ATP and PIP2 incubated for 15 mins by liquid scintillation counting method,CC(=O)Nc1nc2c(s1)CN(c1cccnc1)CC2,CHEMBL3585282,=,=,Ki,nM,0.157,Ki,nM,0.157,CC(=O)Nc1nc2c(s1)CN(c1cccnc1)CC2,2015
Inhibition of human recombinant GST-tagged PI3Kgamma incubated for 180 mins using [33P]gamma-ATP by scintillation proximity assay,O=C1NC(=O)/C(=C\c2ccc3c(c2)OC(F)(F)O3)S1,CHEMBL3585253,=,=,IC50,nM,250.0,IC50,nM,250.0,O=C1NC(=O)/C(=C\c2ccc3c(c2)OC(F)(F)O3)S1,2015
Inhibition of human recombinant GST-tagged PI3Kgamma incubated for 180 mins using [33P]gamma-ATP by scintillation proximity assay,O=C1NC(=O)/C(=C/c2ccc3nccnc3c2)S1,CHEMBL3585253,=,=,IC50,nM,9.0,IC50,nM,9.0,O=C1NC(=O)/C(=C/c2ccc3nccnc3c2)S1,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,CCN1C(=S)N2CCCC2c2c(N3CCOCC3)nc(-c3cccc(OC)c3)nc21,CHEMBL3588749,=,=,IC50,nM,91560.0,IC50,uM,91.56,CCN1C(=S)N2CCCC2c2c(N3CCOCC3)nc(-c3cccc(OC)c3)nc21,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,CCN1C(=S)N2CCCC2c2c(N3CCOCC3)nc(-c3ccc(OC)cc3)nc21,CHEMBL3588749,=,=,IC50,nM,125800.0,IC50,uM,125.8,CCN1C(=S)N2CCCC2c2c(N3CCOCC3)nc(-c3ccc(OC)cc3)nc21,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,COc1cccc(-c2nc(N3CCOCC3)c3c(n2)N(c2ccccc2)C(=S)N2CCCC32)c1,CHEMBL3588749,=,=,IC50,nM,465500.0,IC50,uM,465.5,COc1cccc(-c2nc(N3CCOCC3)c3c(n2)N(c2ccccc2)C(=S)N2CCCC32)c1,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,COc1ccc(-c2nc(N3CCOCC3)c3c(n2)N(c2ccccc2)C(=S)N2CCCC32)cc1,CHEMBL3588749,=,=,IC50,nM,345900.0,IC50,uM,345.9,COc1ccc(-c2nc(N3CCOCC3)c3c(n2)N(c2ccccc2)C(=S)N2CCCC32)cc1,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,CCN1C(=S)N2CCCC2c2c1nc(CN1CCOCC1)[nH]c2=O,CHEMBL3588749,=,=,IC50,nM,7640.0,IC50,uM,7.64,CCN1C(=S)N2CCCC2c2c1nc(CN1CCOCC1)[nH]c2=O,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,CCN1C(=S)N2CCCC2c2c1nc(C(C)N1CCOCC1)[nH]c2=O,CHEMBL3588749,=,=,IC50,nM,4560.0,IC50,uM,4.56,CCN1C(=S)N2CCCC2c2c1nc(C(C)N1CCOCC1)[nH]c2=O,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,O=c1[nH]c(CN2CCOCC2)nc2c1C1CCCN1C(=S)N2c1ccccc1,CHEMBL3588749,=,=,IC50,nM,5780.0,IC50,uM,5.78,O=c1[nH]c(CN2CCOCC2)nc2c1C1CCCN1C(=S)N2c1ccccc1,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,CC(c1nc2c(c(=O)[nH]1)C1CCCN1C(=S)N2c1ccccc1)N1CCOCC1,CHEMBL3588749,=,=,IC50,nM,1340.0,IC50,uM,1.34,CC(c1nc2c(c(=O)[nH]1)C1CCCN1C(=S)N2c1ccccc1)N1CCOCC1,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,S=C1N(c2ccccc2)c2nc(CN3CCOCC3)nc(N3CCOCC3)c2C2CCCN12,CHEMBL3588749,=,=,IC50,nM,781500.0,IC50,uM,781.5,S=C1N(c2ccccc2)c2nc(CN3CCOCC3)nc(N3CCOCC3)c2C2CCCN12,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,CC(c1nc(N2CCOCC2)c2c(n1)N(c1ccccc1)C(=S)N1CCCC21)N1CCOCC1,CHEMBL3588749,=,=,IC50,nM,967700.0,IC50,uM,967.7,CC(c1nc(N2CCOCC2)c2c(n1)N(c1ccccc1)C(=S)N1CCCC21)N1CCOCC1,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,CCN1C(=S)N2CCCC2c2c1nc(-c1cccc(O)c1)c(C#N)c2N1CCOCC1,CHEMBL3588749,=,=,IC50,nM,23640.0,IC50,uM,23.64,CCN1C(=S)N2CCCC2c2c1nc(-c1cccc(O)c1)c(C#N)c2N1CCOCC1,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,CCN1C(=S)N2CCCC2c2c1nc(-c1cccc(OC)c1)c(C#N)c2N1CCOCC1,CHEMBL3588749,=,=,IC50,nM,18480.0,IC50,uM,18.48,CCN1C(=S)N2CCCC2c2c1nc(-c1cccc(OC)c1)c(C#N)c2N1CCOCC1,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,CCN1C(=S)N2CCCC2c2c1nc(-c1ccc(OC)cc1)c(C#N)c2N1CCOCC1,CHEMBL3588749,=,=,IC50,nM,12570.0,IC50,uM,12.57,CCN1C(=S)N2CCCC2c2c1nc(-c1ccc(OC)cc1)c(C#N)c2N1CCOCC1,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,CCN1C(=S)N2CCCC2c2c1nc(-c1ccc(OC)c(O)c1)c(C#N)c2N1CCOCC1,CHEMBL3588749,=,=,IC50,nM,26870.0,IC50,uM,26.87,CCN1C(=S)N2CCCC2c2c1nc(-c1ccc(OC)c(O)c1)c(C#N)c2N1CCOCC1,2015
Inhibition of His-tagged p110gamma (unknown origin) expressed in Sf9/Baculovirus system using [gamma-33P]ATP by scintillation proximity assay,CCN1C(=S)N2CCCC2c2c1nc(-c1ccc(OC)c(OC)c1)c(C#N)c2N1CCOCC1,CHEMBL3588749,=,=,IC50,nM,15560.0,IC50,uM,15.56,CCN1C(=S)N2CCCC2c2c1nc(-c1ccc(OC)c(OC)c1)c(C#N)c2N1CCOCC1,2015
Inhibition of recombinant human PI3Kgamma using PIP2/ATP as substrate preincubated for 20 mins followed by substrate addition measured after 80 mins by Kinase-Glo plus assay,CN(C)CC(=O)N1CCC(n2cc(-c3cnc(N)c(-n4nnc5ccccc54)n3)cn2)CC1,CHEMBL3588784,=,=,IC50,nM,280.0,IC50,uM,0.28,CN(C)CC(=O)N1CCC(n2cc(-c3cnc(N)c(-n4nnc5ccccc54)n3)cn2)CC1,2015
Inhibition of recombinant human PI3Kgamma using PIP2/ATP as substrate preincubated for 20 mins followed by substrate addition measured after 80 mins by Kinase-Glo plus assay,CN(C)CC(=O)N1CCC(c2nc(-c3cnc(N)c(-n4nnc5ccccc54)n3)n(C)n2)CC1,CHEMBL3588784,=,=,IC50,nM,650.0,IC50,uM,0.65,CN(C)CC(=O)N1CCC(c2nc(-c3cnc(N)c(-n4nnc5ccccc54)n3)n(C)n2)CC1,2015
Inhibition of PI3Kgamma (unknown origin) assessed as reduction of ATP level after 40 mins by luciferase based luminescence assay,COc1ncc(-c2ccc3nc(NC(=O)NC4CC4)nn3c2)cc1NS(=O)(=O)c1ccc(F)cc1,CHEMBL3600364,=,=,IC50,nM,14.0,IC50,nM,14.0,COc1ncc(-c2ccc3nc(NC(=O)NC4CC4)nn3c2)cc1NS(=O)(=O)c1ccc(F)cc1,2015
Inhibition of PI3Kgamma (unknown origin) assessed as reduction of ATP level after 40 mins by luciferase based luminescence assay,CCN(CC)CCNC(=O)Nc1nc2ccc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4)c3)cn2n1,CHEMBL3600364,=,=,IC50,nM,22.0,IC50,nM,22.0,CCN(CC)CCNC(=O)Nc1nc2ccc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4)c3)cn2n1,2015
Inhibition of PI3Kgamma (unknown origin) assessed as reduction of ATP level after 40 mins by luciferase based luminescence assay,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL3600364,=,=,IC50,nM,95.0,IC50,nM,95.0,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CCOc1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,1995.26,pIC50,,5.7,CCOc1ccc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",COc1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,398.11,pIC50,,6.4,COc1ccc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CCSc1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,1000.0,pIC50,,6.0,CCSc1ccc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",COCc1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,,,pIC50,,,pIC50,,,COCc1ccc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CNCc1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,50118.72,pIC50,,4.3,CNCc1ccc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CC(C)Oc1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,12589.25,pIC50,,4.9,CC(C)Oc1ccc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CCNc1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,3981.07,pIC50,,5.4,CCNc1ccc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CCN(C)c1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,3981.07,pIC50,,5.4,CCN(C)c1ccc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3ccc(CO)nc3)cc2s1,CHEMBL3600363,,,pIC50,,,pIC50,,,Nc1nc2ccc(-c3ccc(CO)nc3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Cc1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,1258.93,pIC50,,5.9,Cc1ccc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3ccc(C(F)(F)F)nc3)cc2s1,CHEMBL3600363,=,=,IC50,nM,1000.0,pIC50,,6.0,Nc1nc2ccc(-c3ccc(C(F)(F)F)nc3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CS(=O)(=O)c1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,10000.0,pIC50,,5.0,CS(=O)(=O)c1ccc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3ccc(OCCO)nc3)cc2s1,CHEMBL3600363,=,=,IC50,nM,1258.93,pIC50,,5.9,Nc1nc2ccc(-c3ccc(OCCO)nc3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",COCCOc1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,3162.28,pIC50,,5.5,COCCOc1ccc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CNC(=O)c1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,,,pIC50,,,pIC50,,,CNC(=O)c1ccc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CN(C)C(=O)c1ccc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,19952.62,pIC50,,4.7,CN(C)C(=O)c1ccc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CC(C)Oc1cncc(-c2ccc3nc(N)sc3c2)c1,CHEMBL3600363,=,=,IC50,nM,251.19,pIC50,,6.6,CC(C)Oc1cncc(-c2ccc3nc(N)sc3c2)c1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CS(=O)(=O)c1cncc(-c2ccc3nc(N)sc3c2)c1,CHEMBL3600363,=,=,IC50,nM,125.89,pIC50,,6.9,CS(=O)(=O)c1cncc(-c2ccc3nc(N)sc3c2)c1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3ccccc3)cc2s1,CHEMBL3600363,,,pIC50,,,pIC50,,,Nc1nc2ccc(-c3ccccc3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3ccccn3)cc2s1,CHEMBL3600363,=,=,IC50,nM,12589.25,pIC50,,4.9,Nc1nc2ccc(-c3ccccn3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3cccnc3)cc2s1,CHEMBL3600363,,,pIC50,,,pIC50,,,Nc1nc2ccc(-c3cccnc3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3ccncc3)cc2s1,CHEMBL3600363,,,pIC50,,,pIC50,,,Nc1nc2ccc(-c3ccncc3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3ncccn3)cc2s1,CHEMBL3600363,=,=,IC50,nM,31622.78,pIC50,,4.5,Nc1nc2ccc(-c3ncccn3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3cnccn3)cc2s1,CHEMBL3600363,=,=,IC50,nM,3981.07,pIC50,,5.4,Nc1nc2ccc(-c3cnccn3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3ccc(=O)[nH]c3)cc2s1,CHEMBL3600363,=,=,IC50,nM,10000.0,pIC50,,5.0,Nc1nc2ccc(-c3ccc(=O)[nH]c3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3cc[nH]c(=O)c3)cc2s1,CHEMBL3600363,=,=,IC50,nM,1258.93,pIC50,,5.9,Nc1nc2ccc(-c3cc[nH]c(=O)c3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Cn1ccc(-c2ccc3nc(N)sc3c2)n1,CHEMBL3600363,=,=,IC50,nM,2511.89,pIC50,,5.6,Cn1ccc(-c2ccc3nc(N)sc3c2)n1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Cn1nccc1-c1ccc2nc(N)sc2c1,CHEMBL3600363,=,=,IC50,nM,2511.89,pIC50,,5.6,Cn1nccc1-c1ccc2nc(N)sc2c1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Cn1cc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,2511.89,pIC50,,5.6,Cn1cc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CCn1cc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,3162.28,pIC50,,5.5,CCn1cc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CCCn1cc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,1584.89,pIC50,,5.8,CCCn1cc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CC(C)n1cc(-c2ccc3nc(N)sc3c2)cn1,CHEMBL3600363,=,=,IC50,nM,3981.07,pIC50,,5.4,CC(C)n1cc(-c2ccc3nc(N)sc3c2)cn1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3cnn(C4CC4)c3)cc2s1,CHEMBL3600363,=,=,IC50,nM,1000.0,pIC50,,6.0,Nc1nc2ccc(-c3cnn(C4CC4)c3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3cnn(CC4CC4)c3)cc2s1,CHEMBL3600363,=,=,IC50,nM,1258.93,pIC50,,5.9,Nc1nc2ccc(-c3cnn(CC4CC4)c3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3cnn(Cc4ccccc4)c3)cc2s1,CHEMBL3600363,=,=,IC50,nM,1995.26,pIC50,,5.7,Nc1nc2ccc(-c3cnn(Cc4ccccc4)c3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Cn1ccc(-c2ccc3nc(N)sc3c2)cc1=O,CHEMBL3600363,,,pIC50,,,pIC50,,,Cn1ccc(-c2ccc3nc(N)sc3c2)cc1=O,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",CCn1ccc(-c2ccc3nc(N)sc3c2)cc1=O,CHEMBL3600363,=,=,IC50,nM,3162.28,pIC50,,5.5,CCn1ccc(-c2ccc3nc(N)sc3c2)cc1=O,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",Nc1nc2ccc(-c3ccn(CC4CC4)c(=O)c3)cc2s1,CHEMBL3600363,=,=,IC50,nM,1584.89,pIC50,,5.8,Nc1nc2ccc(-c3ccn(CC4CC4)c(=O)c3)cc2s1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",COCCOn1ccc(-c2ccc3nc(N)sc3c2)cc1=O,CHEMBL3600363,=,=,IC50,nM,10000.0,pIC50,,5.0,COCCOn1ccc(-c2ccc3nc(N)sc3c2)cc1=O,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",O=c1cc(-c2ccc3nc(NCC4CCOCC4)sc3c2)ccn1CC1CC1,CHEMBL3600363,=,=,IC50,nM,15848.93,pIC50,,4.8,O=c1cc(-c2ccc3nc(NCC4CCOCC4)sc3c2)ccn1CC1CC1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",C[C@@H](Nc1nc2ccc(-c3ccn(CC4CC4)c(=O)c3)cc2s1)C1CCOCC1,CHEMBL3600363,=,=,IC50,nM,63095.73,pIC50,,4.2,C[C@@H](Nc1nc2ccc(-c3ccn(CC4CC4)c(=O)c3)cc2s1)C1CCOCC1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",C[C@H](Nc1nc2ccc(-c3ccn(CC4CC4)c(=O)c3)cc2s1)C1CCOCC1,CHEMBL3600363,<,>,IC50,nM,199526.23,pIC50,,3.7,C[C@H](Nc1nc2ccc(-c3ccn(CC4CC4)c(=O)c3)cc2s1)C1CCOCC1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",O=c1cc(-c2ccc3nc(NCC4CCS(=O)(=O)CC4)sc3c2)ccn1CC1CC1,CHEMBL3600363,=,=,IC50,nM,50118.72,pIC50,,4.3,O=c1cc(-c2ccc3nc(NCC4CCS(=O)(=O)CC4)sc3c2)ccn1CC1CC1,2015
"Inhibition of PI3Kgamma (unknown origin) pre-incubated for 20 mins before phosphatidylinositol 4, 5-bisphosphate substrate addition by kinase-glo plus luminescence assay",O=c1cc(-c2ccc3nc(NC[C@H]4CC[C@H](C(=O)O)CC4)sc3c2)ccn1CC1CC1,CHEMBL3600363,=,=,IC50,nM,10000.0,pIC50,,5.0,O=c1cc(-c2ccc3nc(NC[C@H]4CC[C@H](C(=O)O)CC4)sc3c2)ccn1CC1CC1,2015
Inhibition of N-terminal poly-His tagged human p110-gamma (114 to 1102 residues) expressed in Hi5 cells incubated for 20 mins by alpha screen assay,CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2s1,CHEMBL3603806,,,Inhibition,%,,INH,,,CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2s1,2015
Inhibition of P110gamma (unknown origin) using PI or PIP2:PS as substrate measured for 15 to 60 mins by TR-FRET analysis,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,CHEMBL3603757,=,=,IC50,nM,250.0,IC50,uM,0.25,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,2015
Inhibition of P110gamma (unknown origin) using PI or PIP2:PS as substrate measured for 15 to 60 mins by TR-FRET analysis,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2cc(C(C)(C)C(F)(F)F)ncc2OC3)[C@@H]1C(N)=O,CHEMBL3603757,=,=,IC50,nM,200.0,IC50,uM,0.2,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2cc(C(C)(C)C(F)(F)F)ncc2OC3)[C@@H]1C(N)=O,2015
Inhibition of P110gamma (unknown origin) using PI or PIP2:PS as substrate measured for 15 to 60 mins by TR-FRET analysis,Cc1nc(NC(=O)N2CC[C@@H](C)[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,CHEMBL3603757,=,=,IC50,nM,230.0,IC50,uM,0.23,Cc1nc(NC(=O)N2CC[C@@H](C)[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,CHEMBL3608263,=,=,IC50,nM,8000.0,IC50,uM,8.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,CC(C)(C)c1nc2c(s1)CCc1nc(NC(=O)N3CCC[C@H]3C(N)=O)sc1-2,CHEMBL3608263,=,=,IC50,nM,160.0,IC50,uM,0.16,CC(C)(C)c1nc2c(s1)CCc1nc(NC(=O)N3CCC[C@H]3C(N)=O)sc1-2,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,NC(=O)[C@@H]1CCCN1C(=O)Nc1nc2c(s1)-c1nc(CC3CC3)sc1CC2,CHEMBL3608263,=,=,IC50,nM,1100.0,IC50,uM,1.1,NC(=O)[C@@H]1CCCN1C(=O)Nc1nc2c(s1)-c1nc(CC3CC3)sc1CC2,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,CC(C)(C)c1nc2c(s1)CCc1nc(NC(=O)N3CCC[C@@]3(C)C(N)=O)sc1-2,CHEMBL3608263,,,IC50,,,IC50,,,CC(C)(C)c1nc2c(s1)CCc1nc(NC(=O)N3CCC[C@@]3(C)C(N)=O)sc1-2,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,CC(C)(C)c1nc2c(s1)CCc1nc(NC(=O)N3CC[C@@H]4C[C@@]43C(N)=O)sc1-2,CHEMBL3608263,=,=,IC50,nM,8000.0,IC50,uM,8.0,CC(C)(C)c1nc2c(s1)CCc1nc(NC(=O)N3CC[C@@H]4C[C@@]43C(N)=O)sc1-2,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,C[C@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)sc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,=,=,IC50,nM,330.0,IC50,uM,0.33,C[C@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)sc2CC3)[C@@H]1C(N)=O,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)sc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,=,=,IC50,nM,200.0,IC50,uM,0.2,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)sc2CC3)[C@@H]1C(N)=O,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C(F)(F)F)sc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,=,=,IC50,nM,160.0,IC50,uM,0.16,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C(F)(F)F)sc2CC3)[C@@H]1C(N)=O,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,CN(C)C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)sc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,=,=,IC50,nM,990.0,IC50,uM,0.99,CN(C)C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)sc2CC3)[C@@H]1C(N)=O,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1,CHEMBL3608263,=,=,IC50,nM,230.0,IC50,uM,0.23,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,CC(C)(C)c1ncc2c(n1)-c1sc(NC(=O)N3CCC[C@H]3C(N)=O)nc1CC2,CHEMBL3608263,=,=,IC50,nM,16.0,IC50,uM,0.016,CC(C)(C)c1ncc2c(n1)-c1sc(NC(=O)N3CCC[C@H]3C(N)=O)nc1CC2,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,CC(C)(C)c1ncc2c(n1)-c1sc(NC(=O)N3CCC[C@@]3(C)C(N)=O)nc1CC2,CHEMBL3608263,=,=,IC50,nM,71.0,IC50,uM,0.071,CC(C)(C)c1ncc2c(n1)-c1sc(NC(=O)N3CCC[C@@]3(C)C(N)=O)nc1CC2,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,CC(C)(C)c1ncc2c(n1)-c1sc(NC(=O)N3CC[C@@H]4C[C@@]43C(N)=O)nc1CC2,CHEMBL3608263,=,=,IC50,nM,180.0,IC50,uM,0.18,CC(C)(C)c1ncc2c(n1)-c1sc(NC(=O)N3CC[C@@H]4C[C@@]43C(N)=O)nc1CC2,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)ncc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,=,=,IC50,nM,5.0,IC50,uM,0.005,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)ncc2CC3)[C@@H]1C(N)=O,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C(F)(F)F)ncc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,=,=,IC50,nM,15.0,IC50,uM,0.015,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C(F)(F)F)ncc2CC3)[C@@H]1C(N)=O,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,CN(C)C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)ncc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,,,IC50,,,IC50,,,CN(C)C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)ncc2CC3)[C@@H]1C(N)=O,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,CN(C)C[C@@]1(C(N)=O)CCCN1C(=O)Nc1nc2c(s1)-c1nc(C(C)(C)C)ncc1CC2,CHEMBL3608263,=,=,IC50,nM,1500.0,IC50,uM,1.5,CN(C)C[C@@]1(C(N)=O)CCCN1C(=O)Nc1nc2c(s1)-c1nc(C(C)(C)C)ncc1CC2,2015
Inhibition of PI3Kgamma (unknown origin) using PI or PIP2:PS as substrate by TR-FRET assay,CN(C)[C@@H]1C[C@@H](C(N)=O)N(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)ncc2CC3)C1,CHEMBL3608263,=,=,IC50,nM,230.0,IC50,uM,0.23,CN(C)[C@@H]1C[C@@H](C(N)=O)N(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)ncc2CC3)C1,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,CHEMBL3608263,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,CC(C)(C)c1nc2c(s1)CCc1nc(NC(=O)N3CCC[C@H]3C(N)=O)sc1-2,CHEMBL3608263,=,=,IC50,nM,1400.0,IC50,uM,1.4,CC(C)(C)c1nc2c(s1)CCc1nc(NC(=O)N3CCC[C@H]3C(N)=O)sc1-2,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,NC(=O)[C@@H]1CCCN1C(=O)Nc1nc2c(s1)-c1nc(CC3CC3)sc1CC2,CHEMBL3608263,=,=,IC50,nM,3400.0,IC50,uM,3.4,NC(=O)[C@@H]1CCCN1C(=O)Nc1nc2c(s1)-c1nc(CC3CC3)sc1CC2,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,CC(C)(C)c1nc2c(s1)CCc1nc(NC(=O)N3CCC[C@@]3(C)C(N)=O)sc1-2,CHEMBL3608263,=,=,IC50,nM,4000.0,IC50,uM,4.0,CC(C)(C)c1nc2c(s1)CCc1nc(NC(=O)N3CCC[C@@]3(C)C(N)=O)sc1-2,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,CC(C)(C)c1nc2c(s1)CCc1nc(NC(=O)N3CC[C@@H]4C[C@@]43C(N)=O)sc1-2,CHEMBL3608263,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(C)(C)c1nc2c(s1)CCc1nc(NC(=O)N3CC[C@@H]4C[C@@]43C(N)=O)sc1-2,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,C[C@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)sc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,=,=,IC50,nM,1000.0,IC50,uM,1.0,C[C@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)sc2CC3)[C@@H]1C(N)=O,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)sc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,=,=,IC50,nM,1500.0,IC50,uM,1.5,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)sc2CC3)[C@@H]1C(N)=O,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C(F)(F)F)sc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,=,=,IC50,nM,590.0,IC50,uM,0.59,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C(F)(F)F)sc2CC3)[C@@H]1C(N)=O,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,CN(C)C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)sc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,=,=,IC50,nM,4000.0,IC50,uM,4.0,CN(C)C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)sc2CC3)[C@@H]1C(N)=O,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1,CHEMBL3608263,=,=,IC50,nM,1500.0,IC50,uM,1.5,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,CC(C)(C)c1ncc2c(n1)-c1sc(NC(=O)N3CCC[C@H]3C(N)=O)nc1CC2,CHEMBL3608263,=,=,IC50,nM,290.0,IC50,uM,0.29,CC(C)(C)c1ncc2c(n1)-c1sc(NC(=O)N3CCC[C@H]3C(N)=O)nc1CC2,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,CC(C)(C)c1ncc2c(n1)-c1sc(NC(=O)N3CCC[C@@]3(C)C(N)=O)nc1CC2,CHEMBL3608263,=,=,IC50,nM,430.0,IC50,uM,0.43,CC(C)(C)c1ncc2c(n1)-c1sc(NC(=O)N3CCC[C@@]3(C)C(N)=O)nc1CC2,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,CC(C)(C)c1ncc2c(n1)-c1sc(NC(=O)N3CC[C@@H]4C[C@@]43C(N)=O)nc1CC2,CHEMBL3608263,=,=,IC50,nM,910.0,IC50,uM,0.91,CC(C)(C)c1ncc2c(n1)-c1sc(NC(=O)N3CC[C@@H]4C[C@@]43C(N)=O)nc1CC2,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)ncc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,=,=,IC50,nM,200.0,IC50,uM,0.2,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)ncc2CC3)[C@@H]1C(N)=O,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C(F)(F)F)ncc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,=,=,IC50,nM,82.0,IC50,uM,0.082,C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C(F)(F)F)ncc2CC3)[C@@H]1C(N)=O,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,CN(C)C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)ncc2CC3)[C@@H]1C(N)=O,CHEMBL3608263,=,=,IC50,nM,1200.0,IC50,uM,1.2,CN(C)C[C@@H]1CCN(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)ncc2CC3)[C@@H]1C(N)=O,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,CN(C)C[C@@]1(C(N)=O)CCCN1C(=O)Nc1nc2c(s1)-c1nc(C(C)(C)C)ncc1CC2,CHEMBL3608263,=,=,IC50,nM,660.0,IC50,uM,0.66,CN(C)C[C@@]1(C(N)=O)CCCN1C(=O)Nc1nc2c(s1)-c1nc(C(C)(C)C)ncc1CC2,2015
Inhibition of N-terminal myristoylated human PI3Kgamma expressed in Rat1 cells assessed as inhibition of Akt phosphorylatuion at Ser473 by ELISA,CN(C)[C@@H]1C[C@@H](C(N)=O)N(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)ncc2CC3)C1,CHEMBL3608263,=,=,IC50,nM,4400.0,IC50,uM,4.4,CN(C)[C@@H]1C[C@@H](C(N)=O)N(C(=O)Nc2nc3c(s2)-c2nc(C(C)(C)C)ncc2CC3)C1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C2(C)CC2)n1,CHEMBL3608239,,,IC50,,,IC50,,,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C2(C)CC2)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,CHEMBL3608239,=,=,IC50,nM,8000.0,IC50,uM,8.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin),CCC(CC)c1nc(-c2sc(NC(=O)N3CCC[C@H]3C(N)=O)nc2C)cs1,CHEMBL3608239,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCC(CC)c1nc(-c2sc(NC(=O)N3CCC[C@H]3C(N)=O)nc2C)cs1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C2CCC2)n1,CHEMBL3608239,=,=,IC50,nM,6100.0,IC50,uM,6.1,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C2CCC2)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(CC2CC2)n1,CHEMBL3608239,=,=,IC50,nM,6300.0,IC50,uM,6.3,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(CC2CC2)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C(C)C)n1,CHEMBL3608239,,,IC50,,,IC50,,,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin),CC(=O)Nc1nc(C)c(-c2csc(C(C)C)n2)s1,CHEMBL3608239,=,=,IC50,nM,1200.0,IC50,uM,1.2,CC(=O)Nc1nc(C)c(-c2csc(C(C)C)n2)s1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,CHEMBL3608239,=,=,IC50,nM,250.0,IC50,uM,0.25,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1,CHEMBL3608239,=,=,IC50,nM,230.0,IC50,uM,0.23,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccc(S(C)(=O)=O)c(F)c1,CHEMBL3608239,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccc(S(C)(=O)=O)c(F)c1,2015
Inhibition of PI3Kgamma (unknown origin),CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)c(F)c2)s1,CHEMBL3608239,=,=,IC50,nM,870.0,IC50,uM,0.87,CC(=O)Nc1nc(C)c(-c2ccc(S(C)(=O)=O)c(F)c2)s1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(N(C)C)n1,CHEMBL3608239,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(N(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(-c2cccnc2)n1,CHEMBL3608239,=,=,IC50,nM,3000.0,IC50,uM,3.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(-c2cccnc2)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(-c2ccccc2F)n1,CHEMBL3608239,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(-c2ccccc2F)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(CN(C)C)n1,CHEMBL3608239,,,IC50,,,IC50,,,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(CN(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C2(C(F)(F)F)CC2)n1,CHEMBL3608239,=,=,IC50,nM,2900.0,IC50,uM,2.9,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C2(C(F)(F)F)CC2)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@@]2(C)C(N)=O)sc1-c1csc(C(C)(C)C)n1,CHEMBL3608239,,,IC50,,,IC50,,,Cc1nc(NC(=O)N2CCC[C@@]2(C)C(N)=O)sc1-c1csc(C(C)(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CCC[C@@]2(C)C(N)=O)sc1-c1csc(C2(C(F)(F)F)CC2)n1,CHEMBL3608239,,,IC50,,,IC50,,,Cc1nc(NC(=O)N2CCC[C@@]2(C)C(N)=O)sc1-c1csc(C2(C(F)(F)F)CC2)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CC[C@H](C)[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,CHEMBL3608239,,,IC50,,,IC50,,,Cc1nc(NC(=O)N2CC[C@H](C)[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CC[C@@H](C)[C@H]2C(N)=O)sc1-c1csc(C2(C(F)(F)F)CC2)n1,CHEMBL3608239,=,=,IC50,nM,2500.0,IC50,uM,2.5,Cc1nc(NC(=O)N2CC[C@@H](C)[C@H]2C(N)=O)sc1-c1csc(C2(C(F)(F)F)CC2)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CC[C@H](O)[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,CHEMBL3608239,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1nc(NC(=O)N2CC[C@H](O)[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CC[C@@H](O)[C@H]2C(N)=O)sc1-c1csc(C2(C(F)(F)F)CC2)n1,CHEMBL3608239,=,=,IC50,nM,5000.0,IC50,uM,5.0,Cc1nc(NC(=O)N2CC[C@@H](O)[C@H]2C(N)=O)sc1-c1csc(C2(C(F)(F)F)CC2)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2C[C@H](F)C[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,CHEMBL3608239,=,=,IC50,nM,8300.0,IC50,uM,8.3,Cc1nc(NC(=O)N2C[C@H](F)C[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2C[C@H](O)C[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,CHEMBL3608239,=,=,IC50,nM,7900.0,IC50,uM,7.9,Cc1nc(NC(=O)N2C[C@H](O)C[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2C[C@@H](O)C[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,CHEMBL3608239,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1nc(NC(=O)N2C[C@@H](O)C[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2C[C@H](N(C)C)C[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,CHEMBL3608239,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1nc(NC(=O)N2C[C@H](N(C)C)C[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2C[C@H](N(C)C)C[C@H]2C(N)=O)sc1-c1csc(C2(C)CC2)n1,CHEMBL3608239,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1nc(NC(=O)N2C[C@H](N(C)C)C[C@H]2C(N)=O)sc1-c1csc(C2(C)CC2)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2C[C@@H](N(C)C)C[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,CHEMBL3608239,,,IC50,,,IC50,,,Cc1nc(NC(=O)N2C[C@@H](N(C)C)C[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin),Cc1nc(NC(=O)N2CC[C@@H]3C[C@@]32C(N)=O)sc1-c1csc(C(C)(C)C)n1,CHEMBL3608239,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1nc(NC(=O)N2CC[C@@H]3C[C@@]32C(N)=O)sc1-c1csc(C(C)(C)C)n1,2015
Inhibition of PI3Kgamma (unknown origin) by alpha screen assay,COc1ncc(Nc2nc3ccc(C(C)(C)O)cn3c2-c2nc(C)nc(N)n2)cc1F,CHEMBL3616407,=,=,Ki,nM,5.3,Ki,nM,5.3,COc1ncc(Nc2nc3ccc(C(C)(C)O)cn3c2-c2nc(C)nc(N)n2)cc1F,2015
Inhibition of recombinant human PI3Kgamma by TR-FRET analysis,C[C@@H]1COCCN1c1cc(=O)n2c(n1)N(Cc1cncc(Cl)c1)[C@H](C(F)(F)F)CC2,CHEMBL3621113,>,>,IC50,nM,10000.0,IC50,uM,10.0,C[C@@H]1COCCN1c1cc(=O)n2c(n1)N(Cc1cncc(Cl)c1)[C@H](C(F)(F)F)CC2,2015
Inhibition of PIK3CG (unknown origin) assessed as remaining activity at 10 uM by high-throughput assay relative to control,O=C1c2ccccc2-c2c1oc1ccccc1c2=O,CHEMBL3627674,=,=,Activity,%,86.0,Activity,%,86.0,O=C1c2ccccc2-c2c1oc1ccccc1c2=O,2015
"Competitive Assay: The PI3 Kinase Activity/Inhibitor Assay is a competitive assay used for the fast and sensitive quantitation of activity of the four class I PI3 kinases (p110 α, β, γ, δ). The PI3 Kinase Activity/Inhibitor Assay works on the principle that PI3 Kinase phosphorylates P1(3,4)P2 (PIP2), converting it to PI(3,4,5)P3 (PIP3). The PH domain of the protein GRP-1 binds PIP3 with high affinity and specificity. The kit includes this recombinant protein that is used as the capture protein. This protein binds to the glutathione plate and captures either the PIP3 generated as part of the kinase reaction or the biotinylated-PIP3 tracer included in the kit. The captured biotinylated-PIP3 is detected using streptavidin-HRP conjugate and a colorimetric read out (OD 450). The lower the signal, the higher the PI3 Kinase activity.",O=S(=O)(Nc1cncc(-c2ccc3ncnc(Oc4cccnc4)c3n2)c1)c1ccccc1,CHEMBL3638420,<,<,IC50,nM,1000.0,IC50,nM,1000.0,O=S(=O)(Nc1cncc(-c2ccc3ncnc(Oc4cccnc4)c3n2)c1)c1ccccc1,2014
"Competitive Assay: The PI3 Kinase Activity/Inhibitor Assay is a competitive assay used for the fast and sensitive quantitation of activity of the four class I PI3 kinases (p110 α, β, γ, δ). The PI3 Kinase Activity/Inhibitor Assay works on the principle that PI3 Kinase phosphorylates P1(3,4)P2 (PIP2), converting it to PI(3,4,5)P3 (PIP3). The PH domain of the protein GRP-1 binds PIP3 with high affinity and specificity. The kit includes this recombinant protein that is used as the capture protein. This protein binds to the glutathione plate and captures either the PIP3 generated as part of the kinase reaction or the biotinylated-PIP3 tracer included in the kit. The captured biotinylated-PIP3 is detected using streptavidin-HRP conjugate and a colorimetric read out (OD 450). The lower the signal, the higher the PI3 Kinase activity.",CN1CCC(Oc2ncnc3ccc(-c4cncc(NS(=O)(=O)c5ccccc5)c4)nc23)CC1,CHEMBL3638420,<,<,IC50,nM,10000.0,IC50,nM,10000.0,CN1CCC(Oc2ncnc3ccc(-c4cncc(NS(=O)(=O)c5ccccc5)c4)nc23)CC1,2014
"Competitive Assay: The PI3 Kinase Activity/Inhibitor Assay is a competitive assay used for the fast and sensitive quantitation of activity of the four class I PI3 kinases (p110 α, β, γ, δ). The PI3 Kinase Activity/Inhibitor Assay works on the principle that PI3 Kinase phosphorylates P1(3,4)P2 (PIP2), converting it to PI(3,4,5)P3 (PIP3). The PH domain of the protein GRP-1 binds PIP3 with high affinity and specificity. The kit includes this recombinant protein that is used as the capture protein. This protein binds to the glutathione plate and captures either the PIP3 generated as part of the kinase reaction or the biotinylated-PIP3 tracer included in the kit. The captured biotinylated-PIP3 is detected using streptavidin-HRP conjugate and a colorimetric read out (OD 450). The lower the signal, the higher the PI3 Kinase activity.",O=S(=O)(Nc1cncc(-c2ccc3ncnc(OC4CCOCC4)c3n2)c1)c1ccccc1,CHEMBL3638420,<,<,IC50,nM,1000.0,IC50,nM,1000.0,O=S(=O)(Nc1cncc(-c2ccc3ncnc(OC4CCOCC4)c3n2)c1)c1ccccc1,2014
"Competitive Assay: The PI3 Kinase Activity/Inhibitor Assay is a competitive assay used for the fast and sensitive quantitation of activity of the four class I PI3 kinases (p110 α, β, γ, δ). The PI3 Kinase Activity/Inhibitor Assay works on the principle that PI3 Kinase phosphorylates P1(3,4)P2 (PIP2), converting it to PI(3,4,5)P3 (PIP3). The PH domain of the protein GRP-1 binds PIP3 with high affinity and specificity. The kit includes this recombinant protein that is used as the capture protein. This protein binds to the glutathione plate and captures either the PIP3 generated as part of the kinase reaction or the biotinylated-PIP3 tracer included in the kit. The captured biotinylated-PIP3 is detected using streptavidin-HRP conjugate and a colorimetric read out (OD 450). The lower the signal, the higher the PI3 Kinase activity.",O=S(=O)(Nc1cc(-c2ccc3ncnc(OC4CCOCC4)c3n2)cnc1Cl)c1ccc(F)cc1F,CHEMBL3638420,<,<,IC50,nM,1000.0,IC50,nM,1000.0,O=S(=O)(Nc1cc(-c2ccc3ncnc(OC4CCOCC4)c3n2)cnc1Cl)c1ccc(F)cc1F,2014
"Competitive Assay: The PI3 Kinase Activity/Inhibitor Assay is a competitive assay used for the fast and sensitive quantitation of activity of the four class I PI3 kinases (p110 α, β, γ, δ). The PI3 Kinase Activity/Inhibitor Assay works on the principle that PI3 Kinase phosphorylates P1(3,4)P2 (PIP2), converting it to PI(3,4,5)P3 (PIP3). The PH domain of the protein GRP-1 binds PIP3 with high affinity and specificity. The kit includes this recombinant protein that is used as the capture protein. This protein binds to the glutathione plate and captures either the PIP3 generated as part of the kinase reaction or the biotinylated-PIP3 tracer included in the kit. The captured biotinylated-PIP3 is detected using streptavidin-HRP conjugate and a colorimetric read out (OD 450). The lower the signal, the higher the PI3 Kinase activity.",CN1CCC(Oc2ncnc3ccc(-c4cnc(Cl)c(NS(=O)(=O)c5ccc(F)cc5F)c4)nc23)CC1,CHEMBL3638420,<,<,IC50,nM,10000.0,IC50,nM,10000.0,CN1CCC(Oc2ncnc3ccc(-c4cnc(Cl)c(NS(=O)(=O)c5ccc(F)cc5F)c4)nc23)CC1,2014
"Competitive Assay: The PI3 Kinase Activity/Inhibitor Assay is a competitive assay used for the fast and sensitive quantitation of activity of the four class I PI3 kinases (p110 α, β, γ, δ). The PI3 Kinase Activity/Inhibitor Assay works on the principle that PI3 Kinase phosphorylates P1(3,4)P2 (PIP2), converting it to PI(3,4,5)P3 (PIP3). The PH domain of the protein GRP-1 binds PIP3 with high affinity and specificity. The kit includes this recombinant protein that is used as the capture protein. This protein binds to the glutathione plate and captures either the PIP3 generated as part of the kinase reaction or the biotinylated-PIP3 tracer included in the kit. The captured biotinylated-PIP3 is detected using streptavidin-HRP conjugate and a colorimetric read out (OD 450). The lower the signal, the higher the PI3 Kinase activity.",O=S(=O)(Nc1cc(-c2ccc3ncnc(NC4CCOCC4)c3n2)cnc1Cl)c1ccc(F)cc1F,CHEMBL3638420,<,<,IC50,nM,10000.0,IC50,nM,10000.0,O=S(=O)(Nc1cc(-c2ccc3ncnc(NC4CCOCC4)c3n2)cnc1Cl)c1ccc(F)cc1F,2014
Inhibition of PIK3Cgamma (unknown origin) at 1 uM by selectscreen kinase profiling assay in presence of ATP,COc1cc2c(cc1OC)CN(CC(=O)Nc1ccc3c(c1)/C(=C/c1cnc[nH]1)C(=O)N3)CC2,CHEMBL3734692,=,=,Inhibition,%,5.0,INH,%,5.0,COc1cc2c(cc1OC)CN(CC(=O)Nc1ccc3c(c1)/C(=C/c1cnc[nH]1)C(=O)N3)CC2,2015
Inhibition of PI3Kgamma (unknown origin) at 1 uM after 1 hr by ADP-Glo Luminescent assay,CC(C)(C#N)c1ccc(Nc2c(C(N)=O)cnc3ccc(-c4cnc5ccccc5c4)cc23)cc1,CHEMBL3734757,=,=,Inhibition,%,-2.4,INH,%,-2.4,CC(C)(C#N)c1ccc(Nc2c(C(N)=O)cnc3ccc(-c4cnc5ccccc5c4)cc23)cc1,2015
Inhibition of PI3Kgamma (unknown origin) at 1 uM after 1 hr by ADP-Glo Luminescent assay,Cl.NC(=O)c1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCNCC2)c(C(F)(F)F)c1,CHEMBL3734757,=,=,Inhibition,%,6.7,INH,%,6.7,Cl.NC(=O)c1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCNCC2)c(C(F)(F)F)c1,2015
Inhibition of PI3Kgamma (unknown origin) after 1 hr by ADP-Glo Luminescent assay,CC(=O)N1CCN(c2ccc(Nc3c(C(N)=O)cnc4ccc(-c5cnc6ccccc6c5)cc34)cc2C(F)(F)F)CC1,CHEMBL3734757,=,=,IC50,nM,939.0,IC50,nM,939.0,CC(=O)N1CCN(c2ccc(Nc3c(C(N)=O)cnc4ccc(-c5cnc6ccccc6c5)cc34)cc2C(F)(F)F)CC1,2015
Inhibition of PI3Kgamma (unknown origin) after 1 hr by ADP-Glo Luminescent assay,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL3734757,=,=,IC50,nM,48.0,IC50,nM,48.0,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2015
Inhibition of PI3Kgamma (unknown origin),C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1,CHEMBL3745712,>,>,IC50,nM,9100.0,IC50,uM,9.1,C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1,2015
Inhibition of PI3K-G (unknown origin) at 1 uM,Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1,CHEMBL3745631,=,=,Inhibition,%,2.5,INH,%,2.5,Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1,2016
Inhibition of PI3Kgamma (unknown origin) after 4 hrs,Fc1ccccc1CO/N=C/c1cn(-c2ccccc2)nc1-c1ccccc1,CHEMBL3751762,=,=,IC50,nM,6570.0,IC50,uM,6.57,Fc1ccccc1CO/N=C/c1cn(-c2ccccc2)nc1-c1ccccc1,2016
Inhibition of PI3Kgamma (unknown origin) after 4 hrs,Cc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccccc2)cc1,CHEMBL3751762,>,>,IC50,nM,25000.0,IC50,uM,25.0,Cc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccccc2)cc1,2016
Inhibition of PI3Kgamma (unknown origin) after 4 hrs,Cc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccccc2Cl)cc1,CHEMBL3751762,=,=,IC50,nM,21450.0,IC50,uM,21.45,Cc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccccc2Cl)cc1,2016
Inhibition of PI3Kgamma (unknown origin) after 4 hrs,Cc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccc(Cl)cc2Cl)cc1,CHEMBL3751762,>,>,IC50,nM,25000.0,IC50,uM,25.0,Cc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccc(Cl)cc2Cl)cc1,2016
Inhibition of PI3Kgamma (unknown origin) after 4 hrs,Fc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccccc2F)cc1,CHEMBL3751762,=,=,IC50,nM,280.0,IC50,uM,0.28,Fc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccccc2F)cc1,2016
Inhibition of PI3Kgamma (unknown origin) after 4 hrs,Fc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccccc2Cl)cc1,CHEMBL3751762,=,=,IC50,nM,3120.0,IC50,uM,3.12,Fc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccccc2Cl)cc1,2016
Inhibition of PI3Kgamma (unknown origin) after 4 hrs,Fc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccc(Cl)cc2Cl)cc1,CHEMBL3751762,=,=,IC50,nM,1260.0,IC50,uM,1.26,Fc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccc(Cl)cc2Cl)cc1,2016
Inhibition of PI3Kgamma (unknown origin) after 4 hrs,Fc1ccccc1CO/N=C/c1cn(-c2ccccc2)nc1-c1ccc(Cl)cc1,CHEMBL3751762,=,=,IC50,nM,12360.0,IC50,uM,12.36,Fc1ccccc1CO/N=C/c1cn(-c2ccccc2)nc1-c1ccc(Cl)cc1,2016
Inhibition of PI3Kgamma (unknown origin) after 4 hrs,Clc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccccc2Cl)cc1,CHEMBL3751762,=,=,IC50,nM,13780.0,IC50,uM,13.78,Clc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccccc2Cl)cc1,2016
Inhibition of PI3Kgamma (unknown origin) after 4 hrs,Clc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccc(Cl)cc2Cl)cc1,CHEMBL3751762,=,=,IC50,nM,9360.0,IC50,uM,9.36,Clc1ccc(-c2nn(-c3ccccc3)cc2/C=N/OCc2ccc(Cl)cc2Cl)cc1,2016
Inhibition of PI3Kgamma (unknown origin) after 4 hrs,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL3751762,=,=,IC50,nM,7200.0,IC50,uM,7.2,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2016
Inhibition of PI3Kgamma (unknown origin) using 1 alpha-phosphatidylinositol as substrate assessed as ATP depletion after 5 mins by KinaseGlo assay,CC(=O)Nc1cn2cc(-c3cnc(N)c(OC(C)C(F)(F)F)n3)ccc2n1,CHEMBL3751828,=,=,IC50,nM,50.0,IC50,uM,0.05,CC(=O)Nc1cn2cc(-c3cnc(N)c(OC(C)C(F)(F)F)n3)ccc2n1,2016
Inhibition of PI3KG (unknown origin) at 100 nM,CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21,CHEMBL3758169,=,=,Inhibition,%,15.1,INH,%,15.1,CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccs3)cccc12,CHEMBL3763148,=,=,Inhibition,%,16.0,INH,%,16.0,O=c1nc(N2CCOCC2)oc2c(-c3cccs3)cccc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccnc3)cccc12,CHEMBL3763148,=,=,Inhibition,%,24.0,INH,%,24.0,O=c1nc(N2CCOCC2)oc2c(-c3cccnc3)cccc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,NC(=O)c1ccc(-c2cccc3c(=O)nc(N4CCOCC4)oc23)cc1,CHEMBL3763148,=,=,Inhibition,%,10.0,INH,%,10.0,NC(=O)c1ccc(-c2cccc3c(=O)nc(N4CCOCC4)oc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,Nc1cccc(-c2cccc3c(=O)nc(N4CCOCC4)oc23)c1,CHEMBL3763148,=,=,Inhibition,%,0.0,INH,%,0.0,Nc1cccc(-c2cccc3c(=O)nc(N4CCOCC4)oc23)c1,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccc(CO)cc3)cccc12,CHEMBL3763148,=,=,Inhibition,%,31.0,INH,%,31.0,O=c1nc(N2CCOCC2)oc2c(-c3ccc(CO)cc3)cccc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)cccc12,CHEMBL3763148,=,=,Inhibition,%,16.0,INH,%,16.0,O=c1nc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)cccc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,COc1ccc(-c2cccc3c(=O)nc(N4CCOCC4)oc23)cc1,CHEMBL3763148,=,=,Inhibition,%,7.0,INH,%,7.0,COc1ccc(-c2cccc3c(=O)nc(N4CCOCC4)oc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccsc3)cccc12,CHEMBL3763148,=,=,Inhibition,%,29.0,INH,%,29.0,O=c1nc(N2CCOCC2)oc2c(-c3ccsc3)cccc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccc4ccccc34)cccc12,CHEMBL3763148,=,=,Inhibition,%,29.0,INH,%,29.0,O=c1nc(N2CCOCC2)oc2c(-c3cccc4ccccc34)cccc12,2016
Inhibition of PI3K-gamma (unknown origin) after 40 mins by ADP-Glo luminescent kinase assay,CCOC(=O)N1CCN(CC#Cc2ccnc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5F)c4)cc23)CC1,CHEMBL3763019,=,=,IC50,nM,4.0,IC50,nM,4.0,CCOC(=O)N1CCN(CC#Cc2ccnc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5F)c4)cc23)CC1,2016
Inhibition of PI3K-gamma (unknown origin) after 40 mins by ADP-Glo luminescent kinase assay,COc1ncc(-c2ccc3nccc(C#CCN4CCN(S(C)(=O)=O)CC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3763019,=,=,IC50,nM,2.7,IC50,nM,2.7,COc1ncc(-c2ccc3nccc(C#CCN4CCN(S(C)(=O)=O)CC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3K-gamma (unknown origin) after 40 mins by ADP-Glo luminescent kinase assay,COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3763019,=,=,IC50,nM,0.6,IC50,nM,0.6,COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3K-gamma (unknown origin) after 40 mins by ADP-Glo luminescent kinase assay,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL3763019,=,=,IC50,nM,63.0,IC50,nM,63.0,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2016
Inhibition of PI3K-gamma (unknown origin) at 10 nM after 40 mins by ADP-Glo luminescent kinase assay,COc1ncc(-c2ccc3nccc(C#CCN(C)C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1,CHEMBL3763019,=,=,Inhibition,%,70.0,INH,%,70.0,COc1ncc(-c2ccc3nccc(C#CCN(C)C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1,2016
Inhibition of PI3K-gamma (unknown origin) at 10 nM after 40 mins by ADP-Glo luminescent kinase assay,COc1ncc(-c2ccc3nccc(C#CCN(C)C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3763019,=,=,Inhibition,%,81.0,INH,%,81.0,COc1ncc(-c2ccc3nccc(C#CCN(C)C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3K-gamma (unknown origin) at 10 nM after 40 mins by ADP-Glo luminescent kinase assay,CCN(CC)CC#Cc1ccnc2ccc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc12,CHEMBL3763019,=,=,Inhibition,%,68.0,INH,%,68.0,CCN(CC)CC#Cc1ccnc2ccc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc12,2016
Inhibition of PI3K-gamma (unknown origin) at 10 nM after 40 mins by ADP-Glo luminescent kinase assay,COc1ncc(-c2ccc3nccc(C#CCN(C)CCO)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3763019,=,=,Inhibition,%,90.0,INH,%,90.0,COc1ncc(-c2ccc3nccc(C#CCN(C)CCO)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3K-gamma (unknown origin) at 10 nM after 40 mins by ADP-Glo luminescent kinase assay,COc1ncc(-c2ccc3nccc(C#CCN(C4CCCCC4)C4CCCCC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3763019,=,=,Inhibition,%,10.0,INH,%,10.0,COc1ncc(-c2ccc3nccc(C#CCN(C4CCCCC4)C4CCCCC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3K-gamma (unknown origin) at 10 nM after 40 mins by ADP-Glo luminescent kinase assay,COc1ncc(-c2ccc3nccc(C#CCN4CCCCC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3763019,=,=,Inhibition,%,55.0,INH,%,55.0,COc1ncc(-c2ccc3nccc(C#CCN4CCCCC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3K-gamma (unknown origin) at 10 nM after 40 mins by ADP-Glo luminescent kinase assay,COc1ncc(-c2ccc3nccc(C#CCN4CCC(C)CC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3763019,=,=,Inhibition,%,49.0,INH,%,49.0,COc1ncc(-c2ccc3nccc(C#CCN4CCC(C)CC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3K-gamma (unknown origin) at 10 nM after 40 mins by ADP-Glo luminescent kinase assay,COc1ncc(-c2ccc3nccc(C#CCN4CCCCC4C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3763019,=,=,Inhibition,%,59.0,INH,%,59.0,COc1ncc(-c2ccc3nccc(C#CCN4CCCCC4C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3K-gamma (unknown origin) at 10 nM after 40 mins by ADP-Glo luminescent kinase assay,COc1ncc(-c2ccc3nccc(C#CCN4CCOCC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3763019,=,=,Inhibition,%,96.0,INH,%,96.0,COc1ncc(-c2ccc3nccc(C#CCN4CCOCC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3K-gamma (unknown origin) at 10 nM after 40 mins by ADP-Glo luminescent kinase assay,CCOC(=O)N1CCN(CC#Cc2ccnc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5F)c4)cc23)CC1,CHEMBL3763019,=,=,Inhibition,%,82.0,INH,%,82.0,CCOC(=O)N1CCN(CC#Cc2ccnc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5F)c4)cc23)CC1,2016
Inhibition of PI3K-gamma (unknown origin) at 10 nM after 40 mins by ADP-Glo luminescent kinase assay,COc1ncc(-c2ccc3nccc(C#CCN4CCN(S(C)(=O)=O)CC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3763019,=,=,Inhibition,%,95.0,INH,%,95.0,COc1ncc(-c2ccc3nccc(C#CCN4CCN(S(C)(=O)=O)CC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccc4c3oc3ccccc34)cccc12,CHEMBL3763148,=,=,Inhibition,%,32.0,INH,%,32.0,O=c1nc(N2CCOCC2)oc2c(-c3cccc4c3oc3ccccc34)cccc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cccc12,CHEMBL3763148,=,=,Inhibition,%,27.0,INH,%,27.0,O=c1nc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cccc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cc4ccccc4s3)cccc12,CHEMBL3763148,=,=,Inhibition,%,17.0,INH,%,17.0,O=c1nc(N2CCOCC2)oc2c(-c3cc4ccccc4s3)cccc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,COc1ccc(-c2cc(Cl)cc3c(=O)nc(N4CCOCC4)oc23)cc1,CHEMBL3763148,=,=,Inhibition,%,0.0,INH,%,0.0,COc1ccc(-c2cc(Cl)cc3c(=O)nc(N4CCOCC4)oc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccs3)cc(Cl)cc12,CHEMBL3763148,=,=,Inhibition,%,0.0,INH,%,0.0,O=c1nc(N2CCOCC2)oc2c(-c3cccs3)cc(Cl)cc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cc4ccccc4s3)cc(Cl)cc12,CHEMBL3763148,=,=,Inhibition,%,14.0,INH,%,14.0,O=c1nc(N2CCOCC2)oc2c(-c3cc4ccccc4s3)cc(Cl)cc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cc(Cl)cc12,CHEMBL3763148,=,=,Inhibition,%,1.0,INH,%,1.0,O=c1nc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cc(Cl)cc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(-c3ccccc3)cc12,CHEMBL3763148,=,=,Inhibition,%,9.0,INH,%,9.0,O=c1nc(N2CCOCC2)oc2ccc(-c3ccccc3)cc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,COc1ccc(-c2ccc3oc(N4CCOCC4)nc(=O)c3c2)cc1,CHEMBL3763148,=,=,Inhibition,%,0.0,INH,%,0.0,COc1ccc(-c2ccc3oc(N4CCOCC4)nc(=O)c3c2)cc1,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(-c3ccc(Cl)cc3)cc12,CHEMBL3763148,=,=,Inhibition,%,10.0,INH,%,10.0,O=c1nc(N2CCOCC2)oc2ccc(-c3ccc(Cl)cc3)cc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(-c3ccc(CO)cc3)cc12,CHEMBL3763148,=,=,Inhibition,%,0.0,INH,%,0.0,O=c1nc(N2CCOCC2)oc2ccc(-c3ccc(CO)cc3)cc12,2016
Inhibition of PI3Kgamma (unknown origin) incubated for 60 mins by kinase-glo luminescence assay,Nc1cccc(-c2ccc3oc(N4CCOCC4)nc(=O)c3c2)c1,CHEMBL3763148,,,IC50,,,IC50,,,Nc1cccc(-c2ccc3oc(N4CCOCC4)nc(=O)c3c2)c1,2016
Inhibition of PI3Kgamma (unknown origin) incubated for 60 mins by kinase-glo luminescence assay,NC(=O)c1ccc(-c2ccc3oc(N4CCOCC4)nc(=O)c3c2)cc1,CHEMBL3763148,,,IC50,,,IC50,,,NC(=O)c1ccc(-c2ccc3oc(N4CCOCC4)nc(=O)c3c2)cc1,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(-c3cccnc3)cc12,CHEMBL3763148,=,=,Inhibition,%,0.0,INH,%,0.0,O=c1nc(N2CCOCC2)oc2ccc(-c3cccnc3)cc12,2016
Inhibition of PI3Kgamma (unknown origin) incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(-c3cccs3)cc12,CHEMBL3763148,,,IC50,,,IC50,,,O=c1nc(N2CCOCC2)oc2ccc(-c3cccs3)cc12,2016
Inhibition of PI3Kgamma (unknown origin) incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(-c3ccsc3)cc12,CHEMBL3763148,,,IC50,,,IC50,,,O=c1nc(N2CCOCC2)oc2ccc(-c3ccsc3)cc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(-c3cccc4ccccc34)cc12,CHEMBL3763148,=,=,Inhibition,%,4.0,INH,%,4.0,O=c1nc(N2CCOCC2)oc2ccc(-c3cccc4ccccc34)cc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(-c3cccc4c3oc3ccccc34)cc12,CHEMBL3763148,=,=,Inhibition,%,0.0,INH,%,0.0,O=c1nc(N2CCOCC2)oc2ccc(-c3cccc4c3oc3ccccc34)cc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(-c3cccc4c3sc3ccccc34)cc12,CHEMBL3763148,=,=,Inhibition,%,0.0,INH,%,0.0,O=c1nc(N2CCOCC2)oc2ccc(-c3cccc4c3sc3ccccc34)cc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(-c3cccc(-c4ccccc4)c3)cc12,CHEMBL3763148,=,=,Inhibition,%,0.0,INH,%,0.0,O=c1nc(N2CCOCC2)oc2ccc(-c3cccc(-c4ccccc4)c3)cc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(/C=C/c3ccccc3)cc12,CHEMBL3763148,=,=,Inhibition,%,4.0,INH,%,4.0,O=c1nc(N2CCOCC2)oc2ccc(/C=C/c3ccccc3)cc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(-c3cc4ccccc4s3)cc12,CHEMBL3763148,=,=,Inhibition,%,3.0,INH,%,3.0,O=c1nc(N2CCOCC2)oc2ccc(-c3cc4ccccc4s3)cc12,2016
Inhibition of PI3Kgamma (unknown origin) incubated for 60 mins by kinase-glo luminescence assay,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL3763148,=,=,IC50,nM,1500.0,IC50,uM,1.5,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,Nc1cccc(-c2ccc3oc(N4CCOCC4)nc(=O)c3c2)c1,CHEMBL3763148,,,Inhibition,%,,INH,,,Nc1cccc(-c2ccc3oc(N4CCOCC4)nc(=O)c3c2)c1,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,NC(=O)c1ccc(-c2ccc3oc(N4CCOCC4)nc(=O)c3c2)cc1,CHEMBL3763148,,,Inhibition,%,,INH,,,NC(=O)c1ccc(-c2ccc3oc(N4CCOCC4)nc(=O)c3c2)cc1,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(-c3cccs3)cc12,CHEMBL3763148,,,Inhibition,%,,INH,,,O=c1nc(N2CCOCC2)oc2ccc(-c3cccs3)cc12,2016
Inhibition of PI3Kgamma (unknown origin) at 10 uM incubated for 60 mins by kinase-glo luminescence assay,O=c1nc(N2CCOCC2)oc2ccc(-c3ccsc3)cc12,CHEMBL3763148,,,Inhibition,%,,INH,,,O=c1nc(N2CCOCC2)oc2ccc(-c3ccsc3)cc12,2016
Inhibition of human recombinant PI3K gamma by scintillation proximity radiometric assay,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL3769354,=,=,IC50,nM,15.0,IC50,nM,15.0,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2016
Inhibition of PI3K gamma (unknown origin) after 1 hr by ADP-Glo luminescent assay,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL3769354,=,=,IC50,nM,51.0,IC50,nM,51.0,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2016
Inhibition of PI3K gamma (unknown origin) after 1 hr by ADP-Glo luminescent assay,N#Cc1ncccc1Nc1ccc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc2c1,CHEMBL3769354,=,=,IC50,nM,64.0,IC50,nM,64.0,N#Cc1ncccc1Nc1ccc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc2c1,2016
Inhibition of human recombinant PIK3CG assessed as residual activity at 10 uM after 1 hr by qPCR analysis relative to control,Cc1c(Cl)cccc1NC(=O)c1sc2nc3c(cc2c1N)C(=O)CC3,CHEMBL3769377,=,=,Activity,%,100.0,Activity,%,100.0,Cc1c(Cl)cccc1NC(=O)c1sc2nc3c(cc2c1N)C(=O)CC3,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL3769326,=,=,IC50,nM,92.0,IC50,nM,92.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C(=O)c4cc(OC)ccc4O)CC3)cc21,CHEMBL3769326,=,=,IC50,nM,112.0,IC50,nM,112.0,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C(=O)c4cc(OC)ccc4O)CC3)cc21,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C(=O)c4cc(Br)ccc4O)CC3)cc21,CHEMBL3769326,=,=,IC50,nM,111.0,IC50,nM,111.0,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C(=O)c4cc(Br)ccc4O)CC3)cc21,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C(=O)c4c(C)cccc4O)CC3)cc21,CHEMBL3769326,=,=,IC50,nM,173.0,IC50,nM,173.0,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C(=O)c4c(C)cccc4O)CC3)cc21,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C(=O)c4cc(Cl)ccc4O)CC3)cc21,CHEMBL3769326,=,=,IC50,nM,98.0,IC50,nM,98.0,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C(=O)c4cc(Cl)ccc4O)CC3)cc21,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,O=C(O)c1cn(C2CC2)c2cc(N3CCN(C(=O)c4cc([N+](=O)[O-])ccc4O)CC3)c(F)cc2c1=O,CHEMBL3769326,=,=,IC50,nM,185.0,IC50,nM,185.0,O=C(O)c1cn(C2CC2)c2cc(N3CCN(C(=O)c4cc([N+](=O)[O-])ccc4O)CC3)c(F)cc2c1=O,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,O=C(O)c1cn(C2CC2)c2cc(N3CCN(C(=O)c4cc(Br)ccc4O)CC3)c(F)cc2c1=O,CHEMBL3769326,=,=,IC50,nM,169.0,IC50,nM,169.0,O=C(O)c1cn(C2CC2)c2cc(N3CCN(C(=O)c4cc(Br)ccc4O)CC3)c(F)cc2c1=O,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,O=C(O)c1cn(C2CC2)c2cc(N3CCN(C(=O)c4cc([N+](=O)[O-])cc([N+](=O)[O-])c4O)CC3)c(F)cc2c1=O,CHEMBL3769326,=,=,IC50,nM,56.0,IC50,nM,56.0,O=C(O)c1cn(C2CC2)c2cc(N3CCN(C(=O)c4cc([N+](=O)[O-])cc([N+](=O)[O-])c4O)CC3)c(F)cc2c1=O,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,COc1ccc(C(=O)N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)c(O)c1,CHEMBL3769326,=,=,IC50,nM,89.0,IC50,nM,89.0,COc1ccc(C(=O)N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)c(O)c1,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,O=C(O)c1cn(C2CC2)c2cc(N3CCN(C(=O)c4cc(Cl)ccc4O)CC3)c(F)cc2c1=O,CHEMBL3769326,=,=,IC50,nM,174.0,IC50,nM,174.0,O=C(O)c1cn(C2CC2)c2cc(N3CCN(C(=O)c4cc(Cl)ccc4O)CC3)c(F)cc2c1=O,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,O=C(O)c1cn(C2CC2)c2cc(N3CCN(C(=O)c4cccnc4Cl)CC3)c(F)cc2c1=O,CHEMBL3769326,=,=,IC50,nM,265.0,IC50,nM,265.0,O=C(O)c1cn(C2CC2)c2cc(N3CCN(C(=O)c4cccnc4Cl)CC3)c(F)cc2c1=O,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,COc1ccc(C(=O)N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)cn1,CHEMBL3769326,=,=,IC50,nM,285.0,IC50,nM,285.0,COc1ccc(C(=O)N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)cn1,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C(=O)c4cccnc4Cl)CC3)cc21,CHEMBL3769326,=,=,IC50,nM,259.0,IC50,nM,259.0,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C(=O)c4cccnc4Cl)CC3)cc21,2015
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C(=O)c4ccc(OC)nc4)CC3)cc21,CHEMBL3769326,=,=,IC50,nM,279.0,IC50,nM,279.0,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C(=O)c4ccc(OC)nc4)CC3)cc21,2015
Inhibition of human PI3Kgamma at <5 uM by TR-FRET assay,CCn1cc(-c2cccc(C(F)(F)F)c2)c2sc(C(=N)NC3CCS(=O)(=O)CC3)cc2c1=O,CHEMBL3769376,,,Inhibition,%,,INH,,,CCn1cc(-c2cccc(C(F)(F)F)c2)c2sc(C(=N)NC3CCS(=O)(=O)CC3)cc2c1=O,2016
Inhibition of PI3kgamma (unknown origin) assessed as remaining activity at 1 uM relative to control,Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1,CHEMBL3774357,=,=,Activity,%,-5.0,Activity,%,-5.0,Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1,2016
Inhibition of PI3kgamma (unknown origin) assessed as remaining activity at 1 uM relative to control,Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1,CHEMBL3774357,=,=,Activity,%,-3.0,Activity,%,-3.0,Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1,2016
Inhibition of PI3K p110gamma (unknown origin) at 5 uM relative to control,CC1C/C(=C\c2ccc3c(c2)CCO3)C(=O)O1,CHEMBL3774321,=,=,Inhibition,%,75.0,INH,%,75.0,CC1C/C(=C\c2ccc3c(c2)CCO3)C(=O)O1,2016
Inhibition of PI3K p110gamma (unknown origin) at 5 uM relative to control,O=C1OCC/C1=C\c1ccc2ncsc2c1,CHEMBL3774321,=,=,Inhibition,%,79.0,INH,%,79.0,O=C1OCC/C1=C\c1ccc2ncsc2c1,2016
Inhibition of PI3K p110gamma (unknown origin) at 1 uM relative to control,O=C1NC(=S)S/C1=C\c1ccc2ncsc2c1,CHEMBL3774321,=,=,Inhibition,%,97.0,INH,%,97.0,O=C1NC(=S)S/C1=C\c1ccc2ncsc2c1,2016
Inhibition of PI3K p110gamma (unknown origin) at 1 uM relative to control,O=C1NC(=S)S/C1=C\c1ccc2ncccc2c1,CHEMBL3774321,=,=,Inhibition,%,97.0,INH,%,97.0,O=C1NC(=S)S/C1=C\c1ccc2ncccc2c1,2016
Inhibition of PI3K p110gamma (unknown origin),O=C1NC(=S)S/C1=C\c1ccc2ncsc2c1,CHEMBL3774321,=,=,IC50,nM,2.3,IC50,nM,2.3,O=C1NC(=S)S/C1=C\c1ccc2ncsc2c1,2016
Inhibition of PI3K p110gamma (unknown origin),O=C1NC(=S)S/C1=C\c1ccc2ncccc2c1,CHEMBL3774321,=,=,IC50,nM,2.3,IC50,nM,2.3,O=C1NC(=S)S/C1=C\c1ccc2ncccc2c1,2016
Inhibition of human recombinant N-terminal GST-tagged PI3K-gamma (39 to 1102 residues) expressed n baculovirus infected TN5 cells using phosphatidylinositol as substrate by scintillation proximity assay in presence of {33P]gammaATP,O=C1NC(=O)/C(=C/c2ccc3nccnc3c2)S1,CHEMBL3774321,=,=,IC50,nM,8.0,IC50,nM,8.0,O=C1NC(=O)/C(=C/c2ccc3nccnc3c2)S1,2016
Inhibition of PI3kgamma (unknown origin) assessed as remaining activity at 1 uM relative to control,CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1,CHEMBL3774357,=,=,Activity,%,-1.0,Activity,%,-1.0,CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1,2016
Inhibition of PI3Kgamma (unknown origin),CNc1ncc(-c2ccnc(Nc3ccncc3)n2)c(CC2CC2)n1,CHEMBL3779810,=,=,IC50,nM,1900.0,IC50,nM,1900.0,CNc1ncc(-c2ccnc(Nc3ccncc3)n2)c(CC2CC2)n1,2016
Inhibition of PI3Kgamma (unknown origin),CNc1ncc(-c2ccnc(N[C@H]3CC[C@H](O)CC3)n2)c(CC2CC2)n1,CHEMBL3779810,=,=,IC50,nM,8500.0,IC50,nM,8500.0,CNc1ncc(-c2ccnc(N[C@H]3CC[C@H](O)CC3)n2)c(CC2CC2)n1,2016
Inhibition of partial length human PIK3Cgamma expressed in mammalian system at 1 uM,Cc1cnc(N)nc1OCC(C)(C)CO,CHEMBL3779767,,,Inhibition,%,,INH,,,Cc1cnc(N)nc1OCC(C)(C)CO,2016
Inhibition of human PI3Kgamma after 1 hr by ADP-Glo luminescent assay,CC(=O)Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCN(C(C)=O)CC2)c(C(F)(F)F)c1,CHEMBL3779897,=,=,IC50,nM,502.0,IC50,nM,502.0,CC(=O)Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCN(C(C)=O)CC2)c(C(F)(F)F)c1,2016
Inhibition of human PI3Kgamma after 1 hr by ADP-Glo luminescent assay,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL3779897,=,=,IC50,nM,48.0,IC50,nM,48.0,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2016
Inhibition of human PI3Kgamma at 1 uM after 1 hr by ADP-Glo luminescent assay,CC(=O)Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCNCC2)c(C(F)(F)F)c1.Cl,CHEMBL3779897,=,=,Inhibition,%,47.3,INH,%,47.3,CC(=O)Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCNCC2)c(C(F)(F)F)c1.Cl,2016
Inhibition of histidine-tagged recombinant human full length PI3Kgamma expressed in insect cells preincubated for 15 mins followed by addition of cold ATP/gamma32P-ATP measured after 15 mins in presence of MgCl2,CC(=O)/N=c1/[nH]c(C)c(-c2ccc(Cl)c(S(=O)(=O)NCCO)c2)s1,CHEMBL3784974,=,=,IC50,nM,17.0,IC50,nM,17.0,CC(=O)/N=c1/[nH]c(C)c(-c2ccc(Cl)c(S(=O)(=O)NCCO)c2)s1,2016
Inhibition of histidine-tagged recombinant human full length PI3Kgamma expressed in insect cells preincubated for 15 mins followed by addition of cold ATP/gamma32P-ATP measured after 15 mins in presence of MgCl2,CC(=O)Nc1nc(C)c(-c2ccc(Br)c(S(=O)(=O)NCCO)c2)s1,CHEMBL3784974,=,=,IC50,nM,21.0,IC50,nM,21.0,CC(=O)Nc1nc(C)c(-c2ccc(Br)c(S(=O)(=O)NCCO)c2)s1,2016
Inhibition of histidine-tagged recombinant human full length PI3Kgamma expressed in insect cells preincubated for 15 mins followed by addition of cold ATP/gamma32P-ATP measured after 15 mins in presence of MgCl2,COc1ccc(-c2sc(NC(C)=O)nc2C)cc1S(=O)(=O)NCCO,CHEMBL3784974,=,=,IC50,nM,181.0,IC50,nM,181.0,COc1ccc(-c2sc(NC(C)=O)nc2C)cc1S(=O)(=O)NCCO,2016
Inhibition of histidine-tagged recombinant human full length PI3Kgamma expressed in insect cells preincubated for 15 mins followed by addition of cold ATP/gamma32P-ATP measured after 15 mins in presence of MgCl2,Cc1nc(NC(=O)C(C)(C)C)sc1-c1ccc(Cl)c(S(=O)(=O)NCCO)c1,CHEMBL3784974,=,=,IC50,nM,3700.0,IC50,nM,3700.0,Cc1nc(NC(=O)C(C)(C)C)sc1-c1ccc(Cl)c(S(=O)(=O)NCCO)c1,2016
Inhibition of histidine-tagged recombinant human full length PI3Kgamma expressed in insect cells preincubated for 15 mins followed by addition of cold ATP/gamma32P-ATP measured after 15 mins in presence of MgCl2,Cc1nc(NC(=O)C2CCCC2)sc1-c1ccc(Cl)c(S(=O)(=O)NCCO)c1,CHEMBL3784974,=,=,IC50,nM,1500.0,IC50,nM,1500.0,Cc1nc(NC(=O)C2CCCC2)sc1-c1ccc(Cl)c(S(=O)(=O)NCCO)c1,2016
Inhibition of histidine-tagged recombinant human full length PI3Kgamma expressed in insect cells preincubated for 15 mins followed by addition of cold ATP/gamma32P-ATP measured after 15 mins in presence of MgCl2,CC(=O)Nc1nc(C)c(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(O)cc3)c2)s1,CHEMBL3784974,=,=,IC50,nM,5.0,IC50,nM,5.0,CC(=O)Nc1nc(C)c(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(O)cc3)c2)s1,2016
Inhibition of histidine-tagged recombinant human full length PI3Kgamma expressed in insect cells preincubated for 15 mins followed by addition of cold ATP/gamma32P-ATP measured after 15 mins in presence of MgCl2,CC(=O)Nc1nc(C)c(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(F)cc3)c2)s1,CHEMBL3784974,=,=,IC50,nM,31.0,IC50,nM,31.0,CC(=O)Nc1nc(C)c(-c2ccc(Cl)c(S(=O)(=O)Nc3ccc(F)cc3)c2)s1,2016
Inhibition of histidine-tagged recombinant human full length PI3Kgamma expressed in insect cells preincubated for 15 mins followed by addition of cold ATP/gamma32P-ATP measured after 15 mins in presence of MgCl2,COc1ccc(-c2sc(NC(=O)C(C)(C)C)nc2C)cc1S(=O)(=O)NCCO,CHEMBL3784974,>,>,IC50,nM,50000.0,IC50,nM,50000.0,COc1ccc(-c2sc(NC(=O)C(C)(C)C)nc2C)cc1S(=O)(=O)NCCO,2016
Inhibition of histidine-tagged recombinant human full length PI3Kgamma expressed in insect cells preincubated for 15 mins followed by addition of cold ATP/gamma32P-ATP measured after 15 mins in presence of MgCl2,COc1ccc(-c2sc(NC(=O)C3CCCC3)nc2C)cc1S(=O)(=O)Nc1ccc(O)cc1,CHEMBL3784974,=,=,IC50,nM,1046.0,IC50,nM,1046.0,COc1ccc(-c2sc(NC(=O)C3CCCC3)nc2C)cc1S(=O)(=O)Nc1ccc(O)cc1,2016
Inhibition of histidine-tagged recombinant human full length PI3Kgamma expressed in insect cells preincubated for 15 mins followed by addition of cold ATP/gamma32P-ATP measured after 15 mins in presence of MgCl2,COc1ccc(-c2sc(NC(=O)C(C)(C)C)nc2C)cc1S(=O)(=O)Nc1ccc(O)cc1,CHEMBL3784974,=,=,IC50,nM,20000.0,IC50,nM,20000.0,COc1ccc(-c2sc(NC(=O)C(C)(C)C)nc2C)cc1S(=O)(=O)Nc1ccc(O)cc1,2016
Inhibition of histidine-tagged recombinant human full length PI3Kgamma expressed in insect cells at 50 uM preincubated for 15 mins followed by addition of cold ATP/gamma32P-ATP measured after 15 mins in presence of MgCl2,COc1ccc(-c2sc(NC(=O)C(C)(C)C)nc2C)cc1S(=O)(=O)NCCO,CHEMBL3784974,<,<,Inhibition,%,20.0,INH,%,20.0,COc1ccc(-c2sc(NC(=O)C(C)(C)C)nc2C)cc1S(=O)(=O)NCCO,2016
Inhibition of PI3Kgamma (unknown origin) in presence of [gamma33P]ATP,CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cc(OC[C@@H]5CCCO5)ccc4F)c4c(N)ncnc43)C2)CC1,CHEMBL3785066,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cc(OC[C@@H]5CCCO5)ccc4F)c4c(N)ncnc43)C2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) in presence of [gamma33P]ATP,Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,CHEMBL3785066,=,=,IC50,nM,3200.0,IC50,uM,3.2,Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,2016
Inhibition of PI3Kgamma (unknown origin) in presence of [gamma33P]ATP,Nc1ncnc2c1c(-c1cccc(OC[C@@H]3CCCO3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,CHEMBL3785066,>,>,IC50,nM,9100.0,IC50,uM,9.1,Nc1ncnc2c1c(-c1cccc(OC[C@@H]3CCCO3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,2016
Inhibition of PI3Kgamma (unknown origin) in presence of [gamma33P]ATP,Nc1ncnc2c1c(-c1cccc(O)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,CHEMBL3785066,=,=,IC50,nM,980.0,IC50,uM,0.98,Nc1ncnc2c1c(-c1cccc(O)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,2016
Inhibition of human recombinant PI3Kgamma using PIP2 as substrate preincubated for 20 mins followed by substrate addition measured after 80 mins by luminescence assay,CN(C)C(=O)c1cc(CN(C)c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3797054,=,=,IC50,nM,1400.0,IC50,uM,1.4,CN(C)C(=O)c1cc(CN(C)c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1,2016
Inhibition of human recombinant PI3Kgamma using PIP2 as substrate preincubated for 20 mins followed by substrate addition measured after 80 mins by luminescence assay,CN(C)C(=O)c1cc(CN2CCOc3c(F)cccc32)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3797054,=,=,IC50,nM,570.0,IC50,uM,0.57,CN(C)C(=O)c1cc(CN2CCOc3c(F)cccc32)c2oc(N3CCOCC3)cc(=O)c2c1,2016
Inhibition of human recombinant PI3Kgamma using PIP2 as substrate preincubated for 20 mins followed by substrate addition measured after 80 mins by luminescence assay,CN(C)C(=O)c1cc(CN2CCOc3ccc(F)cc32)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3797054,=,=,IC50,nM,1900.0,IC50,uM,1.9,CN(C)C(=O)c1cc(CN2CCOc3ccc(F)cc32)c2oc(N3CCOCC3)cc(=O)c2c1,2016
Inhibition of human recombinant PI3Kgamma using PIP2 as substrate preincubated for 20 mins followed by substrate addition measured after 80 mins by luminescence assay,C[C@@H]1CN(c2cc(=O)c3cc(C(=O)N(C)C)cc(CN4CCOc5c(F)cccc54)c3o2)CCO1,CHEMBL3797054,=,=,IC50,nM,120.0,IC50,uM,0.12,C[C@@H]1CN(c2cc(=O)c3cc(C(=O)N(C)C)cc(CN4CCOc5c(F)cccc54)c3o2)CCO1,2016
Inhibition of human recombinant PI3Kgamma using PIP2 as substrate preincubated for 20 mins followed by substrate addition measured after 80 mins by luminescence assay,C[C@@H]1CN(c2cc(=O)c3cc(C(=O)N(C)C)cc(CN4CCOc5ccc(F)cc54)c3o2)CCO1,CHEMBL3797054,=,=,IC50,nM,440.0,IC50,uM,0.44,C[C@@H]1CN(c2cc(=O)c3cc(C(=O)N(C)C)cc(CN4CCOc5ccc(F)cc54)c3o2)CCO1,2016
Inhibition of human recombinant PI3Kgamma using PIP2 as substrate preincubated for 20 mins followed by substrate addition measured after 80 mins by luminescence assay,C[C@@H]1CN(c2cc(=O)c3cc(C(=O)N(C)C)cc(CN4CCOc5c(F)cc(F)cc54)c3o2)CCO1,CHEMBL3797054,=,=,IC50,nM,140.0,IC50,uM,0.14,C[C@@H]1CN(c2cc(=O)c3cc(C(=O)N(C)C)cc(CN4CCOc5c(F)cc(F)cc54)c3o2)CCO1,2016
Inhibition of human recombinant PI3Kgamma using PIP2 as substrate preincubated for 20 mins followed by substrate addition measured after 80 mins by luminescence assay,C[C@@H]1CN(c2cc(=O)c3cc(C(=O)N(C)C)cc(CN(C)c4cc(F)cc(F)c4)c3o2)CCO1,CHEMBL3797054,=,=,IC50,nM,240.0,IC50,uM,0.24,C[C@@H]1CN(c2cc(=O)c3cc(C(=O)N(C)C)cc(CN(C)c4cc(F)cc(F)c4)c3o2)CCO1,2016
Inhibition of human recombinant PI3Kgamma using PIP2 as substrate preincubated for 20 mins followed by substrate addition measured after 80 mins by luminescence assay,CN(C)C(=O)c1cc(CN2CCOc3c(F)cc(F)cc32)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL3797054,=,=,IC50,nM,720.0,IC50,uM,0.72,CN(C)C(=O)c1cc(CN2CCOc3c(F)cc(F)cc32)c2oc(N3CCOCC3)cc(=O)c2c1,2016
"Inhibition of PI3Kgamma (unknown origin) using (poly [Glu, Tyr] 4:1) as substrate assessed as incorporation of 33P in substrate by [gamma33P] ATP-based kinase assay",CCOC(Cn1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21)OCC,CHEMBL3797068,,,IC50,,,IC50,,,CCOC(Cn1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21)OCC,2016
"Inhibition of PI3Kgamma (unknown origin) using (poly [Glu, Tyr] 4:1) as substrate assessed as incorporation of 33P in substrate by [gamma33P] ATP-based kinase assay",CCOC(Cn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)OCC,CHEMBL3797068,=,=,IC50,nM,1340.0,IC50,nM,1340.0,CCOC(Cn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)OCC,2016
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate by HTRF assay,CCOC(Cn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)OCC,CHEMBL3797068,=,=,IC50,nM,1340.0,IC50,nM,1340.0,CCOC(Cn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)OCC,2016
Inhibition of human PI3Kgamma at 10 uM by kinome profiling method,CCOC(Cn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)OCC,CHEMBL3797068,=,=,Inhibition,%,85.0,INH,%,85.0,CCOC(Cn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)OCC,2016
"Inhibition of PI3Kgamma (unknown origin) using (poly [Glu, Tyr] 4:1) as substrate assessed as incorporation of 33P in substrate by [gamma33P] ATP-based kinase assay",Nc1nc2cc(-c3nn(CC4OCCO4)c4ncnc(N)c34)ccc2o1,CHEMBL3797068,=,=,IC50,nM,302.0,IC50,nM,302.0,Nc1nc2cc(-c3nn(CC4OCCO4)c4ncnc(N)c34)ccc2o1,2016
"Inhibition of PI3Kgamma (unknown origin) using (poly [Glu, Tyr] 4:1) as substrate assessed as incorporation of 33P in substrate by [gamma33P] ATP-based kinase assay",COC(Cn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)OC,CHEMBL3797068,=,=,IC50,nM,99.0,IC50,nM,99.0,COC(Cn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)OC,2016
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate by HTRF assay,Nc1nc2cc(-c3nn(CC4CCCC4)c4ncnc(N)c34)ccc2o1,CHEMBL3797068,=,=,IC50,nM,5.0,IC50,nM,5.0,Nc1nc2cc(-c3nn(CC4CCCC4)c4ncnc(N)c34)ccc2o1,2016
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate by HTRF assay,Nc1nc2cc(-c3nn(CC4CCCO4)c4ncnc(N)c34)ccc2o1,CHEMBL3797068,=,=,IC50,nM,77.0,IC50,nM,77.0,Nc1nc2cc(-c3nn(CC4CCCO4)c4ncnc(N)c34)ccc2o1,2016
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate by HTRF assay,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2cncnc21,CHEMBL3797068,=,=,IC50,nM,230.0,IC50,nM,230.0,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2cncnc21,2016
Inhibition of human PIK3CG (144 to 1102 amino acid residues) assessed as enzyme activity at 10 uM by KINOMEScan assay,O=C1C2=C(C(=O)c3c(O)ccc(O)c31)[C@@H](O)[C@@H](O)[C@@H](O)C2,CHEMBL3808372,=,=,Activity,%,68.0,Activity,%,68.0,O=C1C2=C(C(=O)c3c(O)ccc(O)c31)[C@@H](O)[C@@H](O)[C@@H](O)C2,2016
Inhibition of PI3K gamma (unknown origin),Nc1nccc(-c2c[nH]c3ncccc23)n1,CHEMBL3813616,>,>,IC50,nM,10000.0,IC50,uM,10.0,Nc1nccc(-c2c[nH]c3ncccc23)n1,2016
Inhibition of PI3K gamma (unknown origin),CCCCc1cc(-c2c[nH]c3ncccc23)nc(N)n1,CHEMBL3813616,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCCCc1cc(-c2c[nH]c3ncccc23)nc(N)n1,2016
Inhibition of PI3K gamma (unknown origin),CCc1cc(-c2c[nH]c3ncc(-c4ccc(N)nc4)cc23)nc(N)n1,CHEMBL3813616,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCc1cc(-c2c[nH]c3ncc(-c4ccc(N)nc4)cc23)nc(N)n1,2016
Inhibition of PI3K gamma (unknown origin),CCc1cc(-c2c[nH]c3ncc(-c4ccco4)cc23)nc(N)n1,CHEMBL3813616,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCc1cc(-c2c[nH]c3ncc(-c4ccco4)cc23)nc(N)n1,2016
Inhibition of PI3K gamma (unknown origin),CCc1cc(-c2c[nH]c3ncc(-c4cn[nH]c4)cc23)nc(N)n1,CHEMBL3813616,=,=,IC50,nM,7000.0,IC50,uM,7.0,CCc1cc(-c2c[nH]c3ncc(-c4cn[nH]c4)cc23)nc(N)n1,2016
Inhibition of PI3K gamma (unknown origin),CCc1cc(-c2c[nH]c3ncc(-c4ccn[nH]4)cc23)nc(N)n1,CHEMBL3813616,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCc1cc(-c2c[nH]c3ncc(-c4ccn[nH]4)cc23)nc(N)n1,2016
Inhibition of PI3K gamma (unknown origin),CCc1cc(-c2c[nH]c3ncc(-c4cnn(C)c4)cc23)nc(N)n1,CHEMBL3813616,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCc1cc(-c2c[nH]c3ncc(-c4cnn(C)c4)cc23)nc(N)n1,2016
Inhibition of PI3K gamma (unknown origin),CCc1cc(-c2c[nH]c3ncc(-c4cnn(CCN(C)C)c4)cc23)nc(N)n1,CHEMBL3813616,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCc1cc(-c2c[nH]c3ncc(-c4cnn(CCN(C)C)c4)cc23)nc(N)n1,2016
Inhibition of PI3K gamma (unknown origin),CCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1,CHEMBL3813616,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1,2016
Inhibition of PI3K gamma (unknown origin),CCc1cc(-c2c[nH]c3ncc(-c4cnn(CC(C)C)c4)cc23)nc(N)n1,CHEMBL3813616,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCc1cc(-c2c[nH]c3ncc(-c4cnn(CC(C)C)c4)cc23)nc(N)n1,2016
Inhibition of PI3K gamma (unknown origin),CCCCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1,CHEMBL3813616,,,IC50,,,IC50,,,CCCCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1,2016
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay in presence of biotin-PIP3,COc1cncc(-c2cnn3ccc(NC4CCC(O)CC4)nc23)c1,CHEMBL3813684,=,=,IC50,nM,5754.4,pIC50,,5.24,COc1cncc(-c2cnn3ccc(NC4CCC(O)CC4)nc23)c1,2016
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay in presence of biotin-PIP3,FC(F)(F)c1cc(Nc2nc3ccccc3s2)cc(C(F)(F)F)c1,CHEMBL3813684,=,=,IC50,nM,5495.41,pIC50,,5.26,FC(F)(F)c1cc(Nc2nc3ccccc3s2)cc(C(F)(F)F)c1,2016
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay in presence of biotin-PIP3,COc1cc(-c2cnn3ccc(Nc4ccc(C(C)C)cc4)nc23)ccc1O,CHEMBL3813684,=,=,IC50,nM,2398.83,pIC50,,5.62,COc1cc(-c2cnn3ccc(Nc4ccc(C(C)C)cc4)nc23)ccc1O,2016
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay in presence of biotin-PIP3,COc1cc(Nc2ccn3ncc(-c4cccc(C(N)=O)c4)c3n2)cc(OC)c1OC,CHEMBL3813684,=,=,IC50,nM,6165.95,pIC50,,5.21,COc1cc(Nc2ccn3ncc(-c4cccc(C(N)=O)c4)c3n2)cc(OC)c1OC,2016
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay in presence of biotin-PIP3,COc1cc(-c2cnc3ccc(NCc4ccco4)nn23)ccc1O,CHEMBL3813684,=,=,IC50,nM,6918.31,pIC50,,5.16,COc1cc(-c2cnc3ccc(NCc4ccco4)nn23)ccc1O,2016
Inhibition of PI3Kgamma (unknown origin),COc1cc([C@@H](CC(=O)O)c2ccc(C)c(CN3C[C@@H](C)Oc4ccccc4S3(=O)=O)c2)cc2nnn(C)c12,CHEMBL3817762,,,Inhibition,%,,INH,,,COc1cc([C@@H](CC(=O)O)c2ccc(C)c(CN3C[C@@H](C)Oc4ccccc4S3(=O)=O)c2)cc2nnn(C)c12,2016
Inhibition of His-tagged full-length human PIK3CG expressed in baculovirus system at 100 nM by adapta assay,O=C(CNC(=O)c1cccn(Cc2ccc(F)c(F)c2)c1=O)Nc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2,CHEMBL3822377,=,=,Inhibition,%,2.0,INH,%,2.0,O=C(CNC(=O)c1cccn(Cc2ccc(F)c(F)c2)c1=O)Nc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2,2016
Inhibition of His-tagged full length recombinant human p110gamma expressed in baculovirus expression system incubated for 1 hr by ADP-gloreagen assay,COc1ccc(-c2nc(N3CCOCC3)c3nc(CN(C)c4ncc(C(=O)NO)cn4)n(C)c3n2)cc1,CHEMBL3826921,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COc1ccc(-c2nc(N3CCOCC3)c3nc(CN(C)c4ncc(C(=O)NO)cn4)n(C)c3n2)cc1,2016
Inhibition of His-tagged full length recombinant human p110gamma expressed in baculovirus expression system incubated for 1 hr by ADP-gloreagen assay,CN(Cc1nc2c(N3CCOCC3)nc(-c3ccc(N)cc3)nc2n1C)c1ncc(C(=O)NO)cn1,CHEMBL3826921,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CN(Cc1nc2c(N3CCOCC3)nc(-c3ccc(N)cc3)nc2n1C)c1ncc(C(=O)NO)cn1,2016
Inhibition of His-tagged full length recombinant human p110gamma expressed in baculovirus expression system incubated for 1 hr by ADP-gloreagen assay,CN(Cc1nc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc2n1C)c1ncc(C(=O)NO)cn1,CHEMBL3826921,=,=,IC50,nM,8.1,IC50,nM,8.1,CN(Cc1nc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc2n1C)c1ncc(C(=O)NO)cn1,2016
Inhibition of His-tagged full length recombinant human p110gamma expressed in baculovirus expression system incubated for 1 hr by ADP-gloreagen assay,COc1ccc(-c2nc(N3CCOCC3)c3nc(CN(C)c4ncc(C(=O)NO)cn4)n(C)c3n2)cn1,CHEMBL3826921,=,=,IC50,nM,255.0,IC50,nM,255.0,COc1ccc(-c2nc(N3CCOCC3)c3nc(CN(C)c4ncc(C(=O)NO)cn4)n(C)c3n2)cn1,2016
Inhibition of His-tagged full length recombinant human p110gamma expressed in baculovirus expression system incubated for 1 hr by ADP-gloreagen assay,CN(Cc1nc2c(N3CCOCC3)nc(-c3ccncc3)nc2n1C)c1ncc(C(=O)NO)cn1,CHEMBL3826921,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CN(Cc1nc2c(N3CCOCC3)nc(-c3ccncc3)nc2n1C)c1ncc(C(=O)NO)cn1,2016
Inhibition of His-tagged full length recombinant human p110gamma expressed in baculovirus expression system incubated for 1 hr by ADP-gloreagen assay,COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,CHEMBL3826921,=,=,IC50,nM,311.0,IC50,nM,311.0,COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,2016
Inhibition of His-tagged full length recombinant human p110gamma expressed in baculovirus expression system incubated for 1 hr by ADP-gloreagen assay,Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,CHEMBL3826921,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,2016
Binding affinity to human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells by equilibrium fluorescence titration analysis,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,Kd,nM,0.29,Kd,nM,0.29,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,16.0,IC50,nM,16.0,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3ccn(C)n3)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,100.0,IC50,nM,100.0,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3ccn(C)n3)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3nccs3)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,360.0,IC50,nM,360.0,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3nccs3)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cscn3)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,75.0,IC50,nM,75.0,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cscn3)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cncs3)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,110.0,IC50,nM,110.0,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cncs3)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3ccccn3)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,170.0,IC50,nM,170.0,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3ccccn3)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3ccncc3)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,350.0,IC50,nM,350.0,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3ccncc3)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cccnc3)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,110.0,IC50,nM,110.0,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cccnc3)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3ccccc3)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,280.0,IC50,nM,280.0,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3ccccc3)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,CC#Cc1cccc2cc([C@H](C)NC(=O)c3c(N)nn4cccnc34)n(-c3ccccc3)c(=O)c12,CHEMBL3853350,=,=,IC50,nM,25.0,IC50,nM,25.0,CC#Cc1cccc2cc([C@H](C)NC(=O)c3c(N)nn4cccnc34)n(-c3ccccc3)c(=O)c12,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C#Cc1cccc2cc([C@H](C)NC(=O)c3c(N)nn4cccnc34)n(-c3ccccc3)c(=O)c12,CHEMBL3853350,=,=,IC50,nM,14.0,IC50,nM,14.0,C#Cc1cccc2cc([C@H](C)NC(=O)c3c(N)nn4cccnc34)n(-c3ccccc3)c(=O)c12,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C/C=C/c1cccc2cc([C@H](C)NC(=O)c3c(N)nn4cccnc34)n(-c3ccccc3)c(=O)c12,CHEMBL3853350,=,=,IC50,nM,330.0,IC50,nM,330.0,C/C=C/c1cccc2cc([C@H](C)NC(=O)c3c(N)nn4cccnc34)n(-c3ccccc3)c(=O)c12,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(N(C)C)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,1100.0,IC50,nM,1100.0,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(N(C)C)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,CNc1cccc2cc([C@H](C)NC(=O)c3c(N)nn4cccnc34)n(-c3ccccc3)c(=O)c12,CHEMBL3853350,=,=,IC50,nM,1100.0,IC50,nM,1100.0,CNc1cccc2cc([C@H](C)NC(=O)c3c(N)nn4cccnc34)n(-c3ccccc3)c(=O)c12,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,COc1cccc2cc([C@H](C)NC(=O)c3c(N)nn4cccnc34)n(-c3ccccc3)c(=O)c12,CHEMBL3853350,=,=,IC50,nM,1000.0,IC50,nM,1000.0,COc1cccc2cc([C@H](C)NC(=O)c3c(N)nn4cccnc34)n(-c3ccccc3)c(=O)c12,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#N)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,240.0,IC50,nM,240.0,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#N)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,50.0,IC50,nM,50.0,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(F)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,Cc1cccc2cc([C@H](C)NC(=O)c3c(N)nn4cccnc34)n(-c3ccccc3)c(=O)c12,CHEMBL3853350,=,=,IC50,nM,110.0,IC50,nM,110.0,Cc1cccc2cc([C@H](C)NC(=O)c3c(N)nn4cccnc34)n(-c3ccccc3)c(=O)c12,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,CC[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,150.0,IC50,nM,150.0,CC[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,Nc1nn2cccnc2c1C(=O)NCc1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3853350,>,>,IC50,nM,7000.0,IC50,nM,7000.0,Nc1nn2cccnc2c1C(=O)NCc1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)ncc2ccccc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3853350,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](NC(=O)c1c(N)ncc2ccccc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2ccccc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,300.0,IC50,nM,300.0,C[C@H](NC(=O)c1c(N)nn2ccccc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1cncc2cccnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](NC(=O)c1cncc2cccnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1cnn2cccnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,400.0,IC50,nM,400.0,C[C@H](NC(=O)c1cnn2cccnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)ncc2cccnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,60.0,IC50,nM,60.0,C[C@H](NC(=O)c1c(N)ncc2cccnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using diC8PIP2 as substrate incubated for 15 mins followed by substrate addition measured after 2 hr by ADP-Glo luminescence assay,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3853350,=,=,IC50,nM,40.0,IC50,nM,40.0,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL3853357,=,=,IC50,nM,64.0,IC50,nM,64.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,Cc1cc(S(N)(=O)=O)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C,CHEMBL3853357,=,=,IC50,nM,2400.0,IC50,nM,2400.0,Cc1cc(S(N)(=O)=O)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3853357,=,=,IC50,nM,2.9,IC50,nM,2.9,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1,CHEMBL3853357,,,Inhibition,%,,INH,,,C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,CN1C(=O)c2ccccc2N(C)c2nc(Nc3cccc(S(N)(=O)=O)c3)ncc21,CHEMBL3853357,=,=,IC50,nM,4.3,IC50,nM,4.3,CN1C(=O)c2ccccc2N(C)c2nc(Nc3cccc(S(N)(=O)=O)c3)ncc21,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,CN1C(=O)c2ccccc2N(C)c2nc(Nc3ccc(S(N)(=O)=O)cc3)ncc21,CHEMBL3853357,=,=,IC50,nM,15.0,IC50,nM,15.0,CN1C(=O)c2ccccc2N(C)c2nc(Nc3ccc(S(N)(=O)=O)cc3)ncc21,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,Cc1ccc2c(c1)C(=O)N(C)c1cnc(Nc3cccc(S(N)(=O)=O)c3)nc1N2C,CHEMBL3853357,=,=,IC50,nM,110.0,IC50,nM,110.0,Cc1ccc2c(c1)C(=O)N(C)c1cnc(Nc3cccc(S(N)(=O)=O)c3)nc1N2C,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,Cc1ccc2c(c1)C(=O)N(C)c1cnc(Nc3ccc(S(N)(=O)=O)cc3)nc1N2C,CHEMBL3853357,=,=,IC50,nM,20.0,IC50,nM,20.0,Cc1ccc2c(c1)C(=O)N(C)c1cnc(Nc3ccc(S(N)(=O)=O)cc3)nc1N2C,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,Cc1ccc2c(c1)C(=O)N(C)c1cnc(Nc3ccc(S(=O)(=O)N4CCC(O)CC4)cc3)nc1N2C,CHEMBL3853357,=,=,IC50,nM,58.0,IC50,nM,58.0,Cc1ccc2c(c1)C(=O)N(C)c1cnc(Nc3ccc(S(=O)(=O)N4CCC(O)CC4)cc3)nc1N2C,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,Cc1ccc2c(c1)C(=O)N(C)c1cnc(Nc3cccc(S(=O)(=O)N4CCC(O)CC4)c3)nc1N2C,CHEMBL3853357,=,=,IC50,nM,6.5,IC50,nM,6.5,Cc1ccc2c(c1)C(=O)N(C)c1cnc(Nc3cccc(S(=O)(=O)N4CCC(O)CC4)c3)nc1N2C,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,Cc1ccc2c(c1)C(=O)N(C)c1cnc(Nc3ccc(S(=O)(=O)N4CCN(C)CC4)cc3)nc1N2C,CHEMBL3853357,=,=,IC50,nM,3300.0,IC50,nM,3300.0,Cc1ccc2c(c1)C(=O)N(C)c1cnc(Nc3ccc(S(=O)(=O)N4CCN(C)CC4)cc3)nc1N2C,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,Cc1ccc2c(c1)C(=O)N(C)c1cnc(Nc3cccc(S(=O)(=O)N4CCN(C)CC4)c3)nc1N2C,CHEMBL3853357,=,=,IC50,nM,560.0,IC50,nM,560.0,Cc1ccc2c(c1)C(=O)N(C)c1cnc(Nc3cccc(S(=O)(=O)N4CCN(C)CC4)c3)nc1N2C,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,CCC(=O)N1CCN(S(=O)(=O)c2cccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)c2)CC1,CHEMBL3853357,=,=,IC50,nM,11.0,IC50,nM,11.0,CCC(=O)N1CCN(S(=O)(=O)c2cccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)c2)CC1,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,C=CC(=O)Nc1cccc(NS(=O)(=O)c2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)c1,CHEMBL3853357,=,=,IC50,nM,340.0,IC50,nM,340.0,C=CC(=O)Nc1cccc(NS(=O)(=O)c2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)c1,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,C=CC(=O)Nc1cccc(NS(=O)(=O)c2cccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)c2)c1,CHEMBL3853357,=,=,IC50,nM,330.0,IC50,nM,330.0,C=CC(=O)Nc1cccc(NS(=O)(=O)c2cccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)c2)c1,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,C=CC(=O)Nc1ccc(NS(=O)(=O)c2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1,CHEMBL3853357,=,=,IC50,nM,310.0,IC50,nM,310.0,C=CC(=O)Nc1ccc(NS(=O)(=O)c2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,C=CC(=O)Nc1ccc(NS(=O)(=O)c2cccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)c2)cc1,CHEMBL3853357,=,=,IC50,nM,15.0,IC50,nM,15.0,C=CC(=O)Nc1ccc(NS(=O)(=O)c2cccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)c2)cc1,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,C=CC(=O)NC1CCN(S(=O)(=O)c2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)CC1,CHEMBL3853357,=,=,IC50,nM,49.0,IC50,nM,49.0,C=CC(=O)NC1CCN(S(=O)(=O)c2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)CC1,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,C=CC(=O)NC1CCN(S(=O)(=O)c2cccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)c2)CC1,CHEMBL3853357,=,=,IC50,nM,120.0,IC50,nM,120.0,C=CC(=O)NC1CCN(S(=O)(=O)c2cccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)c2)CC1,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,C=CC(=O)N1CCN(S(=O)(=O)c2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)CC1,CHEMBL3853357,=,=,IC50,nM,110.0,IC50,nM,110.0,C=CC(=O)N1CCN(S(=O)(=O)c2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)CC1,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay,C=CC(=O)N1CCN(S(=O)(=O)c2cccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)c2)CC1,CHEMBL3853357,=,=,IC50,nM,2.8,IC50,nM,2.8,C=CC(=O)N1CCN(S(=O)(=O)c2cccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)c2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) using phosphatidylinositol and gamma-32P-ATP incubated for 20 mins by TLC assay or high-throughput membrane capture assay,CC(=O)/N=c1/[nH]c(C)c(-c2ccc(Cl)c(S(=O)(=O)NCCO)c2)s1,CHEMBL3860068,=,=,IC50,nM,16.0,IC50,uM,0.016,CC(=O)/N=c1/[nH]c(C)c(-c2ccc(Cl)c(S(=O)(=O)NCCO)c2)s1,2017
Inhibition of PI3Kgamma (unknown origin),Nc1ncc(-c2ccnc(Nc3ccncc3)n2)c(CC2CC2)n1,CHEMBL3860068,=,=,IC50,nM,3000.0,IC50,uM,3.0,Nc1ncc(-c2ccnc(Nc3ccncc3)n2)c(CC2CC2)n1,2017
Inhibition of human recombinant PI3Kgamma by luciferase-luciferin-coupled chemiluminescence assay,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,CHEMBL3860068,=,=,IC50,nM,23.0,IC50,uM,0.023,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,2017
Binding affinity to human PIK3CG expressed in Escherichia coli BL21 cells incubated for 1 hr by active site directed binding competition assay,CCc1ccc(/N=C2\S/C(=C\c3ccnc(Nc4ccc(C(=O)O)cn4)c3)C(=O)N2C)cc1,CHEMBL3861974,=,=,Kd,nM,1500.0,Kd,nM,1500.0,CCc1ccc(/N=C2\S/C(=C\c3ccnc(Nc4ccc(C(=O)O)cn4)c3)C(=O)N2C)cc1,2016
Inhibition of PI3Kgamma (unknown origin) by ADP-Glo kinase assay,CCc1cc(CNc2cc(Cl)nn3c(-c4ccc(OC)c(S(=O)(=O)NCCO)c4)c(C)nc23)ccn1,CHEMBL3862042,<,<,IC50,nM,10000.0,IC50,uM,10.0,CCc1cc(CNc2cc(Cl)nn3c(-c4ccc(OC)c(S(=O)(=O)NCCO)c4)c(C)nc23)ccn1,2017
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1cc(N2CCOCC2)oc2cc3ccccc3cc12,CHEMBL3864148,=,=,Inhibition,%,-4.0,INH,%,-4.0,O=c1cc(N2CCOCC2)oc2cc3ccccc3cc12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1cc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)c3ccccc3cc12,CHEMBL3864148,=,=,Inhibition,%,3.0,INH,%,3.0,O=c1cc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)c3ccccc3cc12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2ccc3ccccc3c12,CHEMBL3864148,=,=,Inhibition,%,2.0,INH,%,2.0,O=c1nc(N2CCOCC2)oc2ccc3ccccc3c12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2ccc3cc(-c4ccccc4)ccc3c12,CHEMBL3864148,=,=,Inhibition,%,1.0,INH,%,1.0,O=c1nc(N2CCOCC2)oc2ccc3cc(-c4ccccc4)ccc3c12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,COc1ccc(-c2ccc3c(ccc4oc(N5CCOCC5)nc(=O)c43)c2)cc1,CHEMBL3864148,=,=,Inhibition,%,-2.0,INH,%,-2.0,COc1ccc(-c2ccc3c(ccc4oc(N5CCOCC5)nc(=O)c43)c2)cc1,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2ccc3cc(-c4ccc(Cl)cc4)ccc3c12,CHEMBL3864148,=,=,Inhibition,%,0.0,INH,%,0.0,O=c1nc(N2CCOCC2)oc2ccc3cc(-c4ccc(Cl)cc4)ccc3c12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2c1ccc1ccccc12,CHEMBL3864148,=,=,Inhibition,%,4.0,INH,%,4.0,O=c1nc(N2CCOCC2)oc2c1ccc1ccccc12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2c1cc(-c1ccccc1)c1ccccc12,CHEMBL3864148,=,=,Inhibition,%,34.0,INH,%,34.0,O=c1nc(N2CCOCC2)oc2c1cc(-c1ccccc1)c1ccccc12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,COc1ccc(-c2cc3c(=O)nc(N4CCOCC4)oc3c3ccccc23)cc1,CHEMBL3864148,=,=,Inhibition,%,17.0,INH,%,17.0,COc1ccc(-c2cc3c(=O)nc(N4CCOCC4)oc3c3ccccc23)cc1,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2c1cc(-c1cccc3c1oc1ccccc13)c1ccccc12,CHEMBL3864148,=,=,Inhibition,%,24.0,INH,%,24.0,O=c1nc(N2CCOCC2)oc2c1cc(-c1cccc3c1oc1ccccc13)c1ccccc12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2c1cc(-c1cccc3c1sc1ccccc13)c1ccccc12,CHEMBL3864148,=,=,Inhibition,%,12.0,INH,%,12.0,O=c1nc(N2CCOCC2)oc2c1cc(-c1cccc3c1sc1ccccc13)c1ccccc12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption after 60 mins by Kinase-Glo assay,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)c3ccccc3cc12,CHEMBL3864148,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)c3ccccc3cc12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption after 60 mins by Kinase-Glo assay,COc1ccc(-c2c3ccccc3cc3c(=O)cc(N4CCOCC4)oc23)cc1,CHEMBL3864148,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc(-c2c3ccccc3cc3c(=O)cc(N4CCOCC4)oc23)cc1,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2ccc3cc(-c4cccc5c4oc4ccccc45)ccc3c12,CHEMBL3864148,,,Inhibition,%,,INH,,,O=c1nc(N2CCOCC2)oc2ccc3cc(-c4cccc5c4oc4ccccc45)ccc3c12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2ccc3cc(-c4cccc5c4sc4ccccc45)ccc3c12,CHEMBL3864148,,,Inhibition,%,,INH,,,O=c1nc(N2CCOCC2)oc2ccc3cc(-c4cccc5c4sc4ccccc45)ccc3c12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2c1cc(-c1ccc(Cl)cc1)c1ccccc12,CHEMBL3864148,,,Inhibition,%,,INH,,,O=c1nc(N2CCOCC2)oc2c1cc(-c1ccc(Cl)cc1)c1ccccc12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2c1cc(-c1ccc(CO)cc1)c1ccccc12,CHEMBL3864148,,,Inhibition,%,,INH,,,O=c1nc(N2CCOCC2)oc2c1cc(-c1ccc(CO)cc1)c1ccccc12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,Nc1cccc(-c2cc3c(=O)nc(N4CCOCC4)oc3c3ccccc23)c1,CHEMBL3864148,,,Inhibition,%,,INH,,,Nc1cccc(-c2cc3c(=O)nc(N4CCOCC4)oc3c3ccccc23)c1,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,NC(=O)c1ccc(-c2cc3c(=O)nc(N4CCOCC4)oc3c3ccccc23)cc1,CHEMBL3864148,,,Inhibition,%,,INH,,,NC(=O)c1ccc(-c2cc3c(=O)nc(N4CCOCC4)oc3c3ccccc23)cc1,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2c1cc(/C=C/c1ccccc1)c1ccccc12,CHEMBL3864148,,,Inhibition,%,,INH,,,O=c1nc(N2CCOCC2)oc2c1cc(/C=C/c1ccccc1)c1ccccc12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2c1cc(-c1cccs1)c1ccccc12,CHEMBL3864148,,,Inhibition,%,,INH,,,O=c1nc(N2CCOCC2)oc2c1cc(-c1cccs1)c1ccccc12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2c1cc(-c1ccsc1)c1ccccc12,CHEMBL3864148,,,Inhibition,%,,INH,,,O=c1nc(N2CCOCC2)oc2c1cc(-c1ccsc1)c1ccccc12,2016
Inhibition of p110gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM after 60 mins by Kinase-Glo assay relative to control,O=c1nc(N2CCOCC2)oc2c1cc(-c1cccc3ccccc13)c1ccccc12,CHEMBL3864148,,,Inhibition,%,,INH,,,O=c1nc(N2CCOCC2)oc2c1cc(-c1cccc3ccccc13)c1ccccc12,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1c(Cc2c(CN(C)CCS(C)(=O)=O)nc3c(N)cc(N4CCOCC4)nn23)cccc1C(F)(F)F,CHEMBL3864168,>,>,Kd,nM,30200.0,Kd,nM,30200.0,Cc1c(Cc2c(CN(C)CCS(C)(=O)=O)nc3c(N)cc(N4CCOCC4)nn23)cccc1C(F)(F)F,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1c(Cc2c(CNCCS(C)(=O)=O)nc3c(N)cc(N4CCOCC4)nn23)cccc1C(F)(F)F,CHEMBL3864168,>,>,Kd,nM,30200.0,Kd,nM,30200.0,Cc1c(Cc2c(CNCCS(C)(=O)=O)nc3c(N)cc(N4CCOCC4)nn23)cccc1C(F)(F)F,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1nc2c(-c3cnc[nH]3)cc(N3CCOCC3)nn2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL3864168,=,=,Kd,nM,10233.0,Kd,nM,10233.0,Cc1nc2c(-c3cnc[nH]3)cc(N3CCOCC3)nn2c1Cc1cccc(C(F)(F)F)c1C,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1nc2c(C(=O)O)cc(N3CCOCC3)nn2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL3864168,=,=,Kd,nM,5248.0,Kd,nM,5248.0,Cc1nc2c(C(=O)O)cc(N3CCOCC3)nn2c1Cc1cccc(C(F)(F)F)c1C,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1nc2c(C(N)=O)cc(N3CCOCC3)nn2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL3864168,>,>,Kd,nM,30200.0,Kd,nM,30200.0,Cc1nc2c(C(N)=O)cc(N3CCOCC3)nn2c1Cc1cccc(C(F)(F)F)c1C,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,CS(=O)(=O)O.Cc1c(Cc2c(CO)nc3c(N)cc(N4CCOCC4)nn23)cccc1C(F)(F)F,CHEMBL3864168,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CS(=O)(=O)O.Cc1c(Cc2c(CO)nc3c(N)cc(N4CCOCC4)nn23)cccc1C(F)(F)F,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1c(Cc2c(CO)nc3c(N)cc(N4CCOCC4)nn23)cccc1C(F)(F)F.O=S(=O)(O)O,CHEMBL3864168,,,Kd,,,Kd,,,Cc1c(Cc2c(CO)nc3c(N)cc(N4CCOCC4)nn23)cccc1C(F)(F)F.O=S(=O)(O)O,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,CC(=O)NCc1nc2c(-c3cnc[nH]3)cc(N3CCOCC3)nn2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL3864168,>,>,Kd,nM,30200.0,Kd,nM,30200.0,CC(=O)NCc1nc2c(-c3cnc[nH]3)cc(N3CCOCC3)nn2c1Cc1cccc(C(F)(F)F)c1C,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1c(Cc2c(CO)nc3c(C(=O)O)cc(N4CCOCC4)nn23)cccc1C(F)(F)F,CHEMBL3864168,>,>,Kd,nM,15136.0,Kd,nM,15136.0,Cc1c(Cc2c(CO)nc3c(C(=O)O)cc(N4CCOCC4)nn23)cccc1C(F)(F)F,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1nc2c(N)cc(N3CCOCC3)nn2c1Cc1cccc(C(F)(F)F)c1C,CHEMBL3864168,=,=,Kd,nM,11357.0,Kd,nM,11357.0,Cc1nc2c(N)cc(N3CCOCC3)nn2c1Cc1cccc(C(F)(F)F)c1C,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1nc2c(-c3cnc[nH]3)cc(N3CCOCC3)nn2c1Nc1cccc(C(F)(F)F)c1C,CHEMBL3864168,=,=,Kd,nM,2291.0,Kd,nM,2291.0,Cc1nc2c(-c3cnc[nH]3)cc(N3CCOCC3)nn2c1Nc1cccc(C(F)(F)F)c1C,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1nc2c(-c3cnc[nH]3)cc(N3CCOCC3)nn2c1Nc1cccc(C(F)(F)F)c1CN1CC(O)C1,CHEMBL3864168,=,=,Kd,nM,741.0,Kd,nM,741.0,Cc1nc2c(-c3cnc[nH]3)cc(N3CCOCC3)nn2c1Nc1cccc(C(F)(F)F)c1CN1CC(O)C1,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1nc2c(N)cc(N3CCOCC3)nn2c1Nc1cccc(C(F)(F)F)c1CN1CC(O)C1,CHEMBL3864168,=,=,Kd,nM,19628.0,Kd,nM,19628.0,Cc1nc2c(N)cc(N3CCOCC3)nn2c1Nc1cccc(C(F)(F)F)c1CN1CC(O)C1,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1nc2c(N)cc(N3CCOCC3)nn2c1Nc1cccc(C(F)(F)F)c1CN1CCN(C)CC1,CHEMBL3864168,=,=,Kd,nM,12303.0,Kd,nM,12303.0,Cc1nc2c(N)cc(N3CCOCC3)nn2c1Nc1cccc(C(F)(F)F)c1CN1CCN(C)CC1,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1c(Nc2c(CO)nc3c(N)cc(N4CCOC(CO)C4)nn23)cccc1C(F)(F)F,CHEMBL3864168,=,=,Kd,nM,692.0,Kd,nM,692.0,Cc1c(Nc2c(CO)nc3c(N)cc(N4CCOC(CO)C4)nn23)cccc1C(F)(F)F,2016
Binding affinity to human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Cc1c(Nc2c(CO)nc3c(N)cc(N4CCOC(CO)C4)nn23)cccc1C(F)(F)F,CHEMBL3864168,=,=,Kd,nM,13490.0,Kd,nM,13490.0,Cc1c(Nc2c(CO)nc3c(N)cc(N4CCOC(CO)C4)nn23)cccc1C(F)(F)F,2016
Inhibition of PI3Kgamma (unknown origin) in presence of [gamma-32P]ATP by phosphorimaging assay,Cc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)nc2cccc(C)c2c1=O,CHEMBL3864190,=,=,IC50,nM,33.0,IC50,nM,33.0,Cc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)nc2cccc(C)c2c1=O,2016
Inhibition of PI3Kgamma (unknown origin),N[C@@H](Cc1ccccc1)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL3865805,,,Inhibition,%,,INH,,,N[C@@H](Cc1ccccc1)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 1 hr in presence of ATP by ADP-glo based luminescence assay,COc1ncc(-c2ccc3nccc(-c4ccc(CN(C)C)cc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3865829,=,=,IC50,nM,1.5,IC50,nM,1.5,COc1ncc(-c2ccc3nccc(-c4ccc(CN(C)C)cc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 1 hr in presence of ATP by ADP-glo based luminescence assay,COc1ncc(-c2ccc3nccc(-c4ccc(CN(C)CCO)cc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3865829,=,=,IC50,nM,1.1,IC50,nM,1.1,COc1ncc(-c2ccc3nccc(-c4ccc(CN(C)CCO)cc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 1 hr in presence of ATP by ADP-glo based luminescence assay,COc1ncc(-c2ccc3nccc(-c4ccc(Cn5cncn5)cc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3865829,=,=,IC50,nM,0.74,IC50,nM,0.74,COc1ncc(-c2ccc3nccc(-c4ccc(Cn5cncn5)cc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 1 hr in presence of ATP by ADP-glo based luminescence assay,COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3865829,=,=,IC50,nM,0.61,IC50,nM,0.61,COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2016
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 1 hr in presence of ATP by ADP-glo based luminescence assay,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL3865829,=,=,IC50,nM,18.0,IC50,nM,18.0,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,COc1ccc(-c2ccc3ncnc(O[C@H]4CCN(C(C)=O)C4)c3c2)cc1OC,CHEMBL3867474,=,=,IC50,nM,194.0,IC50,uM,0.194,COc1ccc(-c2ccc3ncnc(O[C@H]4CCN(C(C)=O)C4)c3c2)cc1OC,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cc1OC,CHEMBL3867474,=,=,IC50,nM,220.0,IC50,uM,0.22,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cc1OC,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,COc1ccc(-c2ccc3ncnc(O[C@H]4CCN(C(=O)OC(C)(C)C)C4)c3c2)cc1OC,CHEMBL3867474,=,=,IC50,nM,282.0,IC50,uM,0.282,COc1ccc(-c2ccc3ncnc(O[C@H]4CCN(C(=O)OC(C)(C)C)C4)c3c2)cc1OC,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,CCC(=O)N1CC[C@@H](Oc2cnc3ccc(-c4ccc(OC)c(OC)c4)cc3n2)C1,CHEMBL3867474,=,=,IC50,nM,366.0,IC50,uM,0.366,CCC(=O)N1CC[C@@H](Oc2cnc3ccc(-c4ccc(OC)c(OC)c4)cc3n2)C1,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,COc1ccc(-c2ccc3ncnc(O[C@@H]4CCN(C(=O)OC(C)(C)C)C4)c3c2)cc1OC,CHEMBL3867474,=,=,IC50,nM,642.0,IC50,uM,0.642,COc1ccc(-c2ccc3ncnc(O[C@@H]4CCN(C(=O)OC(C)(C)C)C4)c3c2)cc1OC,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,CCC(=O)N1CC[C@H](Oc2ncnc3ccc(-c4ccc(OC)nc4)cc23)C1,CHEMBL3867474,=,=,IC50,nM,698.0,IC50,uM,0.698,CCC(=O)N1CC[C@H](Oc2ncnc3ccc(-c4ccc(OC)nc4)cc23)C1,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,CCC(=O)N1CC[C@H](Oc2ccnc3ccc(-c4ccc(OC)nc4)cc23)C1,CHEMBL3867474,=,=,IC50,nM,828.0,IC50,uM,0.828,CCC(=O)N1CC[C@H](Oc2ccnc3ccc(-c4ccc(OC)nc4)cc23)C1,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,CCC(=O)N1CC[C@H](Oc2ncnc3ccc(-c4cnc(OC)c(C#N)c4)cc23)C1,CHEMBL3867474,=,=,IC50,nM,978.0,IC50,uM,0.978,CCC(=O)N1CC[C@H](Oc2ncnc3ccc(-c4cnc(OC)c(C#N)c4)cc23)C1,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,COc1ccc(-c2ccc3ncnc(O[C@H]4CCN(C)C4)c3c2)cc1OC,CHEMBL3867474,=,=,IC50,nM,1210.0,IC50,uM,1.21,COc1ccc(-c2ccc3ncnc(O[C@H]4CCN(C)C4)c3c2)cc1OC,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,COc1ccc(-c2ccc3ncnc(O[C@@H]4CCN(C(C)=O)C4)c3c2)cc1OC,CHEMBL3867474,=,=,IC50,nM,1230.0,IC50,uM,1.23,COc1ccc(-c2ccc3ncnc(O[C@@H]4CCN(C(C)=O)C4)c3c2)cc1OC,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,COc1ccc(-c2ccc3ncnc(O[C@@H]4CCN(C)C4)c3c2)cc1OC,CHEMBL3867474,=,=,IC50,nM,2070.0,IC50,uM,2.07,COc1ccc(-c2ccc3ncnc(O[C@@H]4CCN(C)C4)c3c2)cc1OC,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cn1,CHEMBL3867474,=,=,IC50,nM,2700.0,IC50,uM,2.7,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cn1,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,CCC(=O)N1CC[C@H](Oc2ccnc3ccc(-c4ccc(OC)nc4)nc23)C1,CHEMBL3867474,=,=,IC50,nM,2940.0,IC50,uM,2.94,CCC(=O)N1CC[C@H](Oc2ccnc3ccc(-c4ccc(OC)nc4)nc23)C1,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,CCC(=O)N1CC[C@H](Oc2cnc3ccc(-c4ccc(OC)c(OC)c4)cc3n2)C1,CHEMBL3867474,=,=,IC50,nM,3780.0,IC50,uM,3.78,CCC(=O)N1CC[C@H](Oc2cnc3ccc(-c4ccc(OC)c(OC)c4)cc3n2)C1,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cc1C#N,CHEMBL3867474,=,=,IC50,nM,4630.0,IC50,uM,4.63,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cc1C#N,2016
Inhibition of PI3K-gamma (unknown origin) by KinaseGlo assay,CCC(=O)N1CC[C@H](Oc2cnnc3ccc(-c4ccc(OC)nc4)cc23)C1,CHEMBL3867474,>,>,IC50,nM,9100.0,IC50,uM,9.1,CCC(=O)N1CC[C@H](Oc2cnnc3ccc(-c4ccc(OC)nc4)cc23)C1,2016
Inhibition of PI3Kgamma (unknown origin) using PI:PS as substrate after 2 hrs in presence of [33P]ATP by liquid scintillation counting method,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,CHEMBL3868583,=,=,IC50,nM,6.4,IC50,nM,6.4,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,2016
Inhibition of human recombinant PI3Kgamma using PIP2 as substrate preincubated for 20 mins followed by substrate addition measured after 20 mins by aplhascreen assay,Cc1cc([C@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1,CHEMBL3868583,=,=,IC50,nM,870.0,IC50,nM,870.0,Cc1cc([C@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1,2016
Inhibition of PI3Kgamma (unknown origin),Nc1nc2cc(-c3ccc4ncc(C(=O)N5CCOCC5)n4c3)ccc2o1,CHEMBL3868583,=,=,IC50,nM,1900.0,IC50,nM,1900.0,Nc1nc2cc(-c3ccc4ncc(C(=O)N5CCOCC5)n4c3)ccc2o1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus co-expressing p85 using l-alpha-phosphatidylinositol as substrate after 120 mins by kinase-glo assay,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL3868583,=,=,IC50,nM,7.0,IC50,uM,0.007,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4ccccc4)cc23)cc1,CHEMBL3868583,=,=,IC50,nM,6950.0,IC50,uM,6.95,N#CCc1ccc(Nc2ncnc3ccc(-c4ccccc4)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc(F)cc4F)cc23)cc1,CHEMBL3868583,,,IC50,,,IC50,,,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc(F)cc4F)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4ccccc4C=O)cc23)cc1,CHEMBL3868583,,,IC50,,,IC50,,,N#CCc1ccc(Nc2ncnc3ccc(-c4ccccc4C=O)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,CC(=O)c1ccc(-c2ccc3ncnc(Nc4ccc(CC#N)cc4)c3c2)cc1,CHEMBL3868583,=,=,IC50,nM,150.0,IC50,uM,0.15,CC(=O)c1ccc(-c2ccc3ncnc(Nc4ccc(CC#N)cc4)c3c2)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4cccc(O)c4)cc23)cc1,CHEMBL3868583,=,=,IC50,nM,1840.0,IC50,uM,1.84,N#CCc1ccc(Nc2ncnc3ccc(-c4cccc(O)c4)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4cccc([N+](=O)[O-])c4)cc23)cc1,CHEMBL3868583,=,=,IC50,nM,850.0,IC50,uM,0.85,N#CCc1ccc(Nc2ncnc3ccc(-c4cccc([N+](=O)[O-])c4)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,Cc1ccccc1-c1ccc2ncnc(Nc3ccc(CC#N)cc3)c2c1,CHEMBL3868583,,,IC50,,,IC50,,,Cc1ccccc1-c1ccc2ncnc(Nc3ccc(CC#N)cc3)c2c1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,C=Cc1ccc(-c2ccc3ncnc(Nc4ccc(CC#N)cc4)c3c2)cc1,CHEMBL3868583,=,=,IC50,nM,520.0,IC50,uM,0.52,C=Cc1ccc(-c2ccc3ncnc(Nc4ccc(CC#N)cc4)c3c2)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc(OCc5ccc(F)cc5)cc4)cc23)cc1,CHEMBL3868583,,,IC50,,,IC50,,,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc(OCc5ccc(F)cc5)cc4)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,CC(=O)Nc1cccc(-c2ccc3ncnc(Nc4ccc(CC#N)cc4)c3c2)c1,CHEMBL3868583,,,IC50,,,IC50,,,CC(=O)Nc1cccc(-c2ccc3ncnc(Nc4ccc(CC#N)cc4)c3c2)c1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc(-c5ccccc5)cc4)cc23)cc1,CHEMBL3868583,,,IC50,,,IC50,,,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc(-c5ccccc5)cc4)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,CCOc1ccc(-c2ccc(-c3ccc4ncnc(Nc5ccc(CC#N)cc5)c4c3)cc2)cc1,CHEMBL3868583,,,IC50,,,IC50,,,CCOc1ccc(-c2ccc(-c3ccc4ncnc(Nc5ccc(CC#N)cc5)c4c3)cc2)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc(-c5ccccc5)cc4F)cc23)cc1,CHEMBL3868583,,,IC50,,,IC50,,,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc(-c5ccccc5)cc4F)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc5ccccc5c4)cc23)cc1,CHEMBL3868583,,,IC50,,,IC50,,,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc5ccccc5c4)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc5c(c4)OCCO5)cc23)cc1,CHEMBL3868583,=,=,IC50,nM,1370.0,IC50,uM,1.37,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc5c(c4)OCCO5)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc5c(c4)OCO5)cc23)cc1,CHEMBL3868583,=,=,IC50,nM,190.0,IC50,uM,0.19,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc5c(c4)OCO5)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4cc5ccccc5o4)cc23)cc1,CHEMBL3868583,,,IC50,,,IC50,,,N#CCc1ccc(Nc2ncnc3ccc(-c4cc5ccccc5o4)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4cc5ccccc5s4)cc23)cc1,CHEMBL3868583,,,IC50,,,IC50,,,N#CCc1ccc(Nc2ncnc3ccc(-c4cc5ccccc5s4)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4cccc5c4oc4ccccc45)cc23)cc1,CHEMBL3868583,,,IC50,,,IC50,,,N#CCc1ccc(Nc2ncnc3ccc(-c4cccc5c4oc4ccccc45)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4cccc5c4sc4ccccc45)cc23)cc1,CHEMBL3868583,,,IC50,,,IC50,,,N#CCc1ccc(Nc2ncnc3ccc(-c4cccc5c4sc4ccccc45)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc5[nH]ccc5c4)cc23)cc1,CHEMBL3868583,=,=,IC50,nM,750.0,IC50,uM,0.75,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc5[nH]ccc5c4)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4cnc5ccccc5c4)cc23)cc1,CHEMBL3868583,,,IC50,,,IC50,,,N#CCc1ccc(Nc2ncnc3ccc(-c4cnc5ccccc5c4)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4ccncc4)cc23)cc1,CHEMBL3868583,=,=,IC50,nM,360.0,IC50,uM,0.36,N#CCc1ccc(Nc2ncnc3ccc(-c4ccncc4)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,N#CCc1ccc(Nc2ncnc3ccc(-c4cncc5ccccc45)cc23)cc1,CHEMBL3868583,=,=,IC50,nM,8440.0,IC50,uM,8.44,N#CCc1ccc(Nc2ncnc3ccc(-c4cncc5ccccc45)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) using diC8 PIP2 as substrate after 75 mins by ADP-glo assay,COc1cc2ncnc(Nc3ccc(CC#N)cc3)c2cc1OC,CHEMBL3868583,=,=,IC50,nM,40000.0,IC50,uM,40.0,COc1cc2ncnc(Nc3ccc(CC#N)cc3)c2cc1OC,2016
Inhibition of N-terminal His-tagged full length recombinant human PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,C[C@H](Nc1ncnc(N)c1C#N)c1nn2ccc(C#N)c2c(=O)n1-c1ccccc1,CHEMBL3872285,=,=,IC50,nM,72.0,IC50,nM,72.0,C[C@H](Nc1ncnc(N)c1C#N)c1nn2ccc(C#N)c2c(=O)n1-c1ccccc1,2017
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system assessed as residual activity at 100 nM by KINOMEScan assay relative to control,O=C(CCCCCCOc1ccc2cc1COC/C=C/COCc1cccc(c1)-c1ccnc(n1)N2)NO,CHEMBL3877241,=,=,Activity,%,5.7,Activity,%,5.7,O=C(CCCCCCOc1ccc2cc1COC/C=C/COCc1cccc(c1)-c1ccnc(n1)N2)NO,2016
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system by KINOMEScan assay,O=C(CCCCCCOc1ccc2cc1COC/C=C/COCc1cccc(c1)-c1ccnc(n1)N2)NO,CHEMBL3877241,=,=,IC50,nM,10.0,IC50,nM,10.0,O=C(CCCCCCOc1ccc2cc1COC/C=C/COCc1cccc(c1)-c1ccnc(n1)N2)NO,2016
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,C=C(C)c1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2)c2ncnc(N)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,C=C(C)c1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2)c2ncnc(N)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C(F)F)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(C(F)F)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,C=Cc1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2)c2ncnc(N)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,C=Cc1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2)c2ncnc(N)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(C(=O)NO)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2nc(C(=O)NO)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(C(N)=O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2nc(C(N)=O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]nc(Cl)c34)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]nc(Cl)c34)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3cc(N)nc(N)n3)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc([C@H](C)Nc3cc(N)nc(N)n3)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3nc(F)nc4[nH]cnc34)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc([C@H](C)Nc3nc(F)nc4[nH]cnc34)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(=O)Nc1nc2cc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4)c4ncnc(N)c34)ccc2s1,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,CC(=O)Nc1nc2cc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4)c4ncnc(N)c34)ccc2s1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3nc(N)ncc3F)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc([C@H](C)Nc3nc(N)ncc3F)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4)c4ncnc(N)c34)cc2o1,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4)c4ncnc(N)c34)cc2o1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3nc(Cl)nc4[nH]cnc34)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc([C@H](C)Nc3nc(Cl)nc4[nH]cnc34)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3nc(N)ncc3Cl)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc([C@H](C)Nc3nc(N)ncc3Cl)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CNc1ncc(Cl)c(N[C@@H](C)c2cc3cccc(C)c3c(=O)n2-c2ccccc2)n1,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,CNc1ncc(Cl)c(N[C@@H](C)c2cc3cccc(C)c3c(=O)n2-c2ccccc2)n1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4ccccc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc([C@H](C)Nc3ncnc4ccccc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc5nc(N)oc5c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,uM,0.1,Cc1cccc2cc(Cn3nc(-c4ccc5nc(N)oc5c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(C3CCOCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(C3CCOCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(-c3cccc(F)c3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(-c3cccc(F)c3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(-c3cc(F)cc(F)c3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(-c3cc(F)cc(F)c3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(Nc1ncnc2[nH]cnc12)c1cc2ccccc2c(=O)n1-c1ccccc1,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,CC(Nc1ncnc2[nH]cnc12)c1cc2ccccc2c(=O)n1-c1ccccc1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc(C)c1-n1c(CNc2ncnc3[nH]cnc23)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc(C)c1-n1c(CNc2ncnc3[nH]cnc23)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(-c3c(F)cccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(-c3c(F)cccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cn[nH]c4)c4c(N)ncnc43)n(-c3ccccc3C(F)(F)F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(-c4cn[nH]c4)c4c(N)ncnc43)n(-c3ccccc3C(F)(F)F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1C1CCC1,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1C1CCC1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(C(C)C)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(C(C)C)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cn[nH]c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(-c4cn[nH]c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1-c1ccccc1C,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1-c1ccccc1C,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cn[nH]c4)c4c(N)ncnc43)n(-c3ccccc3Cl)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(-c4cn[nH]c4)c4c(N)ncnc43)n(-c3ccccc3Cl)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,C=Cc1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2C)c2ncnc(N)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,C=Cc1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2C)c2ncnc(N)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cn[nH]c4)c4c(N)ncnc43)n(-c3cccc(F)c3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(-c4cn[nH]c4)c4c(N)ncnc43)n(-c3cccc(F)c3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3cnn(C)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2nc(-c3cnn(C)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cnn(CCO)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(-c4cnn(CCO)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cn[nH]c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(-c4cn[nH]c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(-c3ccccc3OCCN3CCOCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(-c3ccccc3OCCN3CCOCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(-c3ccccc3OCCN3CCOCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(-c3ccccc3OCCN3CCOCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COc1cccc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3C)c3ncnc(N)c23)c1,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,COc1cccc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3C)c3ncnc(N)c23)c1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(-c3ccccc3OCCN3CCOCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(-c3ccccc3OCCN3CCOCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCc1ccccc1-n1c(Cn2nc(C#C[C@@H](C)O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,CCc1ccccc1-n1c(Cn2nc(C#C[C@@H](C)O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(-c3ccccc3Cl)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(-c3ccccc3Cl)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccnc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2ccccc2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccnc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2ccccc2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COc1ccccc1-n1c(Cn2nc(C#C[C@@H](C)O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,COc1ccccc1-n1c(Cn2nc(C#C[C@@H](C)O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccncc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccncc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(-c3ccccc3Cl)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(-c3ccccc3Cl)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccnc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccnc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2Cc1cc2cccc(I)c2c(=O)n1C1CCCC1,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2Cc1cc2cccc(I)c2c(=O)n1C1CCCC1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COc1ccccc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,COc1ccccc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(C(C)C)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(C(C)C)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(C3CCCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(C3CCCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2cccc(F)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2cccc(F)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2ccccc2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2ccccc2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc(Cl)cc3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc(Cl)cc3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COc1ccc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3F)c3ncnc(N)c23)cc1OC,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,COc1ccc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3F)c3ncnc(N)c23)cc1OC,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COc1ccc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3F)c3ncnc(N)c23)cc1,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,COc1ccc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3F)c3ncnc(N)c23)cc1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3cccc(F)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2nc(-c3cccc(F)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3cccc(Cl)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2nc(-c3cccc(Cl)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc(F)cc3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc(F)cc3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COc1cc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3F)c3ncnc(N)c23)ccc1Cl,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,COc1cc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3F)c3ncnc(N)c23)ccc1Cl,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(Cl)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2nc(Cl)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccnc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccnc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(C#CC3CC3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2nc(C#CC3CC3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(C#CCO)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2nc(C#CCO)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc(F)c(O)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(-c4ccc(F)c(O)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C#CCO)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(C#CCO)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,uM,0.1,Cc1ccccc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4)c4ncnc(N)c34)cc2[nH]1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4)c4ncnc(N)c34)cc2[nH]1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3cnn(CCO)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2nc(-c3cnn(CCO)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(CN(C)c2ncnc3[nH]cnc23)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccccc1-n1c(CN(C)c2ncnc3[nH]cnc23)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3cnc4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3cnc4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C#CC4CC4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(C#CC4CC4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3ncc4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3ncc4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccnc1-n1c(Cn2nc(Cl)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccnc1-n1c(Cn2nc(Cl)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cccc(Cl)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,=,=,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(-c4cccc(Cl)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(C#C[C@@H](C)O)c3c(N)ncnc32)cc2cccc(F)c2c1=O,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccccc1-n1c(Cn2nc(C#C[C@@H](C)O)c3c(N)ncnc32)cc2cccc(F)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(C(C)C)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(C(C)C)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccnc1-n1c(Cn2nc(C#C[C@@H](C)O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccnc1-n1c(Cn2nc(C#C[C@@H](C)O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C#N)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(C#N)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(/C=C4/CCNC4=O)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(/C=C4/CCNC4=O)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(/C=C/C(=O)N3CCOCC3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccccc1-n1c(Cn2nc(/C=C/C(=O)N3CCOCC3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(CCC(=O)N3CCOCC3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccccc1-n1c(Cn2nc(CCC(=O)N3CCOCC3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(CN3CCOCC3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccccc1-n1c(Cn2nc(CN3CCOCC3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@@H](C)Nc3ncnc4[nH]cnc34)n(C3CC3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@@H](C)Nc3ncnc4[nH]cnc34)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(C3CCN(C)CC3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(C3CCN(C)CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1C1CCN(C)CC1,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1C1CCN(C)CC1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(CCN3CCCC3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(CCN3CCCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)NC3CCOCC3)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)NC3CCOCC3)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]c(O)nc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]c(O)nc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]c(Cl)nc34)n(C3CC3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]c(Cl)nc34)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3nc(N)ncc3F)n(C3CC3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)Nc3nc(N)ncc3F)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3nc(N)ncc3C(N)=O)n(C3CC3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)Nc3nc(N)ncc3C(N)=O)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3cc(N)nc(Cl)n3)n(C3CC3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)Nc3cc(N)nc(Cl)n3)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COCc1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2C)c2ncnc(N)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,COCc1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2C)c2ncnc(N)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C4=CCOCC4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(C4=CCOCC4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C(C)C)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(C(C)C)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C(C)(C)O)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(C(C)(C)O)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3nc(O)ncc3N)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(C(C)Nc3nc(O)ncc3N)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3nc(Cl)ncc3N)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(C(C)Nc3nc(Cl)ncc3N)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncc(C(F)(F)F)c(N)n3)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)Nc3ncc(C(F)(F)F)c(N)n3)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccnc1-n1c(Cn2nc(Br)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccnc1-n1c(Cn2nc(Br)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(Cl)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(Cl)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(Br)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(Br)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(C#C[C@@H](C)O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccccc1-n1c(Cn2nc(C#C[C@@H](C)O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cccc(F)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(-c4cccc(F)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2cccc(F)c2c1=O,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccccc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2cccc(F)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Nc1ncnc2c1c(I)nn2Cc1cc2cccc(I)c2c(=O)n1C1CCCC1,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Nc1ncnc2c1c(I)nn2Cc1cc2cccc(I)c2c(=O)n1C1CCCC1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(C(C)C)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(C(C)C)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(C3CCCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(C3CCCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(-c3ccccc3O)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(-c3ccccc3O)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccnc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2ccccc2c1=O,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccnc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2ccccc2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccnc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2ccccc2c1=O,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccnc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2ccccc2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(C3CCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(C3CCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(C)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(C)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cnn(C)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(-c4cnn(C)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(C#N)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccccc1-n1c(Cn2nc(C#N)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(CCC(N)=O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccccc1-n1c(Cn2nc(CCC(N)=O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,C=Cc1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2F)c2ncnc(N)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,C=Cc1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2F)c2ncnc(N)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COc1cc(F)cc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3C)c3ncnc(N)c23)c1,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,COc1cc(F)cc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3C)c3ncnc(N)c23)c1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccn[nH]4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(-c4ccn[nH]4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCN(Cc1cc2cccc(C)c2c(=O)n1-c1ccccc1C)c1ncnc2[nH]cnc12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,CCN(Cc1cc2cccc(C)c2c(=O)n1-c1ccccc1C)c1ncnc2[nH]cnc12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3cn[nH]c3)c3c(N)ncnc32)cc2ccccc2c1=O,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccccc1-n1c(Cn2nc(-c3cn[nH]c3)c3c(N)ncnc32)cc2ccccc2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Nc1ncnc2c1c(-c1cn[nH]c1)nn2Cc1cc2cccc(F)c2c(=O)n1-c1ccccc1F,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Nc1ncnc2c1c(-c1cn[nH]c1)nn2Cc1cc2cccc(F)c2c(=O)n1-c1ccccc1F,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@@H](C)Nc3ncnc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@@H](C)Nc3ncnc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@@H](C)Nc3ncnc4[nH]cnc34)n(C3CCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@@H](C)Nc3ncnc4[nH]cnc34)n(C3CCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1C(C)C,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1C(C)C,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCC(Nc1ncnc2[nH]cnc12)c1cc2ccccc2c(=O)n1-c1ccccc1,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,CCC(Nc1ncnc2[nH]cnc12)c1cc2ccccc2c(=O)n1-c1ccccc1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1-c1cc(F)cc(F)c1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(CCN3CCOCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(CCN3CCOCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc5nc(N)cn5c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(-c4ccc5nc(N)cn5c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)NC(=O)c3cnn4ccccc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)NC(=O)c3cnn4ccccc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1nc2c(N[C@@H](C)c3cc4cccc(C)c4c(=O)n3-c3ccccc3)ncnc2[nH]1,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1nc2c(N[C@@H](C)c3cc4cccc(C)c4c(=O)n3-c3ccccc3)ncnc2[nH]1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3c(C#N)cnc4ccccc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)Nc3c(C#N)cnc4ccccc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3nc(Cl)ncc3Cl)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)Nc3nc(Cl)ncc3Cl)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]ncc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]ncc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]c(Cl)nc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]c(Cl)nc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(=O)Nc1nc2cc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4C)c4ncnc(N)c34)ccc2s1,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,CC(=O)Nc1nc2cc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4C)c4ncnc(N)c34)ccc2s1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3cc(N)nc(N)n3)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)Nc3cc(N)nc(N)n3)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3cc(N)nc(Cl)n3)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc([C@H](C)Nc3cc(N)nc(Cl)n3)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCc1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2C)c2ncnc(N)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,CCc1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2C)c2ncnc(N)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COC(=O)c1nn(CC2=Cc3cccc(C)c3C(=O)C2c2ccccc2C)c2ncnc(N)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)c1nn(CC2=Cc3cccc(C)c3C(=O)C2c2ccccc2C)c2ncnc(N)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCc1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2)c2ncnc(N)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,CCc1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2)c2ncnc(N)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CNC(=O)c1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2C)c2ncnc(N)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,CNC(=O)c1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2C)c2ncnc(N)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C(N)=O)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc2cc(Cn3nc(C(N)=O)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CNC(=O)c1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2)c2ncnc(N)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,CNC(=O)c1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2)c2ncnc(N)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(CC#N)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccccc1-n1c(Cn2nc(CC#N)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(CO)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccccc1-n1c(Cn2nc(CO)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(=O)c1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2)c2ncnc(N)c12,CHEMBL3879901,<,<,IC50,nM,10000.0,IC50,uM,10.0,CC(=O)c1nn(Cc2cc3cccc(C)c3c(=O)n2-c2ccccc2)c2ncnc(N)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc(F)c(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc(F)c(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccnc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccnc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(Br)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(Br)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COc1cc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3C)c3ncnc(N)c23)ccc1Cl,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,COc1cc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3C)c3ncnc(N)c23)ccc1Cl,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc(Cl)c(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc(Cl)c(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc(Cl)c(O)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4ccc(Cl)c(O)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc(O)c(Cl)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc(O)c(Cl)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc(O)c(Cl)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4ccc(O)c(Cl)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc(O)c(F)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4ccc(O)c(F)c4)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc(O)c(F)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc(O)c(F)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2ccccc2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2ccccc2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2ccccc2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2ccccc2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc(O)cc3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc(O)cc3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COc1ccc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3C)c3ncnc(N)c23)cc1OC,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,COc1ccc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3C)c3ncnc(N)c23)cc1OC,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COc1ccc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3C)c3ncnc(N)c23)cc1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,COc1ccc(-c2nn(Cc3cc4cccc(C)c4c(=O)n3-c3ccccc3C)c3ncnc(N)c23)cc1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc4cc[nH]c4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc4cc[nH]c4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc(Cl)c(O)c3)c3c(N)ncnc32)cc2ccccc2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc(Cl)c(O)c3)c3c(N)ncnc32)cc2ccccc2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4C)c4ncnc(N)c34)cc2s1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4C)c4ncnc(N)c34)cc2s1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc(F)c(O)c3)c3c(N)ncnc32)cc2ccccc2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc(F)c(O)c3)c3c(N)ncnc32)cc2ccccc2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc(F)c(O)c3)c3c(N)ncnc32)cc2cccc(F)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc(F)c(O)c3)c3c(N)ncnc32)cc2cccc(F)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2cccc(F)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2cccc(F)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(C(C)C)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(C(C)C)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(C3CCCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(C3CCCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc(F)c(O)c4)c4c(N)ncnc43)n(C3CCCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4ccc(F)c(O)c4)c4c(N)ncnc43)n(C3CCCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc(F)c(O)c4)c4c(N)ncnc43)n(C(C)C)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4ccc(F)c(O)c4)c4c(N)ncnc43)n(C(C)C)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccnc1-n1c(Cn2nc(-c3ccc(F)c(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccnc1-n1c(Cn2nc(-c3ccc(F)c(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccnc1-n1c(Cn2nc(-c3ccc(Cl)c(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccnc1-n1c(Cn2nc(-c3ccc(Cl)c(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,COc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(-c3ccccc3C(C)C)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(-c3ccccc3C(C)C)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCc1ccccc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CCc1ccccc1-n1c(Cn2nc(I)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(-c3ccccc3O)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(-c3ccccc3O)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(-c3ccccc3O)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(-c3ccccc3O)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(-c3ccccc3C(C)C)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(-c3ccccc3C(C)C)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(-c3ccccc3C(C)C)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(C#C[C@@H](C)O)c4c(N)ncnc43)n(-c3ccccc3C(C)C)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,COc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,COc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(C3CCCCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(I)c4c(N)ncnc43)n(C3CCCCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CCc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CCc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(-c3ccccc3O)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(-c3ccccc3O)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(-c3ccccc3C(C)C)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(-c3ccccc3C(C)C)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(-c3ccccc3Cl)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(-c3ccccc3Cl)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(-c3ccccc3Cl)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(-c3ccccc3Cl)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Nc1ncnc2c1c(-c1cc(O)cc(F)c1)nn2Cc1cc2cccc(Cl)c2c(=O)n1C1CC1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Nc1ncnc2c1c(-c1cc(O)cc(F)c1)nn2Cc1cc2cccc(Cl)c2c(=O)n1C1CC1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc4nc(N)sc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc4nc(N)sc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CNC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4C)c4ncnc(N)c34)cc2s1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CNC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4C)c4ncnc(N)c34)cc2s1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc4nc(N)ccc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc4nc(N)ccc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc4nc(N)ncc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc4nc(N)ncc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc4nc(N)oc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc4nc(N)oc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc4ncnc(N)c4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc4ncnc(N)c4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3cn[nH]c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3cn[nH]c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(/C=C4/SC(=O)NC4=O)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(/C=C4/SC(=O)NC4=O)c4c(N)ncnc43)n(-c3ccccc3F)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(/C=C3/SC(=O)NC3=O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(/C=C3/SC(=O)NC3=O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(/C=C/C(N)=O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(/C=C/C(N)=O)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCn1c(Cn2nc(-c3ccc4nc(NC(C)=O)sc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CCn1c(Cn2nc(-c3ccc4nc(NC(C)=O)sc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4)c4ncnc(N)c34)cc2s1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4)c4ncnc(N)c34)cc2s1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4cccc(F)c4)c4ncnc(N)c34)cc2s1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4cccc(F)c4)c4ncnc(N)c34)cc2s1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccn[nH]3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccn[nH]3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4cn[nH]c4)c4c(N)ncnc43)n(-c3ccccc3C(C)C)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4cn[nH]c4)c4c(N)ncnc43)n(-c3ccccc3C(C)C)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCc1ccccc1-n1c(Cn2nc(-c3cn[nH]c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CCc1ccccc1-n1c(Cn2nc(-c3cn[nH]c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(C(C)Nc2ncnc3[nH]cnc23)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(C(C)Nc2ncnc3[nH]cnc23)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cnc34)n(C3CCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cnc34)n(C3CCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cnc34)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cnc34)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc5oc(N)nc5c4)c4c(N)ncnc43)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4ccc5oc(N)nc5c4)c4c(N)ncnc43)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc5oc(N)nc5c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4ccc5oc(N)nc5c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3nn[nH]n3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3nn[nH]n3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc5oc(N)nc5c4)c4c(N)ncnc43)n(C3CCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4ccc5oc(N)nc5c4)c4c(N)ncnc43)n(C3CCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1-c1ccccc1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1-c1ccccc1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(-c3ccc(F)cc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(-c3ccc(F)cc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(C3CCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(C3CCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1-c1ccc(F)cc1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CCC(Nc1ncnc2[nH]cnc12)c1cc2cccc(C)c2c(=O)n1-c1ccc(F)cc1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cnc34)n(C(C)C)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cnc34)n(C(C)C)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(C3CCCC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(C(C)Nc3ncnc4[nH]cnc34)n(C3CCCC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CC(Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccnc1-n1c(Cn2nc(-c3ccc4oc(N)nc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccnc1-n1c(Cn2nc(-c3ccc4oc(N)nc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc4oc(N)nc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc4oc(N)nc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3nc(Cl)nc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3nc(Cl)nc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3nc(F)nc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3nc(F)nc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]ccc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]ccc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3nc(N)ncc3Cl)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3nc(N)ncc3Cl)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(=O)Nc1nc2cc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4C)c4ncnc(N)c34)ccc2o1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CC(=O)Nc1nc2cc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4C)c4ncnc(N)c34)ccc2o1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc5nc(N)sc5c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4ccc5nc(N)sc5c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(=O)Nc1nc2cc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4)c4ncnc(N)c34)ccc2o1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CC(=O)Nc1nc2cc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4)c4ncnc(N)c34)ccc2o1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(F)c34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(F)c34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]nc(C#N)c34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]nc(C#N)c34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]nc(C(N)=O)c34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]nc(C(N)=O)c34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(Br)c34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(Br)c34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cnc34)n(-c3ccc(F)cc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cnc34)n(-c3ccc(F)cc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(Cl)c34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(Cl)c34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(C#N)c34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(C#N)c34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]nc(Cl)c34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]nc(Cl)c34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4C)c4ncnc(N)c34)cc2o1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4C)c4ncnc(N)c34)cc2o1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1C1CC1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1C1CC1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(Br)c34)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(Br)c34)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]ccc34)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]ccc34)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc4sc(N)nc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc4sc(N)nc4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc5sc(N)nc5c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4ccc5sc(N)nc5c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(F)c34)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(F)c34)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(C(N)=O)c34)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(C(N)=O)c34)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(C(N)=O)c34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(C(N)=O)c34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(C#N)c34)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cc(C#N)c34)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cnc34)n(-c3cccc(F)c3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]cnc34)n(-c3cccc(F)c3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]nc(C(N)=O)c34)n(C3CC3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3ncnc4[nH]nc(C(N)=O)c34)n(C3CC3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(-c3ccc4nc(N)[nH]c4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(-c3ccc4nc(N)[nH]c4c3)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4C)c4ncnc(N)c34)cc2[nH]1,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,CC(=O)Nc1nc2ccc(-c3nn(Cc4cc5cccc(C)c5c(=O)n4-c4ccccc4C)c4ncnc(N)c34)cc2[nH]1,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(-c4ccc5nc(N)[nH]c5c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(-c4ccc5nc(N)[nH]c5c4)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(C(F)F)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(C(F)F)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1ccccc1-n1c(Cn2nc(CF)c3c(N)ncnc32)cc2cccc(C)c2c1=O,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccccc1-n1c(Cn2nc(CF)c3c(N)ncnc32)cc2cccc(C)c2c1=O,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(Cn3nc(CF)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(Cn3nc(CF)c4c(N)ncnc43)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc(C(C)Nc3nc(N)nc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc(C(C)Nc3nc(N)nc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3nc(N)nc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3nc(N)nc4[nH]cnc34)n(-c3ccccc3)c(=O)c12,2012
Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method,Cc1cccc2cc([C@H](C)Nc3nc(N)ncc3C(F)(F)F)n(-c3ccccc3)c(=O)c12,CHEMBL3879901,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1cccc2cc([C@H](C)Nc3nc(N)ncc3C(F)(F)F)n(-c3ccccc3)c(=O)c12,2012
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,CC(=O)Nc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1,CHEMBL3882246,<,<,IC50,nM,1000.0,IC50,uM,1.0,CC(=O)Nc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,CC(C)n1nc(-c2ccc3nc(N)oc3c2)c2c(N)ncnc21,CHEMBL3882246,<,<,IC50,nM,1000.0,IC50,uM,1.0,CC(C)n1nc(-c2ccc3nc(N)oc3c2)c2c(N)ncnc21,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,CNc1noc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc12,CHEMBL3882246,<,<,IC50,nM,1000.0,IC50,uM,1.0,CNc1noc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc12,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,CC(C)n1nc(-c2ccc3c(NC4CC4)noc3c2)c2c(N)ncnc21,CHEMBL3882246,<,<,IC50,nM,1000.0,IC50,uM,1.0,CC(C)n1nc(-c2ccc3c(NC4CC4)noc3c2)c2c(N)ncnc21,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,[2H]C([2H])([2H])C([2H])(n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)C([2H])([2H])[2H],CHEMBL3882246,<,<,IC50,nM,1000.0,IC50,uM,1.0,[2H]C([2H])([2H])C([2H])(n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)C([2H])([2H])[2H],2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,CC(=O)Nc1nc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc2o1,CHEMBL3882246,<,<,IC50,nM,10000.0,IC50,uM,10.0,CC(=O)Nc1nc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc2o1,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,Nc1nc2cc(-c3nn(C4CCC(N5CCOCC5)CC4)c4ncnc(N)c34)ccc2o1,CHEMBL3882246,<,<,IC50,nM,10000.0,IC50,uM,10.0,Nc1nc2cc(-c3nn(C4CCC(N5CCOCC5)CC4)c4ncnc(N)c34)ccc2o1,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,CC(=O)N1CCC(n2nc(-c3ccc4oc(N)nc4c3)c3c(N)ncnc32)CC1,CHEMBL3882246,<,<,IC50,nM,10000.0,IC50,uM,10.0,CC(=O)N1CCC(n2nc(-c3ccc4oc(N)nc4c3)c3c(N)ncnc32)CC1,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,CNc1noc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc12,CHEMBL3882246,>,>,IC50,nM,10000.0,IC50,uM,10.0,CNc1noc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc12,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,CC(C)n1nc(-c2ccc3onc(NC4CC4)c3c2)c2c(N)ncnc21,CHEMBL3882246,<,<,IC50,nM,10000.0,IC50,uM,10.0,CC(C)n1nc(-c2ccc3onc(NC4CC4)c3c2)c2c(N)ncnc21,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,Nc1noc2ccc(-c3nn(CC(=O)N4CCOCC4)c4ncnc(N)c34)cc12,CHEMBL3882246,>,>,IC50,nM,10000.0,IC50,uM,10.0,Nc1noc2ccc(-c3nn(CC(=O)N4CCOCC4)c4ncnc(N)c34)cc12,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,Nc1noc2ccc(-c3nn(CCN4CCOCC4)c4ncnc(N)c34)cc12,CHEMBL3882246,>,>,IC50,nM,10000.0,IC50,uM,10.0,Nc1noc2ccc(-c3nn(CCN4CCOCC4)c4ncnc(N)c34)cc12,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,Cc1nc(N)c2c(-c3ccc4oc(N)nc4c3)nn(C(C)C)c2n1,CHEMBL3882246,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1nc(N)c2c(-c3ccc4oc(N)nc4c3)nn(C(C)C)c2n1,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,CC(CO)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,CHEMBL3882246,<,<,IC50,nM,10000.0,IC50,uM,10.0,CC(CO)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,CCOC(=O)C(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,CHEMBL3882246,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCOC(=O)C(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,CC(C)(CO)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,CHEMBL3882246,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(C)(CO)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,Nc1nc2cc(-c3nn(C4CC(=O)C4)c4ncnc(N)c34)ccc2o1,CHEMBL3882246,<,<,IC50,nM,100.0,IC50,nM,100.0,Nc1nc2cc(-c3nn(C4CC(=O)C4)c4ncnc(N)c34)ccc2o1,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,Nc1nc2cc(-c3nn(C4CC(O)C4)c4ncnc(N)c34)ccc2o1,CHEMBL3882246,<,<,IC50,nM,100.0,IC50,nM,100.0,Nc1nc2cc(-c3nn(C4CC(O)C4)c4ncnc(N)c34)ccc2o1,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,CHEMBL3882246,<,<,IC50,nM,100.0,IC50,nM,100.0,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,Nc1nc2cc(-c3nn(C4CCOCC4)c4ncnc(N)c34)ccc2o1,CHEMBL3882246,<,<,IC50,nM,1000.0,IC50,uM,1.0,Nc1nc2cc(-c3nn(C4CCOCC4)c4ncnc(N)c34)ccc2o1,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,CC(C)n1cc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,CHEMBL3882246,<,<,IC50,nM,1000.0,IC50,uM,1.0,CC(C)n1cc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,2010
Inhibition of human PI3Kgamma using PIP2 as substrate by HTRF assay,Nc1nc2cc(-c3cn(C4CCOCC4)c4ncnc(N)c34)ccc2o1,CHEMBL3882246,<,<,IC50,nM,1000.0,IC50,uM,1.0,Nc1nc2cc(-c3cn(C4CCOCC4)c4ncnc(N)c34)ccc2o1,2010
Inhibition of PI3K-gamma (unknown origin),COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,CHEMBL3882389,=,=,IC50,nM,36.0,IC50,nM,36.0,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,2014
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COC(=O)c1ccc(OC)cc1Nc1nc2ccccc2nc1NS(=O)(=O)c1cn(C)cn1,CHEMBL3638446,=,=,IC50,nM,21.0,IC50,nM,21.0,COC(=O)c1ccc(OC)cc1Nc1nc2ccccc2nc1NS(=O)(=O)c1cn(C)cn1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COC(=O)c1ccc(OC)cc1Nc1nc2ccccc2nc1NS(=O)(=O)c1cccnc1,CHEMBL3638446,=,=,IC50,nM,88.0,IC50,nM,88.0,COC(=O)c1ccc(OC)cc1Nc1nc2ccccc2nc1NS(=O)(=O)c1cccnc1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COC(=O)c1ccc(OC)cc1Nc1nc2ccccc2nc1NS(C)(=O)=O,CHEMBL3638446,=,=,IC50,nM,1650.0,IC50,nM,1650.0,COC(=O)c1ccc(OC)cc1Nc1nc2ccccc2nc1NS(C)(=O)=O,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)cc(C(=O)N2CCN(C)CC2)c1,CHEMBL3638446,=,=,IC50,nM,3340.0,IC50,nM,3340.0,COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)cc(C(=O)N2CCN(C)CC2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)cc(C(=O)N2CCOCC2)c1,CHEMBL3638446,=,=,IC50,nM,3100.0,IC50,nM,3100.0,COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)cc(C(=O)N2CCOCC2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1cc(Nc2nc3ccccc3nc2NS(C)(=O)=O)cc(C(=O)N2CCOCC2)c1,CHEMBL3638446,=,=,IC50,nM,5620.0,IC50,nM,5620.0,COc1cc(Nc2nc3ccccc3nc2NS(C)(=O)=O)cc(C(=O)N2CCOCC2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCOCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,49.0,IC50,nM,49.0,COc1ccc(CC2CCOCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCOCC2)c(Nc2nc3ccccc3nc2NS(C)(=O)=O)c1,CHEMBL3638446,=,=,IC50,nM,130.0,IC50,nM,130.0,COc1ccc(CC2CCOCC2)c(Nc2nc3ccccc3nc2NS(C)(=O)=O)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCOCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,CHEMBL3638446,=,=,IC50,nM,27.0,IC50,nM,27.0,COc1ccc(CC2CCOCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCOCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(F)cc2)c1,CHEMBL3638446,=,=,IC50,nM,150.0,IC50,nM,150.0,COc1ccc(CC2CCOCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(F)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCN(C)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,43.0,IC50,nM,43.0,COc1ccc(CC2CCN(C)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCN(C)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,CHEMBL3638446,=,=,IC50,nM,45.0,IC50,nM,45.0,COc1ccc(CC2CCN(C)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCN(C)CC2)c(Nc2nc3ccccc3nc2NS(C)(=O)=O)c1,CHEMBL3638446,=,=,IC50,nM,110.0,IC50,nM,110.0,COc1ccc(CC2CCN(C)CC2)c(Nc2nc3ccccc3nc2NS(C)(=O)=O)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CC(C)(C)N(C)C(C)(C)C2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,420.0,IC50,nM,420.0,COc1ccc(CC2CC(C)(C)N(C)C(C)(C)C2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2C[C@H]3CC[C@@H](C2)N3C)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,110.0,IC50,nM,110.0,COc1ccc(CC2C[C@H]3CC[C@@H](C2)N3C)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCN(C(C)=O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,89.0,IC50,nM,89.0,COc1ccc(CC2CCN(C(C)=O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCN(C(C)=O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,CHEMBL3638446,=,=,IC50,nM,51.0,IC50,nM,51.0,COc1ccc(CC2CCN(C(C)=O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCN(C(C)=O)CC2)c(Nc2nc3ccccc3nc2NS(C)(=O)=O)c1,CHEMBL3638446,=,=,IC50,nM,170.0,IC50,nM,170.0,COc1ccc(CC2CCN(C(C)=O)CC2)c(Nc2nc3ccccc3nc2NS(C)(=O)=O)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCCCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,CHEMBL3638446,=,=,IC50,nM,490.0,IC50,nM,490.0,COc1ccc(CC2CCCCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCCCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,450.0,IC50,nM,450.0,COc1ccc(CC2CCCCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCC(O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,18.0,IC50,nM,18.0,COc1ccc(CC2CCC(O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCC(O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,CHEMBL3638446,=,=,IC50,nM,20.0,IC50,nM,20.0,COc1ccc(CC2CCC(O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,180.0,IC50,nM,180.0,COc1ccc(CC2CCCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCSCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,100.0,IC50,nM,100.0,COc1ccc(CC2CCSCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCS(=O)(=O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,30.0,IC50,nM,30.0,COc1ccc(CC2CCS(=O)(=O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,CHEMBL3638446,=,=,IC50,nM,40.0,IC50,nM,40.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,21.0,IC50,nM,21.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(C(CO)CO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,550.0,IC50,nM,550.0,COc1ccc(C(CO)CO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(C(C)C)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,200.0,IC50,nM,200.0,COc1ccc(C(C)C)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCN(C)C)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,11.0,IC50,nM,11.0,COc1ccc(CCCN(C)C)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(C(=O)N(C)C)cc2)c1,CHEMBL3638446,=,=,IC50,nM,250.0,IC50,nM,250.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(C(=O)N(C)C)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(C)[n+]([O-])c2)c1,CHEMBL3638446,=,=,IC50,nM,106.0,IC50,nM,106.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(C)[n+]([O-])c2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(C#N)cc2)c1,CHEMBL3638446,=,=,IC50,nM,22.0,IC50,nM,22.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(C#N)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,48.0,IC50,nM,48.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(F)cc2)c1,CHEMBL3638446,=,=,IC50,nM,23.0,IC50,nM,23.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(F)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(C)(=O)=O)c1,CHEMBL3638446,=,=,IC50,nM,95.0,IC50,nM,95.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(C)(=O)=O)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",CCS(=O)(=O)Nc1nc2ccccc2nc1Nc1cc(OC)ccc1CCO,CHEMBL3638446,=,=,IC50,nM,60.0,IC50,nM,60.0,CCS(=O)(=O)Nc1nc2ccccc2nc1Nc1cc(OC)ccc1CCO,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",CCCS(=O)(=O)Nc1nc2ccccc2nc1Nc1cc(OC)ccc1CCO,CHEMBL3638446,=,=,IC50,nM,44.0,IC50,nM,44.0,CCCS(=O)(=O)Nc1nc2ccccc2nc1Nc1cc(OC)ccc1CCO,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,84.0,IC50,nM,84.0,COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COC(=O)CCc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2cc(OC)ccc2CCO)cc1,CHEMBL3638446,=,=,IC50,nM,70.0,IC50,nM,70.0,COC(=O)CCc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2cc(OC)ccc2CCO)cc1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2c(C)noc2C)c1,CHEMBL3638446,=,=,IC50,nM,130.0,IC50,nM,130.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2c(C)noc2C)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2c(C)noc2C)c1,CHEMBL3638446,=,=,IC50,nM,286.0,IC50,nM,286.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2c(C)noc2C)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(C)(=O)=O)c1,CHEMBL3638446,=,=,IC50,nM,200.0,IC50,nM,200.0,COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(C)(=O)=O)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)C2CCCCC2)c1,CHEMBL3638446,=,=,IC50,nM,57.0,IC50,nM,57.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)C2CCCCC2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(C)(=O)=O)c1,CHEMBL3638446,=,=,IC50,nM,64.0,IC50,nM,64.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(C)(=O)=O)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)c(CN(C)C)n2)c1,CHEMBL3638446,=,=,IC50,nM,28.0,IC50,nM,28.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)c(CN(C)C)n2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",CCS(=O)(=O)Nc1nc2ccccc2nc1Nc1cc(OC)ccc1CCCO,CHEMBL3638446,=,=,IC50,nM,59.0,IC50,nM,59.0,CCS(=O)(=O)Nc1nc2ccccc2nc1Nc1cc(OC)ccc1CCCO,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",CCCS(=O)(=O)Nc1nc2ccccc2nc1Nc1cc(OC)ccc1CCCO,CHEMBL3638446,=,=,IC50,nM,49.0,IC50,nM,49.0,CCCS(=O)(=O)Nc1nc2ccccc2nc1Nc1cc(OC)ccc1CCCO,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)C(C)C)c1,CHEMBL3638446,=,=,IC50,nM,72.0,IC50,nM,72.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)C(C)C)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",CCS(=O)(=O)Nc1nc2ccccc2nc1Nc1cc(OC)ccc1CCS(C)(=O)=O,CHEMBL3638446,=,=,IC50,nM,88.0,IC50,nM,88.0,CCS(=O)(=O)Nc1nc2ccccc2nc1Nc1cc(OC)ccc1CCS(C)(=O)=O,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)C(C)C)c1,CHEMBL3638446,=,=,IC50,nM,160.0,IC50,nM,160.0,COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)C(C)C)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",CCCS(=O)(=O)Nc1nc2ccccc2nc1Nc1cc(OC)ccc1CCS(C)(=O)=O,CHEMBL3638446,=,=,IC50,nM,87.0,IC50,nM,87.0,CCCS(=O)(=O)Nc1nc2ccccc2nc1Nc1cc(OC)ccc1CCS(C)(=O)=O,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2c(C)noc2C)c1,CHEMBL3638446,=,=,IC50,nM,190.0,IC50,nM,190.0,COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2c(C)noc2C)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccccc2)c1,CHEMBL3638446,=,=,IC50,nM,42.0,IC50,nM,42.0,COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccccc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)C2CCS(=O)(=O)C2)c1,CHEMBL3638446,=,=,IC50,nM,86.0,IC50,nM,86.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)C2CCS(=O)(=O)C2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)CCCSC)c1,CHEMBL3638446,=,=,IC50,nM,140.0,IC50,nM,140.0,COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)CCCSC)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)CCCSC)c1,CHEMBL3638446,=,=,IC50,nM,75.0,IC50,nM,75.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)CCCSC)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)CCCS(C)(=O)=O)c1,CHEMBL3638446,=,=,IC50,nM,350.0,IC50,nM,350.0,COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)CCCS(C)(=O)=O)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)CCCS(C)(=O)=O)c1,CHEMBL3638446,=,=,IC50,nM,120.0,IC50,nM,120.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)CCCS(C)(=O)=O)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)CCCS(C)(=O)=O)c1,CHEMBL3638446,=,=,IC50,nM,120.0,IC50,nM,120.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)CCCS(C)(=O)=O)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COCCc1ccc(OC)cc1Nc1nc2ccccc2nc1NS(=O)(=O)c1cn(C)cn1,CHEMBL3638446,=,=,IC50,nM,83.0,IC50,nM,83.0,COCCc1ccc(OC)cc1Nc1nc2ccccc2nc1NS(=O)(=O)c1cn(C)cn1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)C2CCS(=O)(=O)C2)c1,CHEMBL3638446,=,=,IC50,nM,130.0,IC50,nM,130.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)C2CCS(=O)(=O)C2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(S(=O)(=O)NCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)CCCS(C)(=O)=O)c1,CHEMBL3638446,=,=,IC50,nM,300.0,IC50,nM,300.0,COc1ccc(S(=O)(=O)NCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)CCCS(C)(=O)=O)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)c(CN(C)C)n2)c1,CHEMBL3638446,=,=,IC50,nM,87.0,IC50,nM,87.0,COc1ccc(CCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)c(CN(C)C)n2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)C2CCN(C(=O)OCc3ccccc3)CC2)c1,CHEMBL3638446,=,=,IC50,nM,720.0,IC50,nM,720.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)C2CCN(C(=O)OCc3ccccc3)CC2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)cc(C(=O)NCCO)c1,CHEMBL3638446,=,=,IC50,nM,100.0,IC50,nM,100.0,COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)cc(C(=O)NCCO)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,50.0,IC50,nM,50.0,COc1ccc(CCCS(C)(=O)=O)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)CO)cc2)c1,CHEMBL3638446,=,=,IC50,nM,65.0,IC50,nM,65.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)CO)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)CN(C)C)cc2)c1,CHEMBL3638446,=,=,IC50,nM,27.0,IC50,nM,27.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)CN(C)C)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)CN(C)C)cc2)c1,CHEMBL3638446,=,=,IC50,nM,32.0,IC50,nM,32.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)CN(C)C)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)COCc3ccccc3)c2)c1,CHEMBL3638446,=,=,IC50,nM,480.0,IC50,nM,480.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)COCc3ccccc3)c2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)CCCS(C)(=O)=O)cc(C(=O)NCCO)c1,CHEMBL3638446,=,=,IC50,nM,350.0,IC50,nM,350.0,COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)CCCS(C)(=O)=O)cc(C(=O)NCCO)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)c(CO)n2)c1,CHEMBL3638446,=,=,IC50,nM,84.0,IC50,nM,84.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)c(CO)n2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)cc(C(=O)N(C)C)c1,CHEMBL3638446,=,=,IC50,nM,760.0,IC50,nM,760.0,COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)cc(C(=O)N(C)C)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)c(CS(C)(=O)=O)n2)c1,CHEMBL3638446,=,=,IC50,nM,87.0,IC50,nM,87.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)c(CS(C)(=O)=O)n2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC(O)CO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,120.0,IC50,nM,120.0,COc1ccc(CC(O)CO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)CN(C)C)c2)c1,CHEMBL3638446,=,=,IC50,nM,30.0,IC50,nM,30.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)CN(C)C)c2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COCCc1ccc(OC)cc1Nc1nc2ccccc2nc1NS(=O)(=O)c1cn(C)c(CS(C)(=O)=O)n1,CHEMBL3638446,=,=,IC50,nM,200.0,IC50,nM,200.0,COCCc1ccc(OC)cc1Nc1nc2ccccc2nc1NS(=O)(=O)c1cn(C)c(CS(C)(=O)=O)n1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COCCNC(=O)c1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)cc(OC)c1,CHEMBL3638446,=,=,IC50,nM,400.0,IC50,nM,400.0,COCCNC(=O)c1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)cc(OC)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CN2CCN(C)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,CHEMBL3638446,=,=,IC50,nM,49.0,IC50,nM,49.0,COc1ccc(CN2CCN(C)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CN2CCN(C)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(F)cc2)c1,CHEMBL3638446,=,=,IC50,nM,110.0,IC50,nM,110.0,COc1ccc(CN2CCN(C)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(F)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CN2CCOCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,CHEMBL3638446,=,=,IC50,nM,72.0,IC50,nM,72.0,COc1ccc(CN2CCOCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCC(O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN(C)C)cc2)c1,CHEMBL3638446,=,=,IC50,nM,26.0,IC50,nM,26.0,COc1ccc(CC2CCC(O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN(C)C)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCS(=O)(=O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN(C)C)cc2)c1,CHEMBL3638446,=,=,IC50,nM,10.0,IC50,nM,10.0,COc1ccc(CC2CCS(=O)(=O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN(C)C)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCOCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN(C)C)cc2)c1,CHEMBL3638446,=,=,IC50,nM,30.0,IC50,nM,30.0,COc1ccc(CC2CCOCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN(C)C)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCCCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN(C)C)cc2)c1,CHEMBL3638446,=,=,IC50,nM,760.0,IC50,nM,760.0,COc1ccc(CC2CCCCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN(C)C)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCSCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN(C)C)cc2)c1,CHEMBL3638446,=,=,IC50,nM,35.0,IC50,nM,35.0,COc1ccc(CC2CCSCC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN(C)C)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN(C)C)cc2)c1,CHEMBL3638446,=,=,IC50,nM,26.0,IC50,nM,26.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN(C)C)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN3CCC(F)CC3)cc2)c1,CHEMBL3638446,=,=,IC50,nM,43.0,IC50,nM,43.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CN3CCC(F)CC3)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,470.0,IC50,nM,470.0,COc1ccc(CO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1cc(CN2CCN(C)CC2)cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,CHEMBL3638446,=,=,IC50,nM,970.0,IC50,nM,970.0,COc1cc(CN2CCN(C)CC2)cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CCCO)cc2)c1,CHEMBL3638446,=,=,IC50,nM,36.0,IC50,nM,36.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(CCCO)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(OCCO)cc2)c1,CHEMBL3638446,=,=,IC50,nM,34.0,IC50,nM,34.0,COc1ccc(CCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(OCCO)cc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1cc(CN(C)C)cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,1100.0,IC50,nM,1100.0,COc1cc(CN(C)C)cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCN(C(=O)CN(C)C)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,100.0,IC50,nM,100.0,COc1ccc(CC2CCN(C(=O)CN(C)C)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CC2CCN(S(C)(=O)=O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,160.0,IC50,nM,160.0,COc1ccc(CC2CCN(S(C)(=O)=O)CC2)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(C(=O)O)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,CHEMBL3638446,=,=,IC50,nM,4680.0,IC50,nM,4680.0,COc1ccc(C(=O)O)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccnc2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)C2CCNCC2)c1,CHEMBL3638446,=,=,IC50,nM,26.0,IC50,nM,26.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)C2CCNCC2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COCCc1ccc(OC)cc1Nc1nc2ccccc2nc1NS(=O)(=O)C1CCNCC1,CHEMBL3638446,=,=,IC50,nM,98.0,IC50,nM,98.0,COCCc1ccc(OC)cc1Nc1nc2ccccc2nc1NS(=O)(=O)C1CCNCC1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COCCc1ccc(OC)cc1Nc1nc2ccccc2nc1NS(=O)(=O)C1CCN(C(C)=O)CC1,CHEMBL3638446,=,=,IC50,nM,300.0,IC50,nM,300.0,COCCc1ccc(OC)cc1Nc1nc2ccccc2nc1NS(=O)(=O)C1CCN(C(C)=O)CC1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)CO)c2)c1,CHEMBL3638446,=,=,IC50,nM,12.0,IC50,nM,12.0,COc1ccc(CCCO)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)CO)c2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCOC(=O)[C@@H](NC(=O)OCC2c3ccccc3-c3ccccc32)C(C)C)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,1840.0,IC50,nM,1840.0,COc1ccc(CCOC(=O)[C@@H](NC(=O)OCC2c3ccccc3-c3ccccc32)C(C)C)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"Biological Assay: The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.",COc1ccc(CCOC(=O)[C@@H](N)C(C)C)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,CHEMBL3638446,=,=,IC50,nM,100.0,IC50,nM,100.0,COc1ccc(CCOC(=O)[C@@H](N)C(C)C)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cn(C)cn2)c1,2013
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)Nc1nc(C)c(-c2csc(Nc3cccc(C(=O)O)c3)n2)s1,CHEMBL3639328,=,=,IC50,nM,10.0,IC50,nM,10.0,CC(=O)Nc1nc(C)c(-c2csc(Nc3cccc(C(=O)O)c3)n2)s1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)Nc1nc(C)c(-c2csc(N3CCCCC3)n2)s1,CHEMBL3639328,=,=,IC50,nM,630.0,IC50,nM,630.0,CC(=O)Nc1nc(C)c(-c2csc(N3CCCCC3)n2)s1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",C=CCNc1nc(-c2sc(NC(C)=O)nc2C)cs1,CHEMBL3639328,=,=,IC50,nM,202.0,IC50,nM,202.0,C=CCNc1nc(-c2sc(NC(C)=O)nc2C)cs1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)Nc1nc(C)c(-c2csc(Nc3cccnc3)n2)s1,CHEMBL3639328,=,=,IC50,nM,94.0,IC50,nM,94.0,CC(=O)Nc1nc(C)c(-c2csc(Nc3cccnc3)n2)s1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)Nc1nc(C)c(-c2csc(N)n2)s1,CHEMBL3639328,=,=,IC50,nM,575.0,IC50,nM,575.0,CC(=O)Nc1nc(C)c(-c2csc(N)n2)s1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)Nc1nc(C)c(-c2csc(N3CCOCC3)n2)s1,CHEMBL3639328,=,=,IC50,nM,844.0,IC50,nM,844.0,CC(=O)Nc1nc(C)c(-c2csc(N3CCOCC3)n2)s1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)Nc1nc(C)c(-c2csc(NC(C)(C)C)n2)s1,CHEMBL3639328,=,=,IC50,nM,314.0,IC50,nM,314.0,CC(=O)Nc1nc(C)c(-c2csc(NC(C)(C)C)n2)s1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)Nc1nc(C)c(-c2csc(NCCN3CCOCC3)n2)s1,CHEMBL3639328,=,=,IC50,nM,871.0,IC50,nM,871.0,CC(=O)Nc1nc(C)c(-c2csc(NCCN3CCOCC3)n2)s1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",COCCNc1nc(-c2sc(NC(C)=O)nc2C)cs1,CHEMBL3639328,=,=,IC50,nM,355.0,IC50,nM,355.0,COCCNc1nc(-c2sc(NC(C)=O)nc2C)cs1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)Nc1nc(C)c(-c2csc(NCC(O)c3ccccc3)n2)s1,CHEMBL3639328,=,=,IC50,nM,70.0,IC50,nM,70.0,CC(=O)Nc1nc(C)c(-c2csc(NCC(O)c3ccccc3)n2)s1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)Nc1nc(C)c(-c2csc(Nc3cccnc3F)n2)s1,CHEMBL3639328,=,=,IC50,nM,38.0,IC50,nM,38.0,CC(=O)Nc1nc(C)c(-c2csc(Nc3cccnc3F)n2)s1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CCOC(CCNc1nc(-c2sc(NC(C)=O)nc2C)cs1)OCC,CHEMBL3639328,=,=,IC50,nM,612.0,IC50,nM,612.0,CCOC(CCNc1nc(-c2sc(NC(C)=O)nc2C)cs1)OCC,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)Nc1nc(C)c(-c2csc(Nc3cccc(-c4nnn[nH]4)c3)n2)s1,CHEMBL3639328,=,=,IC50,nM,9.0,IC50,nM,9.0,CC(=O)Nc1nc(C)c(-c2csc(Nc3cccc(-c4nnn[nH]4)c3)n2)s1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)Nc1nc(C)c(-c2csc(NCCc3n[nH]c(=O)o3)n2)s1,CHEMBL3639328,=,=,IC50,nM,377.0,IC50,nM,377.0,CC(=O)Nc1nc(C)c(-c2csc(NCCc3n[nH]c(=O)o3)n2)s1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)NCCNc1nc(-c2sc(NC(C)=O)nc2C)cs1,CHEMBL3639328,=,=,IC50,nM,189.0,IC50,nM,189.0,CC(=O)NCCNc1nc(-c2sc(NC(C)=O)nc2C)cs1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)Nc1nc(C)c(-c2csc(NCCC(N)=O)n2)s1,CHEMBL3639328,=,=,IC50,nM,64.0,IC50,nM,64.0,CC(=O)Nc1nc(C)c(-c2csc(NCCC(N)=O)n2)s1,2014
"High Throughput PI3K Lipid Kinase Assay: The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay.The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin.To a 384 wells MTP containing 5 ul of the test compound of Formula (I) (solubilized in 6% DMSO; to yield a concentration of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.001 uM of the test compound), the following assay components are added.",CC(=O)Nc1nc(C)c(-c2csc(Nc3cccc(CCC(=O)O)c3)n2)s1,CHEMBL3639328,=,=,IC50,nM,64.0,IC50,nM,64.0,CC(=O)Nc1nc(C)c(-c2csc(Nc3cccc(CCC(=O)O)c3)n2)s1,2014
"PI3K Inhibition Assay: PI3K inhibition assay (PI3K Assay (Emmanuelle M, Huang Y, Yan H G et al. Targeting Protein Translation in Human Non-Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression. Cancer Res 67:(23). (2007).) was carried out by PI3 Kinase activity/inhibitor assay kit, where PI3 kinase reaction was set up in Glutathione-coated strips/plate for inhibitor reaction. Kinase and inhibitors were pre-incubated for 10 minutes prior to the addition of PIP2 substrate. 5 uL of 5x kinase reaction buffer were added in each well followed by the further addition of 5 uL/well of PIP2 substrate. Then distilled H2O was added to each well so as to make up a final volume of 25 uL/well. Incubation was done at rt for 1 hour which was followed by washing the wells 3 times with 200 uL of 1xTBST per well and then 2 times with 200 uL of IX TBS per well. Then 100 uL of the Substrate TMB per well was added and then to keep for colour development in the dark.",CC1(C)CCCC2(C)c3c(oc4c(B(O)O)c(O)c(O)cc34)CCC12,CHEMBL3886408,=,=,IC50,nM,85390.0,IC50,nM,85390.0,CC1(C)CCCC2(C)c3c(oc4c(B(O)O)c(O)c(O)cc34)CCC12,2015
"Homogeneous Time Resolved Fluorescence Assay: The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, were determined using a commercially available lipid kinase assay run in Homogeneous Time Resolved Fluorescence (HTRF) format. Assay DescriptionAssay principle: The PIP3 product is detected by displacement of biotin-PIP3 from an energy transfer complex consisting of Europium labeled anti-GST monoclonal antibody, a GST-tagged pleckstrin homology (PH) domain, biotinylated PIP3 and Streptavidin-Allophycocyanin (APC). Excitation of Europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm. The PIP3 product formed by PI 3-Kinase(h) activity displaces biotin-PIP3 from the complex resulting in a loss of energy transfer and thus a decrease in signal.This is a 3-step reaction: First, the kinase reaction with PIP2 substrate is carried out in the presence of ATP, and the reaction is quenched.",O=c1c2c(F)cccc2nc([C@H](CC(F)(F)F)Nc2ncnc3[nH]cnc23)n1-c1ccccc1,CHEMBL3886434,=,=,IC50,nM,1800.0,IC50,nM,1800.0,O=c1c2c(F)cccc2nc([C@H](CC(F)(F)F)Nc2ncnc3[nH]cnc23)n1-c1ccccc1,2015
"Homogeneous Time Resolved Fluorescence Assay: The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, were determined using a commercially available lipid kinase assay run in Homogeneous Time Resolved Fluorescence (HTRF) format. Assay DescriptionAssay principle: The PIP3 product is detected by displacement of biotin-PIP3 from an energy transfer complex consisting of Europium labeled anti-GST monoclonal antibody, a GST-tagged pleckstrin homology (PH) domain, biotinylated PIP3 and Streptavidin-Allophycocyanin (APC). Excitation of Europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm. The PIP3 product formed by PI 3-Kinase(h) activity displaces biotin-PIP3 from the complex resulting in a loss of energy transfer and thus a decrease in signal.This is a 3-step reaction: First, the kinase reaction with PIP2 substrate is carried out in the presence of ATP, and the reaction is quenched.",CC[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL3886434,=,=,IC50,nM,1200.0,IC50,nM,1200.0,CC[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2015
"Homogeneous Time Resolved Fluorescence Assay: The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, were determined using a commercially available lipid kinase assay run in Homogeneous Time Resolved Fluorescence (HTRF) format. Assay DescriptionAssay principle: The PIP3 product is detected by displacement of biotin-PIP3 from an energy transfer complex consisting of Europium labeled anti-GST monoclonal antibody, a GST-tagged pleckstrin homology (PH) domain, biotinylated PIP3 and Streptavidin-Allophycocyanin (APC). Excitation of Europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm. The PIP3 product formed by PI 3-Kinase(h) activity displaces biotin-PIP3 from the complex resulting in a loss of energy transfer and thus a decrease in signal.This is a 3-step reaction: First, the kinase reaction with PIP2 substrate is carried out in the presence of ATP, and the reaction is quenched.",CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1cccc(CC(F)(F)F)c1,CHEMBL3886434,=,=,IC50,nM,300.0,IC50,nM,300.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1cccc(CC(F)(F)F)c1,2015
"Homogeneous Time Resolved Fluorescence Assay: The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, were determined using a commercially available lipid kinase assay run in Homogeneous Time Resolved Fluorescence (HTRF) format. Assay DescriptionAssay principle: The PIP3 product is detected by displacement of biotin-PIP3 from an energy transfer complex consisting of Europium labeled anti-GST monoclonal antibody, a GST-tagged pleckstrin homology (PH) domain, biotinylated PIP3 and Streptavidin-Allophycocyanin (APC). Excitation of Europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm. The PIP3 product formed by PI 3-Kinase(h) activity displaces biotin-PIP3 from the complex resulting in a loss of energy transfer and thus a decrease in signal.This is a 3-step reaction: First, the kinase reaction with PIP2 substrate is carried out in the presence of ATP, and the reaction is quenched.",CC[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(F)c2c(=O)n1-c1cccc(CC(F)(F)F)c1,CHEMBL3886434,=,=,IC50,nM,1300.0,IC50,nM,1300.0,CC[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(F)c2c(=O)n1-c1cccc(CC(F)(F)F)c1,2015
"Homogeneous Time Resolved Fluorescence Assay: The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, were determined using a commercially available lipid kinase assay run in Homogeneous Time Resolved Fluorescence (HTRF) format. Assay DescriptionAssay principle: The PIP3 product is detected by displacement of biotin-PIP3 from an energy transfer complex consisting of Europium labeled anti-GST monoclonal antibody, a GST-tagged pleckstrin homology (PH) domain, biotinylated PIP3 and Streptavidin-Allophycocyanin (APC). Excitation of Europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm. The PIP3 product formed by PI 3-Kinase(h) activity displaces biotin-PIP3 from the complex resulting in a loss of energy transfer and thus a decrease in signal.This is a 3-step reaction: First, the kinase reaction with PIP2 substrate is carried out in the presence of ATP, and the reaction is quenched.",CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1cccc(OCC(F)(F)F)c1,CHEMBL3886434,=,=,IC50,nM,740.0,IC50,nM,740.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1cccc(OCC(F)(F)F)c1,2015
"Homogeneous Time Resolved Fluorescence Assay: The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, were determined using a commercially available lipid kinase assay run in Homogeneous Time Resolved Fluorescence (HTRF) format. Assay DescriptionAssay principle: The PIP3 product is detected by displacement of biotin-PIP3 from an energy transfer complex consisting of Europium labeled anti-GST monoclonal antibody, a GST-tagged pleckstrin homology (PH) domain, biotinylated PIP3 and Streptavidin-Allophycocyanin (APC). Excitation of Europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm. The PIP3 product formed by PI 3-Kinase(h) activity displaces biotin-PIP3 from the complex resulting in a loss of energy transfer and thus a decrease in signal.This is a 3-step reaction: First, the kinase reaction with PIP2 substrate is carried out in the presence of ATP, and the reaction is quenched.",CC[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(F)c2c(=O)n1-c1cccc(OCC(F)(F)F)c1,CHEMBL3886434,=,=,IC50,nM,3000.0,IC50,nM,3000.0,CC[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(F)c2c(=O)n1-c1cccc(OCC(F)(F)F)c1,2015
"Homogeneous Time Resolved Fluorescence Assay: The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, were determined using a commercially available lipid kinase assay run in Homogeneous Time Resolved Fluorescence (HTRF) format. Assay DescriptionAssay principle: The PIP3 product is detected by displacement of biotin-PIP3 from an energy transfer complex consisting of Europium labeled anti-GST monoclonal antibody, a GST-tagged pleckstrin homology (PH) domain, biotinylated PIP3 and Streptavidin-Allophycocyanin (APC). Excitation of Europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm. The PIP3 product formed by PI 3-Kinase(h) activity displaces biotin-PIP3 from the complex resulting in a loss of energy transfer and thus a decrease in signal.This is a 3-step reaction: First, the kinase reaction with PIP2 substrate is carried out in the presence of ATP, and the reaction is quenched.",C[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(F)c2c(=O)n1-c1ccc(OCC(F)(F)F)cc1,CHEMBL3886434,=,=,IC50,nM,740.0,IC50,nM,740.0,C[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(F)c2c(=O)n1-c1ccc(OCC(F)(F)F)cc1,2015
"Homogeneous Time Resolved Fluorescence Assay: The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, were determined using a commercially available lipid kinase assay run in Homogeneous Time Resolved Fluorescence (HTRF) format. Assay DescriptionAssay principle: The PIP3 product is detected by displacement of biotin-PIP3 from an energy transfer complex consisting of Europium labeled anti-GST monoclonal antibody, a GST-tagged pleckstrin homology (PH) domain, biotinylated PIP3 and Streptavidin-Allophycocyanin (APC). Excitation of Europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm. The PIP3 product formed by PI 3-Kinase(h) activity displaces biotin-PIP3 from the complex resulting in a loss of energy transfer and thus a decrease in signal.This is a 3-step reaction: First, the kinase reaction with PIP2 substrate is carried out in the presence of ATP, and the reaction is quenched.",CC[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(F)c2c(=O)n1-c1ccc(OCC(F)(F)F)cc1,CHEMBL3886434,=,=,IC50,nM,5400.0,IC50,nM,5400.0,CC[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(F)c2c(=O)n1-c1ccc(OCC(F)(F)F)cc1,2015
"Homogeneous Time Resolved Fluorescence Assay: The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, were determined using a commercially available lipid kinase assay run in Homogeneous Time Resolved Fluorescence (HTRF) format. Assay DescriptionAssay principle: The PIP3 product is detected by displacement of biotin-PIP3 from an energy transfer complex consisting of Europium labeled anti-GST monoclonal antibody, a GST-tagged pleckstrin homology (PH) domain, biotinylated PIP3 and Streptavidin-Allophycocyanin (APC). Excitation of Europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm. The PIP3 product formed by PI 3-Kinase(h) activity displaces biotin-PIP3 from the complex resulting in a loss of energy transfer and thus a decrease in signal.This is a 3-step reaction: First, the kinase reaction with PIP2 substrate is carried out in the presence of ATP, and the reaction is quenched.",C[C@H](Nc1ncnc2[nH]cc(F)c12)c1nc2cccc(F)c2c(=O)n1-c1cccc(OCC(F)(F)F)c1,CHEMBL3886434,=,=,IC50,nM,1200.0,IC50,nM,1200.0,C[C@H](Nc1ncnc2[nH]cc(F)c12)c1nc2cccc(F)c2c(=O)n1-c1cccc(OCC(F)(F)F)c1,2015
"Homogeneous Time Resolved Fluorescence Assay: The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, were determined using a commercially available lipid kinase assay run in Homogeneous Time Resolved Fluorescence (HTRF) format. Assay DescriptionAssay principle: The PIP3 product is detected by displacement of biotin-PIP3 from an energy transfer complex consisting of Europium labeled anti-GST monoclonal antibody, a GST-tagged pleckstrin homology (PH) domain, biotinylated PIP3 and Streptavidin-Allophycocyanin (APC). Excitation of Europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm. The PIP3 product formed by PI 3-Kinase(h) activity displaces biotin-PIP3 from the complex resulting in a loss of energy transfer and thus a decrease in signal.This is a 3-step reaction: First, the kinase reaction with PIP2 substrate is carried out in the presence of ATP, and the reaction is quenched.",C[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(F)c2c(=O)n1-c1cccc(OCC(F)(F)C(F)(F)F)c1,CHEMBL3886434,=,=,IC50,nM,4500.0,IC50,nM,4500.0,C[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(F)c2c(=O)n1-c1cccc(OCC(F)(F)C(F)(F)F)c1,2015
"Homogeneous Time Resolved Fluorescence Assay: The ability of the compounds of the present invention to inhibit the activity of four PI3K isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, were determined using a commercially available lipid kinase assay run in Homogeneous Time Resolved Fluorescence (HTRF) format. Assay DescriptionAssay principle: The PIP3 product is detected by displacement of biotin-PIP3 from an energy transfer complex consisting of Europium labeled anti-GST monoclonal antibody, a GST-tagged pleckstrin homology (PH) domain, biotinylated PIP3 and Streptavidin-Allophycocyanin (APC). Excitation of Europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm. The PIP3 product formed by PI 3-Kinase(h) activity displaces biotin-PIP3 from the complex resulting in a loss of energy transfer and thus a decrease in signal.This is a 3-step reaction: First, the kinase reaction with PIP2 substrate is carried out in the presence of ATP, and the reaction is quenched.",C[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(OCC(F)(F)F)c1,CHEMBL3886434,=,=,IC50,nM,460.0,IC50,nM,460.0,C[C@H](Nc1ncnc2[nH]ccc12)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(OCC(F)(F)F)c1,2015
"Enzyme Inhibition Assay: The PI3K enzymes catalyse the phosphorylation of phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) in the presence of ATP and Mg2+ ions. The PIP3 product can be detected by displacement of biotin-PIP3 from energy transfer complexes consisting of europium labelled anti-GST monoclonal antibody, a GST-tagged Pleckstrin homology (PH) domain, biotinylated PIP3 and streptavidin-allophycocyanin (APC) by the time-resolved fluorescence resonance energy transfer (TR-FRET) (HTRF PI3K enzyme assay, Millipore). Excitation, at 330 nm, of europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm although europium itself emits at its characteristic wavelength of 620 nm. The PIP3 product formed by PI3K activity displaces biotin-PIP3 from the complex and results in a loss of energy transfer (decreasing signal).The compound to be tested was added, at the desired final concentrations, to a mixture of PIP2 substrate.",COCCOCCOCC#Cc1cccc2nc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(Cc3ccccc3C(F)(F)F)c(=O)c12,CHEMBL3886466,=,=,IC50,nM,28.0,IC50,nM,28.0,COCCOCCOCC#Cc1cccc2nc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(Cc3ccccc3C(F)(F)F)c(=O)c12,2016
"Enzyme Inhibition Assay: The PI3K enzymes catalyse the phosphorylation of phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) in the presence of ATP and Mg2+ ions. The PIP3 product can be detected by displacement of biotin-PIP3 from energy transfer complexes consisting of europium labelled anti-GST monoclonal antibody, a GST-tagged Pleckstrin homology (PH) domain, biotinylated PIP3 and streptavidin-allophycocyanin (APC) by the time-resolved fluorescence resonance energy transfer (TR-FRET) (HTRF PI3K enzyme assay, Millipore). Excitation, at 330 nm, of europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm although europium itself emits at its characteristic wavelength of 620 nm. The PIP3 product formed by PI3K activity displaces biotin-PIP3 from the complex and results in a loss of energy transfer (decreasing signal).The compound to be tested was added, at the desired final concentrations, to a mixture of PIP2 substrate.",COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3ccccc3Cl)c(=O)c12,CHEMBL3886466,=,=,IC50,nM,25.0,IC50,nM,25.0,COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3ccccc3Cl)c(=O)c12,2016
"Enzyme Inhibition Assay: The PI3K enzymes catalyse the phosphorylation of phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) in the presence of ATP and Mg2+ ions. The PIP3 product can be detected by displacement of biotin-PIP3 from energy transfer complexes consisting of europium labelled anti-GST monoclonal antibody, a GST-tagged Pleckstrin homology (PH) domain, biotinylated PIP3 and streptavidin-allophycocyanin (APC) by the time-resolved fluorescence resonance energy transfer (TR-FRET) (HTRF PI3K enzyme assay, Millipore). Excitation, at 330 nm, of europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm although europium itself emits at its characteristic wavelength of 620 nm. The PIP3 product formed by PI3K activity displaces biotin-PIP3 from the complex and results in a loss of energy transfer (decreasing signal).The compound to be tested was added, at the desired final concentrations, to a mixture of PIP2 substrate.",COCCOCCOCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3ccccc3F)c(=O)c12,CHEMBL3886466,=,=,IC50,nM,120.0,IC50,nM,120.0,COCCOCCOCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3ccccc3F)c(=O)c12,2016
"Cell Based Assay: As a means of assessing the activation of PI3K γ in response to stimuli, the phosphorylation status of the protein, Akt, a downstream product of PI3K γ signalling, was determined following stimulation with MCP-1.U937 cells were differentiated to macrophage-type cells by incubation with PMA (100 ng/mL) for 48 to 72 hr. Cells were then pre-incubated with either the test compound or vehicle for 2 hr and were then stimulated briefly with MCP-1 (10 nM, 1 min) and the reaction stopped by replacing the media with 4% formaldehyde solution. Endogenous peroxide activity and formaldehyde were inactivated by incubating with quenching buffer (0.1% sodium azide, 1% H2O2 in PBS with 0.1% Triton X-100) for 20 min. The cells were washed with buffer (PBS containing 0.1% Triton X-100) and were incubated with blocking solution (1% BSA in PBS) for 1 hr and were then re-washed with buffer and incubated overnight with either anti-pAkt antibody or anti-pan-Akt antibody.",Nc1ncnc2c1c(-c1cc(O)cc(F)c1)nn2Cc1nc2cccc(C#CCOCCOCCO)c2c(=O)n1Cc1ccccc1C(F)(F)F,CHEMBL3886466,=,=,IC50,nM,577.0,IC50,nM,577.0,Nc1ncnc2c1c(-c1cc(O)cc(F)c1)nn2Cc1nc2cccc(C#CCOCCOCCO)c2c(=O)n1Cc1ccccc1C(F)(F)F,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(F)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(F)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)cccc2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)cccc2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",COC(=O)c1ccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)nc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,COC(=O)c1ccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)nc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(F)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(F)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(Cl)cccc2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(Cl)cccc2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(F)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(F)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",COc1ccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3c(Cl)ccc(Cl)c3c(=O)n2-c2ccccc2)nc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,COc1ccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3c(Cl)ccc(Cl)c3c(=O)n2-c2ccccc2)nc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(Cl)ccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(Cl)ccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",COc1ccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3c(F)cccc3c(=O)n2-c2ccccc2)nc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,COc1ccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3c(F)cccc3c(=O)n2-c2ccccc2)nc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)cccc2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)cccc2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cccnn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cccnn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cccc(N)n1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1cccc(N)n1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)cc1C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)cc1C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)cc1C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)cc1C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CC(O)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC(O)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CC(O)C#Cc1c(N)ncnc1N[C@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC(O)C#Cc1c(N)ncnc1N[C@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CC(O)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC(O)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CC(O)C#Cc1c(N)ncnc1N[C@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC(O)C#Cc1c(N)ncnc1N[C@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#CC1CC1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#CC1CC1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#CC1CC1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#CC1CC1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1nc(N)nc(N)c1C#Cc1ccccc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1nc(N)nc(N)c1C#Cc1ccccc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(OC(F)(F)F)cc1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(OC(F)(F)F)cc1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(OC(F)(F)F)cc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(OC(F)(F)F)cc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#CC(C)(C)O)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#CC(C)(C)O)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#CC(C)(C)O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#CC(C)(C)O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ccccn3)n(-c3ccccc3)c(=O)c12,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ccccn3)n(-c3ccccc3)c(=O)c12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cccc(N)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1cccc(N)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)nc1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)nc1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)nc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)nc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(N)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(N)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(N)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(N)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Nc1ncnc(N2CCCC[C@H]2c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1C#Cc1ccccn1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Nc1ncnc(N2CCCC[C@H]2c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1C#Cc1ccccn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Nc1ncnc(N2CCC[C@H]2c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1C#Cc1ccccn1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,Nc1ncnc(N2CCC[C@H]2c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1C#Cc1ccccn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(C(N)=O)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(C(N)=O)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CCNS(=O)(=O)c1cccc(-n2c([C@H](C)Nc3ncnc(N)c3C#Cc3ccccn3)nc3cccc(Cl)c3c2=O)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,CCNS(=O)(=O)c1cccc(-n2c([C@H](C)Nc3ncnc(N)c3C#Cc3ccccn3)nc3cccc(Cl)c3c2=O)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(S(N)(=O)=O)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(S(N)(=O)=O)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cncnc1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cncnc1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cncnc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1cncnc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cccnc1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1cccnc1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cccnc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1cccnc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc2nc(N)sc2c1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc2nc(N)sc2c1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",COc1cc(F)cc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,COc1cc(F)cc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cn[nH]c1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1cn[nH]c1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(O)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(O)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1ccc(Cl)c2c(=O)n(-c3ccccc3)c([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)nc12,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1ccc(Cl)c2c(=O)n(-c3ccccc3)c([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)nc12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)n(-c3ccccc3)c(=O)c12,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)n(-c3ccccc3)c(=O)c12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C#N)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C#N)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1cccc2c(=O)n(-c3ccccc3)c([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)nc12,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1cccc2c(=O)n(-c3ccccc3)c([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)nc12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CCCCc1cccc(-n2c([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)nc3cccc(Cl)c3c2=O)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CCCCc1cccc(-n2c([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)nc3cccc(Cl)c3c2=O)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(S(C)(=O)=O)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(S(C)(=O)=O)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(C(C)(C)C)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(C(C)(C)C)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(-c2ccccc2)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(-c2ccccc2)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CCc1cccc(-n2c([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)nc3cccc(Cl)c3c2=O)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CCc1cccc(-n2c([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)nc3cccc(Cl)c3c2=O)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1ccc(F)c2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)n(-c3ccccc3)c(=O)c12,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,Cc1ccc(F)c2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)n(-c3ccccc3)c(=O)c12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",COc1cc(F)cc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3c(F)ccc(F)c3c(=O)n2-c2ccccc2)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COc1cc(F)cc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3c(F)ccc(F)c3c(=O)n2-c2ccccc2)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",COc1cc(F)cc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3c(F)cccc3c(=O)n2-c2ccccc2)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COc1cc(F)cc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3c(F)cccc3c(=O)n2-c2ccccc2)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",COc1cc(F)cc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(F)c3c(=O)n2-c2ccccc2)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COc1cc(F)cc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(F)c3c(=O)n2-c2ccccc2)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1ccc(F)c2c(=O)n(-c3ccccc3)c([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)nc12,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1ccc(F)c2c(=O)n(-c3ccccc3)c([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)nc12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1cccc(C#N)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1cccc(C#N)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1cccc(C#N)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1cccc(C#N)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1ccc(F)c2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)n(-c3cccc(C#N)c3)c(=O)c12,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1ccc(F)c2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)n(-c3cccc(C#N)c3)c(=O)c12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1ccc(F)c2nc([C@H](C)Nc3ncnc(N)c3C#Cc3cnccn3)n(-c3cccc(C#N)c3)c(=O)c12,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1ccc(F)c2nc([C@H](C)Nc3ncnc(N)c3C#Cc3cnccn3)n(-c3cccc(C#N)c3)c(=O)c12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CC[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1ccc(F)c2nc([C@H](C)Nc3ncnc(N)c3C#Cc3cnccn3)n(-c3ccccc3)c(=O)c12,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,Cc1ccc(F)c2nc([C@H](C)Nc3ncnc(N)c3C#Cc3cnccn3)n(-c3ccccc3)c(=O)c12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1nc(N)nc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1nc(N)nc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ncccc1F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ncccc1F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",COc1cccnc1C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,COc1cccnc1C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",COc1cccc(-n2c([C@H](C)Nc3ncnc(N)c3C#Cc3ncccc3F)nc3cccc(Cl)c3c2=O)c1C,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COc1cccc(-n2c([C@H](C)Nc3ncnc(N)c3C#Cc3ncccc3F)nc3cccc(Cl)c3c2=O)c1C,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",COc1cccc(-n2c([C@H](C)Nc3ncnc(N)c3C#Cc3ncccc3F)nc3cccc(Cl)c3c2=O)c1C,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COc1cccc(-n2c([C@H](C)Nc3ncnc(N)c3C#Cc3ncccc3F)nc3cccc(Cl)c3c2=O)c1C,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ncc(F)cc1F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ncc(F)cc1F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1nc(N)nc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1nc(N)nc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(Cl)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(Cl)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(C#N)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(C#N)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(C#N)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(C#N)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2ccc(F)cc2c(=O)n1-c1cccc(C#N)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2ccc(F)cc2c(=O)n1-c1cccc(C#N)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2ccc(F)cc2c(=O)n1-c1cccc(C#N)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2ccc(F)cc2c(=O)n1-c1cccc(C#N)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2ccc(F)cc2c(=O)n1-c1cccc(Cl)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2ccc(F)cc2c(=O)n1-c1cccc(Cl)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2ccc(F)cc2c(=O)n1-c1cccc(Cl)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2ccc(F)cc2c(=O)n1-c1cccc(Cl)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3cnccn3)n(-c3ccccc3)c(=O)c12,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3cnccn3)n(-c3ccccc3)c(=O)c12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(F)c2c(=O)n1-c1cccc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(F)c2c(=O)n1-c1cccc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2c(F)cccc2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2c(F)cccc2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1cccc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1cccc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ncccn3)n(-c3ccccc3)c(=O)c12,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ncccn3)n(-c3ccccc3)c(=O)c12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ncccn3)n(-c3cc(F)cc(F)c3)c(=O)c12,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ncccn3)n(-c3cc(F)cc(F)c3)c(=O)c12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3cnccn3)n(-c3cccc(F)c3)c(=O)c12,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3cnccn3)n(-c3cccc(F)c3)c(=O)c12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CC[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CC[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(F)c2c(=O)n1-c1cccc(C#N)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(F)c2c(=O)n1-c1cccc(C#N)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(F)c2c(=O)n1-c1cccc(F)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(F)c2c(=O)n1-c1cccc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(S(C)(=O)=O)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(S(C)(=O)=O)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(S(C)(=O)=O)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(S(C)(=O)=O)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(C#N)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(C#N)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1cccnc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1cccnc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(F)c2c(=O)n1-c1cccnc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(F)c2c(=O)n1-c1cccnc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3cnccn3)n(-c3cccnc3)c(=O)c12,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3cnccn3)n(-c3cccnc3)c(=O)c12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3cnccn3)n(-c3cncc(F)c3)c(=O)c12,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3cnccn3)n(-c3cncc(F)c3)c(=O)c12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1N1CCOCC1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1N1CCOCC1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",COc1cc(F)cc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2N2CCOCC2)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COc1cc(F)cc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2N2CCOCC2)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(CNS(C)(=O)=O)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(CNS(C)(=O)=O)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1C1C[C@H]2CC[C@@H](C1)N2C,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1C1C[C@H]2CC[C@@H](C1)N2C,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1C1C[C@H]2CC[C@@H](C1)N2C,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1C1C[C@H]2CC[C@@H](C1)N2C,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1N1CCCCCC1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1N1CCCCCC1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1N1CCNCC1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1N1CCNCC1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)n(-c3cccc(CN(C)S(C)(=O)=O)c3)c(=O)c12,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1cccc2nc([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)n(-c3cccc(CN(C)S(C)(=O)=O)c3)c(=O)c12,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@@H](c1nc2cccc(Cl)c2c(=O)n1-c1cccc(CN(C)S(C)(=O)=O)c1)N(C)c1ncnc(N)c1C#Cc1ccc(F)cn1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@@H](c1nc2cccc(Cl)c2c(=O)n1-c1cccc(CN(C)S(C)(=O)=O)c1)N(C)c1ncnc(N)c1C#Cc1ccc(F)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(CNS(C)(=O)=O)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(CNS(C)(=O)=O)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CC(C)CS(=O)(=O)NCc1cccc(-n2c([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)nc3cccc(Cl)c3c2=O)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC(C)CS(=O)(=O)NCc1cccc(-n2c([C@H](C)Nc3ncnc(N)c3C#Cc3ccc(F)cn3)nc3cccc(Cl)c3c2=O)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(C(F)(F)F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(C(F)(F)F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1ccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)nc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,Cc1ccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)nc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(C(F)(F)F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(C(F)(F)F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(C(N)=O)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(C(N)=O)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(C(N)=O)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(C(N)=O)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CC(C)OC(=O)c1ccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)nc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC(C)OC(=O)c1ccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)nc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ccc(C(=O)O)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ccc(C(=O)O)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Nc1ncnc(N[C@H](CO)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1C#Cc1ccc(F)cn1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Nc1ncnc(N[C@H](CO)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1C#Cc1ccc(F)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1nc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)ccc1F,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1nc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)ccc1F,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1cccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)n1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,Cc1cccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)n1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ncccc1C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1ncccc1C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1cccnc1C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,Cc1cccnc1C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#CC1CCCC1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#CC1CCCC1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#CC1CCCCC1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#CC1CCCCC1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",COC[C@@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COC[C@@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1ccnc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,Cc1ccnc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cc(C(F)(F)F)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1cc(C(F)(F)F)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cc(C(F)F)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1cc(C(F)F)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CCc1ccnc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,CCc1ccnc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cccc(C(F)(F)F)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1cccc(C(F)(F)F)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CC(=O)c1cccnc1C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC(=O)c1cccnc1C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CC(=O)c1cccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)n1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,CC(=O)c1cccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)n1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cc(CO)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1cc(CO)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cccc(CO)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#Cc1cccc(CO)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cc(C(N)=O)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,C[C@H](Nc1ncnc(N)c1C#Cc1cc(C(N)=O)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CC(O)c1cccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)n1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,CC(O)c1cccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)n1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",COC(=O)c1ccnc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COC(=O)c1ccnc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cccc(CN)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cccc(CN)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cc(C(=O)O)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cc(C(=O)O)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",CC(=O)c1cccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1,CHEMBL3886547,<,<,IC50,nM,100.0,IC50,nM,100.0,CC(=O)c1cccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1cccc(CO)c1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1cccc(CO)c1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",C[C@H](Nc1ncnc(N)c1C#Cc1ncccc1CO)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL3886547,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](Nc1ncnc(N)c1C#Cc1ncccc1CO)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 1% (v/v) DMSO at the following concentrations for each isoform: PI3K alpha, beta, delta, and gamma at 50 picomolar (pM) and PI3Kgamma at 2 nanomolar (nM). After an assay reaction time of 30 minutes at 25° C., reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window).",Cc1ccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2cc(F)cc(F)c2)nc1,CHEMBL3886547,=,=,IC50,nM,550.0,IC50,nM,550.0,Cc1ccc(C#Cc2c(N)ncnc2N[C@@H](C)c2nc3cccc(Cl)c3c(=O)n2-c2cc(F)cc(F)c2)nc1,2016
"Inhibition Assay: PI3 kinases catalyse the phosphorylation of phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) in the presence of ATP and Mg2+ ions. The PIP3 product can be detected by displacement of biotin-PIP3 from energy transfer complexes consisting of europium labelled anti-GST monoclonal antibody, a GST-tagged Pleckstrin homology (PH) domain, biotinylated PIP3 and streptavidin-allophycocyanin (APC) by the time-resolved fluorescence resonance energy transfer (TR-FRET) (HTRF® PI3K enzyme assay, Millipore). Excitation (330 nm) of europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm although europium itself emits at its characteristic 620 nm. The PIP3 product formed by PI3K activity displaces biotin-PIP3 from the complex and results in a loss of energy transfer (decreasing signal). The compound to be tested was added, at the desired final concentrations, to a mixture of PIP2 substrate and recombinant PI3 kinase α, δ or γ enzymes (Millipore), and the mixture incubated for 2 hr at RT. Following this incubation period, ATP (20 μM) was added to the enzyme/compound/PIP2 substrate mixture and the resulting mixture was incubated for 30 min at RT. A stopping solution containing biotinylated PIP3 and the detection mix containing the GST tagged GRP1 pleckstrin homology (PH) domain and fluorophores were then added and the mixture was incubated at RT for 15-18 hr, prior to detection in a fluorescence microplate reader (Varioskan® Flash, ThermoFisher Scientific).",C#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3ccccc3Cl)c(=O)c12,CHEMBL3886675,=,=,IC50,nM,234.0,IC50,nM,234.0,C#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3ccccc3Cl)c(=O)c12,2016
"Inhibition Assay: PI3 kinases catalyse the phosphorylation of phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) in the presence of ATP and Mg2+ ions. The PIP3 product can be detected by displacement of biotin-PIP3 from energy transfer complexes consisting of europium labelled anti-GST monoclonal antibody, a GST-tagged Pleckstrin homology (PH) domain, biotinylated PIP3 and streptavidin-allophycocyanin (APC) by the time-resolved fluorescence resonance energy transfer (TR-FRET) (HTRF® PI3K enzyme assay, Millipore). Excitation (330 nm) of europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm although europium itself emits at its characteristic 620 nm. The PIP3 product formed by PI3K activity displaces biotin-PIP3 from the complex and results in a loss of energy transfer (decreasing signal). The compound to be tested was added, at the desired final concentrations, to a mixture of PIP2 substrate and recombinant PI3 kinase α, δ or γ enzymes (Millipore), and the mixture incubated for 2 hr at RT. Following this incubation period, ATP (20 μM) was added to the enzyme/compound/PIP2 substrate mixture and the resulting mixture was incubated for 30 min at RT. A stopping solution containing biotinylated PIP3 and the detection mix containing the GST tagged GRP1 pleckstrin homology (PH) domain and fluorophores were then added and the mixture was incubated at RT for 15-18 hr, prior to detection in a fluorescence microplate reader (Varioskan® Flash, ThermoFisher Scientific).",Nc1ncnc2c1c(-c1ccc(O)cc1)nn2Cc1nc2cccc(C#CCCCC(=O)O)c2c(=O)n1Cc1ccccc1Cl,CHEMBL3886675,=,=,IC50,nM,20.0,IC50,nM,20.0,Nc1ncnc2c1c(-c1ccc(O)cc1)nn2Cc1nc2cccc(C#CCCCC(=O)O)c2c(=O)n1Cc1ccccc1Cl,2016
"Inhibition Assay: PI3 kinases catalyse the phosphorylation of phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) in the presence of ATP and Mg2+ ions. The PIP3 product can be detected by displacement of biotin-PIP3 from energy transfer complexes consisting of europium labelled anti-GST monoclonal antibody, a GST-tagged Pleckstrin homology (PH) domain, biotinylated PIP3 and streptavidin-allophycocyanin (APC) by the time-resolved fluorescence resonance energy transfer (TR-FRET) (HTRF® PI3K enzyme assay, Millipore). Excitation (330 nm) of europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm although europium itself emits at its characteristic 620 nm. The PIP3 product formed by PI3K activity displaces biotin-PIP3 from the complex and results in a loss of energy transfer (decreasing signal). The compound to be tested was added, at the desired final concentrations, to a mixture of PIP2 substrate and recombinant PI3 kinase α, δ or γ enzymes (Millipore), and the mixture incubated for 2 hr at RT. Following this incubation period, ATP (20 μM) was added to the enzyme/compound/PIP2 substrate mixture and the resulting mixture was incubated for 30 min at RT. A stopping solution containing biotinylated PIP3 and the detection mix containing the GST tagged GRP1 pleckstrin homology (PH) domain and fluorophores were then added and the mixture was incubated at RT for 15-18 hr, prior to detection in a fluorescence microplate reader (Varioskan® Flash, ThermoFisher Scientific).",Nc1ncnc2c1c(-c1ccc(O)cc1)nn2Cc1nc2cccc(C#CCCCC(=O)N3CCOCC3)c2c(=O)n1Cc1ccccc1Cl,CHEMBL3886675,=,=,IC50,nM,16.0,IC50,nM,16.0,Nc1ncnc2c1c(-c1ccc(O)cc1)nn2Cc1nc2cccc(C#CCCCC(=O)N3CCOCC3)c2c(=O)n1Cc1ccccc1Cl,2016
"Inhibition Assay: PI3 kinases catalyse the phosphorylation of phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) in the presence of ATP and Mg2+ ions. The PIP3 product can be detected by displacement of biotin-PIP3 from energy transfer complexes consisting of europium labelled anti-GST monoclonal antibody, a GST-tagged Pleckstrin homology (PH) domain, biotinylated PIP3 and streptavidin-allophycocyanin (APC) by the time-resolved fluorescence resonance energy transfer (TR-FRET) (HTRF® PI3K enzyme assay, Millipore). Excitation (330 nm) of europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm although europium itself emits at its characteristic 620 nm. The PIP3 product formed by PI3K activity displaces biotin-PIP3 from the complex and results in a loss of energy transfer (decreasing signal). The compound to be tested was added, at the desired final concentrations, to a mixture of PIP2 substrate and recombinant PI3 kinase α, δ or γ enzymes (Millipore), and the mixture incubated for 2 hr at RT. Following this incubation period, ATP (20 μM) was added to the enzyme/compound/PIP2 substrate mixture and the resulting mixture was incubated for 30 min at RT. A stopping solution containing biotinylated PIP3 and the detection mix containing the GST tagged GRP1 pleckstrin homology (PH) domain and fluorophores were then added and the mixture was incubated at RT for 15-18 hr, prior to detection in a fluorescence microplate reader (Varioskan® Flash, ThermoFisher Scientific).",C#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3cccc(OC)c3)c(=O)c12,CHEMBL3886675,=,=,IC50,nM,289.0,IC50,nM,289.0,C#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3cccc(OC)c3)c(=O)c12,2016
"Inhibition Assay: PI3 kinases catalyse the phosphorylation of phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) in the presence of ATP and Mg2+ ions. The PIP3 product can be detected by displacement of biotin-PIP3 from energy transfer complexes consisting of europium labelled anti-GST monoclonal antibody, a GST-tagged Pleckstrin homology (PH) domain, biotinylated PIP3 and streptavidin-allophycocyanin (APC) by the time-resolved fluorescence resonance energy transfer (TR-FRET) (HTRF® PI3K enzyme assay, Millipore). Excitation (330 nm) of europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm although europium itself emits at its characteristic 620 nm. The PIP3 product formed by PI3K activity displaces biotin-PIP3 from the complex and results in a loss of energy transfer (decreasing signal). The compound to be tested was added, at the desired final concentrations, to a mixture of PIP2 substrate and recombinant PI3 kinase α, δ or γ enzymes (Millipore), and the mixture incubated for 2 hr at RT. Following this incubation period, ATP (20 μM) was added to the enzyme/compound/PIP2 substrate mixture and the resulting mixture was incubated for 30 min at RT. A stopping solution containing biotinylated PIP3 and the detection mix containing the GST tagged GRP1 pleckstrin homology (PH) domain and fluorophores were then added and the mixture was incubated at RT for 15-18 hr, prior to detection in a fluorescence microplate reader (Varioskan® Flash, ThermoFisher Scientific).",COCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3cccc(C(F)(F)F)c3)c(=O)c12,CHEMBL3886675,=,=,IC50,nM,1613.0,IC50,nM,1613.0,COCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3cccc(C(F)(F)F)c3)c(=O)c12,2016
"Inhibition Assay: PI3 kinases catalyse the phosphorylation of phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) in the presence of ATP and Mg2+ ions. The PIP3 product can be detected by displacement of biotin-PIP3 from energy transfer complexes consisting of europium labelled anti-GST monoclonal antibody, a GST-tagged Pleckstrin homology (PH) domain, biotinylated PIP3 and streptavidin-allophycocyanin (APC) by the time-resolved fluorescence resonance energy transfer (TR-FRET) (HTRF® PI3K enzyme assay, Millipore). Excitation (330 nm) of europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm although europium itself emits at its characteristic 620 nm. The PIP3 product formed by PI3K activity displaces biotin-PIP3 from the complex and results in a loss of energy transfer (decreasing signal). The compound to be tested was added, at the desired final concentrations, to a mixture of PIP2 substrate and recombinant PI3 kinase α, δ or γ enzymes (Millipore), and the mixture incubated for 2 hr at RT. Following this incubation period, ATP (20 μM) was added to the enzyme/compound/PIP2 substrate mixture and the resulting mixture was incubated for 30 min at RT. A stopping solution containing biotinylated PIP3 and the detection mix containing the GST tagged GRP1 pleckstrin homology (PH) domain and fluorophores were then added and the mixture was incubated at RT for 15-18 hr, prior to detection in a fluorescence microplate reader (Varioskan® Flash, ThermoFisher Scientific).",CC(C)NC(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4ccc(O)cc4)c4c(N)ncnc43)n(Cc3ccccc3Cl)c(=O)c12,CHEMBL3886675,=,=,IC50,nM,22.0,IC50,nM,22.0,CC(C)NC(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4ccc(O)cc4)c4c(N)ncnc43)n(Cc3ccccc3Cl)c(=O)c12,2016
"Inhibition Assay: PI3 kinases catalyse the phosphorylation of phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) in the presence of ATP and Mg2+ ions. The PIP3 product can be detected by displacement of biotin-PIP3 from energy transfer complexes consisting of europium labelled anti-GST monoclonal antibody, a GST-tagged Pleckstrin homology (PH) domain, biotinylated PIP3 and streptavidin-allophycocyanin (APC) by the time-resolved fluorescence resonance energy transfer (TR-FRET) (HTRF® PI3K enzyme assay, Millipore). Excitation (330 nm) of europium in the complex results in an energy transfer to the APC and a fluorescent emission at 665 nm although europium itself emits at its characteristic 620 nm. The PIP3 product formed by PI3K activity displaces biotin-PIP3 from the complex and results in a loss of energy transfer (decreasing signal). The compound to be tested was added, at the desired final concentrations, to a mixture of PIP2 substrate and recombinant PI3 kinase α, δ or γ enzymes (Millipore), and the mixture incubated for 2 hr at RT. Following this incubation period, ATP (20 μM) was added to the enzyme/compound/PIP2 substrate mixture and the resulting mixture was incubated for 30 min at RT. A stopping solution containing biotinylated PIP3 and the detection mix containing the GST tagged GRP1 pleckstrin homology (PH) domain and fluorophores were then added and the mixture was incubated at RT for 15-18 hr, prior to detection in a fluorescence microplate reader (Varioskan® Flash, ThermoFisher Scientific).",Nc1ncnc2c1c(-c1ccc(O)cc1)nn2Cc1nc2cccc(C#CCCCC(=O)N3CCCC3)c2c(=O)n1Cc1ccccc1Cl,CHEMBL3886675,=,=,IC50,nM,47.0,IC50,nM,47.0,Nc1ncnc2c1c(-c1ccc(O)cc1)nn2Cc1nc2cccc(C#CCCCC(=O)N3CCCC3)c2c(=O)n1Cc1ccccc1Cl,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,=,=,IC50,nM,630.0,IC50,nM,630.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1ncnc(N)c1C#N)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1ncnc(N)c1C#N)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1ncnc2[nH]nnc12)c1nc2c(F)cccc2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1ncnc2[nH]nnc12)c1nc2c(F)cccc2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1ncnc2occc12)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1ncnc2occc12)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,=,=,IC50,nM,280.0,IC50,nM,280.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2cccc(Cl)c2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,=,=,IC50,nM,4000.0,IC50,nM,4000.0,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2cccc(Cl)c2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",Nc1cnc(-n2c([C@@H](Nc3nc(N)nc(N)c3Cl)C3CC3)nc3cccc(Cl)c3c2=O)cn1,CHEMBL3887021,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Nc1cnc(-n2c([C@@H](Nc3nc(N)nc(N)c3Cl)C3CC3)nc3cccc(Cl)c3c2=O)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",N#Cc1c(N)nc(N)nc1N[C@H](c1nc2cccc(Cl)c2c(=O)n1-c1cnc(N)cn1)C1CC1,CHEMBL3887021,=,=,IC50,nM,900.0,IC50,nM,900.0,N#Cc1c(N)nc(N)nc1N[C@H](c1nc2cccc(Cl)c2c(=O)n1-c1cnc(N)cn1)C1CC1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",N#Cc1c(N)nc(N)nc1N[C@H](c1nc2c(Cl)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1)C1CC1,CHEMBL3887021,=,=,IC50,nM,3100.0,IC50,nM,3100.0,N#Cc1c(N)nc(N)nc1N[C@H](c1nc2c(Cl)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1)C1CC1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(Cl)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,=,=,IC50,nM,1500.0,IC50,nM,1500.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(Cl)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",Nc1cnc(-n2c([C@@H](Nc3nc(N)nc(N)c3Cl)C3CC3)nc3c(Cl)ccc(Cl)c3c2=O)cn1,CHEMBL3887021,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Nc1cnc(-n2c([C@@H](Nc3nc(N)nc(N)c3Cl)C3CC3)nc3c(Cl)ccc(Cl)c3c2=O)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(Cl)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(Cl)ccc(Cl)c2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(F)cc(F)cc2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(F)cc(F)cc2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(F)cc(F)cc2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,=,=,IC50,nM,1500.0,IC50,nM,1500.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(F)cc(F)cc2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,=,=,IC50,nM,4900.0,IC50,nM,4900.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1ncnc(N)c1Cl)c1nc2cccc(Cl)c2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1ncnc(N)c1Cl)c1nc2cccc(Cl)c2c(=O)n1-c1cnc(N)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",Nc1cnc(-n2c([C@@H](Nc3ncnc(N)c3Cl)C3CC3)nc3c(Cl)ccc(Cl)c3c2=O)cn1,CHEMBL3887021,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Nc1cnc(-n2c([C@@H](Nc3ncnc(N)c3Cl)C3CC3)nc3c(Cl)ccc(Cl)c3c2=O)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",Nc1cnc(-n2c([C@@H](Nc3ncnc(N)c3Cl)C3CC3)nc3cccc(Cl)c3c2=O)cn1,CHEMBL3887021,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Nc1cnc(-n2c([C@@H](Nc3ncnc(N)c3Cl)C3CC3)nc3cccc(Cl)c3c2=O)cn1,2016
"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site. Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (75-500 uM), 2 uM PIP2, 5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 uM, and PI3Kγ at 2 nM. The compounds of Table 1 and Compound X ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) and Compound Y ((S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile) were added to the assay solution and incubated for 30 minutes at 25° C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 us delay and 500 us read window). The results were normalized based on positive (1 uM wortmanin) and negative (DMSO) controls, and the IC50 values for PI3K α, β, δ and γ were calculated from the fit of the dose-response curves to a four-parameter equation.",C[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cnc(N)cn1,CHEMBL3887021,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cnc(N)cn1,2016
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate after 1 hr by ADP-Glo kinase assay,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL3992539,=,=,IC50,nM,25.53,IC50,nM,25.53,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate after 1 hr by ADP-Glo kinase assay,COc1ncc(-c2ccc3ncc(NC(=O)CN4CCOCC4)c(OC)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3992539,=,=,IC50,nM,8.4,IC50,nM,8.4,COc1ncc(-c2ccc3ncc(NC(=O)CN4CCOCC4)c(OC)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2017
Inhibition of human PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by KINOMEscan assay relative to control,CNc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)c(C)c2)ncn1,CHEMBL3994581,=,=,Activity,%,95.0,Activity,%,95.0,CNc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)c(C)c2)ncn1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate incubated for 30 mins by ADP-Glo assay,CC(=O)N1C[C@@H](C)N(c2cccc(-c3cc(-c4ccnn4C4CCOCC4)c4c(N)ncnn34)c2)[C@@H](C)C1,CHEMBL3994626,=,=,IC50,nM,1.3,IC50,nM,1.3,CC(=O)N1C[C@@H](C)N(c2cccc(-c3cc(-c4ccnn4C4CCOCC4)c4c(N)ncnn34)c2)[C@@H](C)C1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1CC1CCOCC1,CHEMBL4000207,=,=,IC50,nM,316.23,pIC50,,6.5,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1CC1CCOCC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C(C)(C)C1CCOCC1,CHEMBL4000207,=,=,IC50,nM,398.11,pIC50,,6.4,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C(C)(C)C1CCOCC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1CN1CCOCC1,CHEMBL4000207,=,=,IC50,nM,398.11,pIC50,,6.4,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1CN1CCOCC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,C[C@@H](c1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nn1C)N1CCOCC1,CHEMBL4000207,=,=,IC50,nM,1584.89,pIC50,,5.8,C[C@@H](c1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nn1C)N1CCOCC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,C[C@H](c1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nn1C)N1CCOCC1,CHEMBL4000207,<,>,IC50,nM,1000.0,pIC50,,6.0,C[C@H](c1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nn1C)N1CCOCC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C1(N2CCOCC2)CC1,CHEMBL4000207,=,=,IC50,nM,794.33,pIC50,,6.1,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C1(N2CCOCC2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1Cc1ccccc1,CHEMBL4000207,=,=,IC50,nM,316.23,pIC50,,6.5,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1Cc1ccccc1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,C[C@H](c1ccccc1)c1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nn1C,CHEMBL4000207,,,pIC50,,,pIC50,,,C[C@H](c1ccccc1)c1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nn1C,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,C[C@@H](c1ccccc1)c1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nn1C,CHEMBL4000207,=,=,IC50,nM,501.19,pIC50,,6.3,C[C@@H](c1ccccc1)c1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nn1C,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C(C)(C)c1ccccc1,CHEMBL4000207,,,pIC50,,,pIC50,,,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C(C)(C)c1ccccc1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,501.19,pIC50,,6.3,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C1(CO)CC1,CHEMBL4000207,=,=,IC50,nM,501.19,pIC50,,6.3,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C1(CO)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C1(S(C)(=O)=O)CC1,CHEMBL4000207,=,=,IC50,nM,630.96,pIC50,,6.2,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C1(S(C)(=O)=O)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CN1CCN(C2(c3nc(-c4cnc(N)c(-n5nnc6ccccc65)n4)nn3C)CC2)CC1,CHEMBL4000207,=,=,IC50,nM,10000.0,pIC50,,5.0,CN1CCN(C2(c3nc(-c4cnc(N)c(-n5nnc6ccccc65)n4)nn3C)CC2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C1(Cc2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,398.11,pIC50,,6.4,Cn1nc(-c2cnc(N)c(-n3nnc4ccccc43)n2)nc1C1(Cc2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3ncc4ccccc43)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,2511.89,pIC50,,5.6,Cn1nc(-c2cnc(N)c(-n3ncc4ccccc43)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3cnc4ccccc43)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,7943.28,pIC50,,5.1,Cn1nc(-c2cnc(N)c(-n3cnc4ccccc43)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-c3c[nH]c4ccccc34)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,398.11,pIC50,,6.4,Cn1nc(-c2cnc(N)c(-c3c[nH]c4ccccc34)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)cn2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,<,>,IC50,nM,31622.78,pIC50,,4.5,Cn1nc(-c2cnc(N)cn2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(C#N)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,<,>,IC50,nM,25118.86,pIC50,,4.6,Cn1nc(-c2cnc(N)c(C#N)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-c3ccc(F)nc3)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,15848.93,pIC50,,4.8,Cn1nc(-c2cnc(N)c(-c3ccc(F)nc3)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-c3ccc(N)nc3)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,6309.57,pIC50,,5.2,Cn1nc(-c2cnc(N)c(-c3ccc(N)nc3)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-c3cn[nH]c3)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,2511.89,pIC50,,5.6,Cn1nc(-c2cnc(N)c(-c3cn[nH]c3)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-c3cc[nH]n3)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,6309.57,pIC50,,5.2,Cn1nc(-c2cnc(N)c(-c3cc[nH]n3)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1n[nH]c(C)c1-c1nc(-c2nc(C3(c4ccccc4)CC3)n(C)n2)cnc1N,CHEMBL4000207,<,>,IC50,nM,19952.62,pIC50,,4.7,Cc1n[nH]c(C)c1-c1nc(-c2nc(C3(c4ccccc4)CC3)n(C)n2)cnc1N,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-c3nnc(C(C)(C)C)o3)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,251.19,pIC50,,6.6,Cn1nc(-c2cnc(N)c(-c3nnc(C(C)(C)C)o3)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-c3cnn(C(N)=O)c3)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,3981.07,pIC50,,5.4,Cn1nc(-c2cnc(N)c(-c3cnn(C(N)=O)c3)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CN(C)S(=O)(=O)n1cc(-c2nc(-c3nc(C4(c5ccccc5)CC4)n(C)n3)cnc2N)cn1,CHEMBL4000207,=,=,IC50,nM,630.96,pIC50,,6.2,CN(C)S(=O)(=O)n1cc(-c2nc(-c3nc(C4(c5ccccc5)CC4)n(C)n3)cnc2N)cn1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3cc(C(N)=O)cn3)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,1000.0,pIC50,,6.0,Cn1nc(-c2cnc(N)c(-n3cc(C(N)=O)cn3)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-n3ccc(C(N)=O)n3)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,6309.57,pIC50,,5.2,Cn1nc(-c2cnc(N)c(-n3ccc(C(N)=O)n3)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-c3ccc(C(N)=O)cc3)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,1000.0,pIC50,,6.0,Cn1nc(-c2cnc(N)c(-c3ccc(C(N)=O)cc3)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cn1nc(-c2cnc(N)c(-c3ccc(C(N)=O)c(F)c3)n2)nc1C1(c2ccccc2)CC1,CHEMBL4000207,=,=,IC50,nM,1584.89,pIC50,,5.8,Cn1nc(-c2cnc(N)c(-c3ccc(C(N)=O)c(F)c3)n2)nc1C1(c2ccccc2)CC1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4004819,=,=,IC50,nM,2100.0,IC50,nM,2100.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccc(O)cc1,CHEMBL4004819,=,=,IC50,nM,4300.0,IC50,nM,4300.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccc(O)cc1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4004819,=,=,IC50,nM,154.0,IC50,nM,154.0,C[C@H](Nc1ncnc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1ccc(O)cc1,CHEMBL4004819,=,=,IC50,nM,187.0,IC50,nM,187.0,C[C@H](Nc1ncnc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1ccc(O)cc1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,=,=,IC50,nM,990.0,IC50,nM,990.0,C[C@H](Nc1ncnc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cn[nH]c1,CHEMBL4004819,=,=,IC50,nM,990.0,IC50,nM,990.0,C[C@H](Nc1ncnc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cn[nH]c1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,=,=,IC50,nM,54.0,IC50,nM,54.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,N#Cc1c(N)nc(N)nc1N[C@H](c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1)C1CC1,CHEMBL4004819,=,=,IC50,nM,199.0,IC50,nM,199.0,N#Cc1c(N)nc(N)nc1N[C@H](c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1)C1CC1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1cc(N)nc(N)n1)c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1cc(N)nc(N)n1)c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,=,=,IC50,nM,1247.0,IC50,nM,1247.0,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,Nc1nc(N)c(Cl)c(N[C@H](c2nc3cccc(Cl)c3c(=O)n2-c2cc[nH]n2)C2CC2)n1,CHEMBL4004819,=,=,IC50,nM,4150.0,IC50,nM,4150.0,Nc1nc(N)c(Cl)c(N[C@H](c2nc3cccc(Cl)c3c(=O)n2-c2cc[nH]n2)C2CC2)n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,Cc1nc(N)nc(N[C@H](c2nc3cccc(Cl)c3c(=O)n2-c2cc[nH]n2)C2CC2)c1C#N,CHEMBL4004819,=,=,IC50,nM,267.0,IC50,nM,267.0,Cc1nc(N)nc(N[C@H](c2nc3cccc(Cl)c3c(=O)n2-c2cc[nH]n2)C2CC2)c1C#N,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,N#Cc1c(Cl)nc(N)nc1N[C@H](c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1)C1CC1,CHEMBL4004819,=,=,IC50,nM,1300.0,IC50,nM,1300.0,N#Cc1c(Cl)nc(N)nc1N[C@H](c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1)C1CC1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,N#Cc1c(N[C@H](c2nc3cccc(Cl)c3c(=O)n2-c2cc[nH]n2)C2CC2)nc(N)nc1C(F)F,CHEMBL4004819,=,=,IC50,nM,1131.0,IC50,nM,1131.0,N#Cc1c(N[C@H](c2nc3cccc(Cl)c3c(=O)n2-c2cc[nH]n2)C2CC2)nc(N)nc1C(F)F,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(C(F)(F)F)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1nc(N)nc(C(F)(F)F)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2cccc(F)c2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2cccc(F)c2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2ccc(F)cc2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2ccc(F)cc2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(F)cccc2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(F)cccc2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(F)cc(F)cc2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,=,=,IC50,nM,4407.0,IC50,nM,4407.0,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(F)cc(F)cc2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,Nc1nc(N)c(Cl)c(N[C@H](c2nc3c(Cl)cc(F)cc3c(=O)n2-c2cc[nH]n2)C2CC2)n1,CHEMBL4004819,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Nc1nc(N)c(Cl)c(N[C@H](c2nc3c(Cl)cc(F)cc3c(=O)n2-c2cc[nH]n2)C2CC2)n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,CC[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CC[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2cccc(F)c2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2cccc(F)c2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2ccc(F)cc2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,=,=,IC50,nM,7989.0,IC50,nM,7989.0,C[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2ccc(F)cc2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2c(F)cccc2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,=,=,IC50,nM,4262.0,IC50,nM,4262.0,C[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2c(F)cccc2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2c(F)cc(F)cc2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,=,=,IC50,nM,2311.0,IC50,nM,2311.0,C[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2c(F)cc(F)cc2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,=,=,IC50,nM,1277.0,IC50,nM,1277.0,C[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,N#Cc1c(N[C@H](c2nc3c(Cl)cc(F)cc3c(=O)n2-c2cc[nH]n2)C2CC2)nc(N)nc1C(F)F,CHEMBL4004819,=,=,IC50,nM,3466.0,IC50,nM,3466.0,N#Cc1c(N[C@H](c2nc3c(Cl)cc(F)cc3c(=O)n2-c2cc[nH]n2)C2CC2)nc(N)nc1C(F)F,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,CC[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cc[nH]n1,CHEMBL4004819,=,=,IC50,nM,7836.0,IC50,nM,7836.0,CC[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cc[nH]n1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2cccc(Cl)c2c(=O)n1-c1ccon1,CHEMBL4004819,=,=,IC50,nM,499.0,IC50,nM,499.0,C[C@H](Nc1nc(N)nc(N)c1Cl)c1nc2cccc(Cl)c2c(=O)n1-c1ccon1,2017
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay,N#Cc1c(N)nc(N)nc1N[C@H](c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cc[nH]n1)C1CC1,CHEMBL4004819,=,=,IC50,nM,632.0,IC50,nM,632.0,N#Cc1c(N)nc(N)nc1N[C@H](c1nc2c(Cl)cc(F)cc2c(=O)n1-c1cc[nH]n1)C1CC1,2017
"Inhibition of human PI3K p120gamma at 10 uM using phosphatidylinositol 4,5-bisphosphate as substrate after 30 mins by HTRF assay relative to control",C[C@H]1COCCN1c1cc(-c2ccc(NC(=O)Nc3cccnc3)cc2)nn2ccnc12,CHEMBL4007445,=,=,Inhibition,%,40.0,INH,%,40.0,C[C@H]1COCCN1c1cc(-c2ccc(NC(=O)Nc3cccnc3)cc2)nn2ccnc12,2017
"Inhibition of human PI3K p120gamma at 10 uM using phosphatidylinositol 4,5-bisphosphate as substrate after 30 mins by HTRF assay relative to control",C[C@H]1COCCN1c1cc(-c2ccc(NC(=O)Nc3ccncc3)cc2)nn2ccnc12,CHEMBL4007445,=,=,Inhibition,%,39.0,INH,%,39.0,C[C@H]1COCCN1c1cc(-c2ccc(NC(=O)Nc3ccncc3)cc2)nn2ccnc12,2017
"Inhibition of human PI3K p120gamma at 10 uM using phosphatidylinositol 4,5-bisphosphate as substrate after 30 mins by HTRF assay relative to control",COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO,CHEMBL4007445,=,=,Inhibition,%,29.0,INH,%,29.0,COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO,2017
"Inhibition of human PI3K p120gamma at 10 uM using phosphatidylinositol 4,5-bisphosphate as substrate after 30 mins by HTRF assay relative to control",Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL4007445,=,=,Inhibition,%,98.0,INH,%,98.0,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2017
Inhibition of human PI3Kgamma,O=C(c1ccc(Nc2nc3ccccc3n3nnnc23)cc1)N1CCN(c2ncccn2)CC1,CHEMBL4011625,=,=,IC50,nM,31622.78,pIC50,,4.5,O=C(c1ccc(Nc2nc3ccccc3n3nnnc23)cc1)N1CCN(c2ncccn2)CC1,2017
Inhibition of recombinant human PI3Kgamma using PIP2 as substrate preincubated for 20 mins followed by substrate addition measured after 80 mins in presence of ATP by Kinase Glo luminescence assay,CN(C)C(=O)c1cc([C@H]2CCCN2c2ccc(F)cc2)c2oc(N3CCOCC3)cc(=O)c2c1,CHEMBL4014298,=,=,IC50,nM,330.0,IC50,uM,0.33,CN(C)C(=O)c1cc([C@H]2CCCN2c2ccc(F)cc2)c2oc(N3CCOCC3)cc(=O)c2c1,2017
Inhibition of recombinant human PI3Kgamma using PIP2 as substrate preincubated for 20 mins followed by substrate addition measured after 80 mins in presence of ATP by Kinase Glo luminescence assay,O=C(c1cc([C@H]2CCCN2c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1)N1CCOCC1,CHEMBL4014298,=,=,IC50,nM,190.0,IC50,uM,0.19,O=C(c1cc([C@H]2CCCN2c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1)N1CCOCC1,2017
Inhibition of recombinant human PI3Kgamma using PIP2 as substrate preincubated for 20 mins followed by substrate addition measured after 80 mins in presence of ATP by Kinase Glo luminescence assay,O=C(c1cc([C@H]2CCCN2c2cccc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1)N1CCOCC1,CHEMBL4014298,=,=,IC50,nM,340.0,IC50,uM,0.34,O=C(c1cc([C@H]2CCCN2c2cccc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1)N1CCOCC1,2017
Inhibition of human PI3Kgamma (2 to 1102 residues) by ADP Glo HTS assay,O=C(c1cc([C@H]2CCCN2c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1)N1CCOCC1,CHEMBL4014298,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C(c1cc([C@H]2CCCN2c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1)N1CCOCC1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3ccccc3)c(=O)n12,CHEMBL4014331,=,=,IC50,nM,12.59,pIC50,,7.9,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3ccccc3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(Cc3cccc(CN)c3)c(=O)n12,CHEMBL4014331,=,=,IC50,nM,199.53,pIC50,,6.7,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(Cc3cccc(CN)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CNCc1cccc(Cc2c([C@H](C)Nc3ncnc(N)c3C#N)cc3scc(C)n3c2=O)c1,CHEMBL4014331,=,=,IC50,nM,630.96,pIC50,,6.2,CNCc1cccc(Cc2c([C@H](C)Nc3ncnc(N)c3C#N)cc3scc(C)n3c2=O)c1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(Cc3cccc(CN(C)C)c3)c(=O)n12,CHEMBL4014331,=,=,IC50,nM,630.96,pIC50,,6.2,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(Cc3cccc(CN(C)C)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,COCCNCc1cccc(Cc2c([C@H](C)Nc3ncnc(N)c3C#N)cc3scc(C)n3c2=O)c1,CHEMBL4014331,=,=,IC50,nM,398.11,pIC50,,6.4,COCCNCc1cccc(Cc2c([C@H](C)Nc3ncnc(N)c3C#N)cc3scc(C)n3c2=O)c1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(Cc3cccc(CN(C)CC(C)C)c3)c(=O)n12,CHEMBL4014331,<,>,IC50,nM,794.33,pIC50,,6.1,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(Cc3cccc(CN(C)CC(C)C)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(Cc3cccc(CN4CCC4)c3)c(=O)n12,CHEMBL4014331,=,=,IC50,nM,501.19,pIC50,,6.3,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(Cc3cccc(CN4CCC4)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(Cc3cccc(CNCCCCOCCc4ccccc4)c3)c(=O)n12,CHEMBL4014331,=,=,IC50,nM,316.23,pIC50,,6.5,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(Cc3cccc(CNCCCCOCCc4ccccc4)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CCN(C)C)c3)c(=O)n12,CHEMBL4014331,<,>,IC50,nM,1000.0,pIC50,,6.0,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CCN(C)C)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(OCCN(C)C)c3)c(=O)n12,CHEMBL4014331,=,=,IC50,nM,316.23,pIC50,,6.5,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(OCCN(C)C)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CC4CCN(C(C)C)CC4)c3)c(=O)n12,CHEMBL4014331,=,=,IC50,nM,251.19,pIC50,,6.6,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CC4CCN(C(C)C)CC4)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CNCCN4CCOCC4)c3)c(=O)n12,CHEMBL4014331,<=,>=,IC50,nM,199.53,pIC50,,6.7,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CNCCN4CCOCC4)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN4CCC(N(C)C)CC4)c3)c(=O)n12,CHEMBL4014331,<=,>=,IC50,nM,199.53,pIC50,,6.7,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN4CCC(N(C)C)CC4)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN4CCC(CN(C)CC(C)C)CC4)c3)c(=O)n12,CHEMBL4014331,<=,>=,IC50,nM,199.53,pIC50,,6.7,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN4CCC(CN(C)CC(C)C)CC4)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN4CCN(CCN5CCOCC5)CC4)c3)c(=O)n12,CHEMBL4014331,<=,>=,IC50,nM,199.53,pIC50,,6.7,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN4CCN(CCN5CCOCC5)CC4)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN4CCC(N(C)CCC(F)(F)F)CC4)c3)c(=O)n12,CHEMBL4014331,<=,>=,IC50,nM,199.53,pIC50,,6.7,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN4CCC(N(C)CCC(F)(F)F)CC4)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN4CCC(N(C)CC(C)C)CC4)c3)c(=O)n12,CHEMBL4014331,<=,>=,IC50,nM,199.53,pIC50,,6.7,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN4CCC(N(C)CC(C)C)CC4)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN4CCC(CN(C)Cc5ccccn5)CC4)c3)c(=O)n12,CHEMBL4014331,<=,>=,IC50,nM,199.53,pIC50,,6.7,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN4CCC(CN(C)Cc5ccccn5)CC4)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CCN(CCN1CCOCC1)Cc1cccc(-c2c([C@H](C)Nc3ncnc(N)c3C#N)cc3scc(C)n3c2=O)c1,CHEMBL4014331,<=,>=,IC50,nM,199.53,pIC50,,6.7,CCN(CCN1CCOCC1)Cc1cccc(-c2c([C@H](C)Nc3ncnc(N)c3C#N)cc3scc(C)n3c2=O)c1,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN(C)CCCN(C)Cc4ccc(Cl)cc4)c3)c(=O)n12,CHEMBL4014331,<=,>=,IC50,nM,199.53,pIC50,,6.7,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN(C)CCCN(C)Cc4ccc(Cl)cc4)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN(C)CCCN4C[C@@H](C)O[C@@H](C)C4)c3)c(=O)n12,CHEMBL4014331,<=,>=,IC50,nM,199.53,pIC50,,6.7,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN(C)CCCN4C[C@@H](C)O[C@@H](C)C4)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN(C)CCCCN4C[C@@H](C)O[C@@H](C)C4)c3)c(=O)n12,CHEMBL4014331,<=,>=,IC50,nM,199.53,pIC50,,6.7,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN(C)CCCCN4C[C@@H](C)O[C@@H](C)C4)c3)c(=O)n12,2017
Inhibition of recombinant human His6-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN(C)CCCCN(C)Cc4ccccc4)c3)c(=O)n12,CHEMBL4014331,<=,>=,IC50,nM,199.53,pIC50,,6.7,Cc1csc2cc([C@H](C)Nc3ncnc(N)c3C#N)c(-c3cccc(CN(C)CCCCN(C)Cc4ccccc4)c3)c(=O)n12,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate after 30 mins by ADP-Glo assay,CC(=O)N1CCN(c2cccc(-c3cc(-c4ccnn4C4CCOCC4)c4c(N)ncnn34)c2)C(=O)C1(C)C,CHEMBL4014340,=,=,IC50,nM,21.0,IC50,nM,21.0,CC(=O)N1CCN(c2cccc(-c3cc(-c4ccnn4C4CCOCC4)c4c(N)ncnn34)c2)C(=O)C1(C)C,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate after 30 mins by ADP-Glo assay,CC(=O)N1CCN(c2cc(-c3cc(C(F)(F)F)c4c(N)ncnn34)ccc2C#N)C(=O)C1(C)C,CHEMBL4014340,=,=,IC50,nM,170.0,IC50,nM,170.0,CC(=O)N1CCN(c2cc(-c3cc(C(F)(F)F)c4c(N)ncnn34)ccc2C#N)C(=O)C1(C)C,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,CC(=O)N1CCN(c2cc(-c3cc(C(F)(F)F)c4c(N)ncnn34)ccc2C#N)C(=O)C1(C)C,CHEMBL4014340,=,=,IC50,nM,41.0,IC50,nM,41.0,CC(=O)N1CCN(c2cc(-c3cc(C(F)(F)F)c4c(N)ncnn34)ccc2C#N)C(=O)C1(C)C,2017
Inhibition of PI3Kgamma (unknown origin),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4014340,=,=,IC50,nM,63.0,IC50,nM,63.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2017
Inhibition of PI3Kgamma (unknown origin),C[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4014340,=,=,IC50,nM,12.0,IC50,nM,12.0,C[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2017
Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by HTRF assay,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,CHEMBL4017467,=,=,Ki,nM,179.0,Ki(app),nM,179.0,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,2017
Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by HTRF assay,Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CCN(S(=O)(=O)C2CC2)C4)cn1,CHEMBL4017467,=,=,Ki,nM,126.0,Ki(app),nM,126.0,Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CCN(S(=O)(=O)C2CC2)C4)cn1,2017
Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by HTRF assay,Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CCN(S(=O)(=O)c2ccc(F)cc2)C4)cn1,CHEMBL4017467,=,=,Ki,nM,113.0,Ki(app),nM,113.0,Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CCN(S(=O)(=O)c2ccc(F)cc2)C4)cn1,2017
Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by HTRF assay,CS(=O)(=O)N1CCc2c(nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn23)C1,CHEMBL4017467,=,=,Ki,nM,50.1,Ki(app),nM,50.1,CS(=O)(=O)N1CCc2c(nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn23)C1,2017
Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by HTRF assay,Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CN(C(=O)NCc2ccc(F)cc2)CC4)cn1,CHEMBL4017467,=,=,Ki,nM,66.7,Ki(app),nM,66.7,Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CN(C(=O)NCc2ccc(F)cc2)CC4)cn1,2017
Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by HTRF assay,Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CN(C(=O)NC2CCCCC2)CC4)cn1,CHEMBL4017467,=,=,Ki,nM,84.3,Ki(app),nM,84.3,Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CN(C(=O)NC2CCCCC2)CC4)cn1,2017
Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by HTRF assay,Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CN(CCc2ccc(F)cc2)CC4)cn1,CHEMBL4017467,>,>,Ki,nM,490.0,Ki(app),nM,490.0,Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CN(CCc2ccc(F)cc2)CC4)cn1,2017
Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by HTRF assay,CS(=O)(=O)NCCN1CCc2c(nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn23)C1,CHEMBL4017467,=,=,Ki,nM,361.0,Ki(app),nM,361.0,CS(=O)(=O)NCCN1CCc2c(nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn23)C1,2017
Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by HTRF assay,Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CN(c2ccc(F)cc2)CC4)cn1,CHEMBL4017467,>,>,Ki,nM,490.0,Ki(app),nM,490.0,Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CN(c2ccc(F)cc2)CC4)cn1,2017
Inhibition of PI3Kgamma (unknown origin),Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,CHEMBL4017506,=,=,IC50,nM,778.0,IC50,nM,778.0,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,2017
Inhibition of PI3Kgamma (unknown origin),Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,CHEMBL4017506,=,=,IC50,nM,708.0,IC50,nM,708.0,Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,2017
Binding affinity to human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system by Kinomescan assay,Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,CHEMBL4017506,=,=,Kd,nM,25.0,Kd,nM,25.0,Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,2017
Binding affinity to human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system by Kinomescan assay,Nc1ncc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)c(C(F)(F)F)n1,CHEMBL4017506,=,=,Kd,nM,11.0,Kd,nM,11.0,Nc1ncc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)c(C(F)(F)F)n1,2017
Binding affinity to human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system by Kinomescan assay,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,CHEMBL4017506,=,=,Kd,nM,24.0,Kd,nM,24.0,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,2017
Binding affinity to human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system by Kinomescan assay,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,CHEMBL4017506,=,=,Kd,nM,130.0,Kd,nM,130.0,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,2017
Binding affinity to human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system by Kinomescan assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4017506,=,=,Kd,nM,7.7,Kd,nM,7.7,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2017
Binding affinity to human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system by Kinomescan assay,Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL4017506,=,=,Kd,nM,2.6,Kd,nM,2.6,Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2017
Inhibition of full length recombinant human PI3K p120gamma at 1 uM relative to control,N#CCN1CCC(n2c(=O)cnc3cnc4ccc(-c5ccc(N)nc5)cc4c32)CC1,CHEMBL4020823,=,=,Inhibition,%,4.0,INH,%,4.0,N#CCN1CCC(n2c(=O)cnc3cnc4ccc(-c5ccc(N)nc5)cc4c32)CC1,2018
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4024705,=,=,IC50,nM,63.0,IC50,nM,63.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,C[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4024705,=,=,IC50,nM,12.0,IC50,nM,12.0,C[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,Nc1ncnn2c(-c3cccc(N4CCOCC4=O)c3)cc(-c3ccnn3CC(F)(F)F)c12,CHEMBL4024705,=,=,IC50,nM,27.0,IC50,nM,27.0,Nc1ncnn2c(-c3cccc(N4CCOCC4=O)c3)cc(-c3ccnn3CC(F)(F)F)c12,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,Nc1ncnn2c(-c3cccc(N4CCOCC4=O)c3)cc(Cl)c12,CHEMBL4024705,=,=,IC50,nM,29.0,IC50,nM,29.0,Nc1ncnn2c(-c3cccc(N4CCOCC4=O)c3)cc(Cl)c12,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,Nc1ncnn2c(-c3cccc(N4CCOCC4=O)c3)cc(C(F)(F)F)c12,CHEMBL4024705,=,=,IC50,nM,390.0,IC50,nM,390.0,Nc1ncnn2c(-c3cccc(N4CCOCC4=O)c3)cc(C(F)(F)F)c12,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,CC1(C)OCCN(c2cccc(-c3cc(-c4ccnn4CC(F)(F)F)c4c(N)ncnn34)c2)C1=O,CHEMBL4024705,=,=,IC50,nM,99.0,IC50,nM,99.0,CC1(C)OCCN(c2cccc(-c3cc(-c4ccnn4CC(F)(F)F)c4c(N)ncnn34)c2)C1=O,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,CC1(C)OCCN(c2cccc(-c3cc(Cl)c4c(N)ncnn34)c2)C1=O,CHEMBL4024705,=,=,IC50,nM,130.0,IC50,nM,130.0,CC1(C)OCCN(c2cccc(-c3cc(Cl)c4c(N)ncnn34)c2)C1=O,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,CC1(C)OCCN(c2cccc(-c3cc(C(F)(F)F)c4c(N)ncnn34)c2)C1=O,CHEMBL4024705,=,=,IC50,nM,220.0,IC50,nM,220.0,CC1(C)OCCN(c2cccc(-c3cc(C(F)(F)F)c4c(N)ncnn34)c2)C1=O,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,COc1ccc(-c2cc(-c3ccnn3CC(F)(F)F)c3c(N)ncnn23)cc1N1CCOC(C)(C)C1=O,CHEMBL4024705,=,=,IC50,nM,16.0,IC50,nM,16.0,COc1ccc(-c2cc(-c3ccnn3CC(F)(F)F)c3c(N)ncnn23)cc1N1CCOC(C)(C)C1=O,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,COc1ccc(-c2cc(Cl)c3c(N)ncnn23)cc1N1CCOC(C)(C)C1=O,CHEMBL4024705,=,=,IC50,nM,150.0,IC50,nM,150.0,COc1ccc(-c2cc(Cl)c3c(N)ncnn23)cc1N1CCOC(C)(C)C1=O,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,COc1ccc(-c2cc(C(F)(F)F)c3c(N)ncnn23)cc1N1CCOC(C)(C)C1=O,CHEMBL4024705,=,=,IC50,nM,190.0,IC50,nM,190.0,COc1ccc(-c2cc(C(F)(F)F)c3c(N)ncnn23)cc1N1CCOC(C)(C)C1=O,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,CC1(C)OCCN(c2cc(-c3cc(-c4ccnn4CC(F)(F)F)c4c(N)ncnn34)ccc2C#N)C1=O,CHEMBL4024705,=,=,IC50,nM,4.7,IC50,nM,4.7,CC1(C)OCCN(c2cc(-c3cc(-c4ccnn4CC(F)(F)F)c4c(N)ncnn34)ccc2C#N)C1=O,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,CC1(C)OCCN(c2cc(-c3cc(Cl)c4c(N)ncnn34)ccc2C#N)C1=O,CHEMBL4024705,=,=,IC50,nM,20.0,IC50,nM,20.0,CC1(C)OCCN(c2cc(-c3cc(Cl)c4c(N)ncnn34)ccc2C#N)C1=O,2017
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay,CC1(C)OCCN(c2cc(-c3cc(C(F)(F)F)c4c(N)ncnn34)ccc2C#N)C1=O,CHEMBL4024705,=,=,IC50,nM,61.0,IC50,nM,61.0,CC1(C)OCCN(c2cc(-c3cc(C(F)(F)F)c4c(N)ncnn34)ccc2C#N)C1=O,2017
Inhibition of wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control,C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1,CHEMBL4024706,=,=,Activity,%,100.0,Activity,%,100.0,C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1,2017
Inhibition of PI3Kgamma (unknown origin),CN(C)CC(=O)N1CCC(n2cc(-c3cnc(N)c(-n4nnc5ccccc54)n3)cn2)CC1,CHEMBL4033707,=,=,IC50,nM,280.0,IC50,uM,0.28,CN(C)CC(=O)N1CCC(n2cc(-c3cnc(N)c(-n4nnc5ccccc54)n3)cn2)CC1,2017
Inhibition of PI3Kgamma (unknown origin),CNC(=O)c1nc(-c2nc(-c3cnc4ccccn34)c(C)nc2N)n(C)n1,CHEMBL4033707,=,=,IC50,nM,43.0,IC50,uM,0.043,CNC(=O)c1nc(-c2nc(-c3cnc4ccccn34)c(C)nc2N)n(C)n1,2017
Inhibition of human PI3Kgamma (2 to 1102 residues) at 50 uM by ADP Glo HTS assay,CNC(=O)c1nc(-c2nc(-c3cnc4ccccn34)c(C)nc2N)n(C)n1,CHEMBL4033707,,,Inhibition,%,,INH,,,CNC(=O)c1nc(-c2nc(-c3cnc4ccccn34)c(C)nc2N)n(C)n1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 30 mins by HTRF assay,CC[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(C#CCCCC(=O)N3CCCC3)c2c(=O)n1-c1ccccc1,CHEMBL4041516,=,=,IC50,nM,125.0,IC50,nM,125.0,CC[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(C#CCCCC(=O)N3CCCC3)c2c(=O)n1-c1ccccc1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 30 mins by HTRF assay,CC[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(C#CCCCC(=O)N3CCOCC3)c2c(=O)n1-c1ccccc1,CHEMBL4041516,=,=,IC50,nM,91.9,IC50,nM,91.9,CC[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(C#CCCCC(=O)N3CCOCC3)c2c(=O)n1-c1ccccc1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 30 mins by HTRF assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4041516,=,=,IC50,nM,241.0,IC50,nM,241.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 30 mins by HTRF assay,Cc1nc(N)nc(N2CCC[C@H]2c2nc3cccc(C#CCCCC(=O)N4CCCC4)c3c(=O)n2-c2ccccc2)c1C#N,CHEMBL4041516,=,=,IC50,nM,132.0,IC50,nM,132.0,Cc1nc(N)nc(N2CCC[C@H]2c2nc3cccc(C#CCCCC(=O)N4CCCC4)c3c(=O)n2-c2ccccc2)c1C#N,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 30 mins by HTRF assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(C#CCCCC(=O)N3CCOCC3)c2c(=O)n1-c1ccccc1,CHEMBL4041516,=,=,IC50,nM,291.0,IC50,nM,291.0,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(C#CCCCC(=O)N3CCOCC3)c2c(=O)n1-c1ccccc1,2017
Inhibition of recombinant human full length His-tagged PI3Kgamma expressed in insect cells,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4041516,=,=,IC50,nM,89.0,IC50,nM,89.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2017
Inhibition of PI3Kgamma (unknown origin) using biotinylated PIP2 as substrate after 2 hrs by TR-FRET assay,COCCOCCNC(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3ccccc3Cl)c(=O)c12,CHEMBL4041516,=,=,IC50,nM,47.0,IC50,nM,47.0,COCCOCCNC(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3ccccc3Cl)c(=O)c12,2017
Inhibition of wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in HEK293 cells assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control,COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl,CHEMBL4043093,=,=,Activity,%,100.0,Activity,%,100.0,COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl,2017
Inhibition of PIK3CG ATP binding site (KKPLWLEFK) in human PBMC at 1 uM,CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1,CHEMBL4043168,=,=,Inhibition,%,-22.9,INH,%,-22.9,CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1,2017
Inhibition of PIK3CG ATP binding site (KKPLWLEFK) in human PBMC at 0.1 uM,CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1,CHEMBL4043168,=,=,Inhibition,%,-23.8,INH,%,-23.8,CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccccc3)c(OCc3ccccc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,5.4,INH,%,5.4,O=c1nc(N2CCOCC2)oc2c(-c3ccccc3)c(OCc3ccccc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)c(OCc3ccccc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,9.8,INH,%,9.8,O=c1nc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)c(OCc3ccccc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,COc1ccc(-c2c(OCc3ccccc3)ccc3c(=O)nc(N4CCOCC4)oc23)cc1,CHEMBL4043200,=,=,Inhibition,%,-0.5,INH,%,-0.5,COc1ccc(-c2c(OCc3ccccc3)ccc3c(=O)nc(N4CCOCC4)oc23)cc1,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,Nc1cccc(-c2c(OCc3ccccc3)ccc3c(=O)nc(N4CCOCC4)oc23)c1,CHEMBL4043200,=,=,Inhibition,%,19.8,INH,%,19.8,Nc1cccc(-c2c(OCc3ccccc3)ccc3c(=O)nc(N4CCOCC4)oc23)c1,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccs3)c(OCc3ccccc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,-3.5,INH,%,-3.5,O=c1nc(N2CCOCC2)oc2c(-c3cccs3)c(OCc3ccccc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccsc3)c(OCc3ccccc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,-24.9,INH,%,-24.9,O=c1nc(N2CCOCC2)oc2c(-c3ccsc3)c(OCc3ccccc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cc4ccccc4s3)c(OCc3ccccc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,-7.1,INH,%,-7.1,O=c1nc(N2CCOCC2)oc2c(-c3cc4ccccc4s3)c(OCc3ccccc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)c(OCc3ccccc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,-15.8,INH,%,-15.8,O=c1nc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)c(OCc3ccccc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccc4c3oc3ccccc34)c(OCc3ccccc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,-4.1,INH,%,-4.1,O=c1nc(N2CCOCC2)oc2c(-c3cccc4c3oc3ccccc34)c(OCc3ccccc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccc(CO)cc3)c(OCc3ccccc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,-17.7,INH,%,-17.7,O=c1nc(N2CCOCC2)oc2c(-c3ccc(CO)cc3)c(OCc3ccccc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccnc3)c(OCc3ccccc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,-2.3,INH,%,-2.3,O=c1nc(N2CCOCC2)oc2c(-c3cccnc3)c(OCc3ccccc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccc4ccccc34)c(OCc3ccccc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,-19.34,INH,%,-19.34,O=c1nc(N2CCOCC2)oc2c(-c3cccc4ccccc34)c(OCc3ccccc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccc4c3Sc3ccccc3S4)c(OCc3ccccc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,-16.1,INH,%,-16.1,O=c1nc(N2CCOCC2)oc2c(-c3cccc4c3Sc3ccccc3S4)c(OCc3ccccc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccccc3)c(OCc3ccccn3)ccc12,CHEMBL4043200,=,=,Inhibition,%,38.09,INH,%,38.09,O=c1nc(N2CCOCC2)oc2c(-c3ccccc3)c(OCc3ccccn3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)c(OCc3ccccn3)ccc12,CHEMBL4043200,=,=,Inhibition,%,23.53,INH,%,23.53,O=c1nc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)c(OCc3ccccn3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,COc1ccc(-c2c(OCc3ccccn3)ccc3c(=O)nc(N4CCOCC4)oc23)cc1,CHEMBL4043200,=,=,Inhibition,%,12.6,INH,%,12.6,COc1ccc(-c2c(OCc3ccccn3)ccc3c(=O)nc(N4CCOCC4)oc23)cc1,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,Nc1cccc(-c2c(OCc3ccccn3)ccc3c(=O)nc(N4CCOCC4)oc23)c1,CHEMBL4043200,=,=,Inhibition,%,6.4,INH,%,6.4,Nc1cccc(-c2c(OCc3ccccn3)ccc3c(=O)nc(N4CCOCC4)oc23)c1,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccs3)c(OCc3ccccn3)ccc12,CHEMBL4043200,=,=,Inhibition,%,0.1,INH,%,0.1,O=c1nc(N2CCOCC2)oc2c(-c3cccs3)c(OCc3ccccn3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccsc3)c(OCc3ccccn3)ccc12,CHEMBL4043200,=,=,Inhibition,%,4.4,INH,%,4.4,O=c1nc(N2CCOCC2)oc2c(-c3ccsc3)c(OCc3ccccn3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cc4ccccc4s3)c(OCc3ccccn3)ccc12,CHEMBL4043200,=,=,Inhibition,%,-1.0,INH,%,-1.0,O=c1nc(N2CCOCC2)oc2c(-c3cc4ccccc4s3)c(OCc3ccccn3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccccc3)c(OCc3cccnc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,25.7,INH,%,25.7,O=c1nc(N2CCOCC2)oc2c(-c3ccccc3)c(OCc3cccnc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)c(OCc3cccnc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,20.0,INH,%,20.0,O=c1nc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)c(OCc3cccnc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,COc1ccc(-c2c(OCc3cccnc3)ccc3c(=O)nc(N4CCOCC4)oc23)cc1,CHEMBL4043200,=,=,Inhibition,%,-2.2,INH,%,-2.2,COc1ccc(-c2c(OCc3cccnc3)ccc3c(=O)nc(N4CCOCC4)oc23)cc1,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,Nc1cccc(-c2c(OCc3cccnc3)ccc3c(=O)nc(N4CCOCC4)oc23)c1,CHEMBL4043200,=,=,Inhibition,%,-6.9,INH,%,-6.9,Nc1cccc(-c2c(OCc3cccnc3)ccc3c(=O)nc(N4CCOCC4)oc23)c1,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccs3)c(OCc3cccnc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,1.7,INH,%,1.7,O=c1nc(N2CCOCC2)oc2c(-c3cccs3)c(OCc3cccnc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccsc3)c(OCc3cccnc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,3.8,INH,%,3.8,O=c1nc(N2CCOCC2)oc2c(-c3ccsc3)c(OCc3cccnc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cc4ccccc4s3)c(OCc3cccnc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,-8.1,INH,%,-8.1,O=c1nc(N2CCOCC2)oc2c(-c3cc4ccccc4s3)c(OCc3cccnc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccccc3)c(OCc3ccncc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,8.2,INH,%,8.2,O=c1nc(N2CCOCC2)oc2c(-c3ccccc3)c(OCc3ccncc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)c(OCc3ccncc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,26.5,INH,%,26.5,O=c1nc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)c(OCc3ccncc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,COc1ccc(-c2c(OCc3ccncc3)ccc3c(=O)nc(N4CCOCC4)oc23)cc1,CHEMBL4043200,=,=,Inhibition,%,143.0,INH,%,143.0,COc1ccc(-c2c(OCc3ccncc3)ccc3c(=O)nc(N4CCOCC4)oc23)cc1,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,Nc1cccc(-c2c(OCc3ccncc3)ccc3c(=O)nc(N4CCOCC4)oc23)c1,CHEMBL4043200,=,=,Inhibition,%,-5.5,INH,%,-5.5,Nc1cccc(-c2c(OCc3ccncc3)ccc3c(=O)nc(N4CCOCC4)oc23)c1,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cccs3)c(OCc3ccncc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,-1.5,INH,%,-1.5,O=c1nc(N2CCOCC2)oc2c(-c3cccs3)c(OCc3ccncc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccsc3)c(OCc3ccncc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,7.7,INH,%,7.7,O=c1nc(N2CCOCC2)oc2c(-c3ccsc3)c(OCc3ccncc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3cc4ccccc4s3)c(OCc3ccncc3)ccc12,CHEMBL4043200,=,=,Inhibition,%,0.2,INH,%,0.2,O=c1nc(N2CCOCC2)oc2c(-c3cc4ccccc4s3)c(OCc3ccncc3)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccccc3)c(OCCBr)ccc12,CHEMBL4043200,=,=,Inhibition,%,-6.4,INH,%,-6.4,O=c1nc(N2CCOCC2)oc2c(-c3ccccc3)c(OCCBr)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,O=c1nc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)c(OCCBr)ccc12,CHEMBL4043200,=,=,Inhibition,%,-17.41,INH,%,-17.41,O=c1nc(N2CCOCC2)oc2c(-c3ccc(Cl)cc3)c(OCCBr)ccc12,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,COc1ccc(-c2c(OCCBr)ccc3c(=O)nc(N4CCOCC4)oc23)cc1,CHEMBL4043200,=,=,Inhibition,%,-8.6,INH,%,-8.6,COc1ccc(-c2c(OCCBr)ccc3c(=O)nc(N4CCOCC4)oc23)cc1,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,CN1CCN(CCOc2ccc3c(=O)nc(N4CCOCC4)oc3c2-c2ccccc2)CC1,CHEMBL4043200,=,=,Inhibition,%,4.3,INH,%,4.3,CN1CCN(CCOc2ccc3c(=O)nc(N4CCOCC4)oc3c2-c2ccccc2)CC1,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,CN1CCN(CCOc2ccc3c(=O)nc(N4CCOCC4)oc3c2-c2ccc(Cl)cc2)CC1,CHEMBL4043200,=,=,Inhibition,%,1.4,INH,%,1.4,CN1CCN(CCOc2ccc3c(=O)nc(N4CCOCC4)oc3c2-c2ccc(Cl)cc2)CC1,2017
Inhibition of wild type PI3K-gamma (unknown origin) assessed as decrease in ATP consumption at 10 uM using phosphotidylinositol bisphosphate and ATP measured after 60 mins by Kinase-Glo reagent based luminescence assay,COc1ccc(-c2c(OCCN3CCN(C)CC3)ccc3c(=O)nc(N4CCOCC4)oc23)cc1,CHEMBL4043200,=,=,Inhibition,%,6.23,INH,%,6.23,COc1ccc(-c2c(OCCN3CCN(C)CC3)ccc3c(=O)nc(N4CCOCC4)oc23)cc1,2017
Inhibition of recombinant human His-tagged PI3K p110gamma expressed in baculovirus using PIP2 as substrate after 1 hr by kinase-glo luminescence assay,C[C@@H]1CN(c2nc(N3CCOCC3)c3sc(-c4cnc(N)nc4)cc3n2)C[C@H](C)O1,CHEMBL4049442,=,=,IC50,nM,35.0,IC50,nM,35.0,C[C@@H]1CN(c2nc(N3CCOCC3)c3sc(-c4cnc(N)nc4)cc3n2)C[C@H](C)O1,2017
Inhibition of recombinant human His-tagged PI3K p110gamma expressed in baculovirus using PIP2 as substrate after 1 hr by kinase-glo luminescence assay,C[C@@H]1CN(c2nc(N3CCOCC3)c3sc(-c4ccn[nH]4)cc3n2)C[C@H](C)O1,CHEMBL4049442,=,=,IC50,nM,75.0,IC50,nM,75.0,C[C@@H]1CN(c2nc(N3CCOCC3)c3sc(-c4ccn[nH]4)cc3n2)C[C@H](C)O1,2017
Inhibition of recombinant human His-tagged PI3K p110gamma expressed in baculovirus using PIP2 as substrate after 1 hr by kinase-glo luminescence assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4049442,=,=,IC50,nM,46.0,IC50,nM,46.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4052600,=,=,IC50,nM,251.19,pIC50,,6.6,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1,CHEMBL4052600,=,=,IC50,nM,1584.89,pIC50,,5.8,CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,Cc1nncn1C1CCN(Cc2cc3nc(-c4cccc(O)c4)nc(N4CCOCC4)c3s2)CC1,CHEMBL4052600,=,=,IC50,nM,199.53,pIC50,,6.7,Cc1nncn1C1CCN(Cc2cc3nc(-c4cccc(O)c4)nc(N4CCOCC4)c3s2)CC1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,Cc1nncn1C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4052600,=,=,IC50,nM,1000.0,pIC50,,6.0,Cc1nncn1C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,Cc1nncn1C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4052600,=,=,IC50,nM,1995.26,pIC50,,5.7,Cc1nncn1C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,Oc1cccc(-c2nc(N3CCOCC3)c3sc(CN4CCC(n5cnnc5C(F)(F)F)CC4)cc3n2)c1,CHEMBL4052600,=,=,IC50,nM,158.49,pIC50,,6.8,Oc1cccc(-c2nc(N3CCOCC3)c3sc(CN4CCC(n5cnnc5C(F)(F)F)CC4)cc3n2)c1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,FC(F)(F)c1nncn1C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4052600,=,=,IC50,nM,794.33,pIC50,,6.1,FC(F)(F)c1nncn1C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,FC(F)(F)c1nncn1C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4052600,=,=,IC50,nM,3162.28,pIC50,,5.5,FC(F)(F)c1nncn1C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,FC(F)(F)c1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ncc56)nc(N5CCOCC5)c4s3)C[C@H]1CC2,CHEMBL4052600,=,=,IC50,nM,794.33,pIC50,,6.1,FC(F)(F)c1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ncc56)nc(N5CCOCC5)c4s3)C[C@H]1CC2,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,Oc1cccc(-c2nc(N3CCOCC3)c3sc(CN4CC[C@H]5[C@H](CCc6nnc(C(F)(F)F)n65)C4)cc3n2)c1,CHEMBL4052600,=,=,IC50,nM,158.49,pIC50,,6.8,Oc1cccc(-c2nc(N3CCOCC3)c3sc(CN4CC[C@H]5[C@H](CCc6nnc(C(F)(F)F)n65)C4)cc3n2)c1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,Cc1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ncc56)nc(N5CCOCC5)c4s3)C[C@H]1CC2,CHEMBL4052600,=,=,IC50,nM,1258.93,pIC50,,5.9,Cc1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ncc56)nc(N5CCOCC5)c4s3)C[C@H]1CC2,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,FC(F)(F)c1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ccc56)nc(N5CCOCC5)c4s3)C[C@H]1CC2,CHEMBL4052600,=,=,IC50,nM,630.96,pIC50,,6.2,FC(F)(F)c1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ccc56)nc(N5CCOCC5)c4s3)C[C@H]1CC2,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,Cc1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ccc56)nc(N5CCOCC5)c4s3)C[C@H]1CC2,CHEMBL4052600,=,=,IC50,nM,1584.89,pIC50,,5.8,Cc1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ccc56)nc(N5CCOCC5)c4s3)C[C@H]1CC2,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,FC(F)(F)c1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ncc56)nc(N5CCOCC5)c4s3)C[C@@H]1CC2,CHEMBL4052600,=,=,IC50,nM,1000.0,pIC50,,6.0,FC(F)(F)c1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ncc56)nc(N5CCOCC5)c4s3)C[C@@H]1CC2,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,Oc1cccc(-c2nc(N3CCOCC3)c3sc(CN4CC[C@H]5[C@@H](CCc6nnc(C(F)(F)F)n65)C4)cc3n2)c1,CHEMBL4052600,=,=,IC50,nM,199.53,pIC50,,6.7,Oc1cccc(-c2nc(N3CCOCC3)c3sc(CN4CC[C@H]5[C@@H](CCc6nnc(C(F)(F)F)n65)C4)cc3n2)c1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,Cc1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ncc56)nc(N5CCOCC5)c4s3)C[C@@H]1CC2,CHEMBL4052600,=,=,IC50,nM,316.23,pIC50,,6.5,Cc1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ncc56)nc(N5CCOCC5)c4s3)C[C@@H]1CC2,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,FC(F)(F)c1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ccc56)nc(N5CCOCC5)c4s3)C[C@@H]1CC2,CHEMBL4052600,=,=,IC50,nM,398.11,pIC50,,6.4,FC(F)(F)c1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ccc56)nc(N5CCOCC5)c4s3)C[C@@H]1CC2,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,Cc1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ccc56)nc(N5CCOCC5)c4s3)C[C@@H]1CC2,CHEMBL4052600,=,=,IC50,nM,794.33,pIC50,,6.1,Cc1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc6[nH]ccc56)nc(N5CCOCC5)c4s3)C[C@@H]1CC2,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of ATP by HTRF method,Cc1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc(O)c5)nc(N5CCOCC5)c4s3)C[C@@H]1CC2,CHEMBL4052600,=,=,IC50,nM,501.19,pIC50,,6.3,Cc1nnc2n1[C@H]1CCN(Cc3cc4nc(-c5cccc(O)c5)nc(N5CCOCC5)c4s3)C[C@@H]1CC2,2017
Inhibition of wild-type human partial length PI3KCG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by Kinomescan method relative to control,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N,CHEMBL4052645,=,=,Activity,%,100.0,Activity,%,100.0,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N,2017
Inhibition of wild-type human partial length PI3KCG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by Kinomescan method relative to control,COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1,CHEMBL4052645,=,=,Activity,%,100.0,Activity,%,100.0,COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1,2017
Binding affinity to wild-type human PIK3Cgamma (S144 to A1102 residues) expressed in mammalian expression system by KINOMEScan assay,CN(C)C(=O)c1cc([C@H]2CCCN2c2cc(F)cc(F)c2)c2nc(N3CCOCC3)cnc2c1,CHEMBL4118086,=,=,Kd,nM,313.0,Kd,nM,313.0,CN(C)C(=O)c1cc([C@H]2CCCN2c2cc(F)cc(F)c2)c2nc(N3CCOCC3)cnc2c1,2017
Binding affinity to wild-type human PIK3Cgamma (S144 to A1102 residues) expressed in mammalian expression system by KINOMEScan assay,CN(C)C(=O)c1cc([C@@H]2CCCN2c2cc(F)cc(F)c2)c2nc(N3CCOCC3)cnc2c1,CHEMBL4118086,>,>,Kd,nM,30200.0,Kd,nM,30200.0,CN(C)C(=O)c1cc([C@@H]2CCCN2c2cc(F)cc(F)c2)c2nc(N3CCOCC3)cnc2c1,2017
Binding affinity to wild-type human PIK3Cgamma (S144 to A1102 residues) expressed in mammalian expression system by KINOMEScan assay,CN(C)C(=O)c1cc(C2CCCN2c2cc(F)cc(F)c2)c2nc(N3CCOCC3)cnc2c1,CHEMBL4118086,=,=,Kd,nM,1318.0,Kd,nM,1318.0,CN(C)C(=O)c1cc(C2CCCN2c2cc(F)cc(F)c2)c2nc(N3CCOCC3)cnc2c1,2017
Binding affinity to wild-type human PIK3Cgamma (S144 to A1102 residues) expressed in mammalian expression system by KINOMEScan assay,C[C@@H]1CN(C(=O)c2cc(C3CCCN3c3cc(F)cc(F)c3)c3nc(N4CCOCC4)cnc3c2)C[C@H](C)N1,CHEMBL4118086,=,=,Kd,nM,214.0,Kd,nM,214.0,C[C@@H]1CN(C(=O)c2cc(C3CCCN3c3cc(F)cc(F)c3)c3nc(N4CCOCC4)cnc3c2)C[C@H](C)N1,2017
Binding affinity to wild-type human PIK3Cgamma (S144 to A1102 residues) expressed in mammalian expression system by KINOMEScan assay,C[C@@H](Nc1cccc(F)c1)c1cc(C(=O)NCCO)cc2ncc(N3CCOCC3)nc12,CHEMBL4118086,=,=,Kd,nM,3412.0,Kd,nM,3412.0,C[C@@H](Nc1cccc(F)c1)c1cc(C(=O)NCCO)cc2ncc(N3CCOCC3)nc12,2017
Binding affinity to wild-type human PIK3Cgamma (S144 to A1102 residues) expressed in mammalian expression system by KINOMEScan assay,C[C@H](Nc1cccc(F)c1)c1cc(C(=O)NCCO)cc2ncc(N3CCOCC3)nc12,CHEMBL4118086,=,=,Kd,nM,2851.0,Kd,nM,2851.0,C[C@H](Nc1cccc(F)c1)c1cc(C(=O)NCCO)cc2ncc(N3CCOCC3)nc12,2017
Binding affinity to wild-type human PIK3Cgamma (S144 to A1102 residues) expressed in mammalian expression system by KINOMEScan assay,CC(Nc1cc(F)cc(F)c1)c1cc(C(=O)NCCN(C)C)cc2ncc(N3CCOCC3)nc12,CHEMBL4118086,=,=,Kd,nM,1738.0,Kd,nM,1738.0,CC(Nc1cc(F)cc(F)c1)c1cc(C(=O)NCCN(C)C)cc2ncc(N3CCOCC3)nc12,2017
Binding affinity to wild-type human PIK3Cgamma (S144 to A1102 residues) expressed in mammalian expression system by KINOMEScan assay,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)NCCN(C)C)cc2ncc(N3CCOCC3)nc12,CHEMBL4118086,=,=,Kd,nM,994.0,Kd,nM,994.0,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)NCCN(C)C)cc2ncc(N3CCOCC3)nc12,2017
Binding affinity to wild-type human PIK3Cgamma (S144 to A1102 residues) expressed in mammalian expression system by KINOMEScan assay,C[C@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)NCCN(C)C)cc2ncc(N3CCOCC3)nc12,CHEMBL4118086,=,=,Kd,nM,4266.0,Kd,nM,4266.0,C[C@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)NCCN(C)C)cc2ncc(N3CCOCC3)nc12,2017
Binding affinity to wild-type human PIK3Cgamma (S144 to A1102 residues) expressed in mammalian expression system by KINOMEScan assay,CNCCNC(=O)c1cc(C(C)Nc2cccc(F)c2)c2nc(N3CCOCC3)cnc2c1,CHEMBL4118086,=,=,Kd,nM,1820.0,Kd,nM,1820.0,CNCCNC(=O)c1cc(C(C)Nc2cccc(F)c2)c2nc(N3CCOCC3)cnc2c1,2017
Binding affinity to wild-type human PIK3Cgamma (S144 to A1102 residues) expressed in mammalian expression system by KINOMEScan assay,Cc1c(F)cccc1NCc1cc(C(=O)NCCN(C)C)cc2ncc(N3CCOCC3)nc12,CHEMBL4118086,=,=,Kd,nM,6607.0,Kd,nM,6607.0,Cc1c(F)cccc1NCc1cc(C(=O)NCCN(C)C)cc2ncc(N3CCOCC3)nc12,2017
Inhibition of recombinant human full length His-tagged PI3K p110gamma expressed in baculovirus expression system by TR-FRET assay,O=C(NOCCOCCOCCOCCC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,CHEMBL4118094,=,=,IC50,nM,2293.0,IC50,nM,2293.0,O=C(NOCCOCCOCCOCCC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,2017
Inhibition of recombinant human full length His-tagged PI3K p110gamma expressed in baculovirus expression system by TR-FRET assay,NOCCOCCOCCOCCC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL4118094,=,=,IC50,nM,140.0,IC50,nM,140.0,NOCCOCCOCCOCCC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2017
Inhibition of recombinant human full length His-tagged PI3K p110gamma expressed in baculovirus expression system by TR-FRET assay,CC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL4118094,=,=,IC50,nM,21.0,IC50,nM,21.0,CC(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2017
Inhibition of recombinant human full length His-tagged PI3K p110gamma expressed in baculovirus expression system by TR-FRET assay,O=C(NOCCOCCOCCOCCN1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,CHEMBL4118094,=,=,IC50,nM,5803.0,IC50,nM,5803.0,O=C(NOCCOCCOCCOCCN1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,2017
Inhibition of recombinant human full length His-tagged PI3K p110gamma expressed in baculovirus expression system by TR-FRET assay,FC(F)c1nc2ccccc2n1-c1nc(N2CCNCC2)nc(N2CCOCC2)n1,CHEMBL4118094,=,=,IC50,nM,1873.0,IC50,nM,1873.0,FC(F)c1nc2ccccc2n1-c1nc(N2CCNCC2)nc(N2CCOCC2)n1,2017
Inhibition of recombinant human full length His-tagged PI3K p110gamma expressed in baculovirus expression system by TR-FRET assay,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL4118094,=,=,IC50,nM,20.8,IC50,nM,20.8,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2017
Inhibition of recombinant full length His-tagged human PI3KG at 1 uM by FRET assay relative to control,CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@H]1[C@@H]2CN(C3COC3)C[C@@H]21,CHEMBL4118097,=,=,Inhibition,%,-13.9,INH,%,-13.9,CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@H]1[C@@H]2CN(C3COC3)C[C@@H]21,2017
Inhibition of recombinant full length His-tagged human PI3KG at 1 uM by FRET assay relative to control,Nc1ncc(-c2cc([C@H]3[C@@H]4CN(C5COC5)C[C@@H]43)n(CC3CC3)n2)cc1C(F)(F)F,CHEMBL4118097,=,=,Inhibition,%,12.4,INH,%,12.4,Nc1ncc(-c2cc([C@H]3[C@@H]4CN(C5COC5)C[C@@H]43)n(CC3CC3)n2)cc1C(F)(F)F,2017
Inhibition of PI3Kgamma (unknown origin),O=C(O)c1ccc(-c2ccnc(Nc3cccc(-c4ccccc4)c3)n2)cc1,CHEMBL4118126,=,=,IC50,nM,12.59,pIC50,,7.9,O=C(O)c1ccc(-c2ccnc(Nc3cccc(-c4ccccc4)c3)n2)cc1,2018
Inhibition of PI3Kgamma (unknown origin),NC(=O)c1ccc(-c2ccnc(Nc3cccc(-c4ccccc4)c3)n2)cc1,CHEMBL4118126,=,=,IC50,nM,100.0,pIC50,,7.0,NC(=O)c1ccc(-c2ccnc(Nc3cccc(-c4ccccc4)c3)n2)cc1,2018
Inhibition of PI3Kgamma (unknown origin),NC(=O)c1ccc(-c2ccnc(Nc3cc(-c4ccccc4)ccc3F)n2)cc1,CHEMBL4118126,<,>,IC50,nM,10000.0,pIC50,,5.0,NC(=O)c1ccc(-c2ccnc(Nc3cc(-c4ccccc4)ccc3F)n2)cc1,2018
Inhibition of PI3Kgamma (unknown origin),Cc1ccc(-c2ccccc2)cc1Nc1nccc(-c2ccc(C(N)=O)cc2)n1,CHEMBL4118126,<,>,IC50,nM,10000.0,pIC50,,5.0,Cc1ccc(-c2ccccc2)cc1Nc1nccc(-c2ccc(C(N)=O)cc2)n1,2018
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2ccccc2)cc1Nc1nccc(-c2ccc(C(N)=O)cc2)n1,CHEMBL4118126,=,=,IC50,nM,7943.28,pIC50,,5.1,COc1ccc(-c2ccccc2)cc1Nc1nccc(-c2ccc(C(N)=O)cc2)n1,2018
Inhibition of PI3Kgamma (unknown origin),COc1ccccc1Nc1nccc(-c2ccc(C(N)=O)cc2)n1,CHEMBL4118126,<,>,IC50,nM,10000.0,pIC50,,5.0,COc1ccccc1Nc1nccc(-c2ccc(C(N)=O)cc2)n1,2018
Inhibition of PI3Kgamma (unknown origin),COc1ccccc1Nc1nccc(-c2ccc(C(N)=O)c(C(C)C)c2)n1,CHEMBL4118126,=,=,IC50,nM,2511.89,pIC50,,5.6,COc1ccccc1Nc1nccc(-c2ccc(C(N)=O)c(C(C)C)c2)n1,2018
Inhibition of PI3Kgamma (unknown origin),COc1ccccc1Nc1ncc(F)c(-c2ccc(C(N)=O)c(C(C)C)c2)n1,CHEMBL4118126,<,>,IC50,nM,10000.0,pIC50,,5.0,COc1ccccc1Nc1ncc(F)c(-c2ccc(C(N)=O)c(C(C)C)c2)n1,2018
Inhibition of PI3Kgamma (unknown origin),COc1ccccc1Nc1ncc(Cl)c(-c2ccc(C(N)=O)c(C(C)C)c2)n1,CHEMBL4118126,=,=,IC50,nM,6309.57,pIC50,,5.2,COc1ccccc1Nc1ncc(Cl)c(-c2ccc(C(N)=O)c(C(C)C)c2)n1,2018
Inhibition of PI3Kgamma (unknown origin),COc1ccccc1Nc1nccc(-c2ccc(C(=O)O)cc2)n1,CHEMBL4118126,=,=,IC50,nM,3981.07,pIC50,,5.4,COc1ccccc1Nc1nccc(-c2ccc(C(=O)O)cc2)n1,2018
Inhibition of PI3Kgamma (unknown origin),COc1ccccc1Nc1nccc(-c2ccc(C(=O)O)c(C(C)C)c2)n1,CHEMBL4118126,=,=,IC50,nM,1584.89,pIC50,,5.8,COc1ccccc1Nc1nccc(-c2ccc(C(=O)O)c(C(C)C)c2)n1,2018
Inhibition of PI3Kgamma (unknown origin),COc1ccccc1Nc1ncc(F)c(-c2ccc(C(=O)O)c(C(C)C)c2)n1,CHEMBL4118126,=,=,IC50,nM,6309.57,pIC50,,5.2,COc1ccccc1Nc1ncc(F)c(-c2ccc(C(=O)O)c(C(C)C)c2)n1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,C#CCn1cc(N2Cc3nc(-c4cnc(OC)c(OC)c4)ccc3C2=O)cn1,CHEMBL4118224,=,=,Ki,nM,9.0,Ki,uM,0.009,C#CCn1cc(N2Cc3nc(-c4cnc(OC)c(OC)c4)ccc3C2=O)cn1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,COc1cc(-c2ccc3c(n2)CN(c2cnn(CC(F)F)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,Ki,nM,9.0,Ki,uM,0.009,COc1cc(-c2ccc3c(n2)CN(c2cnn(CC(F)F)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,COc1cc(-c2ccc3c(n2)CN(c2cnn(C(C)(C)C#N)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,Ki,nM,28.0,Ki,uM,0.028,COc1cc(-c2ccc3c(n2)CN(c2cnn(C(C)(C)C#N)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,COc1cc(-c2ccc3c(n2)CN(c2cnn(CCC#N)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,Ki,nM,20.0,Ki,uM,0.02,COc1cc(-c2ccc3c(n2)CN(c2cnn(CCC#N)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,COc1cc(-c2ccc3c(n2)[C@H](C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,Ki,nM,7.0,Ki,uM,0.007,COc1cc(-c2ccc3c(n2)[C@H](C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,COc1cc(-c2ccc3c(n2)[C@@H](C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,Ki,nM,4.0,Ki,uM,0.004,COc1cc(-c2ccc3c(n2)[C@@H](C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,COc1cc(-c2ccc3c(n2)C(C)(C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,Ki,nM,11.0,Ki,uM,0.011,COc1cc(-c2ccc3c(n2)C(C)(C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,CCCn1cnc(CCNC(=O)Nc2nc3ccc(-c4cncc(OC)c4)cc3s2)c1,CHEMBL4118224,=,=,Ki,nM,2.0,Ki,nM,2.0,CCCn1cnc(CCNC(=O)Nc2nc3ccc(-c4cncc(OC)c4)cc3s2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,COc1cc(-c2ccc3c(n2)CN(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,Ki,nM,4.0,Ki,uM,0.004,COc1cc(-c2ccc3c(n2)CN(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,CCn1cc(N2Cc3nc(-c4cnc(OC)c(OC)c4)ccc3C2=O)cn1,CHEMBL4118224,=,=,Ki,nM,8.0,Ki,uM,0.008,CCn1cc(N2Cc3nc(-c4cnc(OC)c(OC)c4)ccc3C2=O)cn1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,COc1cc(-c2ccc3c(n2)CN(c2cnn(C)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,Ki,nM,60.0,Ki,uM,0.06,COc1cc(-c2ccc3c(n2)CN(c2cnn(C)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,COc1cc(-c2ccc3c(n2)CN(c2cn[nH]c2)C3=O)cnc1OC,CHEMBL4118224,=,=,Ki,nM,11.0,Ki,uM,0.011,COc1cc(-c2ccc3c(n2)CN(c2cn[nH]c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,COc1cc(-c2ccc3c(n2)CN(c2cnn(CC#N)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,Ki,nM,3.0,Ki,uM,0.003,COc1cc(-c2ccc3c(n2)CN(c2cnn(CC#N)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,COc1cc(-c2ccc3c(c2)CN(c2cnn(CC#N)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,Ki,nM,6.0,Ki,uM,0.006,COc1cc(-c2ccc3c(c2)CN(c2cnn(CC#N)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,COc1cc(-c2ccc3c(c2)CN(c2cccc(CC#N)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,Ki,nM,35.0,Ki,uM,0.035,COc1cc(-c2ccc3c(c2)CN(c2cccc(CC#N)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting method,COc1ccc(-c2ccc3c(c2)CN(c2cccc(CC#N)c2)C3=O)cc1OC,CHEMBL4118224,=,=,Ki,nM,160.0,Ki,uM,0.16,COc1ccc(-c2ccc3c(c2)CN(c2cccc(CC#N)c2)C3=O)cc1OC,2018
Inhibition of PI3Kgamma in human THP1 cells assessed as inhibition of MCP1-induced Akt phosphorylation at Ser-47 residue preincubated for 1 hr followed by MCP1 stimulation for 3 mins by FACS analysis,COc1cc(-c2ccc3c(n2)CN(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,IC50,nM,280.0,IC50,uM,0.28,COc1cc(-c2ccc3c(n2)CN(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma in human THP1 cells assessed as inhibition of MCP1-induced Akt phosphorylation at Ser-47 residue preincubated for 1 hr followed by MCP1 stimulation for 3 mins by FACS analysis,COc1cc(-c2ccc3c(n2)[C@H](C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,IC50,nM,210.0,IC50,uM,0.21,COc1cc(-c2ccc3c(n2)[C@H](C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma in human THP1 cells assessed as inhibition of MCP1-induced Akt phosphorylation at Ser-47 residue preincubated for 1 hr followed by MCP1 stimulation for 3 mins by FACS analysis,COc1cc(-c2ccc3c(n2)[C@@H](C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,IC50,nM,170.0,IC50,uM,0.17,COc1cc(-c2ccc3c(n2)[C@@H](C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma in human THP1 cells assessed as inhibition of MCP1-induced Akt phosphorylation at Ser-47 residue preincubated for 1 hr followed by MCP1 stimulation for 3 mins by FACS analysis,COc1cc(-c2ccc3c(n2)C(C)(C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,IC50,nM,340.0,IC50,uM,0.34,COc1cc(-c2ccc3c(n2)C(C)(C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma in TNFalpha primed human neutrophils assessed as inhibition of fMLP-induced ROS generation preincubated for 30 to 60 mins followed by TNFalpha priming for 15 mins and subsequent stimulation with fMLP for 15 mins by DHR-123 dye based FACS analysis,COc1cc(-c2ccc3c(n2)[C@@H](C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,IC50,nM,140.0,IC50,uM,0.14,COc1cc(-c2ccc3c(n2)[C@@H](C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,2018
Inhibition of PI3Kgamma in TNFalpha primed human whole blood assessed as inhibition of fMLP-induced ROS generation preincubated for 30 to 60 mins followed by TNFalpha priming for 15 mins and subsequent stimulation with fMLP for 15 mins by DHR-123 dye based FACS analysis,COc1cc(-c2ccc3c(n2)[C@@H](C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,CHEMBL4118224,=,=,IC50,nM,500.0,IC50,uM,0.5,COc1cc(-c2ccc3c(n2)[C@@H](C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,COCCS(=O)(=O)Nc1cc(-c2sc(NC(C)=O)nc2C)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4118226,=,=,IC50,nM,1.0,pIC50,,9.0,COCCS(=O)(=O)Nc1cc(-c2sc(NC(C)=O)nc2C)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CC(=O)Nc1nc(C)c(-c2cc3c(c(NS(C)(=O)=O)c2)C(=O)N([C@@H](C)C2CC2)C3)s1,CHEMBL4118226,=,=,IC50,nM,0.631,pIC50,,9.2,CC(=O)Nc1nc(C)c(-c2cc3c(c(NS(C)(=O)=O)c2)C(=O)N([C@@H](C)C2CC2)C3)s1,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CC(=O)Nc1nc(C)c(-c2cc3c(c(S(=O)(=O)CCCO)c2)C(=O)N([C@@H](C)C2CC2)C3)s1,CHEMBL4118226,=,=,IC50,nM,1.259,pIC50,,8.9,CC(=O)Nc1nc(C)c(-c2cc3c(c(S(=O)(=O)CCCO)c2)C(=O)N([C@@H](C)C2CC2)C3)s1,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CC(=O)Nc1nc(C)c(-c2cc3c(c(S(C)(=O)=O)c2)C(=O)N([C@@H](C)C2CC2)C3)s1,CHEMBL4118226,>=,<=,IC50,nM,0.7943,pIC50,,9.1,CC(=O)Nc1nc(C)c(-c2cc3c(c(S(C)(=O)=O)c2)C(=O)N([C@@H](C)C2CC2)C3)s1,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,COCCNS(=O)(=O)c1cc(-c2sc(NC(C)=O)nc2C)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4118226,=,=,IC50,nM,1.259,pIC50,,8.9,COCCNS(=O)(=O)c1cc(-c2sc(NC(C)=O)nc2C)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CNS(=O)(=O)c1cc(-c2sc(NC(C)=O)nc2C)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4118226,=,=,IC50,nM,0.7943,pIC50,,9.1,CNS(=O)(=O)c1cc(-c2sc(NC(C)=O)nc2C)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CC(=O)Nc1nc(C)c(-c2cc3c(c(S(N)(=O)=O)c2)C(=O)N([C@@H](C)C2CC2)C3)s1,CHEMBL4118226,=,=,IC50,nM,0.631,pIC50,,9.2,CC(=O)Nc1nc(C)c(-c2cc3c(c(S(N)(=O)=O)c2)C(=O)N([C@@H](C)C2CC2)C3)s1,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CC(=O)Nc1nc(C)c(-c2cc(C)c3c(c2)CNC3=O)s1,CHEMBL4118226,=,=,IC50,nM,63.1,pIC50,,7.2,CC(=O)Nc1nc(C)c(-c2cc(C)c3c(c2)CNC3=O)s1,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CC(=O)Nc1nc(C)c(-c2cc(Cl)c3c(c2)CN([C@H](C)C2CC2)C3=O)s1,CHEMBL4118226,=,=,IC50,nM,1.259,pIC50,,8.9,CC(=O)Nc1nc(C)c(-c2cc(Cl)c3c(c2)CN([C@H](C)C2CC2)C3=O)s1,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CC(=O)Nc1nc(C)c(-c2cc(C)c3c(c2)CN([C@@H](C)C2CC2)C3=O)s1,CHEMBL4118226,=,=,IC50,nM,0.631,pIC50,,9.2,CC(=O)Nc1nc(C)c(-c2cc(C)c3c(c2)CN([C@@H](C)C2CC2)C3=O)s1,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CC(=O)Nc1nc(C)c(-c2cc(Cl)c3c(c2)CN([C@@H](C)C2CC2)C3=O)s1,CHEMBL4118226,=,=,IC50,nM,0.7943,pIC50,,9.1,CC(=O)Nc1nc(C)c(-c2cc(Cl)c3c(c2)CN([C@@H](C)C2CC2)C3=O)s1,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CC(=O)Nc1ncc(-c2cc(Cl)c3c(c2)CN([C@@H](C)C2CC2)C3=O)s1,CHEMBL4118226,=,=,IC50,nM,1.259,pIC50,,8.9,CC(=O)Nc1ncc(-c2cc(Cl)c3c(c2)CN([C@@H](C)C2CC2)C3=O)s1,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CNC(=O)c1nc(-c2cc(C)c3c(c2)CN([C@@H](C)C2CC2)C3=O)cnc1N,CHEMBL4118226,=,=,IC50,nM,7.943,pIC50,,8.1,CNC(=O)c1nc(-c2cc(C)c3c(c2)CN([C@@H](C)C2CC2)C3=O)cnc1N,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1cc(-c2cnc3[nH]ccc3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4118226,=,=,IC50,nM,6.31,pIC50,,8.2,Cc1cc(-c2cnc3[nH]ccc3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,Cc1cc(-c2nccnc2N)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4118226,=,=,IC50,nM,25.12,pIC50,,7.6,Cc1cc(-c2nccnc2N)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,C[C@@H](C1CC1)N1Cc2cc(-c3cnc(N)nc3)cc(Cl)c2C1=O,CHEMBL4118226,=,=,IC50,nM,10.0,pIC50,,8.0,C[C@@H](C1CC1)N1Cc2cc(-c3cnc(N)nc3)cc(Cl)c2C1=O,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CC(=O)N(C)c1cc(-c2cc(Cl)c3c(c2)CN([C@@H](C)C2CC2)C3=O)on1,CHEMBL4118226,<,>,IC50,nM,1000.0,pIC50,,6.0,CC(=O)N(C)c1cc(-c2cc(Cl)c3c(c2)CN([C@@H](C)C2CC2)C3=O)on1,2018
Inhibition of recombinant human 6His-tagged PI3Kgamma (144 to 1102 residues) using DiC8-PIP2 as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by ADP-Glo assay,CC(=O)Nc1cc(-c2cc(Cl)c3c(c2)CN([C@@H](C)C2CC2)C3=O)on1,CHEMBL4118226,=,=,IC50,nM,158.49,pIC50,,6.8,CC(=O)Nc1cc(-c2cc(Cl)c3c(c2)CN([C@@H](C)C2CC2)C3=O)on1,2018
Inhibition of recombinant human full length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM relative to control,CC(=O)Nc1nc(C)c(-c2cc(C)c3c(c2)CN([C@@H](C)C2CC2)C3=O)s1,CHEMBL4118226,=,=,Inhibition,%,100.0,INH,%,100.0,CC(=O)Nc1nc(C)c(-c2cc(C)c3c(c2)CN([C@@H](C)C2CC2)C3=O)s1,2018
Inhibition of recombinant human full length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM relative to control,CC(=O)Nc1nc(C)c(-c2cc3c(c(S(C)(=O)=O)c2)C(=O)N([C@@H](C)C2CC2)C3)s1,CHEMBL4118226,=,=,Inhibition,%,95.0,INH,%,95.0,CC(=O)Nc1nc(C)c(-c2cc3c(c(S(C)(=O)=O)c2)C(=O)N([C@@H](C)C2CC2)C3)s1,2018
Inhibition of PI3Kgamma (unknown origin) using phosphatidyl inositol as substrate measured after 30 mins by Alexa Fluor647-labelled ADP tracer based TR-FRET assay,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cc1C#N,CHEMBL4130456,=,=,IC50,nM,4630.0,IC50,uM,4.63,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cc1C#N,2017
Inhibition of PI3Kgamma (unknown origin) using phosphatidyl inositol as substrate measured after 30 mins by Alexa Fluor647-labelled ADP tracer based TR-FRET assay,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cn1,CHEMBL4130456,=,=,IC50,nM,2700.0,IC50,uM,2.7,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cn1,2017
Inhibition of PI3Kgamma (unknown origin) using phosphatidyl inositol as substrate measured after 30 mins by Alexa Fluor647-labelled ADP tracer based TR-FRET assay,COc1ccc(N2CCc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3C2)cn1,CHEMBL4130456,>,>,IC50,nM,9100.0,IC50,uM,9.1,COc1ccc(N2CCc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3C2)cn1,2017
Inhibition of PI3Kgamma (unknown origin) using phosphatidyl inositol as substrate measured after 30 mins by Alexa Fluor647-labelled ADP tracer based TR-FRET assay,COc1ccc(N2CCc3ncnc(-c4cccc(OC5CCN(C(C)=O)CC5)c4)c3C2)cn1,CHEMBL4130456,>,>,IC50,nM,9100.0,IC50,uM,9.1,COc1ccc(N2CCc3ncnc(-c4cccc(OC5CCN(C(C)=O)CC5)c4)c3C2)cn1,2017
Inhibition of PI3Kgamma (unknown origin) using phosphatidyl inositol as substrate measured after 30 mins by Alexa Fluor647-labelled ADP tracer based TR-FRET assay,CCC(=O)N1CC[C@H](Oc2ncnc3c2CN(c2ccc(OC)nc2)CC3)C1,CHEMBL4130456,>,>,IC50,nM,9100.0,IC50,uM,9.1,CCC(=O)N1CC[C@H](Oc2ncnc3c2CN(c2ccc(OC)nc2)CC3)C1,2017
Inhibition of PI3Kgamma (unknown origin) using phosphatidyl inositol as substrate measured after 30 mins by Alexa Fluor647-labelled ADP tracer based TR-FRET assay,CCC(=O)N1CC[C@H](Oc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1,CHEMBL4130456,>,>,IC50,nM,9100.0,IC50,uM,9.1,CCC(=O)N1CC[C@H](Oc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1,2017
Inhibition of PI3Kgamma (unknown origin) using phosphatidyl inositol as substrate measured after 30 mins by Alexa Fluor647-labelled ADP tracer based TR-FRET assay,COc1ncc(N2CCc3ncnc(O[C@H]4CCN(C(=O)C5CCOCC5)C4)c3C2)cc1C,CHEMBL4130456,=,=,IC50,nM,6600.0,IC50,uM,6.6,COc1ncc(N2CCc3ncnc(O[C@H]4CCN(C(=O)C5CCOCC5)C4)c3C2)cc1C,2017
Inhibition of PI3Kgamma (unknown origin) using phosphatidyl inositol as substrate measured after 30 mins by Alexa Fluor647-labelled ADP tracer based TR-FRET assay,COc1ncc(N2CCc3ncnc(O[C@H]4CCN(C(=O)C5CCOCC5)C4)c3C2)cc1C(F)(F)F,CHEMBL4130456,>,>,IC50,nM,9100.0,IC50,uM,9.1,COc1ncc(N2CCc3ncnc(O[C@H]4CCN(C(=O)C5CCOCC5)C4)c3C2)cc1C(F)(F)F,2017
Inhibition of PI3Kgamma (unknown origin) using phosphatidyl inositol as substrate measured after 30 mins by Alexa Fluor647-labelled ADP tracer based TR-FRET assay,COc1ncc(N2CCc3ncnc(N[C@H]4CCN(C(=O)C5CCOCC5)C4)c3C2)cc1C,CHEMBL4130456,=,=,IC50,nM,3290.0,IC50,uM,3.29,COc1ncc(N2CCc3ncnc(N[C@H]4CCN(C(=O)C5CCOCC5)C4)c3C2)cc1C,2017
Inhibition of PI3Kgamma (unknown origin) using phosphatidyl inositol as substrate measured after 30 mins by Alexa Fluor647-labelled ADP tracer based TR-FRET assay,COc1ncc(N2CCc3ncnc(N[C@H]4CCN(C(=O)C5CCOCC5)C4)c3C2)cc1C(F)(F)F,CHEMBL4130456,=,=,IC50,nM,1060.0,IC50,uM,1.06,COc1ncc(N2CCc3ncnc(N[C@H]4CCN(C(=O)C5CCOCC5)C4)c3C2)cc1C(F)(F)F,2017
Inhibition of PI3Kgamma (unknown origin) using phosphatidyl inositol as substrate measured after 30 mins by Alexa Fluor647-labelled ADP tracer based TR-FRET assay,CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C)c2)CC3)C1,CHEMBL4130456,,,IC50,,,IC50,,,CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C)c2)CC3)C1,2017
Inhibition of PI3Kgamma (unknown origin) using phosphatidyl inositol as substrate measured after 30 mins by Alexa Fluor647-labelled ADP tracer based TR-FRET assay,CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1,CHEMBL4130456,=,=,IC50,nM,2230.0,IC50,uM,2.23,CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1,2017
Inhibition of PI3Kgamma in human U937 cells assessed as reduction in MIP-1 alpha stimulated ATK phosphorylation at ser473 residue pretreated for 30 mins followed by MIP-1 alpha addition measured after 3 mins by fluorescence assay,CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1,CHEMBL4130456,>,>,IC50,nM,7400.0,IC50,uM,7.4,CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate pretreated for 15 mins followed by substrate addition measured after 1 hr,O=C(Nc1n[nH]c2cc(-c3ccc(O)cc3)ccc12)C1CC1,CHEMBL4130529,<,>,IC50,nM,25118.86,pIC50,,4.6,O=C(Nc1n[nH]c2cc(-c3ccc(O)cc3)ccc12)C1CC1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate pretreated for 15 mins followed by substrate addition measured after 1 hr,O=C(Nc1cc(-c2ccc(O)cc2)cc2[nH]ncc12)C1CC1,CHEMBL4130529,<,>,IC50,nM,25118.86,pIC50,,4.6,O=C(Nc1cc(-c2ccc(O)cc2)cc2[nH]ncc12)C1CC1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate pretreated for 15 mins followed by substrate addition measured after 1 hr,O=C(Nc1cc(-c2ccc(O)cc2)cc2[nH]ncc12)c1ccccn1,CHEMBL4130529,=,=,IC50,nM,5011.87,pIC50,,5.3,O=C(Nc1cc(-c2ccc(O)cc2)cc2[nH]ncc12)c1ccccn1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate pretreated for 15 mins followed by substrate addition measured after 1 hr,O=C(Nc1cc(-c2ccccc2)cc2[nH]ncc12)C1CC1,CHEMBL4130529,=,=,IC50,nM,25118.86,pIC50,,4.6,O=C(Nc1cc(-c2ccccc2)cc2[nH]ncc12)C1CC1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate pretreated for 15 mins followed by substrate addition measured after 1 hr,O=C(Nc1cc(-c2cccc(O)c2)cc2[nH]ncc12)C1CC1,CHEMBL4130529,=,=,IC50,nM,7943.28,pIC50,,5.1,O=C(Nc1cc(-c2cccc(O)c2)cc2[nH]ncc12)C1CC1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate pretreated for 15 mins followed by substrate addition measured after 1 hr,O=C(Nc1cc(-c2cccc(O)c2)cc2[nH]ncc12)c1ccccn1,CHEMBL4130529,=,=,IC50,nM,7943.28,pIC50,,5.1,O=C(Nc1cc(-c2cccc(O)c2)cc2[nH]ncc12)c1ccccn1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate pretreated for 15 mins followed by substrate addition measured after 1 hr,O=C(Nc1cc(-c2cccc3[nH]ccc23)cc2[nH]ncc12)C1CC1,CHEMBL4130529,<,>,IC50,nM,25118.86,pIC50,,4.6,O=C(Nc1cc(-c2cccc3[nH]ccc23)cc2[nH]ncc12)C1CC1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate pretreated for 15 mins followed by substrate addition measured after 1 hr,O=C(Nc1cc(-c2cccc3[nH]ccc23)cc2[nH]ncc12)c1ccccn1,CHEMBL4130529,=,=,IC50,nM,6309.57,pIC50,,5.2,O=C(Nc1cc(-c2cccc3[nH]ccc23)cc2[nH]ncc12)c1ccccn1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate pretreated for 15 mins followed by substrate addition measured after 1 hr,O=C(Nc1cc(-c2ccc3cc[nH]c3c2)cc2[nH]ncc12)c1ccccn1,CHEMBL4130529,=,=,IC50,nM,15848.93,pIC50,,4.8,O=C(Nc1cc(-c2ccc3cc[nH]c3c2)cc2[nH]ncc12)c1ccccn1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,CCOc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3C[C@@H](C)O[C@@H](C)C3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,CCOc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3C[C@@H](C)O[C@@H](C)C3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3C[C@@H](C)O[C@@H](C)C3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3C[C@@H](C)O[C@@H](C)C3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2cc(Cl)c(CN3CCN(C(C)C)CC3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2cc(Cl)c(CN3CCN(C(C)C)CC3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)N(COC(=O)C(C)(C)C)c1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)N(COC(=O)C(C)(C)C)c1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,CCOC(=O)CN(c1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1)S(=O)(=O)c1cc(N2CCOCC2)cnc1OC,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,CCOC(=O)CN(c1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1)S(=O)(=O)c1cc(N2CCOCC2)cnc1OC,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)N(c1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1)C(C)C,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)N(c1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1)C(C)C,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,CCCN(c1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1)S(=O)(=O)c1cc(N2CCOCC2)cnc1OC,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,CCCN(c1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1)S(=O)(=O)c1cc(N2CCOCC2)cnc1OC,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,CCN(c1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1)S(=O)(=O)c1cc(N2CCOCC2)cnc1OC,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,CCN(c1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1)S(=O)(=O)c1cc(N2CCOCC2)cnc1OC,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)N(C)c1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)N(C)c1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)N(C)c1ccnc(-c2ccc(CN3CCN(C(C)(C)C)CC3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)N(C)c1ccnc(-c2ccc(CN3CCN(C(C)(C)C)CC3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,CN(C)c1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)(C)C)CC3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,CN(C)c1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)(C)C)CC3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,CC(C)N1CCN(Cc2ccc(-c3cc(NS(=O)(=O)c4cc(N5CCOCC5)cnc4N(C)C)ccn3)c(F)c2)CC1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,CC(C)N1CCN(Cc2ccc(-c3cc(NS(=O)(=O)c4cc(N5CCOCC5)cnc4N(C)C)ccn3)c(F)c2)CC1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCNCC3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCNCC3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCOCC3)cc2)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCOCC3)cc2)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3C[C@@H](C)O[C@@H](C)C3)cc2)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3C[C@@H](C)O[C@@H](C)C3)cc2)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCC(C(C)(C)O)CC3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCC(C(C)(C)O)CC3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCCCC3)cc2F)c1.O=CO,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCCCC3)cc2F)c1.O=CO,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCCC3C)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCCC3C)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCC(C)C3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCC(C)C3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COCCN1CCN(Cc2ccc(-c3cc(NS(=O)(=O)c4cc(N5CCOCC5)cnc4OC)ccn3)c(F)c2)CC1.O=CO,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COCCN1CCN(Cc2ccc(-c3cc(NS(=O)(=O)c4cc(N5CCOCC5)cnc4OC)ccn3)c(F)c2)CC1.O=CO,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2cc(F)c(CN3CCN(C(C)C)CC3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2cc(F)c(CN3CCN(C(C)C)CC3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C4CCC4)CC3)cc2F)c1.O=CO,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C4CCC4)CC3)cc2F)c1.O=CO,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C4COC4)CC3)cc2F)c1.O=CO.O=CO.O=CO,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C4COC4)CC3)cc2F)c1.O=CO.O=CO.O=CO,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)c(F)c2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)c(F)c2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C4COC4)CC3)cc2)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C4COC4)CC3)cc2)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2cc(F)c(CN3CCN(C(C)C)CC3)c(F)c2)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2cc(F)c(CN3CCN(C(C)C)CC3)c(F)c2)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCCC3)c(F)c2)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCCC3)c(F)c2)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCCC3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCCC3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,CCC(C)N1CCN(Cc2ccc(-c3cc(NS(=O)(=O)c4cc(N5CCOCC5)cnc4OC)ccn3)cc2)CC1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,CCC(C)N1CCN(Cc2ccc(-c3cc(NS(=O)(=O)c4cc(N5CCOCC5)cnc4OC)ccn3)cc2)CC1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2c(F)cc(CN3CCN(C(C)C)CC3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2c(F)cc(CN3CCN(C(C)C)CC3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C4CCC4)CC3)cc2)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C4CCC4)CC3)cc2)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)(C)C)CC3)cc2)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)(C)C)CC3)cc2)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)c(F)c2)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)c(F)c2)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN(C)C)cc2)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN(C)C)cc2)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)(C)C)CC3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)(C)C)CC3)cc2F)c1,2017
Inhibition of GST-tagged PI3Kgamma PH domain (unknown origin) using PIP2 as subtrate after 1 hr in presence of biotin-labeled PIP3 by TR-FRET assay,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1,CHEMBL4130587,>=,<=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(N2CCOCC2)cc1S(=O)(=O)Nc1ccnc(-c2ccc(CN3CCN(C(C)C)CC3)cc2F)c1,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate by ADP-Glo assay,COc1ncc(-c2cc(OC3CCOCC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4145625,=,=,IC50,nM,1.3,IC50,nM,1.3,COc1ncc(-c2cc(OC3CCOCC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2018
Inhibition of wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control,COc1ncc(-c2cc(OC3CCOCC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4145625,=,=,Activity,%,0.0,Activity,%,0.0,COc1ncc(-c2cc(OC3CCOCC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate by ADP-Glo assay,COc1ncc(-c2cc(O[C@@H]3CCOC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4145625,=,=,IC50,nM,1.2,IC50,nM,1.2,COc1ncc(-c2cc(O[C@@H]3CCOC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate by ADP-Glo assay,CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(OC3CCOCC3)c2n1,CHEMBL4145625,=,=,IC50,nM,1.7,IC50,nM,1.7,CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(OC3CCOCC3)c2n1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate by ADP-Glo assay,CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(O[C@@H]3CCOC3)c2n1,CHEMBL4145625,=,=,IC50,nM,0.93,IC50,nM,0.93,CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(O[C@@H]3CCOC3)c2n1,2018
Inhibition of human PIK3CG expressed in mammalian expression system at 1 uM,O=c1ccc2cnc3ccc(-c4cn[nH]c4)cc3c2n1-c1ccc(F)cc1C(F)(F)F,CHEMBL4145687,,,Inhibition,%,,INH,,,O=c1ccc2cnc3ccc(-c4cn[nH]c4)cc3c2n1-c1ccc(F)cc1C(F)(F)F,2018
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system,CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)cn1,CHEMBL4152224,=,=,IC50,nM,1100.0,IC50,uM,1.1,CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)cn1,2018
Inhibition of recombinant full length human His-tagged PI3K p110ggamma at 500 nM by Z-LYTE assay relative to control,OC[C@@H](Nc1ncnc2sc(-c3ccc(O)cc3)cc12)c1ccccc1,CHEMBL4152312,=,=,Inhibition,%,-2.0,INH,%,-2.0,OC[C@@H](Nc1ncnc2sc(-c3ccc(O)cc3)cc12)c1ccccc1,2018
Inhibition of recombinant full length human His-tagged PI3K p110ggamma at 500 nM by Z-LYTE assay relative to control,CCC(=O)Nc1ccc(-c2c[nH]c3ncnc(N[C@H](C)c4ccccc4)c23)cc1,CHEMBL4152312,=,=,Inhibition,%,1.0,INH,%,1.0,CCC(=O)Nc1ccc(-c2c[nH]c3ncnc(N[C@H](C)c4ccccc4)c23)cc1,2018
Inhibition of recombinant full length human His-tagged PI3K p110ggamma at 500 nM by Z-LYTE assay relative to control,CN(C)CCn1cc(-c2cccc(O)c2)c2c(N)ncnc21,CHEMBL4152312,=,=,Inhibition,%,5.0,INH,%,5.0,CN(C)CCn1cc(-c2cccc(O)c2)c2c(N)ncnc21,2018
Inhibition of recombinant full length human His-tagged PI3K p110ggamma at 500 nM by Z-LYTE assay relative to control,OCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1,CHEMBL4152312,=,=,Inhibition,%,4.0,INH,%,4.0,OCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,CC(=O)Nc1nc(C)c(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)s1,CHEMBL4152344,=,=,IC50,nM,6.0,IC50,nM,6.0,CC(=O)Nc1nc(C)c(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)s1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,CCC(=O)Nc1nc(C)c(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)s1,CHEMBL4152344,=,=,IC50,nM,17.0,IC50,nM,17.0,CCC(=O)Nc1nc(C)c(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)s1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)CN)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,28.0,IC50,nM,28.0,Cc1nc(NC(=O)CN)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,COc1ncc(-c2sc(NC(=O)CN)nc2C)cc1NS(=O)(=O)c1ccccc1,CHEMBL4152344,=,=,IC50,nM,303.0,IC50,nM,303.0,COc1ncc(-c2sc(NC(=O)CN)nc2C)cc1NS(=O)(=O)c1ccccc1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)CN)sc1-c1cnc(O)c(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,236.0,IC50,nM,236.0,Cc1nc(NC(=O)CN)sc1-c1cnc(O)c(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1ncc(-c2sc(NC(=O)CN)nc2C)cc1NS(=O)(=O)c1ccccc1,CHEMBL4152344,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1ncc(-c2sc(NC(=O)CN)nc2C)cc1NS(=O)(=O)c1ccccc1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)CN)sc1-c1cncc(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,1590.0,IC50,nM,1590.0,Cc1nc(NC(=O)CN)sc1-c1cncc(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)CN)sc1-c1ccc(Cl)c(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,1207.0,IC50,nM,1207.0,Cc1nc(NC(=O)CN)sc1-c1ccc(Cl)c(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](C)N)sc1-c1cncc(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,47.0,IC50,nM,47.0,Cc1nc(NC(=O)[C@@H](C)N)sc1-c1cncc(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@H](C)N)sc1-c1cncc(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,62.0,IC50,nM,62.0,Cc1nc(NC(=O)[C@H](C)N)sc1-c1cncc(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)C(C)(C)N)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,31.0,IC50,nM,31.0,Cc1nc(NC(=O)C(C)(C)N)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)C2(N)CC2)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,708.0,IC50,nM,708.0,Cc1nc(NC(=O)C2(N)CC2)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)CO)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,41.0,IC50,nM,41.0,Cc1nc(NC(=O)[C@@H](N)CO)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)[C@@H](C)O)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,751.0,IC50,nM,751.0,Cc1nc(NC(=O)[C@@H](N)[C@@H](C)O)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,CC[C@H](N)C(=O)Nc1nc(C)c(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)s1,CHEMBL4152344,=,=,IC50,nM,255.7,IC50,nM,255.7,CC[C@H](N)C(=O)Nc1nc(C)c(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)s1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,CC[C@@H](N)C(=O)Nc1nc(C)c(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)s1,CHEMBL4152344,=,=,IC50,nM,408.0,IC50,nM,408.0,CC[C@@H](N)C(=O)Nc1nc(C)c(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)s1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,120.5,IC50,nM,120.5,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,1036.0,IC50,nM,1036.0,Cc1nc(NC(=O)[C@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)C(N)C2CC2)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,2628.0,IC50,nM,2628.0,Cc1nc(NC(=O)C(N)C2CC2)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)CC(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,456.7,IC50,nM,456.7,Cc1nc(NC(=O)[C@@H](N)CC(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,CCC(C)[C@H](N)C(=O)Nc1nc(C)c(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)s1,CHEMBL4152344,=,=,IC50,nM,893.1,IC50,nM,893.1,CCC(C)[C@H](N)C(=O)Nc1nc(C)c(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)s1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)Cc2ccccc2)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,CHEMBL4152344,=,=,IC50,nM,358.3,IC50,nM,358.3,Cc1nc(NC(=O)[C@@H](N)Cc2ccccc2)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(C(F)(F)F)cc2)c1,CHEMBL4152344,=,=,IC50,nM,256.0,IC50,nM,256.0,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(C(F)(F)F)cc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(C(C)C)cc2)c1,CHEMBL4152344,=,=,IC50,nM,602.1,IC50,nM,602.1,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(C(C)C)cc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)c1,CHEMBL4152344,=,=,IC50,nM,1898.0,IC50,nM,1898.0,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(-c3ccccc3)cc2)c1,CHEMBL4152344,=,=,IC50,nM,1591.0,IC50,nM,1591.0,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(-c3ccccc3)cc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2c(F)cccc2F)c1,CHEMBL4152344,=,=,IC50,nM,118.1,IC50,nM,118.1,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2c(F)cccc2F)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1ccccc1S(=O)(=O)Nc1cc(-c2sc(NC(=O)[C@@H](N)C(C)C)nc2C)cnc1Cl,CHEMBL4152344,=,=,IC50,nM,245.5,IC50,nM,245.5,Cc1ccccc1S(=O)(=O)Nc1cc(-c2sc(NC(=O)[C@@H](N)C(C)C)nc2C)cnc1Cl,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1ccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)cc1,CHEMBL4152344,=,=,IC50,nM,193.7,IC50,nM,193.7,Cc1ccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)cc1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1,CHEMBL4152344,=,=,IC50,nM,202.7,IC50,nM,202.7,Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2Cl)c1,CHEMBL4152344,=,=,IC50,nM,110.0,IC50,nM,110.0,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2Cl)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2cccc(Cl)c2)c1,CHEMBL4152344,=,=,IC50,nM,596.3,IC50,nM,596.3,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2cccc(Cl)c2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(Cl)cc2)c1,CHEMBL4152344,=,=,IC50,nM,146.0,IC50,nM,146.0,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(Cl)cc2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2cccc(Cl)c2Cl)c1,CHEMBL4152344,=,=,IC50,nM,64.0,IC50,nM,64.0,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2cccc(Cl)c2Cl)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(Cl)cc2Cl)c1,CHEMBL4152344,=,=,IC50,nM,140.0,IC50,nM,140.0,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(Cl)cc2Cl)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2cc(Cl)ccc2Cl)c1,CHEMBL4152344,=,=,IC50,nM,76.0,IC50,nM,76.0,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2cc(Cl)ccc2Cl)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(Cl)c(Cl)c2)c1,CHEMBL4152344,=,=,IC50,nM,170.0,IC50,nM,170.0,Cc1nc(NC(=O)[C@@H](N)C(C)C)sc1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(Cl)c(Cl)c2)c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4152344,=,=,IC50,nM,67.0,IC50,nM,67.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4152344,=,=,IC50,nM,110.5,IC50,nM,110.5,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2018
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control,Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1,CHEMBL4152344,=,=,Activity,%,0.8,Activity,%,0.8,Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,C[C@H](Nc1ncnc(N)c1C#N)c1nn2cccc2c(=O)n1-c1ccccc1,CHEMBL4152386,=,=,IC50,nM,280.0,IC50,nM,280.0,C[C@H](Nc1ncnc(N)c1C#N)c1nn2cccc2c(=O)n1-c1ccccc1,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3C#N)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,65.0,IC50,nM,65.0,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3C#N)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3ccc(O)cc3)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,160.0,IC50,nM,160.0,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3ccc(O)cc3)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3ccc(O)c(F)c3)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,11.0,IC50,nM,11.0,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3ccc(O)c(F)c3)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3cnc(N)nc3)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,120.0,IC50,nM,120.0,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3cnc(N)nc3)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3cc(O)cc(F)c3)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,40.0,IC50,nM,40.0,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3cc(O)cc(F)c3)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3cc(O)cc(C(F)(F)F)c3)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,6.8,IC50,nM,6.8,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3cc(O)cc(C(F)(F)F)c3)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3cc(O)cc(NS(C)(=O)=O)c3)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,15.0,IC50,nM,15.0,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3cc(O)cc(NS(C)(=O)=O)c3)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3cccc(NS(C)(=O)=O)c3)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,1.7,IC50,nM,1.7,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3cccc(NS(C)(=O)=O)c3)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3ccc4cc[nH]c4c3)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,420.0,IC50,nM,420.0,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3ccc4cc[nH]c4c3)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3ccc4oc(=O)[nH]c4c3)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,430.0,IC50,nM,430.0,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3ccc4oc(=O)[nH]c4c3)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3Sc3cccc(O)c3)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,45.0,IC50,nM,45.0,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3Sc3cccc(O)c3)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3C(=O)Nc3cccc(O)c3)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,10.0,IC50,nM,10.0,Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3C(=O)Nc3cccc(O)c3)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,COc1cccc(-c2c[nH]c3ncnc(N[C@@H](C)c4nn5ccc(C)c5c(=O)n4-c4ccccc4)c23)c1O,CHEMBL4152386,=,=,IC50,nM,81.0,IC50,nM,81.0,COc1cccc(-c2c[nH]c3ncnc(N[C@@H](C)c4nn5ccc(C)c5c(=O)n4-c4ccccc4)c23)c1O,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cccc(F)c5O)c34)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,12.0,IC50,nM,12.0,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cccc(F)c5O)c34)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cc(C(F)(F)F)ccc5O)c34)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,3.3,IC50,nM,3.3,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cc(C(F)(F)F)ccc5O)c34)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5ccc(O)cc5)c34)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,0.7,IC50,nM,0.7,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5ccc(O)cc5)c34)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,COc1cc(-c2c[nH]c3ncnc(N[C@@H](C)c4nn5ccc(C)c5c(=O)n4-c4ccccc4)c23)ccc1O,CHEMBL4152386,=,=,IC50,nM,0.3,IC50,nM,0.3,COc1cc(-c2c[nH]c3ncnc(N[C@@H](C)c4nn5ccc(C)c5c(=O)n4-c4ccccc4)c23)ccc1O,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cc(O)cc(F)c5)c34)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,0.6,IC50,nM,0.6,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cc(O)cc(F)c5)c34)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cc(O)cc(NS(C)(=O)=O)c5)c34)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,0.7,IC50,nM,0.7,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cc(O)cc(NS(C)(=O)=O)c5)c34)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cccc(NS(C)(=O)=O)c5)c34)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,3.1,IC50,nM,3.1,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cccc(NS(C)(=O)=O)c5)c34)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cccc6[nH]ccc56)c34)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,17.0,IC50,nM,17.0,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cccc6[nH]ccc56)c34)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cnn(C)c5)c34)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,3.6,IC50,nM,3.6,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cnn(C)c5)c34)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(Cc5cccc(O)c5)c34)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,64.0,IC50,nM,64.0,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(Cc5cccc(O)c5)c34)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(C(=O)Nc5cccc(O)c5)c34)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,13.0,IC50,nM,13.0,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(C(=O)Nc5cccc(O)c5)c34)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant human N-terminal His6-tagged full length p110gamma using PIP2 as substrate preincubated for 30 mins followed by substrate addition by HTRF assay,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cc(NS(C)(=O)=O)cc6[nH]ccc56)c34)n(-c3ccccc3)c(=O)c12,CHEMBL4152386,=,=,IC50,nM,36.0,IC50,nM,36.0,Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cc(NS(C)(=O)=O)cc6[nH]ccc56)c34)n(-c3ccccc3)c(=O)c12,2018
Inhibition of recombinant full-length human N-terminal His6-tagged p110gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate by HTRF assay,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,CHEMBL4177600,=,=,Ki,nM,179.0,Ki(app),nM,179.0,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,2017
Inhibition of recombinant full-length human N-terminal His6-tagged p110gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate by HTRF assay,CS(=O)(=O)N1CCN(Cc2cc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3n2)CC1,CHEMBL4177600,=,=,Ki,nM,49.1,Ki(app),nM,49.1,CS(=O)(=O)N1CCN(Cc2cc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3n2)CC1,2017
Inhibition of recombinant full-length human N-terminal His6-tagged p110gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate by HTRF assay,CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3n2)CC1,CHEMBL4177600,=,=,Ki,nM,20.7,Ki(app),nM,20.7,CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3n2)CC1,2017
Inhibition of recombinant full-length human N-terminal His6-tagged p110gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate by HTRF assay,CS(=O)(=O)N1CCN(Cc2cn3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,CHEMBL4177600,=,=,Ki,nM,40.6,Ki(app),nM,40.6,CS(=O)(=O)N1CCN(Cc2cn3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,2017
Inhibition of recombinant full-length human N-terminal His6-tagged p110gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate by HTRF assay,CS(=O)(=O)N1CCN(Cc2cc3c(N4CCOCC4)nc(-c4cnc(N)nc4)c(Cl)n3n2)CC1,CHEMBL4177600,=,=,Ki,nM,16.7,Ki(app),nM,16.7,CS(=O)(=O)N1CCN(Cc2cc3c(N4CCOCC4)nc(-c4cnc(N)nc4)c(Cl)n3n2)CC1,2017
Inhibition of recombinant full-length human N-terminal His6-tagged p110gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate by HTRF assay,CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)c(Cl)n3n2)CC1,CHEMBL4177600,=,=,Ki,nM,42.4,Ki(app),nM,42.4,CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)c(Cl)n3n2)CC1,2017
Inhibition of recombinant human full length N-terminal His6-tagged/untagged PI3Kinase (p120gamma) expressed in baculovirus Sf21 insect cells at 10 uM by filter binding radioactive ATP transferase assay relative to control,C=C(C)n1c(=O)n(C(C)=O)c2cc(Br)cnc21,CHEMBL4177654,=,=,Inhibition,%,2.0,INH,%,2.0,C=C(C)n1c(=O)n(C(C)=O)c2cc(Br)cnc21,2017
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control,C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1,CHEMBL4184148,=,=,Activity,%,24.0,Activity,%,24.0,C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1,2017
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control,CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1,CHEMBL4184148,=,=,Activity,%,20.0,Activity,%,20.0,CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1,2017
Inhibition of wild-type human partial length PIK3CG expressed in mammalian expression system assessed as residual activity at 10 uM by Kinomescan method relative to control,Fc1cc(F)cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1,CHEMBL4184198,=,=,Activity,%,100.0,Activity,%,100.0,Fc1cc(F)cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1,2018
"Inhibition of recombinant full-length human p120g at 1 uM using phosphatidylinositol-4,5-bisphosphate as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method",CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1,CHEMBL4190187,=,=,Inhibition,%,10.0,INH,%,10.0,CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1,2017
Inhibition of N-terminal His6-tagged recombinant full-length human PI3Kgamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate by HTRF colorimetric assay,COc1ncc(-c2ccc3ncc(C(=O)NCCN4CCOCC4)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4190317,=,=,IC50,nM,45.0,IC50,nM,45.0,COc1ncc(-c2ccc3ncc(C(=O)NCCN4CCOCC4)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2017
Inhibition of N-terminal His6-tagged recombinant full-length human PI3Kgamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate by HTRF colorimetric assay,COc1ncc(-c2ccc3ncc(C(=O)NCCCN4CCOCC4)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4190317,=,=,IC50,nM,37.0,IC50,nM,37.0,COc1ncc(-c2ccc3ncc(C(=O)NCCCN4CCOCC4)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2017
Inhibition of N-terminal His6-tagged recombinant full-length human PI3Kgamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate by HTRF colorimetric assay,COc1ncc(-c2ccc3ncn(CCCN4CCOCC4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4190317,=,=,IC50,nM,116.0,IC50,nM,116.0,COc1ncc(-c2ccc3ncn(CCCN4CCOCC4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2017
Inhibition of N-terminal His6-tagged recombinant full-length human PI3Kgamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate by HTRF colorimetric assay,CCOC(=O)c1cnc2ccc(-c3cncc(NS(=O)(=O)c4ccccc4)c3)cn12,CHEMBL4190317,=,=,IC50,nM,104.0,IC50,nM,104.0,CCOC(=O)c1cnc2ccc(-c3cncc(NS(=O)(=O)c4ccccc4)c3)cn12,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,Nc1ccc(-c2cncc(NS(=O)(=O)c3ccccc3)c2)cn1,CHEMBL4190336,=,=,IC50,nM,1593.0,IC50,nM,1593.0,Nc1ccc(-c2cncc(NS(=O)(=O)c3ccccc3)c2)cn1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,Nc1ccc(-c2cnc(N)c(NS(=O)(=O)c3ccccc3)c2)cn1,CHEMBL4190336,=,=,IC50,nM,2966.0,IC50,nM,2966.0,Nc1ccc(-c2cnc(N)c(NS(=O)(=O)c3ccccc3)c2)cn1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,COc1ncc(-c2ccc(N)nc2)cc1NS(=O)(=O)c1ccccc1,CHEMBL4190336,=,=,IC50,nM,2062.0,IC50,nM,2062.0,COc1ncc(-c2ccc(N)nc2)cc1NS(=O)(=O)c1ccccc1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,Cc1ncc(-c2ccc(N)nc2)cc1NS(=O)(=O)c1ccccc1,CHEMBL4190336,=,=,IC50,nM,381.0,IC50,nM,381.0,Cc1ncc(-c2ccc(N)nc2)cc1NS(=O)(=O)c1ccccc1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,Nc1ccc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)cn1,CHEMBL4190336,=,=,IC50,nM,375.0,IC50,nM,375.0,Nc1ccc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)cn1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,CCNc1ccc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)cn1,CHEMBL4190336,=,=,IC50,nM,1491.0,IC50,nM,1491.0,CCNc1ccc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)cn1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,CC(=O)Nc1ccc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)cn1,CHEMBL4190336,=,=,IC50,nM,420.0,IC50,nM,420.0,CC(=O)Nc1ccc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)cn1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,O=C(Nc1ccc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)cn1)C1CC1,CHEMBL4190336,=,=,IC50,nM,445.0,IC50,nM,445.0,O=C(Nc1ccc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)cn1)C1CC1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,CN(C)C(=O)Nc1ccc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)cn1,CHEMBL4190336,=,=,IC50,nM,68.0,IC50,nM,68.0,CN(C)C(=O)Nc1ccc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)cn1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,CS(=O)(=O)Nc1ccc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)cn1,CHEMBL4190336,=,=,IC50,nM,4752.0,IC50,nM,4752.0,CS(=O)(=O)Nc1ccc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)cn1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,O=S(=O)(Nc1cc(-c2cnc3[nH]ccc3c2)cnc1Cl)c1ccccc1,CHEMBL4190336,=,=,IC50,nM,97.0,IC50,nM,97.0,O=S(=O)(Nc1cc(-c2cnc3[nH]ccc3c2)cnc1Cl)c1ccccc1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,O=S(=O)(Nc1cc(-c2cnc3[nH]ncc3c2)cnc1Cl)c1ccccc1,CHEMBL4190336,=,=,IC50,nM,37.0,IC50,nM,37.0,O=S(=O)(Nc1cc(-c2cnc3[nH]ncc3c2)cnc1Cl)c1ccccc1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,Cc1cc2cc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4)c3)cnc2[nH]1,CHEMBL4190336,=,=,IC50,nM,63.0,IC50,nM,63.0,Cc1cc2cc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4)c3)cnc2[nH]1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,CCc1cc2cc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4)c3)cnc2[nH]1,CHEMBL4190336,=,=,IC50,nM,155.0,IC50,nM,155.0,CCc1cc2cc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4)c3)cnc2[nH]1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,O=S(=O)(Nc1cc(-c2cnc3[nH]c(-c4ccccc4)cc3c2)cnc1Cl)c1ccccc1,CHEMBL4190336,=,=,IC50,nM,268.0,IC50,nM,268.0,O=S(=O)(Nc1cc(-c2cnc3[nH]c(-c4ccccc4)cc3c2)cnc1Cl)c1ccccc1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,O=S(=O)(Nc1cc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)cnc1Cl)c1ccccc1,CHEMBL4190336,=,=,IC50,nM,15.0,IC50,nM,15.0,O=S(=O)(Nc1cc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)cnc1Cl)c1ccccc1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,O=S(=O)(Nc1cc(-c2cnc3[nH]nc(-c4ccccc4)c3c2)cnc1Cl)c1ccccc1,CHEMBL4190336,=,=,IC50,nM,17.0,IC50,nM,17.0,O=S(=O)(Nc1cc(-c2cnc3[nH]nc(-c4ccccc4)c3c2)cnc1Cl)c1ccccc1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,O=S(=O)(Nc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cnc1Cl)c1ccccc1,CHEMBL4190336,=,=,IC50,nM,0.5,IC50,nM,0.5,O=S(=O)(Nc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cnc1Cl)c1ccccc1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,O=S(=O)(Nc1cc(-c2cnc3[nH]nc(-c4ccncc4)c3c2)cnc1Cl)c1ccccc1,CHEMBL4190336,=,=,IC50,nM,7.0,IC50,nM,7.0,O=S(=O)(Nc1cc(-c2cnc3[nH]nc(-c4ccncc4)c3c2)cnc1Cl)c1ccccc1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,O=S(=O)(Nc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cnc1Cl)c1ccccc1F,CHEMBL4190336,=,=,IC50,nM,0.7,IC50,nM,0.7,O=S(=O)(Nc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cnc1Cl)c1ccccc1F,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,O=S(=O)(Nc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cnc1Cl)c1ccc(F)cc1,CHEMBL4190336,=,=,IC50,nM,0.7,IC50,nM,0.7,O=S(=O)(Nc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cnc1Cl)c1ccc(F)cc1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,CHEMBL4190336,,,Inhibition,%,,INH,,,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL4190336,,,Inhibition,%,,INH,,,Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4190336,,,Inhibition,%,,INH,,,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,CHEMBL4190336,,,Inhibition,%,,INH,,,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,2017
Inhibition of recombinant full length His-tagged human PI3K p110gamma expressed in baculovirus expression system using PIP2/PS as substrate after 1 hr by ADP-Glo luminescence assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4190336,,,Inhibition,%,,INH,,,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2017
Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by ELISA,CCS(=O)(=O)Nc1cc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cnc1OC,CHEMBL4196007,=,=,IC50,nM,3560.0,IC50,nM,3560.0,CCS(=O)(=O)Nc1cc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cnc1OC,2018
Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by ELISA,CCS(=O)(=O)Nc1cc(-c2ccc3ncnc(Nc4cccc(C(=O)OC)c4)c3c2)cnc1OC,CHEMBL4196007,=,=,IC50,nM,1783.0,IC50,nM,1783.0,CCS(=O)(=O)Nc1cc(-c2ccc3ncnc(Nc4cccc(C(=O)OC)c4)c3c2)cnc1OC,2018
Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,CHEMBL4196007,,,IC50,,,IC50,,,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,2018
Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by ELISA,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4196007,=,=,IC50,nM,23.6,IC50,nM,23.6,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2018
Inhibition of recombinant human full-length His-tagged p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 1 hr by Alexa633 Tracer-based fluorescence polarization assay,CS(=O)(=O)Cc1cc(-c2cnc(N)cc2C(F)(F)F)nc(N2CCOCC2)n1,CHEMBL4196123,,,IC50,,,IC50,,,CS(=O)(=O)Cc1cc(-c2cnc(N)cc2C(F)(F)F)nc(N2CCOCC2)n1,2018
Inhibition of recombinant human full-length His-tagged p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 1 hr by Alexa633 Tracer-based fluorescence polarization assay,CS(=O)(=O)C1(c2cc(-c3cnc(N)cc3C(F)(F)F)nc(N3CCOCC3)n2)CC1,CHEMBL4196123,=,=,IC50,nM,288.0,IC50,uM,0.288,CS(=O)(=O)C1(c2cc(-c3cnc(N)cc3C(F)(F)F)nc(N3CCOCC3)n2)CC1,2018
Inhibition of recombinant human full-length His-tagged p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 1 hr by Alexa633 Tracer-based fluorescence polarization assay,C[C@H]1COCCN1c1nc(-c2cnc(N)cc2C(F)(F)F)cc(C2(S(C)(=O)=O)CC2)n1,CHEMBL4196123,=,=,IC50,nM,164.0,IC50,uM,0.164,C[C@H]1COCCN1c1nc(-c2cnc(N)cc2C(F)(F)F)cc(C2(S(C)(=O)=O)CC2)n1,2018
Inhibition of recombinant human full-length His-tagged p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 1 hr by Alexa633 Tracer-based fluorescence polarization assay,C[C@H]1COCCN1c1nc(-c2cnc(N)cc2F)cc(C2(S(C)(=O)=O)CC2)n1,CHEMBL4196123,=,=,IC50,nM,204.0,IC50,uM,0.204,C[C@H]1COCCN1c1nc(-c2cnc(N)cc2F)cc(C2(S(C)(=O)=O)CC2)n1,2018
Inhibition of recombinant human full-length His-tagged p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 1 hr by Alexa633 Tracer-based fluorescence polarization assay,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,CHEMBL4196123,=,=,IC50,nM,372.0,IC50,uM,0.372,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,2018
Inhibition of recombinant human PI3Kgamma using PIP2 as substrate pretreated for 20 mins followed by substrate addition and measured after 80 mins by luminescence assay,C[C@H](Nc1c(C(N)=O)nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc12)C1CCOCC1,CHEMBL4196159,=,=,IC50,nM,2900.0,IC50,uM,2.9,C[C@H](Nc1c(C(N)=O)nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc12)C1CCOCC1,2018
Inhibition of recombinant human PI3Kgamma using PIP2 as substrate pretreated for 20 mins followed by substrate addition and measured after 80 mins by luminescence assay,CNC(=O)c1nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc2c1N[C@@H](C)C1CCOCC1,CHEMBL4196159,=,=,IC50,nM,3000.0,IC50,uM,3.0,CNC(=O)c1nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc2c1N[C@@H](C)C1CCOCC1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 1 hr by Kinase-Glo luminescence assay,COc1ncc(-c2cc3c(C)nc(N)nc3s2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4219058,=,=,IC50,nM,10.0,IC50,nM,10.0,COc1ncc(-c2cc3c(C)nc(N)nc3s2)cc1NS(=O)(=O)c1ccc(F)cc1F,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 1 hr by Kinase-Glo luminescence assay,COc1ncc(-c2cc3c(C)nc(NC(C)=O)nc3s2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4219058,=,=,IC50,nM,11.0,IC50,nM,11.0,COc1ncc(-c2cc3c(C)nc(NC(C)=O)nc3s2)cc1NS(=O)(=O)c1ccc(F)cc1F,2018
Inhibition of recombinant human N-terminal His6-tagged full length PI3K p120gamma expressed in baculovirus infected Sf21 insect cells by ELISA,CCCCS(=O)(=O)Nc1cc(-c2ccc3ncnc(NCCN(C)C)c3c2)cnc1OC,CHEMBL4219088,=,=,IC50,nM,117.5,IC50,nM,117.5,CCCCS(=O)(=O)Nc1cc(-c2ccc3ncnc(NCCN(C)C)c3c2)cnc1OC,2018
Inhibition of recombinant human N-terminal His6-tagged full length PI3K p120gamma expressed in baculovirus infected Sf21 insect cells by ELISA,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4219088,=,=,IC50,nM,23.6,IC50,nM,23.6,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2018
Inhibition of PI3K-gamma (unknown origin) by cell free biochemical assay,Cc1ccccc1-n1c(Cn2cc(-c3ccccc3)nn2)nc2cccc(C)c2c1=O,CHEMBL4219103,=,=,IC50,nM,1000.0,IC50,uM,1.0,Cc1ccccc1-n1c(Cn2cc(-c3ccccc3)nn2)nc2cccc(C)c2c1=O,2018
Inhibition of PI3K-gamma (unknown origin) by cell free biochemical assay,COc1ccc(-c2cn(Cc3nc4cccc(C)c4c(=O)n3-c3ccccc3C)nn2)c(C)c1,CHEMBL4219103,=,=,IC50,nM,3000.0,IC50,uM,3.0,COc1ccc(-c2cn(Cc3nc4cccc(C)c4c(=O)n3-c3ccccc3C)nn2)c(C)c1,2018
Inhibition of PI3K-gamma (unknown origin) by cell free biochemical assay,Cc1ccccc1-n1c(Cn2cnc3c(N)ncnc32)nc2cccc(C)c2c1=O,CHEMBL4219103,=,=,IC50,nM,70000.0,IC50,uM,70.0,Cc1ccccc1-n1c(Cn2cnc3c(N)ncnc32)nc2cccc(C)c2c1=O,2018
Inhibition of PI3K p110gamma (unknown origin) using lipid substrate after 40 mins by kinase-Glo assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4219144,=,=,IC50,nM,139.4,IC50,nM,139.4,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2018
Inhibition of PI3K p110gamma (unknown origin) using lipid substrate after 40 mins by kinase-Glo assay,COc1ccc(-c2ccc3ncnc(N[C@H]4CCN(C(=O)C5CC5)C4)c3c2)cn1,CHEMBL4219144,=,=,IC50,nM,223.9,IC50,nM,223.9,COc1ccc(-c2ccc3ncnc(N[C@H]4CCN(C(=O)C5CC5)C4)c3c2)cn1,2018
Inhibition of PI3K p110gamma (unknown origin) using lipid substrate after 40 mins by kinase-Glo assay,COc1ncc(-c2ccc3ncnc(N[C@H]4CCN(C(=O)C5CCOCC5)C4)c3c2)cc1C#N,CHEMBL4219144,=,=,IC50,nM,174.2,IC50,nM,174.2,COc1ncc(-c2ccc3ncnc(N[C@H]4CCN(C(=O)C5CCOCC5)C4)c3c2)cc1C#N,2018
Inhibition of PI3K p110gamma (unknown origin) using lipid substrate after 40 mins by kinase-Glo assay,COc1ncc(-c2ccc3ncnc(N[C@H]4CCN(C(=O)C5CCOCC5)C4)c3c2)cc1[N+](=O)[O-],CHEMBL4219144,=,=,IC50,nM,198.5,IC50,nM,198.5,COc1ncc(-c2ccc3ncnc(N[C@H]4CCN(C(=O)C5CCOCC5)C4)c3c2)cc1[N+](=O)[O-],2018
Inhibition of PI3Kgamma (unknown origin),CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1,CHEMBL4219163,=,=,IC50,nM,10.0,IC50,uM,0.01,CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1,2018
Inhibition of PI3Kgamma (unknown origin) at 1 uM,CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1,CHEMBL4219163,>,>,Inhibition,%,70.0,INH,%,70.0,CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1,2018
Inhibition of recombinant human full length N-terminal His-tagged PI3Kgamma expressed in Sf9 insect cells using PIP2 as substrate after 35 to 40 mins by HTRF assay,COc1ncc(-c2cc(O[C@@H]3CCN(Cc4c(C)nn(C)c4C)C3)c3cnn(C)c3n2)cc1NS(C)(=O)=O,CHEMBL4219210,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ncc(-c2cc(O[C@@H]3CCN(Cc4c(C)nn(C)c4C)C3)c3cnn(C)c3n2)cc1NS(C)(=O)=O,2018
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CHEMBL4229344,=,=,Activity,%,99.0,Activity,%,99.0,Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1,2018
Inhibition of PI3Kgamma (unknown origin) using Biotin-S11S12 as substrate after 60 mins in presence of ATP by ADPGlo luminescence assay,Cc1cccc(C)c1-n1c(Cn2nc(-c3ccc4[nH]ccc4c3)c3c(N)ncnc32)nc2cccc(F)c2c1=O,CHEMBL4229370,=,=,IC50,nM,363.0,IC50,nM,363.0,Cc1cccc(C)c1-n1c(Cn2nc(-c3ccc4[nH]ccc4c3)c3c(N)ncnc32)nc2cccc(F)c2c1=O,2018
Inhibition of PI3Kgamma (unknown origin) using Biotin-S11S12 as substrate after 60 mins in presence of ATP by ADPGlo luminescence assay,COc1ccc(-c2nn(Cc3nc4cccc(F)c4c(=O)n3-c3c(C)cccc3C)c3ncnc(N)c23)cc1OC,CHEMBL4229370,=,=,IC50,nM,62.0,IC50,nM,62.0,COc1ccc(-c2nn(Cc3nc4cccc(F)c4c(=O)n3-c3c(C)cccc3C)c3ncnc(N)c23)cc1OC,2018
Inhibition of PI3Kgamma (unknown origin) using Biotin-S11S12 as substrate after 60 mins in presence of ATP by ADPGlo luminescence assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4229370,=,=,IC50,nM,139.0,IC50,nM,139.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2018
Inhibition of human PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual activity at 5 uM by KINOMEscan assay relative to control,CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12,CHEMBL4229410,=,=,Activity,%,100.0,Activity,%,100.0,CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12,2018
Binding affinity to human PIK3CG (S144 to A1102 residues) expressed in mammalian expression system by KINOMEscan assay,CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12,CHEMBL4229410,>=,>=,Kd,nM,5000.0,Kd,uM,5.0,CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12,2018
Inhibition of recombinant human PI3K-gamma using PIP2:3PS as substrate preincubated for 15 mins followed by ATP addition measured after 1 hr by ADP-Glo assay,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4229415,=,=,IC50,nM,23.6,IC50,nM,23.6,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2018
Inhibition of recombinant human PI3K-gamma using PIP2:3PS as substrate preincubated for 15 mins followed by ATP addition measured after 1 hr by ADP-Glo assay,COc1ncc(-c2ccc3c(c2)N(CCCN2CCOCC2)C(=O)CO3)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4229415,=,=,IC50,nM,184.7,IC50,nM,184.7,COc1ncc(-c2ccc3c(c2)N(CCCN2CCOCC2)C(=O)CO3)cc1NS(=O)(=O)c1ccc(F)cc1F,2018
Inhibition of PI3Kgamma (unknown origin),Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4229497,=,=,IC50,nM,5.0,IC50,nM,5.0,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2018
Inhibition of PI3Kgamma (unknown origin),COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1,CHEMBL4229497,=,=,IC50,nM,38.0,IC50,nM,38.0,COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1,2018
Inhibition of recombinant human full length His-tagged PI3K p110gamma expressed in baculovirus expression system using lipid substrate after 60 mins by ADP-Glo assay,C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)cc1,CHEMBL4229497,=,=,IC50,nM,684.0,IC50,nM,684.0,C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)cc1,2018
Inhibition of PI3Kgamma (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,CHEMBL4229506,>,>,Ki,nM,4000.0,Ki,nM,4000.0,CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,2018
Inhibition of PI3Kgamma (unknown origin),O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1,CHEMBL4229506,,,Ki,,,Ki,,,O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1,2018
Inhibition of PI3Kgamma (unknown origin),CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1,CHEMBL4229506,>,>,Ki,nM,4000.0,Ki,nM,4000.0,CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1,2018
Inhibition of PI3K gamma (unknown origin) at 0.1 uM by ADP-Glo assay relative to control,CC1=Nc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc2C12CCCC2,CHEMBL4251601,=,=,Inhibition,%,-5.0,INH,%,-5.0,CC1=Nc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc2C12CCCC2,2018
Inhibition of PI3K gamma (unknown origin) at 1 uM by ADP-Glo assay relative to control,CC1=Nc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc2C12CCCC2,CHEMBL4251601,=,=,Inhibition,%,19.0,INH,%,19.0,CC1=Nc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc2C12CCCC2,2018
Inhibition of wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control,CCNc1cc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2C(F)(F)F)ccn1,CHEMBL4251622,=,=,Activity,%,74.0,Activity,%,74.0,CCNc1cc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2C(F)(F)F)ccn1,2018
"Inhibition of human PI3K p120gamma using phosphatidylinositol 4,5-bisphosphate as substrate after 30 mins by HTRF assay",COc1ncc(-c2ccc3ncc(Cl)c(=O)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4251704,=,=,IC50,nM,1.0,IC50,nM,1.0,COc1ncc(-c2ccc3ncc(Cl)c(=O)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2018
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control,COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1,CHEMBL4261600,=,=,Activity,%,99.0,Activity,%,99.0,COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1,2018
Inhibition of N-terminal His6-tagged recombinant full length human p120gamma expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control,CN(C)[C@H]1CC[C@H](Nc2ncnc3[nH]cc([C@H]4CC[C@H](C(N)=O)CC4)c23)CC1,CHEMBL4265877,=,=,Inhibition,%,1.0,INH,%,1.0,CN(C)[C@H]1CC[C@H](Nc2ncnc3[nH]cc([C@H]4CC[C@H](C(N)=O)CC4)c23)CC1,2018
Inhibition of N-terminal His6-tagged recombinant full length human p120gamma expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control,CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C(C)C)c34)CC2)CC1,CHEMBL4265877,=,=,Inhibition,%,3.0,INH,%,3.0,CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C(C)C)c34)CC2)CC1,2018
Inhibition of N-terminal His6-tagged recombinant full length human p120gamma expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control,CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C5CCOCC5)c34)CC2)CC1,CHEMBL4265877,=,=,Inhibition,%,2.0,INH,%,2.0,CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C5CCOCC5)c34)CC2)CC1,2018
Inhibition of PI3KCgamma (unknown origin),COc1cc(OC)c(/C=C/C(=O)c2c(OC)cc(OC)c(C3CCN(C)CC3)c2O)c(OC)c1,CHEMBL4265934,=,=,IC50,nM,10000.0,IC50,uM,10.0,COc1cc(OC)c(/C=C/C(=O)c2c(OC)cc(OC)c(C3CCN(C)CC3)c2O)c(OC)c1,2018
Inhibition of PI3KCgamma (unknown origin),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4265934,=,=,IC50,nM,250.0,IC50,uM,0.25,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2018
Inhibition of PI3KCgamma (unknown origin),C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4265934,=,=,IC50,nM,12.0,IC50,uM,0.012,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2018
Inhibition of PI3Kgamma (unknown origin) after 40 mins by kinase-Glo reagent based luminescence assay,Oc1ccc(-c2n[nH]cc2-c2ccc(Cl)c(Cl)c2)c(O)c1O,CHEMBL4265945,=,=,EC50,nM,10000.0,EC50,uM,10.0,Oc1ccc(-c2n[nH]cc2-c2ccc(Cl)c(Cl)c2)c(O)c1O,2018
Inhibition of PI3Kgamma (unknown origin) after 40 mins by kinase-Glo reagent based luminescence assay,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL4265945,=,=,EC50,nM,51.0,EC50,uM,0.051,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2018
Inhibition of PI3Kgamma (unknown origin) after 40 mins by kinase-Glo reagent based luminescence assay,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4265945,=,=,EC50,nM,67.0,EC50,uM,0.067,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2018
Binding affinity to human PI3Kgamma after 1 hr by KINOMEscan assay,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,CHEMBL4266033,=,=,Kd,nM,15.0,Kd,nM,15.0,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O,2018
Binding affinity to human PI3Kgamma after 1 hr by KINOMEscan assay,CO/C=C/C(=O)c1cc2c3c(c(N)cc(NC(=O)C(C)C)c3n1)N=C2,CHEMBL4266033,=,=,Kd,nM,3.5,Kd,nM,3.5,CO/C=C/C(=O)c1cc2c3c(c(N)cc(NC(=O)C(C)C)c3n1)N=C2,2018
Binding affinity to human PI3Kgamma equilibrate for 6 hrs by scan-kinetic platform assay,CO/C=C/C(=O)c1cc2c3c(c(N)cc(NC(=O)C(C)C)c3n1)N=C2,CHEMBL4266033,=,=,Kd,nM,1.9,Kd,nM,1.9,CO/C=C/C(=O)c1cc2c3c(c(N)cc(NC(=O)C(C)C)c3n1)N=C2,2018
Binding affinity to human PI3Kgamma equilibrate for 1 hr followed by 30 fold dilution and re-equilibrate for 5 hrs by scan-kinetic platform assay,CO/C=C/C(=O)c1cc2c3c(c(N)cc(NC(=O)C(C)C)c3n1)N=C2,CHEMBL4266033,=,=,Kd,nM,4.4,Kd,nM,4.4,CO/C=C/C(=O)c1cc2c3c(c(N)cc(NC(=O)C(C)C)c3n1)N=C2,2018
Binding affinity to human PI3Kgamma equilibrate for 1 hr by scan-kinetic platform assay,CO/C=C/C(=O)c1cc2c3c(c(N)cc(NC(=O)C(C)C)c3n1)N=C2,CHEMBL4266033,=,=,Kd,nM,2.0,Kd,nM,2.0,CO/C=C/C(=O)c1cc2c3c(c(N)cc(NC(=O)C(C)C)c3n1)N=C2,2018
Binding affinity to human PI3Kgamma diluted 30 fold and equilibrate for 6 hrs by scan-kinetic platform assay,CO/C=C/C(=O)c1cc2c3c(c(N)cc(NC(=O)C(C)C)c3n1)N=C2,CHEMBL4266033,=,=,Kd,nM,80.0,Kd,nM,80.0,CO/C=C/C(=O)c1cc2c3c(c(N)cc(NC(=O)C(C)C)c3n1)N=C2,2018
Inhibition of PI3K-gamma (unknown origin) after 40 mins by Kinase-Glo assay,Fc1ccccc1-c1cc2nc(-c3ccco3)c(-c3ccco3)nc2cc1Br,CHEMBL4270587,=,=,EC50,nM,9890.0,EC50,uM,9.89,Fc1ccccc1-c1cc2nc(-c3ccco3)c(-c3ccco3)nc2cc1Br,2018
Inhibition of PI3K-gamma (unknown origin) after 40 mins by Kinase-Glo assay,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL4270587,=,=,EC50,nM,51.0,EC50,uM,0.051,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2018
Inhibition of PI3K-gamma (unknown origin) after 40 mins by Kinase-Glo assay,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4270587,=,=,EC50,nM,67.0,EC50,uM,0.067,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2018
Inhibition of human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,Nc1cc(C(F)F)c(-c2nc(N3C4CCC3COC4)nc(N3C4CCC3COC4)n2)cn1,CHEMBL4270669,=,=,Kd,nM,18000.0,Kd,nM,18000.0,Nc1cc(C(F)F)c(-c2nc(N3C4CCC3COC4)nc(N3C4CCC3COC4)n2)cn1,2018
Inhibition of human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,CHEMBL4270669,=,=,Kd,nM,3.7,Kd,nM,3.7,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,2018
Inhibition of human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,CCC(CC)n1cnc2c(-c3cnc(N)cn3)nc(N3CC4CCC(C3)O4)nc21,CHEMBL4270669,=,=,Kd,nM,22000.0,Kd,nM,22000.0,CCC(CC)n1cnc2c(-c3cnc(N)cn3)nc(N3CC4CCC(C3)O4)nc21,2018
Inhibition of human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21,CHEMBL4270669,=,=,Kd,nM,42.0,Kd,nM,42.0,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21,2018
Inhibition of human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,CO[C@H]1CC[C@H](N2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1,CHEMBL4270669,=,=,Kd,nM,7100.0,Kd,nM,7100.0,CO[C@H]1CC[C@H](N2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1,2018
Inhibition of human PI3Kgamma (144 to 1102 residues) expressed in mammalian expression system by KINOMEscan assay,CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,CHEMBL4270669,=,=,Kd,nM,8400.0,Kd,nM,8400.0,CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,2018
Inhibition of wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system at 1 uM by Kinomescan method,O=C(Nc1ccc2[nH]nc(-c3ccc4[nH]ccc4c3)c2c1)c1c(Cl)cccc1Cl,CHEMBL4304739,,,Inhibition,%,,INH,,,O=C(Nc1ccc2[nH]nc(-c3ccc4[nH]ccc4c3)c2c1)c1c(Cl)cccc1Cl,2019
Inhibition of PI3K gamma (unknown origin) using lipid substrate measured after 40 mins in presence of ATP by Kinase-Glo plus reagent based luminescence assay,COc1ncc(-c2ccc3ncnc(NCCN4CCOCC4)c3c2)cc1NS(C)(=O)=O,CHEMBL4304761,=,=,IC50,nM,6.0,IC50,nM,6.0,COc1ncc(-c2ccc3ncnc(NCCN4CCOCC4)c3c2)cc1NS(C)(=O)=O,2019
Inhibition of PI3K gamma (unknown origin) using lipid substrate measured after 40 mins in presence of ATP by Kinase-Glo plus reagent based luminescence assay,COc1ncc(-c2ccc3ncnc(N[C@H]4CCN(C(C)=O)C4)c3c2)cc1NS(C)(=O)=O,CHEMBL4304761,=,=,IC50,nM,4.3,IC50,nM,4.3,COc1ncc(-c2ccc3ncnc(N[C@H]4CCN(C(C)=O)C4)c3c2)cc1NS(C)(=O)=O,2019
Inhibition of PI3K gamma (unknown origin) using lipid substrate measured after 40 mins in presence of ATP by Kinase-Glo plus reagent based luminescence assay,COc1ncc(-c2ccc3ncnc(N[C@H]4CCN(C(=O)C5CCOCC5)C4)c3c2)cc1NS(C)(=O)=O,CHEMBL4304761,=,=,IC50,nM,6.5,IC50,nM,6.5,COc1ncc(-c2ccc3ncnc(N[C@H]4CCN(C(=O)C5CCOCC5)C4)c3c2)cc1NS(C)(=O)=O,2019
Inhibition of PI3K gamma (unknown origin) using lipid substrate measured after 40 mins in presence of ATP by Kinase-Glo plus reagent based luminescence assay,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4304761,=,=,IC50,nM,169.0,IC50,nM,169.0,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2019
Inhibition of PI3K gamma (unknown origin) using lipid substrate measured after 40 mins in presence of ATP by Kinase-Glo plus reagent based luminescence assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4304761,=,=,IC50,nM,381.0,IC50,nM,381.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2019
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control,CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl,CHEMBL4304811,=,=,Activity,%,70.0,Activity,%,70.0,CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl,2019
Inhibition of PI3K p110gamma (unknown origin),CC(C)C(=O)CN1c2nc(N3CCOC[C@H]3C)cc(=O)n2CC[C@H]1C(F)(F)F,CHEMBL4308824,=,=,IC50,nM,2500.0,IC50,uM,2.5,CC(C)C(=O)CN1c2nc(N3CCOC[C@H]3C)cc(=O)n2CC[C@H]1C(F)(F)F,2018
Inhibition of PI3K p110gamma (unknown origin),CS(=O)(=O)O.CS(=O)(=O)O.O.O.c1cnc2ccc(Nc3nc(NC4CC4)c4nc[nH]c4n3)cc2c1,CHEMBL4308824,=,=,IC50,nM,89.7,IC50,nM,89.7,CS(=O)(=O)O.CS(=O)(=O)O.O.O.c1cnc2ccc(Nc3nc(NC4CC4)c4nc[nH]c4n3)cc2c1,2018
Inhibition of wild type human PI3K p110gamma using PIP2 as substrate by TR-FRET assay,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,CHEMBL4308824,=,=,IC50,nM,6.0,IC50,nM,6.0,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,2018
Inhibition of recombinant human His-tagged PIK3CG expressed in baculovirus expression system using PIP2 as substrate incubated for 1 hr by ADP-glo assay,COc1ncc(-c2cc(OCCCCCCC(=O)NO)c3ncnc(C)c3c2)cc1F,CHEMBL4311940,=,=,IC50,nM,67.0,IC50,nM,67.0,COc1ncc(-c2cc(OCCCCCCC(=O)NO)c3ncnc(C)c3c2)cc1F,2019
Inhibition of recombinant human His-tagged PIK3CG expressed in baculovirus expression system using PIP2 as substrate incubated for 1 hr by ADP-glo assay,COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,CHEMBL4311940,=,=,IC50,nM,374.0,IC50,nM,374.0,COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,2019
Inhibition of recombinant human His-tagged PIK3CG expressed in baculovirus expression system using PIP2 as substrate incubated for 1 hr by ADP-glo assay,COc1ccc(-c2cc(OCCN(C)c3ncc(C(=O)NO)cn3)c3ncnc(C)c3c2)cn1,CHEMBL4311940,=,=,IC50,nM,467.0,IC50,nM,467.0,COc1ccc(-c2cc(OCCN(C)c3ncc(C(=O)NO)cn3)c3ncnc(C)c3c2)cn1,2019
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,COc1ncc(-c2cc(OCCCCCCC(=O)NO)c3ncnc(C)c3c2)cc1F,CHEMBL4311940,=,=,Activity,%,1.4,Activity,%,1.4,COc1ncc(-c2cc(OCCCCCCC(=O)NO)c3ncnc(C)c3c2)cc1F,2019
Inhibition of recombinant human N-terminal His-tagged full-length p120gamma expressed in Sf9 insect cells using PIP2 as substrate by ADP-glo assay,COc1ncc(-c2cc(OCC3(C)COC3)c3ncnc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4321792,=,=,IC50,nM,1.6,IC50,nM,1.6,COc1ncc(-c2cc(OCC3(C)COC3)c3ncnc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2019
Inhibition of recombinant human N-terminal His-tagged full-length p120gamma expressed in Sf9 insect cells using PIP2 as substrate by ADP-glo assay,COc1ncc(-c2cc(O[C@@H]3CCOC3)c3ncnc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4321792,=,=,IC50,nM,1.5,IC50,nM,1.5,COc1ncc(-c2cc(O[C@@H]3CCOC3)c3ncnc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2019
Inhibition of recombinant human N-terminal His-tagged full-length p120gamma expressed in Sf9 insect cells using PIP2 as substrate by ADP-glo assay,COc1ncc(-c2cc(OC3CCOCC3)c3ncnc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4321792,=,=,IC50,nM,2.1,IC50,nM,2.1,COc1ncc(-c2cc(OC3CCOCC3)c3ncnc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2019
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by kinomescan assay relative to control,COc1ncc(-c2cc(OCC3(C)COC3)c3ncnc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4321792,=,=,Activity,%,0.0,Activity,%,0.0,COc1ncc(-c2cc(OCC3(C)COC3)c3ncnc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2019
Binding affinity to human wild-type partial length PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system by kinome scan assay,C[C@@H]1COCCN1c1nc(-c2ccc(N)nc2)nc2c1C[C@@H]1COCCN21,CHEMBL4321805,=,=,Kd,nM,8700.0,Kd,nM,8700.0,C[C@@H]1COCCN1c1nc(-c2ccc(N)nc2)nc2c1C[C@@H]1COCCN21,2019
Binding affinity to human wild-type partial length PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system by kinome scan assay,C[C@@H]1COCCN1c1nc(-c2cnc(N)nc2)nc2c1C[C@@H]1COCCN21,CHEMBL4321805,=,=,Kd,nM,1800.0,Kd,nM,1800.0,C[C@@H]1COCCN1c1nc(-c2cnc(N)nc2)nc2c1C[C@@H]1COCCN21,2019
Binding affinity to human wild-type partial length PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system by kinome scan assay,C[C@@H]1COCCN1c1nc(-c2cnc(N)cn2)nc2c1C[C@@H]1COCCN21,CHEMBL4321805,=,=,Kd,nM,11000.0,Kd,nM,11000.0,C[C@@H]1COCCN1c1nc(-c2cnc(N)cn2)nc2c1C[C@@H]1COCCN21,2019
Binding affinity to human wild-type partial length PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system by kinome scan assay,Nc1cc(C(F)F)c(-c2nc(N3C4CCC3COC4)nc(N3C4CCC3COC4)n2)cn1,CHEMBL4321805,=,=,Kd,nM,18000.0,Kd,nM,18000.0,Nc1cc(C(F)F)c(-c2nc(N3C4CCC3COC4)nc(N3C4CCC3COC4)n2)cn1,2019
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(NC(=O)CC4CCOCC4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,3162.28,pIC50,,5.5,COc1ncc(-c2cc3c(c(NC(=O)CC4CCOCC4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(NC(=O)C[C@@H]4C[C@@H](C)O[C@@H](C)C4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,6309.57,pIC50,,5.2,COc1ncc(-c2cc3c(c(NC(=O)C[C@@H]4C[C@@H](C)O[C@@H](C)C4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(NC(=O)CN4C[C@@H](C)O[C@@H](C)C4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,15848.93,pIC50,,4.8,COc1ncc(-c2cc3c(c(NC(=O)CN4C[C@@H](C)O[C@@H](C)C4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(C(=O)NC[C@H]4C[C@@H](C)O[C@@H](C)C4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,316.23,pIC50,,6.5,COc1ncc(-c2cc3c(c(C(=O)NC[C@H]4C[C@@H](C)O[C@@H](C)C4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(CC(=O)CN4CCOCC4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,5011.87,pIC50,,5.3,COc1ncc(-c2cc3c(c(CC(=O)CN4CCOCC4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc(CCCN3C[C@@H](C)O[C@@H](C)C3)c3c(c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,3981.07,pIC50,,5.4,COc1ncc(-c2cc(CCCN3C[C@@H](C)O[C@@H](C)C3)c3c(c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(OCCN4CCOCC4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,794.33,pIC50,,6.1,COc1ncc(-c2cc3c(c(OCCN4CCOCC4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(OCCN4C[C@@H](C)O[C@@H](C)C4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,1000.0,pIC50,,6.0,COc1ncc(-c2cc3c(c(OCCN4C[C@@H](C)O[C@@H](C)C4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(NC(=O)C4CCCN(C)C4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,12589.25,pIC50,,4.9,COc1ncc(-c2cc3c(c(NC(=O)C4CCCN(C)C4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(OCC4CCCN(C)C4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,5011.87,pIC50,,5.3,COc1ncc(-c2cc3c(c(OCC4CCCN(C)C4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(OCC4CCCN(C)C4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,1995.26,pIC50,,5.7,COc1ncc(-c2cc3c(c(OCC4CCCN(C)C4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(OC[C@@H]4CN(C)CCO4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,1258.93,pIC50,,5.9,COc1ncc(-c2cc3c(c(OC[C@@H]4CN(C)CCO4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(OC[C@H]4CN(C)CCO4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,630.96,pIC50,,6.2,COc1ncc(-c2cc3c(c(OC[C@H]4CN(C)CCO4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(NC(=O)CN4CCN(C)CC4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,6309.57,pIC50,,5.2,COc1ncc(-c2cc3c(c(NC(=O)CN4CCN(C)CC4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(NC(=O)CN4CCN(C(C)C)CC4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,10000.0,pIC50,,5.0,COc1ncc(-c2cc3c(c(NC(=O)CN4CCN(C(C)C)CC4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(NC(=O)CN4CCC(C(C)(C)O)CC4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,12589.25,pIC50,,4.9,COc1ncc(-c2cc3c(c(NC(=O)CN4CCC(C(C)(C)O)CC4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(NCCN4CCC(C(C)(C)O)CC4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,3162.28,pIC50,,5.5,COc1ncc(-c2cc3c(c(NCCN4CCC(C(C)(C)O)CC4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,3981.07,pIC50,,5.4,COc1ncc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc(OCCN3CCC(C(C)(C)O)CC3)c3c(c2Cl)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,79432.82,pIC50,,4.1,COc1ncc(-c2cc(OCCN3CCC(C(C)(C)O)CC3)c3c(c2Cl)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc(OCCN3CCC(C(C)(C)O)CC3)c3c(c2F)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,19952.62,pIC50,,4.7,COc1ncc(-c2cc(OCCN3CCC(C(C)(C)O)CC3)c3c(c2F)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2F)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,5011.87,pIC50,,5.3,COc1ncc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2F)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)n2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,630.96,pIC50,,6.2,COc1ncc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)n2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc(OC[C@H]3CN(C)CCO3)c3c(n2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,12589.25,pIC50,,4.9,COc1ncc(-c2cc(OC[C@H]3CN(C)CCO3)c3c(n2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc(OCCN3CCC(C(C)(C)O)CC3)c3c(c2)[C@@H](C)OC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,3981.07,pIC50,,5.4,COc1ncc(-c2cc(OCCN3CCC(C(C)(C)O)CC3)c3c(c2)[C@@H](C)OC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2)COC3)cc1NS(=O)(=O)CC#N,CHEMBL4321873,=,=,IC50,nM,501.19,pIC50,,6.3,COc1ncc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2)COC3)cc1NS(=O)(=O)CC#N,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2)COC3)cnc1OC,CHEMBL4321873,=,=,IC50,nM,5011.87,pIC50,,5.3,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2)COC3)cnc1OC,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@H](C)N4CCC(C(C)(C)O)CC4)c2)COC3)cnc1OC,CHEMBL4321873,=,=,IC50,nM,10000.0,pIC50,,5.0,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@H](C)N4CCC(C(C)(C)O)CC4)c2)COC3)cnc1OC,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@@H](C)N4CCC(C(C)(C)O)CC4)c2)COC3)cnc1OC,CHEMBL4321873,=,=,IC50,nM,6309.57,pIC50,,5.2,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@@H](C)N4CCC(C(C)(C)O)CC4)c2)COC3)cnc1OC,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(O[C@@H](C)CN4CCC(C(C)(C)O)CC4)c2)COC3)cnc1OC,CHEMBL4321873,=,=,IC50,nM,12589.25,pIC50,,4.9,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(O[C@@H](C)CN4CCC(C(C)(C)O)CC4)c2)COC3)cnc1OC,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(O[C@H](C)CN4CCC(C(C)(C)O)CC4)c2)COC3)cnc1OC,CHEMBL4321873,=,=,IC50,nM,5011.87,pIC50,,5.3,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(O[C@H](C)CN4CCC(C(C)(C)O)CC4)c2)COC3)cnc1OC,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2)CCOC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,3162.28,pIC50,,5.5,COc1ncc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2)CCOC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2)CCOC3)cnc1OC,CHEMBL4321873,=,=,IC50,nM,3981.07,pIC50,,5.4,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2)CCOC3)cnc1OC,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(OC[C@H]4CN(CC(C)(C)O)CCO4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,501.19,pIC50,,6.3,COc1ncc(-c2cc3c(c(OC[C@H]4CN(CC(C)(C)O)CCO4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@H]4CN(CC(C)(C)O)CCO4)c2)COC3)cnc1OC,CHEMBL4321873,=,=,IC50,nM,1995.26,pIC50,,5.7,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@H]4CN(CC(C)(C)O)CCO4)c2)COC3)cnc1OC,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COCCN1CCO[C@@H](COc2cc(-c3cnc(OC)c(NS(C)(=O)=O)c3)cc3c2COC3)C1,CHEMBL4321873,=,=,IC50,nM,630.96,pIC50,,6.2,COCCN1CCO[C@@H](COc2cc(-c3cnc(OC)c(NS(C)(=O)=O)c3)cc3c2COC3)C1,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@H]4CN(C(C)C)CCO4)c2)COC3)cnc1OC,CHEMBL4321873,=,=,IC50,nM,2511.89,pIC50,,5.6,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@H]4CN(C(C)C)CCO4)c2)COC3)cnc1OC,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@H]4CN(C5CCC5)CCO4)c2)COC3)cnc1OC,CHEMBL4321873,=,=,IC50,nM,1258.93,pIC50,,5.9,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@H]4CN(C5CCC5)CCO4)c2)COC3)cnc1OC,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COc1ncc(-c2cc3c(c(OC[C@H]4CN(C5COC5)CCO4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,IC50,nM,251.19,pIC50,,6.6,COc1ncc(-c2cc3c(c(OC[C@H]4CN(C5COC5)CCO4)c2)COC3)cc1NS(C)(=O)=O,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@@H]4CN(C5COC5)CCO4)c2)COC3)cnc1OC,CHEMBL4321873,=,=,IC50,nM,316.23,pIC50,,6.5,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@@H]4CN(C5COC5)CCO4)c2)COC3)cnc1OC,2020
Inhibition of recombinant human full-length N-terminal His6-tagged p120gamma expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins in presence of biotin-PIP3 by HTRF assay,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@H]4CN(C5COC5)CCO4)c2)COC3)cnc1OC,CHEMBL4321873,=,=,IC50,nM,316.23,pIC50,,6.5,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@H]4CN(C5COC5)CCO4)c2)COC3)cnc1OC,2020
Binding affinity to PI3Kgamma in human HL60 cell extract measured after 2 hrs by kinobeads based pull down assay,COc1ncc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2)COC3)cc1NS(C)(=O)=O,CHEMBL4321873,=,=,Kd,nM,2511.89,pKd(app),,5.6,COc1ncc(-c2cc3c(c(OCCN4CCC(C(C)(C)O)CC4)c2)COC3)cc1NS(C)(=O)=O,2020
Binding affinity to PI3Kgamma in human HL60 cell extract measured after 2 hrs by kinobeads based pull down assay,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@H]4CN(C5COC5)CCO4)c2)COC3)cnc1OC,CHEMBL4321873,=,=,Kd,nM,501.19,pKd(app),,6.3,COCCS(=O)(=O)Nc1cc(-c2cc3c(c(OC[C@H]4CN(C5COC5)CCO4)c2)COC3)cnc1OC,2020
Inhibition of full length human PI3Kgamma using PIP2 as substrate after 30 mins by TR-FRET assay,Nc1nccc(-c2cc(-c3nnc[nH]3)c3ncn(-c4ccnc5c(F)ccc(F)c45)c3c2)c1F,CHEMBL4325835,=,=,IC50,nM,440.0,IC50,nM,440.0,Nc1nccc(-c2cc(-c3nnc[nH]3)c3ncn(-c4ccnc5c(F)ccc(F)c45)c3c2)c1F,2018
Inhibition of full length human PI3Kgamma using PIP2 as substrate after 30 mins by TR-FRET assay,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3F)cc2n1-c1ccnc2c(F)ccc(F)c12,CHEMBL4325835,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3F)cc2n1-c1ccnc2c(F)ccc(F)c12,2018
Inhibition of full length human PI3Kgamma using PIP2 as substrate after 30 mins by TR-FRET assay,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3F)cc2n1-c1ccnc2c(F)ccc(F)c12,CHEMBL4325835,=,=,IC50,nM,4269.0,IC50,nM,4269.0,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3F)cc2n1-c1ccnc2c(F)ccc(F)c12,2018
Inhibition of full length human PI3Kgamma using PIP2 as substrate after 30 mins by TR-FRET assay,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3F)cc2n1-c1ccnc2c(F)ccc(F)c12,CHEMBL4325835,=,=,IC50,nM,4156.0,IC50,nM,4156.0,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3F)cc2n1-c1ccnc2c(F)ccc(F)c12,2018
Inhibition of PI3Kgamma (unknown origin),C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4330088,=,=,IC50,nM,2.5,IC50,nM,2.5,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2019
Inhibition of PI3Kgamma (unknown origin),O=C1NC(=O)/C(=C/c2ccc3nccnc3c2)S1,CHEMBL4330088,=,=,IC50,nM,8.0,IC50,nM,8.0,O=C1NC(=O)/C(=C/c2ccc3nccnc3c2)S1,2019
Inhibition of PI3Kgamma (unknown origin),Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,CHEMBL4330088,=,=,IC50,nM,83.0,IC50,nM,83.0,Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,2019
Inhibition of PI3Kgamma (unknown origin),C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1,CHEMBL4330088,=,=,IC50,nM,0.29,IC50,nM,0.29,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1,2019
Inhibition of PI3Kgamma (unknown origin),Fc1ccc2[nH]ccc2c1-c1nc(N2CCOCC2)c2sc(CN3CCN(CC4CC4)CC3)cc2n1,CHEMBL4330088,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Fc1ccc2[nH]ccc2c1-c1nc(N2CCOCC2)c2sc(CN3CCN(CC4CC4)CC3)cc2n1,2019
Inhibition of PI3Kgamma (unknown origin),Cc1csc2nc([C@H](C)Nc3ncnc4[nH]cnc34)c(-c3cccc(F)c3)c(=O)n12,CHEMBL4330088,=,=,IC50,nM,2297.0,IC50,nM,2297.0,Cc1csc2nc([C@H](C)Nc3ncnc4[nH]cnc34)c(-c3cccc(F)c3)c(=O)n12,2019
Inhibition of PI3Kgamma (unknown origin),CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,CHEMBL4330088,=,=,IC50,nM,1400.0,IC50,nM,1400.0,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,2019
Inhibition of PI3Kgamma (unknown origin),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4330088,=,=,IC50,nM,63.0,IC50,nM,63.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2019
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N,CHEMBL4330132,=,=,Activity,%,100.0,Activity,%,100.0,CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccccc3)cc12,CHEMBL4340546,=,=,IC50,nM,38290.0,IC50,uM,38.29,O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccccc3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",Cc1ccc(S(=O)(=O)n2cc3c(=O)oc4ccccc4c3n2)cc1,CHEMBL4340546,=,=,IC50,nM,10530.0,IC50,uM,10.53,Cc1ccc(S(=O)(=O)n2cc3c(=O)oc4ccccc4c3n2)cc1,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",COc1ccc(S(=O)(=O)n2cc3c(=O)oc4ccccc4c3n2)cc1,CHEMBL4340546,=,=,IC50,nM,18240.0,IC50,uM,18.24,COc1ccc(S(=O)(=O)n2cc3c(=O)oc4ccccc4c3n2)cc1,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",CC(C)(C)c1ccc(S(=O)(=O)n2cc3c(=O)oc4ccccc4c3n2)cc1,CHEMBL4340546,=,=,IC50,nM,17810.0,IC50,uM,17.81,CC(C)(C)c1ccc(S(=O)(=O)n2cc3c(=O)oc4ccccc4c3n2)cc1,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccc(F)cc3)cc12,CHEMBL4340546,=,=,IC50,nM,42570.0,IC50,uM,42.57,O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccc(F)cc3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccc(Cl)cc3)cc12,CHEMBL4340546,=,=,IC50,nM,24640.0,IC50,uM,24.64,O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccc(Cl)cc3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccc(Br)cc3)cc12,CHEMBL4340546,=,=,IC50,nM,32180.0,IC50,uM,32.18,O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccc(Br)cc3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccccc3[N+](=O)[O-])cc12,CHEMBL4340546,=,=,IC50,nM,19030.0,IC50,uM,19.03,O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccccc3[N+](=O)[O-])cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",O=c1oc2ccccc2c2nn(S(=O)(=O)c3cccc([N+](=O)[O-])c3)cc12,CHEMBL4340546,=,=,IC50,nM,9470.0,IC50,uM,9.47,O=c1oc2ccccc2c2nn(S(=O)(=O)c3cccc([N+](=O)[O-])c3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccc([N+](=O)[O-])cc3)cc12,CHEMBL4340546,=,=,IC50,nM,5100.0,IC50,uM,5.1,O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccc([N+](=O)[O-])cc3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccc(C(F)(F)F)cc3)cc12,CHEMBL4340546,=,=,IC50,nM,3480.0,IC50,uM,3.48,O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccc(C(F)(F)F)cc3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",Cc1ccc(C)c(S(=O)(=O)n2cc3c(=O)oc4ccccc4c3n2)c1,CHEMBL4340546,=,=,IC50,nM,1900.0,IC50,uM,1.9,Cc1ccc(C)c(S(=O)(=O)n2cc3c(=O)oc4ccccc4c3n2)c1,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccc(Cl)c([N+](=O)[O-])c3)cc12,CHEMBL4340546,=,=,IC50,nM,1870.0,IC50,uM,1.87,O=c1oc2ccccc2c2nn(S(=O)(=O)c3ccc(Cl)c([N+](=O)[O-])c3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",Cc1cc(C)c(S(=O)(=O)n2cc3c(=O)oc4ccccc4c3n2)c(C)c1,CHEMBL4340546,=,=,IC50,nM,800.0,IC50,uM,0.8,Cc1cc(C)c(S(=O)(=O)n2cc3c(=O)oc4ccccc4c3n2)c(C)c1,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",CC(C)c1cc(C(C)C)c(S(=O)(=O)n2cc3c(=O)oc4ccccc4c3n2)c(C(C)C)c1,CHEMBL4340546,=,=,IC50,nM,280.0,IC50,uM,0.28,CC(C)c1cc(C(C)C)c(S(=O)(=O)n2cc3c(=O)oc4ccccc4c3n2)c(C(C)C)c1,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs by fluorescence polarization assay",O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL4340546,=,=,IC50,nM,940.0,IC50,uM,0.94,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2019
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual bound protein level at 10 uM by Kinomescan method relative to control,COc1ccc2c3ccnc(C)c3n(CCCC(N)=O)c2c1,CHEMBL4342463,=,=,Activity,%,13.0,Activity,%,13.0,COc1ccc2c3ccnc(C)c3n(CCCC(N)=O)c2c1,2020
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual bound protein level at 10 uM by Kinomescan method relative to control,COc1ccc2c(c1)[nH]c1c(C)nccc12,CHEMBL4342463,=,=,Activity,%,49.0,Activity,%,49.0,COc1ccc2c(c1)[nH]c1c(C)nccc12,2020
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual bound protein level at 10 uM by Kinomescan method relative to control,COc1ccc2c(c1)[nH]c1c(CO)nccc12,CHEMBL4342463,=,=,Activity,%,44.0,Activity,%,44.0,COc1ccc2c(c1)[nH]c1c(CO)nccc12,2020
Inhibition of PI3Kgamma (unknown origin),CC(c1cc2ccccn2c1-c1ccc(=O)n(CCN2CCOCC2)n1)n1nc(-c2cc(O)cc(F)c2)c2c(N)ncnc21,CHEMBL4350952,<,<,IC50,nM,10.0,IC50,nM,10.0,CC(c1cc2ccccn2c1-c1ccc(=O)n(CCN2CCOCC2)n1)n1nc(-c2cc(O)cc(F)c2)c2c(N)ncnc21,2019
Inhibition of PI3Kgamma (unknown origin),C[C@H](Nc1ncnc(N)c1C#N)c1cc2ncc(Cl)n2cc1-c1ccccc1,CHEMBL4350952,=,=,IC50,nM,87.0,IC50,nM,87.0,C[C@H](Nc1ncnc(N)c1C#N)c1cc2ncc(Cl)n2cc1-c1ccccc1,2019
Inhibition of PI3Kgamma (unknown origin),N#Cc1c[nH]c2ncnc(N3CCC[C@H]3c3nn4cccc4c(=O)n3-c3ccccc3)c12,CHEMBL4350952,=,=,IC50,nM,42.0,IC50,nM,42.0,N#Cc1c[nH]c2ncnc(N3CCC[C@H]3c3nn4cccc4c(=O)n3-c3ccccc3)c12,2019
Inhibition of PI3Kgamma (unknown origin),CC(c1oc(=O)c2ccccc2c1C1=CCN(C)CC1)n1nc(-c2cc(O)cc(F)c2)c2c(N)ncnc21,CHEMBL4350952,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC(c1oc(=O)c2ccccc2c1C1=CCN(C)CC1)n1nc(-c2cc(O)cc(F)c2)c2c(N)ncnc21,2019
Inhibition of PI3Kgamma (unknown origin),Cc1nc(N)nc(N[C@@H](C)c2c(-c3ccccc3)c(=O)n3cc(F)ccc3c2-c2ccc(F)cc2)c1C#N,CHEMBL4350952,=,=,IC50,nM,90.0,IC50,nM,90.0,Cc1nc(N)nc(N[C@@H](C)c2c(-c3ccccc3)c(=O)n3cc(F)ccc3c2-c2ccc(F)cc2)c1C#N,2019
Inhibition of PI3Kgamma (unknown origin),CC(Nc1nc(N)nc(N)c1C#N)c1c(-c2ccccc2)[nH]c2c(Cl)cccc2c1=O,CHEMBL4350952,=,=,IC50,nM,5.7,IC50,nM,5.7,CC(Nc1nc(N)nc(N)c1C#N)c1c(-c2ccccc2)[nH]c2c(Cl)cccc2c1=O,2019
Inhibition of PI3Kgamma (unknown origin),CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,CHEMBL4350952,=,=,IC50,nM,33.0,IC50,nM,33.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,2019
Inhibition of PI3Kgamma in basophil derived from B-cell malignant patient,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4350952,=,=,IC50,nM,89.0,IC50,nM,89.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2019
Inhibition of PI3Kgamma in basophil derived from B-cell malignant patient,Cc1csc2nc([C@H](C)Nc3ncnc4[nH]cnc34)c(-c3cccc(F)c3)c(=O)n12,CHEMBL4350952,=,=,IC50,nM,2300.0,IC50,nM,2300.0,Cc1csc2nc([C@H](C)Nc3ncnc4[nH]cnc34)c(-c3cccc(F)c3)c(=O)n12,2019
Inhibition of recombinant N-terminal His-tagged full length human PI3Kgamma expressed in baculovirus expression system after 80 mins by fluorescence polarization assay,C[C@H]1CN(c2nc(N)nc3c2S(=O)(=O)CC3)[C@@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4350952,=,=,IC50,nM,3.0,IC50,nM,3.0,C[C@H]1CN(c2nc(N)nc3c2S(=O)(=O)CC3)[C@@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,2019
Inhibition of recombinant N-terminal His-tagged full length human PI3Kgamma expressed in baculovirus expression system after 80 mins by fluorescence polarization assay,C[C@H](Nc1ncnc(N)c1C#N)c1cc2ncc(Cl)n2nc1-c1ccccc1,CHEMBL4350952,=,=,IC50,nM,38.0,IC50,nM,38.0,C[C@H](Nc1ncnc(N)c1C#N)c1cc2ncc(Cl)n2nc1-c1ccccc1,2019
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 10 mins followed by ATP addition measured after 30 mins by HTRF assay,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,CHEMBL4350952,>,>,IC50,nM,120.0,IC50,nM,120.0,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,2019
Inhibition of GST-tagged PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 2 hrs followed by ATP addition measured after 30 mins by TR-FRET assay,C[C@H](Nc1ncnc2[nH]cnc12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1,CHEMBL4350952,=,=,IC50,nM,3000.0,IC50,nM,3000.0,C[C@H](Nc1ncnc2[nH]cnc12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1,2019
Inhibition of PI3Kgamma in human Neutrophil cells,[O-][n+]1cccc(-c2nc3c(Cl)cccc3cc2[C@@H](Nc2ncnc3cccnc23)C(F)(F)F)c1,CHEMBL4350952,=,=,IC50,nM,280.0,IC50,nM,280.0,[O-][n+]1cccc(-c2nc3c(Cl)cccc3cc2[C@@H](Nc2ncnc3cccnc23)C(F)(F)F)c1,2019
Inhibition of PI3Kgamma in human Raji cells,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4350952,=,=,IC50,nM,27.0,IC50,nM,27.0,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2019
Inhibition of GST-tagged PI3Kgamma in human U937 cells using PIP2 as substrate preincubated for 10 mins followed by ATP addition measured after 30 mins by HTRF assay,COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3ccccc3Cl)c(=O)c12,CHEMBL4350952,=,=,IC50,nM,25.0,IC50,nM,25.0,COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc43)n(Cc3ccccc3Cl)c(=O)c12,2019
Inhibition of GST-tagged PI3Kgamma in human U937 cells using PIP2 as substrate preincubated for 10 mins followed by ATP addition measured after 30 mins by HTRF assay,COCCOCCOCC#Cc1cccc2nc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(Cc3ccccc3C(F)(F)F)c(=O)c12,CHEMBL4350952,=,=,IC50,nM,28.0,IC50,nM,28.0,COCCOCCOCC#Cc1cccc2nc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc43)n(Cc3ccccc3C(F)(F)F)c(=O)c12,2019
Inhibition of PI3Kgamma in human SUDHL6 cells,C[C@H](Nc1ncnc2[nH]cnc12)C1=Nc2cccc(Cl)c2S(=O)(=O)N1c1ccccc1,CHEMBL4350952,=,=,IC50,nM,34.0,IC50,nM,34.0,C[C@H](Nc1ncnc2[nH]cnc12)C1=Nc2cccc(Cl)c2S(=O)(=O)N1c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4350965,=,=,IC50,nM,104.0,IC50,uM,0.104,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4350965,=,=,IC50,nM,2.0,IC50,uM,0.002,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,O=c1c2c(Cl)ccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,CHEMBL4350965,=,=,IC50,nM,12.0,IC50,uM,0.012,O=c1c2c(Cl)ccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,N#Cc1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,=,=,IC50,nM,4.0,IC50,uM,0.004,N#Cc1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,O=c1c2c(F)ccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,CHEMBL4350965,=,=,IC50,nM,67.0,IC50,uM,0.067,O=c1c2c(F)ccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,O=c1c2cccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,CHEMBL4350965,=,=,IC50,nM,108.0,IC50,uM,0.108,O=c1c2cccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,O=c1c2c(Cl)ccn2nc([C@@H]2C[C@H](F)CN2c2ncnc3[nH]cnc23)n1-c1ccccc1,CHEMBL4350965,=,=,IC50,nM,16.0,IC50,uM,0.016,O=c1c2c(Cl)ccn2nc([C@@H]2C[C@H](F)CN2c2ncnc3[nH]cnc23)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,O=c1c2c(Cl)ccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1cccc(F)c1,CHEMBL4350965,=,=,IC50,nM,11.0,IC50,uM,0.011,O=c1c2c(Cl)ccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1cccc(F)c1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,N#Cc1c[nH]c2ncnc(N3CCC[C@H]3c3nn4cccc4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,=,=,IC50,nM,19.0,IC50,uM,0.019,N#Cc1c[nH]c2ncnc(N3CCC[C@H]3c3nn4cccc4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,N#Cc1c[nH]c2ncnc(N3C[C@@H](F)C[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,=,=,IC50,nM,3.0,IC50,uM,0.003,N#Cc1c[nH]c2ncnc(N3C[C@@H](F)C[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,CC(=O)c1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,=,=,IC50,nM,2.0,IC50,uM,0.002,CC(=O)c1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,CC(=O)c1c[nH]c2ncnc(N3C[C@@H](F)C[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,=,=,IC50,nM,13.0,IC50,uM,0.013,CC(=O)c1c[nH]c2ncnc(N3C[C@@H](F)C[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,CC(=O)c1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3cccc(F)c3)c12,CHEMBL4350965,=,=,IC50,nM,6.0,IC50,uM,0.006,CC(=O)c1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3cccc(F)c3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,CC(=O)c1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(F)c4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,=,=,IC50,nM,4.0,IC50,uM,0.004,CC(=O)c1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(F)c4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,N#Cc1cnc(N)nc1N1CCC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4350965,=,=,IC50,nM,7.0,IC50,uM,0.007,N#Cc1cnc(N)nc1N1CCC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,O=c1c2c(Cl)ccn2nc([C@@H]2CCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,CHEMBL4350965,=,=,IC50,nM,271.0,IC50,uM,0.271,O=c1c2c(Cl)ccn2nc([C@@H]2CCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,N#Cc1c[nH]c2ncnc(N3CC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,=,=,IC50,nM,34.0,IC50,uM,0.034,N#Cc1c[nH]c2ncnc(N3CC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,CC(=O)c1c[nH]c2ncnc(N3CC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,=,=,IC50,nM,5.0,IC50,uM,0.005,CC(=O)c1c[nH]c2ncnc(N3CC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,N#Cc1cnc(N)nc1N1CC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4350965,=,=,IC50,nM,27.0,IC50,uM,0.027,N#Cc1cnc(N)nc1N1CC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,Nc1ncc(Cl)c(N2CC[C@H]2c2nn3ccc(Cl)c3c(=O)n2-c2ccccc2)n1,CHEMBL4350965,=,=,IC50,nM,182.0,IC50,uM,0.182,Nc1ncc(Cl)c(N2CC[C@H]2c2nn3ccc(Cl)c3c(=O)n2-c2ccccc2)n1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,C#Cc1cnc(N)nc1N1CC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4350965,=,=,IC50,nM,52.0,IC50,uM,0.052,C#Cc1cnc(N)nc1N1CC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,CC(=O)c1cnc(N)nc1N1CC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4350965,=,=,IC50,nM,4.0,IC50,uM,0.004,CC(=O)c1cnc(N)nc1N1CC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay,Nc1ncc(C(=O)C(F)(F)F)c(N2CC[C@H]2c2nn3ccc(Cl)c3c(=O)n2-c2ccccc2)n1,CHEMBL4350965,=,=,IC50,nM,43.0,IC50,uM,0.043,Nc1ncc(C(=O)C(F)(F)F)c(N2CC[C@H]2c2nn3ccc(Cl)c3c(=O)n2-c2ccccc2)n1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4350965,<,<,Inhibition,%,50.0,INH,%,50.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4350965,=,=,Inhibition,%,81.0,INH,%,81.0,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,O=c1c2c(Cl)ccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,CHEMBL4350965,<,<,Inhibition,%,50.0,INH,%,50.0,O=c1c2c(Cl)ccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,N#Cc1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,<,<,Inhibition,%,50.0,INH,%,50.0,N#Cc1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,O=c1c2c(F)ccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,CHEMBL4350965,<,<,Inhibition,%,50.0,INH,%,50.0,O=c1c2c(F)ccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,O=c1c2cccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,CHEMBL4350965,=,=,Inhibition,%,14.4,INH,%,14.4,O=c1c2cccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,O=c1c2c(Cl)ccn2nc([C@@H]2C[C@H](F)CN2c2ncnc3[nH]cnc23)n1-c1ccccc1,CHEMBL4350965,<,<,Inhibition,%,50.0,INH,%,50.0,O=c1c2c(Cl)ccn2nc([C@@H]2C[C@H](F)CN2c2ncnc3[nH]cnc23)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,O=c1c2c(Cl)ccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1cccc(F)c1,CHEMBL4350965,<,<,Inhibition,%,50.0,INH,%,50.0,O=c1c2c(Cl)ccn2nc([C@@H]2CCCN2c2ncnc3[nH]cnc23)n1-c1cccc(F)c1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,N#Cc1c[nH]c2ncnc(N3CCC[C@H]3c3nn4cccc4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,=,=,Inhibition,%,21.2,INH,%,21.2,N#Cc1c[nH]c2ncnc(N3CCC[C@H]3c3nn4cccc4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,N#Cc1c[nH]c2ncnc(N3C[C@@H](F)C[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,<,<,Inhibition,%,50.0,INH,%,50.0,N#Cc1c[nH]c2ncnc(N3C[C@@H](F)C[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,CC(=O)c1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,<,<,Inhibition,%,50.0,INH,%,50.0,CC(=O)c1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,CC(=O)c1c[nH]c2ncnc(N3C[C@@H](F)C[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,<,<,Inhibition,%,50.0,INH,%,50.0,CC(=O)c1c[nH]c2ncnc(N3C[C@@H](F)C[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,CC(=O)c1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3cccc(F)c3)c12,CHEMBL4350965,<,<,Inhibition,%,50.0,INH,%,50.0,CC(=O)c1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(Cl)c4c(=O)n3-c3cccc(F)c3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,CC(=O)c1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(F)c4c(=O)n3-c3ccccc3)c12,CHEMBL4350965,<,<,Inhibition,%,50.0,INH,%,50.0,CC(=O)c1c[nH]c2ncnc(N3CCC[C@H]3c3nn4ccc(F)c4c(=O)n3-c3ccccc3)c12,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,N#Cc1cnc(N)nc1N1CCC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4350965,<,<,Inhibition,%,50.0,INH,%,50.0,N#Cc1cnc(N)nc1N1CCC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,CS(=O)(=O)c1cnc(N)nc1N1CC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4350965,=,=,Inhibition,%,20.4,INH,%,20.4,CS(=O)(=O)c1cnc(N)nc1N1CC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,2019
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control,Nc1ncc(C(=O)C2CC2)c(N2CC[C@H]2c2nn3ccc(Cl)c3c(=O)n2-c2ccccc2)n1,CHEMBL4350965,=,=,Inhibition,%,50.7,INH,%,50.7,Nc1ncc(C(=O)C2CC2)c(N2CC[C@H]2c2nn3ccc(Cl)c3c(=O)n2-c2ccccc2)n1,2019
Inhibition of PI3Kgamma in human whole blood assessed as reduction in anti-IgE-stimulated CD63 expression in basophils preincubated for 30 mins followed by anti-IgE stimulation,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4350965,=,=,IC50,nM,15.0,IC50,uM,0.015,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,2019
Inhibition of PI3Kgamma in human whole blood assessed as reduction in anti-IgE-stimulated CD63 expression in basophils preincubated for 30 mins followed by anti-IgE stimulation,CC(=O)c1cnc(N)nc1N1CC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4350965,=,=,IC50,nM,42.0,IC50,uM,0.042,CC(=O)c1cnc(N)nc1N1CC[C@H]1c1nn2ccc(Cl)c2c(=O)n1-c1ccccc1,2019
Inhibition of His-tagged recombinant human PIK3CG expressed in Baculovirus expression system,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4354810,=,=,IC50,nM,2100.0,IC50,uM,2.1,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2020
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl,CHEMBL4354843,=,=,Activity,%,100.0,Activity,%,100.0,C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl,2020
Inhibition of recombinant human full-length His-tagged p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 1 hr by ADP-glo assay,COc1ncc(-c2ccc3ncc(-c4nnc(CCN5CCN(C)CC5)o4)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4354853,=,=,IC50,nM,1.2,IC50,nM,1.2,COc1ncc(-c2ccc3ncc(-c4nnc(CCN5CCN(C)CC5)o4)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2020
Inhibition of recombinant human full-length His-tagged p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 1 hr by ADP-glo assay,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,CHEMBL4354853,=,=,IC50,nM,1.68,IC50,nM,1.68,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,2020
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,COc1ncc(-c2ccc3ncc(-c4nnc(CCN5CCN(C)CC5)o4)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4354853,=,=,Activity,%,0.05,Activity,%,0.05,COc1ncc(-c2ccc3ncc(-c4nnc(CCN5CCN(C)CC5)o4)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2020
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system by quantitative PCR based KINOMEscan assay,C[C@H]1COCCN1c1nc(-c2cnc(N)cc2C(F)F)nc(N2CCOCC2)n1,CHEMBL4359834,=,=,Kd,nM,10.0,Kd,nM,10.0,C[C@H]1COCCN1c1nc(-c2cnc(N)cc2C(F)F)nc(N2CCOCC2)n1,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",CC(C)(C)c1ccc(S(=O)(=O)N2CCN(Cn3cc4c(=O)oc5ccccc5c4n3)CC2)cc1,CHEMBL4359902,=,=,IC50,nM,1320.0,IC50,uM,1.32,CC(C)(C)c1ccc(S(=O)(=O)N2CCN(Cn3cc4c(=O)oc5ccccc5c4n3)CC2)cc1,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccc(F)cc4)CC3)cc12,CHEMBL4359902,=,=,IC50,nM,7510.0,IC50,uM,7.51,O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccc(F)cc4)CC3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccc(Cl)cc4)CC3)cc12,CHEMBL4359902,=,=,IC50,nM,2650.0,IC50,uM,2.65,O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccc(Cl)cc4)CC3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccc(Br)cc4)CC3)cc12,CHEMBL4359902,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccc(Br)cc4)CC3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccc([N+](=O)[O-])cc4)CC3)cc12,CHEMBL4359902,=,=,IC50,nM,4010.0,IC50,uM,4.01,O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccc([N+](=O)[O-])cc4)CC3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4cccc([N+](=O)[O-])c4)CC3)cc12,CHEMBL4359902,=,=,IC50,nM,9340.0,IC50,uM,9.34,O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4cccc([N+](=O)[O-])c4)CC3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccccc4[N+](=O)[O-])CC3)cc12,CHEMBL4359902,=,=,IC50,nM,8420.0,IC50,uM,8.42,O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccccc4[N+](=O)[O-])CC3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccc(C(F)(F)F)cc4)CC3)cc12,CHEMBL4359902,=,=,IC50,nM,2300.0,IC50,uM,2.3,O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccc(C(F)(F)F)cc4)CC3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",Cc1ccc(C)c(S(=O)(=O)N2CCN(Cn3cc4c(=O)oc5ccccc5c4n3)CC2)c1,CHEMBL4359902,=,=,IC50,nM,810.0,IC50,uM,0.81,Cc1ccc(C)c(S(=O)(=O)N2CCN(Cn3cc4c(=O)oc5ccccc5c4n3)CC2)c1,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccc(Cl)c([N+](=O)[O-])c4)CC3)cc12,CHEMBL4359902,=,=,IC50,nM,81.0,IC50,uM,0.081,O=c1oc2ccccc2c2nn(CN3CCN(S(=O)(=O)c4ccc(Cl)c([N+](=O)[O-])c4)CC3)cc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",Cc1cc(C)c(S(=O)(=O)N2CCN(Cn3cc4c(=O)oc5ccccc5c4n3)CC2)c(C)c1,CHEMBL4359902,=,=,IC50,nM,140.0,IC50,uM,0.14,Cc1cc(C)c(S(=O)(=O)N2CCN(Cn3cc4c(=O)oc5ccccc5c4n3)CC2)c(C)c1,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",CC(C)c1cc(C(C)C)c(S(=O)(=O)N2CCN(Cn3cc4c(=O)oc5ccccc5c4n3)CC2)c(C(C)C)c1,CHEMBL4359902,=,=,IC50,nM,110.0,IC50,uM,0.11,CC(C)c1cc(C(C)C)c(S(=O)(=O)N2CCN(Cn3cc4c(=O)oc5ccccc5c4n3)CC2)c(C(C)C)c1,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL4359902,=,=,IC50,nM,950.0,IC50,uM,0.95,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2019
"Inhibition of PI3Kgamma (unknown origin) using diC8-PI(4,5)P2 as substrate incubated for 3 hrs in presence of ATP by fluorescence polarization assay",Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4359902,=,=,IC50,nM,27.0,IC50,uM,0.027,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2019
Inhibition of wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by Kinomescan method relative to control,O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1,CHEMBL4364269,=,=,Activity,%,30.0,Activity,%,30.0,O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1,2019
Inhibition of recombinant human full length N-terminal DYKDDDDK-tagged PI3Kgamma (1 to 1102 residues) expressed in baculovirus expression system using PIP2 as substrate incubated for 2 hrs by ADP-Glo assay,COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1,CHEMBL4364276,=,=,IC50,nM,22.0,IC50,nM,22.0,COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1,2019
Inhibition of recombinant human full length N-terminal DYKDDDDK-tagged PI3Kgamma (1 to 1102 residues) expressed in baculovirus expression system using PIP2 as substrate incubated for 2 hrs by ADP-Glo assay,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4364276,=,=,IC50,nM,104.2,IC50,nM,104.2,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2019
Inhibition of recombinant human full length N-terminal DYKDDDDK-tagged PI3Kgamma (1 to 1102 residues) expressed in baculovirus expression system using PIP2 as substrate incubated for 2 hrs by ADP-Glo assay,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL4364276,=,=,IC50,nM,64.03,IC50,nM,64.03,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2019
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 2 hrs by ADP-Glo assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4368891,=,=,IC50,nM,60.0,IC50,nM,60.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2019
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 2 hrs by ADP-Glo assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(F)c2c(=O)n1C1CCCC1,CHEMBL4368891,=,=,IC50,nM,354.0,IC50,nM,354.0,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(F)c2c(=O)n1C1CCCC1,2019
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 2 hrs by ADP-Glo assay,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(F)c2c(=O)n1Cc1ccccc1,CHEMBL4368891,=,=,IC50,nM,587.0,IC50,nM,587.0,N#Cc1c(N)ncnc1N1CCC[C@H]1c1nc2cccc(F)c2c(=O)n1Cc1ccccc1,2019
Inhibition of recombinant human PI3Kgamma using PIP2 as substrate after 35 to 40 mins by HTRF assay,COc1ncc(N2CCc3ncnc(-c4ccnc(NC5CCOCC5)c4)c3C2)cc1C,CHEMBL4368932,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COc1ncc(N2CCc3ncnc(-c4ccnc(NC5CCOCC5)c4)c3C2)cc1C,2019
Inhibition of recombinant human PI3Kgamma using PIP2 as substrate after 35 to 40 mins by HTRF assay,COCC(=O)N1CCC(Nc2cc(-c3ncnc4c3CN(c3cnc(OC)c(C)c3)CC4)ccn2)CC1,CHEMBL4368932,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COCC(=O)N1CCC(Nc2cc(-c3ncnc4c3CN(c3cnc(OC)c(C)c3)CC4)ccn2)CC1,2019
Inhibition of recombinant human PI3Kgamma using PIP2 as substrate after 35 to 40 mins by HTRF assay,COc1ncc(N2CCc3ncnc(-c4ccnc(NC5CCN(C)CC5)c4)c3C2)cc1C,CHEMBL4368932,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COc1ncc(N2CCc3ncnc(-c4ccnc(NC5CCN(C)CC5)c4)c3C2)cc1C,2019
Inhibition of recombinant human PI3Kgamma using PIP2 as substrate after 35 to 40 mins by HTRF assay,COc1ncc(N2CCc3ncnc(-c4ccnc(NC5CCNCC5)c4)c3C2)cc1C,CHEMBL4368932,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COc1ncc(N2CCc3ncnc(-c4ccnc(NC5CCNCC5)c4)c3C2)cc1C,2019
Inhibition of recombinant human PI3Kgamma using PIP2 as substrate after 35 to 40 mins by HTRF assay,CCN1CCC(Nc2cc(-c3ncnc4c3CN(c3cnc(OC)c(C)c3)CC4)ccn2)CC1,CHEMBL4368932,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CCN1CCC(Nc2cc(-c3ncnc4c3CN(c3cnc(OC)c(C)c3)CC4)ccn2)CC1,2019
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system measured after 1 hr by kinomescan method,O=C(Nc1ccc2cc(C(=O)Nc3nccs3)ccc2c1)c1ccc(Cl)c(Cl)c1,CHEMBL4373706,=,=,Kd,nM,7110.0,Kd,uM,7.11,O=C(Nc1ccc2cc(C(=O)Nc3nccs3)ccc2c1)c1ccc(Cl)c(Cl)c1,2019
Inhibition of PI3Kgamma (unknown origin),CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4373732,=,=,IC50,nM,580.0,IC50,nM,580.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2019
Reversible competitive inhibition of PI3K p110gamma (unknown origin),COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,CHEMBL4373732,=,=,IC50,nM,383.0,IC50,nM,383.0,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,2019
Inhibition of PI3K p110gamma (unknown origin),CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21,CHEMBL4373732,=,=,IC50,nM,9.0,IC50,nM,9.0,CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21,2019
Competitive inhibition of PI3Kgamma (unknown origin),FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,CHEMBL4373732,=,=,IC50,nM,49.0,IC50,nM,49.0,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,2019
Inhibition of PI3K p110gamma (unknown origin),Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,CHEMBL4373732,=,=,IC50,nM,256.0,IC50,nM,256.0,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,2019
Inhibition of PI3Kgamma (unknown origin),CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,CHEMBL4373732,=,=,IC50,nM,33.2,IC50,nM,33.2,CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,2019
Inhibition of PI3Kgamma (unknown origin),COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,CHEMBL4373732,=,=,IC50,nM,0.7,IC50,nM,0.7,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,2019
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 1 hr by ADP-glo plus luminescence assay,Nc1cc(C(F)(F)F)c(-c2nc3c(c(N4CCOCC4)n2)CCN(C(=O)c2cc(Cc4n[nH]c(=O)c5ccccc45)ccc2F)C3)cn1,CHEMBL4376860,=,=,IC50,nM,831.76,pIC50,,6.08,Nc1cc(C(F)(F)F)c(-c2nc3c(c(N4CCOCC4)n2)CCN(C(=O)c2cc(Cc4n[nH]c(=O)c5ccccc45)ccc2F)C3)cn1,2020
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 1 hr by ADP-glo plus luminescence assay,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,CHEMBL4376860,=,=,IC50,nM,263.03,pIC50,,6.58,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,2020
Inhibition of PI3Kgamma (unknown origin),C[C@@H]1COCCN1c1nc(N2CCOC[C@@H]2C)nc2sc(-c3cc[nH]n3)nc12,CHEMBL4376889,>,>,IC50,nM,10000.0,IC50,uM,10.0,C[C@@H]1COCCN1c1nc(N2CCOC[C@@H]2C)nc2sc(-c3cc[nH]n3)nc12,2020
Inhibition of PI3Kgamma (unknown origin),C[C@@H]1COCCN1c1nc(N2CCOC[C@@H]2C)nc2[nH]c(-c3cccc4[nH]ccc34)nc12,CHEMBL4376889,=,=,IC50,nM,6600.0,IC50,uM,6.6,C[C@@H]1COCCN1c1nc(N2CCOC[C@@H]2C)nc2[nH]c(-c3cccc4[nH]ccc34)nc12,2020
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,=,=,Activity,%,98.0,Activity,%,98.0,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C,2017
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,COc1ncc(C2=CCOCC2)cc1NS(=O)(=O)c1cn(Cc2ccccc2)c(C)n1,CHEMBL4382269,=,=,IC50,nM,1000.0,pIC50,,6.0,COc1ncc(C2=CCOCC2)cc1NS(=O)(=O)c1cn(Cc2ccccc2)c(C)n1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,COc1ncc(C2=CCOCC2)cc1NS(=O)(=O)c1ccccc1,CHEMBL4382269,=,=,IC50,nM,1258.93,pIC50,,5.9,COc1ncc(C2=CCOCC2)cc1NS(=O)(=O)c1ccccc1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,O=S(=O)(Nc1cc(-c2ccccc2)cnc1Cl)c1ccccc1,CHEMBL4382269,=,=,IC50,nM,12589.25,pIC50,,4.9,O=S(=O)(Nc1cc(-c2ccccc2)cnc1Cl)c1ccccc1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,O=S(=O)(Nc1cc(C2=CCOCC2)cnc1Cl)c1ccccc1,CHEMBL4382269,=,=,IC50,nM,501.19,pIC50,,6.3,O=S(=O)(Nc1cc(C2=CCOCC2)cnc1Cl)c1ccccc1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,CS(=O)(=O)Nc1cc(-c2cnc(N)nc2)cnc1Cl,CHEMBL4382269,=,=,IC50,nM,199.53,pIC50,,6.7,CS(=O)(=O)Nc1cc(-c2cnc(N)nc2)cnc1Cl,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,CS(=O)(=O)Nc1cc(C2=CCOCC2)cnc1Cl,CHEMBL4382269,=,=,IC50,nM,3162.28,pIC50,,5.5,CS(=O)(=O)Nc1cc(C2=CCOCC2)cnc1Cl,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,c1cc(-c2ccc3ccncc3c2)c2cc[nH]c2c1,CHEMBL4382269,=,=,IC50,nM,15848.93,pIC50,,4.8,c1cc(-c2ccc3ccncc3c2)c2cc[nH]c2c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,CS(=O)(=O)Nc1cc(-c2ccc3ccncc3c2)cnc1Cl,CHEMBL4382269,=,=,IC50,nM,794.33,pIC50,,6.1,CS(=O)(=O)Nc1cc(-c2ccc3ccncc3c2)cnc1Cl,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,c1cc(-c2ccncc2)c2cc[nH]c2c1,CHEMBL4382269,<,>,IC50,nM,50118.72,pIC50,,4.3,c1cc(-c2ccncc2)c2cc[nH]c2c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,CS(=O)(=O)Nc1cc(-c2ccncc2)cnc1Cl,CHEMBL4382269,=,=,IC50,nM,3981.07,pIC50,,5.4,CS(=O)(=O)Nc1cc(-c2ccncc2)cnc1Cl,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,CS(=O)(=O)Nc1cc(-c2ccc3cn[nH]c3c2)cnc1Cl,CHEMBL4382269,=,=,IC50,nM,2511.89,pIC50,,5.6,CS(=O)(=O)Nc1cc(-c2ccc3cn[nH]c3c2)cnc1Cl,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,c1cc(-c2nnc(CN3CCOCC3)o2)c2cn[nH]c2c1,CHEMBL4382269,=,=,IC50,nM,25118.86,pIC50,,4.6,c1cc(-c2nnc(CN3CCOCC3)o2)c2cn[nH]c2c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,COc1ncc(-c2ccc3cn[nH]c3c2)cc1NS(C)(=O)=O,CHEMBL4382269,=,=,IC50,nM,2511.89,pIC50,,5.6,COc1ncc(-c2ccc3cn[nH]c3c2)cc1NS(C)(=O)=O,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,c1cc(-c2ccc3cn[nH]c3c2)c2cc[nH]c2c1,CHEMBL4382269,<,>,IC50,nM,158489.32,pIC50,,3.8,c1cc(-c2ccc3cn[nH]c3c2)c2cc[nH]c2c1,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,COc1ncc(-c2cc(-c3ncc(CN4C[C@@H](C)O[C@@H](C)C4)o3)c3cn[nH]c3c2)cc1NS(C)(=O)=O,CHEMBL4382269,=,=,IC50,nM,316.23,pIC50,,6.5,COc1ncc(-c2cc(-c3ncc(CN4C[C@@H](C)O[C@@H](C)C4)o3)c3cn[nH]c3c2)cc1NS(C)(=O)=O,2018
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by HTRF method,CC(C)N1CCN(Cc2cnc(-c3cc(-c4cccc5[nH]ccc45)cc4[nH]ncc34)o2)CC1,CHEMBL4382269,=,=,IC50,nM,6309.57,pIC50,,5.2,CC(C)N1CCN(Cc2cnc(-c3cc(-c4cccc5[nH]ccc45)cc4[nH]ncc34)o2)CC1,2018
Inhibition of PI3Kgamma in human THP1 cells assessed as reduction in MCP1-induced Akt phosphorylation at Thr308/Ser473 residue preincubated for 1 hr followed by MCP1 stimulation for 3 mins by FACS analysis,COc1cc(-c2cc3c(c(C)n2)C(=O)N(c2cnn(CC(F)(F)F)c2)C3)cnc1OC,CHEMBL4382294,=,=,IC50,nM,270.0,IC50,nM,270.0,COc1cc(-c2cc3c(c(C)n2)C(=O)N(c2cnn(CC(F)(F)F)c2)C3)cnc1OC,2019
Inhibition of PI3Kgamma in human THP1 cells assessed as reduction in MCP1-induced Akt phosphorylation at Thr308/Ser473 residue preincubated for 1 hr followed by MCP1 stimulation for 3 mins by FACS analysis,COc1cc(-c2ccc3c(n2)CN(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,CHEMBL4382294,=,=,IC50,nM,47.0,IC50,nM,47.0,COc1cc(-c2ccc3c(n2)CN(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,2019
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 15 mins in presence of [33P]ATP by scintillation counting method,COc1cc(-c2cc3c(c(C)n2)C(=O)N(c2cnn(CC(F)(F)F)c2)C3)cnc1OC,CHEMBL4382294,=,=,Ki,nM,14.0,Ki,nM,14.0,COc1cc(-c2cc3c(c(C)n2)C(=O)N(c2cnn(CC(F)(F)F)c2)C3)cnc1OC,2019
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 15 mins in presence of [33P]ATP by scintillation counting method,COc1cc(-c2ccc3c(n2)CN(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,CHEMBL4382294,=,=,Ki,nM,4.0,Ki,nM,4.0,COc1cc(-c2ccc3c(n2)CN(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC,2019
Inhibition of His-tagged recombinant human full length PI3K p110gamma expressed in baculovirus expression system using lipid substrate incubated for 2 hrs by ADP-Glo assay,C[C@H](Nc1ncnc2[nH]cnc12)C1=Nc2cccc(Cl)c2S(=O)(=O)N1c1ccccc1,CHEMBL4385593,=,=,IC50,nM,156.0,IC50,nM,156.0,C[C@H](Nc1ncnc2[nH]cnc12)C1=Nc2cccc(Cl)c2S(=O)(=O)N1c1ccccc1,2019
Inhibition of His-tagged recombinant human full length PI3K p110gamma expressed in baculovirus expression system using lipid substrate incubated for 2 hrs by ADP-Glo assay,C[C@@H](Nc1ncnc2[nH]cnc12)C1=Nc2cccc(Cl)c2S(=O)(=O)N1c1ccccc1,CHEMBL4385593,=,=,IC50,nM,1905.0,IC50,nM,1905.0,C[C@@H](Nc1ncnc2[nH]cnc12)C1=Nc2cccc(Cl)c2S(=O)(=O)N1c1ccccc1,2019
Inhibition of His-tagged recombinant human full length PI3K p110gamma expressed in baculovirus expression system using lipid substrate incubated for 2 hrs by ADP-Glo assay,C[C@H](Nc1ncnc(N)c1C#N)C1=Nc2cccc(Cl)c2S(=O)(=O)N1c1ccccc1,CHEMBL4385593,=,=,IC50,nM,100.0,IC50,nM,100.0,C[C@H](Nc1ncnc(N)c1C#N)C1=Nc2cccc(Cl)c2S(=O)(=O)N1c1ccccc1,2019
Inhibition of His-tagged recombinant human full length PI3K p110gamma expressed in baculovirus expression system using lipid substrate incubated for 2 hrs by ADP-Glo assay,C[C@@H](Nc1ncnc(N)c1C#N)C1=Nc2cccc(Cl)c2S(=O)(=O)N1c1ccccc1,CHEMBL4385593,=,=,IC50,nM,112.0,IC50,nM,112.0,C[C@@H](Nc1ncnc(N)c1C#N)C1=Nc2cccc(Cl)c2S(=O)(=O)N1c1ccccc1,2019
Inhibition of His-tagged recombinant human full length PI3K p110gamma expressed in baculovirus expression system using lipid substrate incubated for 2 hrs by ADP-Glo assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4385593,=,=,IC50,nM,63.0,IC50,nM,63.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2019
Inhibition of recombinant human GST-tagged PI3Kgamma catalytic domain (468 to 1203 residues) expressed in insect expression system at 0.1 uM using PI Lipid Kinase as substrate incubated for 60 mins by Adapta assay relative to control,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,CHEMBL4385643,=,=,Inhibition,%,-6.3,INH,%,-6.3,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,2019
Inhibition of recombinant human GST-tagged PI3Kgamma catalytic domain (468 to 1203 residues) expressed in insect expression system at 0.1 uM using PI Lipid Kinase as substrate incubated for 60 mins by Adapta assay relative to control,CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2,CHEMBL4385643,=,=,Inhibition,%,2.0,INH,%,2.0,CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2,2019
Inhibition of wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control,O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1,CHEMBL4387741,=,=,Inhibition,%,75.0,INH,%,75.0,O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1,2019
Inhibition of wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control,O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1,CHEMBL4387741,=,=,Inhibition,%,84.0,INH,%,84.0,O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1,2019
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control,O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O,CHEMBL4390652,=,=,Activity,%,100.0,Activity,%,100.0,O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O,2019
Inhibition of human PI3Kgamma using PIP2 as substrate after 1 hr,COc1ccc(Cn2c(=O)n(C)c3c4cc(-c5cnc6ccccc6c5)ccc4ncc32)cc1,CHEMBL4390691,=,=,IC50,nM,38.0,IC50,nM,38.0,COc1ccc(Cn2c(=O)n(C)c3c4cc(-c5cnc6ccccc6c5)ccc4ncc32)cc1,2019
Inhibition of human PI3Kgamma using PIP2 as substrate after 1 hr,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4390691,=,=,IC50,nM,6.0,IC50,nM,6.0,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2019
Inhibition of human PI3Kgamma using PIP2 as substrate after 1 hr,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4390691,=,=,IC50,nM,92.0,IC50,nM,92.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2019
Inhibition of human PI3Kgamma using PIP2 as substrate after 1 hr,COc1ccc(Cn2c(=O)n(C)c3c4cc(-c5cnc(OC)c(NS(C)(=O)=O)c5)ccc4ncc32)cc1,CHEMBL4390691,=,=,IC50,nM,112.0,IC50,nM,112.0,COc1ccc(Cn2c(=O)n(C)c3c4cc(-c5cnc(OC)c(NS(C)(=O)=O)c5)ccc4ncc32)cc1,2019
Inhibition of human PI3Kgamma using PIP2 as substrate after 1 hr,COc1ccc(Cn2c(=O)n(C)c3cnc4ccc(-c5cnc(OC)c(NS(C)(=O)=O)c5)cc4c32)cc1,CHEMBL4390691,=,=,IC50,nM,42.0,IC50,nM,42.0,COc1ccc(Cn2c(=O)n(C)c3cnc4ccc(-c5cnc(OC)c(NS(C)(=O)=O)c5)cc4c32)cc1,2019
Inhibition of N-terminal His6-tagged recombinant human PI3Kgamma (468 to 1203 residues) using biotinylated PIP3 as substrate by HTRF analysis,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL4393651,=,=,INH,nM,53.0,INH,nM,53.0,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2019
Inhibition of N-terminal His-tagged truncated human PI3Kgamma (deltaN 1 to 108 residues) after 2 hrs in presence of [33P]ATP by BetaPlate liquid scintillation counting analysis,O/C(=C\C1=Nc2ccccc2C2=NCCN12)c1ccccc1,CHEMBL4393651,=,=,IC50,nM,810.0,IC50,nM,810.0,O/C(=C\C1=Nc2ccccc2C2=NCCN12)c1ccccc1,2019
Inhibition of N-terminal His-tagged truncated human PI3Kgamma (deltaN 1 to 108 residues) after 2 hrs in presence of [33P]ATP by BetaPlate liquid scintillation counting analysis,O=C(NC1=Nc2ccccc2C2=NCCN12)c1cccnc1,CHEMBL4393651,=,=,IC50,nM,60.0,IC50,nM,60.0,O=C(NC1=Nc2ccccc2C2=NCCN12)c1cccnc1,2019
Inhibition of N-terminal His-tagged truncated human PI3Kgamma (deltaN 1 to 108 residues) after 2 hrs in presence of [33P]ATP by BetaPlate liquid scintillation counting analysis,COc1cc2c(cc1OC)C1=NCCN1C(NC(=O)c1cccnc1)=N2,CHEMBL4393651,=,=,IC50,nM,60.0,IC50,nM,60.0,COc1cc2c(cc1OC)C1=NCCN1C(NC(=O)c1cccnc1)=N2,2019
Inhibition of PI3Kgamma (unknown origin),COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,CHEMBL4393651,=,=,IC50,nM,6.4,IC50,nM,6.4,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,2019
Inhibition of PI3Kgamma (unknown origin),Cc1nc(C(=O)Nc2cc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4)c3)cc3[nH]ncc23)cs1,CHEMBL4393651,=,=,IC50,nM,50.12,pIC50,,7.3,Cc1nc(C(=O)Nc2cc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4)c3)cc3[nH]ncc23)cs1,2019
Inhibition of PI3Kgamma (unknown origin),COc1ncc(-c2cc(-c3ncc(CN4C[C@@H](C)O[C@@H](C)C4)o3)c3cn[nH]c3c2)cc1NS(C)(=O)=O,CHEMBL4393651,=,=,Ki,nM,501.19,pKi,,6.3,COc1ncc(-c2cc(-c3ncc(CN4C[C@@H](C)O[C@@H](C)C4)o3)c3cn[nH]c3c2)cc1NS(C)(=O)=O,2019
Inhibition of PI3K gamma (unknown origin) using phosphatidyl inositol as substrate measured after 60 mins in presence of ATP by Kinase-Glo Plus reagent-based luminescence assay,COc1ncc(-c2ccc3ncnc(N[C@H]4CCCN(C(=O)C(C)N)C4)c3c2)cc1C#N,CHEMBL4396940,=,=,IC50,nM,210.7,IC50,nM,210.7,COc1ncc(-c2ccc3ncnc(N[C@H]4CCCN(C(=O)C(C)N)C4)c3c2)cc1C#N,2019
Inhibition of PI3K gamma (unknown origin) using phosphatidyl inositol as substrate measured after 60 mins in presence of ATP by Kinase-Glo Plus reagent-based luminescence assay,COc1ncc(-c2ccc3ncnc(N[C@H]4CCCN(C(=O)CN(C)C)C4)c3c2)cc1C#N,CHEMBL4396940,=,=,IC50,nM,250.4,IC50,nM,250.4,COc1ncc(-c2ccc3ncnc(N[C@H]4CCCN(C(=O)CN(C)C)C4)c3c2)cc1C#N,2019
Inhibition of PI3K gamma (unknown origin) using phosphatidyl inositol as substrate measured after 60 mins in presence of ATP by Kinase-Glo Plus reagent-based luminescence assay,COc1ncc(-c2ccc3ncnc(N[C@H]4CCCN(C(=O)c5cccnc5)C4)c3c2)cc1C#N,CHEMBL4396940,=,=,IC50,nM,2.0,IC50,nM,2.0,COc1ncc(-c2ccc3ncnc(N[C@H]4CCCN(C(=O)c5cccnc5)C4)c3c2)cc1C#N,2019
Inhibition of PI3K gamma (unknown origin) using phosphatidyl inositol as substrate measured after 60 mins in presence of ATP by Kinase-Glo Plus reagent-based luminescence assay,COc1ncc(-c2ccc3ncnc(N[C@H]4CCCN(C(=O)c5coc([N+](=O)[O-])c5)C4)c3c2)cc1C#N,CHEMBL4396940,=,=,IC50,nM,19.3,IC50,nM,19.3,COc1ncc(-c2ccc3ncnc(N[C@H]4CCCN(C(=O)c5coc([N+](=O)[O-])c5)C4)c3c2)cc1C#N,2019
Inhibition of PI3K gamma (unknown origin) using phosphatidyl inositol as substrate measured after 60 mins in presence of ATP by Kinase-Glo Plus reagent-based luminescence assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4396940,=,=,IC50,nM,145.3,IC50,nM,145.3,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2019
Inhibition of PI3Kgamma (unknown origin) up to 10000 nM,CC(C)(O)[C@H]1CC[C@H](NC(=O)c2cnc3cc(OC(F)F)ccc3c2)CC1,CHEMBL4400569,,,Inhibition,%,,INH,,,CC(C)(O)[C@H]1CC[C@H](NC(=O)c2cnc3cc(OC(F)F)ccc3c2)CC1,2019
Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant full-length human His-tagged p110gamma expressed in baculovirus expression system measured after 60 mins by LanthaScreen assay,Cc1cc2ncnn2cc1Nc1ncc2c(n1)n(C1CCOCC1)c(=O)n2C,CHEMBL4402552,=,=,IC50,nM,52.0,IC50,nM,52.0,Cc1cc2ncnn2cc1Nc1ncc2c(n1)n(C1CCOCC1)c(=O)n2C,2020
Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant full-length human His-tagged p110gamma expressed in baculovirus expression system at 1 uM measured after 60 mins by LanthaScreen assay relative to control,Cc1cc2ncnn2cc1Nc1ncc2c(n1)n(C1CCOCC1)c(=O)n2C,CHEMBL4402552,>,>,Inhibition,%,50.0,INH,%,50.0,Cc1cc2ncnn2cc1Nc1ncc2c(n1)n(C1CCOCC1)c(=O)n2C,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CNC(=O)c3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,234.0,IC50,nM,234.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CNC(=O)c3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CNc3ncc(C(=O)NO)cn3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,995.0,IC50,nM,995.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CNc3ncc(C(=O)NO)cn3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(CNC(=O)c3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,10.0,IC50,nM,10.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(CNC(=O)c3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(CNc3ncc(C(=O)NO)cn3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,15.0,IC50,nM,15.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(CNc3ncc(C(=O)NO)cn3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CCCCCC(=O)NO)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,43.0,IC50,nM,43.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CCCCCC(=O)NO)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,,,IC50,,,IC50,,,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(-c3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,,,IC50,,,IC50,,,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(-c3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,103.0,IC50,nM,103.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)NO)c(C)c3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,203.0,IC50,nM,203.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)NO)c(C)c3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)NO)nc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,,,IC50,,,IC50,,,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)NO)nc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)NO)cn3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,135.0,IC50,nM,135.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)NO)cn3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)N(C)O)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,162.0,IC50,nM,162.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)N(C)O)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(CCCCCC(=O)NO)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,3.0,IC50,nM,3.0,CC[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(CCCCCC(=O)NO)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(CCCCCC(=O)NO)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,2.0,IC50,nM,2.0,CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(CCCCCC(=O)NO)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1nc(N)ncc1C)c1nc2cccc(CCCCCC(=O)NO)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,1769.0,IC50,nM,1769.0,CC[C@H](Nc1nc(N)ncc1C)c1nc2cccc(CCCCCC(=O)NO)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(CCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,2.0,IC50,nM,2.0,CC[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(CCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCCCCC(=O)NO)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,8.0,IC50,nM,8.0,CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCCCCC(=O)NO)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,45.0,IC50,nM,45.0,CC[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,9.0,IC50,nM,9.0,CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1ncnc(N)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,752.0,IC50,nM,752.0,CC[C@H](Nc1ncnc(N)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,222.0,IC50,nM,222.0,CC[C@H](Nc1nc(N)nc(C(F)F)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,IC50,nM,4.0,IC50,nM,4.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,Cc1nc(N)nc(N[C@@H](C)c2nc3cccc(NCc4ccc(C(=O)NO)cc4)c3c(=O)n2-c2ccccc2)c1C#N,CHEMBL4402587,=,=,IC50,nM,2.0,IC50,nM,2.0,Cc1nc(N)nc(N[C@@H](C)c2nc3cccc(NCc4ccc(C(=O)NO)cc4)c3c(=O)n2-c2ccccc2)c1C#N,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL4402587,=,=,IC50,nM,81.0,IC50,nM,81.0,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,O=C(NCC1(c2nc(-c3ccccc3)cs2)CCOCC1)c1cccc(-c2noc(C(F)(F)F)n2)c1,CHEMBL4402587,,,IC50,,,IC50,,,O=C(NCC1(c2nc(-c3ccccc3)cs2)CCOCC1)c1cccc(-c2noc(C(F)(F)F)n2)c1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay,CC(/C=C/C(=O)NO)=C\[C@@H](C)C(=O)c1ccc(N(C)C)cc1,CHEMBL4402587,,,IC50,,,IC50,,,CC(/C=C/C(=O)NO)=C\[C@@H](C)C(=O)c1ccc(N(C)C)cc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to control,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CNc3ncc(C(=O)NO)s3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,Inhibition,%,59.9,INH,%,59.9,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CNc3ncc(C(=O)NO)s3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to control,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(-c3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,Inhibition,%,81.6,INH,%,81.6,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(-c3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to control,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(-c3ccc(CC(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,Inhibition,%,79.1,INH,%,79.1,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(-c3ccc(CC(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to control,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(-c3nc4ccc(C(=O)NO)cc4s3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,Inhibition,%,88.0,INH,%,88.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(-c3nc4ccc(C(=O)NO)cc4s3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to control,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)NO)nc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,Inhibition,%,39.9,INH,%,39.9,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)NO)nc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to control,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)NO)o3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,Inhibition,%,48.0,INH,%,48.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(NCc3ccc(C(=O)NO)o3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to control,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CNCc3nc(C(=O)NO)cs3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,Inhibition,%,-12.2,INH,%,-12.2,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CNCc3nc(C(=O)NO)cs3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to control,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CNCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,Inhibition,%,-9.1,INH,%,-9.1,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(CNCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to control,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL4402587,=,=,Inhibition,%,63.0,INH,%,63.0,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2020
Inhibition of human PI3Kgamma assessed as reduction in PIP3 product complex formation by measuring displacement of biotin-labelled PIP3 from complex at 1 uM using PIP2 as substrate measured after 30 mins in presence of ATP by HTRF assay relative to control,CC(/C=C/C(=O)NO)=C\[C@@H](C)C(=O)c1ccc(N(C)C)cc1,CHEMBL4402587,,,Inhibition,%,,INH,,,CC(/C=C/C(=O)NO)=C\[C@@H](C)C(=O)c1ccc(N(C)C)cc1,2020
"Inhibition of human PI3Kgamma at 1 uM using phosphatidylinositol 4,5-bisphosphate as substrate in presence of 10 uM ATP by ADP-Glo assay relative to control",CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,CHEMBL4402587,=,=,Inhibition,%,100.0,INH,%,100.0,CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1,2020
"Inhibition of recombinant human full length PI3K p120gamma at 1 uM using phosphatidylinositol-4, 5-bisphosphate as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control",Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1,CHEMBL4406821,=,=,Inhibition,%,14.0,INH,%,14.0,Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1,2019
"Inhibition of PI3Kgamma (unknown origin) using D-myophosphatidylinositol 4,5-bisphosphate as substrate incubated for 120 mins by [gamma-33P]-ATP based scintillation counting method",CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1,CHEMBL4406913,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1,2019
Inhibition of wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system at 10 uM by Kinomescan method,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(=O)[nH]cnc21,CHEMBL4406914,,,Inhibition,%,,INH,,,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(=O)[nH]cnc21,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1000.0,pIC50,,6.0,COCC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,1584.89,pIC50,,5.8,CC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1995.26,pIC50,,5.7,COCC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,630.96,pIC50,,6.2,CC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,1995.26,pIC50,,5.7,COCC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CN(C1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1)S(C)(=O)=O,CHEMBL4414631,=,=,IC50,nM,501.19,pIC50,,6.3,CN(C1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1)S(C)(=O)=O,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CS(=O)(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,19.95,pIC50,,7.7,CS(=O)(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CN(C1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1)S(C)(=O)=O,CHEMBL4414631,=,=,IC50,nM,25.12,pIC50,,7.6,CN(C1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1)S(C)(=O)=O,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)N(C)C1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,7.943,pIC50,,8.1,COCC(=O)N(C)C1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4414631,=,=,IC50,nM,199.53,pIC50,,6.7,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,12.59,pIC50,,7.9,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1995.26,pIC50,,5.7,CC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1258.93,pIC50,,5.9,CC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,79.43,pIC50,,7.1,CC(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,2511.89,pIC50,,5.6,COCC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,794.33,pIC50,,6.1,COCC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,50.12,pIC50,,7.3,COCC(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CNC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,3981.07,pIC50,,5.4,CNC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CNC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1258.93,pIC50,,5.9,CNC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CNC(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,158.49,pIC50,,6.8,CNC(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CS(=O)(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1584.89,pIC50,,5.8,CS(=O)(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CS(=O)(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1258.93,pIC50,,5.9,CS(=O)(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,1995.26,pIC50,,5.7,CC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,1584.89,pIC50,,5.8,CC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,158.49,pIC50,,6.8,CC(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,3981.07,pIC50,,5.4,COCC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,1584.89,pIC50,,5.8,COCC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,63.1,pIC50,,7.2,COCC(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CNC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,6309.57,pIC50,,5.2,CNC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CNC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,1258.93,pIC50,,5.9,CNC(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CNC(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,63.1,pIC50,,7.2,CNC(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CS(=O)(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,1000.0,pIC50,,6.0,CS(=O)(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CS(=O)(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,794.33,pIC50,,6.1,CS(=O)(=O)NC1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CS(=O)(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,63.1,pIC50,,7.2,CS(=O)(=O)NC1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,2511.89,pIC50,,5.6,CC(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1258.93,pIC50,,5.9,CC(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)NC1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,158.49,pIC50,,6.8,CC(=O)NC1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1995.26,pIC50,,5.7,COCC(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,2511.89,pIC50,,5.6,COCC(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)NC1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,630.96,pIC50,,6.2,COCC(=O)NC1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CNC(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,2511.89,pIC50,,5.6,CNC(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CNC(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,3162.28,pIC50,,5.5,CNC(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CNC(=O)NC1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,158.49,pIC50,,6.8,CNC(=O)NC1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CS(=O)(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1000.0,pIC50,,6.0,CS(=O)(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CS(=O)(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1584.89,pIC50,,5.8,CS(=O)(=O)NC1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CS(=O)(=O)NC1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,39.81,pIC50,,7.4,CS(=O)(=O)NC1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1000.0,pIC50,,6.0,CC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)N(C)C1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,39.81,pIC50,,7.4,CC(=O)N(C)C1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1000.0,pIC50,,6.0,COCC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CNC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,1584.89,pIC50,,5.8,CNC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CN(C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1)S(C)(=O)=O,CHEMBL4414631,=,=,IC50,nM,501.19,pIC50,,6.3,CN(C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1)S(C)(=O)=O,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CN(C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1)S(C)(=O)=O,CHEMBL4414631,=,=,IC50,nM,398.11,pIC50,,6.4,CN(C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1)S(C)(=O)=O,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CN(C1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1)S(C)(=O)=O,CHEMBL4414631,=,=,IC50,nM,12.59,pIC50,,7.9,CN(C1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1)S(C)(=O)=O,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,1000.0,pIC50,,6.0,CC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)N(C)C1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,39.81,pIC50,,7.4,CC(=O)N(C)C1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,1258.93,pIC50,,5.9,COCC(=O)N(C)C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)N(C)C1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,CHEMBL4414631,=,=,IC50,nM,125.89,pIC50,,6.9,COCC(=O)N(C)C1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CN(C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1)S(C)(=O)=O,CHEMBL4414631,=,=,IC50,nM,794.33,pIC50,,6.1,CN(C1CCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1)S(C)(=O)=O,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CN(C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1)S(C)(=O)=O,CHEMBL4414631,=,=,IC50,nM,794.33,pIC50,,6.1,CN(C1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1)S(C)(=O)=O,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,2511.89,pIC50,,5.6,CC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,501.19,pIC50,,6.3,CC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,100.0,pIC50,,7.0,CC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,3162.28,pIC50,,5.5,COCC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,COCC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,125.89,pIC50,,6.9,COCC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CNC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,6309.57,pIC50,,5.2,CNC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cccc5[nH]ccc45)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CNC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,199.53,pIC50,,6.7,CNC(=O)N(C)C1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CN(C1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1)S(C)(=O)=O,CHEMBL4414631,=,=,IC50,nM,794.33,pIC50,,6.1,CN(C1CCCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)C1)S(C)(=O)=O,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CN(C1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1)S(C)(=O)=O,CHEMBL4414631,=,=,IC50,nM,25.12,pIC50,,7.6,CN(C1CCCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1)S(C)(=O)=O,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)N[C@@H]1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,125.89,pIC50,,6.9,CC(=O)N[C@@H]1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)N[C@H]1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,251.19,pIC50,,6.6,CC(=O)N[C@H]1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)N(C)[C@@H]1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,25.12,pIC50,,7.6,CC(=O)N(C)[C@@H]1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay,CC(=O)N(C)[C@H]1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,CHEMBL4414631,=,=,IC50,nM,15.85,pIC50,,7.8,CC(=O)N(C)[C@H]1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)C1,2019
Inhibition of PI3Kgamma (unknown origin) by ADP-gloassay,C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)cc1,CHEMBL4422626,=,=,IC50,nM,684.0,IC50,nM,684.0,C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)cc1,2019
Inhibition of PI3Kgamma (unknown origin) by ADP-gloassay,C=CC(=O)Nc1cccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)c1,CHEMBL4422626,=,=,IC50,nM,2183.0,IC50,nM,2183.0,C=CC(=O)Nc1cccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)c1,2019
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1,CHEMBL4428047,=,=,IC50,nM,850.0,IC50,nM,850.0,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(-c2ccccn2)c1-c1ccccn1,CHEMBL4428047,=,=,IC50,nM,850.0,IC50,nM,850.0,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(-c2ccccn2)c1-c1ccccn1,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(N)=O)c1-c1ccccc1,CHEMBL4428047,=,=,IC50,nM,301.0,IC50,nM,301.0,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(N)=O)c1-c1ccccc1,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,CNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,CHEMBL4428047,=,=,IC50,nM,634.0,IC50,nM,634.0,CNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N(C)C)c1-c1ccccc1,CHEMBL4428047,=,=,IC50,nM,146.0,IC50,nM,146.0,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N(C)C)c1-c1ccccc1,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,CCNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,CHEMBL4428047,=,=,IC50,nM,4650.0,IC50,nM,4650.0,CCNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,CC(C)NC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,CHEMBL4428047,=,=,IC50,nM,853.0,IC50,nM,853.0,CC(C)NC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CCS(=O)(=O)CC2)c1-c1ccccc1,CHEMBL4428047,=,=,IC50,nM,35.4,IC50,nM,35.4,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CCS(=O)(=O)CC2)c1-c1ccccc1,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CCNCC2)c1-c1ccccc1,CHEMBL4428047,=,=,IC50,nM,22.5,IC50,nM,22.5,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CCNCC2)c1-c1ccccc1,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CC(O)C2)c1-c1ccccc1,CHEMBL4428047,=,=,IC50,nM,507.0,IC50,nM,507.0,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CC(O)C2)c1-c1ccccc1,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,CNCCNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,CHEMBL4428047,=,=,IC50,nM,9550.0,IC50,nM,9550.0,CNCCNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,CNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,CHEMBL4428047,=,=,IC50,nM,3530.0,IC50,nM,3530.0,CNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,CCNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,CHEMBL4428047,=,=,IC50,nM,5360.0,IC50,nM,5360.0,CCNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CCNCC2)c1-c1ccccn1,CHEMBL4428047,=,=,IC50,nM,964.0,IC50,nM,964.0,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CCNCC2)c1-c1ccccn1,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CC(O)C2)c1-c1ccccn1,CHEMBL4428047,=,=,IC50,nM,3590.0,IC50,nM,3590.0,CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CC(O)C2)c1-c1ccccn1,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,CNCCNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,CHEMBL4428047,=,=,IC50,nM,23200.0,IC50,nM,23200.0,CNCCNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,2016
Inhibition of N-terminal polyHis tagged full length recombinant PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in Hi5 cells co-expressing p85 incubated for 20 mins by alpha screen assay,CNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2cccc(F)c12,CHEMBL4428047,=,=,IC50,nM,3220.0,IC50,nM,3220.0,CNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2cccc(F)c12,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4428080,=,=,IC50,nM,313.0,IC50,uM,0.313,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,c1ccc2ncc(-c3ccc4ncncc4c3)cc2c1,CHEMBL4428080,>,>,IC50,nM,10000.0,IC50,uM,10.0,c1ccc2ncc(-c3ccc4ncncc4c3)cc2c1,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,c1ccc(-c2ncnc3ccc(-c4cnc5ccccc5c4)cc23)cc1,CHEMBL4428080,=,=,IC50,nM,5600.0,IC50,uM,5.6,c1ccc(-c2ncnc3ccc(-c4cnc5ccccc5c4)cc23)cc1,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,COc1ccc(-c2ncnc3ccc(-c4cnc5ccccc5c4)cc23)cc1OC,CHEMBL4428080,=,=,IC50,nM,2600.0,IC50,uM,2.6,COc1ccc(-c2ncnc3ccc(-c4cnc5ccccc5c4)cc23)cc1OC,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,CN1CCN(C(=O)c2cccc(-c3ncnc4ccc(-c5cnc6ccccc6c5)cc34)c2)CC1,CHEMBL4428080,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN1CCN(C(=O)c2cccc(-c3ncnc4ccc(-c5cnc6ccccc6c5)cc34)c2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C)CC5)c4)c3c2)cc1OC,CHEMBL4428080,=,=,IC50,nM,740.0,IC50,uM,0.74,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C)CC5)c4)c3c2)cc1OC,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C)CC5)c4)c3c2)cc1C#N,CHEMBL4428080,=,=,IC50,nM,9200.0,IC50,uM,9.2,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C)CC5)c4)c3c2)cc1C#N,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C)CC5)c4)c3c2)cc1C(F)(F)F,CHEMBL4428080,=,=,IC50,nM,9300.0,IC50,uM,9.3,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C)CC5)c4)c3c2)cc1C(F)(F)F,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C)CC5)c4)c3c2)cn1,CHEMBL4428080,=,=,IC50,nM,7900.0,IC50,uM,7.9,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C)CC5)c4)c3c2)cn1,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,COc1ccc(-c2ccc3ncnc(-c4cncc(C(=O)N5CCN(C)CC5)c4)c3c2)cn1,CHEMBL4428080,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2ccc3ncnc(-c4cncc(C(=O)N5CCN(C)CC5)c4)c3c2)cn1,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,COc1ccc(-c2ccc3ncnc(N4CCC[C@H](C(=O)N5CCN(C)CC5)C4)c3c2)cn1,CHEMBL4428080,=,=,IC50,nM,4500.0,IC50,uM,4.5,COc1ccc(-c2ccc3ncnc(N4CCC[C@H](C(=O)N5CCN(C)CC5)C4)c3c2)cn1,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,CC(=O)N1CCN(C(=O)c2cccc(-c3ncnc4ccc(-c5cnc6ccccc6c5)cc34)c2)CC1,CHEMBL4428080,=,=,IC50,nM,5600.0,IC50,uM,5.6,CC(=O)N1CCN(C(=O)c2cccc(-c3ncnc4ccc(-c5cnc6ccccc6c5)cc34)c2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cc1OC,CHEMBL4428080,=,=,IC50,nM,220.0,IC50,uM,0.22,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cc1OC,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cn1,CHEMBL4428080,=,=,IC50,nM,2700.0,IC50,uM,2.7,COc1ccc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cn1,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cc1C(F)(F)F,CHEMBL4428080,=,=,IC50,nM,1400.0,IC50,uM,1.4,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cc1C(F)(F)F,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ADP formation using phosphatidyl inositol as substrate after 30 to 60 mins by TR-FRET assay,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cc1C#N,CHEMBL4428080,=,=,IC50,nM,4630.0,IC50,uM,4.63,COc1ncc(-c2ccc3ncnc(-c4cccc(C(=O)N5CCN(C(C)=O)CC5)c4)c3c2)cc1C#N,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,O=C([C@H]1CCCN1)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL4431368,=,=,IC50,nM,5859.0,IC50,nM,5859.0,O=C([C@H]1CCCN1)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,O=C(C[C@@H]1CCCN1)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL4431368,=,=,IC50,nM,5756.0,IC50,nM,5756.0,O=C(C[C@@H]1CCCN1)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,O=C(CN1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1)[C@H]1CCCN1,CHEMBL4431368,=,=,IC50,nM,6081.0,IC50,nM,6081.0,O=C(CN1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1)[C@H]1CCCN1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,O=C([C@@H]1CCCCN1)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL4431368,=,=,IC50,nM,5533.0,IC50,nM,5533.0,O=C([C@@H]1CCCCN1)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,O=C([C@H]1CCCCN1)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL4431368,=,=,IC50,nM,3594.0,IC50,nM,3594.0,O=C([C@H]1CCCCN1)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,N[C@H]1CC[C@@H](C(=O)N2CCN(c3nc(N4CCOCC4)nc(-n4c(C(F)F)nc5ccccc54)n3)CC2)CC1,CHEMBL4431368,>,>,IC50,nM,10000.0,IC50,nM,10000.0,N[C@H]1CC[C@@H](C(=O)N2CCN(c3nc(N4CCOCC4)nc(-n4c(C(F)F)nc5ccccc54)n3)CC2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,O=C(O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL4431368,=,=,IC50,nM,64.0,IC50,nM,64.0,O=C(O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,O=C(O)[C@H]1CCCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)C1,CHEMBL4431368,=,=,IC50,nM,231.0,IC50,nM,231.0,O=C(O)[C@H]1CCCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)C1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,O=C(O)[C@@H]1CCCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)C1,CHEMBL4431368,=,=,IC50,nM,247.0,IC50,nM,247.0,O=C(O)[C@@H]1CCCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)C1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,NC(=O)CNC(=O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL4431368,=,=,IC50,nM,496.0,IC50,nM,496.0,NC(=O)CNC(=O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,NC(=O)[C@H](Cc1ccccc1)NC(=O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL4431368,=,=,IC50,nM,708.0,IC50,nM,708.0,NC(=O)[C@H](Cc1ccccc1)NC(=O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,C[C@H](NC(=O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1)C(N)=O,CHEMBL4431368,=,=,IC50,nM,434.0,IC50,nM,434.0,C[C@H](NC(=O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1)C(N)=O,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,C[C@@H](NC(=O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1)C(N)=O,CHEMBL4431368,=,=,IC50,nM,536.0,IC50,nM,536.0,C[C@@H](NC(=O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1)C(N)=O,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,NC(=O)[C@H](CO)NC(=O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,CHEMBL4431368,=,=,IC50,nM,521.0,IC50,nM,521.0,NC(=O)[C@H](CO)NC(=O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,CC(C)[C@H](NC(=O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1)C(N)=O,CHEMBL4431368,=,=,IC50,nM,440.0,IC50,nM,440.0,CC(C)[C@H](NC(=O)C1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1)C(N)=O,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,NC(=O)CNC(=O)[C@H]1CCCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)C1,CHEMBL4431368,=,=,IC50,nM,194.0,IC50,nM,194.0,NC(=O)CNC(=O)[C@H]1CCCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)C1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,NC(=O)CNC(=O)[C@@H]1CCCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)C1,CHEMBL4431368,=,=,IC50,nM,445.0,IC50,nM,445.0,NC(=O)CNC(=O)[C@@H]1CCCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)C1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)C1,CHEMBL4431368,=,=,IC50,nM,1983.0,IC50,nM,1983.0,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)C1,2016
Inhibition of PI3Kgamma (unknown origin) expressed in baculovirus expression system by kinase-glo luminescence assay,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)C1,CHEMBL4431368,=,=,IC50,nM,1378.0,IC50,nM,1378.0,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)C1,2016
Inhibition of full length His-tagged human recombinant PI3Kgamma expressed in baculovirus by select screen kinase profiling assay,CC[C@@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4431368,=,=,IC50,nM,89.0,IC50,nM,89.0,CC[C@@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2016
Inhibition of human recombinant PI3Kgamma using PIP2/ATP as substrate incubated for 20 mins followed by substrate addition by Kinase Glo reagent based luminescence assay,O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1,CHEMBL4477207,>,>,IC50,nM,1000.0,IC50,uM,1.0,O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1,2016
Inhibition of human recombinant PI3Kgamma using PIP2/ATP as substrate incubated for 20 mins followed by substrate addition by Kinase Glo reagent based luminescence assay,O=c1cc(-c2cccc3c2Sc2ccccc2C3)oc(N2CCOCC2)c1,CHEMBL4477207,>,>,IC50,nM,1000.0,IC50,uM,1.0,O=c1cc(-c2cccc3c2Sc2ccccc2C3)oc(N2CCOCC2)c1,2016
Inhibition of human recombinant PI3Kgamma using PIP2/ATP as substrate incubated for 20 mins followed by substrate addition by Kinase Glo reagent based luminescence assay,COc1cc2ncnc(-n3nc(-c4ccccn4)nc3N)c2cc1OC,CHEMBL4477207,>,>,IC50,nM,1000.0,IC50,uM,1.0,COc1cc2ncnc(-n3nc(-c4ccccn4)nc3N)c2cc1OC,2016
Inhibition of human recombinant PI3Kgamma using PIP2/ATP as substrate incubated for 20 mins followed by substrate addition by Kinase Glo reagent based luminescence assay,CCC(CC)CNc1c(C(N)=O)cnc2ccc(C#N)cc12,CHEMBL4477207,>,>,IC50,nM,1000.0,IC50,uM,1.0,CCC(CC)CNc1c(C(N)=O)cnc2ccc(C#N)cc12,2016
Inhibition of human recombinant PI3Kgamma using PIP2/ATP as substrate incubated for 20 mins followed by substrate addition by Kinase Glo reagent based luminescence assay,C[C@@H](Nc1c(C(N)=O)cnc2ccc(C#N)cc12)c1ccc(Cl)cc1,CHEMBL4477207,=,=,IC50,nM,204.0,IC50,uM,0.204,C[C@@H](Nc1c(C(N)=O)cnc2ccc(C#N)cc12)c1ccc(Cl)cc1,2016
Inhibition of human recombinant PI3Kgamma using PIP2/ATP as substrate incubated for 20 mins followed by substrate addition by Kinase Glo reagent based luminescence assay,C[C@@H](Nc1c(C(N)=O)cnc2ccc(-c3cccnc3)cc12)c1ccc(Cl)cc1,CHEMBL4477207,=,=,IC50,nM,45.0,IC50,uM,0.045,C[C@@H](Nc1c(C(N)=O)cnc2ccc(-c3cccnc3)cc12)c1ccc(Cl)cc1,2016
Inhibition of human recombinant PI3Kgamma using PIP2/ATP as substrate incubated for 20 mins followed by substrate addition by Kinase Glo reagent based luminescence assay,COCc1ccc(-c2ccc3ncc(C(N)=O)c(N[C@@H](C)C4CCOCC4)c3c2)cn1,CHEMBL4477207,>,>,IC50,nM,1000.0,IC50,uM,1.0,COCc1ccc(-c2ccc3ncc(C(N)=O)c(N[C@@H](C)C4CCOCC4)c3c2)cn1,2016
Inhibition of human recombinant PI3Kgamma using PIP2/ATP as substrate incubated for 20 mins followed by substrate addition by Kinase Glo reagent based luminescence assay,COCc1ccc(-c2cc3c(N[C@@H](C)c4ccn(C)n4)c(C(N)=O)cnc3cc2F)cn1,CHEMBL4477207,=,=,IC50,nM,7100.0,IC50,uM,7.1,COCc1ccc(-c2cc3c(N[C@@H](C)c4ccn(C)n4)c(C(N)=O)cnc3cc2F)cn1,2016
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of biotin-labeled PIP3 by HTRF assay,COc1ncc(-c2ccc3cn[nH]c3c2)cc1NS(C)(=O)=O,CHEMBL4477235,=,=,IC50,nM,2511.89,pIC50,,5.6,COc1ncc(-c2ccc3cn[nH]c3c2)cc1NS(C)(=O)=O,2016
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of biotin-labeled PIP3 by HTRF assay,COc1ncc(-c2ccc3c(c2)COC3)cc1NS(C)(=O)=O,CHEMBL4477235,=,=,IC50,nM,3162.28,pIC50,,5.5,COc1ncc(-c2ccc3c(c2)COC3)cc1NS(C)(=O)=O,2016
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins in presence of biotin-labeled PIP3 by HTRF assay,COc1ncc(-c2cc(-c3ncc(CN4C[C@@H](C)O[C@@H](C)C4)o3)c3cn[nH]c3c2)cc1NS(C)(=O)=O,CHEMBL4477235,=,=,IC50,nM,501.19,pIC50,,6.3,COc1ncc(-c2cc(-c3ncc(CN4C[C@@H](C)O[C@@H](C)C4)o3)c3cn[nH]c3c2)cc1NS(C)(=O)=O,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ATP depletion using lipid substrate after 40 mins by Kinase-Glo luminescent assay,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4477271,=,=,IC50,nM,169.0,IC50,nM,169.0,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ATP depletion using lipid substrate after 40 mins by Kinase-Glo luminescent assay,COc1ncc(-c2ccc3ncnc(NCCN4CCOCC4)c3c2)cc1C#N,CHEMBL4477271,=,=,IC50,nM,934.0,IC50,nM,934.0,COc1ncc(-c2ccc3ncnc(NCCN4CCOCC4)c3c2)cc1C#N,2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ATP depletion using lipid substrate after 40 mins by Kinase-Glo luminescent assay,COc1ncc(-c2ccc3ncnc(NCCN4CCCCC4)c3c2)cc1[N+](=O)[O-],CHEMBL4477271,,,IC50,,,IC50,,,COc1ncc(-c2ccc3ncnc(NCCN4CCCCC4)c3c2)cc1[N+](=O)[O-],2016
Inhibition of PI3Kgamma (unknown origin) assessed as reduction in ATP depletion using lipid substrate after 40 mins by Kinase-Glo luminescent assay,COc1ncc(-c2ccc3ncnc(NCCN(C)C)c3c2)cc1C#N,CHEMBL4477271,,,IC50,,,IC50,,,COc1ncc(-c2ccc3ncnc(NCCN(C)C)c3c2)cc1C#N,2016
Inhibition of His-tagged recombinant human full length PI3K p110gamma expressed in baculovirus expression system using PIP2:PS lipid as substrate incubated for 1 hr in presence of ATP by Adapta assay,C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C,CHEMBL4602617,=,=,IC50,nM,945.0,IC50,uM,0.945,C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccncc3)cc2n1-c1ccnc2c(F)ccc(F)c12,CHEMBL4616704,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccncc3)cc2n1-c1ccnc2c(F)ccc(F)c12,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(Cl)c3)cc2n1-c1ccnc2c(F)ccc(F)c12,CHEMBL4616704,=,=,IC50,nM,6268.0,IC50,nM,6268.0,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(Cl)c3)cc2n1-c1ccnc2c(F)ccc(F)c12,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1cc(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)ccn1,CHEMBL4616704,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cc(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)ccn1,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1nccc(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)n1,CHEMBL4616704,=,=,IC50,nM,2717.0,IC50,nM,2717.0,Cc1nccc(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)n1,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1cc(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)ncn1,CHEMBL4616704,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cc(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)ncn1,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(C(F)F)c3)cc2n1-c1ccnc2c(F)ccc(F)c12,CHEMBL4616704,=,=,IC50,nM,9421.0,IC50,nM,9421.0,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(C(F)F)c3)cc2n1-c1ccnc2c(F)ccc(F)c12,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(C#N)c3)cc2n1-c1ccnc2c(F)ccc(F)c12,CHEMBL4616704,=,=,IC50,nM,6608.0,IC50,nM,6608.0,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(C#N)c3)cc2n1-c1ccnc2c(F)ccc(F)c12,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3)cc2n1-c1ccnc2c(F)ccc(F)c12,CHEMBL4616704,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3)cc2n1-c1ccnc2c(F)ccc(F)c12,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1cc(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)cc(N)n1,CHEMBL4616704,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cc(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)cc(N)n1,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1c(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)ccnc1N,CHEMBL4616704,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1c(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)ccnc1N,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3Cl)cc2n1-c1ccnc2c(F)ccc(F)c12,CHEMBL4616704,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3Cl)cc2n1-c1ccnc2c(F)ccc(F)c12,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3F)cc2n1-c1ccnc2c(F)ccc(F)c12,CHEMBL4616704,=,=,IC50,nM,4157.0,IC50,nM,4157.0,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3F)cc2n1-c1ccnc2c(F)ccc(F)c12,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1nc2c(-c3nnc[nH]3)cc(-c3cc(N)ncc3F)cc2n1-c1ccnc2c(F)ccc(F)c12,CHEMBL4616704,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1nc2c(-c3nnc[nH]3)cc(-c3cc(N)ncc3F)cc2n1-c1ccnc2c(F)ccc(F)c12,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1nc2c(-c3nnc[nH]3)cc(-c3c(F)cnc(N)c3F)cc2n1-c1ccnc2c(F)ccc(F)c12,CHEMBL4616704,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1nc2c(-c3nnc[nH]3)cc(-c3c(F)cnc(N)c3F)cc2n1-c1ccnc2c(F)ccc(F)c12,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,CNc1nccc(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)c1F,CHEMBL4616704,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CNc1nccc(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)c1F,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F,CHEMBL4616704,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Clc1cccc2c(-n3cnc4c(-c5nnc[nH]5)cc(N5CCOCC5)cc43)ccnc12,CHEMBL4616704,=,=,IC50,nM,350.0,IC50,nM,350.0,Clc1cccc2c(-n3cnc4c(-c5nnc[nH]5)cc(N5CCOCC5)cc43)ccnc12,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Clc1cccc2c(-n3cnc4c(-c5nnc[nH]5)cc(-c5ccncc5)cc43)ccnc12,CHEMBL4616704,=,=,IC50,nM,5300.0,IC50,nM,5300.0,Clc1cccc2c(-n3cnc4c(-c5nnc[nH]5)cc(-c5ccncc5)cc43)ccnc12,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL4616704,=,=,IC50,nM,6000.0,IC50,nM,6000.0,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2020
Inhibition of human full length p110gamma using PIP2 as substrate after 30 mins in presence of ATP at 2xKm concentration by TR-FRET assay,Cc1cc(C(C)Nc2ccccc2)c2nc(N3CCOCC3)cc(=O)n2c1,CHEMBL4616704,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cc(C(C)Nc2ccccc2)c2nc(N3CCOCC3)cc(=O)n2c1,2020
Inhibition of human PI3K p110gamma by HTRF assay,CNC(=O)c1cc2c(N3CCOCC3)nc(-c3cnc(N)cc3C(F)(F)F)nn2c1,CHEMBL4619747,=,=,IC50,nM,663.0,IC50,nM,663.0,CNC(=O)c1cc2c(N3CCOCC3)nc(-c3cnc(N)cc3C(F)(F)F)nn2c1,2020
Inhibition of human PI3K p110gamma by HTRF assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4619747,=,=,IC50,nM,746.0,IC50,nM,746.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2020
Inhibition of PI3Kgamma (unknown origin),COc1ncc(N2CCOc3ccc(CN(C)C)cc32)cc1NS(C)(=O)=O,CHEMBL4619790,=,=,IC50,nM,25118.86,pIC50,,4.6,COc1ncc(N2CCOc3ccc(CN(C)C)cc32)cc1NS(C)(=O)=O,2020
Inhibition of PI3Kgamma (unknown origin),COc1ncc2cc1NS(=O)(=O)CCN(C)Cc1ccc3c(c1)N2CCO3,CHEMBL4619790,=,=,IC50,nM,1584.89,pIC50,,5.8,COc1ncc2cc1NS(=O)(=O)CCN(C)Cc1ccc3c(c1)N2CCO3,2020
Inhibition of PI3Kgamma (unknown origin) using lipid as substrate incubated for 15 mins followed by substrate addition and measured after 60 mins ADPGloTM reagent based assay,COc1ncc(-c2ccc3ncnc(Nc4cnn(CCO)c4)c3c2)cc1NS(C)(=O)=O,CHEMBL4665651,,,Inhibition,%,,INH,,,COc1ncc(-c2ccc3ncnc(Nc4cnn(CCO)c4)c3c2)cc1NS(C)(=O)=O,2019
Inhibition of PI3Kgamma (unknown origin) using lipid as substrate incubated for 15 mins followed by substrate addition and measured after 60 mins ADPGloTM reagent based assay,COc1ncc(-c2ccc3ncnc(Nc4cnn(CCO)c4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4665651,=,=,IC50,nM,0.58,IC50,nM,0.58,COc1ncc(-c2ccc3ncnc(Nc4cnn(CCO)c4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2019
Inhibition of PI3Kgamma (unknown origin) using lipid as substrate incubated for 15 mins followed by substrate addition and measured after 60 mins ADPGloTM reagent based assay,COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL4665651,=,=,IC50,nM,1.19,IC50,nM,1.19,COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2019
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",CC(=O)Nc1nc(C)c(-c2cc(C)c3c(c2)CN([C@@H](C)C2CC2)C3=O)s1,CHEMBL4665778,=,=,IC50,nM,3.6,IC50,nM,3.6,CC(=O)Nc1nc(C)c(-c2cc(C)c3c(c2)CN([C@@H](C)C2CC2)C3=O)s1,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccc3[nH]c(N)nc3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cc(-c2ccc3[nH]c(N)nc3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",CC(=O)Nc1nc2cc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2[nH]1,CHEMBL4665778,=,=,IC50,nM,482.0,IC50,nM,482.0,CC(=O)Nc1nc2cc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2[nH]1,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccn3nc(N)nc3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,50.0,IC50,nM,50.0,Cc1cc(-c2ccn3nc(N)nc3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",CC(=O)Nc1nc2cc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccn2n1,CHEMBL4665778,=,=,IC50,nM,80.0,IC50,nM,80.0,CC(=O)Nc1nc2cc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccn2n1,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccc3nc(N)nn3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,291.0,IC50,nM,291.0,Cc1cc(-c2ccc3nc(N)nn3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",CC(=O)Nc1nc2ccc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)cn2n1,CHEMBL4665778,=,=,IC50,nM,76.0,IC50,nM,76.0,CC(=O)Nc1nc2ccc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)cn2n1,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccc3nc(N)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,425.0,IC50,nM,425.0,Cc1cc(-c2ccc3nc(N)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",CC(=O)Nc1cn2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2n1,CHEMBL4665778,=,=,IC50,nM,5.5,IC50,nM,5.5,CC(=O)Nc1cn2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2n1,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccc3nc(N)c(-c4cnn(C)c4)n3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,17.0,IC50,nM,17.0,Cc1cc(-c2ccc3nc(N)c(-c4cnn(C)c4)n3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccc3ncc(-c4cnn(C)c4)n3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,15.0,IC50,nM,15.0,Cc1cc(-c2ccc3ncc(-c4cnn(C)c4)n3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccn3nc(N)cc3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,60.0,IC50,nM,60.0,Cc1cc(-c2ccn3nc(N)cc3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",CC(=O)Nc1cc2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccn2n1,CHEMBL4665778,=,=,IC50,nM,4.4,IC50,nM,4.4,CC(=O)Nc1cc2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccn2n1,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccn3nc(N)c(-c4cnn(C)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,2.9,IC50,nM,2.9,Cc1cc(-c2ccn3nc(N)c(-c4cnn(C)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",CC(=O)Nc1nn2ccc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)nc2c1-c1cnn(C)c1,CHEMBL4665778,=,=,IC50,nM,429.0,IC50,nM,429.0,CC(=O)Nc1nn2ccc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)nc2c1-c1cnn(C)c1,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccn3ncc(-c4cnn(C)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,9.1,IC50,nM,9.1,Cc1cc(-c2ccn3ncc(-c4cnn(C)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",CCC(=O)Nc1cn2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2n1,CHEMBL4665778,=,=,IC50,nM,7.3,IC50,nM,7.3,CCC(=O)Nc1cn2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2n1,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",COCC(=O)Nc1cn2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2n1,CHEMBL4665778,=,=,IC50,nM,14.0,IC50,nM,14.0,COCC(=O)Nc1cn2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2n1,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccc3nc(NC(=O)C(C)C)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,70.0,IC50,nM,70.0,Cc1cc(-c2ccc3nc(NC(=O)C(C)C)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccc3nc(NC(=O)c4ccccc4)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,93.0,IC50,nM,93.0,Cc1cc(-c2ccc3nc(NC(=O)c4ccccc4)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccc3nc(NS(C)(=O)=O)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,5300.0,IC50,nM,5300.0,Cc1cc(-c2ccc3nc(NS(C)(=O)=O)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccc3nc(NC(=O)N4CCC[C@H]4C(N)=O)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,2.9,IC50,nM,2.9,Cc1cc(-c2ccc3nc(NC(=O)N4CCC[C@H]4C(N)=O)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccn3nc(N)c(-c4cnn(CCO)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,6.4,IC50,nM,6.4,Cc1cc(-c2ccn3nc(N)c(-c4cnn(CCO)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1ncc(-c2c(N)nn3ccc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)nc23)o1,CHEMBL4665778,=,=,IC50,nM,5.9,IC50,nM,5.9,Cc1ncc(-c2c(N)nn3ccc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)nc23)o1,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccn3nc(N)c(-c4ccn[nH]4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,44.0,IC50,nM,44.0,Cc1cc(-c2ccn3nc(N)c(-c4ccn[nH]4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccn3nc(N)c(-c4nc[nH]n4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,31.0,IC50,nM,31.0,Cc1cc(-c2ccn3nc(N)c(-c4nc[nH]n4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccn3nc(N)c(-c4ccccn4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,64.0,IC50,nM,64.0,Cc1cc(-c2ccn3nc(N)c(-c4ccccn4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccn3nc(N)c(-c4ccncn4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,7.5,IC50,nM,7.5,Cc1cc(-c2ccn3nc(N)c(-c4ccncn4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2c(N)nn3ccc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)nc23)ccc1C(=O)O,CHEMBL4665778,=,=,IC50,nM,2.2,IC50,nM,2.2,Cc1cc(-c2c(N)nn3ccc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)nc23)ccc1C(=O)O,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1cc(-c2ccn3nc(N)c(-c4ccc(CC(=O)O)cc4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,2.1,IC50,nM,2.1,Cc1cc(-c2ccn3nc(N)c(-c4ccc(CC(=O)O)cc4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",CC(=O)Nc1cc2nc(-c3cc4c(c(C(F)(F)F)c3)C(=O)N([C@@H](C)C3CC3)C4)ccn2n1,CHEMBL4665778,=,=,IC50,nM,2.2,IC50,nM,2.2,CC(=O)Nc1cc2nc(-c3cc4c(c(C(F)(F)F)c3)C(=O)N([C@@H](C)C3CC3)C4)ccn2n1,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",CC(=O)Nc1cc2nc(-c3cc4c(c(NS(C)(=O)=O)c3)C(=O)N([C@@H](C)C3CC3)C4)ccn2n1,CHEMBL4665778,=,=,IC50,nM,1.3,IC50,nM,1.3,CC(=O)Nc1cc2nc(-c3cc4c(c(NS(C)(=O)=O)c3)C(=O)N([C@@H](C)C3CC3)C4)ccn2n1,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",CNS(=O)(=O)c1cc(-c2ccn3nc(NC(C)=O)cc3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,2.7,IC50,nM,2.7,CNS(=O)(=O)c1cc(-c2ccn3nc(NC(C)=O)cc3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1c(-c2c(N)nn3ccc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)nc23)cnn1C,CHEMBL4665778,=,=,IC50,nM,6.6,IC50,nM,6.6,Cc1c(-c2c(N)nn3ccc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)nc23)cnn1C,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",Cc1nn(C)cc1-c1c(N)nn2ccc(-c3cc4c(c(C(F)(F)F)c3)C(=O)N([C@@H](C)C3CC3)C4)nc12,CHEMBL4665778,=,=,IC50,nM,8.0,IC50,nM,8.0,Cc1nn(C)cc1-c1c(N)nn2ccc(-c3cc4c(c(C(F)(F)F)c3)C(=O)N([C@@H](C)C3CC3)C4)nc12,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",C[C@@H](C1CC1)N1Cc2cc(-c3ccn4nc(N)c(-c5ncccn5)c4n3)cc(C(F)(F)F)c2C1=O,CHEMBL4665778,=,=,IC50,nM,53.0,IC50,nM,53.0,C[C@@H](C1CC1)N1Cc2cc(-c3ccn4nc(N)c(-c5ncccn5)c4n3)cc(C(F)(F)F)c2C1=O,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",CC(C)c1cc(-c2c(N)nn3ccc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)nc23)ccc1C(=O)O,CHEMBL4665778,=,=,IC50,nM,1.0,IC50,nM,1.0,CC(C)c1cc(-c2c(N)nn3ccc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)nc23)ccc1C(=O)O,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",CC(C)c1cc(-c2cnn3ccc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)nc23)ccc1C(=O)O,CHEMBL4665778,=,=,IC50,nM,2.1,IC50,nM,2.1,CC(C)c1cc(-c2cnn3ccc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)nc23)ccc1C(=O)O,2020
"Inhibition of recombinant N-terminal His-tagged full-length human PI3K p120gamma expressed in Sf9 insect cells using phosphatidylinositol 4,5-bisphosphate as substrate preincubated for 60 mins followed by substrate addition and measured after 1 hr in presence of ATP by ADP-Glo lipid kinase assay",C[C@@H](C1CC1)N1Cc2cc(-c3ccn4nc(N)c(-c5cnn(C)c5)c4n3)cc(C(F)(F)F)c2C1=O,CHEMBL4665778,=,=,IC50,nM,1.9,IC50,nM,1.9,C[C@@H](C1CC1)N1Cc2cc(-c3ccn4nc(N)c(-c5cnn(C)c5)c4n3)cc(C(F)(F)F)c2C1=O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,CC(=O)Nc1nc(C)c(-c2cc(C)c3c(c2)CN([C@@H](C)C2CC2)C3=O)s1,CHEMBL4665778,=,=,IC50,nM,87.0,IC50,uM,0.087,CC(=O)Nc1nc(C)c(-c2cc(C)c3c(c2)CN([C@@H](C)C2CC2)C3=O)s1,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccc3[nH]c(N)nc3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,,,IC50,,,IC50,,,Cc1cc(-c2ccc3[nH]c(N)nc3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,CC(=O)Nc1nc2cc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2[nH]1,CHEMBL4665778,=,=,IC50,nM,1000.0,IC50,uM,1.0,CC(=O)Nc1nc2cc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2[nH]1,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccn3nc(N)nc3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,3100.0,IC50,uM,3.1,Cc1cc(-c2ccn3nc(N)nc3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,CC(=O)Nc1nc2cc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccn2n1,CHEMBL4665778,=,=,IC50,nM,3900.0,IC50,uM,3.9,CC(=O)Nc1nc2cc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccn2n1,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccc3nc(N)nn3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,15000.0,IC50,uM,15.0,Cc1cc(-c2ccc3nc(N)nn3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,CC(=O)Nc1nc2ccc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)cn2n1,CHEMBL4665778,=,=,IC50,nM,3000.0,IC50,uM,3.0,CC(=O)Nc1nc2ccc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)cn2n1,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccc3nc(N)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,1500.0,IC50,uM,1.5,Cc1cc(-c2ccc3nc(N)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,CC(=O)Nc1cn2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2n1,CHEMBL4665778,=,=,IC50,nM,450.0,IC50,uM,0.45,CC(=O)Nc1cn2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2n1,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccc3nc(N)c(-c4cnn(C)c4)n3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,490.0,IC50,uM,0.49,Cc1cc(-c2ccc3nc(N)c(-c4cnn(C)c4)n3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccc3ncc(-c4cnn(C)c4)n3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,440.0,IC50,uM,0.44,Cc1cc(-c2ccc3ncc(-c4cnn(C)c4)n3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccn3nc(N)cc3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,4200.0,IC50,uM,4.2,Cc1cc(-c2ccn3nc(N)cc3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,CC(=O)Nc1cc2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccn2n1,CHEMBL4665778,=,=,IC50,nM,240.0,IC50,uM,0.24,CC(=O)Nc1cc2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccn2n1,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccn3nc(N)c(-c4cnn(C)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,200.0,IC50,uM,0.2,Cc1cc(-c2ccn3nc(N)c(-c4cnn(C)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,CC(=O)Nc1nn2ccc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)nc2c1-c1cnn(C)c1,CHEMBL4665778,=,=,IC50,nM,1500.0,IC50,uM,1.5,CC(=O)Nc1nn2ccc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)nc2c1-c1cnn(C)c1,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccn3ncc(-c4cnn(C)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,300.0,IC50,uM,0.3,Cc1cc(-c2ccn3ncc(-c4cnn(C)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,CCC(=O)Nc1cn2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2n1,CHEMBL4665778,=,=,IC50,nM,830.0,IC50,uM,0.83,CCC(=O)Nc1cn2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2n1,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,COCC(=O)Nc1cn2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2n1,CHEMBL4665778,=,=,IC50,nM,690.0,IC50,uM,0.69,COCC(=O)Nc1cn2nc(-c3cc(C)c4c(c3)CN([C@@H](C)C3CC3)C4=O)ccc2n1,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccc3nc(NC(=O)C(C)C)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,9400.0,IC50,uM,9.4,Cc1cc(-c2ccc3nc(NC(=O)C(C)C)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccc3nc(NC(=O)c4ccccc4)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,12000.0,IC50,uM,12.0,Cc1cc(-c2ccc3nc(NC(=O)c4ccccc4)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccc3nc(NS(C)(=O)=O)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,>,>,IC50,nM,30000.0,IC50,uM,30.0,Cc1cc(-c2ccc3nc(NS(C)(=O)=O)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccc3nc(NC(=O)N4CCC[C@H]4C(N)=O)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,460.0,IC50,uM,0.46,Cc1cc(-c2ccc3nc(NC(=O)N4CCC[C@H]4C(N)=O)cn3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccn3nc(N)c(-c4cnn(CCO)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,400.0,IC50,uM,0.4,Cc1cc(-c2ccn3nc(N)c(-c4cnn(CCO)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1ncc(-c2c(N)nn3ccc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)nc23)o1,CHEMBL4665778,=,=,IC50,nM,230.0,IC50,uM,0.23,Cc1ncc(-c2c(N)nn3ccc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)nc23)o1,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccn3nc(N)c(-c4ccn[nH]4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,620.0,IC50,uM,0.62,Cc1cc(-c2ccn3nc(N)c(-c4ccn[nH]4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccn3nc(N)c(-c4nc[nH]n4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,630.0,IC50,uM,0.63,Cc1cc(-c2ccn3nc(N)c(-c4nc[nH]n4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccn3nc(N)c(-c4ccccn4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,2300.0,IC50,uM,2.3,Cc1cc(-c2ccn3nc(N)c(-c4ccccn4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccn3nc(N)c(-c4ccncn4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,550.0,IC50,uM,0.55,Cc1cc(-c2ccn3nc(N)c(-c4ccncn4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2c(N)nn3ccc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)nc23)ccc1C(=O)O,CHEMBL4665778,=,=,IC50,nM,210.0,IC50,uM,0.21,Cc1cc(-c2c(N)nn3ccc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)nc23)ccc1C(=O)O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1cc(-c2ccn3nc(N)c(-c4ccc(CC(=O)O)cc4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,870.0,IC50,uM,0.87,Cc1cc(-c2ccn3nc(N)c(-c4ccc(CC(=O)O)cc4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,CC(=O)Nc1cc2nc(-c3cc4c(c(C(F)(F)F)c3)C(=O)N([C@@H](C)C3CC3)C4)ccn2n1,CHEMBL4665778,=,=,IC50,nM,150.0,IC50,uM,0.15,CC(=O)Nc1cc2nc(-c3cc4c(c(C(F)(F)F)c3)C(=O)N([C@@H](C)C3CC3)C4)ccn2n1,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,CC(=O)Nc1cc2nc(-c3cc4c(c(NS(C)(=O)=O)c3)C(=O)N([C@@H](C)C3CC3)C4)ccn2n1,CHEMBL4665778,=,=,IC50,nM,160.0,IC50,uM,0.16,CC(=O)Nc1cc2nc(-c3cc4c(c(NS(C)(=O)=O)c3)C(=O)N([C@@H](C)C3CC3)C4)ccn2n1,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,CNS(=O)(=O)c1cc(-c2ccn3nc(NC(C)=O)cc3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4665778,=,=,IC50,nM,240.0,IC50,uM,0.24,CNS(=O)(=O)c1cc(-c2ccn3nc(NC(C)=O)cc3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1c(-c2c(N)nn3ccc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)nc23)cnn1C,CHEMBL4665778,=,=,IC50,nM,440.0,IC50,uM,0.44,Cc1c(-c2c(N)nn3ccc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)nc23)cnn1C,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,Cc1nn(C)cc1-c1c(N)nn2ccc(-c3cc4c(c(C(F)(F)F)c3)C(=O)N([C@@H](C)C3CC3)C4)nc12,CHEMBL4665778,=,=,IC50,nM,470.0,IC50,uM,0.47,Cc1nn(C)cc1-c1c(N)nn2ccc(-c3cc4c(c(C(F)(F)F)c3)C(=O)N([C@@H](C)C3CC3)C4)nc12,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,C[C@@H](C1CC1)N1Cc2cc(-c3ccn4nc(N)c(-c5ncccn5)c4n3)cc(C(F)(F)F)c2C1=O,CHEMBL4665778,=,=,IC50,nM,800.0,IC50,uM,0.8,C[C@@H](C1CC1)N1Cc2cc(-c3ccn4nc(N)c(-c5ncccn5)c4n3)cc(C(F)(F)F)c2C1=O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,CC(C)c1cc(-c2c(N)nn3ccc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)nc23)ccc1C(=O)O,CHEMBL4665778,=,=,IC50,nM,76.0,IC50,uM,0.076,CC(C)c1cc(-c2c(N)nn3ccc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)nc23)ccc1C(=O)O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,CC(C)c1cc(-c2cnn3ccc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)nc23)ccc1C(=O)O,CHEMBL4665778,=,=,IC50,nM,74.0,IC50,uM,0.07400000000000001,CC(C)c1cc(-c2cnn3ccc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)nc23)ccc1C(=O)O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins by alphalisa assay,C[C@@H](C1CC1)N1Cc2cc(-c3ccn4nc(N)c(-c5cnn(C)c5)c4n3)cc(C(F)(F)F)c2C1=O,CHEMBL4665778,=,=,IC50,nM,64.0,IC50,uM,0.064,C[C@@H](C1CC1)N1Cc2cc(-c3ccn4nc(N)c(-c5cnn(C)c5)c4n3)cc(C(F)(F)F)c2C1=O,2020
Inhibition of N-terminal His6 tagged recombinant full-length human PI3Kgamma expressed in baculovirus infected Sf21 cells assessed as reduction in PIP3 product formation using PIP2 as substrate preincubated for 15 mins followed by further incubation with substrate and ATP for 1 hr by HTRF assay,Cc1ncc(-c2ccn3ncc(-c4ccc5c(c4)[C@](C)(Cc4ccccc4)C(=O)N5)c3n2)cn1,CHEMBL4665917,,,Inhibition,%,,INH,,,Cc1ncc(-c2ccn3ncc(-c4ccc5c(c4)[C@](C)(Cc4ccccc4)C(=O)N5)c3n2)cn1,2020
Inhibition of N-terminal His6 tagged recombinant full-length human PI3Kgamma expressed in baculovirus infected Sf21 cells assessed as reduction in PIP3 product formation using PIP2 as substrate preincubated for 15 mins followed by further incubation with substrate and ATP for 1 hr by HTRF assay,Cc1ncc(-c2ccn3ncc(-c4ccc5c(c4)[C@](C)(CC4CC4)C(=O)N5)c3n2)cn1,CHEMBL4665917,,,Inhibition,%,,INH,,,Cc1ncc(-c2ccn3ncc(-c4ccc5c(c4)[C@](C)(CC4CC4)C(=O)N5)c3n2)cn1,2020
Inhibition of N-terminal His6 tagged recombinant full-length human PI3Kgamma expressed in baculovirus infected Sf21 cells assessed as reduction in PIP3 product formation using PIP2 as substrate preincubated for 15 mins followed by further incubation with substrate and ATP for 1 hr by HTRF assay,Cc1ncc(-c2nc3c(-c4ccc5c(c4)[C@](C)(CC4CC4)C(=O)N5)ncnc3n2C)cn1,CHEMBL4665917,,,Inhibition,%,,INH,,,Cc1ncc(-c2nc3c(-c4ccc5c(c4)[C@](C)(CC4CC4)C(=O)N5)ncnc3n2C)cn1,2020
Inhibition of N-terminal His6 tagged recombinant full-length human PI3Kgamma expressed in baculovirus infected Sf21 cells assessed as reduction in PIP3 product formation using PIP2 as substrate preincubated for 15 mins followed by further incubation with substrate and ATP for 1 hr by HTRF assay,CCn1c(-c2cnc(C)nc2)nc2c(-c3ccc4c(c3)[C@](C)(CC3CC3)C(=O)N4)ncnc21,CHEMBL4665917,,,Inhibition,%,,INH,,,CCn1c(-c2cnc(C)nc2)nc2c(-c3ccc4c(c3)[C@](C)(CC3CC3)C(=O)N4)ncnc21,2020
Inhibition of N-terminal His6 tagged recombinant full-length human PI3Kgamma expressed in baculovirus infected Sf21 cells assessed as reduction in PIP3 product formation using PIP2 as substrate preincubated for 15 mins followed by further incubation with substrate and ATP for 1 hr by HTRF assay,CCn1c(-c2cnc(C)nc2)nc2c(-c3ccc4c(c3)[C@@]3(CCCN3C(C)C)C(=O)N4)ncnc21,CHEMBL4665917,,,Inhibition,%,,INH,,,CCn1c(-c2cnc(C)nc2)nc2c(-c3ccc4c(c3)[C@@]3(CCCN3C(C)C)C(=O)N4)ncnc21,2020
Inhibition of N-terminal His6 tagged recombinant full-length human PI3Kgamma expressed in baculovirus infected Sf21 cells assessed as reduction in PIP3 product formation using PIP2 as substrate preincubated for 15 mins followed by further incubation with substrate and ATP for 1 hr by HTRF assay,Cc1ncc(-c2nc3c(-c4ccc5c(c4)[C@@]4(CCCN4C(=O)C4CC4)C(=O)N5)ncnc3n2C)cn1,CHEMBL4665917,,,Inhibition,%,,INH,,,Cc1ncc(-c2nc3c(-c4ccc5c(c4)[C@@]4(CCCN4C(=O)C4CC4)C(=O)N5)ncnc3n2C)cn1,2020
Inhibition of N-terminal His6 tagged recombinant full-length human PI3Kgamma expressed in baculovirus infected Sf21 cells assessed as reduction in PIP3 product formation using PIP2 as substrate preincubated for 15 mins followed by further incubation with substrate and ATP for 1 hr by HTRF assay,CCn1c(-c2cnc(C)nc2)nc2c(-c3ccc4c(c3)[C@@]3(CCCN3C(=O)C3CC3)C(=O)N4)ncnc21,CHEMBL4665917,,,Inhibition,%,,INH,,,CCn1c(-c2cnc(C)nc2)nc2c(-c3ccc4c(c3)[C@@]3(CCCN3C(=O)C3CC3)C(=O)N4)ncnc21,2020
Inhibition of N-terminal His6 tagged recombinant full-length human PI3Kgamma expressed in baculovirus infected Sf21 cells assessed as reduction in PIP3 product formation using PIP2 as substrate preincubated for 15 mins followed by further incubation with substrate and ATP for 1 hr by HTRF assay,Cc1ncc(-c2nc3c(-c4ccc5c(c4)[C@@]4(CCCN4C(=O)C4CC4)C(=O)N5C)ncnc3n2C)cn1,CHEMBL4665917,,,Inhibition,%,,INH,,,Cc1ncc(-c2nc3c(-c4ccc5c(c4)[C@@]4(CCCN4C(=O)C4CC4)C(=O)N5C)ncnc3n2C)cn1,2020
Inhibition of N-terminal His6 tagged recombinant full-length human PI3Kgamma expressed in baculovirus infected Sf21 cells assessed as reduction in PIP3 product formation using PIP2 as substrate preincubated for 15 mins followed by further incubation with substrate and ATP for 1 hr by HTRF assay,CCn1c(-c2cnc(C)nc2)nc2c(-c3ccc4c(c3)[C@@]3(CCCN3C(=O)C3CC3)C(=O)N4C)ncnc21,CHEMBL4665917,,,Inhibition,%,,INH,,,CCn1c(-c2cnc(C)nc2)nc2c(-c3ccc4c(c3)[C@@]3(CCCN3C(=O)C3CC3)C(=O)N4C)ncnc21,2020
Inhibition of PI3K-gamma (unknown origin) by HTRF assay,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,CHEMBL4673190,>,>,IC50,nM,200.0,IC50,nM,200.0,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,2020
Inhibition of human PI3Kgamma by ADP-Glo kinase assay,CNC(=O)c1ccc(-c2cnc3cnc(C(=O)N(C)c4ccc(Cl)cc4)cn23)cc1,CHEMBL4680147,=,=,IC50,nM,5917.0,IC50,nM,5917.0,CNC(=O)c1ccc(-c2cnc3cnc(C(=O)N(C)c4ccc(Cl)cc4)cn23)cc1,2020
Inhibition of human PI3Kgamma by ADP-Glo kinase assay,CNC(=O)c1cncc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)c1,CHEMBL4680147,=,=,IC50,nM,324.0,IC50,nM,324.0,CNC(=O)c1cncc(-c2cnc(Cl)c(NS(=O)(=O)c3ccccc3)c2)c1,2020
Inhibition of recombinant human full-length His-tagged p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 2 hrs by ADP-glo assay,O=c1c2c(Cl)cccc2nc([C@@H]2CC3(CC3)CN2c2ncnc3[nH]cnc23)n1-c1ccccc1,CHEMBL4680196,=,=,IC50,nM,113.0,IC50,nM,113.0,O=c1c2c(Cl)cccc2nc([C@@H]2CC3(CC3)CN2c2ncnc3[nH]cnc23)n1-c1ccccc1,2020
Inhibition of recombinant human full-length His-tagged p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 2 hrs by ADP-glo assay,N#Cc1c(N)nc(N)nc1N1CC2(CC2)C[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4680196,=,=,IC50,nM,4.3,IC50,nM,4.3,N#Cc1c(N)nc(N)nc1N1CC2(CC2)C[C@H]1c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2020
Inhibition of PI3Kgamma in human SUDHL-6 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-6 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-6 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-6 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-6 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-6 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-6 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-6 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(C)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(C)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-6 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CC(F)(F)CN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CC(F)(F)CN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-6 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-6 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-10 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-10 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-10 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-10 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-10 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-10 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-10 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-10 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(C)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(C)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-10 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CC(F)(F)CN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CC(F)(F)CN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-10 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human SUDHL-10 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,CC[C@H](C)[C@H](NC(=O)OC(C)(C)C)C(=O)OC1=C(C)[C@@H]2C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@H]4[C@]5(C(=O)OC)OC[C@]34[C@H]([C@@H](O)[C@@H]5O)[C@@]2(C)CC1=O,CHEMBL4699517,,,Inhibition,%,,INH,,,CC[C@H](C)[C@H](NC(=O)OC(C)(C)C)C(=O)OC1=C(C)[C@@H]2C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@H]4[C@]5(C(=O)OC)OC[C@]34[C@H]([C@@H](O)[C@@H]5O)[C@@]2(C)CC1=O,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CCCN5C(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CCCN5C(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](N)C(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](N)C(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](N)CC(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](N)CC(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,CC[C@H](C)[C@H](N)C(=O)OC1=C(C)[C@@H]2C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@H]4[C@]5(C(=O)OC)OC[C@]34[C@H]([C@@H](O)[C@@H]5O)[C@@]2(C)CC1=O,CHEMBL4699517,,,Inhibition,%,,INH,,,CC[C@H](C)[C@H](N)C(=O)OC1=C(C)[C@@H]2C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@H]4[C@]5(C(=O)OC)OC[C@]34[C@H]([C@@H](O)[C@@H]5O)[C@@]2(C)CC1=O,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(C)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(C)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NS(C)(=O)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NS(C)(=O)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](N)C(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](N)C(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](N)C5CC5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](N)C5CC5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](N)C(F)(F)F)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](N)C(F)(F)F)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CC(F)(F)CN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CC(F)(F)CN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(N)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(N)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)COC1=C(C)[C@@H]2C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@H]4[C@]5(C(=O)OC)OC[C@]34[C@H]([C@@H](O)[C@@H]5O)[C@@]2(C)CC1=O,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)COC1=C(C)[C@@H]2C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@H]4[C@]5(C(=O)OC)OC[C@]34[C@H]([C@@H](O)[C@@H]5O)[C@@]2(C)CC1=O,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCC(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCC(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NC(Cc5ccccc5)C(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NC(Cc5ccccc5)C(=O)OC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCC(=O)O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCC(=O)O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NC(Cc5ccccc5)C(=O)O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NC(Cc5ccccc5)C(=O)O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)C5CC5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)C5CC5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)C(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)C(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NC(C)(C)C)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human Raji cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescence assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human MOLT-4 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human MOLT-4 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human MOLT-4 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human MOLT-4 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human MOLT-4 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human MOLT-4 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human MOLT-4 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human MOLT-4 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(C)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(C)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human MOLT-4 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CC(F)(F)CN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CC(F)(F)CN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human MOLT-4 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human MOLT-4 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human RPMI-8226 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human RPMI-8226 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human RPMI-8226 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human RPMI-8226 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human RPMI-8226 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human RPMI-8226 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human RPMI-8226 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human RPMI-8226 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(C)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(C)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human RPMI-8226 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CC(F)(F)CN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CC(F)(F)CN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human RPMI-8226 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human RPMI-8226 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human LCL-1 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human LCL-1 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human LCL-1 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(=O)C[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human LCL-1 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H](C)NC(=O)[C@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human LCL-1 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)CNC(=O)CNC(=O)CN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human LCL-1 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human LCL-1 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@H]5CCCN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human LCL-1 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(C)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)C[C@H](C)NC(C)=O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human LCL-1 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CC(F)(F)CN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H]5CC(F)(F)CN5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human LCL-1 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCC(=O)NCCN)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Inhibition of PI3Kgamma in human LCL-1 cells assessed as inhibition of cell viability at 100 nM after 72 hrs by CellTiter-Glo luminescent assay,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,CHEMBL4699517,,,Inhibition,%,,INH,,,COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OC(=O)[C@@H](C)N)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24,2020
Binding affinity to human PI3Kgamma at 1 uM by KINOMEscan binding assay,CC[C@@H](c1nc2cccc(F)c2c(=O)n1C1CC1)n1nc(-c2ccc(OC)c(F)c2)c2c(N)ncnc21,CHEMBL4699641,,,Activity,,,Activity,,,CC[C@@H](c1nc2cccc(F)c2c(=O)n1C1CC1)n1nc(-c2ccc(OC)c(F)c2)c2c(N)ncnc21,2020
Inhibition of human PI3Kgamma incubated for 1 hr by ADP-Glo kinase assay,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL4706478,,,IC50,,,IC50,,,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2018
Inhibition of human PI3Kgamma incubated for 1 hr by ADP-Glo kinase assay,Nc1ccc(-c2nc(N3CCOCC3)c3ncn(CCCCCCC(=O)NO)c3n2)cn1,CHEMBL4706478,=,=,IC50,nM,793.0,IC50,nM,793.0,Nc1ccc(-c2nc(N3CCOCC3)c3ncn(CCCCCCC(=O)NO)c3n2)cn1,2018
Inhibition of human PI3Kgamma incubated for 1 hr by ADP-Glo kinase assay,O=C(CCCCCCn1cnc2c(N3CCOCC3)nc(-c3cccc(CO)c3)nc21)NO,CHEMBL4706478,=,=,IC50,nM,177.0,IC50,nM,177.0,O=C(CCCCCCn1cnc2c(N3CCOCC3)nc(-c3cccc(CO)c3)nc21)NO,2018
Inhibition of human PI3Kgamma incubated for 1 hr by ADP-Glo kinase assay,Nc1ncc(-c2nc(N3CCOCC3)c3ncn(CCCCCCC(=O)NO)c3n2)cn1,CHEMBL4706478,=,=,IC50,nM,98.0,IC50,nM,98.0,Nc1ncc(-c2nc(N3CCOCC3)c3ncn(CCCCCCC(=O)NO)c3n2)cn1,2018
Inhibition of human PI3Kgamma incubated for 1 hr by ADP-Glo kinase assay,COc1ncc(-c2nc(N3CCOCC3)c3ncn(CCCCCCC(=O)NO)c3n2)cn1,CHEMBL4706478,=,=,IC50,nM,692.0,IC50,nM,692.0,COc1ncc(-c2nc(N3CCOCC3)c3ncn(CCCCCCC(=O)NO)c3n2)cn1,2018
Inhibition of human PI3Kgamma incubated for 1 hr by ADP-Glo kinase assay,Nc1ncc(-c2nc(N3CCOCC3)c3ccn(CCCCCCC(=O)NO)c3n2)cn1,CHEMBL4706478,=,=,IC50,nM,92.0,IC50,nM,92.0,Nc1ncc(-c2nc(N3CCOCC3)c3ccn(CCCCCCC(=O)NO)c3n2)cn1,2018
Inhibition of human PI3Kgamma incubated for 1 hr by ADP-Glo kinase assay,COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,CHEMBL4706478,=,=,IC50,nM,112.0,IC50,nM,112.0,COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,2018
Inhibition of human PI3Kgamma incubated for 1 hr by ADP-Glo kinase assay,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL4706478,=,=,IC50,nM,71.0,IC50,nM,71.0,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2018
Inhibition of human wild type partial length PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system by Kinomescan method,O=C(CCCCCCn1cnc2c(N3CCOCC3)nc(-c3cccc(CO)c3)nc21)NO,CHEMBL4706478,=,=,Kd,nM,86.0,Kd,nM,86.0,O=C(CCCCCCn1cnc2c(N3CCOCC3)nc(-c3cccc(CO)c3)nc21)NO,2018
Inhibition of human wild type partial length PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system by Kinomescan method,Nc1ncc(-c2nc(N3CCOCC3)c3ccn(CCCCCCC(=O)NO)c3n2)cn1,CHEMBL4706478,=,=,Kd,nM,100.0,Kd,nM,100.0,Nc1ncc(-c2nc(N3CCOCC3)c3ccn(CCCCCCC(=O)NO)c3n2)cn1,2018
Inhibition of PI3Kgamma (unknown origin),Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL4706599,=,=,IC50,nM,656.6,IC50,nM,656.6,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2020
Inhibition of PI3Kgamma (unknown origin),C=CC(=O)Nc1cc(Nc2ncnc3ccc(-c4cnc5ccccc5c4)cc23)ccc1C,CHEMBL4706599,=,=,IC50,nM,1248.8,IC50,nM,1248.8,C=CC(=O)Nc1cc(Nc2ncnc3ccc(-c4cnc5ccccc5c4)cc23)ccc1C,2020
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1cccc(S(C)(=O)=O)c1,CHEMBL4715688,=,=,IC50,nM,3340.0,IC50,uM,3.34,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1cccc(S(C)(=O)=O)c1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1ccccc1S(C)(=O)=O,CHEMBL4715688,=,=,IC50,nM,63400.0,IC50,uM,63.4,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1ccccc1S(C)(=O)=O,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1cc(F)cc(F)c1,CHEMBL4715688,=,=,IC50,nM,3550.0,IC50,uM,3.55,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1cc(F)cc(F)c1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1ccc(F)cc1,CHEMBL4715688,=,=,IC50,nM,1420.0,IC50,uM,1.42,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1ccc(F)cc1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1ccccc1,CHEMBL4715688,=,=,IC50,nM,27500.0,IC50,uM,27.5,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1ccccc1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1cncc(F)c1,CHEMBL4715688,=,=,IC50,nM,24800.0,IC50,uM,24.8,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1cncc(F)c1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1cccnc1,CHEMBL4715688,=,=,IC50,nM,82500.0,IC50,uM,82.5,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1cccnc1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1ccccn1,CHEMBL4715688,=,=,IC50,nM,7920.0,IC50,uM,7.92,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cn2c1-c1ccccn1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1cncc(F)c1,CHEMBL4715688,=,=,IC50,nM,5900.0,IC50,uM,5.9,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1cncc(F)c1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1cccnc1,CHEMBL4715688,=,=,IC50,nM,5800.0,IC50,uM,5.8,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1cccnc1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1ccccn1,CHEMBL4715688,=,=,IC50,nM,12600.0,IC50,uM,12.6,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1ccccn1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1ccccc1,CHEMBL4715688,=,=,IC50,nM,1400.0,IC50,uM,1.4,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1ccccc1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1C1CC1,CHEMBL4715688,=,=,IC50,nM,144.0,IC50,uM,0.14400000000000002,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1C1CC1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1cc(F)cc(F)c1,CHEMBL4715688,=,=,IC50,nM,270.0,IC50,uM,0.27,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1cc(F)cc(F)c1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1ccc(F)cc1,CHEMBL4715688,=,=,IC50,nM,191.0,IC50,uM,0.191,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1ccc(F)cc1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1cccc(F)c1,CHEMBL4715688,=,=,IC50,nM,118.0,IC50,uM,0.11800000000000001,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1cccc(F)c1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1ccccc1S(C)(=O)=O,CHEMBL4715688,=,=,IC50,nM,61900.0,IC50,uM,61.9,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1ccccc1S(C)(=O)=O,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2cc(F)ccc2n1-c1cccc(S(C)(=O)=O)c1,CHEMBL4715688,=,=,IC50,nM,14000.0,IC50,uM,14.0,C[C@H](Nc1ncnc(N)c1C#N)c1nc2cc(F)ccc2n1-c1cccc(S(C)(=O)=O)c1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@@H](Nc1ncnc(N)c1C#N)c1nc2cc(F)ccc2n1-c1cccc(S(C)(=O)=O)c1,CHEMBL4715688,>,>,IC50,nM,125000.0,IC50,uM,125.0,C[C@@H](Nc1ncnc(N)c1C#N)c1nc2cc(F)ccc2n1-c1cccc(S(C)(=O)=O)c1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1cccc(S(C)(=O)=O)c1,CHEMBL4715688,=,=,IC50,nM,2880.0,IC50,uM,2.88,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1cccc(S(C)(=O)=O)c1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,C[C@@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1cccc(S(C)(=O)=O)c1,CHEMBL4715688,=,=,IC50,nM,29500.0,IC50,uM,29.5,C[C@@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1cccc(S(C)(=O)=O)c1,2016
Inhibition of recombinant full length N-terminal polyHis-tagged PI3Kgamma (114 to 1102 residues) (unknown origin) expressed in baculovirus infected Hi-5 cells using PIP2 as substrate in presence of ATP incubated for 20 mins by Alphascreen assay,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC2(CCOCC2)c2ncc(N3CCOCC3)cc21,CHEMBL4715688,=,=,IC50,nM,825.0,IC50,uM,0.825,Cc1c(-c2ccccn2)nc2cc(F)ccc2c1N1CC2(CCOCC2)c2ncc(N3CCOCC3)cc21,2016
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in HEK293 cells measured after 1 hr by Kinomescan method,C[C@@H]1COCCN1c1nc(-c2cnc(N)cc2C(F)F)nc(N2[C@H](C)COC[C@@H]2C)n1,CHEMBL4715860,=,=,Kd,nM,1350.0,Kd,nM,1350.0,C[C@@H]1COCCN1c1nc(-c2cnc(N)cc2C(F)F)nc(N2[C@H](C)COC[C@@H]2C)n1,2020
Binding affinity to wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in HEK293 cells measured after 1 hr by Kinomescan method,C[C@@H]1COCCN1c1nc(-c2cnc(N)cc2C(F)F)nc(N2CCOCC2(C)C)n1,CHEMBL4715860,=,=,Kd,nM,595.0,Kd,nM,595.0,C[C@@H]1COCCN1c1nc(-c2cnc(N)cc2C(F)F)nc(N2CCOCC2(C)C)n1,2020
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate in presence of ATP measured after 45 mins by HTRF assay relative to control,C[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4715876,=,=,IC50,nM,20.5,IC50,nM,20.5,C[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2020
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate in presence of ATP measured after 45 mins by HTRF assay relative to control,C[C@H](Nc1nc(N)nc(N)c1C#N)c1c(-c2ccccc2)c(=O)n2cc(F)ccc2c1-c1ccc(F)cc1,CHEMBL4715876,=,=,IC90,nM,159.8,IC90,nM,159.8,C[C@H](Nc1nc(N)nc(N)c1C#N)c1c(-c2ccccc2)c(=O)n2cc(F)ccc2c1-c1ccc(F)cc1,2020
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate in presence of ATP measured after 45 mins by HTRF assay relative to control,C[C@H](Nc1nc(N)nc(N)c1C#N)c1c(-c2ccccc2)c(=O)n2cc(F)ccc2c1-c1ccc(F)cc1,CHEMBL4715876,=,=,IC50,nM,17.9,IC50,nM,17.9,C[C@H](Nc1nc(N)nc(N)c1C#N)c1c(-c2ccccc2)c(=O)n2cc(F)ccc2c1-c1ccc(F)cc1,2020
Inhibition of PI3Kgamma (unknown origin),CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C4CCCC4)C(=O)C3)cc2n1,CHEMBL4725342,>,>,IC50,nM,500.0,IC50,nM,500.0,CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C4CCCC4)C(=O)C3)cc2n1,2020
Inhibition of PI3Kgamma (unknown origin),CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C4CCCC4)CC3=O)cc2n1,CHEMBL4725342,=,=,IC50,nM,370.0,IC50,nM,370.0,CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C4CCCC4)CC3=O)cc2n1,2020
Inhibition of PI3Kgamma (unknown origin),C=CCN1CCN(Cc2cc3nc(-n4c(CC)nc5ccccc54)nc(N4CCOCC4)c3s2)C(=O)C1,CHEMBL4725342,=,=,IC50,nM,266.0,IC50,nM,266.0,C=CCN1CCN(Cc2cc3nc(-n4c(CC)nc5ccccc54)nc(N4CCOCC4)c3s2)C(=O)C1,2020
Inhibition of PI3Kgamma (unknown origin),CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C(=O)C4CC4)CC3=O)cc2n1,CHEMBL4725342,=,=,IC50,nM,185.0,IC50,nM,185.0,CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C(=O)C4CC4)CC3=O)cc2n1,2020
Inhibition of PI3Kgamma (unknown origin),CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C(=O)C4CCC4)CC3=O)cc2n1,CHEMBL4725342,=,=,IC50,nM,303.0,IC50,nM,303.0,CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C(=O)C4CCC4)CC3=O)cc2n1,2020
Inhibition of PI3Kgamma (unknown origin),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4725342,=,=,IC50,nM,245.0,IC50,nM,245.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2020
Inhibition of recombinant human His-tagged PI3Kgamma expressed in baculovirus expression system using PIP2:PS as substrate incubated for 1 hr by invitrogen adapta assay,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL4725342,=,=,IC50,nM,89.0,IC50,nM,89.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2020
Inhibition of wild-type human partial length PIK3CG (S144 to A1102 residues) expressed in mammalian expression system at 1 uM by Kinomescan method,COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12,CHEMBL4725356,,,Inhibition,%,,INH,,,COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3c(c2)CC(=O)N3)cc2c1C(=O)N(C(C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,600.0,IC50,uM,0.6,Cc1cc(-c2cnc3c(c2)CC(=O)N3)cc2c1C(=O)N(C(C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]c(=O)ccc3c2)cc2c1C(=O)N(C(C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,530.0,IC50,uM,0.53,Cc1cc(-c2cnc3[nH]c(=O)ccc3c2)cc2c1C(=O)N(C(C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]nnc3c2)cc2c1C(=O)N(C(C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,1600.0,IC50,uM,1.6,Cc1cc(-c2cnc3[nH]nnc3c2)cc2c1C(=O)N(C(C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]ncc3c2)cc2c1C(=O)N(C(C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,90.0,IC50,uM,0.09,Cc1cc(-c2cnc3[nH]ncc3c2)cc2c1C(=O)N(C(C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3cn[nH]c3c2)cc2c1C(=O)N(C(C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,490.0,IC50,uM,0.49,Cc1cc(-c2cnc3cn[nH]c3c2)cc2c1C(=O)N(C(C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]ncc3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,35.0,IC50,uM,0.035,Cc1cc(-c2cnc3[nH]ncc3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]ncc3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,80.0,IC50,uM,0.08,Cc1cc(-c2cnc3[nH]ncc3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]ccc3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,50.0,IC50,uM,0.05,Cc1cc(-c2cnc3[nH]ccc3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]nc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,8.0,IC50,nM,8.0,Cc1cc(-c2cnc3[nH]nc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,3.4,IC50,nM,3.4,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,9.0,IC50,nM,9.0,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4cccnc4)c3c2)cc2c1C(=O)N(C(C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,7.0,IC50,nM,7.0,Cc1cc(-c2cnc3[nH]cc(-c4cccnc4)c3c2)cc2c1C(=O)N(C(C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccccn4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,33.0,IC50,nM,33.0,Cc1cc(-c2cnc3[nH]cc(-c4ccccn4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(C)(C)O)nc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,3.3,IC50,nM,3.3,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(C)(C)O)nc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccc(C#N)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,42.0,IC50,nM,42.0,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C#N)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccnc(N)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,5.8,IC50,nM,5.8,Cc1cc(-c2cnc3[nH]cc(-c4ccnc(N)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccnc(C(F)(F)F)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,16.0,IC50,nM,16.0,Cc1cc(-c2cnc3[nH]cc(-c4ccnc(C(F)(F)F)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccn(C)c(=O)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,26.0,IC50,nM,26.0,Cc1cc(-c2cnc3[nH]cc(-c4ccn(C)c(=O)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,3.26,IC50,nM,3.26,Cc1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(C4CCNC4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,281.0,IC50,nM,281.0,Cc1cc(-c2cnc3[nH]cc(C4CCNC4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(C(=O)O)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,13.0,IC50,nM,13.0,Cc1cc(-c2cnc3[nH]cc(C(=O)O)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(C(=O)Nc4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,12.0,IC50,nM,12.0,Cc1cc(-c2cnc3[nH]cc(C(=O)Nc4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(C(=O)NC4CCOCC4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,4.5,IC50,nM,4.5,Cc1cc(-c2cnc3[nH]cc(C(=O)NC4CCOCC4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,2.5,IC50,nM,2.5,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)ccc1C(=O)O,CHEMBL4725475,=,=,IC50,nM,2.8,IC50,nM,2.8,Cc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)ccc1C(=O)O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(C(C)C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,2.1,IC50,nM,2.1,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(C(C)C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(C5CC5)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,1.6,IC50,nM,1.6,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(C5CC5)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)cc(C)c1C(=O)O,CHEMBL4725475,=,=,IC50,nM,2.2,IC50,nM,2.2,Cc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)cc(C)c1C(=O)O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4cc(C)c(C(=O)O)c(C5CC5)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,1.2,IC50,nM,1.2,Cc1cc(-c2cnc3[nH]cc(-c4cc(C)c(C(=O)O)c(C5CC5)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(F)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,3.1,IC50,nM,3.1,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(F)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(C(F)(F)F)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,1.64,IC50,nM,1.64,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(C(F)(F)F)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",COc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)ccc1C(=O)O,CHEMBL4725475,=,=,IC50,nM,1.5,IC50,nM,1.5,COc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)ccc1C(=O)O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(N5CCCC5)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,4.0,IC50,nM,4.0,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(N5CCCC5)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4cccc(C(=O)O)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,2.7,IC50,nM,2.7,Cc1cc(-c2cnc3[nH]cc(-c4cccc(C(=O)O)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1ccc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)cc1C(=O)O,CHEMBL4725475,=,=,IC50,nM,5.0,IC50,nM,5.0,Cc1ccc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)cc1C(=O)O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccccc4C(=O)O)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,180.0,IC50,nM,180.0,Cc1cc(-c2cnc3[nH]cc(-c4ccccc4C(=O)O)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(N)=O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,2.59,IC50,nM,2.59,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(N)=O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccc(S(N)(=O)=O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,5.0,IC50,nM,5.0,Cc1cc(-c2cnc3[nH]cc(-c4ccc(S(N)(=O)=O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",CC[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5ccncc5)c4c3)cc(C)c2C1=O,CHEMBL4725475,=,=,IC50,nM,6.0,IC50,nM,6.0,CC[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5ccncc5)c4c3)cc(C)c2C1=O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C(C1CC1)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,6.8,IC50,nM,6.8,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C(C1CC1)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",COC[C@H](C)N1Cc2cc(-c3cnc4[nH]cc(-c5ccncc5)c4c3)cc(C)c2C1=O,CHEMBL4725475,=,=,IC50,nM,9.0,IC50,nM,9.0,COC[C@H](C)N1Cc2cc(-c3cnc4[nH]cc(-c5ccncc5)c4c3)cc(C)c2C1=O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C1CCOCC1)C2,CHEMBL4725475,=,=,IC50,nM,50.0,IC50,nM,50.0,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C1CCOCC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C(C)(C)C)C2,CHEMBL4725475,=,=,IC50,nM,26.0,IC50,nM,26.0,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C(C)(C)C)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C(C)(C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,28.0,IC50,nM,28.0,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C(C)(C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)c1ccc(F)cc1)C2,CHEMBL4725475,=,=,IC50,nM,40.0,IC50,nM,40.0,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)c1ccc(F)cc1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(CC(F)(F)F)C2,CHEMBL4725475,=,=,IC50,nM,25.3,IC50,nM,25.3,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(CC(F)(F)F)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",CC(C)c1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,4.2,IC50,nM,4.2,CC(C)c1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",COc1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,4.3,IC50,nM,4.3,COc1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(Cl)c2C1=O,CHEMBL4725475,=,=,IC50,nM,2.4,IC50,nM,2.4,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(Cl)c2C1=O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(C#N)c2C1=O,CHEMBL4725475,=,=,IC50,nM,3.7,IC50,nM,3.7,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(C#N)c2C1=O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(C(F)(F)F)c2C1=O,CHEMBL4725475,=,=,IC50,nM,2.4,IC50,nM,2.4,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(C(F)(F)F)c2C1=O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",CNC(=O)c1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,7.9,IC50,nM,7.9,CNC(=O)c1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",CC(=O)Nc1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,2.5,IC50,nM,2.5,CC(=O)Nc1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",CNS(=O)(=O)c1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,4.0,IC50,nM,4.0,CNS(=O)(=O)c1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(S(=O)(=O)N(C)C)c2C1=O,CHEMBL4725475,=,=,IC50,nM,2.6,IC50,nM,2.6,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(S(=O)(=O)N(C)C)c2C1=O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(NS(C)(=O)=O)c2C1=O,CHEMBL4725475,=,=,IC50,nM,4.0,IC50,nM,4.0,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(NS(C)(=O)=O)c2C1=O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(S(C)(=O)=O)c2C1=O,CHEMBL4725475,=,=,IC50,nM,1.5,IC50,nM,1.5,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(S(C)(=O)=O)c2C1=O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2c[nH]c3ncc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)cc23)ccc1C(=O)O,CHEMBL4725475,=,=,IC50,nM,1.2,IC50,nM,1.2,Cc1cc(-c2c[nH]c3ncc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)cc23)ccc1C(=O)O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2c[nH]c3ncc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)cc23)cc(C)c1C(=O)O,CHEMBL4725475,=,=,IC50,nM,2.8,IC50,nM,2.8,Cc1cc(-c2c[nH]c3ncc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)cc23)cc(C)c1C(=O)O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccc(CC(=O)O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,2.6,IC50,nM,2.6,Cc1cc(-c2cnc3[nH]cc(-c4ccc(CC(=O)O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)ccc1CC(=O)O,CHEMBL4725475,=,=,IC50,nM,3.3,IC50,nM,3.3,Cc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)ccc1CC(=O)O,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(C)(C)C(=O)O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,2.1,IC50,nM,2.1,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(C)(C)C(=O)O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",Cc1cc(-c2cnc3[nH]cc(-c4ccc(C5(C(=O)O)CC5)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,3.3,IC50,nM,3.3,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C5(C(=O)O)CC5)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
"Inhibition of PI3K p120gamma (unknown origin) using phosphatidylinositol 4,5-bisphosphate as substrate in presence of ATP incubated for 60 mins by ADP-Glo assay",C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5ccc(C6(C(=O)O)CC6)cc5)c4c3)cc(C(F)(F)F)c2C1=O,CHEMBL4725475,=,=,IC50,nM,3.6,IC50,nM,3.6,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5ccc(C6(C(=O)O)CC6)cc5)c4c3)cc(C(F)(F)F)c2C1=O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,220.0,IC50,uM,0.22,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4cccnc4)c3c2)cc2c1C(=O)N(C(C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,400.0,IC50,uM,0.4,Cc1cc(-c2cnc3[nH]cc(-c4cccnc4)c3c2)cc2c1C(=O)N(C(C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccccn4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,3500.0,IC50,uM,3.5,Cc1cc(-c2cnc3[nH]cc(-c4ccccn4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(C)(C)O)nc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,600.0,IC50,uM,0.6,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(C)(C)O)nc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C#N)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,3500.0,IC50,uM,3.5,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C#N)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccnc(N)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,400.0,IC50,uM,0.4,Cc1cc(-c2cnc3[nH]cc(-c4ccnc(N)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccnc(C(F)(F)F)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,4000.0,IC50,uM,4.0,Cc1cc(-c2cnc3[nH]cc(-c4ccnc(C(F)(F)F)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccn(C)c(=O)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,200.0,IC50,uM,0.2,Cc1cc(-c2cnc3[nH]cc(-c4ccn(C)c(=O)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,200.0,IC50,uM,0.2,Cc1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(C4CCNC4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,3800.0,IC50,uM,3.8,Cc1cc(-c2cnc3[nH]cc(C4CCNC4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(C(=O)O)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,11000.0,IC50,uM,11.0,Cc1cc(-c2cnc3[nH]cc(C(=O)O)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(C(=O)Nc4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,1300.0,IC50,uM,1.3,Cc1cc(-c2cnc3[nH]cc(C(=O)Nc4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(C(=O)NC4CCOCC4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,320.0,IC50,uM,0.32,Cc1cc(-c2cnc3[nH]cc(C(=O)NC4CCOCC4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,140.0,IC50,uM,0.14,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)ccc1C(=O)O,CHEMBL4725475,=,=,IC50,nM,78.0,IC50,uM,0.078,Cc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)ccc1C(=O)O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(C(C)C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,59.0,IC50,uM,0.059000000000000004,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(C(C)C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(C5CC5)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,40.0,IC50,uM,0.04,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(C5CC5)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)cc(C)c1C(=O)O,CHEMBL4725475,=,=,IC50,nM,90.0,IC50,uM,0.09,Cc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)cc(C)c1C(=O)O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4cc(C)c(C(=O)O)c(C5CC5)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,70.0,IC50,uM,0.07,Cc1cc(-c2cnc3[nH]cc(-c4cc(C)c(C(=O)O)c(C5CC5)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(F)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,700.0,IC50,uM,0.7,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(F)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(C(F)(F)F)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,350.0,IC50,uM,0.35,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(C(F)(F)F)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,COc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)ccc1C(=O)O,CHEMBL4725475,=,=,IC50,nM,170.0,IC50,uM,0.17,COc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)ccc1C(=O)O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(N5CCCC5)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,170.0,IC50,uM,0.17,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(=O)O)c(N5CCCC5)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4cccc(C(=O)O)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,110.0,IC50,uM,0.11,Cc1cc(-c2cnc3[nH]cc(-c4cccc(C(=O)O)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1ccc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)cc1C(=O)O,CHEMBL4725475,=,=,IC50,nM,260.0,IC50,uM,0.26,Cc1ccc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)cc1C(=O)O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccccc4C(=O)O)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,15000.0,IC50,uM,15.0,Cc1cc(-c2cnc3[nH]cc(-c4ccccc4C(=O)O)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(N)=O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,230.0,IC50,uM,0.23,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(N)=O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccc(S(N)(=O)=O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,400.0,IC50,uM,0.4,Cc1cc(-c2cnc3[nH]cc(-c4ccc(S(N)(=O)=O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,CC[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5ccncc5)c4c3)cc(C)c2C1=O,CHEMBL4725475,=,=,IC50,nM,800.0,IC50,uM,0.8,CC[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5ccncc5)c4c3)cc(C)c2C1=O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C(C1CC1)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,800.0,IC50,uM,0.8,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C(C1CC1)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,COC[C@H](C)N1Cc2cc(-c3cnc4[nH]cc(-c5ccncc5)c4c3)cc(C)c2C1=O,CHEMBL4725475,=,=,IC50,nM,600.0,IC50,uM,0.6,COC[C@H](C)N1Cc2cc(-c3cnc4[nH]cc(-c5ccncc5)c4c3)cc(C)c2C1=O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C1CCOCC1)C2,CHEMBL4725475,=,=,IC50,nM,1000.0,IC50,uM,1.0,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C1CCOCC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C(C)(C)C)C2,CHEMBL4725475,=,=,IC50,nM,720.0,IC50,uM,0.72,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C(C)(C)C)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C(C)(C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,1100.0,IC50,uM,1.1,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(C(C)(C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)c1ccc(F)cc1)C2,CHEMBL4725475,=,=,IC50,nM,2100.0,IC50,uM,2.1,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)c1ccc(F)cc1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(CC(F)(F)F)C2,CHEMBL4725475,=,=,IC50,nM,1600.0,IC50,uM,1.6,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N(CC(F)(F)F)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,CC(C)c1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,300.0,IC50,uM,0.3,CC(C)c1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,COc1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,170.0,IC50,uM,0.17,COc1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(Cl)c2C1=O,CHEMBL4725475,=,=,IC50,nM,170.0,IC50,uM,0.17,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(Cl)c2C1=O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(C#N)c2C1=O,CHEMBL4725475,=,=,IC50,nM,170.0,IC50,uM,0.17,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(C#N)c2C1=O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(C(F)(F)F)c2C1=O,CHEMBL4725475,=,=,IC50,nM,90.0,IC50,uM,0.09,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(C(F)(F)F)c2C1=O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,CNC(=O)c1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,730.0,IC50,uM,0.73,CNC(=O)c1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,CC(=O)Nc1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,500.0,IC50,uM,0.5,CC(=O)Nc1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,CNS(=O)(=O)c1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,70.0,IC50,uM,0.07,CNS(=O)(=O)c1cc(-c2cnc3[nH]cc(-c4cnn(C)c4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(S(=O)(=O)N(C)C)c2C1=O,CHEMBL4725475,=,=,IC50,nM,100.0,IC50,uM,0.1,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(S(=O)(=O)N(C)C)c2C1=O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(NS(C)(=O)=O)c2C1=O,CHEMBL4725475,=,=,IC50,nM,150.0,IC50,uM,0.15,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(NS(C)(=O)=O)c2C1=O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(S(C)(=O)=O)c2C1=O,CHEMBL4725475,=,=,IC50,nM,50.0,IC50,uM,0.05,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5cnn(C)c5)c4c3)cc(S(C)(=O)=O)c2C1=O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2c[nH]c3ncc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)cc23)ccc1C(=O)O,CHEMBL4725475,=,=,IC50,nM,40.0,IC50,uM,0.04,Cc1cc(-c2c[nH]c3ncc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)cc23)ccc1C(=O)O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2c[nH]c3ncc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)cc23)cc(C)c1C(=O)O,CHEMBL4725475,=,=,IC50,nM,30.0,IC50,uM,0.03,Cc1cc(-c2c[nH]c3ncc(-c4cc5c(c(C(F)(F)F)c4)C(=O)N([C@@H](C)C4CC4)C5)cc23)cc(C)c1C(=O)O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccc(CC(=O)O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,160.0,IC50,uM,0.16,Cc1cc(-c2cnc3[nH]cc(-c4ccc(CC(=O)O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)ccc1CC(=O)O,CHEMBL4725475,=,=,IC50,nM,150.0,IC50,uM,0.15,Cc1cc(-c2c[nH]c3ncc(-c4cc(C)c5c(c4)CN([C@@H](C)C4CC4)C5=O)cc23)ccc1CC(=O)O,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(C)(C)C(=O)O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,180.0,IC50,uM,0.18,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C(C)(C)C(=O)O)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C5(C(=O)O)CC5)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,CHEMBL4725475,=,=,IC50,nM,150.0,IC50,uM,0.15,Cc1cc(-c2cnc3[nH]cc(-c4ccc(C5(C(=O)O)CC5)cc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,2020
Inhibition of PI3Kgamma in human THP-1 cells assessed as reduction in Akt phosphorylation at S473 residue incubated for 60 mins measured after 120 mins by by alphalisa assay,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5ccc(C6(C(=O)O)CC6)cc5)c4c3)cc(C(F)(F)F)c2C1=O,CHEMBL4725475,=,=,IC50,nM,110.0,IC50,uM,0.11,C[C@@H](C1CC1)N1Cc2cc(-c3cnc4[nH]cc(-c5ccc(C6(C(=O)O)CC6)cc5)c4c3)cc(C(F)(F)F)c2C1=O,2020
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,CHEMBL4765230,=,=,IC50,nM,7.0,IC50,nM,7.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1,CHEMBL4765230,=,=,IC50,nM,72.0,IC50,nM,72.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cncc(F)c1,CHEMBL4765230,=,=,IC50,nM,150.0,IC50,nM,150.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cncc(F)c1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cncc(Cl)c1,CHEMBL4765230,=,=,IC50,nM,1200.0,IC50,nM,1200.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cncc(Cl)c1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",COc1cncc(-n2c([C@H](C)Nc3nc(N)nc(N)c3C#N)nc3cccc(Cl)c3c2=O)c1,CHEMBL4765230,=,=,IC50,nM,830.0,IC50,nM,830.0,COc1cncc(-n2c([C@H](C)Nc3nc(N)nc(N)c3C#N)nc3cccc(Cl)c3c2=O)c1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cncc(C2CC2)c1,CHEMBL4765230,=,=,IC50,nM,2300.0,IC50,nM,2300.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cncc(C2CC2)c1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cncc(C(F)(F)F)c1,CHEMBL4765230,=,=,IC50,nM,1300.0,IC50,nM,1300.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cncc(C(F)(F)F)c1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cncc(C#N)c1,CHEMBL4765230,=,=,IC50,nM,700.0,IC50,nM,700.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2cccc(Cl)c2c(=O)n1-c1cncc(C#N)c1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",Cc1ncccc1-n1c([C@H](C)Nc2nc(N)nc(N)c2C#N)nc2cccc(Cl)c2c1=O,CHEMBL4765230,=,=,IC50,nM,160.0,IC50,nM,160.0,Cc1ncccc1-n1c([C@H](C)Nc2nc(N)nc(N)c2C#N)nc2cccc(Cl)c2c1=O,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",Cc1ncccc1-n1c([C@H](C)Nc2nc(N)nc(N)c2C#N)nc2cccc(Cl)c2c1=O,CHEMBL4765230,=,=,IC50,nM,650.0,IC50,nM,650.0,Cc1ncccc1-n1c([C@H](C)Nc2nc(N)nc(N)c2C#N)nc2cccc(Cl)c2c1=O,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",Cc1ccncc1-n1c([C@H](C)Nc2nc(N)nc(N)c2C#N)nc2cccc(Cl)c2c1=O,CHEMBL4765230,=,=,IC50,nM,70.0,IC50,nM,70.0,Cc1ccncc1-n1c([C@H](C)Nc2nc(N)nc(N)c2C#N)nc2cccc(Cl)c2c1=O,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",Cc1ccncc1-n1c([C@H](C)Nc2nc(N)nc(N)c2C#N)nc2cccc(Cl)c2c1=O,CHEMBL4765230,=,=,IC50,nM,1300.0,IC50,nM,1300.0,Cc1ccncc1-n1c([C@H](C)Nc2nc(N)nc(N)c2C#N)nc2cccc(Cl)c2c1=O,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",Cc1c(F)cncc1-n1c([C@H](C)Nc2nc(N)nc(N)c2C#N)nc2cccc(Cl)c2c1=O,CHEMBL4765230,=,=,IC50,nM,25.0,IC50,nM,25.0,Cc1c(F)cncc1-n1c([C@H](C)Nc2nc(N)nc(N)c2C#N)nc2cccc(Cl)c2c1=O,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",Cc1c(F)cncc1-n1c([C@H](C)Nc2nc(N)nc(N)c2C#N)nc2cccc(Cl)c2c1=O,CHEMBL4765230,=,=,IC50,nM,6900.0,IC50,nM,6900.0,Cc1c(F)cncc1-n1c([C@H](C)Nc2nc(N)nc(N)c2C#N)nc2cccc(Cl)c2c1=O,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(Cl)cccc2c(=O)n1-c1cccnc1,CHEMBL4765230,=,=,IC50,nM,1100.0,IC50,nM,1100.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(Cl)cccc2c(=O)n1-c1cccnc1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(Cl)ccc(Cl)c2c(=O)n1-c1cccnc1,CHEMBL4765230,=,=,IC50,nM,330.0,IC50,nM,330.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(Cl)ccc(Cl)c2c(=O)n1-c1cccnc1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(F)ccc(F)c2c(=O)n1-c1cccnc1,CHEMBL4765230,=,=,IC50,nM,940.0,IC50,nM,940.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(F)ccc(F)c2c(=O)n1-c1cccnc1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cccnc1,CHEMBL4765230,=,=,IC50,nM,51.0,IC50,nM,51.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cccnc1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cncc(F)c1,CHEMBL4765230,=,=,IC50,nM,120.0,IC50,nM,120.0,C[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cncc(F)c1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",CC[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cccnc1,CHEMBL4765230,=,=,IC50,nM,520.0,IC50,nM,520.0,CC[C@H](Nc1nc(N)nc(N)c1C#N)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cccnc1,2016
"Inhibition of human full length PI3K p110gamma using phosphatidylinositol 3,4,5-trisphosphate as substrate measured after 30 mins by TR-FRET assay",N#Cc1c(N)nc(N)nc1N[C@H](c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cccnc1)C1CC1,CHEMBL4765230,=,=,IC50,nM,190.0,IC50,nM,190.0,N#Cc1c(N)nc(N)nc1N[C@H](c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cccnc1)C1CC1,2016
Inhibition of PI3K p110gamma in human basophil assessed as reduction in fMLP-induced basophil activation by flow cytometry analysis,N#Cc1c(N)nc(N)nc1N[C@H](c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cccnc1)C1CC1,CHEMBL4765230,=,=,EC50,nM,403.6,EC50,nM,403.6,N#Cc1c(N)nc(N)nc1N[C@H](c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cccnc1)C1CC1,2016
Inhibition of PI3K p110gamma in human basophil assessed as reduction in fMLP-induced basophil activation in presence of 25% serum by flow cytometry analysis,N#Cc1c(N)nc(N)nc1N[C@H](c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cccnc1)C1CC1,CHEMBL4765230,=,=,EC50,nM,581.0,EC50,nM,581.0,N#Cc1c(N)nc(N)nc1N[C@H](c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cccnc1)C1CC1,2016
"Inhibition of recombinant human full length PI3K p120gamma assessed as residual activity at 10 uM using phosphatidylinositol-4, 5-bisphosphate as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control",CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1,CHEMBL4765237,=,=,Activity,%,89.0,Activity,%,89.0,CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1,2018
Inhibition of GST-tagged human recombinant PI3Kgamma catalytic domain (468 to 1203 residues) expressed in insect cells using PIP2 peptide as substrate incubated for 1 hr in presence ATP by ADP-Glo Kinase Assay,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)Nc2ccc(F)cc2)cc1,CHEMBL4765307,=,=,IC50,nM,289.0,IC50,nM,289.0,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)Nc2ccc(F)cc2)cc1,2020
Inhibition of GST-tagged human recombinant PI3Kgamma catalytic domain (468 to 1203 residues) expressed in insect cells using PIP2 peptide as substrate incubated for 1 hr in presence ATP by ADP-Glo Kinase Assay,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)Nc2ccccc2F)cc1,CHEMBL4765307,=,=,IC50,nM,302.0,IC50,nM,302.0,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)Nc2ccccc2F)cc1,2020
Inhibition of GST-tagged human recombinant PI3Kgamma catalytic domain (468 to 1203 residues) expressed in insect cells using PIP2 peptide as substrate incubated for 1 hr in presence ATP by ADP-Glo Kinase Assay,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)Nc2ccccc2Cl)cc1,CHEMBL4765307,=,=,IC50,nM,258.0,IC50,nM,258.0,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)Nc2ccccc2Cl)cc1,2020
Inhibition of GST-tagged human recombinant PI3Kgamma catalytic domain (468 to 1203 residues) expressed in insect cells using PIP2 peptide as substrate incubated for 1 hr in presence ATP by ADP-Glo Kinase Assay,N#Cc1ccc(-c2c(-c3ncn[nH]3)sc(N3CCOCC3)c2C#N)c(F)c1,CHEMBL4765307,=,=,IC50,nM,60.0,IC50,nM,60.0,N#Cc1ccc(-c2c(-c3ncn[nH]3)sc(N3CCOCC3)c2C#N)c(F)c1,2020
Inhibition of GST-tagged human recombinant PI3Kgamma catalytic domain (468 to 1203 residues) expressed in insect cells using PIP2 peptide as substrate incubated for 1 hr in presence ATP by ADP-Glo Kinase Assay,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)N/N=C/c2cccc(O)c2)cc1,CHEMBL4765307,=,=,IC50,nM,440.0,IC50,nM,440.0,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)N/N=C/c2cccc(O)c2)cc1,2020
Inhibition of GST-tagged human recombinant PI3Kgamma catalytic domain (468 to 1203 residues) expressed in insect cells using PIP2 peptide as substrate incubated for 1 hr in presence ATP by ADP-Glo Kinase Assay,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)N/N=C/c2ccco2)cc1,CHEMBL4765307,=,=,IC50,nM,204.0,IC50,nM,204.0,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)N/N=C/c2ccco2)cc1,2020
Inhibition of GST-tagged human recombinant PI3Kgamma catalytic domain (468 to 1203 residues) expressed in insect cells using PIP2 peptide as substrate incubated for 1 hr in presence ATP by ADP-Glo Kinase Assay,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)N/N=C/c2ccccn2)cc1,CHEMBL4765307,=,=,IC50,nM,274.0,IC50,nM,274.0,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)N/N=C/c2ccccn2)cc1,2020
Inhibition of GST-tagged human recombinant PI3Kgamma catalytic domain (468 to 1203 residues) expressed in insect cells using PIP2 peptide as substrate incubated for 1 hr in presence ATP by ADP-Glo Kinase Assay,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,CHEMBL4765307,=,=,IC50,nM,94.0,IC50,nM,94.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,2020
Inhibition of GST-tagged human recombinant PI3Kgamma catalytic domain (468 to 1203 residues) expressed in insect cells using PIP2 peptide as substrate incubated for 1 hr in presence ATP by ADP-Glo Kinase Assay,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)Nc2ccccc2Cl)cc1,CHEMBL4765307,=,=,Ki,nM,193.0,Ki,nM,193.0,N#Cc1c(N2CCOCC2)sc(-c2nc[nH]n2)c1-c1ccc(NC(=O)Nc2ccccc2Cl)cc1,2020
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 1 hr in presence of ATP by ADP-Glo reagent based assay,NC(=O)[C@H]1CCCN1C(=O)c1ccc2nc(Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)[nH]c2c1,CHEMBL4765397,=,=,IC50,nM,444000.0,IC50,uM,444.0,NC(=O)[C@H]1CCCN1C(=O)c1ccc2nc(Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)[nH]c2c1,2020
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 1 hr in presence of ATP by ADP-Glo reagent based assay,NC(=O)C1CCN(C(=O)c2ccc3nc(Nc4ccc(-c5nc(N6CCOCC6)nc(N6CCOCC6)n5)cc4)[nH]c3c2)CC1,CHEMBL4765397,=,=,IC50,nM,849000.0,IC50,uM,849.0,NC(=O)C1CCN(C(=O)c2ccc3nc(Nc4ccc(-c5nc(N6CCOCC6)nc(N6CCOCC6)n5)cc4)[nH]c3c2)CC1,2020
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 1 hr in presence of ATP by ADP-Glo reagent based assay,C[C@H](NC(=O)c1ccc2nc(Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)[nH]c2c1)C(N)=O,CHEMBL4765397,=,=,IC50,nM,645000.0,IC50,uM,645.0,C[C@H](NC(=O)c1ccc2nc(Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)[nH]c2c1)C(N)=O,2020
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 1 hr in presence of ATP by ADP-Glo reagent based assay,O=C(c1ccc2nc(Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)[nH]c2c1)N1CCOCC1,CHEMBL4765397,>,>,IC50,nM,100000.0,IC50,uM,100.0,O=C(c1ccc2nc(Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)[nH]c2c1)N1CCOCC1,2020
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 1 hr in presence of ATP by ADP-Glo reagent based assay,CN1CCN(C(=O)c2ccc3nc(Nc4ccc(-c5nc(N6CCOCC6)nc(N6CCOCC6)n5)cc4)[nH]c3c2)CC1,CHEMBL4765397,>,>,IC50,nM,100000.0,IC50,uM,100.0,CN1CCN(C(=O)c2ccc3nc(Nc4ccc(-c5nc(N6CCOCC6)nc(N6CCOCC6)n5)cc4)[nH]c3c2)CC1,2020
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 1 hr in presence of ATP by ADP-Glo reagent based assay,CN(C)C1CCN(C(=O)c2cccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)c2)CC1,CHEMBL4765397,=,=,IC50,nM,41400.0,IC50,uM,41.4,CN(C)C1CCN(C(=O)c2cccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)c2)CC1,2020
Inhibition of human His-tagged PIK3CG expressed in baculovirus expression system at 1 uM relative to control,Cc1cc2ncnn2cc1Nc1ncc2c(n1)n(C1CCOCC1)c(=O)n2C,CHEMBL4765462,>,>,Inhibition,%,50.0,INH,%,50.0,Cc1cc2ncnn2cc1Nc1ncc2c(n1)n(C1CCOCC1)c(=O)n2C,2020
Inhibition of PIK3CG in human NCI-H929 cells by mass spectroscopic analysis,Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,% inhibition,uM,12.4,% inhibition,uM,12.4,Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O,2020
Inhibition of PIK3CG in human NCI-H929 cells by mass spectroscopic analysis,CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1,CHEMBL4804281,=,=,% inhibition,uM,1.7,% inhibition,uM,1.7,CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1,2020
Inhibition of PIK3CG in human NCI-H929 cells by mass spectroscopic analysis,COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1,CHEMBL4804281,=,=,% inhibition,uM,-5.5,% inhibition,uM,-5.5,COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1,2020
Inhibition of PIK3CG in human NCI-H929 cells by mass spectroscopic analysis,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,% inhibition,uM,-146.5,% inhibition,uM,-146.5,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O,2020
Inhibition of PIK3CG in human NCI-H929 cells by mass spectroscopic analysis,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,% inhibition,uM,-64.0,% inhibition,uM,-64.0,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O,2020
Inhibition of PIK3CG in human NCI-H929 cells by mass spectroscopic analysis,Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,% inhibition,uM,16.3,% inhibition,uM,16.3,Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O,2020
Inhibition of PIK3CG in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control,Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,Inhibition,%,0.0,INH,%,0.0,Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O,2020
Inhibition of PIK3CG in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control,CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1,CHEMBL4804281,=,=,Inhibition,%,0.0,INH,%,0.0,CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1,2020
Inhibition of PIK3CG in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control,COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1,CHEMBL4804281,=,=,Inhibition,%,0.0,INH,%,0.0,COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1,2020
Inhibition of PIK3CG in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,Inhibition,%,0.0,INH,%,0.0,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O,2020
Inhibition of PIK3CG in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,Inhibition,%,0.0,INH,%,0.0,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O,2020
Inhibition of PIK3CG in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control,Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,Inhibition,%,0.0,INH,%,0.0,Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O,2020
Inhibition of human PIK3CG assessed as percent of control at 2000 nM by KINOMEscan assay relative to control,CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1,CHEMBL4804282,=,=,Activity,%,76.0,Activity,%,76.0,CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1,2020
Inhibition of human PIK3CG assessed as percent of control at 1000 nM by KINOMEscan assay relative to control,COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F,CHEMBL4804283,=,=,Activity,%,83.0,Activity,%,83.0,COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F,2020
Inhibition of DNA-tagged human PIK3CG assessed as percent of control at 50000 nM by qPCR analysis relative to control,CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21,CHEMBL4804284,=,=,Activity,%,100.0,Activity,%,100.0,CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21,2020
Inhibition of human PIK3CG assessed as percent of control at 2000 nM by KINOMEscan assay relative to control,CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1,CHEMBL4804286,=,=,Activity,%,79.0,Activity,%,79.0,CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1,2020
Inhibition of human PIK3CG assessed as percent of control at 2000 nM by KINOMEscan assay relative to control,CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1,CHEMBL4804286,=,=,Activity,%,76.0,Activity,%,76.0,CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1,2020
Inhibition of PI3Kgamma (unknown origin),CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21,CHEMBL4806966,=,=,IC50,nM,36.0,IC50,nM,36.0,CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21,2020
Inhibition of C-terminal His-tagged full-length PI3K p110gamma (unknown origin) expressed in baculovirus incubated for 60 mins by Kinase-Glo luminescence assay,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL5230127,=,=,IC50,nM,7.0,IC50,nM,7.0,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2020
Inhibition of PI3Kgamma (unknown origin),CO[C@@H](C)Cn1c(=O)n(C)c2cnc3ccc(-c4cncc(C(C)(C)O)c4)cc3c21,CHEMBL5230127,=,=,IC50,nM,38.0,IC50,nM,38.0,CO[C@@H](C)Cn1c(=O)n(C)c2cnc3ccc(-c4cncc(C(C)(C)O)c4)cc3c21,2020
Inhibition of PI3Kgamma (unknown origin),Cc1nc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc2n1C(C)C,CHEMBL5230127,=,=,IC50,nM,16.0,IC50,nM,16.0,Cc1nc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc2n1C(C)C,2020
Inhibition of human PI3Kgamma assessed as inhibition constant,COc1ccc(-c2cc3c(C)nc(N)nc3n(C3CCC(OCCO)CC3)c2=O)cn1,CHEMBL5230127,=,=,Ki,nM,1.6,Ki,nM,1.6,COc1ccc(-c2cc3c(C)nc(N)nc3n(C3CCC(OCCO)CC3)c2=O)cn1,2020
Inhibition of PI3Kgamma (unknown origin),O=c1cc(N2CCOCC2)oc2c(-c3ccc4c(c3)OCCO4)csc12,CHEMBL5252533,=,=,IC50,nM,158.0,IC50,nM,158.0,O=c1cc(N2CCOCC2)oc2c(-c3ccc4c(c3)OCCO4)csc12,2016
Inhibition of PI3Kgamma (unknown origin),CCOC(=O)c1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,CHEMBL5252533,=,=,IC50,nM,1170.0,IC50,nM,1170.0,CCOC(=O)c1ccc(-c2csc3c(=O)cc(N4CCOCC4)oc23)cc1,2016
Inhibition of PI3K-gamma (unknown origin) upto 10000 nM,CC(C)(O)[C@H]1CC[C@H](NC(=O)c2cnc3nc(C4CC4)ccc3c2)CC1,CHEMBL5260850,,,Inhibition,%,,INH,,,CC(C)(O)[C@H]1CC[C@H](NC(=O)c2cnc3nc(C4CC4)ccc3c2)CC1,2020
